<SEC-DOCUMENT>0000874015-25-000266.txt : 20251029
<SEC-HEADER>0000874015-25-000266.hdr.sgml : 20251029
<ACCEPTANCE-DATETIME>20251029164355
ACCESSION NUMBER:		0000874015-25-000266
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		79
CONFORMED PERIOD OF REPORT:	20250930
FILED AS OF DATE:		20251029
DATE AS OF CHANGE:		20251029

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IONIS PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000874015
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				330336973
		STATE OF INCORPORATION:			CA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19125
		FILM NUMBER:		251430586

	BUSINESS ADDRESS:	
		STREET 1:		2855 GAZELLE COURT
		CITY:			CARLSBAD
		STATE:			CA
		ZIP:			92010
		BUSINESS PHONE:		7609319200

	MAIL ADDRESS:	
		STREET 1:		2855 GAZELLE COURT
		CITY:			CARLSBAD
		STATE:			CA
		ZIP:			92010

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ISIS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19930328
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>form10q.htm
<DESCRIPTION>IONIS PHARMACEUTICALS, INC. 10-Q 9-30-2025
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Wed Oct 29 20:43:09 UTC 2025 -->
<!-- Created by CompSci Resources, LLC on Thu May 29 17:31:04 UTC 2025 -->
<html xmlns:compsci="http://compsciresources.com" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:dtr="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:ions="http://ionis.com/20250930" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml">
 <head>
  <title> </title>

<meta content="text/html" http-equiv="Content-Type"/>
</head>
 <body><div style="font-family: 'Times New Roman'; font-size: 10pt; padding-top: 48px; padding-bottom: 48px; vertical-align: bottom;"><div>
  </div><div style="text-align: center;">
   <span style="font-size: 18.0pt; color: #000000; font-weight: bold;">UNITED STATES</span>
  </div><div>
  </div><div style="text-align: center;">
   <span style="font-size: 18.0pt; color: #000000; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</span>
  </div><div>
  </div><div style="text-align: center;">
   <span style="color: #000000; font-weight: bold;">Washington, DC 20549</span>
  </div><div>
  </div><div style="font-size: 8pt;">&#160;
  </div><div>
  </div><div style="text-align: center;"> <span style="font-size: 18.0pt; color: #000000; font-weight: bold;">Form <ix:nonNumeric contextRef="c0" name="dei:DocumentType" id="ixv-11124">10-Q</ix:nonNumeric></span> </div><div>
  </div><div style="text-align: justify;">
   <span style="color: #000000; font-weight: bold;">(Mark One)</span>
  </div><div>
  </div><div style="font-size: 8pt;">&#160;
  </div><div>
  </div><div style="text-indent: -27pt; padding-left: 47.25pt;"> <div style="float: left; width: 27.0pt; white-space: nowrap;"> <ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="ixv-29"><span style="font-family: Segoe UI Emoji; color: #000000;">&#9746;</span></ix:nonNumeric> </div> <div> <span style="color: #000000;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span> </div> </div><div>
  </div><div style="font-size: 8pt;">&#160;
  </div><div>
  </div><div style="text-align: center;"> <span style="color: #000000; font-weight: bold;">For the Quarterly Period Ended&#160;<ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="ixv-11125">September 30, <ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalYearFocus" id="ixv-11126">2025</ix:nonNumeric></ix:nonNumeric></span> </div><div>
  </div><div style="font-size: 8pt;">&#160;
  </div><div>
  </div><div style="text-align: center;">
   <span style="color: #000000; font-weight: bold;">OR</span>
  </div><div>
  </div><div style="font-size: 8pt;">&#160;
  </div><div>
  </div><div style="text-indent: -27pt; padding-left: 47.25pt;"> <div style="float: left; width: 27.0pt; white-space: nowrap;"> <ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="ixv-48"><span style="font-family: Segoe UI Emoji; color: #000000;">&#9744;</span></ix:nonNumeric> </div> <div> <span style="color: #000000;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934</span> </div> </div><div>
  </div><div style="font-size: 8pt;">&#160;
  </div><div>
  </div><div style="text-align: center;">
   <span style="color: #000000; font-weight: bold;">For the transition period from _____ to _____</span>
  </div><div>
  </div><div style="font-size: 8pt;">&#160;
  </div><div>
  </div><div style="text-align: center;"> <span style="color: #000000; font-weight: bold;">Commission file number <ix:nonNumeric contextRef="c0" name="dei:EntityFileNumber" id="ixv-11127">000-19125</ix:nonNumeric></span> </div><div>
  </div><div style="text-align: center; font-size: 8pt;">&#160;
  </div><div>
  </div><table style="font-size: 10pt; border-spacing: 0px; border-collapse: collapse; margin: auto;">
   <tr style="vertical-align: top;">
    <td style="padding: 0; width: 180.9pt; padding-left: 5.4pt; padding-right: 5.4pt;">
     <div style="font-size: 8pt;">&#160;
     </div>
    </td>
    <td style="padding: 0; width: 189pt; border-bottom: 1pt solid #000000; padding-left: 5.4pt; padding-right: 5.4pt;">
     <div style="font-size: 8pt;">&#160;
     </div>
    </td>
    <td style="padding: 0; width: 180.9pt; padding-left: 5.4pt; padding-right: 5.4pt;">
     <div style="font-size: 8pt;">&#160;
     </div>
    </td>
   </tr>
  </table><div>
  </div><div style="text-align: center; color: #000000;">&#160;
  </div><div>

  </div><div style="text-align: center; font-size: 18.0pt; color: #000000;"> <ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName" id="ixv-77"><span style="font-size: 18.0pt; font-weight: bold;">Ionis Pharmaceuticals, Inc.</span></ix:nonNumeric> </div><div style="text-align: center; font-size: 12pt; color: #000000;">
   <span style="font-size: 10.0pt;">(Exact name of Registrant as specified in its charter)</span>
  </div><div>
  </div><div style="text-align: center; font-size: 12pt; color: #000000;">
   <span style="font-size: 5.0pt;">&#160;</span>
  </div><div>
  </div><table style="font-size: 10pt; border-spacing: 0px; border-collapse: collapse; margin: auto; width: 100%;"> <tr style="vertical-align: top;"> <td style="padding: 0; width: 48.94%;"> <div style="text-align: center; font-size: 12pt; color: #000000;"> <ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="ixv-89"><span style="font-size: 10.0pt; font-weight: bold;">Delaware</span></ix:nonNumeric> </div> </td> <td style="padding: 0; width: 2.14%; vertical-align: bottom;"> <div style="font-size: 12pt; color: #000000;"> <span style="font-size: 1.0pt; font-weight: bold;">&#160;</span> </div> </td> <td style="padding: 0; width: 48.92%;"> <div style="text-align: center; font-size: 12pt; color: #000000;"> <ix:nonNumeric contextRef="c0" name="dei:EntityTaxIdentificationNumber" id="ixv-96"><span style="font-size: 10.0pt; font-weight: bold;">33-0336973</span></ix:nonNumeric> </div> </td> </tr> <tr style="vertical-align: top;"> <td style="padding: 0; width: 48.94%;"> <div style="text-align: center; font-size: 12pt; color: #000000;"> <span style="font-size: 10.0pt;">(State or other jurisdiction of incorporation or organization)</span> </div> </td> <td style="padding: 0; width: 2.14%; vertical-align: bottom;"> <div style="font-size: 12pt; color: #000000;"> <span style="font-size: 1.0pt;">&#160;</span> </div> </td> <td style="padding: 0; width: 48.92%;"> <div style="text-align: center; font-size: 12pt; color: #000000;"> <span style="font-size: 10.0pt;">(IRS Employer Identification No.)</span> </div> </td> </tr> </table><div>
  </div><div style="text-align: center; font-size: 12pt; color: #000000;">
   <span style="font-size: 5.0pt; font-weight: bold;">&#160;</span>
  </div><div>
  </div><table style="font-size: 10pt; border-spacing: 0px; border-collapse: collapse; width: 100%;"> <tr style="vertical-align: top;"> <td style="padding: 0; width: 49%; vertical-align: bottom;"> <div style="text-align: center;"> <span style="font-weight: bold;"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1" id="ixv-11128">2855 Gazelle Court</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown" id="ixv-11129">Carlsbad</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="ixv-11130">California</ix:nonNumeric></span> </div> </td> <td style="padding: 0; width: 2%; vertical-align: bottom; font-size: 0;">&#160; </td> <td style="padding: 0; width: 49%; vertical-align: bottom;"> <div style="text-align: center;"> <ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode" id="ixv-120"><span style="color: #000000; font-weight: bold;">92010</span></ix:nonNumeric> </div> </td> </tr> <tr style="vertical-align: top;"> <td style="padding: 0; width: 49%;"> <div style="text-align: center;"> <span style="color: #000000;">(Address of Principal Executive Offices)</span> </div> </td> <td style="padding: 0; width: 2%; vertical-align: bottom;"> <div> <span style="color: #000000;">&#160;</span> </div> </td> <td style="padding: 0; width: 49%;"> <div style="text-align: center;"> <span style="color: #000000;">(Zip Code)</span> </div> </td> </tr> </table><div>
  </div><div style="text-align: center; font-size: 12pt; color: #000000;">
   <span style="font-size: 5.0pt;">&#160;</span>
  </div><div>
  </div><div style="text-align: center; font-size: 12pt; color: #000000;"> <span style="font-size: 10.0pt; font-weight: bold;"><ix:nonNumeric contextRef="c0" name="dei:CityAreaCode" id="ixv-11131">760</ix:nonNumeric>-<ix:nonNumeric contextRef="c0" name="dei:LocalPhoneNumber" id="ixv-11132">931-9200</ix:nonNumeric></span> </div><div>
  </div><div style="text-align: center; font-size: 12pt; color: #000000;">
   <span style="font-size: 10.0pt;">(Registrant&#8217;s telephone number, including area code)</span>
  </div><div>
  </div><div style="text-align: center; font-size: 12pt; color: #000000;">
   <span style="font-size: 5.0pt;">&#160;</span>
  </div><div>
  </div><div style="text-align: center;">
   <span style="color: #000000; font-weight: bold;">Securities registered pursuant to Section 12(b) of the Act:</span>
  </div><div>
  </div><div style="text-align: center;">&#160;
  </div><div>

  </div><table style="font-size: 10pt; border-spacing: 0px; border-collapse: collapse; margin: auto; width: 100%;"> <tr style="height: 0px; font-size: 0px;"><td style="width: 33%;"/><td style="width: 1%;"/><td style="width: 32%;"/><td style="width: 1%;"/><td style="width: 33%;"/></tr><tr style="vertical-align: top;"> <td style="padding: 0px 5.4pt; border-bottom: 1pt solid black; vertical-align: bottom;"> <div style="text-align: center;"> <span style="color: #000000;">Title of each class</span> </div> </td> <td style="padding: 0px 5.4pt; vertical-align: bottom;">&#160; </td> <td style="padding: 0px 5.4pt; border-bottom: 1pt solid black; vertical-align: bottom;"> <div style="text-align: center;"> <span style="color: #000000;">Trading symbol</span> </div> </td> <td style="padding: 0px 5.4pt; vertical-align: bottom;">&#160; </td> <td style="padding: 0px 5.4pt; border-bottom: 1pt solid black; vertical-align: bottom;"> <div style="text-align: center;"> <span style="color: #000000;">Name of each exchange on which registered</span> </div> </td> </tr> <tr style="vertical-align: top;"> <td style="padding: 1.45pt 5.75pt 0px; border-top: 1pt solid black; vertical-align: bottom;"> <div style="text-align: center;"> <ix:nonNumeric contextRef="c0" name="dei:Security12bTitle" id="ixv-172"><span style="color: #000000;">Common Stock, $.001 Par Value</span></ix:nonNumeric> </div> </td> <td style="padding: 0px 5.4pt; vertical-align: bottom;">&#160; </td> <td style="padding: 1.45pt 5.75pt 0px; border-top: 1pt solid black; vertical-align: bottom;"> <div style="margin-bottom: 2.2pt; text-align: center;"> <span style="color: #000000;">&#8220;<ix:nonNumeric contextRef="c0" name="dei:TradingSymbol" id="ixv-11133">IONS</ix:nonNumeric>&#8221;</span> </div> </td> <td style="padding: 0px 5.4pt; vertical-align: bottom;">&#160; </td> <td style="padding: 0px 5.4pt; border-top: 1pt solid black; vertical-align: bottom;"> <div style="margin-bottom: 2.2pt; text-align: center;"> <span style="color: #000000;">The <ix:nonNumeric contextRef="c0" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="ixv-11134">Nasdaq</ix:nonNumeric> Stock Market LLC</span> </div> </td> </tr> </table><div style="text-indent: 18pt; font-size: 12pt; color: #000000;">
   <span style="font-size: 5.0pt;">&#160;</span>
  </div><div>
  </div><table style="font-size: 10pt; border-spacing: 0px; border-collapse: collapse; margin: auto;">
   <tr style="vertical-align: top;">
    <td style="padding: 0; width: 180.9pt; padding-left: 5.4pt; padding-right: 5.4pt;">
     <div style="font-size: 8pt;">&#160;
     </div>
    </td>
    <td style="padding: 0; width: 189pt; border-bottom: 1pt solid #000000; padding-left: 5.4pt; padding-right: 5.4pt;">
     <div style="font-size: 8pt;">&#160;
     </div>
    </td>
    <td style="padding: 0; width: 180.9pt; padding-left: 5.4pt; padding-right: 5.4pt;">
     <div style="font-size: 8pt;">&#160;
     </div>
    </td>
   </tr>
  </table><div>
  </div><div style="font-size: 8pt; color: #000000;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;"> <span style="color: #000000;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="c0" name="dei:EntityCurrentReportingStatus" id="ixv-11135">Yes</ix:nonNumeric> </span><span style="font-family: Segoe UI Emoji; color: #000000;">&#9746;</span><span style="color: #000000;"> No </span><span style="font-family: Segoe UI Emoji; color: #000000;">&#9744;</span> </div><div>
  </div><div style="font-size: 8pt;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;"> <span style="color: #000000;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="c0" name="dei:EntityInteractiveDataCurrent" id="ixv-11136">Yes</ix:nonNumeric> </span><span style="font-family: Segoe UI Emoji; color: #000000;">&#9746;</span><span style="color: #000000;"> No </span><span style="font-family: Segoe UI Emoji; color: #000000;">&#9744;</span> </div><div>
  </div><div style="font-size: 8pt;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span>
  </div><div>
  </div><div style="font-size: 8pt;">&#160;
  </div><div>

  </div><table style="font-size: 10pt; border-spacing: 0px; border-collapse: collapse; width: 100%;"> <tr style="height: 0px; font-size: 0px;"><td style="width: 50%;"/><td style="width: 50%;"/></tr><tr style="vertical-align: top;"> <td style="padding: 0px;"> <div style="text-align: center;"> <span style="color: #000000;"><ix:nonNumeric contextRef="c0" name="dei:EntityFilerCategory" id="ixv-11137">Large Accelerated Filer</ix:nonNumeric> </span><span style="font-family: Segoe UI Emoji; color: #000000;">&#9746;</span> </div> </td> <td style="padding: 0px;"> <div style="text-align: center;"> <span style="color: #000000;">Accelerated Filer </span><span style="font-family: Segoe UI Emoji; color: #000000;">&#9744;</span> </div> </td> </tr> <tr style="vertical-align: top;"> <td style="padding: 0px;"> <div> <span style="color: #000000;">&#160;</span> </div> </td> <td style="padding: 0px;"> <div> <span style="color: #000000;">&#160;</span> </div> </td> </tr> <tr style="vertical-align: top;"> <td style="padding: 0px;"> <div style="text-align: center;"> <span style="color: #000000;">Non-accelerated Filer </span><span style="font-family: Segoe UI Emoji; color: #000000;">&#9744;</span> </div> </td> <td style="padding: 0px;"> <div style="text-align: center;"> <span style="color: #000000;">Smaller Reporting Company </span><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="ixv-245"><span style="font-family: Segoe UI Emoji; color: #000000;">&#9744;</span></ix:nonNumeric> </div> </td> </tr> <tr style="vertical-align: top;"> <td style="padding: 0px;">&#160; </td> <td style="padding: 0px;"> <div style="text-align: center;"> <span style="color: #000000;">Emerging Growth Company </span><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="ixv-252"><span style="font-family: Segoe UI Emoji; color: #000000;">&#9744;</span></ix:nonNumeric> </div> </td> </tr> </table><div style="font-size: 8pt;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-family: Segoe UI Emoji; color: #000000;">&#9744;</span>
  </div><div>
  </div><div style="font-size: 8pt;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;"> <span style="color: #000000;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12(b)-2 of the Securities Exchange Act of 1934). Yes </span><span style="font-family: Segoe UI Emoji; color: #000000;">&#9744;</span><span style="color: #000000;"> No </span><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityShellCompany" id="ixv-266"><span style="font-family: Segoe UI Emoji; color: #000000;">&#9746;</span></ix:nonNumeric> </div><div>
  </div><div style="font-size: 8pt;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt;"> <span style="color: #000000;">The number of shares of voting common stock outstanding as of October 23, 2025 was <ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-11138">161,974,393</ix:nonFraction>.</span> </div><div>
  </div><div>&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 10px; margin-top: 0px; margin-bottom: 0px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="display: none; text-align: center">1</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div>&#160;
  </div><div>
  </div><div style="text-align: center;">
   <span style="color: #000000; font-weight: bold;">IONIS PHARMACEUTICALS, INC.</span>
  </div><div>
  </div><div style="text-align: center;">
   <span style="color: #000000; font-weight: bold;">FORM 10-Q</span>
  </div><div>
  </div><div style="text-align: center;">
   <span style="color: #000000; font-weight: bold;">INDEX</span>
  </div><div>
  </div><div>&#160;
  </div><div>

  </div><table id="tableOfContents0" style="border-spacing: 0px; border-collapse: collapse; width: 100%; font-size: 10pt;">
   <tr style="height: 0px; font-size: 0px;"><td style="width: 10%;">&#160;</td><td style="width: 85%;">&#160;</td><td style="width: 5%;">&#160;</td></tr><tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding: 0px;">
     <div>
      <span style="font-weight: bold;">PART I</span>
     </div>
    </td>
    <td style="padding: 0px;">
     <div>
      <span style="font-weight: bold;">FINANCIAL INFORMATION</span>
     </div>
    </td>
    <td style="padding: 0px; vertical-align: bottom;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px; vertical-align: bottom;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding: 0px;">
     <div>
      ITEM 1:
     </div>
    </td>
    <td style="padding: 0px;">
     <div>
      Financial Statements:
     </div>
    </td>
    <td style="padding: 0px; vertical-align: bottom;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px; vertical-align: bottom;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px;">
     <div style="margin-left: 14.85pt;">
      <a href="#Balance_Sheet">Condensed Consolidated Balance Sheets </a>as of September 30, 2025 (unaudited) and December 31, 2024
     </div>
    </td>
    <td style="padding: 0px; vertical-align: bottom; text-align: right;">
     <div style="margin-right: 9pt;">
      3
     </div>
    </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px; vertical-align: bottom;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px;">
     <div style="margin-left: 14.85pt;">
      <a href="#Income_Statement">Condensed Consolidated Statements of Operations</a> for the three and nine months ended&#160;September 30, 2025 and 2024 (unaudited)
     </div>
    </td>
    <td style="padding: 0px; vertical-align: bottom; text-align: right;">
     <div style="margin-right: 9pt;">
      4
     </div>
    </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px; vertical-align: bottom;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px;">
     <div style="margin-left: 14.85pt;">
      <a href="#Comprehensive_Income">Condensed Consolidated Statements of Comprehensive Loss</a>&#160;for the three and nine months ended September 30, 2025 and 2024 (unaudited)
     </div>
    </td>
    <td style="padding: 0px; vertical-align: bottom; text-align: right;">
     <div style="margin-right: 9pt;">
      5
     </div>
    </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px; vertical-align: bottom;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px;">
     <div style="margin-left: 14.85pt;">
      <span style="color: #0000FF; text-decoration: underline;"><a href="#Equity_Statement">Condensed Consolidated Statements of Stockholders&#8217; Equity</a></span> for the three and nine months ended September 30, 2025 and 2024 (unaudited)
     </div>
    </td>
    <td style="padding: 0px; vertical-align: bottom; text-align: right;">
     <div style="margin-right: 9pt;">
      6
     </div>
    </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px; vertical-align: bottom;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px;">
     <div style="margin-left: 14.85pt;">
      <span style="color: #0000FF; text-decoration: underline;"><a href="#Cash_Flows">Condensed Consolidated Statements of Cash Flows</a></span> for the nine months ended September 30, 2025 and 2024 (unaudited)
     </div>
    </td>
    <td style="padding: 0px; vertical-align: bottom; text-align: right;">
     <div style="margin-right: 9pt;">8</div>
    </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px; vertical-align: bottom;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px;">
     <div style="margin-left: 14.85pt;">
      <span style="color: #0000FF; text-decoration: underline;"><a href="#Notes">Notes to Condensed Consolidated Financial Statements (unaudited</a>)</span></div>
    </td>
    <td style="padding: 0px; vertical-align: bottom; text-align: right;">
     <div style="margin-right: 9pt;">9</div>
    </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px; vertical-align: bottom;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding: 0px;">
     <div>
      ITEM 2:
     </div>
    </td>
    <td style="padding: 0px;">
     <div>
      Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations:
     </div>
    </td>
    <td style="padding: 0px; vertical-align: bottom;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px; vertical-align: bottom;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px;">
     <div style="margin-left: 14.85pt; margin-right: -10.35pt;">
      <a href="#Overview">Overview</a>
     </div>
    </td>
    <td style="padding: 0px; vertical-align: bottom; text-align: right;">
     <div style="margin-right: 9pt;">
      23</div>
    </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px; vertical-align: bottom;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px;">
     <div style="margin-left: 14.85pt; margin-right: -10.35pt;">
      <a href="#Critical_Accounting_Estimates">Critical Accounting Estimates</a>
     </div>
    </td>
    <td style="padding: 0px; vertical-align: bottom; text-align: right;">
     <div style="margin-right: 9pt;">
      25</div>
    </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px; vertical-align: bottom;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px;">
     <div style="margin-left: 14.85pt; margin-right: -10.35pt;">
      <a href="#Results_of_Operations">Results of Operations</a>
     </div>
    </td>
    <td style="padding: 0px; vertical-align: bottom; text-align: right;">
     <div style="margin-right: 9pt;">
      26</div>
    </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px; vertical-align: bottom;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px;">
     <div style="margin-left: 14.85pt; margin-right: -10.35pt;">
      <a href="#Liquidity_and_Capital_Resources">Liquidity and Capital Resources</a>
     </div>
    </td>
    <td style="padding: 0px; vertical-align: bottom; text-align: right;">
     <div style="margin-right: 9pt;">
      31</div>
    </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px; vertical-align: bottom;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding: 0px;">
     <div>
      ITEM 3:
     </div>
    </td>
    <td style="padding: 0px;">
     <div>
      <span style="color: #0000FF; text-decoration: underline;"><a href="#Item_3_-_Market_Risk">Quantitative and Qualitative Disclosures about Market Risk</a></span>
     </div>
    </td>
    <td style="padding: 0px; vertical-align: bottom; text-align: right;">
     <div style="margin-right: 9pt;">
      33</div>
    </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px; vertical-align: bottom;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding: 0px;">
     <div>
      ITEM 4:
     </div>
    </td>
    <td style="padding: 0px;">
     <div>
      <span style="color: #0000FF; text-decoration: underline;"><a href="#Item_4_-_Controls_and_Procedures">Controls and Procedures</a></span>
     </div>
    </td>
    <td style="padding: 0px; vertical-align: bottom; text-align: right;">
     <div style="margin-right: 9pt;">
      33</div>
    </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px; vertical-align: bottom;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding: 0px;">
     <div>
      <span style="font-weight: bold;">PART II</span>
     </div>
    </td>
    <td style="padding: 0px;">
     <div>
      OTHER INFORMATION
     </div>
    </td>
    <td style="padding: 0px; vertical-align: bottom; text-align: right;">
     <div style="margin-right: 9pt;">
      34</div>
    </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px; vertical-align: bottom;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding: 0px;">
     <div>
      ITEM 1:
     </div>
    </td>
    <td style="padding: 0px;">
     <div>
      <span style="color: #0000FF; text-decoration: underline;"><a href="#Item_1_-_Legal_Proceedings">Legal Proceedings</a></span>
     </div>
    </td>
    <td style="padding: 0px; vertical-align: bottom; text-align: right;">
     <div style="margin-right: 9pt;">
      34</div>
    </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px; vertical-align: bottom;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding: 0px;">
     <div>
      ITEM 1A:
     </div>
    </td>
    <td style="padding: 0px;">
     <div>
      <span style="color: #0000FF; text-decoration: underline;"><a href="#Item_1A_-_Risk_Factors">Risk Factors</a></span>
     </div>
    </td>
    <td style="padding: 0px; vertical-align: bottom; text-align: right;">
     <div style="margin-right: 9pt;">
      34</div>
    </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px; vertical-align: bottom;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding: 0px;">
     <div>
      ITEM 2:
     </div>
    </td>
    <td style="padding: 0px;">
     <div>
      <a href="#Item_2_-_Sales_of_Equity_Securities">Unregistered Sales of Equity Securities and Use of Proceeds</a>
     </div>
    </td>
    <td style="padding: 0px; vertical-align: bottom; text-align: right;">
     <div style="margin-right: 9pt;">
      52</div>
    </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px; vertical-align: bottom;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding: 0px;">
     <div>
      ITEM 3:
     </div>
    </td>
    <td style="padding: 0px;">
     <div>
      <span style="color: #0000FF; text-decoration: underline;"><a href="#Item_3_-_Default_upon_Senior_Securities">Default upon Senior Securities</a></span>
     </div>
    </td>
    <td style="padding: 0px; vertical-align: bottom; text-align: right;">
     <div style="margin-right: 9pt;">
      <span style="letter-spacing: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">52</span>
     </div>
    </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px; vertical-align: bottom;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding: 0px;">
     <div>
      ITEM 4:
     </div>
    </td>
    <td style="padding: 0px;">
     <div>
      <span style="color: #0000FF; text-decoration: underline;"><a href="#Item_4_-_Mine_Safety">Mine Safety Disclosures</a></span>
     </div>
    </td>
    <td style="padding: 0px; vertical-align: bottom; text-align: right;">
     <div style="margin-right: 9pt;">
      52</div>
    </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px; vertical-align: bottom;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding: 0px;">
     <div>
      ITEM 5:
     </div>
    </td>
    <td style="padding: 0px;">
     <div>
      <span style="color: #0000FF; text-decoration: underline;"><a href="#Item_5_-_Other_Information">Other Information</a></span>
     </div>
    </td>
    <td style="padding: 0px; vertical-align: bottom; text-align: right;">
     <div style="margin-right: 9pt;">
      52</div>
    </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px; vertical-align: bottom;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td style="padding: 0px;">
     <div>
      ITEM 6:
     </div>
    </td>
    <td style="padding: 0px;">
     <div>
      <span style="color: #0000FF; text-decoration: underline;"><a href="#Item_6_-_Exhibits">Exhibits</a></span>
     </div>
    </td>
    <td style="padding: 0px; vertical-align: bottom; text-align: right;">
     <div style="margin-right: 9pt;">
      53</div>
    </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px; vertical-align: bottom;">&#160;</td>
   </tr>
   <tr style="vertical-align: top; background-color: rgb(204, 238, 255);">
    <td colspan="2" style="padding: 0;">
     <div>
      <a href="#Signatures">SIGNATURES</a></div>
    </td>
    <td style="padding: 0px; vertical-align: bottom; text-align: right;">
     <div style="margin-right: 9pt;">
      54</div>
    </td>
   </tr>
  </table><div>&#160;
  </div><div>
  </div><div style="text-align: center;">
   <span style="color: #000000; font-weight: bold;">TRADEMARKS</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000; font-weight: bold;">&#8220;</span><span style="color: #000000;">Ionis,&#8221; the Ionis logo, and other trademarks or service marks of Ionis Pharmaceuticals, Inc. appearing in this report are the property of Ionis Pharmaceuticals, Inc. &#8220;Akcea,&#8221; the Akcea logo, and other trademarks or service marks of Akcea Therapeutics, Inc. appearing in this report are the property of Akcea Therapeutics, Inc., Ionis&#8217; wholly owned subsidiary. This report contains additional trade names, trademarks and service marks of others, which are the property of their respective owners. Solely for convenience, trademarks and trade names referred to in this report may appear without the &#174; or TM symbols.</span><span style="color: #000000; font-weight: bold;">&#160;</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>



  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 10px; margin-top: 0px; margin-bottom: 0px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">2</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div>&#160;
  </div><div>
  </div><div style="text-align: justify;">
   <span style="color: #000000; font-weight: bold;">PART I &#8212; FINANCIAL INFORMATION</span>
  </div><div>
  </div><div style="margin-left: 72pt;">&#160;
  </div><div>
  </div><div style="text-indent: -72pt; padding-left: 72pt;">
    <div style="float: left; width: 72.0pt; white-space: nowrap;">
     <span style="color: #000000; font-weight: bold;">ITEM 1.</span>
    </div>
    <div>
     <span style="color: #000000; font-weight: bold;">FINANCIAL STATEMENTS</span>
    </div>
  </div><div>
  </div><div style="text-align: center; margin-right: -10.55pt;">&#160;
  </div><div>
  </div><div style="text-align: center; margin-right: -10.55pt;">
   <a id="Balance_Sheet" title="Balance Sheet"></a><span style="color: #000000; font-weight: bold;">IONIS PHARMACEUTICALS, INC.</span>
  </div><div>
  </div><div style="text-align: center;">
   <span style="color: #000000; font-weight: bold;">CONDENSED CONSOLIDATED BALANCE SHEETS</span>
  </div><div>
  </div><div style="text-align: center;">
   <span style="color: #000000; font-weight: bold;">(in thousands, except share data)</span>
  </div><div>
  </div><div>&#160;
  </div><div>







  </div><table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/></tr><tr><td>&#160;</td><td style="width: 1%;" title="Balance Sheets - B2"/><td style="font-weight: bold; text-align: center; vertical-align: bottom; width: 9%;">September 30,</td><td style="width: 1%;" title="Balance Sheets - B2"/><td>&#160;</td><td style="width: 1%;" title="Balance Sheets - D2"/><td style="font-weight: bold; text-align: center; vertical-align: bottom; width: 9%;">December 31,</td><td style="width: 1%;" title="Balance Sheets - D2"/></tr><tr><td>&#160;</td><td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Balance Sheets - B3"/><td style="font-weight: bold; text-align: center; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom; width: 9%;">2025</td><td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Balance Sheets - B3"/><td>&#160;</td><td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Balance Sheets - D3"/><td style="font-weight: bold; text-align: center; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom; width: 9%;">2024</td><td style="width: 1%;" title="Balance Sheets - D3"/></tr><tr><td>&#160;</td><td style="width: 1%;" title="Balance Sheets - B4"/><td style="font-weight: bold; text-align: center; width: 9%;">(unaudited)</td><td style="width: 1%;" title="Balance Sheets - B4"/><td>&#160;</td><td style="width: 1%;" title="Balance Sheets - D4"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Balance Sheets - D4"/></tr><tr><td style="font-weight: bold; text-align: center;">ASSETS</td><td style="width: 1%;" title="Balance Sheets - B5"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Balance Sheets - B5"/><td>&#160;</td><td style="width: 1%;" title="Balance Sheets - D5"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Balance Sheets - D5"/></tr><tr><td>Current assets:</td><td style="width: 1%;" title="Balance Sheets - B6"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Balance Sheets - B6"/><td>&#160;</td><td style="width: 1%;" title="Balance Sheets - D6"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Balance Sheets - D6"/></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 10px;">Cash and cash equivalents  </td><td style="text-align: left; width: 1%;" title="Balance Sheets - B7">$</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-11139">338,341</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Balance Sheets - B7">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Balance Sheets - D7">$</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-11140">242,077</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Balance Sheets - D7">&#160;</td></tr><tr><td style="padding-left: 10px;">Short-term investments  </td><td style="text-align: left; width: 1%;" title="Balance Sheets - B8">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShortTermInvestments" scale="3" unitRef="usd" id="ixv-11141">1,901,830</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Balance Sheets - B8">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Balance Sheets - D8">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShortTermInvestments" scale="3" unitRef="usd" id="ixv-11142">2,055,579</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Balance Sheets - D8">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 10px;">Contracts receivable  </td><td style="text-align: left; width: 1%;" title="Balance Sheets - B9">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="3" unitRef="usd" id="ixv-11143">24,608</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Balance Sheets - B9">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Balance Sheets - D9">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="3" unitRef="usd" id="ixv-11144">92,188</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Balance Sheets - D9">&#160;</td></tr><tr><td style="padding-left: 10px;">Inventories  </td><td style="text-align: left; width: 1%;" title="Balance Sheets - B10">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" unitRef="usd" id="ixv-11145">10,470</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Balance Sheets - B10">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Balance Sheets - D10">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" unitRef="usd" id="ixv-11146">12,512</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Balance Sheets - D10">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 10px;">Other current assets  </td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Balance Sheets - B11">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-11147">243,744</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Balance Sheets - B11">&#160;</td><td style="border-width: initial; border-style: none; border-color: initial;">&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Balance Sheets - D11">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-11148">217,934</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Balance Sheets - D11">&#160;</td></tr><tr><td style="padding-left: 30px;">Total current assets  </td><td style="text-align: left; border-width: initial; border-style: none; border-color: initial; width: 1%;" title="Balance Sheets - B12">&#160;</td><td style="text-align: right; border-width: initial; border-style: none; border-color: initial; width: 9%;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd" id="ixv-11149">2,518,993</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Balance Sheets - B12">&#160;</td><td>&#160;</td><td style="text-align: left; border-width: initial; border-style: none; border-color: initial; width: 1%;" title="Balance Sheets - D12">&#160;</td><td style="text-align: right; border-width: initial; border-style: none; border-color: initial; width: 9%;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd" id="ixv-11150">2,620,290</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Balance Sheets - D12">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Property, plant and equipment, net  </td><td style="text-align: left; width: 1%;" title="Balance Sheets - B13">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-11151">106,117</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Balance Sheets - B13">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Balance Sheets - D13">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-11152">94,251</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Balance Sheets - D13">&#160;</td></tr><tr><td>Right-of-use assets</td><td style="text-align: left; width: 1%;" title="Balance Sheets - B14">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-11153">241,993</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Balance Sheets - B14">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Balance Sheets - D14">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-11154">161,856</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Balance Sheets - D14">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Deposits and other assets  </td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Balance Sheets - B15">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" unitRef="usd" id="ixv-11155">165,988</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Balance Sheets - B15">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Balance Sheets - D15">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" unitRef="usd" id="ixv-11156">127,278</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Balance Sheets - D15">&#160;</td></tr><tr><td style="padding-left: 50px;">Total assets  </td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Balance Sheets - B16">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-11157">3,033,091</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Balance Sheets - B16">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Balance Sheets - D16">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-11158">3,003,675</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Balance Sheets - D16">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>&#160;</td><td style="width: 1%;" title="Balance Sheets - B17"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Balance Sheets - B17"/><td>&#160;</td><td style="width: 1%;" title="Balance Sheets - D17"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Balance Sheets - D17"/></tr><tr><td style="font-weight: bold; text-align: center;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td><td style="width: 1%;" title="Balance Sheets - B18"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Balance Sheets - B18"/><td>&#160;</td><td style="width: 1%;" title="Balance Sheets - D18"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Balance Sheets - D18"/></tr><tr style="background-color: rgb(204, 238, 255);"><td>Current liabilities:</td><td style="width: 1%;" title="Balance Sheets - B19"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Balance Sheets - B19"/><td>&#160;</td><td style="width: 1%;" title="Balance Sheets - D19"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Balance Sheets - D19"/></tr><tr><td style="padding-left: 10px;">Accounts payable  </td><td style="text-align: left; width: 1%;" title="Balance Sheets - B20">$</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" unitRef="usd" id="ixv-11159">14,326</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Balance Sheets - B20">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Balance Sheets - D20">$</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" unitRef="usd" id="ixv-11160">42,964</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Balance Sheets - D20">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 10px;">Accrued compensation  </td><td style="text-align: left; width: 1%;" title="Balance Sheets - B21">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-11161">57,019</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Balance Sheets - B21">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Balance Sheets - D21">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-11162">69,614</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Balance Sheets - D21">&#160;</td></tr><tr><td style="padding-left: 10px;">Accrued liabilities  </td><td style="text-align: left; width: 1%;" title="Balance Sheets - B22">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-11163">99,310</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Balance Sheets - B22">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Balance Sheets - D22">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-11164">108,438</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Balance Sheets - D22">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 10px;">Income taxes payable</td><td style="text-align: left; width: 1%;" title="Balance Sheets - B23">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedIncomeTaxesCurrent" scale="3" unitRef="usd" id="ixv-11165">101</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Balance Sheets - B23">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Balance Sheets - D23">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedIncomeTaxesCurrent" scale="3" unitRef="usd" id="ixv-11166">34</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Balance Sheets - D23">&#160;</td></tr><tr><td style="padding-left: 10px;"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-11167"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-11168">0</ix:nonFraction></ix:nonFraction> percent convertible senior notes, net</td><td style="text-align: left; width: 1%;" title="Balance Sheets - B24">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleDebtCurrent" scale="3" unitRef="usd" id="ixv-11169">630,911</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Balance Sheets - B24">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Balance Sheets - D24">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ConvertibleDebtCurrent" scale="3" unitRef="usd" id="ixv-11170"> - </ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Balance Sheets - D24">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 10px;">Current portion of deferred contract revenue  </td><td style="text-align: left; width: 1%;" title="Balance Sheets - B24">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" unitRef="usd" id="ixv-11171">76,986</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Balance Sheets - B24">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Balance Sheets - D24">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" unitRef="usd" id="ixv-11172">78,989</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Balance Sheets - D24">&#160;</td></tr><tr><td style="padding-left: 10px;">Other current liabilities  </td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Balance Sheets - B25">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-11173">24,803</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Balance Sheets - B25">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Balance Sheets - D25">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-11174">9,279</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Balance Sheets - D25">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 30px;">Total current liabilities  </td><td style="text-align: left; width: 1%;" title="Balance Sheets - B26">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-11175">903,456</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Balance Sheets - B26">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Balance Sheets - D26">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-11176">309,318</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Balance Sheets - D26">&#160;</td></tr><tr><td>Long-term deferred contract revenue  </td><td style="text-align: left; width: 1%;" title="Balance Sheets - B27">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-11177">107,906</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Balance Sheets - B27">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Balance Sheets - D27">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-11178">156,504</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Balance Sheets - D27">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td><ix:nonFraction contextRef="c6" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-11179"><ix:nonFraction contextRef="c7" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-11180">1.75</ix:nonFraction></ix:nonFraction> percent convertible senior notes, net</td><td style="text-align: left; width: 1%;" title="Balance Sheets - B28">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleDebtNoncurrent" scale="3" unitRef="usd" id="ixv-11181">567,123</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Balance Sheets - B28">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Balance Sheets - D28">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleDebtNoncurrent" scale="3" unitRef="usd" id="ixv-11182">565,026</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Balance Sheets - D28">&#160;</td></tr><tr><td><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-11183"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-11184">0</ix:nonFraction></ix:nonFraction> percent convertible senior notes, net</td><td style="text-align: left; width: 1%;" title="Balance Sheets - B29">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ConvertibleDebtNoncurrent" scale="3" unitRef="usd" id="ixv-11185"> - </ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Balance Sheets - B29">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Balance Sheets - D29">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleDebtNoncurrent" scale="3" unitRef="usd" id="ixv-11186">628,535</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Balance Sheets - D29">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Liability related to sale of future royalties, net</td><td style="text-align: left; width: 1%;" title="Balance Sheets - B30">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ions:LiabilityRelatedToSaleOfFutureRoyaltiesNetNoncurrent" scale="3" unitRef="usd" id="ixv-11187">545,182</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Balance Sheets - B30">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Balance Sheets - D30">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ions:LiabilityRelatedToSaleOfFutureRoyaltiesNetNoncurrent" scale="3" unitRef="usd" id="ixv-11188">542,212</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Balance Sheets - D30">&#160;</td></tr><tr><td>Long-term lease liabilities</td><td style="text-align: left; width: 1%;" title="Balance Sheets - B31">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-11189">262,672</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Balance Sheets - B31">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Balance Sheets - D31">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-11190">161,805</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Balance Sheets - D31">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Long-term obligations</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Balance Sheets - B32">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" unitRef="usd" id="ixv-11191">28,785</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Balance Sheets - B32">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Balance Sheets - D32">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" unitRef="usd" id="ixv-11192">51,924</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Balance Sheets - D32">&#160;</td></tr><tr><td style="padding-left: 50px;">Total liabilities  </td><td style="text-align: left; width: 1%;" title="Balance Sheets - B33">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd" id="ixv-11193">2,415,124</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Balance Sheets - B33">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Balance Sheets - D33">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd" id="ixv-11194">2,415,324</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Balance Sheets - D33">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Stockholders&#8217; equity:</td><td style="width: 1%;" title="Balance Sheets - B34"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Balance Sheets - B34"/><td>&#160;</td><td style="width: 1%;" title="Balance Sheets - D34"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Balance Sheets - D34"/></tr><tr><td style="padding-left: 10px;">Common stock, $<ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-11195"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-11196">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-11197"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-11198">300,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-11199"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-11200">161,137,930</ix:nonFraction></ix:nonFraction> and <ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-11201"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-11202">157,908,815</ix:nonFraction></ix:nonFraction> shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively</td><td style="text-align: left; vertical-align: bottom; width: 1%;" title="Balance Sheets - B35">&#160;</td><td style="text-align: right; vertical-align: bottom; width: 9%;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" unitRef="usd" id="ixv-11203">161</ix:nonFraction></td><td style="text-align: left; vertical-align: bottom; width: 1%;" title="Balance Sheets - B35">&#160;</td><td>&#160;</td><td style="text-align: left; vertical-align: bottom; width: 1%;" title="Balance Sheets - D35">&#160;</td><td style="text-align: right; vertical-align: bottom; width: 9%;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" unitRef="usd" id="ixv-11204">158</ix:nonFraction></td><td style="text-align: left; vertical-align: bottom; width: 1%;" title="Balance Sheets - D35">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 10px;">Additional paid-in capital  </td><td style="text-align: left; width: 1%;" title="Balance Sheets - B36">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" unitRef="usd" id="ixv-11205">3,045,585</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Balance Sheets - B36">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Balance Sheets - D36">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" unitRef="usd" id="ixv-11206">2,868,812</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Balance Sheets - D36">&#160;</td></tr><tr><td style="padding-left: 10px;">Accumulated other comprehensive income</td><td style="text-align: left; width: 1%;" title="Balance Sheets - B37">&#160;</td><td style="text-align: right; width: 9%;">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" sign="-" unitRef="usd" id="ixv-11207">25,978</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Balance Sheets - B37">)&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Balance Sheets - D37">&#160;</td><td style="text-align: right; width: 9%;">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" sign="-" unitRef="usd" id="ixv-11208">30,811</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Balance Sheets - D37">)&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 10px;">Accumulated deficit  </td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Balance Sheets - B38">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd" id="ixv-11209">2,401,801</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Balance Sheets - B38">)&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Balance Sheets - D38">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd" id="ixv-11210">2,249,808</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Balance Sheets - D38">)&#160;</td></tr><tr><td style="padding-left: 30px;">Total stockholders' equity</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Balance Sheets - B39">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-11211">617,967</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Balance Sheets - B39">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Balance Sheets - D39">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-11212">588,351</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Balance Sheets - D39">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 50px;">Total liabilities and stockholders&#8217; equity  </td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Balance Sheets - B40">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd" id="ixv-11213">3,033,091</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Balance Sheets - B40">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Balance Sheets - D40">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd" id="ixv-11214">3,003,675</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Balance Sheets - D40">&#160;</td></tr></table><div style="text-align: center;">&#160;</div><div style="text-align: center;">See accompanying notes.</div><div style="text-align: center;">&#160;</div><div style="text-align: center;">&#160;</div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 10px; margin-top: 0px; margin-bottom: 0px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">3</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-align: center;"><a id="Income_Statement" title="Income Statement"></a><span style="color: #000000; font-weight: bold;">IONIS PHARMACEUTICALS, INC.</span>
  </div><div style="text-align: center;">
   <span style="color: #000000; font-weight: bold;">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span>
  </div><div>
  </div><div style="text-align: center;">
   <span style="color: #000000; font-weight: bold;">(in thousands, except  per share amounts)</span>
  </div><div>
  </div><div style="text-align: center;">
   <span style="color: #000000; font-weight: bold;">(Unaudited)</span>
  </div><div>



  </div><div>&#160;</div><div>
  </div><div>&#160;</div><table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold;">Three Months Ended</td><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold;">Nine Months Ended</td></tr><tr><td>&#160;</td><td colspan="7" style="font-weight: bold; text-align: center; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td><td>&#160;</td><td colspan="7" style="font-weight: bold; text-align: center; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td></tr><tr><td>&#160;</td><td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Statements of Operations - B4"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Statements of Operations - B4"/><td>&#160;</td><td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Statements of Operations - D4"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Statements of Operations - D4"/><td>&#160;</td><td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Statements of Operations - F4"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Statements of Operations - F4"/><td>&#160;</td><td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Statements of Operations - H4"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Statements of Operations - H4"/></tr><tr><td>Revenue:</td><td style="width: 1%;" title="Statements of Operations - B5"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Operations - B5"/><td>&#160;</td><td style="width: 1%;" title="Statements of Operations - D5"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Operations - D5"/><td>&#160;</td><td style="width: 1%;" title="Statements of Operations - F5"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Operations - F5"/><td>&#160;</td><td style="width: 1%;" title="Statements of Operations - H5"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Operations - H5"/></tr><tr><td style="padding-left: 10px;">Commercial revenue:</td><td style="width: 1%;" title="Statements of Operations - B6"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Operations - B6"/><td>&#160;</td><td style="width: 1%;" title="Statements of Operations - D6"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Operations - D6"/><td>&#160;</td><td style="width: 1%;" title="Statements of Operations - F6"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Operations - F6"/><td>&#160;</td><td style="width: 1%;" title="Statements of Operations - H6"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Operations - H6"/></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 20px;">Product sales, net</td><td style="width: 1%; text-align: left;" title="Statements of Operations - B7">$</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11215">31,792</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Operations - B7">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Operations - D7">$</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11216"> - </ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Operations - D7">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Operations - F7">$</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11217">57,353</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Operations - F7">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Operations - H7">$</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11218"> - </ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Operations - H7">&#160;</td></tr><tr><td style="padding-left: 20px;">Royalty revenue</td><td style="width: 1%; text-align: left;" title="Statements of Operations - B8">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11219">75,694</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Operations - B8">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Operations - D8">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11220">66,807</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Operations - D8">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Operations - F8">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11221">209,811</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Operations - F8">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Operations - H8">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c15" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11222">180,036</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Operations - H8">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 20px;">Other commercial revenue</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - B9">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11223">8,112</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - B9">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - D9">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c17" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11224">8,924</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - D9">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - F9">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c18" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11225">27,359</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - F9">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - H9">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11226">27,324</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - H9">&#160;</td></tr><tr><td style="padding-left: 40px;">Total commercial revenue</td><td style="width: 1%; text-align: left;" title="Statements of Operations - B10">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11227">115,598</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Operations - B10">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Operations - D10">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11228">75,731</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Operations - D10">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Operations - F10">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c22" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11229">294,523</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Operations - F10">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Operations - H10">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c23" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11230">207,360</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Operations - H10">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 10px;">Research and development revenue:</td><td style="width: 1%;" title="Statements of Operations - B11"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Operations - B11"/><td>&#160;</td><td style="width: 1%;" title="Statements of Operations - D11"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Operations - D11"/><td>&#160;</td><td style="width: 1%;" title="Statements of Operations - F11"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Operations - F11"/><td>&#160;</td><td style="width: 1%;" title="Statements of Operations - H11"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Operations - H11"/></tr><tr><td style="padding-left: 20px;">Collaborative agreement revenue</td><td style="width: 1%; text-align: left;" title="Statements of Operations - B12">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c24" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11231">31,436</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Operations - B12">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Operations - D12">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11232">44,883</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Operations - D12">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Operations - F12">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c26" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11233">413,387</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Operations - F12">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Operations - H12">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11234">235,753</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Operations - H12">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 20px;">WAINUA joint development revenue</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - B13">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c28" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11235">9,685</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - B13">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - D13">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c29" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11236">13,200</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - D13">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - F13">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c30" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11237">32,471</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - F13">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - H13">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c31" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11238">35,449</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - H13">&#160;</td></tr><tr><td style="padding-left: 40px;">Total research and development revenue</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - B14">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c32" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11239">41,121</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - B14">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - D14">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c33" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11240">58,083</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - D14">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - F14">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11241">445,858</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - F14">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - H14">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11242">271,202</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - H14">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 20px;">Total revenue</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - B15">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c36" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11243">156,719</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - B15">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - D15">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11244">133,814</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - D15">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - F15">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11245">740,381</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - F15">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - H15">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11246">478,562</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - H15">&#160;</td></tr><tr><td>&#160;</td><td style="width: 1%;" title="Statements of Operations - B16"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Operations - B16"/><td>&#160;</td><td style="width: 1%;" title="Statements of Operations - D16"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Operations - D16"/><td>&#160;</td><td style="width: 1%;" title="Statements of Operations - F16"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Operations - F16"/><td>&#160;</td><td style="width: 1%;" title="Statements of Operations - H16"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Operations - H16"/></tr><tr style="background-color: rgb(204, 238, 255);"><td>Expenses:</td><td style="width: 1%;" title="Statements of Operations - B17"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Operations - B17"/><td>&#160;</td><td style="width: 1%;" title="Statements of Operations - D17"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Operations - D17"/><td>&#160;</td><td style="width: 1%;" title="Statements of Operations - F17"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Operations - F17"/><td>&#160;</td><td style="width: 1%;" title="Statements of Operations - H17"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Operations - H17"/></tr><tr><td style="padding-left: 10px;">Cost of sales</td><td style="width: 1%; text-align: left;" title="Statements of Operations - B18">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c36" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" unitRef="usd" id="ixv-11247">2,338</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Operations - B18">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Operations - D18">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" unitRef="usd" id="ixv-11248">1,071</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Operations - D18">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Operations - F18">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" unitRef="usd" id="ixv-11249">7,952</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Operations - F18">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Operations - H18">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" unitRef="usd" id="ixv-11250">7,385</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Operations - H18">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 10px;">Research, development and patent</td><td style="width: 1%; text-align: left;" title="Statements of Operations - B19">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c36" decimals="-3" format="ixt:num-dot-decimal" name="ions:ResearchDevelopmentAndPatentExpense" scale="3" unitRef="usd" id="ixv-11251">217,754</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Operations - B19">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Operations - D19">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="ions:ResearchDevelopmentAndPatentExpense" scale="3" unitRef="usd" id="ixv-11252">219,761</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Operations - D19">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Operations - F19">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ions:ResearchDevelopmentAndPatentExpense" scale="3" unitRef="usd" id="ixv-11253">635,973</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Operations - F19">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Operations - H19">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="ions:ResearchDevelopmentAndPatentExpense" scale="3" unitRef="usd" id="ixv-11254">656,040</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Operations - H19">&#160;</td></tr><tr><td style="padding-left: 10px;">Selling, general and administrative  </td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - B20">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c36" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-11255">96,809</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - B20">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - D20">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-11256">61,638</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - D20">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - F20">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-11257">263,681</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - F20">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - H20">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-11258">179,395</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - H20">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 20px;">Total operating expenses  </td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - B21">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c36" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="3" unitRef="usd" id="ixv-11259">316,901</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - B21">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - D21">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="3" unitRef="usd" id="ixv-11260">282,470</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - D21">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - F21">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="3" unitRef="usd" id="ixv-11261">907,606</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - F21">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - H21">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="3" unitRef="usd" id="ixv-11262">842,820</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - H21">&#160;</td></tr><tr><td>&#160;</td><td style="width: 1%;" title="Statements of Operations - B22"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Operations - B22"/><td>&#160;</td><td style="width: 1%;" title="Statements of Operations - D22"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Operations - D22"/><td>&#160;</td><td style="width: 1%;" title="Statements of Operations - F22"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Operations - F22"/><td>&#160;</td><td style="width: 1%;" title="Statements of Operations - H22"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Operations - H22"/></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 20px;">Loss from operations</td><td style="width: 1%; text-align: left;" title="Statements of Operations - B23">&#160;</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c36" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-11263">160,182</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Operations - B23">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Operations - D23">&#160;</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-11264">148,656</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Operations - D23">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Operations - F23">&#160;</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-11265">167,225</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Operations - F23">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Operations - H23">&#160;</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-11266">364,258</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Operations - H23">)&#160;</td></tr><tr><td>&#160;</td><td style="width: 1%;" title="Statements of Operations - B24"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Operations - B24"/><td>&#160;</td><td style="width: 1%;" title="Statements of Operations - D24"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Operations - D24"/><td>&#160;</td><td style="width: 1%;" title="Statements of Operations - F24"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Operations - F24"/><td>&#160;</td><td style="width: 1%;" title="Statements of Operations - H24"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Operations - H24"/></tr><tr style="background-color: rgb(204, 238, 255);"><td>Other income (expense):</td><td style="width: 1%;" title="Statements of Operations - B25"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Operations - B25"/><td>&#160;</td><td style="width: 1%;" title="Statements of Operations - D25"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Operations - D25"/><td>&#160;</td><td style="width: 1%;" title="Statements of Operations - F25"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Operations - F25"/><td>&#160;</td><td style="width: 1%;" title="Statements of Operations - H25"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Operations - H25"/></tr><tr><td style="padding-left: 10px;">Investment income  </td><td style="width: 1%; text-align: left;" title="Statements of Operations - B26">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c36" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeNet" scale="3" unitRef="usd" id="ixv-11267">23,682</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Operations - B26">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Operations - D26">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeNet" scale="3" unitRef="usd" id="ixv-11268">26,228</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Operations - D26">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Operations - F26">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeNet" scale="3" unitRef="usd" id="ixv-11269">73,035</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Operations - F26">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Operations - H26">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeNet" scale="3" unitRef="usd" id="ixv-11270">78,112</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Operations - H26">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 10px;">Interest expense  </td><td style="width: 1%; text-align: left;" title="Statements of Operations - B27">&#160;</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c36" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="3" unitRef="usd" id="ixv-11271">4,212</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Operations - B27">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Operations - D27">&#160;</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="3" unitRef="usd" id="ixv-11272">4,161</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Operations - D27">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Operations - F27">&#160;</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="3" unitRef="usd" id="ixv-11273">12,434</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Operations - F27">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Operations - H27">&#160;</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="3" unitRef="usd" id="ixv-11274">12,803</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Operations - H27">)&#160;</td></tr><tr><td style="padding-left: 10px;">Interest expense related to sale of future royalties</td><td style="width: 1%; text-align: left;" title="Statements of Operations - B28">&#160;</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c36" decimals="-3" format="ixt:num-dot-decimal" name="ions:InterestExpenseAndAmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties" scale="3" unitRef="usd" id="ixv-11275">17,952</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Operations - B28">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Operations - D28">&#160;</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="ions:InterestExpenseAndAmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties" scale="3" unitRef="usd" id="ixv-11276">18,533</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Operations - D28">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Operations - F28">&#160;</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ions:InterestExpenseAndAmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties" scale="3" unitRef="usd" id="ixv-11277">55,422</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Operations - F28">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Operations - H28">&#160;</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="ions:InterestExpenseAndAmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties" scale="3" unitRef="usd" id="ixv-11278">54,788</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Operations - H28">)&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 10px;">Gain (loss) on investments, net</td><td style="width: 1%; text-align: left;" title="Statements of Operations - B29">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c36" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnInvestments" scale="3" unitRef="usd" id="ixv-11279">29,908</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Operations - B29">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Operations - D29">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnInvestments" scale="3" unitRef="usd" id="ixv-11280">879</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Operations - D29">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Operations - F29">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnInvestments" scale="3" unitRef="usd" id="ixv-11281">9,432</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Operations - F29">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Operations - H29">&#160;</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnInvestments" scale="3" sign="-" unitRef="usd" id="ixv-11282">321</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Operations - H29">)&#160;</td></tr><tr><td style="padding-left: 10px;">Other income, net</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - B30">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c36" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" unitRef="usd" id="ixv-11283">363</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - B30">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - D30">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" unitRef="usd" id="ixv-11284">142</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - D30">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - F30">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" unitRef="usd" id="ixv-11285">929</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - F30">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - H30">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" unitRef="usd" id="ixv-11286">1,029</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - H30">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>&#160;</td><td style="width: 1%;" title="Statements of Operations - B31"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Operations - B31"/><td>&#160;</td><td style="width: 1%;" title="Statements of Operations - D31"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Operations - D31"/><td>&#160;</td><td style="width: 1%;" title="Statements of Operations - F31"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Operations - F31"/><td>&#160;</td><td style="width: 1%;" title="Statements of Operations - H31"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Operations - H31"/></tr><tr><td>Loss before income tax benefit (expense)</td><td style="width: 1%; text-align: left;" title="Statements of Operations - B32">&#160;</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c36" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-11287">128,393</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Operations - B32">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Operations - D32">&#160;</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-11288">144,101</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Operations - D32">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Operations - F32">&#160;</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-11289">151,685</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Operations - F32">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Operations - H32">&#160;</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-11290">353,029</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Operations - H32">)&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>&#160;</td><td style="width: 1%;" title="Statements of Operations - B33"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Operations - B33"/><td>&#160;</td><td style="width: 1%;" title="Statements of Operations - D33"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Operations - D33"/><td>&#160;</td><td style="width: 1%;" title="Statements of Operations - F33"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Operations - F33"/><td>&#160;</td><td style="width: 1%;" title="Statements of Operations - H33"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Operations - H33"/></tr><tr><td>Income tax benefit (expense)</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - B34">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">(<ix:nonFraction contextRef="c36" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" unitRef="usd" id="ixv-11291">213</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - B34">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - D34">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" sign="-" unitRef="usd" id="ixv-11292">3,621</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - D34">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - F34">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" unitRef="usd" id="ixv-11293">308</ix:nonFraction></td><td style="width: 1%; text-align: left; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none;" title="Statements of Operations - F34">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - H34">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" sign="-" unitRef="usd" id="ixv-11294">3,481</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - H34">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>&#160;</td><td style="width: 1%;" title="Statements of Operations - B35"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Operations - B35"/><td>&#160;</td><td style="width: 1%;" title="Statements of Operations - D35"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Operations - D35"/><td>&#160;</td><td style="width: 1%;" title="Statements of Operations - F35"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Operations - F35"/><td>&#160;</td><td style="width: 1%;" title="Statements of Operations - H35"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Operations - H35"/></tr><tr><td>Net loss</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - B36">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">(<ix:nonFraction contextRef="c36" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-11295">128,606</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - B36">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - D36">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">(<ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-11296">140,480</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - D36">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - F36">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-11297">151,993</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - F36">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - H36">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">(<ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-11298">349,548</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - H36">)&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>&#160;</td><td style="width: 1%;" title="Statements of Operations - B37"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Operations - B37"/><td>&#160;</td><td style="width: 1%;" title="Statements of Operations - D37"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Operations - D37"/><td>&#160;</td><td style="width: 1%;" title="Statements of Operations - F37"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Operations - F37"/><td>&#160;</td><td style="width: 1%;" title="Statements of Operations - H37"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Operations - H37"/></tr><tr><td>Basic and diluted net loss per share</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - B39">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">(<ix:nonFraction contextRef="c36" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-11299"><ix:nonFraction contextRef="c36" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-11300">0.80</ix:nonFraction></ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - B39">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - D39">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">(<ix:nonFraction contextRef="c37" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-11301"><ix:nonFraction contextRef="c37" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-11302">0.95</ix:nonFraction></ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - D39">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - F39">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-11303"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-11304">0.95</ix:nonFraction></ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - F39">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - H39">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">(<ix:nonFraction contextRef="c38" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-11305"><ix:nonFraction contextRef="c38" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-11306">2.38</ix:nonFraction></ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - H39">)&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Shares used in computing basic and diluted net loss per share</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - B39">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c36" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" unitRef="shares" id="ixv-11307"><ix:nonFraction contextRef="c36" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" unitRef="shares" id="ixv-11308">159,765</ix:nonFraction></ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - B39">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - D39">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" unitRef="shares" id="ixv-11309"><ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" unitRef="shares" id="ixv-11310">148,593</ix:nonFraction></ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - D39">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - F39">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" unitRef="shares" id="ixv-11311"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" unitRef="shares" id="ixv-11312">159,216</ix:nonFraction></ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - F39">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - H39">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" unitRef="shares" id="ixv-11313"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" unitRef="shares" id="ixv-11314">146,703</ix:nonFraction></ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Operations - H39">&#160;</td></tr></table><div style="text-align: center;">&#160;</div><div>
  </div><div style="text-align: center;"><span style="color: #000000;">See accompanying notes.</span>
  </div><div>&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 10px; margin-top: 0px; margin-bottom: 0px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">4</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-align: center;">
   <a id="Comprehensive_Income" title="Comprehensive Income"></a><span style="color: #000000; font-weight: bold;">IONIS PHARMACEUTICALS, INC.</span>
  </div><div>
  </div><div style="text-align: center;">
   <span style="color: #000000; font-weight: bold;">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div>
  </div><div style="text-align: center;">
   <span style="color: #000000; font-weight: bold;">(in thousands)</span>
  </div><div>
  </div><div style="text-align: center;">
   <span style="color: #000000; font-weight: bold;">(Unaudited)</span>
  </div><div>
  </div><div>&#160;
  </div><div>

  </div><table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold;">Three Months Ended</td><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold;">Nine Months Ended</td></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td></tr><tr><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Statements of Comprehensive Loss - B4"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Comprehensive Loss - B4"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Statements of Comprehensive Loss - D4"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Comprehensive Loss - D4"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Statements of Comprehensive Loss - F4"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Comprehensive Loss - F4"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Statements of Comprehensive Loss - H4"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Comprehensive Loss - H4"/></tr><tr style="background-color: rgb(204, 238, 255);"><td>Net loss</td><td style="width: 1%; text-align: left;" title="Statements of Comprehensive Loss - B5">$</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c36" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-11315">128,606</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Comprehensive Loss - B5">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Comprehensive Loss - D5">$</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-11316">140,480</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Comprehensive Loss - D5">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Comprehensive Loss - F5">$</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-11317">151,993</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Comprehensive Loss - F5">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Comprehensive Loss - H5">$</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-11318">349,548</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Comprehensive Loss - H5">)&#160;</td></tr><tr><td style="padding-left: 20px;">Unrealized gains on debt securities, net of tax</td><td style="width: 1%; text-align: left;" title="Statements of Comprehensive Loss - B6">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c36" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" unitRef="usd" id="ixv-11319">2,091</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Comprehensive Loss - B6">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Comprehensive Loss - D6">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" unitRef="usd" id="ixv-11320">10,315</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Comprehensive Loss - D6">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Comprehensive Loss - F6">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" unitRef="usd" id="ixv-11321">4,088</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Comprehensive Loss - F6">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Comprehensive Loss - H6">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" unitRef="usd" id="ixv-11322">8,259</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Comprehensive Loss - H6">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 20px;">Currency translation adjustment</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Comprehensive Loss - B7">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">(<ix:nonFraction contextRef="c36" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" sign="-" unitRef="usd" id="ixv-11323">82</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Comprehensive Loss - B7">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Comprehensive Loss - D7">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" unitRef="usd" id="ixv-11324">350</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Comprehensive Loss - D7">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Comprehensive Loss - F7">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" unitRef="usd" id="ixv-11325">745</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Comprehensive Loss - F7">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Comprehensive Loss - H7">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" unitRef="usd" id="ixv-11326">213</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Comprehensive Loss - H7">&#160;</td></tr><tr><td>Comprehensive loss</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Comprehensive Loss - B8">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">(<ix:nonFraction contextRef="c36" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" sign="-" unitRef="usd" id="ixv-11327">126,597</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Comprehensive Loss - B8">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Comprehensive Loss - D8">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">(<ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" sign="-" unitRef="usd" id="ixv-11328">129,815</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Comprehensive Loss - D8">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Comprehensive Loss - F8">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" sign="-" unitRef="usd" id="ixv-11329">147,160</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Comprehensive Loss - F8">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Comprehensive Loss - H8">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">(<ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" sign="-" unitRef="usd" id="ixv-11330">341,076</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Comprehensive Loss - H8">)&#160;</td></tr></table><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-align: center;">
   <span style="color: #000000;">See accompanying notes.</span>
  </div><div>
  </div><div style="text-align: center;">&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 10px; margin-top: 0px; margin-bottom: 0px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">5</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-align: center;">
   <a id="Equity_Statement" title="Equity Statement"></a><span style="color: #000000; font-weight: bold;">IONIS PHARMACEUTICALS, INC.</span>
  </div><div>
  </div><div style="text-align: center;">
   <span style="color: #000000; font-weight: bold;">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS</span><span style="color: #000000;">&#8217;</span><span style="color: #000000; font-weight: bold;"> EQUITY</span>
  </div><div>
  </div><div style="text-align: center;">
   <span style="color: #000000; font-weight: bold;">(in thousands)</span>
  </div><div>
  </div><div style="text-align: center;">
   <span style="color: #000000; font-weight: bold;">(Unaudited)</span>
  </div><div>
  </div><div>&#160;
  </div><div>


  </div><table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/></tr><tr><td style="vertical-align: bottom; text-align: center; font-weight: bold;">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold;">&#160;</td><td colspan="7" style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom; text-align: center; font-weight: bold;">Common Stock</td><td style="vertical-align: bottom; text-align: center; font-weight: bold;">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; width: 1%;" title="Statements of Equity - G3"/><td style="vertical-align: bottom; text-align: center; font-weight: bold; width: 9%;">Additional</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; width: 1%;" title="Statements of Equity - G3"/><td style="vertical-align: bottom; text-align: center; font-weight: bold;">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; width: 1%;" title="Statements of Equity - I3"/><td style="vertical-align: bottom; text-align: center; font-weight: bold; width: 9%;">Accumulated Other</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; width: 1%;" title="Statements of Equity - I3"/><td style="vertical-align: bottom; text-align: center; font-weight: bold;">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; width: 1%;" title="Statements of Equity - K3"/><td style="vertical-align: bottom; text-align: center; font-weight: bold; width: 9%;">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; width: 1%;" title="Statements of Equity - K3"/><td style="vertical-align: bottom; text-align: center; font-weight: bold;">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; width: 1%;" title="Statements of Equity - M3"/><td style="vertical-align: bottom; text-align: center; font-weight: bold; width: 9%;">Total</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; width: 1%;" title="Statements of Equity - M3"/></tr><tr><td style="font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; text-align: left; vertical-align: bottom;">Description</td><td style="text-align: center; font-weight: bold; vertical-align: bottom;">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Statements of Equity - C4"/><td style="text-align: center; font-weight: bold; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">Shares</td><td style="text-align: center; font-weight: bold; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Statements of Equity - C4"/><td style="text-align: center; font-weight: bold; vertical-align: bottom;">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Statements of Equity - E4"/><td style="text-align: center; font-weight: bold; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">Amount</td><td style="text-align: center; font-weight: bold; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Statements of Equity - E4"/><td style="text-align: center; font-weight: bold; vertical-align: bottom;">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Statements of Equity - G4"/><td style="text-align: center; font-weight: bold; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">Paid in Capital</td><td style="text-align: center; font-weight: bold; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Statements of Equity - G4"/><td style="text-align: center; font-weight: bold; vertical-align: bottom;">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Statements of Equity - I4"/><td style="text-align: center; font-weight: bold; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">Comprehensive Loss</td><td style="text-align: center; font-weight: bold; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Statements of Equity - I4"/><td style="text-align: center; font-weight: bold; vertical-align: bottom;">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Statements of Equity - K4"/><td style="text-align: center; font-weight: bold; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">Accumulated Deficit</td><td style="text-align: center; font-weight: bold; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Statements of Equity - K4"/><td style="text-align: center; font-weight: bold; vertical-align: bottom;">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Statements of Equity - M4"/><td style="text-align: center; font-weight: bold; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">Stockholders' Equity</td><td style="text-align: center; font-weight: bold; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Statements of Equity - M4"/></tr><tr style="background-color: rgb(204, 238, 255);"><td style="font-weight: bold;">Balance at June 30, 2024</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Equity - C5">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c39" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="3" unitRef="shares" id="ixv-11331">146,025</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Equity - C5">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Equity - E5">$</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c39" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-11332">146</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Equity - E5">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Equity - G5">$</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c40" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-11333">2,303,369</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Equity - G5">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Equity - I5">$</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c41" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-11334">34,838</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Equity - I5">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Equity - K5">$</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c42" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-11335">2,004,979</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Equity - K5">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Equity - M5">$</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c43" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-11336">263,698</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Equity - M5">&#160;</td></tr><tr><td>Net loss</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Equity - C6">&#160;</td><td style="width: 9%; text-align: right;"> -   </td><td style="width: 1%; text-align: left;" title="Statements of Equity - C6">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Equity - E6">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c44" decimals="-3" format="ixt:fixed-zero" name="us-gaap:NetIncomeLoss" scale="3" unitRef="usd" id="ixv-11337"> - </ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Equity - E6">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Equity - G6">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c45" decimals="-3" format="ixt:fixed-zero" name="us-gaap:NetIncomeLoss" scale="3" unitRef="usd" id="ixv-11338"> - </ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Equity - G6">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Equity - I6">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c46" decimals="-3" format="ixt:fixed-zero" name="us-gaap:NetIncomeLoss" scale="3" unitRef="usd" id="ixv-11339"> - </ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Equity - I6">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Equity - K6">&#160;</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c47" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-11340">140,480</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Equity - K6">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Equity - M6">&#160;</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-11341">140,480</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Equity - M6">)&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Change in unrealized gains, net of tax</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Equity - C7">&#160;</td><td style="width: 9%; text-align: right;"> -   </td><td style="width: 1%; text-align: left;" title="Statements of Equity - C7">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Equity - E7">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c44" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" unitRef="usd" id="ixv-11342"> - </ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Equity - E7">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Equity - G7">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c45" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" unitRef="usd" id="ixv-11343"> - </ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Equity - G7">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Equity - I7">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c46" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" unitRef="usd" id="ixv-11344">10,315</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Equity - I7">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Equity - K7">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c47" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" unitRef="usd" id="ixv-11345"> - </ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Equity - K7">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Equity - M7">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" unitRef="usd" id="ixv-11346">10,315</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Equity - M7">&#160;</td></tr><tr><td>Foreign currency translation</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Equity - C8">&#160;</td><td style="width: 9%; text-align: right;"> -   </td><td style="width: 1%; text-align: left;" title="Statements of Equity - C8">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Equity - E8">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c44" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" unitRef="usd" id="ixv-11347"> - </ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Equity - E8">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Equity - G8">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c45" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" unitRef="usd" id="ixv-11348"> - </ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Equity - G8">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Equity - I8">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c46" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" unitRef="usd" id="ixv-11349">350</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Equity - I8">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Equity - K8">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c47" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" unitRef="usd" id="ixv-11350"> - </ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Equity - K8">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Equity - M8">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" unitRef="usd" id="ixv-11351">350</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Equity - M8">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Issuance of common stock in connection with employee stock plans, net</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Equity - C9">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c44" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" unitRef="shares" id="ixv-11352">288</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Equity - C9">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Equity - E9">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c44" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" scale="3" unitRef="usd" id="ixv-11353"> - </ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Equity - E9">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Equity - G9">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c45" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" scale="3" unitRef="usd" id="ixv-11354">7,002</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Equity - G9">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Equity - I9">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c46" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" scale="3" unitRef="usd" id="ixv-11355"> - </ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Equity - I9">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Equity - K9">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c47" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" scale="3" unitRef="usd" id="ixv-11356"> - </ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Equity - K9">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Equity - M9">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" scale="3" unitRef="usd" id="ixv-11357">7,002</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Equity - M9">&#160;</td></tr><tr><td>Issuance of public common stock, net</td><td>&#160;</td><td style="width: 1%; text-align: left; border-width: initial; border-style: none; border-color: initial;" title="Statements of Equity - C10">&#160;</td><td style="width: 9%; text-align: right; border-width: initial; border-style: none; border-color: initial;"><ix:nonFraction contextRef="c44" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" unitRef="shares" id="ixv-11358">11,500</ix:nonFraction></td><td style="width: 1%; text-align: left; border-width: initial; border-style: none; border-color: initial;" title="Statements of Equity - C10">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-width: initial; border-style: none; border-color: initial;" title="Statements of Equity - E10">&#160;</td><td style="width: 9%; text-align: right; border-width: initial; border-style: none; border-color: initial;"><ix:nonFraction contextRef="c44" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-11359">12</ix:nonFraction></td><td style="width: 1%; text-align: left; border-width: initial; border-style: none; border-color: initial;" title="Statements of Equity - E10">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-width: initial; border-style: none; border-color: initial;" title="Statements of Equity - G10">&#160;</td><td style="width: 9%; text-align: right; border-width: initial; border-style: none; border-color: initial;"><ix:nonFraction contextRef="c45" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-11360">489,081</ix:nonFraction></td><td style="width: 1%; text-align: left; border-width: initial; border-style: none; border-color: initial;" title="Statements of Equity - G10">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-width: initial; border-style: none; border-color: initial;" title="Statements of Equity - I10">&#160;</td><td style="width: 9%; text-align: right; border-width: initial; border-style: none; border-color: initial;"><ix:nonFraction contextRef="c46" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-11361"> - </ix:nonFraction></td><td style="width: 1%; text-align: left; border-width: initial; border-style: none; border-color: initial;" title="Statements of Equity - I10">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-width: initial; border-style: none; border-color: initial;" title="Statements of Equity - K10">&#160;</td><td style="width: 9%; text-align: right; border-width: initial; border-style: none; border-color: initial;"><ix:nonFraction contextRef="c47" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-11362"> - </ix:nonFraction></td><td style="width: 1%; text-align: left; border-width: initial; border-style: none; border-color: initial;" title="Statements of Equity - K10">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-width: initial; border-style: none; border-color: initial;" title="Statements of Equity - M10">&#160;</td><td style="width: 9%; text-align: right; border-width: initial; border-style: none; border-color: initial;"><ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-11363">489,093</ix:nonFraction></td><td style="width: 1%; text-align: left; border-width: initial; border-style: none; border-color: initial;" title="Statements of Equity - M10">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Stock-based compensation expense</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Equity - C10">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"> -   </td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Equity - C10">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Equity - E10">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c44" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-11364"> - </ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Equity - E10">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Equity - G10">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c45" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-11365">32,490</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Equity - G10">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Equity - I10">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c46" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-11366"> - </ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Equity - I10">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Equity - K10">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c47" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-11367"> - </ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Equity - K10">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Equity - M10">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-11368">32,490</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Equity - M10">&#160;</td></tr><tr><td style="font-weight: bold;">Balance at September 30, 2024</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Equity - C11">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c48" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="3" unitRef="shares" id="ixv-11369">157,813</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Equity - C11">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Equity - E11">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c48" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-11370">158</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Equity - E11">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Equity - G11">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c49" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-11371">2,831,942</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Equity - G11">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Equity - I11">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">(<ix:nonFraction contextRef="c50" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-11372">24,173</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Equity - I11">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Equity - K11">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">(<ix:nonFraction contextRef="c51" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-11373">2,145,459</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Equity - K11">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Equity - M11">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c52" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-11374">662,468</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Equity - M11">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>&#160;</td><td>&#160;</td><td style="width: 1%;" title="Statements of Equity - C12"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Equity - C12"/><td>&#160;</td><td style="width: 1%;" title="Statements of Equity - E12"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Equity - E12"/><td>&#160;</td><td style="width: 1%;" title="Statements of Equity - G12"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Equity - G12"/><td>&#160;</td><td style="width: 1%;" title="Statements of Equity - I12"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Equity - I12"/><td>&#160;</td><td style="width: 1%;" title="Statements of Equity - K12"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Equity - K12"/><td>&#160;</td><td style="width: 1%;" title="Statements of Equity - M12"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Equity - M12"/></tr><tr><td style="font-weight: bold;">Balance at June 30, 2025</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Equity - C13">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c53" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="3" unitRef="shares" id="ixv-11375">159,197</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Equity - C13">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Equity - E13">$</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c53" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-11376">159</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Equity - E13">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Equity - G13">$</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c54" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-11377">2,932,747</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Equity - G13">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Equity - I13">$</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c55" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-11378">27,987</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Equity - I13">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Equity - K13">$</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c56" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-11379">2,273,195</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Equity - K13">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Equity - M13">$</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c57" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-11380">631,724</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Equity - M13">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Net loss</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Equity - C14">&#160;</td><td style="width: 9%; text-align: right;"> -   </td><td style="width: 1%; text-align: left;" title="Statements of Equity - C14">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Equity - E14">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c58" decimals="-3" format="ixt:fixed-zero" name="us-gaap:NetIncomeLoss" scale="3" unitRef="usd" id="ixv-11381"> - </ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Equity - E14">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Equity - G14">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c59" decimals="-3" format="ixt:fixed-zero" name="us-gaap:NetIncomeLoss" scale="3" unitRef="usd" id="ixv-11382"> - </ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Equity - G14">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Equity - I14">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c60" decimals="-3" format="ixt:fixed-zero" name="us-gaap:NetIncomeLoss" scale="3" unitRef="usd" id="ixv-11383"> - </ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Equity - I14">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Equity - K14">&#160;</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c61" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-11384">128,606</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Equity - K14">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Equity - M14">&#160;</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c36" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-11385">128,606</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Equity - M14">)&#160;</td></tr><tr><td>Change in unrealized gains, net of tax</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Equity - C15">&#160;</td><td style="width: 9%; text-align: right;"> -   </td><td style="width: 1%; text-align: left;" title="Statements of Equity - C15">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Equity - E15">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c58" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" unitRef="usd" id="ixv-11386"> - </ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Equity - E15">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Equity - G15">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c59" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" unitRef="usd" id="ixv-11387"> - </ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Equity - G15">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Equity - I15">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c60" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" unitRef="usd" id="ixv-11388">2,091</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Equity - I15">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Equity - K15">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c61" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" unitRef="usd" id="ixv-11389"> - </ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Equity - K15">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Equity - M15">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c36" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" unitRef="usd" id="ixv-11390">2,091</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Equity - M15">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Foreign currency translation</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Equity - C16">&#160;</td><td style="width: 9%; text-align: right;"> -   </td><td style="width: 1%; text-align: left;" title="Statements of Equity - C16">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Equity - E16">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c58" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" unitRef="usd" id="ixv-11391"> - </ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Equity - E16">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Equity - G16">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c59" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" unitRef="usd" id="ixv-11392"> - </ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Equity - G16">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Equity - I16">&#160;</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c60" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" sign="-" unitRef="usd" id="ixv-11393">82</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Equity - I16">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Equity - K16">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c61" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" unitRef="usd" id="ixv-11394"> - </ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Equity - K16">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Equity - M16">&#160;</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c36" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" sign="-" unitRef="usd" id="ixv-11395">82</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Equity - M16">)&#160;</td></tr><tr><td>Issuance of common stock in connection with employee stock plans, net</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Equity - C17">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c58" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" unitRef="shares" id="ixv-11396">1,941</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Equity - C17">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Equity - E17">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c58" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" scale="3" unitRef="usd" id="ixv-11397">2</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Equity - E17">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Equity - G17">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c59" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" scale="3" unitRef="usd" id="ixv-11398">81,257</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Equity - G17">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Equity - I17">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c60" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" scale="3" unitRef="usd" id="ixv-11399"> - </ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Equity - I17">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Equity - K17">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c61" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" scale="3" unitRef="usd" id="ixv-11400"> - </ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Equity - K17">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Equity - M17">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c36" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" scale="3" unitRef="usd" id="ixv-11401">81,259</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Equity - M17">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Stock-based compensation expense</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Equity - C18">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"> -   </td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Equity - C18">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Equity - E18">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c58" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-11402"> - </ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Equity - E18">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Equity - G18">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c59" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-11403">31,581</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Equity - G18">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Equity - I18">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c60" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-11404"> - </ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Equity - I18">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Equity - K18">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c61" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-11405"> - </ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Equity - K18">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Equity - M18">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c36" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-11406">31,581</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Equity - M18">&#160;</td></tr><tr><td style="font-weight: bold;">Balance at September 30, 2025</td><td style="border-width: initial; border-style: none; border-color: initial;">&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Equity - C19">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c62" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="3" unitRef="shares" id="ixv-11407">161,138</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Equity - C19">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Equity - E19">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c62" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-11408">161</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Equity - E19">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Equity - G19">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c63" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-11409">3,045,585</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Equity - G19">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Equity - I19">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">(<ix:nonFraction contextRef="c64" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-11410">25,978</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Equity - I19">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Equity - K19">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">(<ix:nonFraction contextRef="c65" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-11411">2,401,801</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Equity - K19">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Equity - M19">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-11412">617,967</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Equity - M19">&#160;</td></tr></table><div>&#160;
  </div><div>
  </div><div style="text-align: center;">
   <span>See accompanying notes.</span>
  </div><div>
  </div><div>&#160;</div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 10px; margin-top: 0px; margin-bottom: 0px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">6</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-align: center;"><span style="font-weight: 700; letter-spacing: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">IONIS PHARMACEUTICALS, INC.</span></div><div style="text-align: center;"><span style="letter-spacing: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-weight: bold;">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS</span><span style="letter-spacing: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;">&#8217;</span><span style="letter-spacing: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-weight: bold;">&#160;EQUITY</span></div><div style="text-align: center;"><span style="font-weight: 700; letter-spacing: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">(in thousands)</span></div><div style="text-align: center;"><span style="font-weight: 700; letter-spacing: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">(Unaudited)</span></div><div>&#160;</div><table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/></tr><tr><td style="text-align: center; font-weight: bold; vertical-align: bottom;">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom;">&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">Common Stock</td><td style="text-align: center; font-weight: bold; vertical-align: bottom;">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom; width: 1%;" title="Statements of Equity - G23"/><td style="text-align: center; font-weight: bold; vertical-align: bottom; width: 9%;">Additional</td><td style="text-align: center; font-weight: bold; vertical-align: bottom; width: 1%;" title="Statements of Equity - G23"/><td style="text-align: center; font-weight: bold; vertical-align: bottom;">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom; width: 1%;" title="Statements of Equity - I23"/><td style="text-align: center; font-weight: bold; vertical-align: bottom; width: 9%;">Accumulated Other</td><td style="text-align: center; font-weight: bold; vertical-align: bottom; width: 1%;" title="Statements of Equity - I23"/><td style="text-align: center; font-weight: bold; vertical-align: bottom;">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom; width: 1%;" title="Statements of Equity - K23"/><td style="text-align: center; font-weight: bold; vertical-align: bottom; width: 9%;">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom; width: 1%;" title="Statements of Equity - K23"/><td style="text-align: center; font-weight: bold; vertical-align: bottom;">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom; width: 1%;" title="Statements of Equity - M23"/><td style="text-align: center; font-weight: bold; vertical-align: bottom; width: 9%;">Total</td><td style="text-align: center; font-weight: bold; vertical-align: bottom; width: 1%;" title="Statements of Equity - M23"/></tr><tr><td style="font-weight: bold; vertical-align: bottom; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">Description</td><td style="font-weight: bold; text-align: center; vertical-align: bottom;">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Statements of Equity - C24"/><td style="font-weight: bold; text-align: center; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">Shares</td><td style="font-weight: bold; text-align: center; vertical-align: bottom; border-left: none; border-right: none; border-bottom: 1px solid black; border-top: none; width: 1%;" title="Statements of Equity - C24"/><td style="font-weight: bold; text-align: center; vertical-align: bottom;">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Statements of Equity - E24"/><td style="font-weight: bold; text-align: center; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">Amount</td><td style="font-weight: bold; text-align: center; vertical-align: bottom; border-top: none; border-left: none; border-right: none; border-bottom: 1px solid black; width: 1%;" title="Statements of Equity - E24"/><td style="font-weight: bold; text-align: center; vertical-align: bottom;">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Statements of Equity - G24"/><td style="font-weight: bold; text-align: center; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">Paid in Capital</td><td style="font-weight: bold; text-align: center; vertical-align: bottom; border-left: none; border-right: none; border-bottom: 1px solid black; border-top: none; width: 1%;" title="Statements of Equity - G24"/><td style="font-weight: bold; text-align: center; vertical-align: bottom;">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Statements of Equity - I24"/><td style="font-weight: bold; text-align: center; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">Comprehensive Loss</td><td style="font-weight: bold; text-align: center; vertical-align: bottom; border-left: none; border-right: none; border-bottom: 1px solid black; border-top: none; width: 1%;" title="Statements of Equity - I24"/><td style="font-weight: bold; text-align: center; vertical-align: bottom;">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Statements of Equity - K24"/><td style="font-weight: bold; text-align: center; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">Accumulated Deficit</td><td style="font-weight: bold; text-align: center; vertical-align: bottom; border-left: none; border-right: none; border-bottom: 1px solid black; border-top: none; width: 1%;" title="Statements of Equity - K24"/><td style="font-weight: bold; text-align: center; vertical-align: bottom;">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Statements of Equity - M24"/><td style="font-weight: bold; text-align: center; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">Stockholders' Equity</td><td style="font-weight: bold; text-align: center; vertical-align: bottom; border-left: none; border-right: none; border-bottom: 1px solid black; border-top: none; width: 1%;" title="Statements of Equity - M24"/></tr><tr style="background-color: rgb(204, 238, 255);"><td style="font-weight: bold;">Balance at December 31, 2023</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Statements of Equity - C25">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c66" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="3" unitRef="shares" id="ixv-11413">144,341</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Statements of Equity - C25">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Statements of Equity - E25">$</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c66" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-11414">144</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Statements of Equity - E25">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Statements of Equity - G25">$</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c67" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-11415">2,215,098</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Statements of Equity - G25">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Statements of Equity - I25">$</td><td style="text-align: right; width: 9%;">(<ix:nonFraction contextRef="c68" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-11416">32,645</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Statements of Equity - I25">)&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Statements of Equity - K25">$</td><td style="text-align: right; width: 9%;">(<ix:nonFraction contextRef="c69" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-11417">1,795,911</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Statements of Equity - K25">)&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Statements of Equity - M25">$</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c70" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-11418">386,686</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Statements of Equity - M25">&#160;</td></tr><tr><td>Net loss</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Statements of Equity - C26">&#160;</td><td style="text-align: right; width: 9%;"> -   </td><td style="text-align: left; width: 1%;" title="Statements of Equity - C26">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Statements of Equity - E26">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c71" decimals="-3" format="ixt:fixed-zero" name="us-gaap:NetIncomeLoss" scale="3" unitRef="usd" id="ixv-11419"> - </ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Statements of Equity - E26">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Statements of Equity - G26">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c72" decimals="-3" format="ixt:fixed-zero" name="us-gaap:NetIncomeLoss" scale="3" unitRef="usd" id="ixv-11420"> - </ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Statements of Equity - G26">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Statements of Equity - I26">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c73" decimals="-3" format="ixt:fixed-zero" name="us-gaap:NetIncomeLoss" scale="3" unitRef="usd" id="ixv-11421"> - </ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Statements of Equity - I26">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Statements of Equity - K26">&#160;</td><td style="text-align: right; width: 9%;">(<ix:nonFraction contextRef="c74" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-11422">349,548</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Statements of Equity - K26">)&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Statements of Equity - M26">&#160;</td><td style="text-align: right; width: 9%;">(<ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-11423">349,548</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Statements of Equity - M26">)&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Change in unrealized gains, net of tax</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Statements of Equity - C27">&#160;</td><td style="text-align: right; width: 9%;"> -   </td><td style="text-align: left; width: 1%;" title="Statements of Equity - C27">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Statements of Equity - E27">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c71" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" unitRef="usd" id="ixv-11424"> - </ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Statements of Equity - E27">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Statements of Equity - G27">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c72" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" unitRef="usd" id="ixv-11425"> - </ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Statements of Equity - G27">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Statements of Equity - I27">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c73" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" unitRef="usd" id="ixv-11426">8,259</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Statements of Equity - I27">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Statements of Equity - K27">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c74" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" unitRef="usd" id="ixv-11427"> - </ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Statements of Equity - K27">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Statements of Equity - M27">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" unitRef="usd" id="ixv-11428">8,259</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Statements of Equity - M27">&#160;</td></tr><tr><td>Foreign currency translation</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Statements of Equity - C28">&#160;</td><td style="text-align: right; width: 9%;"> -   </td><td style="text-align: left; width: 1%;" title="Statements of Equity - C28">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Statements of Equity - E28">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c71" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" unitRef="usd" id="ixv-11429"> - </ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Statements of Equity - E28">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Statements of Equity - G28">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c72" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" unitRef="usd" id="ixv-11430"> - </ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Statements of Equity - G28">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Statements of Equity - I28">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c73" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" unitRef="usd" id="ixv-11431">213</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Statements of Equity - I28">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Statements of Equity - K28">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c74" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" unitRef="usd" id="ixv-11432"> - </ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Statements of Equity - K28">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Statements of Equity - M28">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" unitRef="usd" id="ixv-11433">213</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Statements of Equity - M28">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Issuance of common stock in connection with employee stock plans, net</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Statements of Equity - C29">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c71" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" unitRef="shares" id="ixv-11434">1,972</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Statements of Equity - C29">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Statements of Equity - E29">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c71" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" scale="3" unitRef="usd" id="ixv-11435">2</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Statements of Equity - E29">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Statements of Equity - G29">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c72" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" scale="3" unitRef="usd" id="ixv-11436">33,205</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Statements of Equity - G29">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Statements of Equity - I29">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c73" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" scale="3" unitRef="usd" id="ixv-11437"> - </ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Statements of Equity - I29">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Statements of Equity - K29">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c74" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" scale="3" unitRef="usd" id="ixv-11438"> - </ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Statements of Equity - K29">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Statements of Equity - M29">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" scale="3" unitRef="usd" id="ixv-11439">33,207</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Statements of Equity - M29">&#160;</td></tr><tr><td>Issuance of public common stock, net</td><td>&#160;</td><td style="text-align: left; border-width: initial; border-style: none; border-color: initial; width: 1%;" title="Statements of Equity - C30">&#160;</td><td style="text-align: right; border-width: initial; border-style: none; border-color: initial; width: 9%;"><ix:nonFraction contextRef="c71" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" unitRef="shares" id="ixv-11440">11,500</ix:nonFraction></td><td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;" title="Statements of Equity - C30">&#160;</td><td>&#160;</td><td style="text-align: left; border-width: initial; border-style: none; border-color: initial; width: 1%;" title="Statements of Equity - E30">&#160;</td><td style="text-align: right; border-width: initial; border-style: none; border-color: initial; width: 9%;"><ix:nonFraction contextRef="c71" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-11441">12</ix:nonFraction></td><td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;" title="Statements of Equity - E30">&#160;</td><td>&#160;</td><td style="text-align: left; border-width: initial; border-style: none; border-color: initial; width: 1%;" title="Statements of Equity - G30">&#160;</td><td style="text-align: right; border-width: initial; border-style: none; border-color: initial; width: 9%;"><ix:nonFraction contextRef="c72" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-11442">489,081</ix:nonFraction></td><td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;" title="Statements of Equity - G30">&#160;</td><td>&#160;</td><td style="text-align: left; border-width: initial; border-style: none; border-color: initial; width: 1%;" title="Statements of Equity - I30">&#160;</td><td style="text-align: right; border-width: initial; border-style: none; border-color: initial; width: 9%;"><ix:nonFraction contextRef="c73" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-11443"> - </ix:nonFraction></td><td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;" title="Statements of Equity - I30">&#160;</td><td>&#160;</td><td style="text-align: left; border-width: initial; border-style: none; border-color: initial; width: 1%;" title="Statements of Equity - K30">&#160;</td><td style="text-align: right; border-width: initial; border-style: none; border-color: initial; width: 9%;"><ix:nonFraction contextRef="c74" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-11444"> - </ix:nonFraction></td><td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;" title="Statements of Equity - K30">&#160;</td><td>&#160;</td><td style="text-align: left; border-width: initial; border-style: none; border-color: initial; width: 1%;" title="Statements of Equity - M30">&#160;</td><td style="text-align: right; border-width: initial; border-style: none; border-color: initial; width: 9%;"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-11445">489,093</ix:nonFraction></td><td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;" title="Statements of Equity - M30">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Stock-based compensation expense</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Statements of Equity - C30">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"> -   </td><td style="text-align: left; width: 1%; border-left: none; border-right: none; border-bottom: 1px solid black; border-top: none;" title="Statements of Equity - C30">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Statements of Equity - E30">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"><ix:nonFraction contextRef="c71" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-11446"> - </ix:nonFraction></td><td style="text-align: left; width: 1%; border-left: none; border-right: none; border-bottom: 1px solid black; border-top: none;" title="Statements of Equity - E30">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Statements of Equity - G30">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"><ix:nonFraction contextRef="c72" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-11447">94,558</ix:nonFraction></td><td style="text-align: left; width: 1%; border-left: none; border-right: none; border-bottom: 1px solid black; border-top: none;" title="Statements of Equity - G30">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Statements of Equity - I30">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"><ix:nonFraction contextRef="c73" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-11448"> - </ix:nonFraction></td><td style="text-align: left; width: 1%; border-left: none; border-right: none; border-bottom: 1px solid black; border-top: none;" title="Statements of Equity - I30">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Statements of Equity - K30">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"><ix:nonFraction contextRef="c74" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-11449"> - </ix:nonFraction></td><td style="text-align: left; width: 1%; border-left: none; border-right: none; border-bottom: 1px solid black; border-top: none;" title="Statements of Equity - K30">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Statements of Equity - M30">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-11450">94,558</ix:nonFraction></td><td style="text-align: left; width: 1%; border-left: none; border-right: none; border-bottom: 1px solid black; border-top: none;" title="Statements of Equity - M30">&#160;</td></tr><tr><td style="font-weight: bold;">Balance at September 30, 2024</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Statements of Equity - C31">&#160;</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;"><ix:nonFraction contextRef="c48" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="3" unitRef="shares" id="ixv-11451">157,813</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Equity - C31">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Statements of Equity - E31">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;"><ix:nonFraction contextRef="c48" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-11452">158</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Equity - E31">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Statements of Equity - G31">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;"><ix:nonFraction contextRef="c49" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-11453">2,831,942</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Equity - G31">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Statements of Equity - I31">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">(<ix:nonFraction contextRef="c50" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-11454">24,173</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Equity - I31">)&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Statements of Equity - K31">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">(<ix:nonFraction contextRef="c51" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-11455">2,145,459</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Equity - K31">)&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Statements of Equity - M31">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;"><ix:nonFraction contextRef="c52" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-11456">662,468</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Equity - M31">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>&#160;</td><td>&#160;</td><td style="width: 1%;" title="Statements of Equity - C32"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Equity - C32"/><td>&#160;</td><td style="width: 1%;" title="Statements of Equity - E32"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Equity - E32"/><td>&#160;</td><td style="width: 1%;" title="Statements of Equity - G32"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Equity - G32"/><td>&#160;</td><td style="width: 1%;" title="Statements of Equity - I32"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Equity - I32"/><td>&#160;</td><td style="width: 1%;" title="Statements of Equity - K32"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Equity - K32"/><td>&#160;</td><td style="width: 1%;" title="Statements of Equity - M32"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Equity - M32"/></tr><tr><td style="font-weight: bold;">Balance at December 31, 2024</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Statements of Equity - C33">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c75" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="3" unitRef="shares" id="ixv-11457">157,909</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Statements of Equity - C33">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Statements of Equity - E33">$</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c75" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-11458">158</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Statements of Equity - E33">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Statements of Equity - G33">$</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c76" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-11459">2,868,812</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Statements of Equity - G33">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Statements of Equity - I33">$</td><td style="text-align: right; width: 9%;">(<ix:nonFraction contextRef="c77" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-11460">30,811</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Statements of Equity - I33">)&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Statements of Equity - K33">$</td><td style="text-align: right; width: 9%;">(<ix:nonFraction contextRef="c78" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-11461">2,249,808</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Statements of Equity - K33">)&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Statements of Equity - M33">$</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-11462">588,351</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Statements of Equity - M33">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Net loss</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Statements of Equity - C34">&#160;</td><td style="text-align: right; width: 9%;"> -   </td><td style="text-align: left; width: 1%;" title="Statements of Equity - C34">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Statements of Equity - E34">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c79" decimals="-3" format="ixt:fixed-zero" name="us-gaap:NetIncomeLoss" scale="3" unitRef="usd" id="ixv-11463"> - </ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Statements of Equity - E34">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Statements of Equity - G34">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c80" decimals="-3" format="ixt:fixed-zero" name="us-gaap:NetIncomeLoss" scale="3" unitRef="usd" id="ixv-11464"> - </ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Statements of Equity - G34">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Statements of Equity - I34">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c81" decimals="-3" format="ixt:fixed-zero" name="us-gaap:NetIncomeLoss" scale="3" unitRef="usd" id="ixv-11465"> - </ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Statements of Equity - I34">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Statements of Equity - K34">&#160;</td><td style="text-align: right; width: 9%;">(<ix:nonFraction contextRef="c82" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-11466">151,993</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Statements of Equity - K34">)&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Statements of Equity - M34">&#160;</td><td style="text-align: right; width: 9%;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-11467">151,993</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Statements of Equity - M34">)&#160;</td></tr><tr><td>Change in unrealized gains, net of tax</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Statements of Equity - C35">&#160;</td><td style="text-align: right; width: 9%;"> -   </td><td style="text-align: left; width: 1%;" title="Statements of Equity - C35">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Statements of Equity - E35">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c79" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" unitRef="usd" id="ixv-11468"> - </ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Statements of Equity - E35">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Statements of Equity - G35">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c80" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" unitRef="usd" id="ixv-11469"> - </ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Statements of Equity - G35">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Statements of Equity - I35">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c81" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" unitRef="usd" id="ixv-11470">4,088</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Statements of Equity - I35">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Statements of Equity - K35">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c82" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" unitRef="usd" id="ixv-11471"> - </ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Statements of Equity - K35">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Statements of Equity - M35">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" unitRef="usd" id="ixv-11472">4,088</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Statements of Equity - M35">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Foreign currency translation</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Statements of Equity - C36">&#160;</td><td style="text-align: right; width: 9%;"> -   </td><td style="text-align: left; width: 1%;" title="Statements of Equity - C36">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Statements of Equity - E36">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c79" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" unitRef="usd" id="ixv-11473"> - </ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Statements of Equity - E36">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Statements of Equity - G36">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c80" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" unitRef="usd" id="ixv-11474"> - </ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Statements of Equity - G36">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Statements of Equity - I36">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c81" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" unitRef="usd" id="ixv-11475">745</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Statements of Equity - I36">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Statements of Equity - K36">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c82" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" unitRef="usd" id="ixv-11476"> - </ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Statements of Equity - K36">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Statements of Equity - M36">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" unitRef="usd" id="ixv-11477">745</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Statements of Equity - M36">&#160;</td></tr><tr><td>Issuance of common stock in connection with employee stock plans, net</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Statements of Equity - C37">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c79" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" unitRef="shares" id="ixv-11478">3,229</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Statements of Equity - C37">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Statements of Equity - E37">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c79" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" scale="3" unitRef="usd" id="ixv-11479">3</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Statements of Equity - E37">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Statements of Equity - G37">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c80" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" scale="3" unitRef="usd" id="ixv-11480">84,784</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Statements of Equity - G37">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Statements of Equity - I37">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c81" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" scale="3" unitRef="usd" id="ixv-11481"> - </ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Statements of Equity - I37">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Statements of Equity - K37">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c82" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" scale="3" unitRef="usd" id="ixv-11482"> - </ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Statements of Equity - K37">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Statements of Equity - M37">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" scale="3" unitRef="usd" id="ixv-11483">84,787</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Statements of Equity - M37">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Stock-based compensation expense</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Statements of Equity - C38">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"> -   </td><td style="text-align: left; width: 1%; border-left: none; border-right: none; border-bottom: 1px solid black; border-top: none;" title="Statements of Equity - C38">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Statements of Equity - E38">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"><ix:nonFraction contextRef="c79" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-11484"> - </ix:nonFraction></td><td style="text-align: left; width: 1%; border-left: none; border-right: none; border-bottom: 1px solid black; border-top: none;" title="Statements of Equity - E38">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Statements of Equity - G38">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"><ix:nonFraction contextRef="c80" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-11485">91,989</ix:nonFraction></td><td style="text-align: left; width: 1%; border-left: none; border-right: none; border-bottom: 1px solid black; border-top: none;" title="Statements of Equity - G38">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Statements of Equity - I38">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"><ix:nonFraction contextRef="c81" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-11486"> - </ix:nonFraction></td><td style="text-align: left; width: 1%; border-left: none; border-right: none; border-bottom: 1px solid black; border-top: none;" title="Statements of Equity - I38">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Statements of Equity - K38">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"><ix:nonFraction contextRef="c82" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-11487"> - </ix:nonFraction></td><td style="text-align: left; width: 1%; border-left: none; border-right: none; border-bottom: 1px solid black; border-top: none;" title="Statements of Equity - K38">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Statements of Equity - M38">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-11488">91,989</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-left: none; border-right: none; border-top: none;" title="Statements of Equity - M38">&#160;</td></tr><tr><td style="font-weight: bold;">Balance at September 30, 2025</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Statements of Equity - C39">&#160;</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;"><ix:nonFraction contextRef="c62" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="3" unitRef="shares" id="ixv-11489">161,138</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Equity - C39">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Statements of Equity - E39">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;"><ix:nonFraction contextRef="c62" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-11490">161</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Equity - E39">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Statements of Equity - G39">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;"><ix:nonFraction contextRef="c63" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-11491">3,045,585</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Equity - G39">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Statements of Equity - I39">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">(<ix:nonFraction contextRef="c64" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-11492">25,978</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Equity - I39">)&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Statements of Equity - K39">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">(<ix:nonFraction contextRef="c65" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-11493">2,401,801</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Equity - K39">)&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Statements of Equity - M39">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-11494">617,967</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Equity - M39">&#160;</td></tr></table><div>&#160;</div><div style="text-align: center;"><span style="letter-spacing: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">See accompanying notes.</span></div><div>&#160;</div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 10px; margin-top: 0px; margin-bottom: 0px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">7</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-align: center;">
   <a id="Cash_Flows" title="Cash Flows"></a><span style="color: #000000; font-weight: bold;">IONIS PHARMACEUTICALS, INC.</span>
  </div><div>
  </div><div style="text-align: center;">
   <span style="color: #000000; font-weight: bold;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span>
  </div><div>
  </div><div style="text-align: center;">
   <span style="color: #000000; font-weight: bold;">(in thousands)</span>
  </div><div>
  </div><div style="text-align: center;">
   <span style="color: #000000; font-weight: bold;">(Unaudited)</span>
  </div><div>


  </div><div>&#160;
  </div><div>
  </div><table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/></tr><tr><td>&#160;</td><td colspan="7" style="font-weight: bold; text-align: center;">Nine Months Ended</td></tr><tr><td>&#160;</td><td colspan="7" style="font-weight: bold; text-align: center; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td></tr><tr><td>&#160;</td><td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Statements of Cash Flows - B5"/><td style="font-weight: bold; text-align: center; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Cash Flows - B5"/><td>&#160;</td><td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Statements of Cash Flows - D5"/><td style="font-weight: bold; text-align: center; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Cash Flows - D5"/></tr><tr><td style="font-weight: bold;">Operating activities:</td><td style="width: 1%;" title="Statements of Cash Flows - B6"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Cash Flows - B6"/><td>&#160;</td><td style="width: 1%;" title="Statements of Cash Flows - D6"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Cash Flows - D6"/></tr><tr style="background-color: rgb(204, 238, 255);"><td>Net loss</td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - B7">$</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-11495">151,993</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - B7">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - D7">$</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-11496">349,548</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - D7">)&#160;</td></tr><tr><td style="padding-left: 10px;">Adjustments to reconcile net loss to net cash used in operating activities:</td><td style="width: 1%;" title="Statements of Cash Flows - B8"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Cash Flows - B8"/><td>&#160;</td><td style="width: 1%;" title="Statements of Cash Flows - D8"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Cash Flows - D8"/></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 10px;">Depreciation</td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - B9">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-11497">6,749</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - B9">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - D9">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-11498">7,374</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - D9">&#160;</td></tr><tr><td style="padding-left: 10px;">Amortization of right-of-use operating lease assets</td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - B10">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" unitRef="usd" id="ixv-11499">6,803</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - B10">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - D10">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" unitRef="usd" id="ixv-11500">7,472</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - D10">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 10px;">Amortization of other assets</td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - B11">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" unitRef="usd" id="ixv-11501">1,801</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - B11">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - D11">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" unitRef="usd" id="ixv-11502">1,877</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - D11">&#160;</td></tr><tr><td style="padding-left: 10px;">Amortization of discount on investments, net</td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - B12">&#160;</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" unitRef="usd" id="ixv-11503">18,063</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - B12">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - D12">&#160;</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" unitRef="usd" id="ixv-11504">28,283</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - D12">)&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 10px;">Amortization of debt issuance costs</td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - B13">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCosts" scale="3" unitRef="usd" id="ixv-11505">4,940</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - B13">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - D13">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCosts" scale="3" unitRef="usd" id="ixv-11506">5,016</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - D13">&#160;</td></tr><tr><td style="padding-left: 10px;">Non-cash royalty revenue related to sale of royalties</td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - B14">&#160;</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ions:RoyaltyPayments" scale="3" unitRef="usd" id="ixv-11507">38,478</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - B14">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - D14">&#160;</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="ions:RoyaltyPayments" scale="3" unitRef="usd" id="ixv-11508">30,422</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - D14">)&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 10px;">Non-cash interest related to sale of future royalties</td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - B15">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ions:InterestExpenseRelatedToSaleOfFutureRoyalties" scale="3" unitRef="usd" id="ixv-11509">54,964</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - B15">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - D15">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="ions:InterestExpenseRelatedToSaleOfFutureRoyalties" scale="3" unitRef="usd" id="ixv-11510">54,330</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - D15">&#160;</td></tr><tr><td style="padding-left: 10px;">Stock-based compensation expense</td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - B16">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-11511">90,554</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - B16">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - D16">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-11512">94,052</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - D16">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 10px;">Loss (gain) on investments, net</td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - B17">&#160;</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RealizedInvestmentGainsLosses" scale="3" unitRef="usd" id="ixv-11513">9,437</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - B17">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - D17">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RealizedInvestmentGainsLosses" scale="3" sign="-" unitRef="usd" id="ixv-11514">320</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - D17">&#160;</td></tr><tr><td style="padding-left: 10px;">Non-cash losses related to other assets</td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - B18">&#160;</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="3" sign="-" unitRef="usd" id="ixv-11515">3,643</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - B18">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - D18">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="3" unitRef="usd" id="ixv-11516">1,009</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - D18">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 10px;">Changes in operating assets and liabilities:</td><td style="width: 1%;" title="Statements of Cash Flows - B19"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Cash Flows - B19"/><td>&#160;</td><td style="width: 1%;" title="Statements of Cash Flows - D19"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Cash Flows - D19"/></tr><tr><td style="padding-left: 30px;">Contracts receivable</td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - B20">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" scale="3" sign="-" unitRef="usd" id="ixv-11517">67,580</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - B20">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - D20">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" scale="3" sign="-" unitRef="usd" id="ixv-11518">79,850</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - D20">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 30px;">Inventories</td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - B21">&#160;</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" unitRef="usd" id="ixv-11519">14,600</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - B21">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - D21">&#160;</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" unitRef="usd" id="ixv-11520">27</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - D21">)&#160;</td></tr><tr><td style="padding-left: 30px;">Other current and long-term assets</td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - B22">&#160;</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" unitRef="usd" id="ixv-11521">123,489</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - B22">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - D22">&#160;</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" unitRef="usd" id="ixv-11522">8,155</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - D22">)&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 30px;">Accounts payable</td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - B23">&#160;</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" sign="-" unitRef="usd" id="ixv-11523">29,116</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - B23">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - D23">&#160;</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" sign="-" unitRef="usd" id="ixv-11524">19,215</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - D23">)&#160;</td></tr><tr><td style="padding-left: 30px;">Income taxes</td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - B24">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="3" unitRef="usd" id="ixv-11525">67</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - B24">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - D24">&#160;</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="3" sign="-" unitRef="usd" id="ixv-11526">2,110</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - D24">)&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 30px;">Accrued compensation</td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - B25">&#160;</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherEmployeeRelatedLiabilities" scale="3" sign="-" unitRef="usd" id="ixv-11527">12,595</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - B25">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - D25">&#160;</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherEmployeeRelatedLiabilities" scale="3" sign="-" unitRef="usd" id="ixv-11528">27,169</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - D25">)&#160;</td></tr><tr><td style="padding-left: 30px;">Accrued liabilities and other liabilities</td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - B26">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" scale="3" unitRef="usd" id="ixv-11529">87,683</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - B26">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - D26">&#160;</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" scale="3" sign="-" unitRef="usd" id="ixv-11530">28,661</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - D26">)&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 30px;">Deferred contract revenue</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Cash Flows - B27">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" sign="-" unitRef="usd" id="ixv-11531">50,601</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Cash Flows - B27">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Cash Flows - D27">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">(<ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" sign="-" unitRef="usd" id="ixv-11532">142,518</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Cash Flows - D27">)&#160;</td></tr><tr><td style="padding-left: 50px;">Net cash used in operating activities</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Cash Flows - B28">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-11533">130,874</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Cash Flows - B28">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Cash Flows - D28">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">(<ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-11534">384,808</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Cash Flows - D28">)&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>&#160;</td><td style="width: 1%;" title="Statements of Cash Flows - B29"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Cash Flows - B29"/><td>&#160;</td><td style="width: 1%;" title="Statements of Cash Flows - D29"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Cash Flows - D29"/></tr><tr><td style="font-weight: bold;">Investing activities:</td><td style="width: 1%;" title="Statements of Cash Flows - B30"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Cash Flows - B30"/><td>&#160;</td><td style="width: 1%;" title="Statements of Cash Flows - D30"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Cash Flows - D30"/></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 10px;">Purchases of short-term investments</td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - B31">&#160;</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" unitRef="usd" id="ixv-11535">1,126,595</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - B31">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - D31">&#160;</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" unitRef="usd" id="ixv-11536">1,519,227</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - D31">)&#160;</td></tr><tr><td style="padding-left: 10px;">Proceeds from sale of short-term investments</td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - B32">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="3" unitRef="usd" id="ixv-11537">1,302,751</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - B32">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - D32">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="3" unitRef="usd" id="ixv-11538">1,339,284</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - D32">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 10px;">Purchases of property, plant and equipment</td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - B33">&#160;</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-11539">30,152</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - B33">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - D33">&#160;</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-11540">19,783</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - D33">)&#160;</td></tr><tr><td style="padding-left: 10px;">Acquisition of licenses and other assets, net</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Cash Flows - B34">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" unitRef="usd" id="ixv-11541">4,275</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Cash Flows - B34">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Cash Flows - D34">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">(<ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" unitRef="usd" id="ixv-11542">2,514</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Cash Flows - D34">)&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 50px;">Net cash provided by (used in) investing activities</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Cash Flows - B35">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" unitRef="usd" id="ixv-11543">141,729</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Cash Flows - B35">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Cash Flows - D35">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">(<ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" sign="-" unitRef="usd" id="ixv-11544">202,240</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Cash Flows - D35">)&#160;</td></tr><tr><td>&#160;</td><td style="width: 1%;" title="Statements of Cash Flows - B36"/><td style="width: 9%;">&#160;</td><td style="width: 1%; border-width: initial; border-style: none; border-color: initial;" title="Statements of Cash Flows - B36"/><td>&#160;</td><td style="width: 1%;" title="Statements of Cash Flows - D36"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Cash Flows - D36"/></tr><tr style="background-color: rgb(204, 238, 255);"><td style="font-weight: bold;">Financing activities:</td><td style="width: 1%;" title="Statements of Cash Flows - B37"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Cash Flows - B37"/><td>&#160;</td><td style="width: 1%;" title="Statements of Cash Flows - D37"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Cash Flows - D37"/></tr><tr><td style="padding-left: 10px;">Proceeds from issuance of common stock through equity plans, net</td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - B38">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" unitRef="usd" id="ixv-11545">84,787</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - B38">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - D38">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" unitRef="usd" id="ixv-11546">33,207</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - D38">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 10px;">Proceeds from issuance of common stock in public offering, net</td><td style="width: 1%; text-align: left; border-width: initial; border-style: none; border-color: initial;" title="Statements of Cash Flows - B39">&#160;</td><td style="width: 9%; text-align: right; border-width: initial; border-style: none; border-color: initial;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" unitRef="usd" id="ixv-11547"> - </ix:nonFraction></td><td style="width: 1%; text-align: left; border-width: initial; border-style: none; border-color: initial;" title="Statements of Cash Flows - B39">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-width: initial; border-style: none; border-color: initial;" title="Statements of Cash Flows - D39">&#160;</td><td style="width: 9%; text-align: right; border-width: initial; border-style: none; border-color: initial;"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" unitRef="usd" id="ixv-11548">489,093</ix:nonFraction></td><td style="width: 1%; text-align: left; border-width: initial; border-style: none; border-color: initial;" title="Statements of Cash Flows - D39">&#160;</td></tr><tr><td style="padding-left: 10px;">Principal payments on mortgage debt</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Cash Flows - B39">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfSecuredDebt" scale="3" unitRef="usd" id="ixv-11549">123</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Cash Flows - B39">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Cash Flows - D39">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">(<ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfSecuredDebt" scale="3" unitRef="usd" id="ixv-11550">126</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Cash Flows - D39">)&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 50px;">Net cash provided by financing activities</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Cash Flows - B40">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" unitRef="usd" id="ixv-11551">84,664</ix:nonFraction></td><td style="width: 1%; text-align: left; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none;" title="Statements of Cash Flows - B40">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Cash Flows - D40">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" unitRef="usd" id="ixv-11552">522,174</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Cash Flows - D40">&#160;</td></tr><tr><td>&#160;</td><td style="width: 1%;" title="Statements of Cash Flows - B41"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Cash Flows - B41"/><td>&#160;</td><td style="width: 1%;" title="Statements of Cash Flows - D41"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Cash Flows - D41"/></tr><tr style="background-color: rgb(204, 238, 255);"><td>Effects of exchange rates on cash</td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - B42">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" unitRef="usd" id="ixv-11553">745</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - B42">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - D42">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" unitRef="usd" id="ixv-11554">213</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - D42">&#160;</td></tr><tr><td>&#160;</td><td style="width: 1%;" title="Statements of Cash Flows - B43"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Cash Flows - B43"/><td>&#160;</td><td style="width: 1%;" title="Statements of Cash Flows - D43"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Cash Flows - D43"/></tr><tr style="background-color: rgb(204, 238, 255);"><td>Net increase (decrease) in cash and cash equivalents</td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - B44">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" unitRef="usd" id="ixv-11555">96,264</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - B44">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - D44">&#160;</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" sign="-" unitRef="usd" id="ixv-11556">64,661</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - D44">)&#160;</td></tr><tr><td style="padding-left: 10px;">Cash and cash equivalents at beginning of period</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Cash Flows - B45">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-11557">242,077</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Cash Flows - B45">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Cash Flows - D45">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c70" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-11558">399,266</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Statements of Cash Flows - D45">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 10px;">Cash and cash equivalents at end of period</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Cash Flows - B46">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-11559">338,341</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Cash Flows - B46">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Cash Flows - D46">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c52" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-11560">334,605</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Statements of Cash Flows - D46">&#160;</td></tr><tr><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - B47">&#160;</td><td style="width: 9%; text-align: right;"/><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - B47">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - D47">&#160;</td><td style="width: 9%; text-align: right;"/><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - D47">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="font-weight: bold;">Supplemental disclosures of cash flow information:</td><td style="width: 1%;" title="Statements of Cash Flows - B48"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Cash Flows - B48"/><td>&#160;</td><td style="width: 1%;" title="Statements of Cash Flows - D48"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Cash Flows - D48"/></tr><tr><td style="padding-left: 10px;">Interest paid</td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - B49">$</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="3" unitRef="usd" id="ixv-11561">5,399</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - B49">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - D49">$</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="3" unitRef="usd" id="ixv-11562">5,714</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - D49">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 10px;">Income taxes paid (refunds received), net</td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - B50">$</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxesPaidNet" scale="3" sign="-" unitRef="usd" id="ixv-11563">661</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - B50">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - D50">$</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxesPaidNet" scale="3" unitRef="usd" id="ixv-11564">2,072</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - D50">&#160;</td></tr><tr><td>&#160;</td><td style="width: 1%;" title="Statements of Cash Flows - B51"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Cash Flows - B51"/><td>&#160;</td><td style="width: 1%;" title="Statements of Cash Flows - D51"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Cash Flows - D51"/></tr><tr style="background-color: rgb(204, 238, 255);"><td style="font-weight: bold;">Supplemental disclosures of non-cash investing and financing activities:</td><td style="width: 1%;" title="Statements of Cash Flows - B52"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Cash Flows - B52"/><td>&#160;</td><td style="width: 1%;" title="Statements of Cash Flows - D52"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Statements of Cash Flows - D52"/></tr><tr><td style="padding-left: 10px;">Right-of-use assets obtained in exchange for lease obligations</td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - B53">$</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" unitRef="usd" id="ixv-11565">86,939</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - B53">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - D53">$</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:fixed-zero" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" unitRef="usd" id="ixv-11566"> - </ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - D53">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 10px;">Amounts accrued for capital and patent expenditures</td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - B53">$</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ions:CapitalAndPatentExpendituresIncurredButNotYetPaid" scale="3" unitRef="usd" id="ixv-11567">478</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - B53">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - D53">$</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="ions:CapitalAndPatentExpendituresIncurredButNotYetPaid" scale="3" unitRef="usd" id="ixv-11568">2,240</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Statements of Cash Flows - D53">&#160;</td></tr></table><div>&#160;
  </div><div>
  </div><div style="text-align: center;">
   <span style="color: #000000;">See accompanying notes.</span></div><div>

  </div><div style="text-align: center;">&#160;</div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 10px; margin-top: 0px; margin-bottom: 0px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">8</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-align: center;">
   <a id="Notes" title="Notes"></a><span style="color: #000000; font-weight: bold;">IONIS PHARMACEUTICALS, INC.</span>
  </div><div>
  </div><div style="text-align: center;">
   <span style="color: #000000; font-weight: bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span>
  </div><div>
  </div><div style="text-align: center;"><span style="color: #000000; font-weight: bold;">September 30, 2025 </span>
  </div><div>
  </div><div style="text-align: center;">
   <span style="color: #000000; font-weight: bold;">(Unaudited)</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="ixv-3362"><div style="text-align: justify;">
   <span style="color: #000000; font-weight: bold;">1.&#160;&#160;Organization and Basis of Presentation</span>
  </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span style="font-weight: bold;">Organization and Business Activity</span>
  </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span>We incorporated in California on January 10, 1989. In conjunction with our initial public offering, we reorganized as a Delaware corporation in April 1991. We are a fully integrated commercial-stage biotechnology company and a leader in the discovery and development of RNA-targeted therapeutics. </span></div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000; font-weight: bold;">Basis of Presentation</span>
  </div>
  <div>&#160;
  </div>
  <ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="ixv-3375"><div style="text-indent: 36pt; text-align: justify;"> <span style="color: #000000;">We prepared the unaudited interim condensed consolidated financial statements for the three and nine months ended September 30, 2025 and 2024 on the same basis as the audited financial statements for the year ended December 31, 2024. We included all normal recurring adjustments in the financial statements, which we considered necessary for a fair presentation of our financial position at such dates and our operating results and cash flows for those periods. Our operating results for the interim periods may not be indicative of what our operating results will be for the entire year. For more complete financial information, these financial statements, and notes thereto, should be read in conjunction with the audited financial statements for the year ended December 31, 2024 included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission, or SEC. </span> </div></ix:nonNumeric>
  <div>&#160;
  </div>
  <ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ConsolidationPolicyTextBlock" id="ixv-3379"><div style="text-indent: 36pt; text-align: justify;"> <span style="color: #000000;">In our condensed consolidated financial statements, we included the accounts of Ionis Pharmaceuticals, Inc. and the consolidated results of our wholly owned subsidiary, Akcea Therapeutics, Inc. and its wholly owned subsidiaries (&#8220;we&#8221;, &#8220;us&#8221; or &#8220;our&#8221;).</span> </div></ix:nonNumeric>
  <div style="text-align: justify;">&#160;
  </div>
  <ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="ixv-3383"><div style="text-indent: 36pt; text-align: justify;"> <span>We operate as a </span><span style="color: #000000;">single </span><span>segment, Ionis operations, because our chief operating decision maker, or CODM, reviews operating results on an aggregate basis and manages our operations as a </span><span style="color: #000000;"><span style="-sec-ix-hidden: hidden-fact-0">single</span> </span><span>operating segment. Refer to Note 15, </span><span style="font-style: italic;">Segment Information</span><span>, for further details on our segment information.</span> </div></ix:nonNumeric>
  <div style="text-align: justify;">&#160;
  </div>
  <ix:nonNumeric contextRef="c0" continuedAt="_UseOfEstimates-c0_cont_1" escape="true" name="us-gaap:UseOfEstimates" id="ixv-3394"><div style="text-indent: 36pt; text-align: justify;"> <span style="color: #000000; font-weight: bold;">Use of Estimates</span> </div></ix:nonNumeric>
  <div style="text-align: justify;">&#160;
  </div>
  <ix:continuation id="_UseOfEstimates-c0_cont_1"><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">We prepare our condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States, or </span><span>U.S., that require us to make estimates and assumptions that affect the amounts reported in our condensed consolidated financial statements and accompanying notes. Actual results could differ from our estimates.</span>
  </div></ix:continuation></ix:nonNumeric><div>
  </div><div>&#160;
  </div><div>
  </div><ix:nonNumeric contextRef="c0" continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="ixv-3405"><div>
   <span style="color: #000000; font-weight: bold;">2.&#160;&#160;Significant Accounting Policies</span>
  </div>
  <div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">Below, we have included our accounting policies for revenue recognition related to product sales, net and cost of sales as a result of our launch of TRYNGOLZA and DAWNZERA in the U.S. Our other significant accounting policies have not changed substantially from those included in our Annual Report on Form 10-K for the year ended December 31, 2024.</span>
  </div>
  <div style="text-align: justify;">&#160;
  </div>
  <ix:nonNumeric contextRef="c0" continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="ixv-3412"><div style="text-indent: 36pt; text-align: justify;"> <span style="color: #000000; font-weight: bold; font-style: italic;">Revenue Recognition</span> </div></ix:nonNumeric>
  <div style="text-align: justify;">&#160;
  </div>
  <ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_2" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_1"><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000; font-style: italic;">Product Sales, Net</span>
  </div></ix:continuation>
  <div style="text-align: justify;">&#160;
  </div>
  <ix:continuation id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_2"><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">We recognize revenue from product sales when the customer obtains control of our product in the amount of the transaction price, which is the amount that reflects the consideration which we expect to receive. We estimate reserves for variable consideration related to applicable discounts, rebates, chargebacks and other allowances included in our agreements with customers, payors and other third parties. We include the amount of variable consideration in the transaction price to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If actual results vary significantly from our estimates, we adjust our estimates in the period that we become aware of such variances.</span>
  </div></ix:continuation></ix:nonNumeric><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 10px; margin-top: 0px; margin-bottom: 0px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">9</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><ix:continuation id="_SignificantAccountingPoliciesTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" continuedAt="_CostOfSalesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CostOfSalesPolicyTextBlock" id="ixv-3433"><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"> <span style="color: #000000; font-weight: bold; font-style: italic;">Cost of Sales</span> </div></ix:nonNumeric>
  <div style="text-align: justify;">&#160;
  </div>
  <ix:continuation continuedAt="_CostOfSalesPolicyTextBlock-c0_cont_2" id="_CostOfSalesPolicyTextBlock-c0_cont_1"><div style="text-indent: 36pt; text-align: justify;">
   <span>Our cost of sales is comprised of costs related to our commercial revenue, including manufacturing costs, transportation and freight costs and indirect overhead costs associated with the manufacturing and distribution of our products. We also may include certain period costs related to manufacturing services and inventory adjustments in cost of sales.</span>
  </div></ix:continuation>
  <div>&#160;
  </div>
  <ix:continuation id="_CostOfSalesPolicyTextBlock-c0_cont_2"><div style="text-indent: 36pt; text-align: justify;">
   <span>Cost of sales for a newly launched product, such as TRYNGOLZA or DAWNZERA, does not include the full cost of manufacturing until we manufacture and sell additional inventory after exhausting pre-launch inventory, which we previously recorded as research and development, or R&amp;D, expense.</span>
  </div></ix:continuation>
  <div>&#160;
  </div>
  <ix:nonNumeric contextRef="c0" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="ixv-3445"><div style="text-indent: 36pt;"> <span style="color: #000000; font-weight: bold;">Recent Accounting Standards</span> </div></ix:nonNumeric>
  <div>&#160;
  </div>
  <ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1"><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">In November 2023, the Financial Accounting Standards Board, or FASB, issued Accounting Standard Update, or ASU, 2023-07, which provides updated guidance on segment reporting. The guidance requires public companies to disclose significant expenses that are regularly provided to the CODM, other segment items for each reportable segment and measures of segment profit or loss used by the CODM for allocating resources. In addition, the updated guidance requires public companies with a single reportable segment to provide all disclosures required under Accounting Standards Codification, or ASC, Topic 280, </span><span style="color: #000000; font-style: italic;">Segment Reporting</span><span style="color: #000000;">, and public companies to include in interim reports all disclosures related to a reportable segment&#8217;s profit or loss and assets that are currently required in annual reports. We adopted the reporting requirements in our 2024 Annual Report on Form 10-K and began providing the interim reporting requirements in our Quarterly Report on Form 10-Q for the first quarter of 2025. Refer to Note 15, </span><span style="color: #000000; font-style: italic;">Segment Information</span><span style="color: #000000;">, for further details on our segment information.</span>
  </div></ix:continuation>
  <div style="text-align: justify;">&#160;</div>
  <ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_3" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2"><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;">In July 2025, the FASB issued ASU 2025-05, which amended the guidance in ASC 326 to simplify the estimation of credit losses on accounts receivable and contract assets from revenue transactions. The amended guidance allows companies to elect a practical expedient to assume that conditions as of the balance sheet date will remain unchanged for the remaining life of the asset when estimating the expected credit losses of the asset. This update is effective for annual periods beginning after December 15, 2025 and interim periods within those annual periods. Early adoption of this guidance is permitted. Companies that elect the practical expedient are required to apply the amendments prospectively. We are currently assessing the impact and timing of adopting this update.</div></ix:continuation><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;">&#160;</div><ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_4" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_3"><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"><span style="letter-spacing: normal; text-align: justify; text-indent: 48px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">In September 2025, the FASB issued ASU 2025-06, which amended and simplified the existing guidance for software costs. The amended guidance removes references to software development stages and allows companies to begin capitalizing software costs when management has authorized and committed to funding the software project and it is probable that the project will be completed with the software performing the intended function.&#160;This update is effective for annual periods beginning after December 15, 2027 and interim periods within those annual periods. Early adoption of this guidance is permitted at the beginning of an annual reporting period. The guidance may be applied on a prospective or retrospective basis. We expect to early adopt this update on January 1, 2026 on a prospective basis.</span></div></ix:continuation><div style="text-align: justify;">&#160;</div><ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_5" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_4"><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"><span style="letter-spacing: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">In September&#160;2025, the FASB issued ASU 2025-07, which clarifies that share-based non-cash consideration received from a customer in exchange for goods or services under a revenue contract is subject to the guidance on non-cash consideration under ASC 606.&#160;This update is effective for annual periods beginning after December 15, 2026 and interim periods within those annual periods. Early adoption of this guidance is permitted. The guidance may be applied on a prospective or modified retrospective basis. We are currently assessing the impact and timing of adopting this update.</span></div></ix:continuation><div style="text-align: justify;">&#160;</div><ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_5"><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">We do not expect any recently issued accounting standards other than the standards mentioned above and those included in our Annual Report on Form 10-K for the year ended December 31, 2024 to have a material impact to our financial results.</span>
  </div></ix:continuation></ix:continuation><div>
  </div><div>&#160;
  </div><div>
  </div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="ixv-3474"><div style="text-align: justify;">
   <span style="color: #000000; font-weight: bold;">3. Supplemental Financial Data</span>
  </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-align: justify; margin-left: 36pt;">
   <span style="color: #000000; font-weight: bold;">Inventories</span>
  </div>
  <div>&#160;
  </div>
  <ix:nonNumeric contextRef="c0" escape="true" name="ions:ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock" id="ixv-3481"><div style="text-indent: 36pt; text-align: justify;"> <span style="color: #000000;">Our inventories consisted of the following (in thousands): </span> </div>

  <div style="text-align: justify; color: #000000;">&#160;</div>
  <table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/></tr><tr style="height: 0px; font-size: 0px;"><td/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/></tr><tr><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Supplemental Financial Data - B4"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">September 30, 2025</td><td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Supplemental Financial Data - B4"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Supplemental Financial Data - D4"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">December 31, 2024</td><td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Supplemental Financial Data - D4"/></tr><tr style="background-color: rgb(204, 238, 255);"><td>Raw materials</td><td style="text-align: left; width: 1%;" title="Note 3. Supplemental Financial Data - B5">$</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ions:InventoryRawMaterialsNet" scale="3" unitRef="usd" id="ixv-11569">424</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 3. Supplemental Financial Data - B5">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 3. Supplemental Financial Data - D5">$</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ions:InventoryRawMaterialsNet" scale="3" unitRef="usd" id="ixv-11570">5,557</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 3. Supplemental Financial Data - D5">&#160;</td></tr><tr><td>Work in process</td><td style="text-align: left; width: 1%;" title="Note 3. Supplemental Financial Data - B6">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ions:InventoryWorkInProcessNet" scale="3" unitRef="usd" id="ixv-11571">26,139</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 3. Supplemental Financial Data - B6">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 3. Supplemental Financial Data - D6">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ions:InventoryWorkInProcessNet" scale="3" unitRef="usd" id="ixv-11572">6,679</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 3. Supplemental Financial Data - D6">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Finished goods</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Supplemental Financial Data - B7">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ions:InventoryFinishedGoodsNet" scale="3" unitRef="usd" id="ixv-11573">549</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 3. Supplemental Financial Data - B7">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Supplemental Financial Data - D7">$</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ions:InventoryFinishedGoodsNet" scale="3" unitRef="usd" id="ixv-11574">276</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 3. Supplemental Financial Data - D7">&#160;</td></tr><tr><td style="padding-left: 20px;">Total</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Supplemental Financial Data - B8">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ions:InventoryCurrentAndNoncurrent" scale="3" unitRef="usd" id="ixv-11575">27,112</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 3. Supplemental Financial Data - B8">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Supplemental Financial Data - D8">&#160;</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ions:InventoryCurrentAndNoncurrent" scale="3" unitRef="usd" id="ixv-11576">12,512</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 3. Supplemental Financial Data - D8">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Reported as:</td><td style="text-align: left; border-width: initial; border-style: none; border-color: initial; width: 1%;" title="Note 3. Supplemental Financial Data - B8">&#160;</td><td style="text-align: right; border-width: initial; border-style: none; border-color: initial; width: 9%;"/><td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;" title="Note 3. Supplemental Financial Data - B8">&#160;</td><td>&#160;</td><td style="text-align: left; border-width: initial; border-style: none; border-color: initial; width: 1%;" title="Note 3. Supplemental Financial Data - D8">&#160;</td><td style="text-align: right; border-width: initial; border-style: none; border-color: initial; width: 9%;"/><td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;" title="Note 3. Supplemental Financial Data - D8">&#160;</td></tr><tr><td style="padding-left: 10px;">Inventories</td><td style="text-align: left; border-width: initial; border-style: none; border-color: initial; width: 1%;" title="Note 3. Supplemental Financial Data - B8">$</td><td style="text-align: right; border-width: initial; border-style: none; border-color: initial; width: 9%;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" unitRef="usd" id="ixv-11577">10,470</ix:nonFraction></td><td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;" title="Note 3. Supplemental Financial Data - B8">&#160;</td><td>&#160;</td><td style="text-align: left; border-width: initial; border-style: none; border-color: initial; width: 1%;" title="Note 3. Supplemental Financial Data - D8">$</td><td style="text-align: right; border-width: initial; border-style: none; border-color: initial; width: 9%;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" unitRef="usd" id="ixv-11578">12,512</ix:nonFraction></td><td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;" title="Note 3. Supplemental Financial Data - D8">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 10px;">Deposits and other assets</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Supplemental Financial Data - B8">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"><ix:nonFraction contextRef="c83" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNoncurrent" scale="3" unitRef="usd" id="ixv-11579">16,642</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 3. Supplemental Financial Data - B8">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Supplemental Financial Data - D8">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"><ix:nonFraction contextRef="c84" decimals="-3" format="ixt:fixed-zero" name="us-gaap:InventoryNoncurrent" scale="3" unitRef="usd" id="ixv-11580"> - </ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 3. Supplemental Financial Data - D8">&#160;</td></tr><tr><td style="padding-left: 20px;">Total</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Supplemental Financial Data - B8">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ions:InventoryCurrentAndNoncurrent" scale="3" unitRef="usd" id="ixv-11581">27,112</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 3. Supplemental Financial Data - B8">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Supplemental Financial Data - D8">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ions:InventoryCurrentAndNoncurrent" scale="3" unitRef="usd" id="ixv-11582">12,512</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 3. Supplemental Financial Data - D8">&#160;</td></tr></table></ix:nonNumeric><div>&#160;</div>
  <div style="text-indent: 36pt; line-height: 1.15; text-align: justify;">We classify inventories as non-current assets when we expect  the inventories to remain on hand beyond one year. We include non-current inventories in deposits and other assets in our condensed consolidated balance sheets. The amount reported as deposits and other assets  as of September 30, 2025  consists of work in process inventory.</div><div>&#160;</div><div style="text-indent: 36pt;">
   <span style="font-weight: bold;">Accrued Liabilities</span>
  </div>
  <div>&#160;
  </div>
  <ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="ixv-3591"><div style="text-indent: 36pt;"> <span>Our accrued liabilities consisted of the following (in thousands):</span> </div>


  <div>&#160;</div>

  <table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/></tr><tr><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Accrued Liabilities - B4"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">September 30, 2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 3. Accrued Liabilities - B4"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Accrued Liabilities - D4"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">December 31, 2024</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 3. Accrued Liabilities - D4"/></tr><tr style="background-color: rgb(204, 238, 255);"><td>Clinical expenses</td><td style="text-align: left; width: 1%;" title="Note 3. Accrued Liabilities - B5">$</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ions:AccruedClinicalExpenses" scale="3" unitRef="usd" id="ixv-11583">54,842</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 3. Accrued Liabilities - B5">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 3. Accrued Liabilities - D5">$</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ions:AccruedClinicalExpenses" scale="3" unitRef="usd" id="ixv-11584">77,436</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 3. Accrued Liabilities - D5">&#160;</td></tr><tr><td>In-licensing expenses</td><td style="text-align: left; width: 1%;" title="Note 3. Accrued Liabilities - B6">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ions:AccruedInLicensingFeesCurrent" scale="3" unitRef="usd" id="ixv-11585">7,770</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 3. Accrued Liabilities - B6">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 3. Accrued Liabilities - D6">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ions:AccruedInLicensingFeesCurrent" scale="3" unitRef="usd" id="ixv-11586">7,951</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 3. Accrued Liabilities - D6">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Commercial expenses</td><td style="text-align: left; width: 1%;" title="Note 3. Accrued Liabilities - B7">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ions:AccruedCommercialExpensesCurrent" scale="3" unitRef="usd" id="ixv-11587">15,017</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 3. Accrued Liabilities - B7">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 3. Accrued Liabilities - D7">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ions:AccruedCommercialExpensesCurrent" scale="3" unitRef="usd" id="ixv-11588">3,589</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 3. Accrued Liabilities - D7">&#160;</td></tr><tr><td>Other miscellaneous expenses</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Accrued Liabilities - B8">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-11589">21,681</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 3. Accrued Liabilities - B8">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Accrued Liabilities - D8">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-11590">19,462</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 3. Accrued Liabilities - D8">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 20px;">Total accrued liabilities</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Accrued Liabilities - B9">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-11591">99,310</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 3. Accrued Liabilities - B9">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Accrued Liabilities - D9">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-11592">108,438</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 3. Accrued Liabilities - D9">&#160;</td></tr></table></ix:nonNumeric></ix:nonNumeric><div>&#160;</div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 10px; margin-top: 0px; margin-bottom: 0px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">10</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><ix:nonNumeric contextRef="c0" continuedAt="_RevenueFromContractWithCustomerTextBlock-c0_cont_1" escape="true" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="ixv-3666"><div>
   <span style="font-weight: bold;">4. Revenues</span>
  </div>
  <div>&#160;
  </div>
  <ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="ixv-3670"><div style="text-indent: 36pt; text-align: justify;"> <span>During the three and nine months ended September 30, 2025 and 2024, our revenues consisted of the following (in thousands):</span> </div>

  <div>&#160;</div>
  <table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold;">Three Months Ended</td><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold;">Nine Months Ended</td></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td></tr><tr><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - B4"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - B4"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - D4"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - D4"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - F4"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - F4"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - H4"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - H4"/></tr><tr><td>Revenue:</td><td style="width: 1%;" title="Note 4. Revenues - B5"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 4. Revenues - B5"/><td>&#160;</td><td style="width: 1%;" title="Note 4. Revenues - D5"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 4. Revenues - D5"/><td>&#160;</td><td style="width: 1%;" title="Note 4. Revenues - F5"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 4. Revenues - F5"/><td>&#160;</td><td style="width: 1%;" title="Note 4. Revenues - H5"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 4. Revenues - H5"/></tr><tr><td style="padding-left: 10px;">Commercial revenue:</td><td style="width: 1%;" title="Note 4. Revenues - B6"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 4. Revenues - B6"/><td>&#160;</td><td style="width: 1%;" title="Note 4. Revenues - D6"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 4. Revenues - D6"/><td>&#160;</td><td style="width: 1%;" title="Note 4. Revenues - F6"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 4. Revenues - F6"/><td>&#160;</td><td style="width: 1%;" title="Note 4. Revenues - H6"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 4. Revenues - H6"/></tr><tr><td style="padding-left: 20px;">Product sales, net:</td><td style="width: 1%;" title="Note 4. Revenues - B7"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 4. Revenues - B7"/><td>&#160;</td><td style="width: 1%;" title="Note 4. Revenues - D7"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 4. Revenues - D7"/><td>&#160;</td><td style="width: 1%;" title="Note 4. Revenues - F7"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 4. Revenues - F7"/><td>&#160;</td><td style="width: 1%;" title="Note 4. Revenues - H7"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 4. Revenues - H7"/></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 30px;">TRYNGOLZA sales, net</td><td style="text-align: left; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none; width: 1%;" title="Note 4. Revenues - B8">$</td><td style="text-align: right; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none; width: 9%;"><ix:nonFraction contextRef="c88" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11593">31,792</ix:nonFraction></td><td style="text-align: left; width: 1%; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none;" title="Note 4. Revenues - B8">&#160;</td><td>&#160;</td><td style="text-align: left; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none; width: 1%;" title="Note 4. Revenues - D8">$</td><td style="text-align: right; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none; width: 9%;"><ix:nonFraction contextRef="c89" decimals="-3" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11594"> - </ix:nonFraction></td><td style="text-align: left; width: 1%; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none;" title="Note 4. Revenues - D8">&#160;</td><td>&#160;</td><td style="text-align: left; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none; width: 1%;" title="Note 4. Revenues - F8">$</td><td style="text-align: right; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none; width: 9%;"><ix:nonFraction contextRef="c90" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11595">57,353</ix:nonFraction></td><td style="text-align: left; width: 1%; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none;" title="Note 4. Revenues - F8">&#160;</td><td>&#160;</td><td style="text-align: left; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none; width: 1%;" title="Note 4. Revenues - H8">$</td><td style="text-align: right; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none; width: 9%;"><ix:nonFraction contextRef="c91" decimals="-3" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11596"> - </ix:nonFraction></td><td style="text-align: left; width: 1%; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none;" title="Note 4. Revenues - H8">&#160;</td></tr><tr><td style="padding-left: 30px;">Total product sales, net</td><td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;" title="Note 4. Revenues - B9">&#160;</td><td style="text-align: right; width: 9%; border-width: initial; border-style: none; border-color: initial;"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11597">31,792</ix:nonFraction></td><td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;" title="Note 4. Revenues - B9">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;" title="Note 4. Revenues - D9">&#160;</td><td style="text-align: right; width: 9%; border-width: initial; border-style: none; border-color: initial;"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11598"> - </ix:nonFraction></td><td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;" title="Note 4. Revenues - D9">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;" title="Note 4. Revenues - F9">&#160;</td><td style="text-align: right; width: 9%; border-width: initial; border-style: none; border-color: initial;"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11599">57,353</ix:nonFraction></td><td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;" title="Note 4. Revenues - F9">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;" title="Note 4. Revenues - H9">&#160;</td><td style="text-align: right; width: 9%; border-width: initial; border-style: none; border-color: initial;"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11600"> - </ix:nonFraction></td><td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;" title="Note 4. Revenues - H9">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 20px;">Royalty revenue:</td><td style="width: 1%;" title="Note 4. Revenues - B10"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 4. Revenues - B10"/><td>&#160;</td><td style="width: 1%;" title="Note 4. Revenues - D10"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 4. Revenues - D10"/><td>&#160;</td><td style="width: 1%;" title="Note 4. Revenues - F10"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 4. Revenues - F10"/><td>&#160;</td><td style="width: 1%;" title="Note 4. Revenues - H10"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 4. Revenues - H10"/></tr><tr><td style="padding-left: 30px;">SPINRAZA royalties</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - B11">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c92" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11601">55,896</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - B11">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - D11">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c93" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11602">57,208</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - D11">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - F11">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c94" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11603">158,243</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - F11">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - H11">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c95" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11604">152,406</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - H11">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 30px;">WAINUA royalties</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - B12">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c96" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11605">13,320</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - B12">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - D12">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c97" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11606">5,371</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - D12">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - F12">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c98" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11607">33,107</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - F12">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - H12">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c99" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11608">10,278</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - H12">&#160;</td></tr><tr><td style="padding-left: 30px;">Other royalties</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 4. Revenues - B13">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; width: 9%;"><ix:nonFraction contextRef="c100" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11609">6,478</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - B13">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 4. Revenues - D13">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; width: 9%;"><ix:nonFraction contextRef="c101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11610">4,228</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - D13">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 4. Revenues - F13">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; width: 9%;"><ix:nonFraction contextRef="c102" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11611">18,461</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - F13">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 4. Revenues - H13">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-right: none; width: 9%;"><ix:nonFraction contextRef="c103" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11612">17,352</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - H13">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 50px;">Total royalty revenue</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - B14">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11613">75,694</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - B14">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - D14">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11614">66,807</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - D14">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - F14">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11615">209,811</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - F14">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - H14">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c15" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11616">180,036</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - H14">&#160;</td></tr><tr><td style="padding-left: 20px;">Other commercial revenue</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - B15"/><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"> <ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11617">8,112</ix:nonFraction> </td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - B15"/><td>&#160;</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - D15"/><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"> <ix:nonFraction contextRef="c17" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11618">8,924</ix:nonFraction> </td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - D15"/><td>&#160;</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - F15"/><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"> <ix:nonFraction contextRef="c18" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11619">27,359</ix:nonFraction> </td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - F15"/><td>&#160;</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - H15"/><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"> <ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11620">27,324</ix:nonFraction> </td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - H15"/></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 70px;">Total commercial revenue</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - B19">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11621">115,598</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - B19">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - D19">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11622">75,731</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - D19">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - F19">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c22" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11623">294,523</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - F19">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - H19">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c23" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11624">207,360</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - H19">&#160;</td></tr><tr><td style="padding-left: 10px;">Research and development revenue:</td><td style="width: 1%;" title="Note 4. Revenues - B20"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 4. Revenues - B20"/><td>&#160;</td><td style="width: 1%;" title="Note 4. Revenues - D20"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 4. Revenues - D20"/><td>&#160;</td><td style="width: 1%;" title="Note 4. Revenues - F20"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 4. Revenues - F20"/><td>&#160;</td><td style="width: 1%;" title="Note 4. Revenues - H20"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 4. Revenues - H20"/></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 30px;">Collaborative agreement revenue</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - B21">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c24" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11625">31,436</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - B21">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - D21">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11626">44,883</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - D21">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - F21">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c26" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11627">413,387</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - F21">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - H21">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11628">235,753</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - H21">&#160;</td></tr><tr><td style="padding-left: 30px;">WAINUA joint development revenue</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - B22">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"><ix:nonFraction contextRef="c28" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11629">9,685</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - B22">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - D22">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"><ix:nonFraction contextRef="c29" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11630">13,200</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - D22">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - F22">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"><ix:nonFraction contextRef="c30" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11631">32,471</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - F22">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - H22">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"><ix:nonFraction contextRef="c31" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11632">35,449</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - H22">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 70px;">Total research and development revenue</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - B23">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"><ix:nonFraction contextRef="c32" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11633">41,121</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - B23">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - D23">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"><ix:nonFraction contextRef="c33" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11634">58,083</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - D23">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - F23">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11635">445,858</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - F23">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - H23">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11636">271,202</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - H23">&#160;</td></tr><tr><td style="padding-left: 90px;">Total revenue  </td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - B24">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;"><ix:nonFraction contextRef="c36" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11637">156,719</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - B24">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - D24">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;"><ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11638">133,814</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - D24">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - F24">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11639">740,381</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - F24">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - H24">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11640">478,562</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - H24">&#160;</td></tr></table></ix:nonNumeric><div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span style="font-weight: bold; text-decoration: underline;">Revenue Sources </span>
  </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span>The following are sources of revenue and when we typically recognize revenue.</span>
  </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span style="font-style: italic;">Commercial Revenue </span>
  </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span>In December 2024, the U.S. Food and Drug Administration, or FDA, approved TRYNGOLZA (olezarsen) for the treatment of familial chylomicronemia syndrome, or FCS. Following the approval, we launched TRYNGOLZA and began earning revenue from TRYNGOLZA sales. </span>
  </div>
  <div style="text-align: justify;">&#160;</div>
  <div style="text-indent: 36pt; line-height: 1.15; text-align: justify;">In August 2025, the FDA approved DAWNZERA (donidalorsen) for prophylaxis to prevent attacks of hereditary angioedema, or HAE, in adult and pediatric patients 12 years of age and older. Our launch of DAWNZERA is currently underway.</div><div style="text-align: justify;">&#160;</div><div style="text-indent: 36pt; text-align: justify;">
   <span>We earn royalty payments primarily on net sales of SPINRAZA, WAINUA and QALSODY.</span>
  </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span>We earn commercial revenue from TEGSEDI and WAYLIVRA sales under our distribution agreements with Swedish Orphan Biovitrum AB, or Sobi. In addition, we receive royalties from PTC Therapeutics International Limited, or PTC, for TEGSEDI and WAYLIVRA sales. Refer to Part IV, Item 15, Note 4, </span><span style="font-style: italic;">Collaborative Arrangements and Licensing Agreements</span><span>, of our audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2024 for details on our commercialization partnerships with Sobi and PTC.</span>
  </div>
  <div style="text-align: justify;">&#160;</div>
  <div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"><span style="letter-spacing: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">Under our distribution agreements with Sobi, we concluded that our performance obligation is to provide services to Sobi over the term of the agreement, which includes supplying finished goods inventory to Sobi. We are also responsible for maintaining the marketing authorization for TEGSEDI and WAYLIVRA in major markets and for leading the global commercial strategy for each medicine. We view this performance obligation as a series of distinct activities that are substantially the same. Therefore, we recognize as revenue the price Sobi pays us for the inventory when we deliver the finished goods inventory to Sobi. We also recognize distribution fee revenue based on Sobi&#8217;s net sales of TEGSEDI and WAYLIVRA. Under our agreements with Sobi, Sobi does not generally have a right of return.</span></div><div style="text-align: justify;">&#160;</div><div style="text-indent: 36pt; text-align: justify;">
   <span style="font-style: italic;">Research and development revenue under collaboration agreements</span>
  </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span>We enter into collaboration agreements to license and sell our technology on an exclusive or non-exclusive basis. Our collaboration agreements typically contain multiple elements, or performance obligations, including technology licenses or options to obtain technology licenses, R&amp;D services and manufacturing services.</span>
  </div></ix:nonNumeric><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 10px; margin-top: 0px; margin-bottom: 0px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">11</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><ix:continuation continuedAt="_RevenueFromContractWithCustomerTextBlock-c0_cont_2" id="_RevenueFromContractWithCustomerTextBlock-c0_cont_1"><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;">
   For R&amp;D services that we recognize over time, we measure our progress using an input method. The input methods we use are based on the effort we expend or costs we incur toward the satisfaction of our performance obligation. We estimate the amount of effort we expend, including the time we estimate it will take us to complete the activities, or costs we incur in a given period, relative to the estimated total effort or costs to satisfy the performance obligation. This results in a percentage that we multiply by the transaction price to determine the amount of revenue we recognize each period. This approach requires us to make numerous estimates that may involve judgement. If our estimates or judgements change over the course of the collaboration, they may affect the timing and amount of revenue that we recognize in the current and future periods.
  </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span style="font-style: italic; text-decoration: underline;">Upfront payments:</span><span> When we enter into a collaboration agreement and receive an upfront payment, we record the entire upfront payment as deferred revenue if our only performance obligation is for R&amp;D services we will provide in the future. We amortize the upfront payment into revenue as we perform the R&amp;D services. If part or all of the upfront payment is a license fee, we recognize as revenue the portion related to the license when we deliver the license to our partner because our partner has full use of the license and we do not have any additional performance obligations related to the license after delivery.</span>
  </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span style="font-style: italic; text-decoration: underline;">Milestone payments:</span><span> We consider milestone payments to be variable consideration and include them in the transaction price when it is probable. We typically include milestone payments for R&amp;D services in the transaction price when they are achieved. We include these milestone payments when they are achieved because there is considerable uncertainty in the research and development processes that trigger these payments. Similarly, we include regulatory milestone payments in the transaction price once the medicine is approved by the applicable regulatory agency. We will recognize sales-based milestone payments in the period in which we achieve the milestone under the sales-based royalty exception allowed under accounting rules.</span>
  </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span>We recognize milestone payments that relate to an ongoing performance obligation over our period of performance. For example, when we achieve a milestone payment from a partner for advancing a clinical study under a collaboration agreement, we add the milestone payment to the transaction price if the milestone relates to an ongoing R&amp;D services performance obligation and recognize revenue related to the milestone payment over our estimated period of performance. If we have partially completed our performance obligation, then we record a cumulative-effect adjustment in the period we add the milestone payment to the transaction price.</span>
  </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span>Conversely, we recognize in full those milestone payments that we earn based on our partners&#8217; activities when our partner achieves the milestone event and we do not have a remaining performance obligation.</span>
  </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span style="font-style: italic; text-decoration: underline;">License fees:</span><span> We recognize as revenue the total amount we determine to be the relative stand-alone selling price of a license when we deliver the license to our partner because our partner has full use of the license and we do not have any additional performance obligations related to the license after delivery.</span>
  </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span style="font-style: italic;">WAINUA (Eplontersen) Collaboration with AstraZeneca</span>
  </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span>In 2021, we entered into a joint development and commercialization agreement with AstraZeneca to develop and commercialize WAINUA for the treatment of transthyretin amyloidosis, or ATTR. Under the terms of the agreement, we received a $<ix:nonFraction contextRef="c85" decimals="-6" format="ixt:num-dot-decimal" name="ions:UpfrontPaymentReceived" scale="6" unitRef="usd" id="ixv-11641">200</ix:nonFraction> million upfront payment in 2021.</span> </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span>We evaluated our WAINUA collaboration under ASC Topic 808, </span><span style="font-style: italic;">Collaborative Arrangements</span><span>, or ASC 808, and identified <ix:nonFraction contextRef="c86" decimals="INF" format="ixt-sec:numwordsen" name="ions:NumberOfMaterialComponents" scale="0" unitRef="Component" id="ixv-11642">four</ix:nonFraction> material components: (i) the license we granted to AstraZeneca in 2021, (ii) the co-development activities that we and AstraZeneca are performing, (iii) the co-commercialization activities that we and AstraZeneca are performing and (iv) the co-medical affairs activities that we and AstraZeneca are performing.</span> </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span>We determined that we had a vendor-customer relationship within the scope of ASC Topic 606, </span><span style="font-style: italic;">Revenue from Contracts with Customers</span><span>, or ASC 606, for the license we granted to AstraZeneca and as a result we had <ix:nonFraction contextRef="c86" decimals="INF" format="ixt-sec:numwordsen" name="ions:RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" scale="0" unitRef="PerformanceObligation" id="ixv-11643">one</ix:nonFraction> performance obligation. For our sole performance obligation, we determined the transaction price was the $<ix:nonFraction contextRef="c86" decimals="-6" format="ixt:num-dot-decimal" name="ions:RevenueFromContractWithCustomerTransactionPrice" scale="6" unitRef="usd" id="ixv-11644">200</ix:nonFraction> million upfront payment we received. We recognized the upfront payment in full in 2021 because we did not have any remaining performance obligations after we delivered the license to AstraZeneca.</span> </div></ix:continuation><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 10px; margin-top: 0px; margin-bottom: 0px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">12</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div>
  </div><ix:continuation id="_RevenueFromContractWithCustomerTextBlock-c0_cont_2"><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;">We also concluded that the co-development activities, the co-commercialization activities and the co-medical affairs activities are within the scope of ASC 808 because we and AstraZeneca are active participants exposed to the risks and benefits of the activities under the collaboration and therefore do not have a vendor-customer relationship. AstraZeneca is currently responsible for <ix:nonFraction contextRef="c87" decimals="2" format="ixt:num-dot-decimal" name="ions:PercentageOfCostsAssociatedWithOngoingGlobalPhase3DevelopmentProgramPaidByCollaborationPartner" scale="-2" unitRef="pure" id="ixv-11645">55</ix:nonFraction> percent of the costs associated with the ongoing global Phase 3 development program. Because we are leading the Phase 3 development program, we made an accounting policy election to recognize as non-customer revenue the cost-share funding from AstraZeneca, net of our share of AstraZeneca&#8217;s development expenses, in the same period we incur the related development expenses. As AstraZeneca is responsible for the majority of the commercial and medical affairs costs in the U.S. and all costs associated with bringing WAINUA to market outside the U.S., we made an accounting policy election to recognize cost-share funding we receive from AstraZeneca related to commercial and medical affairs activities as reductions of our selling, general and administrative, or SG&amp;A, expense and R&amp;D expense, respectively. </div></ix:continuation><div>



  </div><div>&#160;
  </div><div>
  </div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="ixv-4099"><div>
   <span style="color: #000000; font-weight: bold;">5.  Collaborative Arrangements and Licensing Agreements</span>
  </div>
  <div>&#160;
  </div>
  <div style="text-indent: 36pt; font-family: Calibri; font-size: 11pt; color: rgb(0, 0, 0); text-align: justify;">
   <span style="font-family: Times New Roman; font-size: 10.0pt;">Below, we have included our AstraZeneca and Ono collaborations, which were the only collaborations that had either substantive changes or were new from those included in Part IV, Item 15, Note 4, </span><span style="font-family: Times New Roman; font-size: 10.0pt; font-style: italic;">Collaborative Arrangements and Licensing Agreements</span><span style="font-family: Times New Roman; font-size: 10.0pt;">, of our audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2024. </span>
  </div>
  <div>&#160;</div>
  <div>&#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160;<b>AstraZeneca</b></div><div>&#160;</div><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;">We have <ix:nonFraction contextRef="c104" decimals="0" format="ixt-sec:numwordsen" name="ions:NumberOfCollaborationAgreements" scale="0" unitRef="Agreement" id="ixv-11646">two</ix:nonFraction> collaborations with AstraZeneca: <ix:nonFraction contextRef="c105" decimals="0" format="ixt-sec:numwordsen" name="ions:NumberOfCollaborationAgreements" scale="0" unitRef="Agreement" id="ixv-11647">one</ix:nonFraction> focused on the joint development and commercialization of WAINUA and <ix:nonFraction contextRef="c106" decimals="0" format="ixt-sec:numwordsen" name="ions:NumberOfCollaborationAgreements" scale="0" unitRef="Agreement" id="ixv-11648">one</ix:nonFraction> focused on the treatment of cardiovascular, renal and metabolic diseases. From inception through September 30, 2025, we have received more than $<ix:nonFraction contextRef="c104" decimals="-6" format="ixt:num-dot-decimal" name="ions:CumulativePaymentsReceived" scale="6" unitRef="usd" id="ixv-11649">960</ix:nonFraction> million from these collaborations.</div><div>&#160;</div><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;">In the second quarter of 2025, we earned a $<ix:nonFraction contextRef="c107" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" unitRef="usd" id="ixv-11650">30</ix:nonFraction> million milestone payment under our cardiovascular, renal and metabolic diseases collaboration when AstraZeneca initiated the Phase 2b study of opemalirsen (formerly ION532), an investigational medicine designed to reduce the production of apolipoprotein L1, or APOL1, for the treatment of APOL1-mediated kidney disease. We recognized this milestone payment as R&amp;D revenue in full in the second quarter of 2025 because we did not have any remaining performance obligations related to the milestone payment. We will achieve the next payment of $<ix:nonFraction contextRef="c106" decimals="-6" format="ixt:num-dot-decimal" name="ions:NextPaymentToBeAchieved" scale="6" unitRef="usd" id="ixv-11651">20</ix:nonFraction> million if AstraZeneca advances a medicine under this collaboration.</div><div>&#160;</div><ix:nonNumeric contextRef="c117" escape="true" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="ixv-4115"><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;">During the three and nine months ended September 30, 2025 and 2024, we earned the following revenue from our relationship with AstraZeneca (in thousands, except percentage amounts):</div><div>&#160;</div><table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold;">Three Months Ended</td><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold;">Nine Months Ended</td></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td></tr><tr><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 5. Collaborations - B6"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 5. Collaborations - B6"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 5. Collaborations - D6"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 5. Collaborations - D6"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 5. Collaborations - F6"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 5. Collaborations - F6"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 5. Collaborations - H6"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 5. Collaborations - H6"/></tr><tr style="background-color: rgb(204, 238, 255);"><td>Revenue from our relationship with AstraZeneca</td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - B7">$</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c118" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11652">27,128</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - B7">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - D7">$</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c119" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11653">19,461</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - D7">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - F7">$</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c117" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11654">101,705</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - F7">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - H7">$</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c120" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11655">47,106</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - H7">&#160;</td></tr><tr><td>Percentage of total revenue</td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - B8">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c121" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-11656">17</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - B8">%</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - D8">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c122" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-11657">15</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - D8">%</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - F8">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c123" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-11658">14</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - F8">%</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - H8">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c124" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-11659">10</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - H8">%</td></tr></table></ix:nonNumeric><div>&#160;</div><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;">&#160;We did <ix:nonFraction contextRef="c104" decimals="-6" format="ixt:fixed-zero" name="us-gaap:ContractWithCustomerLiability" scale="6" unitRef="usd" id="ixv-11660"><ix:nonFraction contextRef="c108" decimals="-6" format="ixt:fixed-zero" name="us-gaap:ContractWithCustomerLiability" scale="6" unitRef="usd" id="ixv-11661">not</ix:nonFraction></ix:nonFraction> have any deferred revenue from our relationship with AstraZeneca at September 30, 2025 and December 31, 2024.</div><div>&#160;</div><div style="text-indent: 36pt;">
   <span style="color: #000000; font-weight: bold; font-style: italic;">Ono</span>
  </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">In March 2025, we entered into an agreement with Ono Pharmaceutical Co., Ltd., or Ono, to develop and commercialize sapablursen, an investigational RNA-targeted medicine for the potential treatment of polycythemia vera, or PV, a rare and potentially life-threatening hematologic disease. We are responsible for completing the ongoing Phase 2 IMPRSSION study, while Ono will be solely responsible for subsequent development, regulatory filings and commercialization of sapablursen.</span>
  </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span style="color: #000000;">Over the term of this collaboration, we are eligible to receive up to $<ix:nonFraction contextRef="c109" decimals="-6" format="ixt:num-dot-decimal" name="ions:MaximumAmountOfPaymentsReceivableOverTermOfCollaboration" scale="6" unitRef="usd" id="ixv-11662">940</ix:nonFraction> million, which is comprised of a $<ix:nonFraction contextRef="c109" decimals="-6" format="ixt:num-dot-decimal" name="ions:MaximumAmountOfUpfrontPaymentsOverTermOfCollaboration" scale="6" unitRef="usd" id="ixv-11663">280</ix:nonFraction> million upfront payment, a $<ix:nonFraction contextRef="c109" decimals="-6" format="ixt:num-dot-decimal" name="ions:MaximumAmountOfDevelopmentMilestonePaymentsOverTermOfCollaboration" scale="6" unitRef="usd" id="ixv-11664">20</ix:nonFraction> million development milestone payment, up to $<ix:nonFraction contextRef="c109" decimals="-6" format="ixt:num-dot-decimal" name="ions:MaximumAmountOfRegulatoryMilestonePaymentsOverTermOfCollaboration" scale="6" unitRef="usd" id="ixv-11665">20</ix:nonFraction> million in regulatory milestone payments and up to $<ix:nonFraction contextRef="c109" decimals="-6" format="ixt:num-dot-decimal" name="ions:MaximumAmountOfSalesMilestonePaymentsOverTermOfCollaboration" scale="6" unitRef="usd" id="ixv-11666">620</ix:nonFraction> million in sales milestone payments. In addition, we are eligible to receive royalties in the mid-teen percentage range on net sales. From inception through September 30, 2025, we received more than $<ix:nonFraction contextRef="c109" decimals="-6" format="ixt:num-dot-decimal" name="ions:CumulativePaymentsReceived" scale="6" unitRef="usd" id="ixv-11667">280</ix:nonFraction> million from this collaboration, which includes the upfront payment and reimbursements for additional R&amp;D services. We will achieve the next payment of $<ix:nonFraction contextRef="c109" decimals="-6" format="ixt:num-dot-decimal" name="ions:NextPaymentToBeAchieved" scale="6" unitRef="usd" id="ixv-11668">20</ix:nonFraction> million if Ono initiates a pivotal clinical trial under this collaboration.</span>&#160;</div>


  <div style="text-indent: 36pt; text-align: justify;">&#160;</div><div style="text-indent: 36pt; text-align: justify;">At inception, we identified <ix:nonFraction contextRef="c110" decimals="0" format="ixt-sec:numwordsen" name="ions:NumberOfPerformanceObligationsIdentified" scale="0" unitRef="PerformanceObligation" id="ixv-11669">two</ix:nonFraction> performance obligations under this agreement, comprised of our license of sapablursen to Ono and R&amp;D services for sapablursen. We determined the transaction price to be the $<ix:nonFraction contextRef="c111" decimals="-6" format="ixt:num-dot-decimal" name="ions:RevenueFromContractWithCustomerTransactionPrice" scale="6" unitRef="usd" id="ixv-11670">280</ix:nonFraction> million upfront payment we received <span style="letter-spacing: normal; text-indent: 48px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">when this transaction received clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, or HSR Act,&#160;</span>in the second quarter of 2025. We allocated the transaction price based on the estimated stand-alone selling price of each performance obligation as follows:</div><div style="text-indent: 36pt; text-align: justify;">&#160;</div><div style="text-indent: 36pt; text-align: justify;">&#9679;&#160;&#160;&#160;&#160;$<ix:nonFraction contextRef="c112" decimals="-6" format="ixt:num-dot-decimal" name="ions:RevenueFromContractWithCustomerTransactionPrice" scale="6" unitRef="usd" id="ixv-11671">278</ix:nonFraction> million for the license of sapablursen; and</div><div style="text-indent: 36pt; text-align: justify;">&#9679;&#160; &#160; $<ix:nonFraction contextRef="c113" decimals="-6" format="ixt:num-dot-decimal" name="ions:RevenueFromContractWithCustomerTransactionPrice" scale="6" unitRef="usd" id="ixv-11672">2</ix:nonFraction> million for the R&amp;D services for sapablursen.</div><div style="text-indent: 36pt; text-align: justify;">&#160;</div><div style="text-indent: 36pt; text-align: justify;">We recognized $<ix:nonFraction contextRef="c114" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" unitRef="usd" id="ixv-11673">278</ix:nonFraction> million of R&amp;D revenue for the license of sapablursen in the second quarter of 2025 because we completed the performance obligation when we delivered the license to Ono. We recognized revenue for our R&amp;D services performance obligation as we performed services based on our effort to satisfy our performance obligation relative to our total effort expected to satisfy our performance obligation. In the second quarter of 2025, we completed our R&amp;D services performance obligation and recognized $<ix:nonFraction contextRef="c115" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" unitRef="usd" id="ixv-11674">2</ix:nonFraction> million of R&amp;D revenue.</div><div style="text-indent: 36pt; text-align: justify;">&#160;</div><ix:nonNumeric contextRef="c125" escape="true" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="ixv-4217"><div style="text-indent: 36pt; text-align: justify;">During&#160;<span style="letter-spacing: normal; text-indent: 48px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">the three and nine months ended September 30, 2025&#160;and 2024, we earned the following revenue from our relationship with Ono&#160;(in thousands, except percentage amounts):</span></div><div style="text-indent: 36pt; text-align: justify;">&#160;</div><table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/></tr><tr><td>&#160;</td><td style="width: 1%;" title="Note 5. Collaborations - Ono - B2"/><td style="text-align: center; font-weight: bold; width: 9%;">Three Months Ended</td><td style="width: 1%;" title="Note 5. Collaborations - Ono - B2"/><td>&#160;</td><td style="width: 1%;" title="Note 5. Collaborations - Ono - D2"/><td style="text-align: center; font-weight: bold; width: 9%;">Nine Months Ended</td><td style="width: 1%;" title="Note 5. Collaborations - Ono - D2"/></tr><tr><td>&#160;</td><td style="border-left: none; border-right: none; border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 5. Collaborations - Ono - B3"/><td style="text-align: center; font-weight: bold; border-top: none; border-left: none; border-right: none; border-bottom: 1px solid black; width: 9%;">September 30, 2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 5. Collaborations - Ono - B3"/><td>&#160;</td><td style="border-bottom: 1px solid black; border-left: none; border-right: none; border-top: none; width: 1%;" title="Note 5. Collaborations - Ono - D3"/><td style="text-align: center; font-weight: bold; border-left: none; border-right: none; border-bottom: 1px solid black; border-top: none; width: 9%;">September 30, 2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 5. Collaborations - Ono - D3"/></tr><tr style="background-color: rgb(204, 238, 255);"><td>Revenue from our relationship with Ono</td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - Ono - B4">$</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c126" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11675">2,979</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - Ono - B4">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - Ono - D4">$</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c125" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-11676">282,979</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - Ono - D4">&#160;</td></tr><tr><td>Percentage of total revenue</td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - Ono - B5">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c127" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-11677">2</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - Ono - B5">%</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - Ono - D5">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c128" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-11678">38</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - Ono - D5">%</td></tr></table></ix:nonNumeric><div style="text-indent: 36pt; text-align: justify;">&#160;</div><div style="text-indent: 36pt; text-align: justify;"><span style="letter-spacing: normal; text-indent: 48px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">Our condensed consolidated balance sheet at September 30, 2025 included deferred revenue of $<ix:nonFraction contextRef="c109" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="6" unitRef="usd" id="ixv-11679">2.9</ix:nonFraction> million from our relationship with Ono. We did <ix:nonFraction contextRef="c116" decimals="-6" format="ixt:fixed-zero" name="us-gaap:ContractWithCustomerLiability" scale="6" unitRef="usd" id="ixv-11680">not</ix:nonFraction> have any deferred revenue from our relationship with Ono at&#160;December 31, 2024.</span></div></ix:nonNumeric><div>&#160;
  </div><div>
  </div><ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerShareTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerShareTextBlock" id="ixv-4272"><div>
   <span style="color: #000000; font-weight: bold;">6. Basic and Diluted Net Loss Per Share</span>
  </div>
  <div style="font-size: 8pt;">&#160;
  </div>
  <ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock" id="ixv-4276"><div style="text-indent: 36pt; text-align: justify;"> <span style="color: #000000; font-weight: bold;">Basic net loss&#160;per share</span> </div></ix:nonNumeric>
  <div style="text-align: justify; font-size: 8pt;">&#160;
  </div>
  <ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_2" id="_EarningsPerSharePolicyTextBlock-c0_cont_1"><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">We calculated our basic net loss per share for the three and nine months ended September 30, 2025 and 2024 by dividing our net loss&#160;by our weighted-average number of common shares outstanding during the period.</span>
  </div></ix:continuation></ix:nonNumeric><div>
  </div><div>&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 10px; margin-top: 0px; margin-bottom: 0px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">13</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><ix:continuation id="_EarningsPerShareTextBlock-c0_cont_1"><ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_3" id="_EarningsPerSharePolicyTextBlock-c0_cont_2"><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;">
   <span style="color: #000000; font-weight: bold;">Diluted net loss&#160;per share</span>
  </div></ix:continuation>


  <div style="text-indent: 36pt; text-align: justify;">&#160;</div><ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_4" id="_EarningsPerSharePolicyTextBlock-c0_cont_3"><div style="text-indent: 36pt; text-align: justify;"><span style="color: #000000;">For the three and&#160;nine months ended&#160;September 30, 2025 and 2024, we incurred a net loss; therefore, we did not include dilutive common equivalent shares in the computation of diluted net loss per share because the effect would have been anti-dilutive. Common stock from the following would have had an anti-dilutive effect on net loss per share:</span>
  </div></ix:continuation><div>&#160;
  </div>
  <div style="text-indent: -18pt; padding-left: 54pt;">

    <ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_5" id="_EarningsPerSharePolicyTextBlock-c0_cont_4"><div> <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;<ix:nonFraction contextRef="c6" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-11681"><ix:nonFraction contextRef="c129" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-11682">1.75</ix:nonFraction></ix:nonFraction> percent convertible senior notes, or <ix:nonFraction contextRef="c6" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-11683"><ix:nonFraction contextRef="c129" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-11684">1.75</ix:nonFraction></ix:nonFraction>% Notes;</span> </div></ix:continuation>
  </div>
  <div style="text-indent: -18pt; padding-left: 54pt;">

    <ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_6" id="_EarningsPerSharePolicyTextBlock-c0_cont_5"><div> <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;<ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-11685"><ix:nonFraction contextRef="c130" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-11686">0</ix:nonFraction></ix:nonFraction> percent convertible senior notes, or <ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-11687"><ix:nonFraction contextRef="c130" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-11688">0</ix:nonFraction></ix:nonFraction>% Notes;</span> </div></ix:continuation>
  </div>
  <div style="text-indent: -18pt; padding-left: 54pt;">

    <ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_7" id="_EarningsPerSharePolicyTextBlock-c0_cont_6"><div> <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;Note hedges related to the <ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-11689"><ix:nonFraction contextRef="c130" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-11690">0</ix:nonFraction></ix:nonFraction>% Notes;</span> </div></ix:continuation>
  </div>
  <div style="text-indent: -18pt; padding-left: 54pt;">

    <ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_8" id="_EarningsPerSharePolicyTextBlock-c0_cont_7"><div>
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;Dilutive stock options; </span>
    </div></ix:continuation>
  </div>
  <div style="text-indent: -18pt; padding-left: 54pt;">

    <ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_9" id="_EarningsPerSharePolicyTextBlock-c0_cont_8"><div>
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;Unvested restricted stock units, or RSUs; </span>
    </div></ix:continuation>
  </div>
  <div style="text-indent: -18pt; padding-left: 54pt;">

    <ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_10" id="_EarningsPerSharePolicyTextBlock-c0_cont_9"><div>
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;Unvested performance restricted stock units, or PRSUs; and</span>
    </div></ix:continuation>
  </div>
  <div style="text-indent: -18pt; padding-left: 54pt;">

    <ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_11" id="_EarningsPerSharePolicyTextBlock-c0_cont_10"><div>
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;Employee Stock Purchase Plan, or ESPP.</span>
    </div></ix:continuation>
  </div>
  <div>&#160;
  </div>
  <ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_12" id="_EarningsPerSharePolicyTextBlock-c0_cont_11"><div style="text-indent: 36pt; text-align: justify;"> <span>For the three and nine months ended September 30, 2024, common stock underlying the <ix:nonFraction contextRef="c131" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-11691"><ix:nonFraction contextRef="c131" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-11692">0.125</ix:nonFraction></ix:nonFraction> percent</span><span style="color: #000000;"> convertible senior notes, or <ix:nonFraction contextRef="c131" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-11693"><ix:nonFraction contextRef="c131" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-11694">0.125</ix:nonFraction></ix:nonFraction>% Notes</span><span>, and n</span><span style="color: #000000;">ote hedges related to the <ix:nonFraction contextRef="c131" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-11695"><ix:nonFraction contextRef="c131" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-11696">0.125</ix:nonFraction></ix:nonFraction>% Notes </span><span>would also have had an anti-dilutive effect on net loss per share.</span> </div></ix:continuation>
  <div style="text-align: justify;">&#160;
  </div>

  <ix:continuation id="_EarningsPerSharePolicyTextBlock-c0_cont_12"><div style="text-indent: 36pt; text-align: justify;"> As of&#160;September 30, 2025<span style="letter-spacing: normal; text-indent: 48px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">, we had warrants related to our <ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-11697">0</ix:nonFraction>% Notes outstanding.</span> As of September 30, 2024,&#160;we had warrants related to our <ix:nonFraction contextRef="c130" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-11698">0</ix:nonFraction>% and <ix:nonFraction contextRef="c131" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-11699">0.125</ix:nonFraction>% Notes outstanding. We will include the shares issuable under these warrants in our calculation of diluted earnings per share when the average market price per share of our common stock for the reporting period exceeds the strike price of the warrants. </div></ix:continuation></ix:continuation><div>&#160;
  </div><div>
  </div><ix:nonNumeric contextRef="c0" continuedAt="_InvestmentTextBlock-c0_cont_1" escape="true" name="us-gaap:InvestmentTextBlock" id="ixv-4343"><div>
   <span style="color: #000000; font-weight: bold;">7.&#160;&#160;Investments</span>
  </div>
  <div>&#160;
  </div>
  <ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="ixv-4347"><div style="text-indent: 36pt; text-align: justify;"> <span style="color: #000000;">The following table summarizes the contract maturity of the available-for-sale securities we held as of September 30, 2025:</span> </div>
  <div>&#160;</div>
  <div>&#160;</div><table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="background-color: rgb(204, 238, 255);"><td><ix:nonNumeric contextRef="c0" format="ixt-sec:durwordsen" name="ions:MaximumContractMaturityPeriodRange1" id="ixv-11700">One year</ix:nonNumeric> or less </td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B4">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="ions:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage" scale="-2" unitRef="pure" id="ixv-11701">67</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B4">%</td></tr><tr><td>After <ix:nonNumeric contextRef="c0" format="ixt-sec:durwordsen" name="ions:MaximumContractMaturityPeriodRange1" id="ixv-11702">one year</ix:nonNumeric> but within <ix:nonNumeric contextRef="c0" format="ixt-sec:durwordsen" name="ions:MaximumContractMaturityPeriodRange2" id="ixv-11703">two years</ix:nonNumeric> </td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B5">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="ions:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage" scale="-2" unitRef="pure" id="ixv-11704">29</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B5">%</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>After <ix:nonNumeric contextRef="c0" format="ixt-sec:durwordsen" name="ions:MaximumContractMaturityPeriodRange2" id="ixv-11705">two years</ix:nonNumeric> but within <span style="-sec-ix-hidden: hidden-fact-1">three and a half years</span></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B6">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="ions:AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage" scale="-2" unitRef="pure" id="ixv-11706">4</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B6">%</td></tr><tr><td>Total </td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B7">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="ions:AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage" scale="-2" unitRef="pure" id="ixv-11707">100</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B7">%</td></tr></table></ix:nonNumeric>
  <div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span style="color: #000000;">As illustrated above, at September 30, 2025, <ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="ions:AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage" scale="-2" unitRef="pure" id="ixv-11708">96</ix:nonFraction> percent of our available-for-sale securities had a maturity of less than <ix:nonNumeric contextRef="c0" format="ixt-sec:durwordsen" name="ions:MaximumContractMaturityPeriodRange2" id="ixv-11709">two years</ix:nonNumeric>.</span> </div>
  <div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">All of our available-for-sale debt securities are available to us for use in our current operations. As a result, we categorize all of these securities as current assets even though the stated maturity of some individual securities may be one year or more beyond the balance sheet date.</span>
  </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">We invest in debt securities</span><span> with strong credit ratings and an investment grade rating at or above A-1, P-1 or F-1 by Standard &amp; Poor&#8217;s, Moody&#8217;s or Fitch, respectively. </span>
  </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span style="color: #000000;">At September 30, 2025, we had an equity ownership interest of less than 20 percent in <ix:nonFraction contextRef="c2" decimals="INF" format="ixt-sec:numwordsen" name="ions:NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment" scale="0" unitRef="Company" id="ixv-11710">seven</ix:nonFraction> private companies and <ix:nonFraction contextRef="c2" decimals="INF" format="ixt-sec:numwordsen" name="ions:NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment" scale="0" unitRef="Company" id="ixv-11711">three</ix:nonFraction> public companies with which we conduct business. </span> </div></ix:nonNumeric><div>
  </div><div>&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 10px; margin-top: 0px; margin-bottom: 0px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">14</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><ix:nonNumeric contextRef="c0" continuedAt="_UnrealizedGainLossOnInvestmentsTableTextBlock-c0_cont_1" escape="true" name="us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock" id="ixv-4396"><ix:continuation continuedAt="_InvestmentTextBlock-c0_cont_2" id="_InvestmentTextBlock-c0_cont_1"><div> <span style="color: #000000;">The following is a summary of our investments (in thousands):</span> </div>

  <div>&#160;</div><table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/></tr><tr><td>&#160;</td><td style="width: 1%;" title="Note 7. Investments - B9"/><td style="font-weight: bold; text-align: center; width: 9%;">Amortized</td><td style="width: 1%;" title="Note 7. Investments - B9"/><td>&#160;</td><td colspan="7" style="font-weight: bold; text-align: center; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">Gross Unrealized</td><td>&#160;</td><td style="width: 1%;" title="Note 7. Investments - H9"/><td style="font-weight: bold; text-align: center; width: 9%;">Estimated</td><td style="width: 1%;" title="Note 7. Investments - H9"/></tr><tr><td style="font-weight: bold; text-align: left;">September 30, 2025</td><td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - B10"/><td style="font-weight: bold; text-align: center; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">Cost</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B10"/><td>&#160;</td><td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - D10"/><td style="font-weight: bold; text-align: center; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">Gains</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D10"/><td>&#160;</td><td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - F10"/><td style="font-weight: bold; text-align: center; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">Losses</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F10"/><td>&#160;</td><td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - H10"/><td style="font-weight: bold; text-align: center; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">Fair Value</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H10"/></tr><tr><td style="text-decoration: underline;">Available-for-sale debt securities:</td><td style="width: 1%;" title="Note 7. Investments - B11"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 7. Investments - B11"/><td>&#160;</td><td style="width: 1%;" title="Note 7. Investments - D11"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 7. Investments - D11"/><td>&#160;</td><td style="width: 1%;" title="Note 7. Investments - F11"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 7. Investments - F11"/><td>&#160;</td><td style="width: 1%;" title="Note 7. Investments - H11"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 7. Investments - H11"/></tr><tr style="background-color: rgb(204, 238, 255);"><td style="vertical-align: bottom;">Corporate debt securities (1)</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B12">$</td><td style="width: 9%; text-align: right; vertical-align: bottom;"><ix:nonFraction contextRef="c136" decimals="-3" format="ixt:num-dot-decimal" id="ix_0_fact" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" scale="3" unitRef="usd">639,937</ix:nonFraction></td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B12">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D12">$</td><td style="width: 9%; text-align: right; vertical-align: bottom;"><ix:nonFraction contextRef="c136" decimals="-3" format="ixt:num-dot-decimal" name="ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" scale="3" unitRef="usd" id="ixv-11713">815</ix:nonFraction></td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D12">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F12">$</td><td style="width: 9%; text-align: right; vertical-align: bottom;">(<ix:nonFraction contextRef="c136" decimals="-3" format="ixt:num-dot-decimal" name="ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="3" unitRef="usd" id="ixv-11714">69</ix:nonFraction></td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F12">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H12">$</td><td style="width: 9%; text-align: right; vertical-align: bottom;"><ix:nonFraction contextRef="c136" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" unitRef="usd" id="ixv-11715">640,683</ix:nonFraction></td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H12">&#160;</td></tr><tr><td style="vertical-align: bottom;">Debt securities issued by U.S. government agencies</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B13">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;"><ix:nonFraction contextRef="c137" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" scale="3" unitRef="usd" id="ixv-11716">73,905</ix:nonFraction></td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B13">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D13">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;"><ix:nonFraction contextRef="c137" decimals="-3" format="ixt:num-dot-decimal" name="ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" scale="3" unitRef="usd" id="ixv-11717">66</ix:nonFraction></td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D13">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F13">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;">(<ix:nonFraction contextRef="c137" decimals="-3" format="ixt:num-dot-decimal" name="ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="3" unitRef="usd" id="ixv-11718">16</ix:nonFraction></td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F13">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H13">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;"><ix:nonFraction contextRef="c137" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" unitRef="usd" id="ixv-11719">73,955</ix:nonFraction></td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H13">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="vertical-align: bottom;">Debt securities issued by the U.S. Treasury (1)</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B14">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;"><ix:nonFraction contextRef="c138" decimals="-3" format="ixt:num-dot-decimal" id="ix_1_fact" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" scale="3" unitRef="usd">562,662</ix:nonFraction></td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B14">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D14">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;"><ix:nonFraction contextRef="c138" decimals="-3" format="ixt:num-dot-decimal" name="ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" scale="3" unitRef="usd" id="ixv-11721">384</ix:nonFraction></td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D14">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F14">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;">(<ix:nonFraction contextRef="c138" decimals="-3" format="ixt:num-dot-decimal" name="ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="3" unitRef="usd" id="ixv-11722">61</ix:nonFraction></td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F14">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H14">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;"><ix:nonFraction contextRef="c138" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" unitRef="usd" id="ixv-11723">562,985</ix:nonFraction></td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H14">&#160;</td></tr><tr><td style="vertical-align: bottom;">Debt securities issued by states of the U.S. and political subdivisions of&#160;the states</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - B15">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"><ix:nonFraction contextRef="c139" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" scale="3" unitRef="usd" id="ixv-11724">5,151</ix:nonFraction></td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B15">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - D15">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"><ix:nonFraction contextRef="c139" decimals="-3" format="ixt:num-dot-decimal" name="ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" scale="3" unitRef="usd" id="ixv-11725">11</ix:nonFraction></td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D15">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - F15">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"><ix:nonFraction contextRef="c139" decimals="-3" format="ixt:fixed-zero" name="ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="3" unitRef="usd" id="ixv-11726"> - </ix:nonFraction></td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F15">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - H15">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"><ix:nonFraction contextRef="c139" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" unitRef="usd" id="ixv-11727">5,162</ix:nonFraction></td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H15">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="vertical-align: bottom; padding-left: 20px;">Total debt securities with a maturity of one year&#160;or less</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - B16">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" scale="3" unitRef="usd" id="ixv-11728">1,281,655</ix:nonFraction></td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B16">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - D16">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" scale="3" unitRef="usd" id="ixv-11729">1,276</ix:nonFraction></td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D16">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - F16">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="3" unitRef="usd" id="ixv-11730">146</ix:nonFraction></td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F16">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - H16">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" unitRef="usd" id="ixv-11731">1,282,785</ix:nonFraction></td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H16">&#160;</td></tr><tr><td style="vertical-align: bottom;">Corporate debt securities</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B17">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;"><ix:nonFraction contextRef="c136" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" scale="3" unitRef="usd" id="ixv-11732">415,818</ix:nonFraction></td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B17">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D17">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;"><ix:nonFraction contextRef="c136" decimals="-3" format="ixt:num-dot-decimal" name="ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" scale="3" unitRef="usd" id="ixv-11733">1,688</ix:nonFraction></td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D17">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F17">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;">(<ix:nonFraction contextRef="c136" decimals="-3" format="ixt:num-dot-decimal" name="ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" scale="3" unitRef="usd" id="ixv-11734">121</ix:nonFraction></td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F17">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H17">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;"><ix:nonFraction contextRef="c136" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="3" unitRef="usd" id="ixv-11735">417,385</ix:nonFraction></td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H17">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="vertical-align: bottom;">Debt securities issued by U.S. government agencies</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B18">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;"><ix:nonFraction contextRef="c137" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" scale="3" unitRef="usd" id="ixv-11736">76,548</ix:nonFraction></td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B18">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D18">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;"><ix:nonFraction contextRef="c137" decimals="-3" format="ixt:num-dot-decimal" name="ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" scale="3" unitRef="usd" id="ixv-11737">147</ix:nonFraction></td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D18">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F18">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;">(<ix:nonFraction contextRef="c137" decimals="-3" format="ixt:num-dot-decimal" name="ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" scale="3" unitRef="usd" id="ixv-11738">60</ix:nonFraction></td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F18">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H18">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;"><ix:nonFraction contextRef="c137" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="3" unitRef="usd" id="ixv-11739">76,635</ix:nonFraction></td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H18">&#160;</td></tr><tr><td style="vertical-align: bottom;">Debt securities issued by the U.S. Treasury  </td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B19">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;"><ix:nonFraction contextRef="c138" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" scale="3" unitRef="usd" id="ixv-11740">204,656</ix:nonFraction></td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B19">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D19">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;"><ix:nonFraction contextRef="c138" decimals="-3" format="ixt:num-dot-decimal" name="ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" scale="3" unitRef="usd" id="ixv-11741">493</ix:nonFraction></td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D19">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F19">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;">(<ix:nonFraction contextRef="c138" decimals="-3" format="ixt:num-dot-decimal" name="ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" scale="3" unitRef="usd" id="ixv-11742">49</ix:nonFraction></td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F19">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H19">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;"><ix:nonFraction contextRef="c138" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="3" unitRef="usd" id="ixv-11743">205,100</ix:nonFraction></td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H19">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="vertical-align: bottom;">Debt securities issued by states of the U.S. and political subdivisions of&#160;the states</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B20">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;"><ix:nonFraction contextRef="c139" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" scale="3" unitRef="usd" id="ixv-11744">1,117</ix:nonFraction></td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B20">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D20">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;"><ix:nonFraction contextRef="c139" decimals="-3" format="ixt:num-dot-decimal" name="ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" scale="3" unitRef="usd" id="ixv-11745">5</ix:nonFraction></td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D20">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F20">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;"><ix:nonFraction contextRef="c139" decimals="-3" format="ixt:fixed-zero" name="ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" scale="3" unitRef="usd" id="ixv-11746"> - </ix:nonFraction></td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F20">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H20">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;"><ix:nonFraction contextRef="c139" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="3" unitRef="usd" id="ixv-11747">1,122</ix:nonFraction></td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H20">&#160;</td></tr><tr><td style="vertical-align: bottom;">Other municipal debt securities</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - B21">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"><ix:nonFraction contextRef="c140" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" scale="3" unitRef="usd" id="ixv-11748">698</ix:nonFraction></td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B21">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - D21">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"><ix:nonFraction contextRef="c140" decimals="-3" format="ixt:fixed-zero" name="ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" scale="3" unitRef="usd" id="ixv-11749"> - </ix:nonFraction></td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D21">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - F21">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"><ix:nonFraction contextRef="c140" decimals="-3" format="ixt:fixed-zero" name="ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" scale="3" unitRef="usd" id="ixv-11750"> - </ix:nonFraction></td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F21">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - H21">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"><ix:nonFraction contextRef="c140" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="3" unitRef="usd" id="ixv-11751">698</ix:nonFraction></td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H21">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="vertical-align: bottom; padding-left: 20px;">Total debt securities with a maturity of more than one year</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - B22">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" scale="3" unitRef="usd" id="ixv-11752">698,837</ix:nonFraction></td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B22">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - D22">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" scale="3" unitRef="usd" id="ixv-11753">2,333</ix:nonFraction></td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D22">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - F22">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" scale="3" unitRef="usd" id="ixv-11754">230</ix:nonFraction></td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F22">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - H22">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="3" unitRef="usd" id="ixv-11755">700,940</ix:nonFraction></td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H22">&#160;</td></tr><tr><td style="vertical-align: bottom; padding-left: 40px;">Total available-for-sale debt securities</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - B23">$</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" unitRef="usd" id="ixv-11756">1,980,492</ix:nonFraction></td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B23">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - D23">$</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" unitRef="usd" id="ixv-11757">3,609</ix:nonFraction></td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D23">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - F23">$</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" unitRef="usd" id="ixv-11758">376</ix:nonFraction></td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F23">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - H23">$</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" unitRef="usd" id="ixv-11759">1,983,725</ix:nonFraction></td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H23">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="text-decoration: underline; vertical-align: bottom;">Equity securities:</td><td style="width: 1%;" title="Note 7. Investments - B25"/><td style="vertical-align: bottom; width: 9%;">&#160;</td><td style="width: 1%;" title="Note 7. Investments - B25"/><td>&#160;</td><td style="width: 1%;" title="Note 7. Investments - D25"/><td style="vertical-align: bottom; width: 9%;">&#160;</td><td style="width: 1%;" title="Note 7. Investments - D25"/><td>&#160;</td><td style="width: 1%;" title="Note 7. Investments - F25"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 7. Investments - F25"/><td>&#160;</td><td style="width: 1%;" title="Note 7. Investments - H25"/><td style="vertical-align: bottom; width: 9%;">&#160;</td><td style="width: 1%;" title="Note 7. Investments - H25"/></tr><tr><td style="vertical-align: bottom;">Publicly traded equity securities included in other current assets (2)</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B26">$</td><td style="width: 9%; text-align: right; vertical-align: bottom;"><ix:nonFraction contextRef="c141" decimals="-3" format="ixt:num-dot-decimal" id="ix_4_fact" name="us-gaap:EquitySecuritiesFvNiCost" scale="3" unitRef="usd">11,897</ix:nonFraction></td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B26">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D26">$</td><td style="width: 9%; text-align: right; vertical-align: bottom;"><ix:nonFraction contextRef="c141" decimals="-3" format="ixt:num-dot-decimal" name="ions:EquitySecuritiesFvNiAccumulatedGrossUnrealizedGain" scale="3" unitRef="usd" id="ixv-11761">40</ix:nonFraction></td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D26">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F26">$</td><td style="width: 9%; text-align: right; vertical-align: bottom;">(<ix:nonFraction contextRef="c141" decimals="-3" format="ixt:num-dot-decimal" name="ions:EquitySecuritiesFvNiAccumulatedGrossUnrealizedLoss" scale="3" unitRef="usd" id="ixv-11762">8,681</ix:nonFraction></td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F26">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H26">$</td><td style="width: 9%; text-align: right; vertical-align: bottom;"><ix:nonFraction contextRef="c141" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNi" scale="3" unitRef="usd" id="ixv-11763">3,256</ix:nonFraction></td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H26">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="vertical-align: bottom;">Privately held equity securities included in deposits and&#160;other assets (3)</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; vertical-align: bottom;" title="Note 7. Investments - B27">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;"><ix:nonFraction contextRef="c142" decimals="-3" format="ixt:num-dot-decimal" id="ix_6_fact" name="us-gaap:EquitySecuritiesFvNiCost" scale="3" unitRef="usd">4,905</ix:nonFraction></td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B27">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;" title="Note 7. Investments - D27">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;"><ix:nonFraction contextRef="c142" decimals="-3" format="ixt:num-dot-decimal" name="ions:EquitySecuritiesFvNiAccumulatedGrossUnrealizedGain" scale="3" unitRef="usd" id="ixv-11765">54,395</ix:nonFraction></td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D27">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;" title="Note 7. Investments - F27">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;">(<ix:nonFraction contextRef="c142" decimals="-3" format="ixt:num-dot-decimal" name="ions:EquitySecuritiesFvNiAccumulatedGrossUnrealizedLoss" scale="3" unitRef="usd" id="ixv-11766">7,090</ix:nonFraction></td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F27">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;" title="Note 7. Investments - H27">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;"><ix:nonFraction contextRef="c142" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNi" scale="3" unitRef="usd" id="ixv-11767">52,210</ix:nonFraction></td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H27">&#160;</td></tr><tr><td style="vertical-align: bottom; padding-left: 20px;">Total equity securities  </td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;" title="Note 7. Investments - B28">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNiCost" scale="3" unitRef="usd" id="ixv-11768">16,802</ix:nonFraction></td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B28">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;" title="Note 7. Investments - D28">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ions:EquitySecuritiesFvNiAccumulatedGrossUnrealizedGain" scale="3" unitRef="usd" id="ixv-11769">54,435</ix:nonFraction></td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D28">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;" title="Note 7. Investments - F28">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ions:EquitySecuritiesFvNiAccumulatedGrossUnrealizedLoss" scale="3" unitRef="usd" id="ixv-11770">15,771</ix:nonFraction></td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F28">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;" title="Note 7. Investments - H28">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-right: none; vertical-align: bottom;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNi" scale="3" unitRef="usd" id="ixv-11771">55,466</ix:nonFraction></td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H28">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="vertical-align: bottom; padding-left: 40px;">Total available-for-sale debt and equity securities</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - B29">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ions:DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost" scale="3" unitRef="usd" id="ixv-11772">1,997,294</ix:nonFraction></td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B29">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - D29">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ions:DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain" scale="3" unitRef="usd" id="ixv-11773">58,044</ix:nonFraction></td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D29">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - F29">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ions:DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss" scale="3" unitRef="usd" id="ixv-11774">16,147</ix:nonFraction></td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F29">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - H29">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ions:DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi" scale="3" unitRef="usd" id="ixv-11775">2,039,191</ix:nonFraction></td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H29">&#160;</td></tr></table></ix:continuation></ix:nonNumeric><div>&#160;</div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 10px; margin-top: 0px; margin-bottom: 0px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">15</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div>

  </div><ix:continuation id="_InvestmentTextBlock-c0_cont_2"><ix:continuation id="_UnrealizedGainLossOnInvestmentsTableTextBlock-c0_cont_1"><table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/></tr><tr><td>&#160;</td><td style="text-align: center; font-weight: bold; width: 1%;" title="Note 7. Investments - B30"/><td style="text-align: center; font-weight: bold; width: 9%;">Amortized</td><td style="width: 1%;" title="Note 7. Investments - B30"/><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">Gross Unrealized</td><td>&#160;</td><td style="text-align: center; font-weight: bold; width: 1%;" title="Note 7. Investments - H30"/><td style="text-align: center; font-weight: bold; width: 9%;">Estimated</td><td style="width: 1%;" title="Note 7. Investments - H30"/></tr><tr><td style="font-weight: bold;">December 31, 2024</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - B31"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">Cost</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B31"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - D31"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">Gains</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D31"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - F31"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">Losses</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F31"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - H31"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">Fair Value</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H31"/></tr><tr><td style="text-decoration: underline;">Available-for-sale debt securities:</td><td style="width: 1%;" title="Note 7. Investments - B32"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 7. Investments - B32"/><td>&#160;</td><td style="width: 1%;" title="Note 7. Investments - D32"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 7. Investments - D32"/><td>&#160;</td><td style="width: 1%;" title="Note 7. Investments - F32"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 7. Investments - F32"/><td>&#160;</td><td style="width: 1%;" title="Note 7. Investments - H32"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 7. Investments - H32"/></tr><tr style="background-color: rgb(204, 238, 255);"><td>Corporate debt securities (1)</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B33">$</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c143" decimals="-3" format="ixt:num-dot-decimal" id="ix_2_fact" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" scale="3" unitRef="usd">593,810</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B33">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - D33">$</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c143" decimals="-3" format="ixt:num-dot-decimal" name="ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" scale="3" unitRef="usd" id="ixv-11777">487</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 7. Investments - D33">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - F33">$</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c143" decimals="-3" format="ixt:num-dot-decimal" name="ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="3" unitRef="usd" id="ixv-11778">240</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 7. Investments - F33">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - H33">$</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c143" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" unitRef="usd" id="ixv-11779">594,057</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 7. Investments - H33">&#160;</td></tr><tr><td>Debt securities issued by U.S. government agencies</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B34">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c144" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" scale="3" unitRef="usd" id="ixv-11780">143,647</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B34">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - D34">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c144" decimals="-3" format="ixt:num-dot-decimal" name="ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" scale="3" unitRef="usd" id="ixv-11781">287</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 7. Investments - D34">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - F34">&#160;</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c144" decimals="-3" format="ixt:num-dot-decimal" name="ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="3" unitRef="usd" id="ixv-11782">39</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 7. Investments - F34">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - H34">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c144" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" unitRef="usd" id="ixv-11783">143,895</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 7. Investments - H34">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Debt securities issued by the U.S. Treasury (1)</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B35">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c145" decimals="-3" format="ixt:num-dot-decimal" id="ix_3_fact" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" scale="3" unitRef="usd">657,285</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B35">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - D35">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c145" decimals="-3" format="ixt:num-dot-decimal" name="ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" scale="3" unitRef="usd" id="ixv-11785">825</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 7. Investments - D35">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - F35">&#160;</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c145" decimals="-3" format="ixt:num-dot-decimal" name="ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="3" unitRef="usd" id="ixv-11786">120</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 7. Investments - F35">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - H35">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c145" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" unitRef="usd" id="ixv-11787">657,990</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 7. Investments - H35">&#160;</td></tr><tr><td>Debt securities issued by states of the U.S. and political subdivisions of&#160;the states</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B36">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c146" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" scale="3" unitRef="usd" id="ixv-11788">7,516</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B36">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D36">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c146" decimals="-3" format="ixt:num-dot-decimal" name="ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" scale="3" unitRef="usd" id="ixv-11789">8</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D36">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F36">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c146" decimals="-3" format="ixt:fixed-zero" name="ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="3" unitRef="usd" id="ixv-11790"> - </ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F36">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H36">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c146" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" unitRef="usd" id="ixv-11791">7,524</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H36">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 20px;">Total debt securities with a maturity of one year&#160;or less</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B37">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" scale="3" unitRef="usd" id="ixv-11792">1,402,258</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B37">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D37">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" scale="3" unitRef="usd" id="ixv-11793">1,607</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D37">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F37">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="3" unitRef="usd" id="ixv-11794">399</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F37">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H37">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" unitRef="usd" id="ixv-11795">1,403,466</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H37">&#160;</td></tr><tr><td>Corporate debt securities</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B38">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c143" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" scale="3" unitRef="usd" id="ixv-11796">439,561</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B38">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - D38">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c143" decimals="-3" format="ixt:num-dot-decimal" name="ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" scale="3" unitRef="usd" id="ixv-11797">723</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 7. Investments - D38">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - F38">&#160;</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c143" decimals="-3" format="ixt:num-dot-decimal" name="ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" scale="3" unitRef="usd" id="ixv-11798">2,275</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 7. Investments - F38">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - H38">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c143" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="3" unitRef="usd" id="ixv-11799">438,009</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 7. Investments - H38">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Debt securities issued by U.S. government agencies</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B39">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c144" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" scale="3" unitRef="usd" id="ixv-11800">65,255</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B39">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - D39">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c144" decimals="-3" format="ixt:num-dot-decimal" name="ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" scale="3" unitRef="usd" id="ixv-11801">137</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 7. Investments - D39">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - F39">&#160;</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c144" decimals="-3" format="ixt:num-dot-decimal" name="ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" scale="3" unitRef="usd" id="ixv-11802">289</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 7. Investments - F39">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - H39">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c144" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="3" unitRef="usd" id="ixv-11803">65,103</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 7. Investments - H39">&#160;</td></tr><tr><td>Debt securities issued by the U.S. Treasury  </td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B40">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c145" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" scale="3" unitRef="usd" id="ixv-11804">149,086</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B40">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - D40">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c145" decimals="-3" format="ixt:num-dot-decimal" name="ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" scale="3" unitRef="usd" id="ixv-11805">124</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 7. Investments - D40">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - F40">&#160;</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c145" decimals="-3" format="ixt:num-dot-decimal" name="ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" scale="3" unitRef="usd" id="ixv-11806">476</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 7. Investments - F40">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - H40">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c145" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="3" unitRef="usd" id="ixv-11807">148,734</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 7. Investments - H40">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Other municipal debt securities</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B41">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c147" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" scale="3" unitRef="usd" id="ixv-11808">698</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B41">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D41">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c147" decimals="-3" format="ixt:fixed-zero" name="ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" scale="3" unitRef="usd" id="ixv-11809"> - </ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D41">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F41">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">(<ix:nonFraction contextRef="c147" decimals="-3" format="ixt:num-dot-decimal" name="ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" scale="3" unitRef="usd" id="ixv-11810">2</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F41">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H41">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c147" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="3" unitRef="usd" id="ixv-11811">696</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H41">&#160;</td></tr><tr><td style="padding-left: 20px;">Total debt securities with a maturity of more than one year</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none;" title="Note 7. Investments - B42">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" scale="3" unitRef="usd" id="ixv-11812">654,600</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B42">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - D42">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" scale="3" unitRef="usd" id="ixv-11813">984</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D42">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - F42">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" scale="3" unitRef="usd" id="ixv-11814">3,042</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F42">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - H42">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="3" unitRef="usd" id="ixv-11815">652,542</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H42">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 40px;">Total available-for-sale debt securities</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - B43">$</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" unitRef="usd" id="ixv-11816">2,056,858</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B43">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - D43">$</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" unitRef="usd" id="ixv-11817">2,591</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D43">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - F43">$</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" unitRef="usd" id="ixv-11818">3,441</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F43">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - H43">$</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-right: none;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" unitRef="usd" id="ixv-11819">2,056,008</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H43">&#160;</td></tr><tr><td style="text-decoration: underline;">Equity securities:</td><td style="width: 1%;" title="Note 7. Investments - B44"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 7. Investments - B44"/><td>&#160;</td><td style="width: 1%;" title="Note 7. Investments - D44"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 7. Investments - D44"/><td>&#160;</td><td style="width: 1%;" title="Note 7. Investments - F44"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 7. Investments - F44"/><td>&#160;</td><td style="width: 1%;" title="Note 7. Investments - H44"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 7. Investments - H44"/></tr><tr style="background-color: rgb(204, 238, 255);"><td>Publicly traded equity securities included in other current assets (2)</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B45">$</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c148" decimals="-3" format="ixt:num-dot-decimal" id="ix_5_fact" name="us-gaap:EquitySecuritiesFvNiCost" scale="3" unitRef="usd">11,897</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B45">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - D45">$</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c148" decimals="-3" format="ixt:num-dot-decimal" name="ions:EquitySecuritiesFvNiAccumulatedGrossUnrealizedGain" scale="3" unitRef="usd" id="ixv-11821">26</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 7. Investments - D45">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - F45">$</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c148" decimals="-3" format="ixt:num-dot-decimal" name="ions:EquitySecuritiesFvNiAccumulatedGrossUnrealizedLoss" scale="3" unitRef="usd" id="ixv-11822">6,660</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 7. Investments - F45">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - H45">$</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c148" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNi" scale="3" unitRef="usd" id="ixv-11823">5,263</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 7. Investments - H45">&#160;</td></tr><tr><td>Privately held equity securities included in deposits and&#160;other assets (3)</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none;" title="Note 7. Investments - B46">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;"><ix:nonFraction contextRef="c149" decimals="-3" format="ixt:num-dot-decimal" id="ix_7_fact" name="us-gaap:EquitySecuritiesFvNiCost" scale="3" unitRef="usd">23,115</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B46">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - D46">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;"><ix:nonFraction contextRef="c149" decimals="-3" format="ixt:num-dot-decimal" name="ions:EquitySecuritiesFvNiAccumulatedGrossUnrealizedGain" scale="3" unitRef="usd" id="ixv-11825">25,001</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D46">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - F46">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;">(<ix:nonFraction contextRef="c149" decimals="-3" format="ixt:num-dot-decimal" name="ions:EquitySecuritiesFvNiAccumulatedGrossUnrealizedLoss" scale="3" unitRef="usd" id="ixv-11826">7,093</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F46">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - H46">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;"><ix:nonFraction contextRef="c149" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNi" scale="3" unitRef="usd" id="ixv-11827">41,023</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H46">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 20px;">Total equity securities  </td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - B47">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNiCost" scale="3" unitRef="usd" id="ixv-11828">35,012</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B47">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - D47">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ions:EquitySecuritiesFvNiAccumulatedGrossUnrealizedGain" scale="3" unitRef="usd" id="ixv-11829">25,027</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D47">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - F47">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ions:EquitySecuritiesFvNiAccumulatedGrossUnrealizedLoss" scale="3" unitRef="usd" id="ixv-11830">13,753</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F47">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - H47">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-right: none;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNi" scale="3" unitRef="usd" id="ixv-11831">46,286</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H47">&#160;</td></tr><tr><td style="padding-left: 40px;">Total available-for-sale debt and equity securities</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B48">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ions:DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost" scale="3" unitRef="usd" id="ixv-11832">2,091,870</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B48">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D48">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ions:DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain" scale="3" unitRef="usd" id="ixv-11833">27,618</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D48">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F48">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ions:DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss" scale="3" unitRef="usd" id="ixv-11834">17,194</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F48">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H48">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ions:DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi" scale="3" unitRef="usd" id="ixv-11835">2,102,294</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H48">&#160;</td></tr></table><div style="text-align: justify;">&#160;</div><div style="text-indent: -18pt; text-align: justify; padding-left: 18pt;">

    <div> <span style="color: #000000;">(1)&#160;&#160;&#160;<ix:footnote id="ix_0_footnote" xml:lang="en-US">Includes investments classified as cash equivalents in our condensed consolidated balance sheets.</ix:footnote></span> </div>
  </div>
  <div style="margin-left: 18pt;">&#160;
  </div>
  <div style="text-indent: -18pt; text-align: justify; padding-left: 18pt;">

    <div> <span style="color: #000000;">(2)&#160;&#160;<ix:footnote id="ix_1_footnote" xml:lang="en-US">Our publicly traded equity securities are included in other current assets. We recognize publicly traded equity securities at fair value. In the nine months ended September 30, 2025, we recorded a $<ix:nonFraction contextRef="c132" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" scale="6" unitRef="usd" id="ixv-11838">2.0</ix:nonFraction> million net unrealized loss in our condensed consolidated statements of operations related to changes in the fair value of our investments in publicly traded companies.</ix:footnote></span> </div>
  </div>
  <div style="margin-left: 18pt;">&#160;
  </div>
  <div style="text-indent: -18pt; text-align: justify; padding-left: 18pt;">

    <div> <span style="color: #000000;">(3)&#160; <ix:footnote continuedAt="ix_2_footnote_cont_1" id="ix_2_footnote" xml:lang="en-US">Our privately held equity securities are included in deposits and other assets. We recognize our privately held equity securities at</ix:footnote></span><ix:continuation id="ix_2_footnote_cont_1"><span> cost minus impairments, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer, which are Level 3 inputs</span><span style="color: #000000;">. In the nine months ended September 30, 2025, the amortized cost of our privately held equity securities increased $<ix:nonFraction contextRef="c133" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" unitRef="usd" id="ixv-11840">11.2</ix:nonFraction> million. In the third quarter of 2025, we recorded a $<ix:nonFraction contextRef="c134" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGain" scale="6" unitRef="usd" id="ixv-11841">29.4</ix:nonFraction> million unrealized gain related to our investment in a privately held company due to an observable price change in an orderly transaction for a similar investment of the investee. This increase was partially offset by a loss of $<ix:nonFraction contextRef="c135" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" scale="6" unitRef="usd" id="ixv-11842">18.2</ix:nonFraction> million related to an impairment of our investment in another privately held company that we recorded in the second quarter of 2025.</span></ix:continuation></div>
  </div></ix:continuation>
  <div style="text-align: justify; margin-left: 18pt;">&#160;
  </div>
  <ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" id="ixv-5115"><div style="text-indent: 36pt; text-align: justify;"> <span style="color: #000000;">The following is a summary of our investments we consider to be temporarily impaired at September 30, 2025 (in thousands, except for number of investments): </span> </div>

  <div>&#160;</div>
  <table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/></tr><tr><td>&#160;</td><td style="width: 1%;" title="Note 7. Investments - B52"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 7. Investments - B52"/><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">Less than 12 Months of Temporary Impairment</td><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">More than 12 Months of Temporary Impairment</td><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">Total Temporary Impairment</td></tr><tr><td>&#160;</td><td style="width: 1%;" title="Note 7. Investments - B53"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">Number&#160;of Investments</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B53"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - D53"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">Estimated Fair&#160;Value</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D53"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - F53"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">Unrealized Losses</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F53"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - H53"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">Estimated Fair&#160;Value</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H53"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - J53"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">Unrealized Losses</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - J53"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - L53"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">Estimated Fair&#160;Value</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - L53"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - N53"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">Unrealized Losses</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - N53"/></tr><tr style="background-color: rgb(204, 238, 255);"><td>Corporate debt securities  </td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B54">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c136" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" unitRef="Investment" id="ixv-11843">105</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B54">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - D54">$</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c136" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" unitRef="usd" id="ixv-11844">179,031</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 7. Investments - D54">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - F54">$</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c136" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" unitRef="usd" id="ixv-11845">127</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 7. Investments - F54">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - H54">$</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c136" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="3" unitRef="usd" id="ixv-11846">55,955</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 7. Investments - H54">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - J54">$</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c136" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" unitRef="usd" id="ixv-11847">63</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 7. Investments - J54">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - L54">$</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c136" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" unitRef="usd" id="ixv-11848">234,986</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 7. Investments - L54">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - N54">$</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c136" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" unitRef="usd" id="ixv-11849">190</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 7. Investments - N54">)&#160;</td></tr><tr><td>Debt securities issued by&#160;U.S. government agencies</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B55">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c137" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" unitRef="Investment" id="ixv-11850">43</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B55">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - D55">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c137" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" unitRef="usd" id="ixv-11851">71,369</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 7. Investments - D55">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - F55">&#160;</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c137" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" unitRef="usd" id="ixv-11852">60</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 7. Investments - F55">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - H55">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c137" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="3" unitRef="usd" id="ixv-11853">17,286</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 7. Investments - H55">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - J55">&#160;</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c137" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" unitRef="usd" id="ixv-11854">16</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 7. Investments - J55">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - L55">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c137" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" unitRef="usd" id="ixv-11855">88,655</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 7. Investments - L55">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - N55">&#160;</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c137" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" unitRef="usd" id="ixv-11856">76</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 7. Investments - N55">)&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Debt securities issued by the U.S. Treasury  </td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B56">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c138" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" unitRef="Investment" id="ixv-11857">25</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B56">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - D56">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c138" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" unitRef="usd" id="ixv-11858">141,191</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 7. Investments - D56">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - F56">&#160;</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c138" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" unitRef="usd" id="ixv-11859">74</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 7. Investments - F56">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - H56">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c138" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="3" unitRef="usd" id="ixv-11860">46,285</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 7. Investments - H56">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - J56">&#160;</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c138" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" unitRef="usd" id="ixv-11861">36</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 7. Investments - J56">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - L56">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c138" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" unitRef="usd" id="ixv-11862">187,476</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 7. Investments - L56">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - N56">&#160;</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c138" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" unitRef="usd" id="ixv-11863">110</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 7. Investments - N56">)&#160;</td></tr><tr><td>Other municipal debt securities</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B58">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c140" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" unitRef="Investment" id="ixv-11864">1</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B58">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D58">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c140" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" unitRef="usd" id="ixv-11865">698</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D58">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F58">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c140" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" unitRef="usd" id="ixv-11866"> - </ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F58">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H58">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c140" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="3" unitRef="usd" id="ixv-11867"> - </ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H58">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - J58">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c140" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" unitRef="usd" id="ixv-11868"> - </ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - J58">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - L58">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c140" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" unitRef="usd" id="ixv-11869">698</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - L58">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - N58">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c140" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" unitRef="usd" id="ixv-11870"> - </ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - N58">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Total temporarily impaired&#160;debt securities</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B59">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" unitRef="Investment" id="ixv-11871">174</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B59">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D59">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" unitRef="usd" id="ixv-11872">392,289</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D59">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F59">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" unitRef="usd" id="ixv-11873">261</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F59">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H59">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="3" unitRef="usd" id="ixv-11874">119,526</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H59">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - J59">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" unitRef="usd" id="ixv-11875">115</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - J59">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - L59">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" unitRef="usd" id="ixv-11876">511,815</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - L59">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - N59">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" unitRef="usd" id="ixv-11877">376</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - N59">)&#160;</td></tr></table></ix:nonNumeric><div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span>We believe that the decline in value of these securities is temporary and is primarily related to the change in market interest rates since purchase rather than underlying credit deterioration for any of the issuers. We believe it is more likely than not that we will be able to hold our debt securities with declines in value to maturity. Therefore, we intend to hold these securities to maturity and anticipate full recovery of our debt securities&#8217; amortized cost basis at maturity.</span>
  </div></ix:continuation><div>
  </div><div>&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 10px; margin-top: 0px; margin-bottom: 0px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">16</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:FairValueDisclosuresTextBlock" id="ixv-5346"><div>
   <span style="color: #000000; font-weight: bold;">8.&#160;&#160;Fair Value Measurements</span>
  </div>
  <div>&#160;
  </div>
  <ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="ixv-5350"><div style="text-indent: 36pt; text-align: justify;"> <span style="color: #000000;">The following tables present the major security types we held at September 30, 2025 and December 31, 2024 that we regularly measure and carry at fair value. The following tables segregate each security type by the level within the fair value hierarchy of the valuation techniques we utilized to determine the respective security&#8217;s fair value (in thousands):</span> </div>


  <div>&#160;</div>
  <table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/></tr><tr><td>&#160;</td><td style="width: 1%;" title="Note 8. Fair Value Measurements - B3"/><td style="vertical-align: bottom; text-align: center; font-weight: bold; width: 9%;">At</td><td style="width: 1%;" title="Note 8. Fair Value Measurements - B3"/><td>&#160;</td><td style="width: 1%;" title="Note 8. Fair Value Measurements - D3"/><td style="text-align: center; font-weight: bold; vertical-align: bottom; width: 9%;">Quoted&#160;Prices&#160;in Active&#160;Markets</td><td style="width: 1%;" title="Note 8. Fair Value Measurements - D3"/><td>&#160;</td><td style="width: 1%;" title="Note 8. Fair Value Measurements - F3"/><td style="text-align: center; font-weight: bold; width: 9%;">Significant&#160;Other Observable Inputs</td><td style="width: 1%;" title="Note 8. Fair Value Measurements - F3"/></tr><tr><td>&#160;</td><td style="border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 8. Fair Value Measurements - B4"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; width: 9%;">September 30, 2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - B4"/><td>&#160;</td><td style="border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 8. Fair Value Measurements - D4"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; width: 9%;">(Level 1)</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - D4"/><td>&#160;</td><td style="border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 8. Fair Value Measurements - F4"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; width: 9%;">(Level 2)</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - F4"/></tr><tr style="background-color: rgb(204, 238, 255);"><td>Cash equivalents (1)  </td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B5">$</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c157" decimals="-3" format="ixt:num-dot-decimal" id="ix_8_fact" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" unitRef="usd">167,298</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B5">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D5">$</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c158" decimals="-3" format="ixt:num-dot-decimal" id="ix_9_fact" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" unitRef="usd">167,298</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D5">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F5">$</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c159" decimals="-3" format="ixt:fixed-zero" id="ix_10_fact" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" unitRef="usd"> - </ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F5">&#160;</td></tr><tr><td>Corporate debt securities (2)  </td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B6">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c160" decimals="-3" format="ixt:num-dot-decimal" id="ix_14_fact" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" unitRef="usd">1,058,068</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B6">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D6">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c161" decimals="-3" format="ixt:fixed-zero" id="ix_15_fact" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" unitRef="usd"> - </ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D6">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F6">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c162" decimals="-3" format="ixt:num-dot-decimal" id="ix_16_fact" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" unitRef="usd">1,058,068</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F6">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Debt securities issued by U.S. government agencies (3)  </td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B7">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c163" decimals="-3" format="ixt:num-dot-decimal" id="ix_17_fact" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" unitRef="usd">150,590</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B7">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D7">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c164" decimals="-3" format="ixt:fixed-zero" id="ix_18_fact" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" unitRef="usd"> - </ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D7">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F7">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c165" decimals="-3" format="ixt:num-dot-decimal" id="ix_19_fact" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" unitRef="usd">150,590</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F7">&#160;</td></tr><tr><td>Debt securities issued by the U.S. Treasury (4)</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B8">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c166" decimals="-3" format="ixt:num-dot-decimal" id="ix_41_fact" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" unitRef="usd">768,085</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B8">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D8">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c167" decimals="-3" format="ixt:num-dot-decimal" id="ix_42_fact" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" unitRef="usd">768,085</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D8">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F8">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c168" decimals="-3" format="ixt:fixed-zero" id="ix_43_fact" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" unitRef="usd"> - </ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F8">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Debt securities issued by states of the U.S. and political subdivisions of the states (5)</td><td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - B9">&#160;</td><td style="text-align: right; vertical-align: bottom; width: 9%;"><ix:nonFraction contextRef="c169" decimals="-3" format="ixt:num-dot-decimal" id="ix_20_fact" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" unitRef="usd">6,284</ix:nonFraction></td><td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - B9">&#160;</td><td>&#160;</td><td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - D9">&#160;</td><td style="text-align: right; vertical-align: bottom; width: 9%;"><ix:nonFraction contextRef="c170" decimals="-3" format="ixt:fixed-zero" id="ix_21_fact" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" unitRef="usd"> - </ix:nonFraction></td><td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - D9">&#160;</td><td>&#160;</td><td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - F9">&#160;</td><td style="text-align: right; vertical-align: bottom; width: 9%;"><ix:nonFraction contextRef="c171" decimals="-3" format="ixt:num-dot-decimal" id="ix_22_fact" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" unitRef="usd">6,284</ix:nonFraction></td><td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - F9">&#160;</td></tr><tr><td>Other municipal debt securities (5)</td><td style="text-align: left; border-width: initial; border-style: none; border-color: initial; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - B10">&#160;</td><td style="text-align: right; border-width: initial; border-style: none; border-color: initial; vertical-align: bottom; width: 9%;"><ix:nonFraction contextRef="c172" decimals="-3" format="ixt:num-dot-decimal" id="ix_23_fact" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" unitRef="usd">698</ix:nonFraction></td><td style="text-align: left; vertical-align: bottom; border-width: initial; border-style: none; border-color: initial; width: 1%;" title="Note 8. Fair Value Measurements - B10">&#160;</td><td>&#160;</td><td style="text-align: left; border-width: initial; border-style: none; border-color: initial; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - D10">&#160;</td><td style="text-align: right; border-width: initial; border-style: none; border-color: initial; vertical-align: bottom; width: 9%;"><ix:nonFraction contextRef="c173" decimals="-3" format="ixt:fixed-zero" id="ix_24_fact" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" unitRef="usd"> - </ix:nonFraction></td><td style="text-align: left; vertical-align: bottom; border-width: initial; border-style: none; border-color: initial; width: 1%;" title="Note 8. Fair Value Measurements - D10">&#160;</td><td>&#160;</td><td style="text-align: left; border-width: initial; border-style: none; border-color: initial; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - F10">&#160;</td><td style="text-align: right; border-width: initial; border-style: none; border-color: initial; vertical-align: bottom; width: 9%;"><ix:nonFraction contextRef="c174" decimals="-3" format="ixt:num-dot-decimal" id="ix_25_fact" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" unitRef="usd">698</ix:nonFraction></td><td style="text-align: left; vertical-align: bottom; border-width: initial; border-style: none; border-color: initial; width: 1%;" title="Note 8. Fair Value Measurements - F10">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Publicly traded equity securities included in other current assets (6)</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - B10">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; vertical-align: bottom; width: 9%;"><ix:nonFraction contextRef="c175" decimals="-3" format="ixt:num-dot-decimal" id="ix_44_fact" name="us-gaap:EquitySecuritiesFvNi" scale="3" unitRef="usd">3,256</ix:nonFraction></td><td style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - B10">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - D10">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; vertical-align: bottom; width: 9%;"><ix:nonFraction contextRef="c176" decimals="-3" format="ixt:num-dot-decimal" id="ix_45_fact" name="us-gaap:EquitySecuritiesFvNi" scale="3" unitRef="usd">3,256</ix:nonFraction></td><td style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - D10">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - F10">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-right: none; vertical-align: bottom; width: 9%;"><ix:nonFraction contextRef="c177" decimals="-3" format="ixt:fixed-zero" id="ix_46_fact" name="us-gaap:EquitySecuritiesFvNi" scale="3" unitRef="usd"> - </ix:nonFraction></td><td style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - F10">&#160;</td></tr><tr><td style="padding-left: 20px;">Total  </td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 8. Fair Value Measurements - B11">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;"><ix:nonFraction contextRef="c157" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" unitRef="usd" id="ixv-11899">2,154,279</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - B11">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 8. Fair Value Measurements - D11">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;"><ix:nonFraction contextRef="c158" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" unitRef="usd" id="ixv-11900">938,639</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - D11">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 8. Fair Value Measurements - F11">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;"><ix:nonFraction contextRef="c159" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" unitRef="usd" id="ixv-11901">1,215,640</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - F11">&#160;</td></tr></table><div>&#160;</div>
  <table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/></tr><tr><td>&#160;</td><td style="width: 1%;" title="Note 8. Fair Value Measurements - B13"/><td style="vertical-align: bottom; text-align: center; font-weight: bold; width: 9%;">At</td><td style="width: 1%;" title="Note 8. Fair Value Measurements - B13"/><td>&#160;</td><td style="width: 1%;" title="Note 8. Fair Value Measurements - D13"/><td style="text-align: center; font-weight: bold; vertical-align: bottom; width: 9%;">Quoted&#160;Prices&#160;in Active&#160;Markets</td><td style="width: 1%;" title="Note 8. Fair Value Measurements - D13"/><td>&#160;</td><td style="width: 1%;" title="Note 8. Fair Value Measurements - F13"/><td style="text-align: center; font-weight: bold; width: 9%;">Significant&#160;Other Observable Inputs</td><td style="width: 1%;" title="Note 8. Fair Value Measurements - F13"/></tr><tr><td>&#160;</td><td style="border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 8. Fair Value Measurements - B14"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; width: 9%;">December 31, 2024</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - B14"/><td>&#160;</td><td style="border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 8. Fair Value Measurements - D14"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; width: 9%;">(Level 1)</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - D14"/><td>&#160;</td><td style="border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 8. Fair Value Measurements - F14"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; width: 9%;">(Level 2)</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - F14"/></tr><tr style="background-color: rgb(204, 238, 255);"><td>Cash equivalents (1) </td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B15">$</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c178" decimals="-3" format="ixt:num-dot-decimal" id="ix_11_fact" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" unitRef="usd">180,445</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B15">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D15">$</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c179" decimals="-3" format="ixt:num-dot-decimal" id="ix_12_fact" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" unitRef="usd">180,445</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D15">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F15">$</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c180" decimals="-3" format="ixt:fixed-zero" id="ix_13_fact" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" unitRef="usd">-</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F15">&#160;</td></tr><tr><td>Corporate debt securities (5)</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B16">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c181" decimals="-3" format="ixt:num-dot-decimal" id="ix_26_fact" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" unitRef="usd">1,032,066</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B16">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D16">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c182" decimals="-3" format="ixt:fixed-zero" id="ix_27_fact" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" unitRef="usd">-</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D16">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F16">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c183" decimals="-3" format="ixt:num-dot-decimal" id="ix_28_fact" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" unitRef="usd">1,032,066</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F16">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Debt securities issued by U.S. government agencies (5)</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B17">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c184" decimals="-3" format="ixt:num-dot-decimal" id="ix_29_fact" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" unitRef="usd">208,998</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B17">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D17">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c185" decimals="-3" format="ixt:fixed-zero" id="ix_30_fact" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" unitRef="usd">-</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D17">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F17">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c186" decimals="-3" format="ixt:num-dot-decimal" id="ix_31_fact" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" unitRef="usd">208,998</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F17">&#160;</td></tr><tr><td>Debt securities issued by the U.S. Treasury (5)</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B18">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c187" decimals="-3" format="ixt:num-dot-decimal" id="ix_32_fact" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" unitRef="usd">806,724</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B18">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D18">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c188" decimals="-3" format="ixt:num-dot-decimal" id="ix_33_fact" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" unitRef="usd">806,724</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D18">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F18">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c189" decimals="-3" format="ixt:fixed-zero" id="ix_34_fact" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" unitRef="usd">-</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F18">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Debt securities issued by states of the U.S. and political subdivisions of the states (5)</td><td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - B19">&#160;</td><td style="text-align: right; vertical-align: bottom; width: 9%;"><ix:nonFraction contextRef="c190" decimals="-3" format="ixt:num-dot-decimal" id="ix_35_fact" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" unitRef="usd">7,524</ix:nonFraction></td><td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - B19">&#160;</td><td>&#160;</td><td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - D19">&#160;</td><td style="text-align: right; vertical-align: bottom; width: 9%;"><ix:nonFraction contextRef="c191" decimals="-3" format="ixt:fixed-zero" id="ix_36_fact" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" unitRef="usd">-</ix:nonFraction></td><td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - D19">&#160;</td><td>&#160;</td><td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - F19">&#160;</td><td style="text-align: right; vertical-align: bottom; width: 9%;"><ix:nonFraction contextRef="c192" decimals="-3" format="ixt:num-dot-decimal" id="ix_37_fact" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" unitRef="usd">7,524</ix:nonFraction></td><td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - F19">&#160;</td></tr><tr><td>Other municipal debt securities (5)</td><td style="text-align: left; vertical-align: bottom; border-width: initial; border-style: none; border-color: initial; width: 1%;" title="Note 8. Fair Value Measurements - B20">&#160;</td><td style="text-align: right; vertical-align: bottom; border-width: initial; border-style: none; border-color: initial; width: 9%;"><ix:nonFraction contextRef="c193" decimals="-3" format="ixt:num-dot-decimal" id="ix_38_fact" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" unitRef="usd">696</ix:nonFraction></td><td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - B20">&#160;</td><td>&#160;</td><td style="text-align: left; vertical-align: bottom; border-width: initial; border-style: none; border-color: initial; width: 1%;" title="Note 8. Fair Value Measurements - D20">&#160;</td><td style="text-align: right; vertical-align: bottom; border-width: initial; border-style: none; border-color: initial; width: 9%;"><ix:nonFraction contextRef="c194" decimals="-3" format="ixt:fixed-zero" id="ix_39_fact" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" unitRef="usd">-</ix:nonFraction></td><td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - D20">&#160;</td><td>&#160;</td><td style="text-align: left; vertical-align: bottom; border-width: initial; border-style: none; border-color: initial; width: 1%;" title="Note 8. Fair Value Measurements - F20">&#160;</td><td style="text-align: right; vertical-align: bottom; border-width: initial; border-style: none; border-color: initial; width: 9%;"><ix:nonFraction contextRef="c195" decimals="-3" format="ixt:num-dot-decimal" id="ix_40_fact" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" unitRef="usd">696</ix:nonFraction></td><td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - F20">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Publicly traded equity securities included in other current assets (6)</td><td style="text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 8. Fair Value Measurements - B20">&#160;</td><td style="text-align: right; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; width: 9%;"><ix:nonFraction contextRef="c196" decimals="-3" format="ixt:num-dot-decimal" id="ix_47_fact" name="us-gaap:EquitySecuritiesFvNi" scale="3" unitRef="usd">5,263</ix:nonFraction></td><td style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - B20">&#160;</td><td>&#160;</td><td style="text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 8. Fair Value Measurements - D20">&#160;</td><td style="text-align: right; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; width: 9%;"><ix:nonFraction contextRef="c197" decimals="-3" format="ixt:num-dot-decimal" id="ix_48_fact" name="us-gaap:EquitySecuritiesFvNi" scale="3" unitRef="usd">5,263</ix:nonFraction></td><td style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - D20">&#160;</td><td>&#160;</td><td style="text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 8. Fair Value Measurements - F20">&#160;</td><td style="text-align: right; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-right: none; width: 9%;"><ix:nonFraction contextRef="c198" decimals="-3" format="ixt:fixed-zero" id="ix_49_fact" name="us-gaap:EquitySecuritiesFvNi" scale="3" unitRef="usd">-</ix:nonFraction></td><td style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - F20">&#160;</td></tr><tr><td style="padding-left: 20px;">Total </td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 8. Fair Value Measurements - B21">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;"><ix:nonFraction contextRef="c178" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" unitRef="usd" id="ixv-11923">2,241,716</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - B21">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 8. Fair Value Measurements - D21">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;"><ix:nonFraction contextRef="c179" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" unitRef="usd" id="ixv-11924">992,432</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - D21">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 8. Fair Value Measurements - F21">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;"><ix:nonFraction contextRef="c180" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" unitRef="usd" id="ixv-11925">1,249,284</ix:nonFraction></td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - F21">&#160;</td></tr></table><div style="text-align: justify; margin-left: 18pt;">&#160;
  </div>
  <div style="text-align: justify;"> <span style="color: #000000;">The following footnotes reference lines in our condensed consolidated balance sheets:</span></div>
  <div style="text-align: justify;">&#160;</div><div style="text-align: justify;">(1)&#160; &#160; <ix:footnote id="ix_3_footnote" xml:lang="en-US">Included in cash and cash equivalents.</ix:footnote></div><div style="text-align: justify;">&#160;</div><div style="text-align: justify;">(2)&#160;&#160;&#160;&#160;<ix:footnote id="ix_4_footnote" xml:lang="en-US">$<ix:nonFraction contextRef="c150" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" unitRef="usd" id="ixv-11928">39.9</ix:nonFraction> million was included in cash and cash equivalents, with the difference included in short-term investments.</ix:footnote></div><div style="text-align: justify;">&#160;</div><div style="text-align: justify;">(3)&#160; &#160; $<ix:nonFraction contextRef="c151" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" unitRef="usd" id="ixv-11929">6.0</ix:nonFraction> million was included in cash and cash equivalents, with the difference i<span style="letter-spacing: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">ncluded in short-term investments.</span></div><div style="text-align: justify;">&#160;</div><div style="text-align: justify;">(4)&#160; &#160; <ix:footnote id="ix_6_footnote" xml:lang="en-US"><span style="letter-spacing: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">$<ix:nonFraction contextRef="c152" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" unitRef="usd" id="ixv-11930">36.0</ix:nonFraction> million was included in cash and cash equivalents, with the difference included in short-term investments.</span></ix:footnote></div><div style="text-align: justify;">&#160;</div><div style="text-align: justify;">(5)&#160; &#160; <ix:footnote id="ix_5_footnote" xml:lang="en-US">Included in short-term investments.</ix:footnote></div><div style="text-align: justify;">&#160;</div><div style="text-align: justify;">(6)&#160; &#160; <ix:footnote id="ix_7_footnote" xml:lang="en-US">Included in other current assets.</ix:footnote></div></ix:nonNumeric>
  <div style="text-indent: -18pt; text-align: justify; padding-left: 18pt;">


  &#160;</div>








  <div style="text-indent: 36pt;"><span style="color: #000000; font-style: italic;">Convertible Notes</span>
  </div><div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span style="color: #000000;">Our <ix:nonFraction contextRef="c6" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-11933">1.75</ix:nonFraction>% Notes and <ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-11934">0</ix:nonFraction>% Notes had a fair value of $<ix:nonFraction contextRef="c153" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" unitRef="usd" id="ixv-11935">794.5</ix:nonFraction> million and $<ix:nonFraction contextRef="c154" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" unitRef="usd" id="ixv-11936">777.0</ix:nonFraction> million at September 30, 2025, respectively. Our <ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-11937">1.75</ix:nonFraction>% Notes and <ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-11938">0</ix:nonFraction>% Notes had a fair value of $<ix:nonFraction contextRef="c155" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" unitRef="usd" id="ixv-11939">569.3</ix:nonFraction> million and $<ix:nonFraction contextRef="c156" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" unitRef="usd" id="ixv-11940">612.8</ix:nonFraction> million at December 31, 2024, respectively. We determine the fair value of our notes based on quoted market prices for these notes, which are Level 2 measurements because the notes do not trade regularly.</span> </div></ix:nonNumeric><div>
  </div><div>&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 10px; margin-top: 0px; margin-bottom: 0px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">17</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_1" escape="true" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="ixv-5676"><div>
   <span style="color: #000000; font-weight: bold;">9. Stock-based Compensation Expense</span>
  </div>
  <div style="text-align: justify;">&#160;
  </div>
  <ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="ixv-5680"><div style="text-indent: 36pt; text-align: justify;"> <span style="color: #000000;">The following table summarizes stock-based compensation expense for the three and nine months ended September 30, 2025 and 2024 (in thousands):</span> </div>
  <div style="text-indent: 36pt; text-align: justify;">&#160;</div>
  <table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold;">Three Months Ended</td><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold;">Nine Months Ended</td></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td></tr><tr><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 9. Stock-based Compensation Expense - B5"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none;" title="Note 9. Stock-based Compensation Expense - B5"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 9. Stock-based Compensation Expense - D5"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none;" title="Note 9. Stock-based Compensation Expense - D5"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 9. Stock-based Compensation Expense - F5"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none;" title="Note 9. Stock-based Compensation Expense - F5"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 9. Stock-based Compensation Expense - H5"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="width: 1%;" title="Note 9. Stock-based Compensation Expense - H5"/></tr><tr style="background-color: rgb(204, 238, 255);"><td>Cost of sales</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B6">$</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c221" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-11941">145</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B6">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D6">$</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c222" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-11942">159</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D6">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - F6">$</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c223" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-11943">855</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - F6">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - H6">$</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c224" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-11944">609</ix:nonFraction></td><td style="width: 1%; text-align: left; border-width: initial; border-style: none; border-color: initial;" title="Note 9. Stock-based Compensation Expense - H6">&#160;</td></tr><tr><td>Research, development and patent expense</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B7">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c225" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-11945">20,757</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B7">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D7">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c226" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-11946">22,120</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D7">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - F7">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c227" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-11947">60,597</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - F7">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - H7">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c228" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-11948">67,111</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - H7">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Selling, general and administrative expense</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - B8">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c229" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-11949">10,244</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 9. Stock-based Compensation Expense - B8">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - D8">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c230" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-11950">9,705</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 9. Stock-based Compensation Expense - D8">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - F8">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-11951">29,102</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 9. Stock-based Compensation Expense - F8">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - H8">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c232" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-11952">26,332</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 9. Stock-based Compensation Expense - H8">&#160;</td></tr><tr><td style="padding-left: 20px;">Stock-based compensation expense, net of amounts capitalized</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - B9">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c36" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-11953">31,146</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 9. Stock-based Compensation Expense - B9">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - D9">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-11954">31,984</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 9. Stock-based Compensation Expense - D9">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - F9">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-11955">90,554</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 9. Stock-based Compensation Expense - F9">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - H9">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-11956">94,052</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 9. Stock-based Compensation Expense - H9">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Capitalized stock-based compensation expense</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - B10">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c36" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="3" unitRef="usd" id="ixv-11957">435</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - B10">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - D10">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="3" unitRef="usd" id="ixv-11958">506</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 9. Stock-based Compensation Expense - D10">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - F10">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="3" unitRef="usd" id="ixv-11959">1,435</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 9. Stock-based Compensation Expense - F10">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - H10">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="3" unitRef="usd" id="ixv-11960">506</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 9. Stock-based Compensation Expense - H10">&#160;</td></tr><tr><td style="padding-left: 20px;">Total stock-based compensation expense</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - B11">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c36" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" scale="3" unitRef="usd" id="ixv-11961">31,581</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - B11">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - D11">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" scale="3" unitRef="usd" id="ixv-11962">32,490</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - D11">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - F11">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" scale="3" unitRef="usd" id="ixv-11963">91,989</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - F11">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - H11">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" scale="3" unitRef="usd" id="ixv-11964">94,558</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - H11">&#160;</td></tr></table></ix:nonNumeric><div style="text-indent: 36pt; text-align: justify;">&#160;</div>

  <div style="text-indent: 36pt; text-align: justify;"> <span style="color: #000000;">As of September 30, 2025, total unrecognized estimated stock-based compensation expense related to non-vested stock options, RSUs and PRSUs was $<ix:nonFraction contextRef="c199" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" unitRef="usd" id="ixv-11965">37.2</ix:nonFraction> million, $<ix:nonFraction contextRef="c200" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" unitRef="usd" id="ixv-11966">88.1</ix:nonFraction> million and $<ix:nonFraction contextRef="c201" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" unitRef="usd" id="ixv-11967">13.0</ix:nonFraction> million, respectively. Our actual expenses will likely differ from these estimates because we will adjust our unrecognized stock-based compensation expense for future forfeitures, including any PRSUs that do not vest. We expect to recognize the cost of stock-based compensation expense related to our non-vested stock options, RSUs and PRSUs over a weighted average amortization period of <ix:nonNumeric contextRef="c202" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="ixv-11968">1.2</ix:nonNumeric> years, <ix:nonNumeric contextRef="c203" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="ixv-11969">1.5</ix:nonNumeric> years and <ix:nonNumeric contextRef="c204" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="ixv-11970">1.4</ix:nonNumeric> years, respectively.</span> </div>
  <div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">Refer to Part IV, Item 15, Note 1, </span><span style="color: #000000; font-style: italic;">Organization and Significant Accounting Policies</span><span style="color: #000000;">, of our audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2024 for further details on how we determine the fair value of stock options granted, RSUs, PRSUs and stock purchase rights under the ESPP.</span>
  </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">For the nine months ended  September 30, 2025 and 2024, we used the following weighted-average assumptions in our Black-Scholes calculations:</span>
  </div>
  <div>&#160;
  </div>
  <ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="ixv-5843"><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"> <span style="color: #000000; font-style: italic;">Employee Stock Options:</span></div>


  <div style="text-indent: 36pt;">&#160;</div><table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold;">Nine Months Ended</td></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td></tr><tr><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 9. Stock-based Compensation Expense - B17"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - B17"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 9. Stock-based Compensation Expense - D17"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - D17"/></tr><tr style="background-color: rgb(204, 238, 255);"><td>Risk-free interest rate </td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B18">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c205" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-11971">4.4</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B18">%</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D18">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c206" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-11972">4.1</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D18">%</td></tr><tr><td>Dividend yield </td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B19">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c205" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure" id="ixv-11973">0.0</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B19">%</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D19">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c206" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure" id="ixv-11974">0.0</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D19">%</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Volatility </td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B20">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c205" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" unitRef="pure" id="ixv-11975">42.1</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B20">%</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D20">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c206" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" unitRef="pure" id="ixv-11976">43.8</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D20">%</td></tr><tr><td>Expected life</td><td style="width: 1%;" title="Note 9. Stock-based Compensation Expense - B21"/><td style="text-align: right; width: 9%;"><ix:nonNumeric contextRef="c205" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-11977">6.3</ix:nonNumeric> years</td><td style="width: 1%;" title="Note 9. Stock-based Compensation Expense - B21"/><td>&#160;</td><td style="width: 1%;" title="Note 9. Stock-based Compensation Expense - D21"/><td style="text-align: right; width: 9%;"><ix:nonNumeric contextRef="c206" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-11978">6.3</ix:nonNumeric> years</td><td style="width: 1%;" title="Note 9. Stock-based Compensation Expense - D21"/></tr></table><div>&#160;</div><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"><i>Board of Director Stock Options:</i></div><div>&#160;</div><table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold;">Nine Months Ended</td></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td></tr><tr><td>&#160;</td><td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 9. Stock-based Compensation Expense - B35"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 9. Stock-based Compensation Expense - B35"/><td>&#160;</td><td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 9. Stock-based Compensation Expense - D35"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 9. Stock-based Compensation Expense - D35"/></tr><tr style="background-color: rgb(204, 238, 255);"><td>Risk-free interest rate </td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B36">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c233" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-11979">4.0</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B36">%</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D36">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c234" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-11980">4.5</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D36">%</td></tr><tr><td>Dividend yield </td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B37">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c233" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure" id="ixv-11981">0.0</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B37">%</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D37">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c234" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure" id="ixv-11982">0.0</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D37">%</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Volatility </td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B38">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c233" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" unitRef="pure" id="ixv-11983">43.0</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B38">%</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D38">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c234" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" unitRef="pure" id="ixv-11984">49.8</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D38">%</td></tr><tr><td>Expected life</td><td style="width: 1%;" title="Note 9. Stock-based Compensation Expense - B39"/><td style="text-align: right; width: 9%;"><ix:nonNumeric contextRef="c233" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-11985">7.4</ix:nonNumeric> years</td><td style="width: 1%;" title="Note 9. Stock-based Compensation Expense - B39"/><td>&#160;</td><td style="width: 1%;" title="Note 9. Stock-based Compensation Expense - D39"/><td style="text-align: right; width: 9%;"><ix:nonNumeric contextRef="c234" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-11986">7.5</ix:nonNumeric> years</td><td style="width: 1%;" title="Note 9. Stock-based Compensation Expense - D39"/></tr></table></ix:nonNumeric><div>&#160;</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" id="ixv-5974"><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"> <span style="color: #000000; font-style: italic;">ESPP:</span></div>



  <div style="text-indent: 36pt; text-align: justify;">&#160;</div><table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold;">Nine Months Ended</td></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td></tr><tr><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 9. Stock-based Compensation Expense - B26"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - B26"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 9. Stock-based Compensation Expense - D26"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - D26"/></tr><tr style="background-color: rgb(204, 238, 255);"><td>Risk-free interest rate </td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B27">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c235" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-11987">4.2</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B27">%</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D27">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c236" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-11988">5.2</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D27">%</td></tr><tr><td>Dividend yield </td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B28">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c235" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure" id="ixv-11989">0.0</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B28">%</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D28">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c236" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure" id="ixv-11990">0.0</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D28">%</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Volatility </td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B29">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c235" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" unitRef="pure" id="ixv-11991">48.2</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B29">%</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D29">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c236" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" unitRef="pure" id="ixv-11992">37.8</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D29">%</td></tr><tr><td>Expected life</td><td style="width: 1%;" title="Note 9. Stock-based Compensation Expense - B30"/><td style="text-align: right; width: 9%;"><ix:nonNumeric contextRef="c235" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-11993">6</ix:nonNumeric> months</td><td style="width: 1%;" title="Note 9. Stock-based Compensation Expense - B30"/><td>&#160;</td><td style="width: 1%;" title="Note 9. Stock-based Compensation Expense - D30"/><td style="text-align: right; width: 9%;"><ix:nonNumeric contextRef="c236" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-11994">6</ix:nonNumeric> months</td><td style="width: 1%;" title="Note 9. Stock-based Compensation Expense - D30"/></tr></table></ix:nonNumeric></ix:nonNumeric><div>&#160;</div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 10px; margin-top: 0px; margin-bottom: 0px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">18</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><ix:continuation id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_1"><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"><i>Stock Options:</i></div>
  <div style="text-indent: 36pt; line-height: 1.15; text-align: justify;">&#160;</div><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"><span style="letter-spacing: normal; text-align: justify; text-indent: 48px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">The weighted-average grant date fair value of stock options granted to employees for the&#160;</span><span style="cursor: pointer; letter-spacing: normal; text-align: justify; text-indent: 48px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;">nine months ended&#160;September 30, 2025</span><span style="letter-spacing: normal; text-align: justify; text-indent: 48px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">&#160;and&#160;</span><span style="cursor: pointer; letter-spacing: normal; text-align: justify; text-indent: 48px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;">2024</span><span style="letter-spacing: normal; text-align: justify; text-indent: 48px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">&#160;was $<ix:nonFraction contextRef="c205" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-11995">17.21</ix:nonFraction> and $<ix:nonFraction contextRef="c206" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-11996">24.73</ix:nonFraction> per share, respectively.&#160;<span style="text-decoration-thickness: initial; float: none; display: inline !important;">The weighted-average grant date fair value of stock options granted to non-employee directors for the&#160;</span><span style="cursor: pointer; text-decoration-thickness: initial;">nine months ended&#160;September 30, 2025</span><span style="text-decoration-thickness: initial; float: none; display: inline !important;">&#160;and&#160;</span><span style="cursor: pointer; text-decoration-thickness: initial;">2024</span><span style="text-decoration-thickness: initial; float: none; display: inline !important;">&#160;was $<ix:nonFraction contextRef="c207" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-11997">20.86</ix:nonFraction> and $<ix:nonFraction contextRef="c208" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-11998">27.47</ix:nonFraction> per share, respectively.</span></span></div><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;">&#160;</div><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"><span style="color: #000000; font-style: italic;">RSUs:</span>
  </div><div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span style="color: #000000;">The weighted-average grant date fair value of RSUs granted to employees for the nine months ended September 30, 2025 and 2024 was $<ix:nonFraction contextRef="c209" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-11999">33.78</ix:nonFraction> and $<ix:nonFraction contextRef="c210" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-12000">52.08</ix:nonFraction> per share, respectively. </span> </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt;">
   <span style="color: #000000; font-style: italic;">PRSUs:</span>
  </div>
  <div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span>Under the terms of the PRSUs we granted in 2025 and 2024, the PRSUs may vest at the end of the <ix:nonNumeric contextRef="c212" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="ixv-12001"><ix:nonNumeric contextRef="c211" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="ixv-12002">three-year</ix:nonNumeric></ix:nonNumeric> performance period based on our relative total shareholder return, or TSR, as compared to a peer group of companies and as measured at the end of the performance period. Under the terms of the grants, <ix:nonFraction contextRef="c213" decimals="INF" format="ixt:fixed-zero" name="ions:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfUnitsGuaranteedToVest" scale="0" unitRef="shares" id="ixv-12003"><ix:nonFraction contextRef="c214" decimals="INF" format="ixt:fixed-zero" name="ions:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfUnitsGuaranteedToVest" scale="0" unitRef="shares" id="ixv-12004">no</ix:nonFraction></ix:nonFraction> number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of each performance period may be anywhere from <ix:nonFraction contextRef="c215" decimals="INF" format="ixt:fixed-zero" name="ions:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfUnitsGuaranteedToVest" scale="-2" unitRef="pure" id="ixv-12005"><ix:nonFraction contextRef="c216" decimals="INF" format="ixt:fixed-zero" name="ions:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfUnitsGuaranteedToVest" scale="-2" unitRef="pure" id="ixv-12006">zero</ix:nonFraction></ix:nonFraction> to <ix:nonFraction contextRef="c217" decimals="INF" format="ixt:num-dot-decimal" name="ions:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfUnitsGuaranteedToVest" scale="-2" unitRef="pure" id="ixv-12007"><ix:nonFraction contextRef="c218" decimals="INF" format="ixt:num-dot-decimal" name="ions:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfUnitsGuaranteedToVest" scale="-2" unitRef="pure" id="ixv-12008">200</ix:nonFraction></ix:nonFraction> percent of the target number depending on our relative TSR.</span> </div>
  <div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span>The weighted-average grant date fair value of PRSUs we granted to our executive officers for the nine months ended September 30, 2025 and 2024 was $<ix:nonFraction contextRef="c219" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-12009">48.81</ix:nonFraction> and $<ix:nonFraction contextRef="c220" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-12010">78.41</ix:nonFraction> per share, respectively.</span> </div></ix:continuation><div>
  </div><div>&#160;
  </div><div>
  </div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock" id="ixv-6079"><div style="text-indent: -36pt; padding-left: 36pt;">
   <span style="color: #000000; font-weight: bold;">10.&#160;&#160;Income Taxes</span>
  </div>
  <div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span style="color: #000000;">We recorded nominal income tax expense for the three and nine months ended September 30, 2025 compared to income tax benefit of $<ix:nonFraction contextRef="c37" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" sign="-" unitRef="usd" id="ixv-12011">3.6</ix:nonFraction> million and $<ix:nonFraction contextRef="c38" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" sign="-" unitRef="usd" id="ixv-12012">3.5</ix:nonFraction> million for the same periods in 2024.</span></div>
  <div style="text-align: justify;">&#160;</div>
  <div style="text-indent: 36pt; line-height: 1.15; text-align: justify;">The benefit for the three and nine months ended September 30, 2024 was primarily related to the 2023 tax return position for the royalty purchase agreement with Royalty Pharma that we finalized during the third quarter of 2024.</div><div style="text-align: justify;">&#160;</div><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;">In July 2025, the One Big Beautiful Bill Act, or OBBBA, was signed into law, introducing significant changes to U.S. federal tax law. The new law restores current expensing of domestic R&amp;D costs and allows us to accelerate the deduction for a significant amount of such costs we capitalized since 2022.
 The tax law changes from the OBBBA did not have a material effect on our tax expense for the three and nine months ended September 30, 2025.</div><div style="text-align: justify;">&#160;</div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">We continue to maintain a full valuation allowance on all of our net deferred tax assets.</span>
  </div></ix:nonNumeric><div>
  </div><div>&#160;
  </div><div>
  </div><ix:nonNumeric contextRef="c0" continuedAt="_OtherLiabilitiesDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:OtherLiabilitiesDisclosureTextBlock" id="ixv-6095"><div>
   <span style="font-weight: bold;">11. Liability Related to Sale of Future Royalties</span>
  </div>
  <div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span style="color: #000000;">In 2023, we entered into a royalty purchase agreement with Royalty Pharma Investments, or Royalty Pharma, to monetize a portion of our future SPINRAZA and pelacarsen royalties we are entitled to under our arrangements with Biogen and Novartis, respectively. As a result, we received an upfront payment of $<ix:nonFraction contextRef="c237" decimals="-6" format="ixt:num-dot-decimal" name="ions:UpfrontRoyaltyPaymentReceived" scale="6" unitRef="usd" id="ixv-12013">500</ix:nonFraction> million and we are eligible to receive up to $<ix:nonFraction contextRef="c238" decimals="-6" format="ixt:num-dot-decimal" name="ions:MaximumAmountOfPaymentsReceivableForAdditionalMilestones" scale="6" unitRef="usd" id="ixv-12014">625</ix:nonFraction> million in additional milestone payments. Under the terms of the agreement, Royalty Pharma will receive <ix:nonFraction contextRef="c239" decimals="INF" format="ixt:num-dot-decimal" name="ions:PercentageOfRoyaltyPaymentsPaidOnAnnualSalesOfMedicine" scale="-2" unitRef="pure" id="ixv-12015">25</ix:nonFraction> percent of our SPINRAZA royalty payments from 2023 through 2027, increasing to <ix:nonFraction contextRef="c240" decimals="INF" format="ixt:num-dot-decimal" name="ions:PercentageOfRoyaltyPaymentsPaidOnAnnualSalesOfMedicine" scale="-2" unitRef="pure" id="ixv-12016">45</ix:nonFraction> percent of royalty payments in 2028, on up to $<ix:nonFraction contextRef="c241" decimals="-8" format="ixt:num-dot-decimal" name="ions:MaximumAmountOfAnnualSalesOnWhichRoyaltyPaymentsArePaid" scale="9" unitRef="usd" id="ixv-12017">1.5</ix:nonFraction> billion in annual sales. In addition, Royalty Pharma will receive <ix:nonFraction contextRef="c242" decimals="INF" format="ixt:num-dot-decimal" name="ions:PercentageOfRoyaltyPaymentsPaidOnAnnualSalesOfMedicine" scale="-2" unitRef="pure" id="ixv-12018">25</ix:nonFraction> percent of any future royalty payments on pelacarsen, our medicine in development to treat patients with elevated lipoprotein(a)-driven cardiovascular disease. Royalty Pharma&#8217;s royalty interest in SPINRAZA will revert to us after total SPINRAZA royalty payments to Royalty Pharma reach either $<ix:nonFraction contextRef="c239" decimals="-6" format="ixt:num-dot-decimal" name="ions:MaximumRoyaltyPaymentsMadeBeforeRoyaltyInterestRevertsBack" scale="6" unitRef="usd" id="ixv-12019">475</ix:nonFraction> million or $<ix:nonFraction contextRef="c240" decimals="-6" format="ixt:num-dot-decimal" name="ions:MaximumRoyaltyPaymentsMadeBeforeRoyaltyInterestRevertsBack" scale="6" unitRef="usd" id="ixv-12020">550</ix:nonFraction> million, depending on the timing and occurrence of FDA approval of pelacarsen.</span> </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span style="color: #000000;">We recorded the upfront payment of $<ix:nonFraction contextRef="c237" decimals="-6" format="ixt:num-dot-decimal" name="ions:UpfrontRoyaltyPaymentReceived" scale="6" unitRef="usd" id="ixv-12021">500</ix:nonFraction> million as a liability related to the sale of future royalties, net of transaction costs of $<ix:nonFraction contextRef="c237" decimals="-5" format="ixt:num-dot-decimal" name="ions:PaymentsForTransactionCostsRelatedToSaleOfFutureRoyalties" scale="6" unitRef="usd" id="ixv-12022">10.4</ix:nonFraction> million, which we are amortizing over the estimated life of the arrangement using the effective interest rate method. We recognize royalty revenue in the period in which the counterparty sells the related product and recognizes the related revenue. We record royalty payments made to Royalty Pharma as a reduction of the liability.</span> </div>
  <div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span style="color: #000000;">We determine the effective interest rate used to record interest expense under this agreement based on an estimate of future royalty payments to Royalty Pharma. As of September 30, 2025 and 2024, the estimated effective interest rate under the agreement was <ix:nonFraction contextRef="c238" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure" id="ixv-12023">12.4</ix:nonFraction> percent and <ix:nonFraction contextRef="c243" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure" id="ixv-12024">13.5</ix:nonFraction> percent, respectively.</span> </div></ix:nonNumeric><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 10px; margin-top: 0px; margin-bottom: 0px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">19</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><ix:continuation id="_OtherLiabilitiesDisclosureTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:OtherNoncurrentLiabilitiesTableTextBlock" id="ixv-6117"><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"> <span style="color: #000000;">The following table sets forth information on our liability related to sale of future royalties (in thousands):</span> </div>

  <div style="text-align: justify;">&#160;</div><table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="background-color: rgb(204, 238, 255);"><td>Liability related to sale of future royalties, net as of December 31, 2024</td><td style="width: 1%; text-align: left;" title="Note 11. Liability Related to Sale of Future Royalties - B4">$</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c244" decimals="-3" format="ixt:num-dot-decimal" name="ions:LiabilityRelatedToSaleOfFutureRoyaltiesNet" scale="3" unitRef="usd" id="ixv-12025">542,212</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 11. Liability Related to Sale of Future Royalties - B4">&#160;</td></tr><tr><td>Royalty payments to Royalty Pharma</td><td style="width: 1%; text-align: left;" title="Note 11. Liability Related to Sale of Future Royalties - B5">&#160;</td><td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c245" decimals="-3" format="ixt:num-dot-decimal" name="ions:RoyaltyPayments" scale="3" unitRef="usd" id="ixv-12026">38,478</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 11. Liability Related to Sale of Future Royalties - B5">)&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Interest expense related to sale of future royalties</td><td style="width: 1%; text-align: left;" title="Note 11. Liability Related to Sale of Future Royalties - B6">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c245" decimals="-3" format="ixt:num-dot-decimal" name="ions:InterestExpenseRelatedToSaleOfFutureRoyalties" scale="3" unitRef="usd" id="ixv-12027">54,964</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 11. Liability Related to Sale of Future Royalties - B6">&#160;</td></tr><tr><td>Amortization of issuance costs related to sale of future royalties</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none;" title="Note 11. Liability Related to Sale of Future Royalties - B7">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;"><ix:nonFraction contextRef="c245" decimals="-3" format="ixt:num-dot-decimal" name="ions:AmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties" scale="3" unitRef="usd" id="ixv-12028">458</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 11. Liability Related to Sale of Future Royalties - B7">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Liability related to sale of future royalties, net as of September 30, 2025</td><td style="width: 1%; text-align: left;" title="Note 11. Liability Related to Sale of Future Royalties - B8">$</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c238" decimals="-3" format="ixt:num-dot-decimal" name="ions:LiabilityRelatedToSaleOfFutureRoyaltiesNet" scale="3" unitRef="usd" id="ixv-12029">559,156</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 11. Liability Related to Sale of Future Royalties - B8">&#160;</td></tr><tr><td>Less: Current portion (1)</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 11. Liability Related to Sale of Future Royalties - B9">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-right: none;">(<ix:nonFraction contextRef="c246" decimals="-3" format="ixt:num-dot-decimal" name="ions:LiabilityRelatedToSaleOfFutureRoyaltiesNetCurrent" scale="3" unitRef="usd" id="ixv-12030">13,974</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 11. Liability Related to Sale of Future Royalties - B9">)&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Liability related to sale of future royalties, net as of September 30, 2025 &#8211; Non-current</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 11. Liability Related to Sale of Future Royalties - B10">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c238" decimals="-3" format="ixt:num-dot-decimal" name="ions:LiabilityRelatedToSaleOfFutureRoyaltiesNetNoncurrent" scale="3" unitRef="usd" id="ixv-12031">545,182</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 11. Liability Related to Sale of Future Royalties - B10">&#160;</td></tr></table></ix:nonNumeric>
  <div>&#160;
  </div>
  <div style="text-indent: -18pt; text-align: justify; padding-left: 18pt;">

    <div>
     <span style="color: #000000;">(1)&#160; &#160;Included in other current liabilities in our condensed consolidated balance sheet.</span>
    </div>
  </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">There are numerous factors, most of which are not within our control, that could materially impact the amount and timing of royalty payments from Biogen and Novartis, and result in changes to our estimate of future royalty payments to Royalty Pharma. Such factors include, but are not limited to, the commercial sales of SPINRAZA, the regulatory approval and commercial sales of pelacarsen, competing products or other significant events. </span>
  </div></ix:continuation><div>
  </div><div>&#160;
  </div><div>
  </div><ix:nonNumeric contextRef="c0" continuedAt="_DebtDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:DebtDisclosureTextBlock" id="ixv-6167"><div>
   <span style="font-weight: bold;">12. Convertible Debt</span>
  </div>
  <div style="font-size: 9pt;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span style="color: #000000; font-style: italic;"><ix:nonFraction contextRef="c6" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-12032">1.75</ix:nonFraction> Percent Convertible Senior Notes</span> </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span style="font-family: Times;">In 2023, we completed a $<ix:nonFraction contextRef="c247" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" unitRef="usd" id="ixv-12033">575.0</ix:nonFraction> million offering of our <ix:nonFraction contextRef="c6" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-12034">1.75</ix:nonFraction>% Notes. </span> </div>
  <div style="text-align: justify;">&#160;
  </div>
  <ix:nonNumeric contextRef="c250" escape="true" name="us-gaap:ConvertibleDebtTableTextBlock" id="ixv-6177"><div style="text-indent: 36pt; text-align: justify;"> <span>At September 30, 2025, we had the following <ix:nonFraction contextRef="c6" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-12035">1.75</ix:nonFraction>% Notes outstanding (in millions except interest rate and price per share data):</span> </div>
  <div style="text-align: justify; color: #000000;">&#160;
  </div>

  <div>&#160;</div>
  <table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/></tr><tr><td>&#160;</td><td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 12. Convertible Debt - B4"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">1.75% Notes</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 12. Convertible Debt - B4"/></tr><tr style="background-color: rgb(204, 238, 255);"><td>Outstanding principal balance</td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B5">$</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c6" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" unitRef="usd" id="ixv-12036">575.0</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B5">&#160;</td></tr><tr><td>Unamortized debt issuance costs</td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B6">$</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c6" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredFinanceCostsNet" scale="6" unitRef="usd" id="ixv-12037">7.9</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B6">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Maturity date</td><td style="width: 1%;" title="Note 12. Convertible Debt - B7"/><td style="text-align: right; width: 9%;"><div style="-sec-ix-hidden: hidden-fact-2">June 2028</div></td><td style="width: 1%;" title="Note 12. Convertible Debt - B7"/></tr><tr><td>Interest rate</td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B8">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c6" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-12038">1.75</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B8">%</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Effective interest rate</td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B9">$</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c6" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure" id="ixv-12039">2.30</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B9">%</td></tr><tr><td>Conversion price per share</td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B10">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-12040">53.73</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B10">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Total shares of common stock subject to conversion</td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B11">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c6" decimals="-5" format="ixt:num-dot-decimal" name="ions:DebtInstrumentConvertibleSharesSubjectToConversion" scale="6" unitRef="shares" id="ixv-12041">10.7</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B11">&#160;</td></tr></table></ix:nonNumeric><div>&#160;</div><div style="text-indent: 36pt; text-align: justify;"> <span style="color: #000000; font-style: italic;"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-12042">0</ix:nonFraction> Percent Convertible Senior Notes and Call Spread</span><span style="color: #000000; font-weight: bold; font-style: italic;">&#160;</span> </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span>In 2021, we completed a $<ix:nonFraction contextRef="c248" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" unitRef="usd" id="ixv-12043">632.5</ix:nonFraction> million offering of our <ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-12044">0</ix:nonFraction>% Notes. </span></div>
  <div style="text-align: justify;">&#160;
  </div>
  <ix:nonNumeric contextRef="c251" escape="true" name="us-gaap:ConvertibleDebtTableTextBlock" id="ixv-6237"><div style="text-indent: 36pt; text-align: justify;"> <span>At September 30, 2025, we had the following </span><span style="font-family: Times;"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-12045">0</ix:nonFraction>%</span><span> Notes outstanding (in millions except interest rate and price per share data):</span> </div>
  <div style="text-align: justify; color: #000000;">&#160;</div>
  <div style="text-align: justify; color: #000000;">&#160;</div>
  <table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/></tr><tr><td>&#160;</td><td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 12. Convertible Debt - B15"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">0% Notes</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 12. Convertible Debt - B15"/></tr><tr style="background-color: rgb(204, 238, 255);"><td>Outstanding principal balance</td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B16">$</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c4" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" unitRef="usd" id="ixv-12046">632.5</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B16">&#160;</td></tr><tr><td>Unamortized debt issuance costs</td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B17">$</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c4" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredFinanceCostsNet" scale="6" unitRef="usd" id="ixv-12047">1.6</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B17">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Maturity date</td><td style="width: 1%;" title="Note 12. Convertible Debt - B18"/><td style="text-align: right; width: 9%;"><div style="-sec-ix-hidden: hidden-fact-3">April 2026</div></td><td style="width: 1%;" title="Note 12. Convertible Debt - B18"/></tr><tr><td>Interest rate</td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B19">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-12048">0</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B19">%</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Effective interest rate</td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B20">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c4" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure" id="ixv-12049">0.50</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B20">%</td></tr><tr><td>Conversion price per share</td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B21">$</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-12050">57.84</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B21">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Effective conversion price per share with call spread</td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B22">$</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="ions:DebtInstrumentConvertibleConversionPriceIncludingCallSpread" scale="0" unitRef="usdPershares" id="ixv-12051">76.39</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B22">&#160;</td></tr><tr><td>Total shares of common stock subject to conversion</td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B23">&#160;</td><td style="text-align: right; width: 9%;"><ix:nonFraction contextRef="c4" decimals="-5" format="ixt:num-dot-decimal" name="ions:DebtInstrumentConvertibleSharesSubjectToConversion" scale="6" unitRef="shares" id="ixv-12052">10.9</ix:nonFraction></td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B23">&#160;</td></tr></table></ix:nonNumeric></ix:nonNumeric><div style="text-align: justify; color: #000000;">&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 10px; margin-top: 0px; margin-bottom: 0px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">20</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><ix:continuation id="_DebtDisclosureTextBlock-c0_cont_1"><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"> In conjunction with the 2021 offering, we entered into a call spread transaction, which was comprised of purchasing note hedges and selling warrants, to minimize the impact of potential economic dilution upon conversion of our <span style="font-family: Times;"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-12053">0</ix:nonFraction>%</span> Notes by increasing the effective conversion price on our <span style="font-family: Times;"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-12054">0</ix:nonFraction>%</span>&#160;Notes. We increased our effective conversion price to $<ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="ions:DebtInstrumentConvertibleConversionPriceIncludingCallSpread" scale="0" unitRef="usdPershares" id="ixv-12055">76.39</ix:nonFraction> with the same number of underlying shares as our <span style="font-family: Times;"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-12056">0</ix:nonFraction>% </span>Notes. The call spread cost us $<ix:nonFraction contextRef="c249" decimals="-5" format="ixt:num-dot-decimal" name="ions:CallSpread" scale="6" unitRef="usd" id="ixv-12057">46.9</ix:nonFraction> million, of which $<ix:nonFraction contextRef="c249" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForHedgeFinancingActivities" scale="6" unitRef="usd" id="ixv-12058">136.7</ix:nonFraction> million was for the note hedge purchase, offset by $<ix:nonFraction contextRef="c249" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="6" unitRef="usd" id="ixv-12059">89.8</ix:nonFraction> million we received for selling the warrants. Similar to our <span style="font-family: Times;"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-12060">0</ix:nonFraction>%</span> Notes, our note hedges are subject to adjustment. Additionally, our note hedges are exercisable upon conversion of the <span style="font-family: Times;"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-12061">0</ix:nonFraction>%</span>&#160;Notes. The note hedges will expire upon maturity of the <span style="font-family: Times;"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-12062">0</ix:nonFraction>%</span> Notes, or April 2026. The warrants will expire in July 2026. The note hedges and warrants are separate transactions and are not part of the terms of our <span style="font-family: Times;"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-12063">0</ix:nonFraction>%</span> Notes. The holders of the <span style="font-family: Times;"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-12064">0</ix:nonFraction>%</span> Notes do not have any rights with respect to the note hedges and warrants. </div>
  <div style="text-align: justify; color: #000000;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span>We recorded the amount we paid for the note hedges and the amount we received for the warrants in additional paid-in capital in our condensed consolidated balance sheets. Refer to Part IV, Item 15, Note 1, </span><span style="font-style: italic;">Organization and Significant Accounting Policies</span><span>, of our audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2024 for our Call Spread accounting policy. We reassess our ability to continue to classify the note hedges and warrants in shareholders&#8217; equity at each reporting period.</span>
  </div>
  <div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span style="font-style: italic;">Other Terms of Convertible Senior Notes</span>
  </div>
  <div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span style="color: #000000;">The <ix:nonFraction contextRef="c6" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-12065">1.75</ix:nonFraction>% and <ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-12066">0</ix:nonFraction>% Notes are convertible under certain conditions, at the option of the note holders. We can settle conversions of the notes, at our election, in cash, shares of our common stock or a combination of both. We may not redeem the notes prior to maturity, and we do not have to provide a sinking fund for them. Holders of the notes may require us to purchase some or all of their notes upon the occurrence of certain fundamental changes, as set forth in the indentures governing the notes, at a purchase price equal to <ix:nonFraction contextRef="c250" decimals="INF" format="ixt:num-dot-decimal" name="ions:DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange" scale="-2" unitRef="pure" id="ixv-12067"><ix:nonFraction contextRef="c251" decimals="INF" format="ixt:num-dot-decimal" name="ions:DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange" scale="-2" unitRef="pure" id="ixv-12068">100</ix:nonFraction></ix:nonFraction> percent of the principal amount of the notes to be purchased, plus any accrued and unpaid interest.</span> </div></ix:continuation><div>
  </div><div>&#160;</div><div>
  </div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:LesseeOperatingLeasesTextBlock" id="ixv-6328"><div><span style="font-weight: 700; letter-spacing: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">13. Operating Leases</span></div><div>&#160;</div><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;">In 2022, we concurrently entered into <ix:nonFraction contextRef="c252" decimals="INF" format="ixt-sec:numwordsen" name="ions:NumberOfPurchaseAndSaleAgreementsEnteredIntoWithRealEstateInvestor" scale="0" unitRef="Agreement" id="ixv-12069">two</ix:nonFraction> purchase and sale agreements with a real estate investor. In the same period, we closed the first transaction in which we sold the facilities at our headquarters in Carlsbad, California, which includes our primary R&amp;D facility, for a purchase price of $<ix:nonFraction contextRef="c253" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="6" unitRef="usd" id="ixv-12070">263.4</ix:nonFraction> million. In connection with this transaction, we leased back our headquarters facilities for an initial lease term of <ix:nonNumeric contextRef="c254" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="ixv-12071">15</ix:nonNumeric> years with options to extend the lease for <ix:nonFraction contextRef="c254" decimals="INF" format="ixt-sec:numwordsen" name="ions:LesseeOperatingLeaseNumberOfOptionsToExtendLease" scale="0" unitRef="Option" id="ixv-12072">two</ix:nonFraction> additional terms of <ix:nonNumeric contextRef="c254" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="ixv-12073">five years</ix:nonNumeric> each.
</div><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;">&#160;</div><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;">In 2023, we closed the second transaction and transferred legal ownership of <ix:nonFraction contextRef="c255" decimals="INF" format="ixt-sec:numwordsen" name="ions:NumberOfLotsOfUndevelopedLandTransferredToRealEstateInvestor" scale="0" unitRef="Lot" id="ixv-12074">two</ix:nonFraction> lots of undeveloped land adjacent to our headquarters to the real estate investor for a purchase price of $<ix:nonFraction contextRef="c255" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="6" unitRef="usd" id="ixv-12075">33.0</ix:nonFraction> million. In connection with this transaction, we entered into a build-to-suit lease agreement with the same real estate investor to lease a new R&amp;D facility. The lessor developed and constructed a new building composed of R&amp;D and office space. We are designing and constructing tenant improvements to customize the facility&#8217;s interior space.
</div><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;">&#160;</div><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;">The lease commenced in September 2025 when the lessor completed constructing the structure of the new facility. The initial lease term for this facility is <ix:nonNumeric contextRef="c254" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="ixv-12076">15</ix:nonNumeric> years with options to extend the lease for <ix:nonFraction contextRef="c254" decimals="INF" format="ixt:num-dot-decimal" name="ions:LesseeOperatingLeaseNumberOfOptionsToExtendLease" scale="0" unitRef="Option" id="ixv-12077">2</ix:nonFraction> additional terms of <ix:nonNumeric contextRef="c254" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="ixv-12078">five years</ix:nonNumeric> each. We determined at lease inception that it was not reasonably certain that we would exercise any of the options to extend the lease. We estimated our lease payments over the initial term to total approximately $<ix:nonFraction contextRef="c254" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="6" unitRef="usd" id="ixv-12079">230</ix:nonFraction> million. In addition, we expect to receive reimbursements totaling $<ix:nonFraction contextRef="c254" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IncentiveFromLessor" scale="6" unitRef="usd" id="ixv-12080">41.2</ix:nonFraction> million from the lessor for tenant improvements that we own.
</div><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;">&#160;</div><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;">Since the building was under construction and unavailable to lease, we were unable to complete the sale-leaseback evaluation under ASC Topic 842, Leases, in 2023. As a result, the land remained in our consolidated balance sheets and we accounted for the proceeds as a financial liability. In September 2025, we reassessed the transaction under the sale-leaseback accounting guidance when the facility became available for lease commencement. We determined the transaction qualified as a sale-leaseback transaction upon lease commencement. As a result, we de-recognized the land and recorded a net gain of $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleAndLeasebackTransactionGainLossNet" scale="6" unitRef="usd" id="ixv-12081">4.2</ix:nonFraction> million that we reported within operating loss in our condensed consolidated statements of operations. In addition, we recorded a financial liability of $<ix:nonFraction contextRef="c2" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilities" scale="6" unitRef="usd" id="ixv-12082">19.6</ix:nonFraction> million, which reflects the difference in the fair value of the land as of the lease commencement date compared to the purchase price of the land in 2023. W<span style="letter-spacing: normal; text-align: justify; text-indent: 48px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">e reported the current portion of the financial liability in other current liabilities and the non-current portion of the financial liability in long-term obligations in our condensed consolidated balance sheets. We recognize interest expense related to the financial liability based on our incremental borrowing rate at the commencement of the lease. We allocate payments to the lessor between the financial liability and lease expense.</span></div></ix:nonNumeric><div>&#160;</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:LegalMattersAndContingenciesTextBlock" id="ixv-6341"><div>
   <span style="font-weight: bold;">14. Legal Proceedings</span>
  </div>
  <div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">From time to time, we are involved in legal proceedings arising in the ordinary course of our business. Periodically, we evaluate the status of each legal matter and assess our potential financial exposure. If we consider the potential loss from any legal proceeding to be probable and we can reasonably estimate the amount, we accrue a liability for the estimated loss. The outcome of any proceeding is not determinable in advance. Therefore, we are required to use significant judgment to determine the probability of a loss and whether the amount of the loss is reasonably estimable. Our assessment of a potential liability and the amount of accruals we recorded are based only on the information available to us at the time. As additional information becomes available, we reassess the potential liability related to the legal proceeding and may revise our estimates.</span>
  </div>
  <div style="text-align: justify;">&#160;
  </div>

  <div style="text-indent: 36pt; text-align: justify;">
   On September 10, 2025, Arrowhead Pharmaceuticals, Inc., or Arrowhead, filed a lawsuit in the District of Delaware seeking a declaratory judgment that our patent US9,593,333 is invalid or not infringed by use of Arrowhead&#8217;s ApoCIII inhibitor plozasiran.  On September 11, 2025, we filed suit in the Central District of California asserting infringement of that same patent by Arrowhead&#8217;s announced intention to commercialize plozasiran in November 2025. On October 8, 2025, we filed a motion to dismiss, or in the alternative, transfer Arrowhead&#8217;s Delaware suit in favor of the case we brought in the Central District of California.  At present, both lawsuits remain pending.   </div></ix:nonNumeric><div>&#160;
  </div><div>
  </div><ix:nonNumeric contextRef="c0" continuedAt="_SegmentReportingDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:SegmentReportingDisclosureTextBlock" id="ixv-6351"><div>
   <span style="font-weight: bold;">15. Segment Information</span>
  </div>
  <div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span>We operate as a <span style="-sec-ix-hidden: hidden-fact-4">single</span> operating segment, Ionis operations, focused on the research, development and commercialization of our RNA-targeted medicines to bring better futures to people with serious diseases. The CODM, our Chief Executive Officer, manages our company, reviews operating results, assesses performance and allocates resources on an aggregate basis using consolidated net income or loss as the key measure of segment profit or loss. As such, results of our operations are reported on a consolidated basis for purposes of management and segment reporting.</span> </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span>Ionis operations derives its revenues from commercial and R&amp;D revenue sources. Refer to Note 4, </span><span style="font-style: italic;">Revenues</span><span>, for further details on our sources of revenue.</span>
  </div></ix:nonNumeric><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 10px; margin-top: 0px; margin-bottom: 0px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">21</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="ixv-6372"><ix:continuation id="_SegmentReportingDisclosureTextBlock-c0_cont_1"><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"> The following table sets forth information on segment profit or loss, including significant segment expenses (in thousands): </div>
  <div style="text-align: justify;">&#160;</div>

  <table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold;">Three Months Ended</td><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold;">Nine Months Ended</td></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td></tr><tr><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 14. Segment Information - B5"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - B5"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 14. Segment Information - D5"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - D5"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 14. Segment Information - F5"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - F5"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 14. Segment Information - H5"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - H5"/></tr><tr style="background-color: rgb(204, 238, 255);"><td>Revenue</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B6">$</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c256" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-12083">156,719</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B6">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D6">$</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c257" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-12084">133,814</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D6">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F6">$</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c258" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-12085">740,381</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F6">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H6">$</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c259" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" unitRef="usd" id="ixv-12086">478,562</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H6">&#160;</td></tr><tr><td>&#160;</td><td style="width: 1%;" title="Note 14. Segment Information - B7"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 14. Segment Information - B7"/><td>&#160;</td><td style="width: 1%;" title="Note 14. Segment Information - D7"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 14. Segment Information - D7"/><td>&#160;</td><td style="width: 1%;" title="Note 14. Segment Information - F7"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 14. Segment Information - F7"/><td>&#160;</td><td style="width: 1%;" title="Note 14. Segment Information - H7"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 14. Segment Information - H7"/></tr><tr style="background-color: rgb(204, 238, 255);"><td>Less:</td><td style="width: 1%;" title="Note 14. Segment Information - B8"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 14. Segment Information - B8"/><td>&#160;</td><td style="width: 1%;" title="Note 14. Segment Information - D8"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 14. Segment Information - D8"/><td>&#160;</td><td style="width: 1%;" title="Note 14. Segment Information - F8"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 14. Segment Information - F8"/><td>&#160;</td><td style="width: 1%;" title="Note 14. Segment Information - H8"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 14. Segment Information - H8"/></tr><tr><td style="padding-left: 10px;">Cost of sales</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B9">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c256" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" unitRef="usd" id="ixv-12087">2,193</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B9">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D9">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c257" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" unitRef="usd" id="ixv-12088">912</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D9">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F9">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c258" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" unitRef="usd" id="ixv-12089">7,097</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F9">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H9">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c259" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" unitRef="usd" id="ixv-12090">6,815</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H9">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 10px;">Drug discovery</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B10">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c256" decimals="-3" format="ixt:num-dot-decimal" name="ions:DrugDiscoveryExpenses" scale="3" unitRef="usd" id="ixv-12091">28,412</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B10">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D10">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c257" decimals="-3" format="ixt:num-dot-decimal" name="ions:DrugDiscoveryExpenses" scale="3" unitRef="usd" id="ixv-12092">25,790</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D10">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F10">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c258" decimals="-3" format="ixt:num-dot-decimal" name="ions:DrugDiscoveryExpenses" scale="3" unitRef="usd" id="ixv-12093">85,656</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F10">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H10">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c259" decimals="-3" format="ixt:num-dot-decimal" name="ions:DrugDiscoveryExpenses" scale="3" unitRef="usd" id="ixv-12094">80,652</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H10">&#160;</td></tr><tr><td style="padding-left: 10px;">Drug development</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B11">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c256" decimals="-3" format="ixt:num-dot-decimal" name="ions:DrugDevelopmentExpenses" scale="3" unitRef="usd" id="ixv-12095">120,828</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B11">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D11">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c257" decimals="-3" format="ixt:num-dot-decimal" name="ions:DrugDevelopmentExpenses" scale="3" unitRef="usd" id="ixv-12096">132,201</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D11">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F11">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c258" decimals="-3" format="ixt:num-dot-decimal" name="ions:DrugDevelopmentExpenses" scale="3" unitRef="usd" id="ixv-12097">351,463</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F11">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H11">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c259" decimals="-3" format="ixt:num-dot-decimal" name="ions:DrugDevelopmentExpenses" scale="3" unitRef="usd" id="ixv-12098">392,151</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H11">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 10px;">Medical affairs</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B12">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c256" decimals="-3" format="ixt:num-dot-decimal" name="ions:MedicalAffairsExpenses" scale="3" unitRef="usd" id="ixv-12099">8,874</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B12">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D12">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c257" decimals="-3" format="ixt:num-dot-decimal" name="ions:MedicalAffairsExpenses" scale="3" unitRef="usd" id="ixv-12100">5,511</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D12">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F12">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c258" decimals="-3" format="ixt:num-dot-decimal" name="ions:MedicalAffairsExpenses" scale="3" unitRef="usd" id="ixv-12101">22,342</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F12">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H12">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c259" decimals="-3" format="ixt:num-dot-decimal" name="ions:MedicalAffairsExpenses" scale="3" unitRef="usd" id="ixv-12102">17,279</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H12">&#160;</td></tr><tr><td style="padding-left: 10px;">Manufacturing and development chemistry</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B13">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c256" decimals="-3" format="ixt:num-dot-decimal" name="ions:ManufacturingAndDevelopmentChemistryExpenses" scale="3" unitRef="usd" id="ixv-12103">15,790</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B13">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D13">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c257" decimals="-3" format="ixt:num-dot-decimal" name="ions:ManufacturingAndDevelopmentChemistryExpenses" scale="3" unitRef="usd" id="ixv-12104">14,087</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D13">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F13">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c258" decimals="-3" format="ixt:num-dot-decimal" name="ions:ManufacturingAndDevelopmentChemistryExpenses" scale="3" unitRef="usd" id="ixv-12105">51,616</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F13">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H13">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c259" decimals="-3" format="ixt:num-dot-decimal" name="ions:ManufacturingAndDevelopmentChemistryExpenses" scale="3" unitRef="usd" id="ixv-12106">39,723</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H13">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 10px;">R&amp;D support</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B14">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c256" decimals="-3" format="ixt:num-dot-decimal" name="ions:ResearchAndDevelopmentSupportExpenses" scale="3" unitRef="usd" id="ixv-12107">23,092</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B14">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D14">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c257" decimals="-3" format="ixt:num-dot-decimal" name="ions:ResearchAndDevelopmentSupportExpenses" scale="3" unitRef="usd" id="ixv-12108">20,052</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D14">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F14">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c258" decimals="-3" format="ixt:num-dot-decimal" name="ions:ResearchAndDevelopmentSupportExpenses" scale="3" unitRef="usd" id="ixv-12109">64,252</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F14">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H14">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c259" decimals="-3" format="ixt:num-dot-decimal" name="ions:ResearchAndDevelopmentSupportExpenses" scale="3" unitRef="usd" id="ixv-12110">59,065</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H14">&#160;</td></tr><tr><td style="padding-left: 10px;">Selling, general and administrative</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B15">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c256" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-12111">86,565</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B15">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D15">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c257" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-12112">51,933</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D15">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F15">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c258" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-12113">234,626</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F15">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H15">&#160;</td><td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c259" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-12114">153,083</ix:nonFraction></td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H15">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 10px;">Other segment items (1)</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - B16">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">(<ix:nonFraction contextRef="c256" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SegmentReportingOtherItemAmount" scale="3" sign="-" unitRef="usd" id="ixv-12115">429</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - B16">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - D16">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c257" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SegmentReportingOtherItemAmount" scale="3" unitRef="usd" id="ixv-12116">23,808</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - D16">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - F16">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c258" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SegmentReportingOtherItemAmount" scale="3" unitRef="usd" id="ixv-12117">75,322</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - F16">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - H16">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonFraction contextRef="c259" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SegmentReportingOtherItemAmount" scale="3" unitRef="usd" id="ixv-12118">79,342</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - H16">&#160;</td></tr><tr><td>Consolidated net loss</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - B17">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">(<ix:nonFraction contextRef="c256" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-12119">128,606</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - B17">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - D17">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">(<ix:nonFraction contextRef="c257" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-12120">140,480</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - D17">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - F17">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">(<ix:nonFraction contextRef="c258" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-12121">151,993</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - F17">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - H17">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">(<ix:nonFraction contextRef="c259" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-12122">349,548</ix:nonFraction></td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - H17">)&#160;</td></tr></table><div style="text-align: justify; margin-left: 18pt;">&#160;
  </div>
  <div style="text-indent: -18pt; text-align: justify; padding-left: 18pt;">

    <div style="text-align: justify;"> <span style="color: #000000;">(1)&#160; <ix:nonNumeric contextRef="c0" name="us-gaap:SegmentReportingOtherItemCompositionDescription" id="ixv-12123">Other segment items include stock-based compensation expense, investment income, interest expense, gain or loss on investments, other income or expense and income tax expense or benefit.</ix:nonNumeric></span> </div>
  </div></ix:continuation></ix:nonNumeric><div>
  </div><div style="text-align: justify; margin-left: 18pt;">&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 10px; margin-top: 0px; margin-bottom: 0px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">22</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-indent: -72pt; text-align: justify; padding-left: 72pt;">
    <div style="float: left; width: 72.0pt; white-space: nowrap;">
     <span style="color: #000000; font-weight: bold;">ITEM 2.</span>
    </div>
    <div>
     <span style="color: #000000; font-weight: bold;">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span>
    </div>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000; font-style: italic;">In this Report on Form 10-Q, unless the context requires otherwise, &#8220;Ionis,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; and &#8220;us,&#8221; means Ionis Pharmaceuticals, Inc. and its subsidiaries.</span>
  </div><div>
  </div><div style="font-size: 8pt;">&#160;
  </div><div>
  </div><div style="text-align: justify;">
   <span style="color: #000000; font-weight: bold;">Forward-Looking Statements</span>
  </div><div>
  </div><div style="font-size: 8pt;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000; font-weight: bold;">In addition to historical information contained in this Report on Form 10-Q, the Report includes forward-looking statements regarding our business and the therapeutic and commercial potential of our commercial medicines, additional medicines in development and technologies. Any statement describing our goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties and particularly those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Our forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause our results to differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in this report and described in additional detail in our annual report on Form 10-K for the year ended December 31, 2024, which is on file with the U.S. Securities and Exchange Commission and is available from us, and those identified within Part II Item 1A. Risk Factors of this Report. Although our forward-looking statements reflect the good faith judgment of our management, these statements are based only on facts and factors currently known by us. Except as required by law, we undertake no obligation to update any forward-looking statements for any reason. As a result, you are cautioned not to rely on these forward-looking statements.</span>
  </div><div>
  </div><div style="font-size: 8pt;">&#160;
  </div><div>
  </div><div style="text-align: justify;">
   <a id="Overview" title="Overview"></a><span style="color: #000000; font-weight: bold;">Overview</span>
  </div><div>
  </div><div style="font-size: 8pt;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">For three decades, we have invented medicines that bring better futures to people with serious diseases. As a pioneer in RNA-targeted medicines with a deep understanding of disease biology and an industry-leading drug discovery technology, we are driven to deliver innovative, life-changing advances for patients.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>

  </div><div style="text-indent: 36pt; text-align: justify;">
   With our commercial launch of TRYNGOLZA (olezarsen) in the United States, or U.S., following its approval by the U.S. Food and Drug Administration, or FDA, we began a new chapter as a fully integrated commercial-stage biotechnology company. In August 2025, we launched DAWNZERA (donidalorsen) in the U.S. after receiving FDA approval <span style="letter-spacing: normal; text-indent: 48px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">for prophylaxis to prevent attacks of hereditary angioedema, or HAE</span>. We currently have seven marketed medicines to treat serious diseases: TRYNGOLZA, DAWNZERA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). In addition, we are positioned to independently launch two medicines, <span style="letter-spacing: normal; text-indent: 48px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">olezarsen for the treatment of severe hypertriglyceridemia, or sHTG, and</span> zilganersen for Alexander disease, or AxD, by the end of 2026, assuming regulatory approval. We also have a rich innovative pipeline across our focus areas of neurology, cardiometabolic diseases and select areas of high patient need. We currently have three wholly owned medicines and six partnered medicines in Phase 3 development,&#160;<span style="letter-spacing: normal; text-indent: 48px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">including ION582 for Angelman syndrome, or AS, which we advanced into a Phase 3 study in the second quarter of 2025. We also have</span>&#160;additional medicines in early and mid-stage development.
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>Our multiple sources of revenue and strong financial foundation enable our continued investments to support ongoing and upcoming planned launches and to advance our wholly owned medicines in development. Our key recent achievements, combined with our independent and partnered product launches anticipated by the end of 2027, position us well to help patients with serious diseases and to deliver increasing product and royalty revenue.</span>
  </div><div>
  </div><div style="text-align: justify; font-size: 8pt;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="font-style: italic;">Our Marketed Medicines</span>
  </div><div>
  </div><div style="text-align: justify; font-size: 8pt;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">TRYNGOLZA is a once monthly, self-administered LIgand-Conjugated Antisense, or LICA, medicine approved in the U.S. as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome, or FCS. TRYNGOLZA is the first and only FDA-approved treatment that significantly and substantially reduces triglyceride levels in adults with FCS and provides a clinically meaningful reduction in acute pancreatitis, or AP, events. TRYNGOLZA is the first medicine we are commercializing independently in the U.S. In September 2025, TRYNGOLZA was approved in the European Union, or EU, as an adjunct to diet in adult patients for the treatment of genetically confirmed FCS. Sobi has exclusive rights to commercialize TRYNGOLZA in  countries outside of the U.S., Canada and China.</span></div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">&#160;</div><div style="text-indent: 36pt; text-align: justify;">DAWNZERA is an RNA-targeted medicine approved in the U.S. for prophylaxis to prevent attacks of HAE in adult and pediatric patients 12 years of age and older. DAWNZERA 80mg is self-administered via subcutaneous autoinjector once every four or eight weeks. DAWNZERA is the first and only FDA-approved RNA-targeted prophylactic therapy. DAWNZERA has the potential to offer durable efficacy, a favorable safety and tolerability profile, and the longest available dosing interval. DAWNZERA is the second medicine we are commercializing independently in the U.S. DAWNZERA is currently under regulatory review in the EU.&#160;<span style="letter-spacing: normal; text-indent: 48px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">We licensed commercialization rights for DAWNZERA in&#160;Europe and the Asia-Pacific region&#160;to Otsuka Pharmaceutical Co., Ltd., or Otsuka.</span></div><div style="text-align: justify;">&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 10px; margin-top: 0px; margin-bottom: 0px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">23</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">WAINUA (WAINZUA in Europe) is a once monthly, self-administered subcutaneous LICA medicine that is approved in the U.S., European Union, or EU, and numerous other countries for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis, or ATTRv-PN, a debilitating, progressive, and fatal disease. In January 2024, we and AstraZeneca launched WAINUA in the U.S. for the treatment of adults with ATTRv-PN. The launch of WAINUA is underway in numerous countries, including the countries in the EU, following the approval by the European Commission, or EC, in March 2025. We and AstraZeneca are co-commercializing WAINUA in the U.S. AstraZeneca has exclusive rights to commercialize WAINUA outside of the U.S. From inception through September 30, 2025, we have earned more than $590 million in revenues from our WAINUA collaboration, including more than $50 million in royalties on sales of WAINUA.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">SPINRAZA is an antisense medicine for the treatment of patients with spinal muscular atrophy, or SMA, a progressive, debilitating and often fatal genetic disease. Our partner, Biogen, is responsible for commercializing SPINRAZA worldwide</span><span>. From inception through September 30, 2025, we have earned more than $2.4 billion in revenues from our SPINRAZA collaboration, including more than $2.0 billion in royalties on sales of SPINRAZA.</span>
  </div><div>
  </div><div style="text-align: justify; font-size: 8pt;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">QALSODY is an antisense medicine that received accelerated approval from the FDA in April 2023 and marketing authorization under exceptional circumstances from the European Medicines Agency, or EMA, in May 2024 for the treatment of adult patients with superoxide dismutase 1 amyotrophic lateral sclerosis, or SOD1-ALS, a rare, neurodegenerative disorder that causes progressive loss of motor neurons leading to death. QALSODY was the first treatment approved to target a genetic cause of ALS. Our partner, Biogen, is responsible for commercializing QALSODY worldwide. </span><span>Biogen is also evaluating QALSODY as a potential treatment for presymptomatic SOD1-ALS patients in the ongoing ATLAS study. QALSODY was granted Orphan Drug designation by the FDA and EMA.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">TEGSEDI is a once weekly, self-administered subcutaneous medicine approved in Europe and Brazil for the treatment of patients with ATTRv-PN. We currently sell TEGSEDI in Europe through our distribution agreement with Swedish Orphan Biovitrum AB, or Sobi. In Latin America, PTC Therapeutics International Limited, or PTC, is commercializing TEGSEDI in Brazil and is pursuing access in additional Latin American countries through its exclusive license agreement with us.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">WAYLIVRA is a once weekly, self-administered, subcutaneous medicine approved in Europe and Brazil as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk for pancreatitis. We sell WAYLIVRA in Europe through our distribution agreement with Sobi. In Latin America, PTC is commercializing WAYLIVRA in Brazil for two indications, FCS and familial partial lipodystrophy, or FPL, and is pursuing access in additional Latin American countries through its exclusive license agreement with us.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="font-style: italic;">Our Innovative Late-Stage Pipeline of Ionis-Owned Investigational Medicines</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>Olezarsen is our medicine in development for sHTG, a second potential indication which has a large patient population. We are developing olezarsen for the treatment of sHTG. In September 2025, we announced positive topline  results in the pivotal Phase 3 CORE and CORE2 studies in sHTG.&#160;In March 2025, we published the Phase 3 study design and baseline characteristics for the CORE, CORE2 and Essence studies in the </span><span style="font-style: italic;">American Heart Journal</span><span>. In May 2025, we announced positive topline results from the Essence&#160;study in people with moderate hypertriglyceridemia with or at risk for atherosclerotic cardiovascular disease. In August 2025, we published data from the Phase 3 Essence study evaluating olezarsen in patients with moderate hypertriglyceridemia and elevated cardiovascular risk in <i>The New England Journal of Medicine</i>. </span><span style="color: #000000;">We licensed commercialization rights for olezarsen in most countries outside of the U.S., Canada and China to Sobi.</span>
  </div><div>


  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>Zilganersen is our medicine in development for AxD. In September 2025, we announced  positive topline results in the Phase 3 portion of the pivotal study of zilganersen in children and adults living with AxD. We presented additional data from the pivotal study of zilganersen in children and adults living with AxD at the Child Neurology Society Annual Meeting in October 2025. Zilganersen was granted Fast Track designation for the treatment of AxD and Rare Pediatric designation by the FDA. Additionally, zilganersen was granted Orphan Drug designation by the FDA and EMA.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 10px; margin-top: 0px; margin-bottom: 0px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">24</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   ION582 is our medicine in development for AS. In June 2025, <span style="letter-spacing: normal; text-indent: 48px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">we initiated the Phase 3 study, REVEAL, which we designed to evaluate the efficacy and safety of ION582. In addition, w</span>e are continuing to conduct the  open label Phase 1/2 study, HALOS, of ION582 in patients with AS designed to assess the safety, tolerability and activity of multiple ascending doses of ION582 administered intrathecally. In 2024, we presented positive results from the completed multiple ascending dose portion of the study in people with AS. The FDA and EMA granted Orphan Drug designation to ION582. Additionally, the FDA granted Fast Track, Rare Pediatric and Breakthrough Therapy designations to ION582.
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="font-style: italic;">Our Innovative Late-Stage Pipeline of Partnered Investigational Medicines</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>Eplontersen is our medicine in development to treat patients with transthyretin amyloidosis cardiomyopathy, or ATTR-CM. We completed enrollment in the Phase 3 CARDIO-TTRansform study in July 2023. The FDA granted Fast Track designation to eplontersen for the treatment of patients with ATTR-CM. Additionally, the FDA and EMA granted Orphan Drug designation to eplontersen for the treatment of ATTR.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>Pelacarsen is our medicine in development to treat patients with elevated lipoprotein(a)-driven cardiovascular disease, or Lp(a)-driven CVD. Novartis is developing pelacarsen, including conducting the ongoing Phase 3 Lp(a) HORIZON cardiovascular outcome study in patients with elevated Lp(a)-driven CVD, which achieved full enrollment in July 2022 with more than 8,000 patients. The study design and baseline characteristics of the Phase 3 Lp(a) HORIZON study were published in the </span><span style="font-style: italic;">American Heart Journal</span><span> in April 2025. The FDA granted Fast Track designation and the Center for Drug Evaluation of China National Medical Products Administration granted Breakthrough Therapy designation to pelacarsen for the treatment of patients with elevated Lp(a) and established CVD.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>Bepirovirsen is our medicine in development for chronic hepatitis B virus, or HBV. GSK is developing bepirovirsen, including conducting the ongoing B-Well Phase 3 program in patients with HBV, which achieved full enrollment in June 2024. The FDA granted Fast Track designation and the Japanese Ministry of Health, Labour and Welfare granted SENKU designation to bepirovirsen for the treatment of patients with HBV.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>Sefaxersen is our medicine in development for immunoglobulin A, or IgA, nephropathy, or IgAN. In the second quarter of 2023, Roche advanced sefaxersen into Phase 3 development in patients with IgAN based on interim Phase 2 data.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>Ulefnersen is our medicine in development for amyotrophic lateral sclerosis, or ALS, with mutations in the fused in sarcoma gene, or FUS. We are currently conducting a Phase 3 study of ulefnersen in juvenile and adult patients with FUS-ALS. We licensed global commercialization rights for ulefnersen to Otsuka. The FDA and EMA granted Orphan Drug designation to ulefnersen. </span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-align: justify;">
   <a id="Critical_Accounting_Estimates" title="Critical Accounting Estimates"></a><span style="color: #000000; font-weight: bold;">Critical Accounting Estimates</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>We prepare our condensed consolidated financial statements in conformity with accounting principles generally accepted in the U.S. As such, we make certain estimates, judgments and assumptions that we believe are reasonable, based upon the information available to us. These judgments involve making estimates about the effect of matters that are inherently uncertain and may significantly impact our quarterly or annual results of operations and financial condition. Each quarter, our senior management reviews the development, selection and disclosure of such estimates with the audit committee of our board of directors. The following are our significant accounting estimates, which we believe are the most critical to aid in fully understanding and evaluating our reported financial results:</span>
  </div><div>
  </div><div style="text-align: justify; color: #000000;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt; font-size: 12pt; color: #000000;">

    <div>
     <span style="font-size: 10.0pt;">&#9679;&#160;&#160;&#160;&#160;Assessing the propriety of revenue recognition and associated deferred revenue;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt; font-size: 12pt; color: #000000; clear: both;">

    <div>
     <span style="font-size: 10.0pt;">&#9679;&#160;&#160;&#160;&#160;Determining the appropriate cost estimates for unbilled preclinical studies and clinical development activities; and</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt; font-size: 12pt; color: #000000; clear: both;">

    <div>
     <span style="font-size: 10.0pt;">&#9679;&#160;&#160;&#160;&#160;Assessing the appropriate estimate of anticipated future royalty payments under our royalty purchase agreement</span>
    </div>
  </div><div>
  </div><div style="text-align: justify; margin-left: 54pt; color: #000000; clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify; font-family: Calibri; font-size: 11pt; color: #000000;">
   <span style="font-family: Times New Roman; font-size: 10.0pt;">There have been no material changes to our critical accounting estimates from the information provided in Item 7, </span><span style="font-family: Times New Roman; font-size: 10.0pt; font-style: italic;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="font-family: Times New Roman; font-size: 10.0pt;">, included in our Annual Report on Form 10-K for the year ended December 31, 2024.</span>
  </div><div>
  </div><div>&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 10px; margin-top: 0px; margin-bottom: 0px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">25</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div>
   <a id="Results_of_Operations" title="Results of Operations"></a><span style="color: #000000; font-weight: bold;">Results of Operations</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">The following is a summary of our financial results (in millions):</span>
  </div><div>
  </div><div style="line-height: 1.05; text-align: justify;">&#160;</div><div>
  </div><table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold;">Three Months Ended</td><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold;">Nine Months Ended</td></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td></tr><tr><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Results of Operations - B6"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Results of Operations - B6"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Results of Operations - D6"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Results of Operations - D6"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Results of Operations - F6"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Results of Operations - F6"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Results of Operations - H6"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Results of Operations - H6"/></tr><tr style="background-color: rgb(204, 238, 255);"><td>Total revenue</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Results of Operations - B7">$</td><td style="width: 9%; text-align: right;">156.7</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Results of Operations - B7">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Results of Operations - D7">$</td><td style="width: 9%; text-align: right;">133.8</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Results of Operations - D7">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Results of Operations - F7">$</td><td style="width: 9%; text-align: right;">740.4</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Results of Operations - F7">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Results of Operations - H7">$</td><td style="width: 9%; text-align: right;">478.6</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Results of Operations - H7">&#160;</td></tr><tr><td>Total operating expenses</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Results of Operations - B8">$</td><td style="width: 9%; text-align: right;">316.9</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Results of Operations - B8">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Results of Operations - D8">$</td><td style="width: 9%; text-align: right;">282.5</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Results of Operations - D8">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Results of Operations - F8">$</td><td style="width: 9%; text-align: right;">907.6</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Results of Operations - F8">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Results of Operations - H8">$</td><td style="width: 9%; text-align: right;">842.8</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Results of Operations - H8">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Loss from operations</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Results of Operations - B9">$</td><td style="width: 9%; text-align: right;">(160.2</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Results of Operations - B9">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Results of Operations - D9">$</td><td style="width: 9%; text-align: right;">(148.7</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Results of Operations - D9">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Results of Operations - F9">$</td><td style="width: 9%; text-align: right;">(167.2</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Results of Operations - F9">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Results of Operations - H9">$</td><td style="width: 9%; text-align: right;">(364.3</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Results of Operations - H9">)&#160;</td></tr><tr><td>Net loss</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Results of Operations - B10">$</td><td style="width: 9%; text-align: right;">(128.6</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Results of Operations - B10">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Results of Operations - D10">$</td><td style="width: 9%; text-align: right;">(140.5</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Results of Operations - D10">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Results of Operations - F10">$</td><td style="width: 9%; text-align: right;">(152.0</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Results of Operations - F10">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Results of Operations - H10">$</td><td style="width: 9%; text-align: right;">(349.5</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Results of Operations - H10">)&#160;</td></tr></table><div style="line-height: 1.05; text-align: justify;">&#160;</div><div>

  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000; font-weight: bold;">Revenue </span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">Total revenue for the three and nine months ended September 30, 2025 were $156.7 million and $740.4 million, respectively,&#160; compared to $133.8 million and $478.6 million for the same periods in 2024 and was comprised of the following (in millions): </span>
  </div><div>
  </div><div style="text-align: justify;">&#160;</div><div>
  </div><table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold;">Three Months Ended</td><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold;">Nine Months Ended</td></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td></tr><tr><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Revenue - B6"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Revenue - B6"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Revenue - D6"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Revenue - D6"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Revenue - F6"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Revenue - F6"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Revenue - H6"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Revenue - H6"/></tr><tr><td>Revenue:</td><td style="width: 1%;" title="MD&amp;A - Revenue - B7"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="MD&amp;A - Revenue - B7"/><td>&#160;</td><td style="width: 1%;" title="MD&amp;A - Revenue - D7"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="MD&amp;A - Revenue - D7"/><td>&#160;</td><td style="width: 1%;" title="MD&amp;A - Revenue - F7"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="MD&amp;A - Revenue - F7"/><td>&#160;</td><td style="width: 1%;" title="MD&amp;A - Revenue - H7"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="MD&amp;A - Revenue - H7"/></tr><tr><td style="padding-left: 10px;">Commercial revenue:</td><td style="width: 1%;" title="MD&amp;A - Revenue - B8"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="MD&amp;A - Revenue - B8"/><td>&#160;</td><td style="width: 1%;" title="MD&amp;A - Revenue - D8"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="MD&amp;A - Revenue - D8"/><td>&#160;</td><td style="width: 1%;" title="MD&amp;A - Revenue - F8"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="MD&amp;A - Revenue - F8"/><td>&#160;</td><td style="width: 1%;" title="MD&amp;A - Revenue - H8"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="MD&amp;A - Revenue - H8"/></tr><tr><td style="padding-left: 20px;">Product sales, net:</td><td style="width: 1%;" title="MD&amp;A - Revenue - B9"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="MD&amp;A - Revenue - B9"/><td>&#160;</td><td style="width: 1%;" title="MD&amp;A - Revenue - D9"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="MD&amp;A - Revenue - D9"/><td>&#160;</td><td style="width: 1%;" title="MD&amp;A - Revenue - F9"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="MD&amp;A - Revenue - F9"/><td>&#160;</td><td style="width: 1%;" title="MD&amp;A - Revenue - H9"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="MD&amp;A - Revenue - H9"/></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 30px;">TRYNGOLZA sales, net</td><td style="width: 1%; text-align: left; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none;" title="MD&amp;A - Revenue - B10">$</td><td style="width: 9%; text-align: right; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none;">31.8</td><td style="width: 1%; text-align: left; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none;" title="MD&amp;A - Revenue - B10">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none;" title="MD&amp;A - Revenue - D10">$</td><td style="width: 9%; text-align: right; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none;"> -   </td><td style="width: 1%; text-align: left; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none;" title="MD&amp;A - Revenue - D10">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none;" title="MD&amp;A - Revenue - F10">$</td><td style="width: 9%; text-align: right; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none;">57.4</td><td style="width: 1%; text-align: left; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none;" title="MD&amp;A - Revenue - F10">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none;" title="MD&amp;A - Revenue - H10">$</td><td style="width: 9%; text-align: right; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none;"> -   </td><td style="width: 1%; text-align: left; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none;" title="MD&amp;A - Revenue - H10">&#160;</td></tr><tr><td style="padding-left: 30px;">Total product sales, net</td><td style="width: 1%; text-align: left; border-width: initial; border-style: none; border-color: initial;" title="MD&amp;A - Revenue - B11">&#160;</td><td style="width: 9%; text-align: right; border-width: initial; border-style: none; border-color: initial;">31.8</td><td style="width: 1%; text-align: left; border-width: initial; border-style: none; border-color: initial;" title="MD&amp;A - Revenue - B11">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-width: initial; border-style: none; border-color: initial;" title="MD&amp;A - Revenue - D11">&#160;</td><td style="width: 9%; text-align: right; border-width: initial; border-style: none; border-color: initial;"> -   </td><td style="width: 1%; text-align: left; border-width: initial; border-style: none; border-color: initial;" title="MD&amp;A - Revenue - D11">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-width: initial; border-style: none; border-color: initial;" title="MD&amp;A - Revenue - F11">&#160;</td><td style="width: 9%; text-align: right; border-width: initial; border-style: none; border-color: initial;">57.4</td><td style="width: 1%; text-align: left; border-width: initial; border-style: none; border-color: initial;" title="MD&amp;A - Revenue - F11">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-width: initial; border-style: none; border-color: initial;" title="MD&amp;A - Revenue - H11">&#160;</td><td style="width: 9%; text-align: right; border-width: initial; border-style: none; border-color: initial;"> -   </td><td style="width: 1%; text-align: left; border-width: initial; border-style: none; border-color: initial;" title="MD&amp;A - Revenue - H11">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 20px;">Royalty revenue:</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Revenue - B11">&#160;</td><td style="width: 9%; text-align: right;"/><td style="width: 1%; text-align: left;" title="MD&amp;A - Revenue - B11">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Revenue - D11">&#160;</td><td style="width: 9%; text-align: right;"/><td style="width: 1%; text-align: left;" title="MD&amp;A - Revenue - D11">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Revenue - F11">&#160;</td><td style="width: 9%; text-align: right;"/><td style="width: 1%; text-align: left;" title="MD&amp;A - Revenue - F11">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Revenue - H11">&#160;</td><td style="width: 9%; text-align: right;"/><td style="width: 1%; text-align: left; border-left: none; border-right: none;" title="MD&amp;A - Revenue - H11">&#160;</td></tr><tr><td style="padding-left: 30px;">SPINRAZA royalties</td><td style="width: 1%;" title="MD&amp;A - Revenue - B12"/><td style="width: 9%; text-align: right;"> 55.9 </td><td style="width: 1%;" title="MD&amp;A - Revenue - B12"/><td>&#160;</td><td style="width: 1%;" title="MD&amp;A - Revenue - D12"/><td style="width: 9%; text-align: right;"> 57.2 </td><td style="width: 1%;" title="MD&amp;A - Revenue - D12"/><td>&#160;</td><td style="width: 1%;" title="MD&amp;A - Revenue - F12"/><td style="width: 9%; text-align: right;"> 158.2 </td><td style="width: 1%;" title="MD&amp;A - Revenue - F12"/><td>&#160;</td><td style="width: 1%;" title="MD&amp;A - Revenue - H12"/><td style="width: 9%; text-align: right;"> 152.4 </td><td style="width: 1%;" title="MD&amp;A - Revenue - H12"/></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 30px;">WAINUA royalties</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Revenue - B14">&#160;</td><td style="width: 9%; text-align: right;">13.3</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Revenue - B14">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Revenue - D14">&#160;</td><td style="width: 9%; text-align: right;">5.4</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Revenue - D14">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Revenue - F14">&#160;</td><td style="width: 9%; text-align: right;">33.1</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Revenue - F14">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Revenue - H14">&#160;</td><td style="width: 9%; text-align: right;">10.3</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Revenue - H14">&#160;</td></tr><tr><td style="padding-left: 30px;">Other royalties</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Revenue - B15">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">6.5</td><td style="width: 1%; text-align: left; border-left: none; border-right: none; border-bottom: 1px solid black; border-top: none;" title="MD&amp;A - Revenue - B15">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Revenue - D15">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">4.2</td><td style="width: 1%; text-align: left; border-left: none; border-right: none; border-bottom: 1px solid black; border-top: none;" title="MD&amp;A - Revenue - D15">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Revenue - F15">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">18.5</td><td style="width: 1%; text-align: left; border-left: none; border-right: none; border-bottom: 1px solid black; border-top: none;" title="MD&amp;A - Revenue - F15">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Revenue - H15">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">17.4</td><td style="width: 1%; text-align: left; border-left: none; border-right: none; border-bottom: 1px solid black; border-top: none;" title="MD&amp;A - Revenue - H15">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 50px;">Total royalty revenue</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Revenue - B16">&#160;</td><td style="width: 9%; text-align: right;">75.7</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Revenue - B16">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Revenue - D16">&#160;</td><td style="width: 9%; text-align: right;">66.8</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Revenue - D16">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Revenue - F16">&#160;</td><td style="width: 9%; text-align: right;">209.8</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Revenue - F16">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Revenue - H16">&#160;</td><td style="width: 9%; text-align: right;">180.1</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Revenue - H16">&#160;</td></tr><tr><td style="padding-left: 20px;">Other commercial revenue</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Revenue - B17"/><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"> 8.1 </td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Revenue - B17"/><td>&#160;</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Revenue - D17"/><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"> 8.9 </td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Revenue - D17"/><td>&#160;</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Revenue - F17"/><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"> 27.3 </td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Revenue - F17"/><td>&#160;</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Revenue - H17"/><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"> 27.3 </td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Revenue - H17"/></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 70px;">Total commercial revenue</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Revenue - B18">&#160;</td><td style="width: 9%; text-align: right;">115.6</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Revenue - B18">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Revenue - D18">&#160;</td><td style="width: 9%; text-align: right;">75.7</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Revenue - D18">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Revenue - F18">&#160;</td><td style="width: 9%; text-align: right;">294.5</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Revenue - F18">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Revenue - H18">&#160;</td><td style="width: 9%; text-align: right;">207.4</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Revenue - H18">&#160;</td></tr><tr><td style="padding-left: 10px;">Research and development revenue:</td><td style="width: 1%; text-align: left; border-width: initial; border-style: none; border-color: initial;" title="MD&amp;A - Revenue - B19">&#160;</td><td style="width: 9%; text-align: right; border-width: initial; border-style: none; border-color: initial;"/><td style="width: 1%; text-align: left; border-width: initial; border-style: none; border-color: initial;" title="MD&amp;A - Revenue - B19">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-width: initial; border-style: none; border-color: initial;" title="MD&amp;A - Revenue - D19">&#160;</td><td style="width: 9%; text-align: right; border-width: initial; border-style: none; border-color: initial;"/><td style="width: 1%; text-align: left; border-width: initial; border-style: none; border-color: initial;" title="MD&amp;A - Revenue - D19">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-width: initial; border-style: none; border-color: initial;" title="MD&amp;A - Revenue - F19">&#160;</td><td style="width: 9%; text-align: right; border-width: initial; border-style: none; border-color: initial;"/><td style="width: 1%; text-align: left; border-width: initial; border-style: none; border-color: initial;" title="MD&amp;A - Revenue - F19">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-width: initial; border-style: none; border-color: initial;" title="MD&amp;A - Revenue - H19">&#160;</td><td style="width: 9%; text-align: right; border-width: initial; border-style: none; border-color: initial;"/><td style="width: 1%; text-align: left; border-width: initial; border-style: none; border-color: initial;" title="MD&amp;A - Revenue - H19">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 20px;">Collaborative agreement revenue</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Revenue - B23">&#160;</td><td style="width: 9%; text-align: right;">31.4</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Revenue - B23">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Revenue - D23">&#160;</td><td style="width: 9%; text-align: right;">44.9</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Revenue - D23">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Revenue - F23">&#160;</td><td style="width: 9%; text-align: right;">413.4</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Revenue - F23">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Revenue - H23">&#160;</td><td style="width: 9%; text-align: right;">235.8</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Revenue - H23">&#160;</td></tr><tr><td style="padding-left: 20px;">WAINUA joint development revenue</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none;" title="MD&amp;A - Revenue - B24">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;">9.7</td><td style="width: 1%; text-align: left; border-left: none; border-right: none; border-bottom: 1px solid black; border-top: none;" title="MD&amp;A - Revenue - B24">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="MD&amp;A - Revenue - D24">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;">13.2</td><td style="width: 1%; text-align: left; border-left: none; border-right: none; border-bottom: 1px solid black; border-top: none;" title="MD&amp;A - Revenue - D24">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="MD&amp;A - Revenue - F24">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;">32.5</td><td style="width: 1%; text-align: left; border-left: none; border-right: none; border-bottom: 1px solid black; border-top: none;" title="MD&amp;A - Revenue - F24">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="MD&amp;A - Revenue - H24">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;">35.4</td><td style="width: 1%; text-align: left; border-left: none; border-right: none; border-bottom: 1px solid black; border-top: none;" title="MD&amp;A - Revenue - H24">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 70px;">Total research and development revenue</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="MD&amp;A - Revenue - B25">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;">41.1</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-left: none; border-right: none; border-top: none;" title="MD&amp;A - Revenue - B25">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="MD&amp;A - Revenue - D25">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;">58.1</td><td style="width: 1%; text-align: left; border-left: none; border-right: none; border-bottom: 1px solid black; border-top: none;" title="MD&amp;A - Revenue - D25">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="MD&amp;A - Revenue - F25">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;">445.9</td><td style="width: 1%; text-align: left; border-left: none; border-right: none; border-bottom: 1px solid black; border-top: none;" title="MD&amp;A - Revenue - F25">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="MD&amp;A - Revenue - H25">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-right: none;">271.2</td><td style="width: 1%; text-align: left; border-left: none; border-right: none; border-bottom: 1px solid black; border-top: none;" title="MD&amp;A - Revenue - H25">&#160;</td></tr><tr><td style="padding-left: 90px;">Total revenue  </td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Revenue - B26">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">156.7</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Revenue - B26">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Revenue - D26">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">133.8</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Revenue - D26">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Revenue - F26">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">740.4</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Revenue - F26">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Revenue - H26">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">478.6</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Revenue - H26">&#160;</td></tr></table><div style="text-align: justify;">&#160;</div><div>

  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">Commercial revenue for the three and nine months ended September 30, 2025 increased 53% and 42%, respectively, compared to the same periods in 2024. This increase was primarily driven by TRYNGOLZA product sales. Higher royalty revenue also contributed to the year over year increase.</span></div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">The remainder of our revenue came from programs under our research and development, or R&amp;D, collaborations, including revenue from the $280 million upfront payment for the global license of sapablursen to Ono Pharmaceutical Co., Ltd. in the second quarter of 2025, reflecting the value that our pipeline and technology continues to generate.</span></div><div>
  </div><div style="text-align: justify; font-size: 8pt;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000; font-weight: bold; font-style: italic;">WAINUA (Eplontersen) Collaboration with AstraZeneca</span>
  </div><div>
  </div><div style="text-align: justify; font-size: 8pt;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">Our financial results for the three and nine months ended September 30, 2025 and 2024 reflected the cost-sharing provisions related to our collaboration with AstraZeneca to develop and commercialize WAINUA for the treatment of ATTR. Under the terms of the collaboration agreement, AstraZeneca is currently paying 55 percent of the costs associated with the ongoing global Phase 3 development program. Because we are leading and conducting the Phase 3 development program, we are recognizing as R&amp;D revenue the 55 percent of cost-share funding AstraZeneca is responsible for, net of our share of AstraZeneca's development expenses, in the same period we incur the related development expenses.</span>
  </div><div>
  </div><div style="text-align: justify; font-size: 8pt;">&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 10px; margin-top: 0px; margin-bottom: 0px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">26</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">As AstraZeneca is responsible for the majority of the medical affairs and commercial costs in the U.S. and all costs associated with bringing WAINUA to market outside the U.S., we are recognizing cost-share funding we receive from AstraZeneca related to these activities as a reduction of our medical affairs and commercialization expenses, which we classify as R&amp;D and selling, general and administrative, or SG&amp;A expenses, respectively. We expect our medical affairs and commercialization expenses to increase as WAINUA advances toward the market for ATTR-CM under our collaboration with AstraZeneca.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">The following table sets forth information on revenue and expenses under this collaboration (in millions):</span></div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">&#160;</div><div>

  </div><table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold;">Three Months Ended</td><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold;">Nine Months Ended</td></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td></tr><tr><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - WAINUA Collaboration - B4"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - WAINUA Collaboration - B4"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - WAINUA Collaboration - D4"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - WAINUA Collaboration - D4"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - WAINUA Collaboration - F4"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - WAINUA Collaboration - F4"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - WAINUA Collaboration - H4"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - WAINUA Collaboration - H4"/></tr><tr style="background-color: rgb(204, 238, 255);"><td>WAINUA joint development revenue</td><td style="width: 1%; text-align: left;" title="MD&amp;A - WAINUA Collaboration - B5">$</td><td style="width: 9%; text-align: right;">9.7</td><td style="width: 1%; text-align: left;" title="MD&amp;A - WAINUA Collaboration - B5">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="MD&amp;A - WAINUA Collaboration - D5">$</td><td style="width: 9%; text-align: right;">13.2</td><td style="width: 1%; text-align: left;" title="MD&amp;A - WAINUA Collaboration - D5">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="MD&amp;A - WAINUA Collaboration - F5">$</td><td style="width: 9%; text-align: right;">32.5</td><td style="width: 1%; text-align: left;" title="MD&amp;A - WAINUA Collaboration - F5">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="MD&amp;A - WAINUA Collaboration - H5">$</td><td style="width: 9%; text-align: right;">35.4</td><td style="width: 1%; text-align: left;" title="MD&amp;A - WAINUA Collaboration - H5">&#160;</td></tr><tr><td>Research and development expenses related to Phase 3 development of WAINUA</td><td style="width: 1%; text-align: left;" title="MD&amp;A - WAINUA Collaboration - B6">&#160;</td><td style="width: 9%; text-align: right;">19.5</td><td style="width: 1%; text-align: left;" title="MD&amp;A - WAINUA Collaboration - B6">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="MD&amp;A - WAINUA Collaboration - D6">&#160;</td><td style="width: 9%; text-align: right;">28.9</td><td style="width: 1%; text-align: left;" title="MD&amp;A - WAINUA Collaboration - D6">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="MD&amp;A - WAINUA Collaboration - F6">&#160;</td><td style="width: 9%; text-align: right;">65.8</td><td style="width: 1%; text-align: left;" title="MD&amp;A - WAINUA Collaboration - F6">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="MD&amp;A - WAINUA Collaboration - H6">&#160;</td><td style="width: 9%; text-align: right;">77.1</td><td style="width: 1%; text-align: left;" title="MD&amp;A - WAINUA Collaboration - H6">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Medical affairs expenses for WAINUA</td><td style="width: 1%; text-align: left;" title="MD&amp;A - WAINUA Collaboration - B7">&#160;</td><td style="width: 9%; text-align: right;">1.7</td><td style="width: 1%; text-align: left;" title="MD&amp;A - WAINUA Collaboration - B7">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="MD&amp;A - WAINUA Collaboration - D7">&#160;</td><td style="width: 9%; text-align: right;">1.6</td><td style="width: 1%; text-align: left;" title="MD&amp;A - WAINUA Collaboration - D7">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="MD&amp;A - WAINUA Collaboration - F7">&#160;</td><td style="width: 9%; text-align: right;">5.7</td><td style="width: 1%; text-align: left;" title="MD&amp;A - WAINUA Collaboration - F7">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="MD&amp;A - WAINUA Collaboration - H7">&#160;</td><td style="width: 9%; text-align: right;">4.8</td><td style="width: 1%; text-align: left;" title="MD&amp;A - WAINUA Collaboration - H7">&#160;</td></tr><tr><td>Commercialization expenses for WAINUA</td><td style="width: 1%; text-align: left;" title="MD&amp;A - WAINUA Collaboration - B8">&#160;</td><td style="width: 9%; text-align: right;">7.5</td><td style="width: 1%; text-align: left;" title="MD&amp;A - WAINUA Collaboration - B8">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="MD&amp;A - WAINUA Collaboration - D8">&#160;</td><td style="width: 9%; text-align: right;">6.3</td><td style="width: 1%; text-align: left;" title="MD&amp;A - WAINUA Collaboration - D8">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="MD&amp;A - WAINUA Collaboration - F8">&#160;</td><td style="width: 9%; text-align: right;">22.0</td><td style="width: 1%; text-align: left;" title="MD&amp;A - WAINUA Collaboration - F8">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="MD&amp;A - WAINUA Collaboration - H8">&#160;</td><td style="width: 9%; text-align: right;">19.0</td><td style="width: 1%; text-align: left;" title="MD&amp;A - WAINUA Collaboration - H8">&#160;</td></tr></table><div style="text-align: justify;">&#160;</div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000; font-weight: bold;">Operating Expenses</span>
  </div><div>
  </div><div style="font-size: 8pt;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">The following table sets forth information on operating expenses (in millions):</span></div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">&#160;</div><div>
  </div><table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold;">Three Months Ended</td><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold;">Nine Months Ended</td></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td></tr><tr><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - B7"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - B7"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - D7"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - D7"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - F7"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - F7"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - H7"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - H7"/></tr><tr style="background-color: rgb(204, 238, 255);"><td>Operating expenses, excluding non-cash compensation expense related to equity awards</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - B8">$</td><td style="text-align: right; width: 9%;">285.8</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - B8">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - D8">$</td><td style="text-align: right; width: 9%;">250.5</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - D8">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - F8">$</td><td style="text-align: right; width: 9%;">817.0</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - F8">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - H8">$</td><td style="text-align: right; width: 9%;">748.7</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - H8">&#160;</td></tr><tr><td>Non-cash compensation expense related to equity awards</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - B9">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">31.1</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - B9">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - D9">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">32.0</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - D9">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - F9">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">90.6</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - F9">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - H9">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">94.1</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - H9">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Total operating expenses</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - B10">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">316.9</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - B10">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - D10">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">282.5</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - D10">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - F10">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">907.6</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - F10">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - H10">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">842.8</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - H10">&#160;</td></tr></table><div style="text-align: justify; font-size: 8pt;">&#160;</div><div>
  </div><div style="font-size: 8pt;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>Operating expenses, excluding non-cash compensation expense related to equity awards, for the three and nine months ended September&#160;30, 2025 increased  compared to the same periods in 2024. SG&amp;A expenses increased as anticipated year over year primarily due to the launches of TRYNGOLZA, DAWNZERA and WAINUA. This increase was partially offset by a decrease in R&amp;D expenses year over year as several late-stage studies ended. We expect our operating expenses, excluding non-cash compensation expense related to equity awards, to continue to increase during the remainder of 2025 as we advance our commercialization activities.</span>
  </div><div>
  </div><div style="text-align: justify; font-size: 8pt;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">We believe non-cash compensation expense related to equity awards is not indicative of our operating results or cash flows from our operations.</span></div><div>
  </div><div style="font-size: 8pt;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt;">
   <span style="color: #000000; font-weight: bold; font-style: italic;">Cost of Sales</span>
  </div><div>
  </div><div style="font-size: 8pt;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">Our cost of sales is comprised of costs related to our commercial revenue, which consisted of manufacturing costs, transportation and freight, indirect overhead costs associated with the manufacturing and distribution of TRYNGOLZA, DAWNZERA, TEGSEDI and WAYLIVRA and associated period costs.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">Cost of sales for newly launched products, such as TRYNGOLZA and DAWNZERA, does not include the full cost of manufacturing until we manufacture and sell additional inventory after exhausting pre-launch inventory, which we previously recorded as R&amp;D expense.</span>
  </div><div>
  </div><div style="text-align: justify; font-size: 8pt;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">The following table sets forth information on cost of sales (in millions):</span></div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">&#160;</div><div>
  </div><table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold;">Three Months Ended</td><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold;">Nine Months Ended</td></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td></tr><tr><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - B17"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - B17"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - D17"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - D17"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - F17"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - F17"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - H17"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - H17"/></tr><tr style="background-color: rgb(204, 238, 255);"><td>Cost of sales, excluding non-cash compensation expense related to equity awards</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - B18">$</td><td style="text-align: right; width: 9%;">2.2</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - B18">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - D18">$</td><td style="text-align: right; width: 9%;">0.9</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - D18">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - F18">$</td><td style="text-align: right; width: 9%;">7.1</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - F18">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - H18">$</td><td style="text-align: right; width: 9%;">6.8</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - H18">&#160;</td></tr><tr><td>Non-cash compensation expense related to equity awards</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - B19">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">0.1</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - B19">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - D19">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">0.2</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - D19">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - F19">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">0.9</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - F19">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - H19">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">0.6</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - H19">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Total cost of sales</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - B20">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">2.3</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - B20">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - D20">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">1.1</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - D20">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - F20">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">8.0</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - F20">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - H20">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">7.4</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - H20">&#160;</td></tr></table><div style="text-align: justify; font-size: 8pt;">&#160;</div><div>


  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 10px; margin-top: 0px; margin-bottom: 0px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">27</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-indent: 36pt;">
   <span style="color: #000000; font-weight: bold; font-style: italic;">Research, Development and Patent Expenses</span>
  </div><div>
  </div><div style="font-size: 8pt;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">Our research, development and patent expenses consist of expenses for drug discovery, drug development, medical affairs, manufacturing and development chemistry and R&amp;D support expenses.</span>
  </div><div>
  </div><div style="font-size: 8pt;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">The following table sets forth information on research, development and patent expenses (in millions):</span></div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">&#160;</div><div>
  </div><table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold;">Three Months Ended</td><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold;">Nine Months Ended</td></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td></tr><tr><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - B27"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - B27"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - D27"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - D27"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - F27"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - F27"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - H27"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - H27"/></tr><tr style="background-color: rgb(204, 238, 255);"><td>Research, development and patent expenses, excluding non-cash compensation expense related to equity awards</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - B28">$</td><td style="text-align: right; width: 9%;">197.0</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - B28">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - D28">$</td><td style="text-align: right; width: 9%;">197.7</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - D28">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - F28">$</td><td style="text-align: right; width: 9%;">575.4</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - F28">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - H28">$</td><td style="text-align: right; width: 9%;">588.9</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - H28">&#160;</td></tr><tr><td>Non-cash compensation expense related to equity awards</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - B29">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">20.8</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - B29">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - D29">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">22.1</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - D29">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - F29">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">60.6</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - F29">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - H29">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">67.1</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - H29">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Total research, development and patent expenses</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - B30">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">217.8</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - B30">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - D30">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">219.8</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - D30">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - F30">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">636.0</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - F30">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - H30">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">656.0</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - H30">&#160;</td></tr></table><div style="font-size: 8pt; border-width: initial; border-style: none; border-color: initial; border-collapse: collapse;">&#160;</div><div style="font-size: 8pt;">&#160;</div><div>

  </div><div style="text-indent: 36pt; line-height: 1.05;">
   <span style="color: #000000; text-decoration: underline;">Drug Discovery</span>
  </div><div>
  </div><div style="font-size: 8pt;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">We use our proprietary technologies to generate information about the function of genes and to determine the value of genes as drug discovery targets. We use this information to direct our own drug discovery research, and that of our partners. Drug discovery is also the function that is responsible for advancing our core technology. This function is also responsible for making investments in complementary technologies to expand the reach of our technologies.</span>
  </div><div>
  </div><div style="font-size: 8pt;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt;">
   <span style="color: #000000;">The following table sets forth information on drug discovery expenses (in millions):</span></div><div>
  </div><div style="text-indent: 36pt;">&#160;</div><table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold;">Three Months Ended</td><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold;">Nine Months Ended</td></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td></tr><tr><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - B38"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - B38"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - D38"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - D38"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - F38"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - F38"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - H38"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - H38"/></tr><tr style="background-color: rgb(204, 238, 255);"><td>Drug discovery expenses, excluding non-cash compensation expense related to equity awards</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - B39">$</td><td style="text-align: right; width: 9%;">28.4</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - B39">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - D39">$</td><td style="text-align: right; width: 9%;">25.8</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - D39">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - F39">$</td><td style="text-align: right; width: 9%;">85.7</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - F39">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - H39">$</td><td style="text-align: right; width: 9%;">80.7</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - H39">&#160;</td></tr><tr><td>Non-cash compensation expense related to equity awards</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - B40">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">4.0</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - B40">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - D40">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">4.4</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - D40">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - F40">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">11.7</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - F40">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - H40">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">13.3</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - H40">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Total drug discovery expenses</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - B41">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">32.4</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - B41">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - D41">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">30.2</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - D41">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - F41">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">97.4</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - F41">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - H41">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">94.0</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - H41">&#160;</td></tr></table><div>

  </div><div style="line-height: 1.05; font-size: 8pt;">&#160;</div><div>
  </div><div style="line-height: 1.05; font-size: 8pt;">&#160;</div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">Drug discovery expenses</span><span>, excluding non-cash compensation expense related to equity awards,</span><span style="color: #000000;">&#160;increased slightly in the three months and nine months ended September 30, 2025 compared to the same periods in 2024 as we continued to advance our technologies discussed above.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; line-height: 1.05; text-align: justify;">
   <span style="color: #000000; text-decoration: underline;">Drug Development</span>
  </div><div>
  </div><div style="line-height: 1.05;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; line-height: 1.05; text-align: justify;">
   <span style="color: #000000;">The following table sets forth drug development expenses, including expenses for our marketed medicines and those in Phase 3 development for which we have incurred significant costs (in millions):</span>
  </div><div>
  </div><div style="line-height: 1.05; text-align: justify;">&#160;</div><div>
  </div><table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold;">Three Months Ended</td><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold;">Nine Months Ended</td></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td></tr><tr><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - B47"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - B47"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - D47"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - D47"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - F47"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - F47"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - H47"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - H47"/></tr><tr style="background-color: rgb(204, 238, 255);"><td>Eplontersen</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - B48">$</td><td style="text-align: right; width: 9%;">19.1</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - B48">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - D48">$</td><td style="text-align: right; width: 9%;">28.3</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - D48">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - F48">$</td><td style="text-align: right; width: 9%;">64.5</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - F48">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - H48">$</td><td style="text-align: right; width: 9%;">74.3</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - H48">&#160;</td></tr><tr><td>Donidalorsen</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - B49">&#160;</td><td style="text-align: right; width: 9%;">3.7</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - B49">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - D49">&#160;</td><td style="text-align: right; width: 9%;">3.5</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - D49">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - F49">&#160;</td><td style="text-align: right; width: 9%;">11.8</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - F49">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - H49">&#160;</td><td style="text-align: right; width: 9%;">13.4</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - H49">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Olezarsen</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - B50">&#160;</td><td style="text-align: right; width: 9%;">25.6</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - B50">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - D50">&#160;</td><td style="text-align: right; width: 9%;">36.8</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - D50">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - F50">&#160;</td><td style="text-align: right; width: 9%;">68.7</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - F50">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - H50">&#160;</td><td style="text-align: right; width: 9%;">116.3</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - H50">&#160;</td></tr><tr><td>Zilganersen</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - B51">&#160;</td><td style="text-align: right; width: 9%;">2.2</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - B51">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - D51">&#160;</td><td style="text-align: right; width: 9%;">2.5</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - D51">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - F51">&#160;</td><td style="text-align: right; width: 9%;">9.7</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - F51">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - H51">&#160;</td><td style="text-align: right; width: 9%;">6.2</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - H51">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>ION582</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - B52">&#160;</td><td style="text-align: right; width: 9%;">6.8</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - B52">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - D52">&#160;</td><td style="text-align: right; width: 9%;">2.8</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - D52">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - F52">&#160;</td><td style="text-align: right; width: 9%;">24.3</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - F52">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - H52">&#160;</td><td style="text-align: right; width: 9%;">9.6</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - H52">&#160;</td></tr><tr><td>Ulefnersen</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - B53">&#160;</td><td style="text-align: right; width: 9%;">2.8</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - B53">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - D53">&#160;</td><td style="text-align: right; width: 9%;">3.1</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - D53">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - F53">&#160;</td><td style="text-align: right; width: 9%;">8.0</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - F53">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - H53">&#160;</td><td style="text-align: right; width: 9%;">10.0</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - H53">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Other development projects</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - B54">&#160;</td><td style="text-align: right; width: 9%;">23.6</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - B54">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - D54">&#160;</td><td style="text-align: right; width: 9%;">21.0</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - D54">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - F54">&#160;</td><td style="text-align: right; width: 9%;">59.3</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - F54">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - H54">&#160;</td><td style="text-align: right; width: 9%;">65.2</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - H54">&#160;</td></tr><tr><td>Development overhead expenses</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - B55">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">37.0</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - B55">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - D55">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">34.2</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - D55">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - F55">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">105.2</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - F55">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - H55">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">97.2</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - H55">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Total drug development expenses, excluding non-cash compensation expense related to equity awards</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - B56">&#160;</td><td style="text-align: right; width: 9%;">120.8</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - B56">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - D56">&#160;</td><td style="text-align: right; width: 9%;">132.2</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - D56">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - F56">&#160;</td><td style="text-align: right; width: 9%;">351.5</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - F56">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - H56">&#160;</td><td style="text-align: right; width: 9%;">392.2</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - H56">&#160;</td></tr><tr><td>Non-cash compensation expense related to equity awards</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - B57">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">9.2</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - B57">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - D57">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">9.7</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - D57">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - F57">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">26.2</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - F57">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - H57">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">30.4</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - H57">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Total drug development expenses</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - B58">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">130.0</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - B58">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - D58">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">141.9</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - D58">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - F58">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">377.7</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - F58">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - H58">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">422.6</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - H58">&#160;</td></tr></table><div style="line-height: 1.05; text-align: justify;">&#160;</div><div>

  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">Our development expenses</span><span>, excluding non-cash compensation expense related to equity awards,</span><span style="color: #000000;"> decreased for the three and nine months ended September 30, 2025 compared to the same periods in 2024 </span><span>as several late-stage studies ended</span><span style="color: #000000;">. </span><span>We expect our development expenses will continue to stabilize as several late-stage studies end and we reallocate resources toward earlier stage programs.</span>
  </div><div>
  </div><div style="text-align: justify; font-size: 8pt;">&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 10px; margin-top: 0px; margin-bottom: 0px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">28</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">We may conduct multiple clinical trials on a drug candidate, including multiple clinical trials for the various indications we may be studying. Furthermore, as we obtain results from trials, we may elect to discontinue clinical trials for certain drug candidates in certain indications in order to focus our resources on more promising drug candidates or indications. Our Phase 1 and Phase 2 programs are clinical research programs that fuel our Phase 3 pipeline. When our medicines are in Phase 1 or Phase 2 clinical trials, they are in a dynamic state in which we may adjust the development strategy for each medicine. Although we may characterize a medicine as &#8220;in Phase 1&#8221; or &#8220;in Phase 2,&#8221; it does not mean that we are conducting a single, well-defined study with dedicated resources. Instead, we allocate our internal resources on a shared basis across numerous medicines based on each medicine&#8217;s particular needs at that time. This means we are constantly shifting resources among medicines. Therefore, what we spend on each medicine during a particular period is usually a function of what is required to keep the medicines progressing in clinical development, not what medicines we think are most important. For example, the number of people required to start a new study is large, the number of people required to keep a study going is modest and the number of people required to finish a study is large. However, such fluctuations are not indicative of a shift in our emphasis from one medicine to another and cannot be used to accurately predict future costs for each medicine. Because we always have numerous medicines in preclinical and varying stages of clinical research, the fluctuations in expenses from medicine to medicine, in large part, offset one another. If we partner a medicine, it may affect the size of a trial, its timing, its total cost and the timing of the related costs.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000; text-decoration: underline;">Medical Affairs</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">Our medical affairs function is responsible for funding and coordinating investigator-sponsored trials, communicating scientific and clinical information to healthcare providers, medical professionals and patients, and managing publications.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt;">
   <span style="color: #000000;">The following table sets forth information on medical affairs expenses (in millions):</span>
  </div><div>

  </div><div style="line-height: 1.05;">&#160;</div><div>
  </div><table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold;">Three Months Ended</td><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold;">Nine Months Ended</td></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td></tr><tr><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - B64"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - B64"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - D64"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - D64"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - F64"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - F64"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - H64"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - H64"/></tr><tr style="background-color: rgb(204, 238, 255);"><td>Medical affairs expenses, excluding non-cash compensation expense related to equity awards</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - B65">$</td><td style="text-align: right; width: 9%;">8.9</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - B65">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - D65">$</td><td style="text-align: right; width: 9%;">5.5</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - D65">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - F65">$</td><td style="text-align: right; width: 9%;">22.3</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - F65">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - H65">$</td><td style="text-align: right; width: 9%;">17.3</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - H65">&#160;</td></tr><tr><td>Non-cash compensation expense related to equity awards</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - B66">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">1.0</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - B66">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - D66">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">1.1</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - D66">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - F66">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">3.8</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - F66">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - H66">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">3.2</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - H66">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Total medical affairs expenses</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - B67">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">9.9</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - B67">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - D67">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">6.6</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - D67">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - F67">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">26.1</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - F67">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - H67">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">20.5</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - H67">&#160;</td></tr></table><div style="line-height: 1.05;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">Medical affairs expenses</span><span>, excluding non-cash compensation expense related to equity awards, increased in the three and nine months ended September 30, 2025 compared to the same periods in 2024 as we continued advancing our late-stage pipeline.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; line-height: 1.05; text-align: justify;">
   <span style="color: #000000; text-decoration: underline;">Manufacturing and Development Chemistry</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">Expenditures in our manufacturing and development chemistry function consist primarily of personnel costs, specialized chemicals for oligonucleotide manufacturing, validation batches to support regulatory approvals, laboratory supplies and outside services. Our manufacturing and development chemistry function is responsible for providing drug supplies to drug development and our collaboration partners. Our manufacturing procedures include testing to satisfy good laboratory and good manufacturing practice requirements.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">The following table sets forth information on manufacturing and development chemistry expenses (in millions):</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;</div><div>
  </div><table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold;">Three Months Ended</td><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold;">Nine Months Ended</td></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td></tr><tr><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - B73"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - B73"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - D73"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - D73"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - F73"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - F73"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - H73"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - H73"/></tr><tr style="background-color: rgb(204, 238, 255);"><td>Manufacturing and development chemistry expenses, excluding non-cash compensation expense related to equity awards</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - B74">$</td><td style="text-align: right; width: 9%;">15.8</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - B74">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - D74">$</td><td style="text-align: right; width: 9%;">14.1</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - D74">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - F74">$</td><td style="text-align: right; width: 9%;">51.6</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - F74">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - H74">$</td><td style="text-align: right; width: 9%;">39.7</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - H74">&#160;</td></tr><tr><td>Non-cash compensation expense related to equity awards</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - B75">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2.1</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - B75">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - D75">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2.3</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - D75">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - F75">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">5.8</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - F75">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - H75">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">6.9</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - H75">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Total manufacturing and development chemistry expenses</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - B76">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">17.9</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - B76">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - D76">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">16.4</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - D76">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - F76">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">57.4</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - F76">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - H76">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">46.6</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - H76">&#160;</td></tr></table><div style="text-align: justify;">&#160;</div><div>

  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">Manufacturing and development chemistry expenses, excluding non-cash compensation expense related to equity awards, increased in </span><span>the three and nine months ended September 30, 2025 compared to the same periods in 2024 due to the timing of manufacturing performed by our contract manufacturing organizations for drug product and active pharmaceutical ingredients related to several late-stage programs.</span>
  </div><div>
  </div><div>&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 10px; margin-top: 0px; margin-bottom: 0px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">29</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-indent: 36pt;">
   <span style="color: #000000; text-decoration: underline;">R&amp;D Support</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">In our research, development and patent expenses, we include support costs such as rent, repair and maintenance for buildings and equipment, utilities, depreciation of laboratory equipment and facilities, amortization of our intellectual property, information technology costs, procurement costs and waste disposal costs. We call these costs R&amp;D support expenses.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">The following table sets forth information on R&amp;D support expenses (in millions):</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;</div><div>

  </div><table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/></tr><tr><td>&#160;</td><td colspan="7" style="font-weight: bold; text-align: center;">Three Months Ended</td><td>&#160;</td><td colspan="7" style="font-weight: bold; text-align: center;">Nine Months Ended</td></tr><tr><td>&#160;</td><td colspan="7" style="font-weight: bold; text-align: center; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td><td>&#160;</td><td colspan="7" style="font-weight: bold; text-align: center; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td></tr><tr><td>&#160;</td><td style="font-weight: bold; text-align: center; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - B82"/><td style="font-weight: bold; text-align: center; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - B82"/><td>&#160;</td><td style="font-weight: bold; text-align: center; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - D82"/><td style="font-weight: bold; text-align: center; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - D82"/><td>&#160;</td><td style="font-weight: bold; text-align: center; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - F82"/><td style="font-weight: bold; text-align: center; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - F82"/><td>&#160;</td><td style="font-weight: bold; text-align: center; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - H82"/><td style="font-weight: bold; text-align: center; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - H82"/></tr><tr style="background-color: rgb(204, 238, 255);"><td>Personnel costs</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - B83">$</td><td style="text-align: right; width: 9%;">7.6</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - B83">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - D83">$</td><td style="text-align: right; width: 9%;">6.9</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - D83">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - F83">$</td><td style="text-align: right; width: 9%;">21.8</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - F83">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - H83">$</td><td style="text-align: right; width: 9%;">21.9</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - H83">&#160;</td></tr><tr><td>Occupancy</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - B84">&#160;</td><td style="text-align: right; width: 9%;">7.8</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - B84">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - D84">&#160;</td><td style="text-align: right; width: 9%;">7.5</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - D84">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - F84">&#160;</td><td style="text-align: right; width: 9%;">21.6</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - F84">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - H84">&#160;</td><td style="text-align: right; width: 9%;">21.3</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - H84">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Computer software and licenses</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - B85">&#160;</td><td style="text-align: right; width: 9%;">3.4</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - B85">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - D85">&#160;</td><td style="text-align: right; width: 9%;">2.4</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - D85">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - F85">&#160;</td><td style="text-align: right; width: 9%;">9.8</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - F85">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - H85">&#160;</td><td style="text-align: right; width: 9%;">5.7</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - H85">&#160;</td></tr><tr><td>Insurance</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - B86">&#160;</td><td style="text-align: right; width: 9%;">0.9</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - B86">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - D86">&#160;</td><td style="text-align: right; width: 9%;">0.7</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - D86">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - F86">&#160;</td><td style="text-align: right; width: 9%;">2.6</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - F86">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - H86">&#160;</td><td style="text-align: right; width: 9%;">2.4</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - H86">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Patent expenses</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - B87">&#160;</td><td style="text-align: right; width: 9%;">2.6</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - B87">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - D87">&#160;</td><td style="text-align: right; width: 9%;">1.3</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - D87">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - F87">&#160;</td><td style="text-align: right; width: 9%;">4.1</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - F87">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - H87">&#160;</td><td style="text-align: right; width: 9%;">2.7</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - H87">&#160;</td></tr><tr><td>Other</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; width: 1%;" title="MD&amp;A - Operating Expenses - B88">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; width: 9%;">0.8</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - B88">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; width: 1%;" title="MD&amp;A - Operating Expenses - D88">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; width: 9%;">1.3</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - D88">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; width: 1%;" title="MD&amp;A - Operating Expenses - F88">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; width: 9%;">4.4</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - F88">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; width: 1%;" title="MD&amp;A - Operating Expenses - H88">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; width: 9%;">5.1</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - H88">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Total R&amp;D support expenses, excluding non-cash compensation expense related to equity awards</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - B89">&#160;</td><td style="text-align: right; width: 9%;">23.1</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - B89">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - D89">&#160;</td><td style="text-align: right; width: 9%;">20.1</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - D89">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - F89">&#160;</td><td style="text-align: right; width: 9%;">64.3</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - F89">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - H89">&#160;</td><td style="text-align: right; width: 9%;">59.1</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - H89">&#160;</td></tr><tr><td>Non-cash compensation expense related to equity awards</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; width: 1%;" title="MD&amp;A - Operating Expenses - B90">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; width: 9%;">4.5</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - B90">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; width: 1%;" title="MD&amp;A - Operating Expenses - D90">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; width: 9%;">4.6</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - D90">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; width: 1%;" title="MD&amp;A - Operating Expenses - F90">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; width: 9%;">13.1</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - F90">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; width: 1%;" title="MD&amp;A - Operating Expenses - H90">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-right: none; width: 9%;">13.2</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - H90">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Total R&amp;D support expenses</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - B91">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">27.6</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - B91">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - D91">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">24.7</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - D91">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - F91">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">77.4</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - F91">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - H91">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">72.3</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - H91">&#160;</td></tr></table><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">R&amp;D support expenses</span><span>, excluding non-cash compensation expense related to equity awards,</span><span style="color: #000000;">&#160;increased in the three and nine months ended September 30, 2025 compared to the same periods in 2024 primarily due to increased costs relating to computer software and licenses.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000; font-weight: bold; font-style: italic;">Selling, General and Administrative Expenses </span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">SG&amp;A expenses include personnel, information technology systems and outside costs associated with the commercialization and pre-commercialization activities for our medicines and costs to support our company, our employees and our stockholders including, legal, human resources, investor relations and finance. Additionally, we include in SG&amp;A expenses such costs as rent, repair and maintenance of buildings and equipment, depreciation and utilities costs that we need to support the corporate functions listed above. We also include fees we owe under our in-licensing agreements related to SPINRAZA and QALSODY and cost sharing payments associated with co-commercialization activities under our WAINUA collaboration with AstraZeneca.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt;">
   <span style="color: #000000;">The following table sets forth information on SG&amp;A expenses (in millions):</span>
  </div><div>
  </div><div>&#160;</div><div>
  </div><table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold;">Three Months Ended</td><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold;">Nine Months Ended</td></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td></tr><tr><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - B97"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - B97"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - D97"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="width: 1%; border-bottom: 1px solid black; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - D97"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - F97"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="width: 1%; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - F97"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - H97"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="width: 1%; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - H97"/></tr><tr style="background-color: rgb(204, 238, 255);"><td>Selling, general and administrative expenses, excluding non-cash compensation expense related to equity awards</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - B98">$</td><td style="text-align: right; width: 9%;">86.6</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - B98">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - D98">$</td><td style="text-align: right; width: 9%;">51.9</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - D98">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - F98">$</td><td style="text-align: right; width: 9%;">234.6</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - F98">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - H98">$</td><td style="text-align: right; width: 9%;">153.1</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - H98">&#160;</td></tr><tr><td>Non-cash compensation expense related to equity awards</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - B99">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">10.2</td><td style="text-align: left; width: 1%; border-top: none; border-left: none; border-right: none; border-bottom: 1px solid black;" title="MD&amp;A - Operating Expenses - B99">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - D99">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">9.7</td><td style="text-align: left; width: 1%; border-left: none; border-right: none; border-bottom: 1px solid black; border-top: none;" title="MD&amp;A - Operating Expenses - D99">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - F99">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">29.1</td><td style="text-align: left; width: 1%; border-left: none; border-right: none; border-bottom: 1px solid black; border-top: none;" title="MD&amp;A - Operating Expenses - F99">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - H99">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">26.3</td><td style="text-align: left; width: 1%; border-left: none; border-right: none; border-bottom: 1px solid black; border-top: none;" title="MD&amp;A - Operating Expenses - H99">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Total selling, general and administrative expenses</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - B100">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">96.8</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - B100">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - D100">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">61.6</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - D100">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - F100">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">263.7</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Operating Expenses - F100">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Operating Expenses - H100">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">179.4</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Operating Expenses - H100">&#160;</td></tr></table><div>
  </div><div style="border-width: initial; border-style: none; border-color: initial; border-collapse: collapse;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify; font-size: 12pt;">
   <span style="font-size: 10.0pt; color: #000000;">SG&amp;A expenses</span><span style="font-size: 10.0pt;">, excluding non-cash compensation expense related to equity awards,</span><span style="font-size: 10.0pt; color: #000000;">&#160;increased in the three and nine months ended September 30, 2025 compared to the same periods in 2024</span><span style="font-size: 10.0pt;">&#160;primarily due to the  launches of TRYNGOLZA, DAWNZERA and WAINUA. We expect SG&amp;A expenses to increase as we continue to invest in our independent commercial launches.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;">
   <span style="color: #000000; font-weight: bold; font-style: italic;">Investment Income</span>
  </div><div>
  </div><div style="line-height: 1.15; text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;">
   <span style="color: #000000;">The following table sets forth information on investment income (in millions):</span></div><div>


  </div><div>&#160;</div><table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold;">Three Months Ended</td><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold;">Nine Months Ended</td></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td></tr><tr><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Other - B7"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Other - B7"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Other - D7"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Other - D7"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Other - F7"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Other - F7"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Other - H7"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Other - H7"/></tr><tr style="background-color: rgb(204, 238, 255);"><td>Investment income</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Other - B8">$</td><td style="text-align: right; width: 9%;">23.7</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Other - B8">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Other - D8">$</td><td style="text-align: right; width: 9%;">26.2</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Other - D8">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Other - F8">$</td><td style="text-align: right; width: 9%;">73.0</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Other - F8">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Other - H8">$</td><td style="text-align: right; width: 9%;">78.1</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Other - H8">&#160;</td></tr></table><div>&#160;</div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 10px; margin-top: 0px; margin-bottom: 0px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">30</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;">
   <span style="color: #000000; font-weight: bold; font-style: italic;">Interest Expense</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt;">
   <span style="color: #000000;">The following table sets forth information on interest expense (in millions):</span>
  </div><div>
  </div><div>&#160;
  </div><div>


  </div><table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold;">Three Months Ended</td><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold;">Nine Months Ended</td></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td></tr><tr><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Other - B14"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Other - B14"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Other - D14"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Other - D14"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Other - F14"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Other - F14"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Other - H14"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Other - H14"/></tr><tr><td>Convertible notes:</td><td style="width: 1%;" title="MD&amp;A - Other - B15"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="MD&amp;A - Other - B15"/><td>&#160;</td><td style="width: 1%;" title="MD&amp;A - Other - D15"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="MD&amp;A - Other - D15"/><td>&#160;</td><td style="width: 1%;" title="MD&amp;A - Other - F15"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="MD&amp;A - Other - F15"/><td>&#160;</td><td style="width: 1%;" title="MD&amp;A - Other - H15"/><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="MD&amp;A - Other - H15"/></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 10px;">Non-cash amortization of debt issuance costs</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Other - B16">$</td><td style="text-align: right; width: 9%;">1.6</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Other - B16">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Other - D16">$</td><td style="text-align: right; width: 9%;">1.5</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Other - D16">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Other - F16">$</td><td style="text-align: right; width: 9%;">4.6</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Other - F16">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Other - H16">$</td><td style="text-align: right; width: 9%;">4.5</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Other - H16">&#160;</td></tr><tr><td style="padding-left: 10px;">Interest expense payable in cash</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Other - B17">&#160;</td><td style="text-align: right; width: 9%;">2.5</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Other - B17">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Other - D17">&#160;</td><td style="text-align: right; width: 9%;">2.6</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Other - D17">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Other - F17">&#160;</td><td style="text-align: right; width: 9%;">7.6</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Other - F17">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Other - H17">&#160;</td><td style="text-align: right; width: 9%;">8.0</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Other - H17">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Interest on mortgage for manufacturing facility</td><td style="text-align: left; border-top: none; border-left: none; border-right: none; border-bottom: 1px solid black; width: 1%;" title="MD&amp;A - Other - B18">&#160;</td><td style="text-align: right; border-left: none; border-right: none; border-bottom: 1px solid black; border-top: none; width: 9%;">0.1</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Other - B18">&#160;</td><td>&#160;</td><td style="text-align: left; border-left: none; border-right: none; border-bottom: 1px solid black; border-top: none; width: 1%;" title="MD&amp;A - Other - D18">&#160;</td><td style="text-align: right; border-left: none; border-right: none; border-bottom: 1px solid black; border-top: none; width: 9%;">0.1</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Other - D18">&#160;</td><td>&#160;</td><td style="text-align: left; border-left: none; border-right: none; border-bottom: 1px solid black; border-top: none; width: 1%;" title="MD&amp;A - Other - F18">&#160;</td><td style="text-align: right; border-left: none; border-right: none; border-bottom: 1px solid black; border-top: none; width: 9%;">0.2</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Other - F18">&#160;</td><td>&#160;</td><td style="text-align: left; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Other - H18">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-left: none; border-right: none; width: 9%;">0.3</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Other - H18">&#160;</td></tr><tr><td>Total interest expense</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Other - B19">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">4.2</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Other - B19">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Other - D19">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">4.2</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Other - D19">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Other - F19">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">12.4</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Other - F19">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Other - H19">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">12.8</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Other - H19">&#160;</td></tr></table><div>&#160;</div><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;">
   <span style="color: #000000; font-weight: bold; font-style: italic;">Interest Expense Related to Sale of Future Royalties</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;">
   <span style="color: #000000;">We recorded $18.0 million and $55.4 million of interest expense related to the sale of future royalties in the three and nine months ended September 30, 2025, respectively, compared to $18.5 million and $54.8 million in the same periods in 2024, respectively. These amounts are related to the Royalty Pharma Investments, or Royalty Pharma, transaction, in which we sold a minority interest in our future SPINRAZA and pelacarsen royalties to Royalty Pharma for a $500 million upfront payment and $625 million of potential future payments. Refer to </span><span>Part I, Item 1, Note 11, </span><span style="font-style: italic;">Liability Related to Sale of Future Royalties</span><span>, in the Notes to Condensed Consolidated Financial Statements for further details.</span>
  </div><div>
  </div><div style="line-height: 1.15; text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;">
   <span style="color: #000000; font-weight: bold; font-style: italic;">Gain (Loss) on Investments</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;">The following table sets forth information on gain (loss) on investments (in millions):</div><div>
  </div><div>&#160;</div><div>
  </div><table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold;">Three Months Ended</td><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold;">Nine Months Ended</td></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td></tr><tr><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Other - B25"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Other - B25"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Other - D25"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Other - D25"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Other - F25"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Other - F25"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Other - H25"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Other - H25"/></tr><tr style="background-color: rgb(204, 238, 255);"><td>Gain (loss) on investments</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Other - B26">$</td><td style="text-align: right; width: 9%;">29.9</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Other - B26">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Other - D26">$</td><td style="text-align: right; width: 9%;">0.9</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Other - D26">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Other - F26">$</td><td style="text-align: right; width: 9%;">9.4</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Other - F26">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Other - H26">$</td><td style="text-align: right; width: 9%;">(0.3</td><td style="text-align: left; width: 1%;" title="MD&amp;A - Other - H26">)&#160;</td></tr></table><div>&#160;</div><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;">Gain on investments increased in the three and nine months ended September 30, 2025 compared to the same periods in 2024 primarily due to&#160;<span style="letter-spacing: normal; text-align: justify; text-indent: -24px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">a $29.4 million gain related to our investment in a privately held company resulting from an observable price change in an orderly transaction for a similar investment of the issuer <span style="text-decoration-thickness: initial; float: none; display: inline !important;">that we recorded in the third quarter of 2025</span>.</span>&#160;This gain was partially offset by an $18.2 million impairment of our investment in a privately held company that we recorded in the second quarter of 2025.</div><div>&#160;</div><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;">
   <span style="color: #000000; font-weight: bold; font-style: italic;">Income Tax Benefit (Expense)</span></div><div>
  </div><div style="line-height: 1.15; text-align: justify;">&#160;</div><div>

  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="letter-spacing: normal; text-indent: 48px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">We recorded nominal income tax expense for the three and nine months ended September 30, 2025 compared to income tax benefit of $3.6 million and $3.5 million for the same periods in 2024.</span></div><div style="text-indent: 36pt; text-align: justify;">&#160;</div><div style="text-indent: 36pt; text-align: justify;">The benefit for the three and nine months ended September 30, 2024 was primarily related to the 2023 tax return position for the royalty purchase agreement with Royalty Pharma that we finalized during the third quarter of 2024.</div><div style="text-align: justify;">&#160;</div><div>
  </div><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"><span style="letter-spacing: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">In July 2025, the One Big Beautiful Bill Act, or OBBBA, was signed into law, introducing significant changes to U.S. federal tax law. The new law restores current expensing of domestic R&amp;D costs and allows us to accelerate the deduction for a significant amount of such costs we capitalized since 2022. The tax law changes from the OBBBA did not have a material effect on our tax expense for the three and nine months ended September 30, 2025.</span></div><div style="text-align: justify;">&#160;</div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">We continue to maintain a full valuation allowance on all of our net deferred tax assets.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="font-weight: bold; font-style: italic;">Net Loss&#160;and Net Loss&#160;per Share</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">The following table sets forth information on net loss&#160;and net loss per share (in millions, except per share amounts):</div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">&#160;</div><table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold;">Three Months Ended</td><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold;">Nine Months Ended</td></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td></tr><tr><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Net Income and EPS - B4"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Net Income and EPS - B4"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Net Income and EPS - D4"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Net Income and EPS - D4"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Net Income and EPS - F4"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Net Income and EPS - F4"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Net Income and EPS - H4"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Net Income and EPS - H4"/></tr><tr style="background-color: rgb(204, 238, 255);"><td>Net loss</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Net Income and EPS - B5">$</td><td style="width: 9%; text-align: right;">(128.6</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Net Income and EPS - B5">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Net Income and EPS - D5">$</td><td style="width: 9%; text-align: right;">(140.5</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Net Income and EPS - D5">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Net Income and EPS - F5">$</td><td style="width: 9%; text-align: right;">(152.0</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Net Income and EPS - F5">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Net Income and EPS - H5">$</td><td style="width: 9%; text-align: right;">(349.5</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Net Income and EPS - H5">)&#160;</td></tr><tr><td>Basic and diluted net loss per share</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Net Income and EPS - B7">$</td><td style="width: 9%; text-align: right;">(0.80</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Net Income and EPS - B7">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Net Income and EPS - D7">$</td><td style="width: 9%; text-align: right;">(0.95</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Net Income and EPS - D7">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Net Income and EPS - F7">$</td><td style="width: 9%; text-align: right;">(0.95</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Net Income and EPS - F7">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Net Income and EPS - H7">$</td><td style="width: 9%; text-align: right;">(2.38</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Net Income and EPS - H7">)&#160;</td></tr></table><div>&#160;</div><div>
  </div><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"><span style="letter-spacing: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">The period-over-period fluctuations in our net loss&#160;were driven by factors discussed in the sections above.</span></div><div>&#160;</div><div style="text-align: justify; font-size: 12pt; color: #000000;">
   <a id="Liquidity_and_Capital_Resources" title="Liquidity and Capital Resources"></a><span style="font-size: 10.0pt; font-weight: bold;">Liquidity and Capital Resources</span>
  </div><div>
  </div><div style="text-align: justify; color: #000000;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify; font-size: 12pt; color: #000000;">
   <span style="font-size: 10.0pt;">We have financed our operations primarily from research and development collaborative agreements. We also financed our operations from commercial revenue from SPINRAZA, WAINUA and QALSODY royalties and TEGSEDI and WAYLIVRA commercial revenue. In addition, we began earning commercial revenue from TRYNGOLZA product sales in late December 2024 and DAWNZERA product sales in late August 2025. From our inception through September 30, 2025, we have earned approximately $8.7 billion in revenue. We have also financed our operations through the sale of our equity securities, the issuance of long-term debt and the sale of future royalties. From the time we were founded through September 30, 2025, we have raised net proceeds of approximately $2.7 billion from the sale of our equity securities. Additionally, from our inception through September 30, 2025, we have borrowed approximately $2.7 billion under long-term debt arrangements and received proceeds of $0.5 billion from the sale of future royalties to finance a portion of our operations. </span>
  </div><div>
  </div><div style="text-align: justify; color: #000000;">&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 10px; margin-top: 0px; margin-bottom: 0px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">31</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">From December 31, 2024 to </span><span>September 30, 2025, our working capital and long-term obligations decreased  as we reclassified our 0% Notes from non-current liabilities to current liabilities in the second quarter of 2025 because the notes are due in April 2026.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify; font-size: 12pt; color: #000000;">
   <span style="font-size: 10.0pt;">The following table summarizes our contractual obligations, excluding our liability related to the sale of future royalties, as of September 30, 2025. The table provides a breakdown of when obligations become due. </span>
  </div><div>



  </div><div style="color: #000000;">&#160;</div><table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 1%;"/><td style="width: 9%;"/><td style="width: 1%;"/></tr><tr><td>&#160;</td><td>&#160;</td><td colspan="11" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">Payments Due by Period (in millions)</td></tr><tr><td>(selected balances described below)</td><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Contractual Obligations - C6"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">Total</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Contractual Obligations - C6"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Contractual Obligations - E6"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">Less than 1 year</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Contractual Obligations - E6"/><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="MD&amp;A - Contractual Obligations - G6"/><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">More than 1 year</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Contractual Obligations - G6"/></tr><tr style="background-color: rgb(204, 238, 255);"><td>1.75% Notes (principal and interest payable)</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Contractual Obligations - C7">$</td><td style="width: 9%; text-align: right;">605.2</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Contractual Obligations - C7">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Contractual Obligations - E7">$</td><td style="width: 9%; text-align: right;">10.1</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Contractual Obligations - E7">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Contractual Obligations - G7">$</td><td style="width: 9%; text-align: right;">595.1</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Contractual Obligations - G7">&#160;</td></tr><tr><td>0% Notes (principal payable)</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Contractual Obligations - C8">&#160;</td><td style="width: 9%; text-align: right;">632.5</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Contractual Obligations - C8">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Contractual Obligations - E8">&#160;</td><td style="width: 9%; text-align: right;">632.5</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Contractual Obligations - E8">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Contractual Obligations - G8">&#160;</td><td style="width: 9%; text-align: right;">-</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Contractual Obligations - G8">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Operating leases</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Contractual Obligations - C9">&#160;</td><td style="width: 9%; text-align: right;">487.3</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Contractual Obligations - C9">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Contractual Obligations - E9">&#160;</td><td style="width: 9%; text-align: right;">33.8</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Contractual Obligations - E9">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Contractual Obligations - G9">&#160;</td><td style="width: 9%; text-align: right;">453.5</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Contractual Obligations - G9">&#160;</td></tr><tr><td>Building mortgage payments (principal and interest payable)</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Contractual Obligations - C10">&#160;</td><td style="width: 9%; text-align: right;">9.2</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Contractual Obligations - C10">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Contractual Obligations - E10">&#160;</td><td style="width: 9%; text-align: right;">0.5</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Contractual Obligations - E10">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Contractual Obligations - G10">&#160;</td><td style="width: 9%; text-align: right;">8.7</td><td style="width: 1%; text-align: left;" title="MD&amp;A - Contractual Obligations - G10">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Other obligations (principal and interest payable)</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Contractual Obligations - C11">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">0.7</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Contractual Obligations - C11">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Contractual Obligations - E11">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">0.1</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Contractual Obligations - E11">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Contractual Obligations - G11">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">0.6</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Contractual Obligations - G11">&#160;</td></tr><tr><td>Total</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Contractual Obligations - C12">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">1,734.9</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Contractual Obligations - C12">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Contractual Obligations - E12">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">677.0</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Contractual Obligations - E12">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Contractual Obligations - G12">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">1,057.9</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="MD&amp;A - Contractual Obligations - G12">&#160;</td></tr></table><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">Our contractual obligations consist primarily of our convertible debt. In addition, we also have a facility mortgage, facility leases, equipment financing arrangements and other obligations. In the third quarter of 2025, our build-to-suit lease in Carlsbad, California commenced, resulting in an increase to our contractual obligations related to operating leases. We believe our cash, cash equivalents and short-term investments, as well as plans for cash in the future, will be sufficient to fund our planned operations and these obligations. We have not entered into, nor do we currently have, any off-balance sheet arrangements (as defined under SEC rules).</span>
  </div><div>
  </div><div style="font-size: 8pt;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000; font-weight: bold; font-style: italic;">Convertible Debt and Call Spread</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>Refer to Part I, Item 1, Note 12, </span><span style="font-style: italic;">Convertible Debt</span><span>, in the Notes to Condensed Consolidated Financial Statements for the significant terms of each convertible debt instrument.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt;">
   <span style="font-weight: bold; font-style: italic;">Operating Facilities</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>Refer to Part IV, Item 15, Note 7 of our audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2024 for further details on our operating facilities.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="font-weight: bold; font-style: italic;">Operating Leases</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>

  </div><div style="text-indent: 36pt; text-align: justify;">
   Refer to Part I, Item 1, Note 13, <i>Operating Leases</i>, in the Notes to Condensed Consolidated Financial Statements and Part IV, Item 15, Note 7 of our audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2024 for further details on our operating leases.
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="font-weight: bold; font-style: italic;">Liability Related to Sale of Future Royalties</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>Refer to Part I, Item 1, </span><span style="color: #000000;">Note 11, </span><span style="color: #000000; font-style: italic;">Liability Related to Sale of Future Royalties</span><span style="font-style: italic;">, </span><span>in the Notes to Condensed Consolidated Financial Statements for further details on our royalty purchase agreement with Royalty Pharma. </span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt;">
   <span style="color: #000000; font-weight: bold; font-style: italic;">Other Obligations</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify; font-size: 12pt; color: #000000;">
   <span style="font-size: 10.0pt;">In addition to contractual obligations, we had outstanding purchase orders as of September 30, 2025 for the purchase of services, capital equipment and materials as part of our normal course of business.</span>
  </div><div>
  </div><div style="text-align: justify; color: #000000;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify; font-size: 12pt; color: #000000;">
   <span style="font-size: 10.0pt;">We may enter into additional collaborations with partners which could provide for additional revenue to us and we may incur additional cash expenditures related to our obligations under any of the new agreements we may enter into. We currently intend to use our cash, cash equivalents and short-term investments to finance our activities. However, we may also pursue other financing alternatives, like issuing additional shares of our common stock, issuing debt instruments, refinancing our existing debt, securing lines of credit or executing royalty monetization agreements. Whether we use our existing capital resources or choose to obtain financing will depend on various factors, including the future success of our business, the prevailing interest rate environment and the condition of financial markets generally.</span>
  </div><div>
  </div><div>&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 10px; margin-top: 0px; margin-bottom: 0px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">32</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-indent: -72pt; padding-left: 72pt;">
    <div style="float: left; width: 72.0pt; white-space: nowrap;">
     <a id="Item_3_-_Market_Risk" title="Item 3 - Market Risk"></a><span style="color: #000000; font-weight: bold;">ITEM 3.</span>
    </div>
    <div>
     <span style="color: #000000; font-weight: bold;">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span>
    </div>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">We are exposed to changes in interest rates primarily from our investments in certain short-term investments. We primarily invest our excess cash in highly liquid short-term investments of the U.S. Treasury and reputable financial institutions, corporations, and U.S. government agencies with strong credit ratings. We typically hold our investments for the duration of the term of the respective instrument. We do not utilize derivative financial instruments, derivative commodity instruments or other market risk sensitive instruments, positions or transactions to manage exposure to interest rate changes. Accordingly, we believe that, while the securities we hold are subject to changes in the financial standing of the issuer of such securities, we are not subject to any material risks arising from changes in interest rates, foreign currency exchange rates, commodity prices, equity prices or other market changes that affect market risk sensitive instruments.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">We are also exposed to changes in foreign currency exchange rates as we have foreign subsidiaries with functional currencies other than the U.S. dollar. We translate our subsidiaries&#8217; functional currencies into our reporting currency, the U.S. dollar. As a result, our financial position, results of operations and cash flows can be affected by market fluctuations in the foreign currencies to U.S. dollar exchange rate, which are difficult to predict. A hypothetical 10 percent change in foreign exchange rates during any of the periods presented would not have had a material impact on our condensed consolidated financial statements.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: -72pt; padding-left: 72pt;">
    <div style="float: left; width: 72.0pt; white-space: nowrap;">
     <a id="Item_4_-_Controls_and_Procedures" title="Item 4 - Controls and Procedures"></a><span style="color: #000000; font-weight: bold;">ITEM 4.</span>
    </div>
    <div>
     <span style="color: #000000; font-weight: bold;">CONTROLS AND PROCEDURES</span>
    </div>
  </div><div>
  </div><div style="font-size: 8pt;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">We maintain disclosure controls and procedures that are designed to ensure that information we are required to disclose in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. We design and evaluate our disclosure controls and procedures recognizing that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance and not absolute assurance of achieving the desired control objectives.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">As of our most recently completed fiscal year and as of the end of the period covered by this Quarterly Report on Form 10-Q, we carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer. Based on our evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of September 30, 2025. There have been no significant changes in our internal controls or in other factors that could significantly affect internal controls subsequent to September 30, 2025.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">We also performed an evaluation of any changes in our internal controls over financial reporting that occurred during our last fiscal quarter and that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting. We conducted this evaluation under the supervision of and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer. That evaluation did not identify any changes in our internal controls over financial reporting that occurred during our latest fiscal quarter and that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.</span>
  </div><div>
  </div><div>&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 10px; margin-top: 0px; margin-bottom: 0px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">33</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-align: justify;">
   <span style="color: #000000; font-weight: bold;">PART II &#8212; OTHER INFORMATION</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: -72pt; text-align: justify; padding-left: 72pt;">
    <div style="float: left; width: 72.0pt; white-space: nowrap;">
     <a id="Item_1_-_Legal_Proceedings" title="Item 1 - Legal Proceedings"></a><span style="color: #000000; font-weight: bold;">ITEM 1.</span>
    </div>
    <div>
     <span style="color: #000000; font-weight: bold;">LEGAL PROCEEDINGS</span>
    </div>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>For details of legal proceedings, refer to Part I, Item 1, Note 14, </span><span style="font-style: italic;">Legal Proceedings</span><span>, in the Notes to Condensed Consolidated Financial Statements</span><span style="color: #000000;">.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: -72pt; text-align: justify; padding-left: 72pt;">
    <div style="float: left; width: 72.0pt; white-space: nowrap;">
     <a id="Item_1A_-_Risk_Factors" title="Item 1A - Risk Factors"></a><span style="color: #000000; font-weight: bold;">ITEM 1A.</span>
    </div>
    <div>
     <span style="color: #000000; font-weight: bold;">RISK FACTORS</span>
    </div>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000; font-style: italic;">Investing in our securities involves a high degree of risk. You should carefully consider the following information about the risks described below, together with the other information contained in this report and in our other public filings in evaluating our business. If any of the following risks actually occur, our business could be materially harmed, and our financial condition and results of operations could be materially and adversely affected. As a result, the trading price of our securities could decline, and you might lose all or part of your investment. We have marked with an asterisk those risk factors that reflect substantive changes from the risk factors included in our Annual Report on Form 10-K for the year ended December 31, 2024.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-align: center;">
   <span style="color: #000000; font-weight: bold;">Summary of Risk Factors</span>
  </div><div>
  </div><div style="text-align: center;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">There are a number of risks related to our business and our securities. Some of the principal risks related to our business include the following:</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt; font-family: Calibri; font-size: 11pt; color: #000000;">

    <div>
     <span style="font-family: Times New Roman; font-size: 10.0pt;">&#9679;&#160;&#160;&#160;&#160;Our ability to generate substantial revenue from the sale of our medicines;</span></div>
  <div><span style="font-family: &quot;Times New Roman&quot;; font-size: 13.3333px; letter-spacing: normal; text-indent: -24px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">&#9679;&#160;&#160;&#160;&#160;<span style="text-decoration-thickness: initial; font-family: Symbol;">T</span><span style="text-decoration-thickness: initial;">he availability of adequate coverage and payment rates for our medicines</span>;</span></div><div>
     <span style="font-family: Times New Roman; font-size: 10.0pt;">&#9679;&#160;&#160;&#160;&#160;Our and our partners&#8217; ability to compete effectively;</span>
    </div></div><div>


  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt; font-family: Calibri; font-size: 11pt; color: #000000; clear: both;">

    <div>
     <span style="font-family: Times New Roman; font-size: 10.0pt;">&#9679;&#160;&#160;&#160;&#160;Our ability to successfully manufacture our medicines;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt; font-family: Calibri; font-size: 11pt; color: #000000; clear: both;">

    <div>
     <span style="font-family: Times New Roman; font-size: 10.0pt;">&#9679;&#160;&#160;&#160;&#160;Our ability to successfully develop and obtain marketing approvals for our medicines;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt; font-family: Calibri; font-size: 11pt; color: #000000; clear: both;">

    <div>
     <span style="font-family: Times New Roman; font-size: 10.0pt;">&#9679;&#160;&#160;&#160;&#160;Our ability to secure and maintain effective corporate partnerships;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt; font-family: Calibri; font-size: 11pt; color: #000000; clear: both;">

    <div>
     <span style="font-family: Times New Roman; font-size: 10.0pt;">&#9679;&#160;&#160;&#160;&#160;Our ability to sustain cash flows and achieve consistent profitability;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt; font-family: Calibri; font-size: 11pt; color: #000000; clear: both;">

    <div>
     <span style="font-family: Times New Roman; font-size: 10.0pt;">&#9679;&#160;&#160;&#160;&#160;Our ability to protect our intellectual property;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt; font-family: Calibri; font-size: 11pt; color: #000000; clear: both;">

    <div>
     <span style="font-family: Times New Roman; font-size: 10.0pt;">&#9679;&#160;&#160;&#160;&#160;Our ability to maintain the effectiveness of our personnel; </span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt; font-family: Calibri; font-size: 11pt; color: #000000; clear: both;">

    <div>
     <span style="font-family: Times New Roman; font-size: 10.0pt;">&#9679;&#160;&#160;&#160;&#160;The impacts of health epidemics, climate change, war and other events; </span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt; clear: both;">

    <div>
     <span>&#9679;&#160;&#160;&#160;&#160;Our dependence upon our own and third-party information technology systems; and</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt; font-family: Calibri; font-size: 11pt; color: #000000;">

    <div>
     <span style="font-family: Times New Roman; font-size: 10.0pt;">&#9679;&#160;&#160;&#160;&#160;The other factors set forth below.</span>
    </div>
  </div><div>
  </div><div style="clear: both;">&#160;
  </div><div>
  </div><div style="text-align: center;">
   <span style="color: #000000; font-weight: bold;">Risks Related to the Commercialization of our Medicines</span>
  </div><div>
  </div><div style="color: #000000;">&#160;
  </div><div>
  </div><div style="text-align: justify;">
   <span style="color: #000000; font-weight: bold;">We have limited experience as a company in commercializing medicines and we will have to continue to invest significant resources to develop our capabilities. If we are unable to effectively establish or maintain an effective commercialization infrastructure, or enter into agreements with third parties to commercialize our medicines, we may not be able to successfully commercialize our medicines.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">We have historically relied on third parties to commercialize our marketed medicines and have limited experience as a company in commercializing medicines. We currently have two independently launched medicines, TRYNGOLZA and DAWNZERA, and we expect to independently launch additional medicines in the future. Any failure to effectively commercialize our medicines, including our failure to allocate resources to our commercial launches efficiently or timely, could adversely impact the revenue we generate from our medicines. If the commercialization of our independently launched medicines and future sales of such are less successful than anticipated by us or our investors or securities analysts, our stock price could decline and our business may be harmed.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">We will have to continue to invest significant financial and management resources to build and maintain the infrastructure required to successfully commercialize our medicines. We will need to establish and maintain effective sales teams for each of our independently launched medicines and there are significant risks involved in managing a sales organization, including our ability to hire, retain and incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel, and effectively manage a geographically dispersed sales and marketing team. We must also continue to scale-up existing internal support functions to aid our commercialization efforts. Further, these existing support functions will need to work effectively in coordination with new commercial functional areas. Any failure to establish or maintain an effective commercialization infrastructure, including our sales, marketing, market access, distribution, and related capabilities, scale-up our existing support functions, or effectively integrate new functional areas, could adversely affect our ability to successfully commercialize our medicines.</span>
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 10px; margin-top: 0px; margin-bottom: 0px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">34</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">If we choose to rely on third parties to assist us in commercializing our medicines, we may not be able to enter into collaborations or hire consultants or external service providers on acceptable financial terms, or at all. In addition, if we continue to engage third parties to assist us in the commercialization of our medicines, our product revenues and profitability may be lower than if we commercialized such medicines ourselves.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">The proximity of our planned upcoming independent launches could increase the likelihood that the risks set forth above will occur.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-align: justify;">
   <span style="color: #000000; font-weight: bold;">If the market does not accept our medicines, including our commercial medicines and our medicines in development, we are not likely to generate substantial revenues or become consistently profitable.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">Even if our medicines are authorized for marketing, our success will depend upon the medical community, patients and third-party payers accepting our medicines as medically useful, cost-effective, safe and convenient. Even when the FDA or foreign regulatory authorities authorize our or our partners&#8217; medicines for commercialization, doctors may not prescribe our medicines to treat patients. Furthermore, we and our partners may not successfully commercialize additional medicines.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">Additionally, in many of the markets where we or our partners may sell our medicines in the future, if we or our partners cannot agree with the government or other third-party payers regarding the price we can charge for our medicines, we may not be able to sell our medicines in that market. Similarly, cost control initiatives by governments or third-party payers could decrease the price received for our medicines or increase patient coinsurance to a level that makes our medicines, including our commercial medicines and our medicines in development, economically unviable. If the pricing of any of our medicines decreases for any reason, it will reduce our revenue for such medicine. For example, Biogen has in the past disclosed that SPINRAZA revenue decreased in part due to lower pricing in the U.S. and certain rest-of-world markets.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">The degree of market acceptance for our medicines, including our commercial medicines and our medicines in development, depends upon several factors, including the:</span>
  </div><div>
  </div><div style="text-align: justify; margin-left: 54pt;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div>
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;receipt and scope of marketing authorizations;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div style="text-align: left;">
     <span style="color: #000000;">&#9679;&#160; &#160; establishment and demonstration in the medical and patient community of the efficacy and safety of our medicines, public perception regarding our medicines and their potential advantages over competing products; </span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div>
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;cost and effectiveness of our medicines compared to other available therapies;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div>
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;patient convenience of the dosing regimen for our medicines; and</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div>
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;reimbursement policies of government and third-party payers. </span>
    </div>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-align: justify;">
   <span style="color: #000000;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on the profile of our medicines, physicians, patients, patient advocates, payers or the medical community in general may not accept or use any of the medicines that we or our partners may develop. For example, the product label for WAYLIVRA in the EU requires regular blood monitoring, which has negatively affected our ability to attract and retain patients for this medicine. </span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-align: justify;">
   <span style="color: #000000; font-weight: bold;">If government or other third-party payers fail to provide adequate coverage and payment rates for our medicines, including our commercial medicines and our medicines in development, our revenue will be limited.*</span></div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">In both domestic and foreign markets, sales of our current and future products will depend in part upon the availability of coverage and reimbursement from third-party payers. The majority of patients in the U.S. who would fit within our target patient populations for our medicines have their healthcare supported by a combination of Medicare coverage, other government health programs such as Medicaid, managed care providers, private health insurers and other organizations. Coverage decisions may depend upon clinical and economic standards that disfavor new medicines when more established or lower cost therapeutic alternatives are already available or subsequently become available. Assuming coverage is approved, the resulting reimbursement payment rates might not be enough to make our medicines affordable. Even if favorable coverage status and adequate reimbursement rates are attained, less favorable coverage policies and reimbursement rates may be implemented in the future. Accordingly, our commercial medicines and our medicines in development will face competition from other therapies and medicines for limited financial resources. Furthermore, we or our partners may need to conduct post-marketing studies to demonstrate the cost-effectiveness of any future products to satisfy third-party payers. These studies might require us to commit a significant amount of management time and financial and other resources. In addition, third-party payers may never consider our future products as cost-effective and adequate third-party coverage and reimbursement might not be available to enable us to maintain price levels sufficient to realize an appropriate return on investment in product development.</span>
  </div><div>
  </div><div>&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 10px; margin-top: 0px; margin-bottom: 0px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">35</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">Third-party payers, whether foreign or domestic, or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare costs. In addition, in the U.S., no uniform policy of coverage and reimbursement for medicines exists among third-party payers. Therefore, coverage and reimbursement for medicines can differ significantly from payer to payer. For example, the Affordable Care Act, or ACA, was passed in March 2010, and substantially changed the way healthcare is financed by both governmental and private insurers and continues to significantly impact the U.S. pharmaceutical industry. There have been judicial and Congressional challenges to certain aspects of the ACA, as well as efforts to repeal or replace certain aspects of the ACA. It is unclear how future litigation and healthcare reform measures will impact the ACA and our business.</span>
  </div><div>
  </div><div>&#160;
  </div><div>

  </div><div style="text-indent: 36pt; text-align: justify;">
   Further, we believe that future coverage, reimbursement and pricing will likely be subject to increased restrictions both in the U.S. and in international markets. In the U.S., recent health reform measures have resulted in reductions in Medicare and other healthcare funding, and there have been several recent U.S. Congressional inquiries, legislation and executive orders designed to, among other things, reduce drug prices, increase competition (including by enhancing support for generic and biosimilar drugs), lower out-of-pocket drug costs for patients, curtail spread pricing practices by pharmacy benefit managers, and foster scientific innovation to promote better health care and improved health. For example, on May 12,
2025, President Trump issued an executive order implementing the concept of
most-favored nation pricing. Under this order, HHS, in coordination with other
federal agencies, is directed to take actions to ensure that the price of
prescription drugs paid by federal health insurers, including Medicare and
Medicaid, is in line with the prices paid in comparably developed nations.&#160;These and similar actions and policies may significantly reduce U.S. drug prices, potentially impacting manufacturers&#8217; global pricing strategies and profitability, while increasing their operational costs and compliance risks.</div><div style="text-indent: 36pt; text-align: justify;">&#160;</div><div style="text-indent: 36pt; text-align: justify;"><span style="color: #000000;">In addition, the Inflation Reduction Act of 2022, or the IRA, includes key actions aimed at reducing the costs of prescription drugs and allows HHS to negotiate the price of certain single-source drugs covered under Medicare and establish a price cap on such drugs. The IRA, among other things, (1) directs HHS to negotiate the price of certain single-source drugs and biologics that have been on the market for at least seven years covered under Medicare, or the Medicare Drug Price Negotiation Program, and (2) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. These provisions began to take effect progressively starting in fiscal year 2023, although the Medicare Drug Price Negotiation Program is currently subject to legal challenges. Under this program, HHS has already announced the agreed-upon prices of the first drugs that were subject to price negotiations and will announce the agreed-upon prices of additional drugs in the coming years. In response to an October 2022 executive order, on February 14, 2023, HHS released a report outlining three new models for testing by the CMS Innovation Center that will be evaluated on their ability to lower the cost of drugs, promote accessibility, and improve quality of care. It is unclear whether or how these selected models or similar policy initiatives will impact prescription drug pricing in the future.</span>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">Any reduction in reimbursement from Medicare and other government programs may result in a similar reduction in payments from private payers. Our future product sales may be subject to additional discounts from list price in the form of rebates and discounts provided to covered entities under the Public Health Service Act 340B drug pricing program. Changes to the 340B program or to Medicare or Medicaid programs at the federal or state level, including outcomes of ongoing litigation in our industry, may impact our product prices and rebate liability. </span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. For example, on January 5, 2024, the FDA approved Florida&#8217;s Section 804 Importation Program, or SIP, proposal to import certain drugs from Canada for specific state healthcare programs. It is unclear how this program will be implemented, including which drugs will be chosen, and whether it will be subject to legal challenges in the United States or Canada. Other states have also submitted SIP proposals that are pending review by the FDA. Any such approved importation plans, when implemented, may result in lower drug prices for products covered by those programs. Third-party coverage and reimbursement for medicines may not be available or adequate in either the U.S. or international markets, which would negatively affect the potential commercial success of our products, our revenue and our profits.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 10px; margin-top: 0px; margin-bottom: 0px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">36</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-align: justify;">
   <span style="color: #000000; font-weight: bold;">If we or our partners fail to compete effectively, our medicines, including our commercial medicines and our medicines in development, will not generate significant revenues.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">Our competitors engage in drug discovery throughout the world, are numerous, and include, among others, major pharmaceutical companies and specialized biopharmaceutical firms. In addition, other companies are engaged in developing RNA-targeted technology. Our competitors may succeed in developing medicines that are:</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div>
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;priced lower than our medicines;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div>
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;reimbursed more favorably by government and other third-party payers than our medicines; </span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div>
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;safer than our medicines;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div>
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;more effective than our medicines; or</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div>
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;more convenient to use than our medicines.</span>
    </div>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">These competitive developments could make our medicines, including our commercial medicines and our medicines in development, obsolete or non-competitive.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">Certain of our partners are pursuing other technologies or developing other medicines either on their own or in collaboration with others, including our competitors, to treat some of the same diseases that our own programs target. Competition may negatively impact a partner&#8217;s focus on and commitment to our medicines and, as a result, could delay or otherwise negatively affect the commercialization of our medicines, including our commercial medicines and our medicines in development.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">Many of our competitors have substantially greater financial, technical and human resources than we do. In addition, many of these competitors have significantly greater experience than we do in conducting preclinical testing and human clinical studies of new pharmaceutical products, in obtaining FDA and other regulatory authorizations of such products and in commercializing such products. Accordingly, our competitors may succeed in obtaining regulatory authorization for products earlier than we do or more successfully commercialize their products.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">There are several pharmaceutical and biotechnology companies engaged in the development or commercialization in certain geographic markets of products against targets that are also targets of products in our development pipeline or of medicines we are commercializing. For example: </span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; line-height: 1.35; text-align: justify; padding-left: 54pt;">

    <div style="text-align: left;">
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;Onasemnogene abeparvovec and risdiplam compete with SPINRAZA;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; line-height: 1.35; text-align: justify; padding-left: 54pt;">

    <div style="text-align: left;">
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;Acoramidis, patisiran, tafamidis, tafamidis meglumine and vutrisiran compete with WAINUA;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; line-height: 1.35; text-align: justify; padding-left: 54pt;">

    <div style="text-align: left;">
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;Nexiguran ziclumeran, ALXN2220 and NNC6019-0001 could compete with WAINUA;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; line-height: 1.35; text-align: justify; padding-left: 54pt;">

    <div style="text-align: left;">
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;Plozasiran, pegozafermin and NST-1024 could compete with TRYNGOLZA and WAYLIVRA;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; line-height: 1.35; text-align: justify; padding-left: 54pt;">

    <div style="text-align: left;">
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;Lanadelumab-flyo, C1 esterase inhibitor, berotralstat, C1 esterase inhibitor subcutaneous, garadacimab, </span>deucrictibant,<span style="color: #000000;"> NTLA-2002 and STAR-0215 could compete with DAWNZERA;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; line-height: 1.35; text-align: justify; padding-left: 54pt;">

    <div style="text-align: left;">
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;Olpasiran, </span>zerlasiran, lepodisiran and muvalaplin <span style="color: #000000;">could compete with pelacarsen;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div style="text-align: left;">
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;NI-005/AP-101 could compete with QALSODY;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div style="text-align: left;">
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;VIR-2218, VIR-3434, BRII-179, AB-729, selgantolimod,</span>&#160;<span style="color: #000000;">bersacapavir, REP 2139-Mg and VTP-300 could complete with bepirovirsen; </span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div style="text-align: left;">
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;Budesonide, sparsentan, atrasentan, iptacopan, zigakibart, sibeprenlimab, atacicept, ravulizumab, vemircopan, felzartamab, telitacicept and povetacicept could compete with sefaxersen; and</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div style="text-align: left;">
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;GTX-102, alogabat and NNZ-2591 could compete with ION582.</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">
   <span style="color: #000000;">&#160;</span>
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">SPINRAZA injection for intrathecal use is an antisense medicine indicated for the treatment of SMA patients of all ages approved in over 50 countries. Specifically, SPINRAZA faces competition from onasemnogene abeparvovec, a gene therapy product that was approved in the U.S. in May 2019 and in the EU in May 2020 for the treatment of SMA, as well as risdiplam, an oral product for the treatment of SMA that was approved in the U.S. in August 2020 and in the EU in March 2021. Biogen has in the past disclosed that SPINRAZA revenue decreased due to a reduction in demand as a result of increased competition and that future sales of SPINRAZA may be adversely affected by competing products.</span>
  </div><div>
  </div><div>&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 10px; margin-top: 0px; margin-bottom: 0px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">37</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">Additionally, companies that are developing medicines that target the same patient populations as our medicines in development may compete with us to enroll participants in the clinical trials for such medicines, which could make it more difficult for us to complete enrollment for these clinical trials</span><span>.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-align: justify;">
   <span style="color: #000000; font-weight: bold;">Our medicines could be subject to regulatory limitations following approval.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">Following approval of a medicine, we and our partners must comply with comprehensive government regulations regarding the manufacture, marketing and distribution of medicines. The FDA and foreign regulatory bodies have the authority to impose significant restrictions on an approved medicine through the product label.&#160;&#160;We or our partners may not obtain the labeling claims necessary or desirable to successfully commercialize our medicines, including our commercial medicines and our medicines in development.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">Promotional communications regarding prescription medicines must be consistent with the information in the product&#8217;s approved labeling. Additionally, prescription medicines may be promoted only for the approved indication(s) in accordance with the approved label. The FDA and other regulatory authorities actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">In addition, when approved, the FDA or a foreign regulatory authority may condition approval on the performance of post-approval clinical studies or patient monitoring, which could be time consuming and expensive. For example, in connection with the conditional marketing approval for WAYLIVRA in the EU, we are required to conduct a post-authorization safety study to evaluate the safety of WAYLIVRA on thrombocytopenia and bleeding in FCS patients taking WAYLIVRA. If the results of such post-marketing studies are not satisfactory, the FDA, EC or other foreign regulatory authorities may withdraw the marketing authorization or may condition continued marketing on commitments from us or our partners that may be expensive and time consuming to fulfill.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">If we or others identify side effects after any of our medicines are on the market, or if manufacturing problems occur subsequent to regulatory approval, or if we, our CMOs or our partners fail to comply with regulatory requirements, we or our partners may, among other things, lose regulatory approval and be forced to withdraw products from the market, need to conduct additional clinical studies, incur restrictions on the marketing, distribution or manufacturing of the product, and/or change the labeling of our medicines.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div>
   <span style="color: #000000; font-weight: bold;">We depend on our collaborations with Biogen for the development and commercialization of SPINRAZA and QALSODY.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">We have entered into separate collaborative arrangements with Biogen to develop and commercialize SPINRAZA and QALSODY. We entered into these collaborations primarily to:</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt; font-family: Calibri; font-size: 11pt; color: #000000;">

    <div>
     <span style="font-family: Times New Roman; font-size: 10.0pt;">&#9679;&#160;&#160;&#160;&#160;fund our development activities for SPINRAZA and QALSODY;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt; font-family: Calibri; font-size: 11pt; color: #000000; clear: both;">

    <div>
     <span style="font-family: Times New Roman; font-size: 10.0pt;">&#9679;&#160;&#160;&#160;&#160;seek and obtain regulatory approvals for SPINRAZA and QALSODY; and</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt; font-family: Calibri; font-size: 11pt; color: #000000; clear: both;">

    <div>
     <span style="font-family: Times New Roman; font-size: 10.0pt;">&#9679;&#160;&#160;&#160;&#160;successfully commercialize SPINRAZA and QALSODY.</span>
    </div>
  </div><div>
  </div><div style="clear: both;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">We are relying on Biogen to obtain additional regulatory approvals for SPINRAZA and QALSODY, generate additional clinical data for SPINRAZA and QALSODY, manufacture SPINRAZA and QALSODY, and successfully commercialize SPINRAZA and QALSODY. In general, we cannot control the amount and timing of resources that Biogen devotes to our collaborations. If Biogen fails to further develop SPINRAZA or QALSODY, obtain additional regulatory approvals for SPINRAZA or QALSODY, manufacture SPINRAZA or QALSODY, or successfully commercialize SPINRAZA or QALSODY, or if Biogen&#8217;s efforts in any of these respects are ineffective, revenues for SPINRAZA or QALSODY would be negatively affected.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">In addition, our collaborations with Biogen may not continue for various reasons. Biogen can terminate our collaborations at any time. If Biogen stops developing or commercializing SPINRAZA or QALSODY, we would have to seek or spend additional funding, and SPINRAZA&#8217;s or QALSODY&#8217;s commercialization may be harmed.</span>
  </div><div>
  </div><div>&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 10px; margin-top: 0px; margin-bottom: 0px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">38</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div>
   <span style="color: #000000; font-weight: bold;">We depend on our collaboration with AstraZeneca for the joint development and commercialization of WAINUA.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">We have entered into a collaborative arrangement with AstraZeneca to develop and commercialize WAINUA. Under the terms of the collaboration agreement, we and AstraZeneca are co-developing and co-commercializing WAINUA in the U.S. and AstraZeneca has the sole right to commercialize WAINUA in all other countries. As a company we do not have experience with co-commercialization arrangements. We also do not have control over (1) the amount and timing of resources that AstraZeneca devotes to our collaboration, particularly outside of the U.S; (2) the pricing and reimbursement strategies for WAINUA; and (3) whether AstraZeneca elects to terminate the collaborative arrangement. If the co-commercialization arrangement for WAINUA is not successful for any reason, WAINUA may not meet our commercial objectives and our revenues for WAINUA may be limited.</span>
  </div><div>
  </div><div style="font-size: 8pt;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">In addition, a Joint Steering Committee, or JSC, having equal membership from us and AstraZeneca, and various subcommittees oversee and coordinate the development, manufacturing, commercialization and other exploitation activities for WAINUA in the U.S. by mutual agreement. If any subcommittee cannot reach unanimous agreement on any matter within its respective scope of authority, such matter may be referred to the JSC for resolution. If the JSC cannot come to a mutual agreement on any particular matter, this could delay our ability to develop or commercialize WAINUA.</span>
  </div><div>
  </div><div style="font-size: 8pt;">&#160;
  </div><div>
  </div><div style="text-align: justify;">
   <span style="color: #000000; font-weight: bold;">If we are not successful in expanding our manufacturing capabilities or cannot manufacture our medicines or contract with a third party to manufacture our medicines at costs that allow us to charge competitive prices to buyers, we cannot market our products profitably.*</span>
  </div><div>
  </div><div style="font-size: 8pt;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">To successfully commercialize any of our medicines, we need to optimize and manage large-scale commercial manufacturing capabilities either on a standalone basis or through a third-party manufacturer. As our drug development and commercial pipeline increases and matures, we will have a greater need for clinical trial and commercial manufacturing capacity. We will also need to ensure that we have the manufacturing capabilities in place to support advances in our drug development activities, such as new chemistries. While</span><span>&#160;we believe </span><span style="color: #000000;">our current capabilities and those we obtain through third-party manufacturers support our manufacturing needs now, it will be important to expand our manufacturing infrastructure in the future, which will likely require substantial expenditures. If we are not successful in executing this expansion, it could limit our ability to meet our manufacturing requirements and commercial objectives in the future.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">In addition, we have limited experience manufacturing pharmaceutical products of the chemical class represented by our medicines, called oligonucleotides, on a commercial scale for the systemic administration of a medicine. There are a small number of suppliers for certain capital equipment and raw materials that we use to manufacture our medicines, and some of these suppliers will need to increase their scale of production to meet our projected needs for commercial manufacturing. If a supplier chooses to devote more resources to other products, especially products with higher manufacturing capacity needs, that could impact such supplier&#8217;s capability to deliver our requirements timely. Further, we must continue to improve our manufacturing processes to allow us to reduce our drug costs. We or our partners may not be able to manufacture our medicines at a cost or in quantities necessary to make commercially successful products.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">Manufacturers, including us, must adhere to the FDA&#8217;s cGMP regulations and similar regulations in foreign countries, which the applicable regulatory authorities enforce through facilities inspection programs. We, our partners and our contract manufacturers may not comply or maintain compliance with cGMP, or similar foreign regulations. Non-compliance could significantly delay or prevent receipt of marketing authorizations for our medicines, including authorizations for our commercial medicines and our medicines in development, or could result in enforcement action after authorization that might limit the commercial success of our medicines.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">We rely on third-party manufacturers to supply the drug substance and drug product for TRYNGOLZA and WAINUA and drug product for WAYLIVRA. The operations of our suppliers, many of which are located outside of the United States, are subject to additional risks that are beyond our control. For example, tariffs on the raw materials, components, or equipment we use to manufacture our products, or on our drug substance or finished products, will increase our manufacturing costs. There have also been Congressional legislative proposals to discourage contracting with Chinese companies for the development or manufacturing of pharmaceutical products. In addition, merger and acquisition activity within the commercial manufacturing space could reduce the availability of resources from our third-party manufacturers. Delays or disruption to our own or third-party commercial manufacturing capabilities for any reason could limit the commercial success of our medicines</span><span>.</span>
  </div><div>
  </div><div style="text-align: justify; color: #000000;">&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 10px; margin-top: 0px; margin-bottom: 0px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">39</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-align: center;">
   <span style="color: #000000; font-weight: bold;">Risks Related to the Development and Regulatory Approval of our Medicines</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-align: justify;">
   <span style="color: #000000; font-weight: bold;">If we or our partners fail to obtain regulatory approval for our medicines and additional approvals for our commercial medicines, we or our partners cannot sell them in the applicable markets.*</span></div><div>
  </div><div style="font-size: 8pt;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">We cannot guarantee that any of our medicines will be considered safe and effective or will be approved for commercialization. In addition, it is possible that our commercial medicines may not be approved in additional markets or for additional indications. We and our partners must conduct time-consuming, extensive and costly clinical studies to demonstrate the safety and efficacy of each of our medicines before they can be approved or receive additional approvals for sale. We and our partners must conduct these studies in compliance with FDA regulations and with comparable regulations in other countries.</span>
  </div><div>
  </div><div style="font-size: 8pt;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">We and our partners may not obtain necessary regulatory approvals on a timely basis, if at all, for our medicines. It is possible that regulatory authorities will not approve our medicines for marketing or our commercial medicines in additional markets or for additional indications. If the FDA or another regulatory authority believes that we or our partners have not sufficiently demonstrated the safety or efficacy of any of our medicines, including our commercial medicines or our medicines in development, the authority will not approve the specific medicine or will require additional studies, which could be time consuming and expensive and delay or harm commercialization of the medicine. For example, in August 2018 we received a complete response letter from the FDA regarding the new drug application for WAYLIVRA in which the FDA determined that the safety concerns identified with WAYLIVRA in our clinical development program outweighed the expected benefits of triglyceride lowering in patients with FCS. We also received a Notice of Non-Compliance Withdrawal Letter, or Non-W, from Health Canada for WAYLIVRA in November 2018. </span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">The FDA or other comparable foreign regulatory authorities can delay, limit or deny approval of a medicine for many reasons, including:</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div style="text-align: left;">
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;such authorities may disagree with the design or implementation of our clinical studies;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div style="text-align: left;">
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;we or our partners may be unable to demonstrate to the satisfaction of the FDA or other regulatory authorities that a medicine is safe and effective for any indication;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div style="text-align: left;">
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;such authorities may not accept clinical data from studies conducted at clinical facilities that have deficient clinical practices or that are in countries where the standard of care is potentially different from the U.S.;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div style="text-align: left;">
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;we or our partners may be unable to demonstrate that our medicine&#8217;s clinical and other benefits outweigh its safety risks to support approval;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div style="text-align: left;">
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;such authorities may disagree with the interpretation of data from preclinical or clinical studies;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div style="text-align: left;">
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;such authorities may find deficiencies in the manufacturing processes or facilities of third-party manufacturers who manufacture clinical and commercial supplies for our medicines; and</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div style="text-align: left;">
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;the approval policies or regulations of such authorities or their prior guidance to us or our partners during clinical development may significantly change in a manner rendering our clinical data insufficient for approval.</span>
    </div>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>

  </div><div style="text-indent: 36pt; text-align: justify;">For example, while we continue to activate sites in the U.S., Canada, U.K., Australia and Japan, we are revising the study protocol for the REVEAL study of ION582 to address changes requested by EU regulators and plan to resubmit the protocol and initiate EU sites for this study next year. Importantly, we believe we are on track to complete enrollment for this study in 2026.</div><div style="text-indent: 36pt; text-align: justify;">&#160;</div><div style="text-indent: 36pt; text-align: justify;"><span style="color: #000000;">Failure to receive marketing authorization for our medicines in development, or failure to receive additional marketing authorizations for our commercial medicines, or delays in these authorizations, could prevent or delay commercial introduction of the medicine, and, as a result, could negatively impact our ability to generate revenue from product sales.</span>
  </div><div>&#160;
  </div><div>
  </div><div style="text-align: justify;">
   <span style="color: #000000; font-weight: bold;">If the results of clinical testing indicate that any of our medicines are not suitable for commercial use, we may need to abandon one or more of our drug development programs.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">Drug discovery and drug development have inherent risks and the historical failure rate for drugs is high. Antisense medicines are a relatively new approach to therapeutics. If we cannot demonstrate that our medicines are safe and effective for human use in the intended indication(s), we may need to abandon one or more of our drug development programs.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-align: justify;">
   <span style="color: #000000; font-weight: bold;">Even if our medicines are successful in preclinical and human clinical studies, the medicines may not be successful in late-stage clinical studies. Similarly, topline, preliminary or interim data we release for any of our clinical studies may not be indicative of full or final results from such study.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">Successful results in preclinical or initial human clinical studies, including the Phase 2 results for some of our medicines in development, may not predict the results of subsequent clinical studies. If any of our medicines in Phase 3 clinical studies do not show sufficient safety and efficacy in patients with the targeted indication, or if such studies are discontinued for any other reason, it could negatively impact our development and commercialization goals for these medicines and our stock price could decline. In addition, we may release topline, preliminary or interim data for any of our clinical studies. The interim, topline or preliminary results we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. As a result, such data should be viewed with caution until the final data are available.</span>
  </div><div>
  </div><div style="font-size: 8pt;">&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 10px; margin-top: 0px; margin-bottom: 0px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">40</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">In the past, we have invested in clinical studies of medicines that have not met the primary clinical endpoints in their Phase 3 studies or have been discontinued for other reasons. For example, in October 2021, Biogen reported that QALSODY did not meet the primary clinical endpoint in the Phase 3 VALOR study; however, trends favoring QALSODY were seen across multiple secondary and exploratory measures of disease activity and clinical function. In addition, in March 2021, Roche decided to discontinue dosing in the Phase 3 GENERATION HD1 study of tominersen in patients with manifest Huntington&#8217;s disease based on the results of a pre-planned review of data from the Phase 3 study conducted by an unblinded Independent Data Monitoring Committee. Similar results could occur in clinical studies for our other medicines.</span>
  </div><div>
  </div><div style="text-align: justify; font-size: 8pt;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">There are a number of factors that could cause a clinical study to fail or be delayed, including:</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div style="text-align: left;">
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;the clinical study may produce negative or inconclusive results;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div style="text-align: left;">
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;regulators may require that we hold, suspend or terminate clinical research for noncompliance with regulatory requirements;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div style="text-align: left;">
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;we, our partners, the FDA or foreign regulatory authorities could suspend or terminate a clinical study due to adverse side effects of a medicine on subjects or lack of efficacy in the trial;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div style="text-align: left;">
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;we or our partners may decide, or regulators may require us, to conduct additional preclinical testing or clinical studies;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div style="text-align: left;">
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;enrollment in our clinical studies may be slower than we anticipate;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div style="text-align: left;">
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;we or our partners, including our independent clinical investigators, contract research organizations and other third-party service providers on which we rely, may not identify, recruit or train suitable clinical investigators at a sufficient number of study sites or timely enroll a sufficient number of study subjects in the clinical study;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div style="text-align: left;">
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;the institutional review board for a prospective site might withhold or delay its approval for the study;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt; font-family: Calibri; font-size: 11pt; color: #000000;">

    <div style="text-align: left;">
     <span style="font-family: Times New Roman; font-size: 10.0pt;">&#9679;&#160;&#160;&#160;&#160;people who enroll in the clinical study may later drop out due to adverse events, a perception they are not benefiting from participating in the study, fatigue with the clinical study process or personal issues;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt; font-family: Calibri; font-size: 11pt; color: #000000; clear: both;">

    <div style="text-align: left;">
     <span style="font-family: Times New Roman; font-size: 10.0pt;">&#9679;&#160;&#160;&#160;&#160;a clinical study site may deviate from the protocol for the study;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt; clear: both;">

    <div style="text-align: left;">
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;the cost of our clinical studies may be greater than we anticipate;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div style="text-align: left;">
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;our partners may decide not to exercise any existing options to license and conduct additional clinical studies for our medicines; and</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div style="text-align: left;">
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;the supply or quality of our medicines or other materials necessary to conduct our clinical studies may be insufficient, inadequate or delayed.</span>
    </div>
  </div><div>
  </div><div style="font-size: 8pt;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">Further, the FDA or other regulatory authorities could request, among other things, additional information or commitments before we can start or continue a clinical study, protocol amendments, increased safety monitoring, additional product labeling information, and post-approval commitments. This happened in connection with the conditional marketing approval for WAYLIVRA in the EU, as the European Commission is requiring us to conduct a post-authorization safety study to evaluate the safety of WAYLIVRA on thrombocytopenia and bleeding in FCS patients taking WAYLIVRA. In addition, under accelerated approval the FDA is requiring completion of the ongoing Phase 3 trial for QALSODY to confirm the clinical benefit of QALSODY. </span>
  </div><div>
  </div><div style="text-align: justify; font-size: 8pt;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">Moreover, our commercial medicines are chemically similar to each other. As a result, a safety observation we encounter with one of our medicines could have, or be perceived by a regulatory authority to have, an impact on a different medicine we are developing. This could cause the FDA or other regulators to ask questions or take actions that could harm or delay our ability to develop and commercialize our medicines or increase our costs. Any failure or delay in our clinical studies could reduce the commercial potential or viability of our medicines.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-align: justify;">
   <span style="color: #000000; font-weight: bold;">We depend on third parties to conduct clinical studies for our medicines and any failure of those parties to fulfill their obligations could adversely affect our development and commercialization plans.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">We depend on independent clinical investigators, contract research organizations and other third-party service providers to conduct our clinical studies for our medicines and expect to continue to do so in the future. For example, we use clinical research organizations, such as Icon Clinical Research Limited, Medpace, Inc., Parexel International Corporation, Syneos Health, Inc. and Thermo Fisher Scientific Inc. for the clinical studies for our medicines, including WAINUA for the treatment of ATTR-CM, DAWNZERA, olezarsen, ulefnersen, zilganersen and ION582. We rely heavily on these parties for successful execution of our clinical studies, but do not control many aspects of their activities. For example, the investigators are not our employees, but we are responsible for ensuring that such investigators conduct each of our clinical studies in accordance with the general investigational plan and approved protocols for the study. Third parties may not complete activities on schedule or may not conduct our clinical studies in accordance with regulatory requirements or our stated protocols. For example, some of our key vendors have in the past experienced labor shortages, which impacted their ability to perform services for us for certain of our clinical trials. Subsequent failures of these third parties to carry out their obligations, or a termination of our relationship with such third parties, could delay or prevent the development, marketing authorization and commercialization of our medicines.</span>
  </div><div>
  </div><div style="font-size: 8pt;">&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 10px; margin-top: 0px; margin-bottom: 0px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">41</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">In addition, while we do not have any clinical trial sites in Russia, Ukraine or Gaza, we do have a limited number of clinical trial sites in Israel that may be materially impacted by the ongoing military conflicts in Israel and elsewhere in the Middle East and could result in difficulties enrolling or completing our clinical trials in such areas on schedule. </span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-align: justify;">
   <span style="color: #000000; font-weight: bold;">Since corporate partnering is part of our strategy to fund the advancement and commercialization of some of our development programs, if any of our collaborative partners fail to fund our collaborative programs, or if we cannot obtain additional partners, we may have to delay or stop progress on those drug development programs.*</span></div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">To date, corporate partnering has played a significant role in our strategy to fund our development programs and to add key development resources. While we are now commercializing some of our medicines independently, we still plan to continue to rely on additional collaborative arrangements to develop and commercialize some of our unpartnered medicines. However, we may not be able to negotiate favorable collaborative arrangements for these drug programs. If we cannot continue to secure additional collaborative partners, our revenues could decrease and the development of our medicines could suffer.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">Our corporate partners are developing and funding many of the medicines in our development pipeline. For example, we are relying on:</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div>
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;AstraZeneca for the joint development and funding of WAINUA; </span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div>
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;Novartis for development and funding of pelacarsen;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div>
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;GSK for development and funding of bepirovirsen; and</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div>
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;Roche for development and funding of sefaxersen.</span>
    </div>
  </div><div>
  </div><div>&#160;
  </div><div>

  </div><div style="text-indent: 36pt; text-align: justify;">
   If any of these pharmaceutical companies stops developing and funding these medicines, our business could suffer and we may not have, or be willing to dedicate, the resources available to develop these medicines on our own. Our collaborators can terminate their relationships with us under certain circumstances, many of which are outside of our control. For example, in 2022, Pfizer and Bayer decided to discontinue the clinical development programs for vupanorsen and fesomersen, respectively.&#160;Similarly, Novartis decided to return the clinical development program we licensed to Novartis in August 2023 as a follow-on to pelacarsen to pursue a different molecule that is further along in development. Novartis remains fully committed to pelacarsen with Phase 3 data on track for the first half of 2026.</div><div>&#160;
  </div><div>
  </div><div style="text-align: justify;">
   <span style="color: #000000; font-weight: bold;">Even with funding from corporate partners, if our partners do not effectively perform their obligations under our agreements with them, it would delay or stop the progress of our drug development and commercial programs.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">In addition to receiving funding, we enter into collaborative arrangements with third parties to:</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div>
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;conduct clinical studies;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div>
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;seek and obtain marketing authorizations; and</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div>
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;manufacture and commercialize our medicines.</span>
    </div>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">Once we have secured a collaborative arrangement to further develop and commercialize one of our drug development programs, such as our collaborations with AstraZeneca, Biogen, GSK, Novartis, Otsuka and Roche, these collaborations may not continue or result in commercialized medicines, or may not progress as quickly as we anticipated.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">For example, a collaborator such as AstraZeneca, Biogen, GSK, Novartis, Otsuka or Roche, could determine that it is in its financial interest to:</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div style="text-align: left;">
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;pursue alternative technologies or develop alternative products that may be competitive with the medicine that is part of the collaboration with us;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div style="text-align: left;">
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;pursue higher-priority programs or change the focus of its own development programs; or</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div style="text-align: left;">
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;choose to devote fewer resources to our medicines than it does to its own medicines.</span>
    </div>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">If any of these occur, it could affect our partner&#8217;s commitment to the collaboration with us and could delay or otherwise negatively affect the commercialization of our medicines, including QALSODY, SPINRAZA, WAINUA, bepirovirsen, sefaxersen and pelacarsen.</span>
  </div><div>
  </div><div>&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 10px; margin-top: 0px; margin-bottom: 0px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">42</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-align: justify;">
   <span style="color: #000000; font-weight: bold;">We may not be able to benefit from designations for our medicines from regulatory authorities that are intended to confer benefits such as financial incentives or an accelerated regulatory pathway.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 40.8pt; text-align: justify;">
   <span style="color: #000000;">In the U.S., under the Orphan Drug Act, the FDA may designate a medicine as an Orphan Drug if it is intended to treat a rare disease or condition affecting fewer than 200,000 individuals in the U.S. Orphan Drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process, but it can provide financial incentives, such as tax advantages and user-fee waivers, as well as longer regulatory exclusivity periods. The FDA has granted Orphan Drug designation to TRYNGOLZA for the treatment of patients with FCS, to WAINUA for the treatment of patients with ATTR, to ulefnersen for the treatment of patients with FUS-ALS, to ION582 for the treatment of patients with Angelman syndrome, and to some of our earlier stage medicines. The FDA and EMA have granted Orphan Drug designation to DAWNZERA for the treatment of patients with HAE, to WAYLIVRA for the treatment of patients with FCS, to tominersen for the treatment of patients with HD, and to some of our earlier stage medicines. In addition, the EMA has granted Orphan Drug designation to WAYLIVRA for the treatment of patients with FPL. Even if approval is obtained on a medicine that has been designated as an Orphan Drug, we may lose Orphan Drug exclusivity if the FDA or EMA determines that the request for designation was materially defective or if we cannot assure sufficient quantity of the applicable medicine to meet the needs of patients with the rare disease or condition, or if a competitor is able to gain approval for the same or a substantially similar medicine in a safer or more effective form or that makes a major contribution to patient care. If we lose Orphan Drug exclusivity on any of our medicines, we may face increased competition and lose market share for such medicine.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 40.8pt; text-align: justify;">
   <span style="color: #000000;">We may also seek rare pediatric disease designation for some of our medicines. The FDA defines &#8220;rare pediatric disease&#8221; as a serious or life-threatening disease in which the serious or life-threatening manifestations primarily affect individuals aged from birth to 18 years or is a rare disease or condition within the meaning of the Orphan Drug Act. Designation of a medicine as a medicine for a rare pediatric disease does not guarantee that a marketing application for such medicine will meet the eligibility criteria for a rare pediatric disease priority review voucher, or PRV, at the time the application is approved. Under the FDCA, we will need to request a rare pediatric disease PRV in our original marketing application for any potential medicine for which we have received rare pediatric disease designation. The FDA may determine that a marketing application for any such medicine, if approved, does not meet the eligibility criteria for a PRV. Under the current statutory sunset provisions, after December 20, 2024, the FDA may only award a PRV for an approved rare pediatric disease application if the sponsor has rare pediatric disease designation for the drug or biologic that is the subject of such application, and that designation was granted by December 20, 2024. After September 30, 2026, the FDA may not award any rare pediatric disease PRVs. However, it is possible the authority for FDA to award rare pediatric disease PRV will be further extended by Congress.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-align: center;">
   <span style="color: #000000; font-weight: bold;">Risks Associated with our Businesses as a Whole</span>
  </div><div>
  </div><div style="text-align: center;">&#160;
  </div><div>
  </div><div style="text-align: justify;">
   <span style="color: #000000; font-weight: bold; font-style: italic;">Risks related to our financial condition</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div>
   <span style="color: #000000; font-weight: bold;">If we fail to obtain timely funding, we may need to curtail or abandon some of our programs.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">Many of our medicines are undergoing clinical studies or are in the early stages of research and development. Most of our programs will require significant additional research, development, manufacturing, preclinical and clinical testing, marketing authorizations, preclinical activities and commitment of significant additional resources prior to their successful commercialization. In addition, as we commercialize more medicines on our own, we will need to invest significant financial resources to continue developing the infrastructure required to successfully commercialize our medicines, including building and maintaining new support functions and scaling up existing internal support functions and expanding our manufacturing capabilities. All of these activities will require significant cash. As of September 30, 2025, we had cash, cash equivalents and short-term investments equal to $2.2 billion. If we or our partners do not meet our goals to successfully commercialize our medicines, including our commercial medicines, or to license certain medicines and proprietary technologies, we will need additional funding in the future. Our future capital requirements will depend on many factors such as:</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div style="text-align: left;">
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;successful commercialization of our commercial medicines;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div style="text-align: left;">
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;the profile and launch timing of our medicines in development;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div style="text-align: left;">
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;changes in existing collaborative relationships and our ability to establish and maintain additional collaborative arrangements;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div style="text-align: left;">
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;continued scientific progress in our research, drug discovery and development programs;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div style="text-align: left;">
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;the size of our programs and progress with preclinical and clinical studies;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div style="text-align: left;">
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;the time and costs involved in obtaining marketing authorizations;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div style="text-align: left;">
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;competing technological and market developments, including the introduction by others of new therapies that address our markets; and</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div style="text-align: left;">
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;our manufacturing requirements and capacity to fulfill such requirements.</span>
    </div>
  </div><div>
  </div><div>&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 10px; margin-top: 0px; margin-bottom: 0px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">43</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">If we need additional funds, we may need to raise them through public or private financing. Additional financing may not be available on acceptable terms or at all. If we raise additional funds by issuing equity securities, the shares of existing stockholders will be diluted and the price, as well as the price of our other securities, may decline. For example, in September 2024, we completed an underwritten public offering of 11,500,000 shares of our common stock for total net proceeds, after deducting underwriting discounts and commissions and other offering expenses payable by us, of approximately $489.1 million. If adequate funds are not available or not available on acceptable terms, we may have to cut back on one or more of our research, drug discovery or development programs, or commercial operations. Alternatively, we may obtain funds through arrangements with collaborative partners or others, which could require us to give up rights to certain of our technologies or medicines.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-align: justify;">
   <span style="color: #000000; font-weight: bold;">We have incurred losses, and our business will suffer if we fail to consistently achieve profitability in the future.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">Because drug discovery and development require substantial lead-time and money prior to commercialization, our expenses have generally exceeded our revenue since we were founded in January 1989. As of September 30, 2025, we had an accumulated deficit of approximately $2.4 billion and stockholders&#8217; equity of approximately $0.6 billion. Most of our income has historically come from collaborative arrangements, including commercial revenue from royalties and R&amp;D revenue, with additional income from research grants and the sale or licensing of our patents, as well as interest income. We will now and continuing into the foreseeable future need to invest significant financial resources to commercialize medicines on our own and expect that our income in the future will be driven primarily by commercial sales. If we do not earn substantial revenue from commercial sales, we may incur additional operating losses in the future, which could restrict our ability to successfully develop additional medicines or sustain future profitability.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-align: justify;">
   <span style="color: #000000; font-weight: bold;">We may not be entitled to obtain additional milestone payments under our royalty monetization agreement with Royalty Pharma.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">In January 2023, we entered into a Royalty Purchase Agreement with Royalty Pharma Investments. In addition to the $500 million we received at closing, this agreement makes available to us up to an additional $625 million in milestone payments. However, these additional milestone payments are subject to satisfaction of certain conditions related to the regulatory approval or commercial sales of pelacarsen, in certain cases by specific deadlines. Should we not satisfy such conditions by the applicable deadlines, or if we fail to meet our obligations or default under this agreement, the actual amount of additional payments to us could be substantially less than the maximum amounts available thereunder.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div>
   <span style="color: #000000; font-weight: bold; font-style: italic;">Risks related to our intellectual property</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div>
   <span style="color: #000000; font-weight: bold;">If we cannot protect our patent rights or our other proprietary rights, others may compete more effectively against us.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">Our success depends to a significant degree upon whether we can continue to develop, secure and maintain intellectual property rights to proprietary products and services. However, we may not receive issued patents on any of our pending patent applications in the U.S. or in other countries and we may not be able to obtain, maintain or enforce our patents and other intellectual property rights, any of which could impact our ability to compete effectively. In addition, the scope of any of our issued patents may not be sufficiently broad to provide us with a competitive advantage. Furthermore, other parties may successfully challenge, invalidate or circumvent our issued patents or patents licensed to us so that our patent rights do not create an effective competitive barrier or revenue source.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">We cannot be certain that the U.S. Patent and Trademark Office, or U.S. PTO, and courts in the U.S. or the patent offices and courts in foreign countries will consider the claims in our patents and applications covering our commercial medicines, or any of our medicines in development, as patentable. Method-of-use patents protect the use of a product for the specified method. This type of patent does not prevent a competitor from making and marketing a product that is identical to our product for an indication that is outside the scope of the patented method. Moreover, even if competitors do not actively promote their product for our targeted indications, physicians may prescribe these products off-label. Although off-label prescriptions may infringe or contribute to the infringement of method-of-use patents, the practice is common and such infringement is difficult to prevent, even through legal action.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">If we or any licensor partner loses or cannot obtain patent protection for our commercial medicines or any of our medicines in development, it could have a material adverse impact on our business.</span>
  </div><div>
  </div><div>&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 10px; margin-top: 0px; margin-bottom: 0px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">44</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div>
   <span style="color: #000000; font-weight: bold;">Intellectual property litigation could be expensive and prevent us from pursuing our programs.*</span></div><div>
  </div><div>&#160;
  </div><div>

  </div><div style="text-indent: 36pt; text-align: justify;">From time to time, we have to defend our intellectual property rights. If we are involved in an intellectual property dispute, we may need to litigate to defend our rights or assert them against others. Disputes can involve arbitration, litigation or proceedings declared by the U.S. PTO or the International Trade Commission or foreign patent authorities. Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.&#160;For example, in September 2025, we filed a claim against Arrowhead Pharmaceuticals, Inc., or Arrowhead, for patent infringement over Arrowhead's planned commercialization of plozasiran, and Arrowhead filed a separate lawsuit against us seeking to invalidate that same patent.</div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">If a third party claims that our medicines or technology infringe its patents or other intellectual property rights, we may have to discontinue an important product or product line, alter our products and processes, pay license fees or cease certain activities. We may not be able to obtain a license to needed intellectual property on favorable terms, if at all. There are many patents issued or applied for in the biotechnology industry, and we may not be aware of patents or patent applications held by others that relate to our business. This is especially true since patent applications in the U.S. are filed confidentially for the first 18 months. Moreover, the validity and breadth of biotechnology patents involve complex legal and factual questions for which important legal issues remain.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div>
   <span style="color: #000000; font-weight: bold; font-style: italic;">Risks related to product liability</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-align: justify;">
   <span style="color: #000000; font-weight: bold;">We are exposed to potential product liability claims, and insurance against these claims may not be available to us at a reasonable rate in the future or at all.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">Our business exposes us to potential product liability risks that are inherent in the testing, manufacturing, marketing and sale of therapeutic products, including potential product liability claims related to our commercial medicines and our medicines in development. We have clinical study insurance coverage and commercial product liability insurance coverage. However, this insurance coverage may not be adequate to cover claims against us, or be available to us at an acceptable cost, if at all. Regardless of their merit or eventual outcome, product liability claims may result in decreased demand for our medicines, injury to our reputation, withdrawal of clinical study volunteers and loss of revenues. Thus, whether or not we are insured, a product liability claim or product recall may result in losses that could be material.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div>
   <span style="color: #000000; font-weight: bold; font-style: italic;">Risks related to our personnel</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-align: justify;">
   <span style="color: #000000; font-weight: bold;">The loss of key personnel, or the inability to attract and retain highly skilled personnel, could make it more difficult to run our business and reduce our likelihood of success.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">We are dependent on the principal members of our management, scientific and commercial staff. We do not have employment agreements with any of our employees that would prevent them from leaving us. The loss of our key management, scientific or commercial employees might slow the achievement of important research and development or commercial goals. It is also critical to our success that we recruit and retain qualified scientific personnel to perform research and development work and that we recruit and retain qualified marketing, sales, market access, distribution, and related personnel to commercialize our medicines. We may not be able to attract and retain skilled and experienced personnel on acceptable terms because of intense competition for experienced personnel among many pharmaceutical and health care companies, universities and non-profit research institutions. In addition, failure to succeed in clinical studies or in commercializing our medicines may make it more challenging to recruit and retain qualified personnel</span><span>.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-align: justify;">
   <span style="color: #000000; font-weight: bold; font-style: italic;">Risks related to health epidemics, climate change and other events</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-align: justify;">
   <span style="color: #000000; font-weight: bold;">Our business may be adversely affected by health epidemics, climate change, extreme weather events, fires, earthquakes, war, civil or political unrest, terrorism or disruptions of the U.S. government.*</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 40.5pt; text-align: justify;">
   <span style="color: #000000;">Our business could be adversely affected by health epidemics in regions where we or our partners are commercializing our medicines, have concentrations of clinical trial sites or other business operations, and could cause disruption in the operations of third-party manufacturers and contract research organizations upon whom we rely. For example, enrollment in some of our clinical trials was delayed due to the COVID-19 pandemic.</span>
  </div><div>
  </div><div>&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 10px; margin-top: 0px; margin-bottom: 0px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">45</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">In recent years, extreme weather events and changing weather patterns have become more common. As a result, we are potentially exposed to varying natural disaster or extreme weather risks such as fires, hurricanes, tornadoes, droughts, floods, or other events that may result from the impact of climate change on the environment, any of which could impact our business and manufacturing operations. The potential impacts of climate change may also include increased operating costs associated with additional regulatory requirements and investments in reducing energy, water use and greenhouse gas emissions. In addition, we currently manufacture most of our research and clinical supplies in a manufacturing facility located in Carlsbad, California, and various regions within California have recently experienced numerous catastrophic wildfires. We manufacture the finished drug product for TRYNGOLZA, WAYLIVRA and eplontersen for ongoing clinical trials at third-party contract manufacturers. Biogen manufactures the finished drug product for SPINRAZA and QALSODY and AstraZeneca is responsible for WAINUA&#8217;s commercial drug supply. The facilities and the equipment we, our partners and our contract manufacturers use to research, develop and manufacture our medicines would be costly to replace and could require substantial lead time to repair or replace. </span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">Our facilities or those of our partners or contract manufacturers may be harmed by natural disasters or other events outside our control, such as earthquakes, war, civil or political unrest, deliberate acts of sabotage, terrorism or industrial accidents such as fire and explosion, whether due to human or equipment error, and if such facilities are affected by a disaster or other event, our development and commercialization efforts would be delayed. Although we possess property damage and business interruption insurance coverage, this insurance may not be sufficient to cover all of our potential losses and may not continue to be available to us on acceptable terms, or at all. </span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">In addition, our development and commercialization activities could be harmed or delayed by staffing shortages or a shutdown or other significant disruption of the U.S. government, including the FDA or the U.S. PTO. </span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div>
   <span style="color: #000000; font-weight: bold; font-style: italic;">Risks related to personal information, cybersecurity, social media and artificial intelligence</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-align: justify;">
   <span style="color: #000000; font-weight: bold;">We are dependent on data as well as information technology systems and infrastructure, which exposes us to data protection risks.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">We are dependent upon our own and third-party data as well as information technology systems and infrastructure, including mobile technologies, to operate our business. The personal information we process subjects us to stringent and evolving U.S. and foreign laws, rules and regulations, contractual obligations, industry standards and other obligations related to data privacy and security. Our personal information obligations require us to implement and maintain certain practices, including those in relation to cross-border transfers of personal information. The multitude and complexity of our information technology systems and infrastructure make them vulnerable to a variety of evolving threats that may result in systems or data interruption, corruption, destruction, disruption of data integrity, malicious intrusion, or random attacks or other compromise (such as due to malfunctions, software vulnerabilities, natural disasters, telecommunications failures, malicious actors and personnel error). Data privacy or security incidents or breaches pose a risk that sensitive data, including our intellectual property, trade secrets or personal information of our employees, patients, customers or other business partners may be exposed to unauthorized persons. Cyber-attacks are increasing in their frequency, sophistication and intensity, particularly as companies (including us) continue to move to more remote work structures. In addition, the number and frequency of cybersecurity events globally may be heightened during times of geopolitical tension or instability between countries, including, for example, the ongoing war between Russia and Ukraine and military conflicts in the Middle East and the surrounding areas, or collectively, conflicts in Eastern Europe and the Middle East, as well as related political or economic responses and counter-responses by various global actors.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">Cybersecurity related events could include the deployment or use of harmful malware or malicious code, denial-of-service attacks, credential stuffing attacks, credential harvesting attacks, social engineering attacks (including deep fakes), ransomware and other means to affect the confidentiality, integrity or availability of our data as well as information systems and infrastructure. Our current, past and prospective business partners face similar risks and any security breaches of their systems could adversely affect our security posture. A security breach or privacy violation (including perceived breaches or violations) could result in any of the following, any of which could disrupt our business and result in increased costs or loss of revenue:</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div style="text-align: left;">
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;harm our reputation;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div style="text-align: left;">
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;delay progress on the development of our medicines;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div style="text-align: left;">
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;compel us to comply with applicable security or data breach notification obligations (including laws); </span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div style="text-align: left;">
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;result in the diversion of monetary funds and other company resources;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div style="text-align: left;">
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;subject us to financial or other penalties, regulatory investigations or actions, including mandatory and costly corrective actions; and</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div style="text-align: left;">
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;require us to verify the correctness of database contents and otherwise subject us to litigation or other liabilities. </span>
    </div>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 10px; margin-top: 0px; margin-bottom: 0px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">46</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">Risk mitigation strategies such as liability limitations in our contracts and insurance coverage may prove inadequate if there is a security breach or privacy violation. While we have invested, and continue to invest, in the protection of our data and information technology systems and infrastructure, our efforts may not be successful. Non-compliance with relevant data protection obligations or a failure to secure our data, information technology systems or infrastructure could adversely affect our business and operations and result in the loss of critical or sensitive information, which could result in financial, legal, business or reputational harm to us. </span>
  </div><div>
  </div><div style="text-align: justify; font-size: 8pt;">&#160;
  </div><div>
  </div><div style="text-align: justify;">
   <span style="color: #000000; font-weight: bold;">The increasing use of social media platforms and artificial intelligence based software presents new risks and challenges.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">Social media is increasingly being used to communicate about our medicines and the diseases our therapies are designed to treat. Social media practices in the biopharmaceutical industry continue to evolve and regulations relating to such use are not always clear and create uncertainty and risk of noncompliance with regulations applicable to our business. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on social media. We may also encounter criticism on social media regarding our company, management, or medicines. Our reputation could be damaged by negative publicity or if adverse information concerning us is posted on social media platforms or similar mediums, which we may not be able to reverse. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face restrictive regulatory actions or incur other harm to our business. </span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">Additionally, artificial intelligence, or AI, based software is increasingly being used in the biopharmaceutical industry. Use of AI based software may lead to the release of confidential proprietary information, which may impact our ability to realize the benefit of our intellectual property.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-align: justify;">
   <span style="color: #000000; font-weight: bold; font-style: italic;">Risks related to our securities and the global credit markets</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-align: justify;">
   <span style="color: #000000; font-weight: bold;">If we do not progress in our programs as anticipated, the price of our securities could decrease.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">For planning purposes, we estimate and may disclose the timing of a variety of clinical, regulatory and other milestones, such as when we anticipate a certain medicine will enter clinical trials, when we anticipate disclosing clinical data, when we anticipate completing a clinical study, when we anticipate filing an application for, or obtaining, marketing authorization, or when we or our partners plan to commercially launch a medicine. We base our estimates on present facts and a variety of assumptions, many of which are outside of our control. If we do not achieve milestones in accordance with our or our investors&#8217; or securities analysts&#8217; expectations, including milestones related to our commercial medicines and medicines in development, the price of our securities could decrease. In addition, our share price may be dependent upon the valuations and recommendations of the analysts who cover our business. If our results do not meet these analysts&#8217; forecasts, the expectations of our investors or the financial guidance we provide to investors in any period, the market price of our common stock could decline. Our ability to meet analysts&#8217; forecasts, investors&#8217; expectations and our financial guidance is substantially dependent on our ability to maintain or increase sales of our commercial medicines, both partnered and unpartnered. </span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-align: justify;">
   <span style="color: #000000; font-weight: bold;">If the price of our securities continues to be highly volatile, this could make it harder to liquidate your investment and could increase your risk of suffering a loss.*</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">The market price of our common stock, like that of the securities of many other biopharmaceutical companies, has been and is likely to continue to be highly volatile. These fluctuations in our common stock price may significantly affect the trading price of our securities. During the 12 months preceding September 30, 2025, the closing market price of our common stock ranged from $65.42 to $25.51 per share. Many factors can affect the market price of our securities, including, for example, fluctuations in our operating results, financing transactions, announcements of collaborations, clinical study results, technological innovations or new products being developed by us or our competitors, the commercial success of our approved medicines, governmental regulation, marketing authorizations, changes in payers&#8217; reimbursement policies, developments in patent or other proprietary rights and public concern regarding the safety of our medicines.</span>
  </div><div>
  </div><div style="font-size: 8pt;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">Broad market factors may materially harm the market price of our common stock irrespective of our operating performance. For example, events such as recent tariffs announcements and the ongoing conflicts in Eastern Europe and the Middle East have caused disruptions of global financial markets and resulted in increased volatility in the trading price of our common stock. In addition, industry factors may materially harm the market price of our common stock. Nasdaq, and the market for biotechnology companies in particular, have historically experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of the particular companies affected. The trading prices and valuations of these stocks, and of ours, may not be predictable. A loss of investor confidence in the market for biotechnology or pharmaceutical stocks or the stocks of other companies that investors perceive to be similar to us, the opportunities in the biotechnology and pharmaceutical market or the stock market in general, could depress our stock price regardless of our business, prospects, financial conditions or results of operations.</span>
  </div><div>
  </div><div>&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 10px; margin-top: 0px; margin-bottom: 0px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">47</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-align: justify;">
   <span style="color: #000000; font-weight: bold;">Negative conditions in the global credit markets and financial services and other industries may adversely affect our business, financial condition or stock price.*</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">The global credit and financial markets have experienced extreme volatility and disruptions recently, including as a result of tariffs announcements and the ongoing conflicts in Eastern Europe and the Middle East. These disruptions can result in severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. If the current equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our operations, growth plans, financial performance or stock price. In addition, our insurance carriers and insurance policies covering all aspects of our business may become financially unstable or may not be sufficient to cover any or all of our losses and may not continue to be available to us on acceptable terms, or at all.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">A variety of risks associated with operating our business and marketing our medicines internationally could adversely affect our business. In addition to our U.S. operations, we are commercializing WAYLIVRA in the EU, Latin America and certain Caribbean countries. We face risks associated with our international operations, including possible unfavorable regulatory, pricing and reimbursement, political, tax and labor conditions, which could harm our business. Because we have international operations, we are subject to numerous risks associated with international business activities, including</span><span>:</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div style="text-align: left;">
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;compliance with differing or unexpected regulatory requirements for our medicines and foreign employees;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div style="text-align: left;">
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;complexities associated with managing multiple payer reimbursement regimes, government payers or patient self-pay systems;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div style="text-align: left;">
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;difficulties in staffing and managing foreign operations;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div style="text-align: left;">
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;in certain circumstances, increased dependence on the commercialization efforts and regulatory compliance of third-party distributors or strategic partners;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div style="text-align: left;">
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;foreign government taxes, regulations and permit requirements;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div style="text-align: left;">
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;U.S. and foreign government tariffs, trade and export restrictions, price and exchange controls and other regulatory requirements;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div style="text-align: left;">
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;anti-corruption laws, including the Foreign Corrupt Practices Act, or the FCPA, and its equivalent in foreign jurisdictions;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div style="text-align: left;">
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;economic weakness, including inflation, natural disasters, war, acts of terrorism, political instability or public health issues or health epidemics, in particular foreign countries or globally;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div style="text-align: left;">
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;fluctuations in currency exchange rates, which could result in increased operating expenses and reduced revenue, and other obligations related to doing business in another country;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div style="text-align: left;">
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;the potential for a local seller, faced with higher local prices, importing medicines from an international market with lower prices rather than buying such medicines locally, which is referred to as parallel importation;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div style="text-align: left;">
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;compliance with tax, employment, privacy, immigration and labor laws, regulations and restrictions for employees living or traveling abroad;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div style="text-align: left;">
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;workforce uncertainty in countries where labor unrest is more common than in the U.S.; and</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div style="text-align: left;">
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;changes in diplomatic and trade relationships.</span>
    </div>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">Our business activities outside of the U.S. are subject to the FCPA and similar anti-bribery or anti-corruption laws, regulations or rules of other countries in which we operate, including the United Kingdom&#8217;s Bribery Act 2010. In many other countries, the healthcare providers who prescribe pharmaceuticals are employed by their government, and the purchasers of pharmaceuticals are government entities; therefore, any dealings with these prescribers and purchasers may be subject to regulation under the FCPA. There is no certainty that all employees and third-party business partners (including our contract research organizations, contract manufacturing organizations, distributors, wholesalers, agents, contractors and other partners) will comply with anti-bribery laws. Importantly, we do not control the actions of manufacturers and other third-party agents, although we may be liable for their actions. Violation of these laws may result in civil or criminal sanctions, which could include monetary fines, criminal penalties, and disgorgement of past profits, which could have an adverse impact on our business and financial condition.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 10px; margin-top: 0px; margin-bottom: 0px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">48</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-align: justify;">
   <span style="color: #000000; font-weight: bold;">Provisions in our certificate of incorporation, bylaws, convertible notes documents, call spread hedge transaction documents and Delaware law may prevent stockholders from receiving a premium for their shares.*</span></div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">Our certificate of incorporation provides for classified terms for the members of our board of directors. Our certificate also includes a provision that requires at least 66 2/3 percent of our voting stockholders to approve a merger or certain other business transactions with, or proposed by, any holder of 15 percent or more of our voting stock, except in cases where certain directors approve the transaction or certain minimum price criteria and other procedural requirements are met.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">Our certificate of incorporation also requires that any action required or permitted to be taken by our stockholders must be taken at a duly called annual or special meeting of stockholders and may not be taken by written consent. In addition, only our board of directors, chairperson of the board or chief executive officer can call special meetings of our stockholders. We have in the past, and may in the future, implement a stockholders&#8217; rights plan, also called a poison pill, which could make it uneconomical for a third party to acquire our company on a hostile basis. In addition, our board of directors has the authority to fix the rights and preferences of, and issue shares of preferred stock, which may have the effect of delaying or preventing a change in control of our company without action by our stockholders.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">The provisions of our convertible senior notes could make it more difficult or more expensive for a third party to acquire us. Upon the occurrence of certain transactions constituting a fundamental change, holders of the notes will have the right, at their option, to require us to repurchase all of their notes or a portion of their notes, which may discourage certain types of transactions in which our stockholders might otherwise receive a premium for their shares over the then-current market prices.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">In 2023, we completed a $575 million offering of 1.75% Notes and used $488.2 million of the net proceeds from the issuance of the 1.75% Notes to repurchase $504.4 million of our 0.125% Notes. In 2024, we used $44.5 million of the net proceeds to settle the remaining principal balance of our 0.125% Notes upon maturity. In 2021, we completed a $632.5 million offering of 0% Notes and used $319.0 million of the net proceeds from the issuance of the 0% Notes to repurchase the remaining $309.9 million of our 1% Notes. In 2019, we entered into privately negotiated exchange and/or subscription agreements with certain new investors and certain holders of our existing 1% Notes to exchange $375.6 million of our 1% Notes for $439.3 million of our 0.125% Notes, and to issue $109.5 million of our 0.125% Notes. Additionally, in connection with the pricing of our 0% Notes and 0.125% Notes, we entered into call spread transactions in which we purchased note hedges and sold warrants. For our 0.125% Notes, the note hedges expired upon maturity of the 0.125% Notes and the warrants fully expired in June 2025. Terminating or unwinding the call spread transactions for our 0% Notes could require us to make substantial payments to the counterparties under those agreements or may increase our stock price. The costs or any increase in stock price that may arise from terminating or unwinding such agreements could make an acquisition of our company significantly more expensive to the purchaser.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">These provisions, as well as Delaware law, including Section 203 of the Delaware General Corporation Law, and other of our agreements, may discourage certain types of transactions in which our stockholders might otherwise receive a premium for their shares over then-current market prices, and may limit the ability of our stockholders to approve transactions that they think may be in their best interests.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-align: justify;">
   <span style="color: #000000; font-weight: bold;">Future sales of our common stock in the public market could adversely affect the trading price of our securities.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">Future sales of substantial amounts of our common stock in the public market, or the perception that such sales could occur, could adversely affect trading prices of our securities. For example, we may issue approximately 21.6 million shares of our common stock upon conversion of our 1.75% Notes and 0% Notes. In connection with the issuance of the 0% Notes, we entered into certain call spread transactions covering 10.9 million shares </span><span>that we expect will </span><span style="color: #000000;">offset the dilution to holders of common stock upon any conversion </span><span>of those notes. </span><span style="color: #000000;">However, the anti-dilutive effect of the convertible note hedges is offset by certain warrant transactions we entered into in connection with the issuance of the 0% Notes. The addition of any of these shares into the public market may have an adverse effect on the price of our securities.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">In addition, pursuant to the call spread transactions we entered into in connection with the pricing of our 0% Notes, the counterparties are likely to modify their hedge positions from time to time at or prior to the conversion or maturity of the notes by purchasing and selling shares of our common stock, other of our securities, or other instruments, including over-the-counter derivative instruments, that they may wish to use in connection with such hedging, which may have a negative effect on the conversion value of those notes and an adverse impact on the trading price of our common stock. The call spread transactions are expected generally to reduce potential dilution to holders of our common stock upon any conversion of our 0% Notes or offset any cash payments we are required to make in excess of the principal amount of the converted 0% Notes, as the case may be. However, the warrant transactions could separately have a dilutive effect to the extent that the market value per share of our common stock exceeds the applicable strike price of the warrants.</span>
  </div><div>
  </div><div>&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 10px; margin-top: 0px; margin-bottom: 0px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">49</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-align: justify;">
   <span style="color: #000000; font-weight: bold; font-style: italic;">Risks related to compliance with laws</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div>
   <span style="color: #000000; font-weight: bold;">Our operations are subject to extensive legal and regulatory requirements affecting the health care industry.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">Our operations are subject to extensive legal and regulatory requirements affecting the health care industry, including federal and state anti-kickback laws, false claims laws, transparency laws, such as the federal Sunshine Act, and health information privacy and security laws, which are subject to change at any time. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. Penalties for violations of applicable healthcare laws and regulations may include significant civil, criminal and administrative penalties, damages, disgorgement, fines, imprisonment, exclusion of products from government funded healthcare programs, such as Medicare and Medicaid, and additional reporting requirements and oversight if we enter into a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws. In addition, violations may also result in reputational harm, diminished profits and future earnings.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-align: justify;">
   <span style="color: #000000; font-weight: bold;">Because we use biological materials, hazardous materials, chemicals and radioactive compounds, if we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected.</span>
  </div><div>
  </div><div style="font-size: 8pt;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">Our research, development and manufacturing activities involve the use of potentially harmful biological materials as well as materials, chemicals and various radioactive compounds that could be hazardous to human health and safety or the environment. We store most of these materials and various wastes resulting from their use at our facilities in Carlsbad, California pending ultimate use and disposal. We cannot completely eliminate the risk of contamination, which could cause:</span>
  </div><div>
  </div><div style="font-size: 8pt;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div style="text-align: left;">
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;interruption of our research, development and manufacturing efforts;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div style="text-align: left;">
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;injury to our employees and others;</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div style="text-align: left;">
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;environmental damage resulting in costly clean up; and</span>
    </div>
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">

    <div style="text-align: left;">
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;liabilities under federal, state and local laws and regulations governing health and human safety, as well as the use, storage, handling and disposal of these materials and resultant waste products.</span>
    </div>
  </div><div>
  </div><div style="font-size: 8pt;">&#160;
  </div><div>

  </div><div style="text-indent: 36pt; text-align: justify;"><span style="color: #000000;">In such an event, we may be held liable for any resulting damages, and any liability could exceed our resources. Although we carry insurance for pollution liability in amounts and types that we consider commercially reasonable, the coverage or coverage limits of our insurance policies may not be adequate. If our losses exceed our insurance coverage, our financial condition would be adversely affected.</span>
  </div><div style="font-size: 8pt;">&#160;
  </div><div>
  </div><div style="text-align: justify;">
   <span style="color: #000000; font-weight: bold;">Our business is subject to changing regulations for corporate governance and public disclosure that has increased both our costs and the risk of noncompliance.</span>
  </div><div>
  </div><div style="font-size: 8pt;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">Each year we are required to evaluate our internal control systems to allow management to report on, and our Independent Registered Public Accounting Firm to attest to, our internal controls as required by Section 404 of the Sarbanes-Oxley Act. As a result, we continue to incur additional expenses and divert our management&#8217;s time to comply with these regulations. In addition, if we cannot continue to comply with the requirements of Section 404 in a timely manner, we might be subject to sanctions or investigation by regulatory authorities, such as the SEC, the Public Company Accounting Oversight Board, or PCAOB, or The Nasdaq Global Select Market. Any such action could adversely affect our financial results and the market price of our common stock.</span>
  </div><div>
  </div><div style="font-size: 8pt;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">The SEC and other regulators have continued to adopt new rules and regulations and make additional changes to existing regulations that require our compliance. In July 2010, the Dodd-Frank Wall Street Reform and Protection Act, or the Dodd-Frank Act, was enacted, and in August 2022, the SEC adopted additional rules and regulations under the Dodd-Frank Act related to &#8220;say on pay&#8221; and proxy access. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which has and may in the future lead to additional compliance costs and impact the manner in which we operate our business.</span>
  </div><div>
  </div><div style="font-size: 8pt;">&#160;
  </div><div>
  </div><div>
   <span style="color: #000000; font-weight: bold; font-style: italic;">Risks related to taxes </span>
  </div><div>
  </div><div style="font-size: 8pt;">&#160;
  </div><div>
  </div><div style="text-align: justify;">
   <span style="color: #000000; font-weight: bold;">Our ability to use our net operating loss carryovers and certain other tax attributes may be limited.</span>
  </div><div>
  </div><div style="font-size: 8pt;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">Under the Internal Revenue Code of 1986, as amended, or the Code, a corporation is generally allowed a deduction for net operating losses, or NOLs, carried over from a prior taxable year. Under the Code, we can carry forward our NOLs to offset our future taxable income, if any, until such NOLs are used or expire. The same is true of other unused tax attributes, such as tax credits.</span>
  </div><div>
  </div><div style="font-size: 8pt;">&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 10px; margin-top: 0px; margin-bottom: 0px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">50</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">Under the current U.S. federal income tax law, U.S. federal NOLs generated in taxable years beginning after December 31, 2017 may be carried forward indefinitely, but the deductibility of such U.S. federal NOLs is limited to 80 percent of taxable income. </span>
  </div><div>
  </div><div style="text-align: justify; font-size: 8pt;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">In addition, under Sections 382 and 383 of the Code, and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change,&#8221; which is generally defined as a greater than 50 percentage-point cumulative change, by value, in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change NOL carryforwards and other pre-change tax attributes to offset its post-change income or taxes may be limited. We may experience ownership changes in the future as a result of subsequent shifts in our stock ownership, some of which may be outside of our control. If an ownership change occurs and our ability to use our NOL carryforwards or other tax attributes is materially limited, it would harm our future operating results by effectively increasing our future tax obligations. As a result of our merger with Akcea Therapeutics, Inc. in 2020, or the Akcea Merger, we are subject to the separate return limitation year, or SRLY, rules. Under the SRLY rules, our utilization of Akcea&#8217;s pre-merger NOL and tax credit carryforwards is limited to the amount of income that Akcea contributes to our consolidated taxable income. The Akcea pre-merger tax attributes cannot be used to offset any of the income that Ionis contributes to our consolidated taxable income. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. For example, in June 2024, California enacted Senate Bill 167, or SB 167, which, with certain exceptions, suspends the ability to use California net operating losses to offset California income and limits the ability to use California business tax credits to offset California taxes, for taxable years beginning after 2023 and before 2027.</span>
  </div><div>
  </div><div style="font-size: 8pt;">&#160;
  </div><div>
  </div><div style="text-align: justify;">
   <span style="color: #000000; font-weight: bold;">Our future taxable income could be impacted by changes in tax laws, regulations and treaties.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">A change in tax laws, treaties or regulations, or their interpretation, of any country in which we operate could materially affect us.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-align: justify;">
   <span style="color: #000000; font-weight: bold;">We could be subject to additional tax liabilities.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">We are subject to U.S. federal, state, local and foreign income taxes, sales taxes in the U.S., withholding taxes and transaction taxes in foreign jurisdictions. Significant judgment is required in evaluating our tax positions and our worldwide provision for taxes. During the ordinary course of business, there are many activities and transactions for which the ultimate tax determination is uncertain. In addition, our tax obligations and effective tax rates could be adversely affected by changes in the relevant tax, accounting and other laws, regulations, principles and interpretations, including those relating to income tax nexus, by recognizing tax losses or lower than anticipated earnings in jurisdictions where we have lower statutory rates and higher than anticipated earnings in jurisdictions where we have higher statutory rates, by changes in foreign currency exchange rates, or by changes in the valuation of our deferred tax assets and liabilities. </span><span>In particular, our tax obligations and effective tax rate in the jurisdictions in which we conduct business could increase in the future as a result of the base erosion and profit shifting, or BEPS, project led by the Organization for Economic Co-operation and Development, or OECD, and other initiatives led by the OECD or the European Commission. The OECD is leading work on an iteration of the BEPS project based on two &#8220;pillars&#8221; (subject to certain revenue thresholds), involving the reallocation of taxing rights in respect of certain multinational enterprises above a fixed profit margin to the jurisdictions in which they carry on business) (referred to as &#8220;Pillar One&#8221;) and imposing a minimum effective corporate tax rate on certain multinational enterprises (referred to as &#8220;Pillar Two&#8221;). Based on the minimum revenue thresholds we do not expect to fall within the scope of these requirements in the near term.</span>
  </div><div>
  </div><div style="text-align: justify;">&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">We may be audited in various jurisdictions, and such jurisdictions may assess additional income, sales and value-added or other taxes against us. Although we believe our tax estimates are reasonable, the final determination of any tax audits or litigation could be materially different from our historical tax provisions and accruals, which could have a material adverse effect on our operating results or cash flows in the period for which a determination is made</span><span>.</span>
  </div><div>
  </div><div>&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 10px; margin-top: 0px; margin-bottom: 0px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">51</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-indent: -72pt; text-align: justify; padding-left: 72pt;">
    <div style="float: left; width: 72.0pt; white-space: nowrap;">
     <a id="Item_2_-_Sales_of_Equity_Securities" title="Item 2 - Sales of Equity Securities"></a><span style="color: #000000; font-weight: bold;">ITEM 2.</span>
    </div>
    <div>
     <span style="color: #000000; font-weight: bold;">UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span>
    </div>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt;">
   <span>Not applicable.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: -72pt; padding-left: 72pt;">
    <div style="float: left; width: 72.0pt; white-space: nowrap;">
     <a id="Item_3_-_Default_upon_Senior_Securities" title="Item 3 - Default upon Senior Securities"></a><span style="color: #000000; font-weight: bold;">ITEM 3.</span>
    </div>
    <div>
     <span style="color: #000000; font-weight: bold;">DEFAULT UPON SENIOR SECURITIES</span>
    </div>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">Not applicable.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: -72pt; padding-left: 72pt;">
    <div style="float: left; width: 72.0pt; white-space: nowrap;">
     <a id="Item_4_-_Mine_Safety" title="Item 4 - Mine Safety"></a><span style="color: #000000; font-weight: bold;">ITEM 4.</span>
    </div>
    <div>
     <span style="color: #000000; font-weight: bold;">MINE SAFETY DISCLOSURES</span>
    </div>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">Not applicable.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: -72pt; padding-left: 72pt;">
    <div style="float: left; width: 72.0pt; white-space: nowrap;">
     <a id="Item_5_-_Other_Information" title="Item 5 - Other Information"></a><span style="color: #000000; font-weight: bold;">ITEM 5.</span>
    </div>
    <div>
     <span style="color: #000000; font-weight: bold;">OTHER INFORMATION</span>
    </div>
  </div><div>
  </div><div style="margin-left: 72pt;">&#160;
  </div><div>
  </div><div style="text-indent: -72pt; padding-left: 72pt;">
   <span style="color: #000000; font-weight: bold;">Trading Plans</span>
  </div><div>
  </div><div style="margin-left: 72pt;">&#160;
  </div><div>
  </div><ix:nonNumeric contextRef="c36" continuedAt="_MtrlTermsOfTrdArrTextBlock-c36_cont_1" escape="true" name="ecd:MtrlTermsOfTrdArrTextBlock" id="ixv-10827"><div style="text-indent: 36pt; text-align: justify;"> <span style="color: #000000;">During the quarter ended September 30, 2025, our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act), or Section 16 officers and directors, adopted or terminated contracts, instructions or written plans for the purchase or sale of our securities as noted in the table below.</span></div></ix:nonNumeric><div>
  </div><div>&#160;</div><div>
  </div><ix:continuation continuedAt="_MtrlTermsOfTrdArrTextBlock-c36_cont_2" id="_MtrlTermsOfTrdArrTextBlock-c36_cont_1"><div>*&#160; &#160; &#160;&#160;&#160;Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.</div></ix:continuation><ix:continuation continuedAt="_MtrlTermsOfTrdArrTextBlock-c36_cont_3" id="_MtrlTermsOfTrdArrTextBlock-c36_cont_2"><div>**&#160; &#160; "Non-Rule 10b5-1 trading arrangement" as defined in item 408(c) of Regulation S-K under the Exchange Act.</div></ix:continuation><div>&#160;</div><ix:continuation id="_MtrlTermsOfTrdArrTextBlock-c36_cont_3"><table cellpadding="0" class="worksheetTable" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td style="width: 8%;"/><td style="width: 1%;"/><td style="width: 7%;"/><td style="width: 1%;"/><td style="width: 7%;"/><td style="width: 1%;"/><td style="width: 8%;"/><td style="width: 1%;"/><td style="width: 7%;"/><td style="width: 1%;"/><td style="width: 8%;"/><td style="width: 1%;"/><td style="width: 8%;"/><td style="width: 1%;"/><td style="width: 40%;"/></tr><tr><td style="font-weight: bold; text-align: center;"/><td style="font-weight: bold; text-align: center;"/><td style="font-weight: bold; text-align: center;"/><td style="font-weight: bold; text-align: center;"/><td style="font-weight: bold; text-align: center;"/><td style="font-weight: bold; text-align: center;"/><td style="font-weight: bold; text-align: center;"/><td style="font-weight: bold; text-align: center;"/><td colspan="3" style="font-weight: bold; text-align: center; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">Trading Arrangement</td><td style="font-weight: bold; text-align: center;"/><td style="font-weight: bold; text-align: center;">Total Shares</td><td style="font-weight: bold; text-align: center;"/><td style="font-weight: bold; text-align: center;"/></tr><tr><td style="font-weight: bold; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; text-align: left;">Name</td><td style="font-weight: bold; text-align: center; vertical-align: bottom;"/><td style="font-weight: bold; text-align: center; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">Title</td><td style="font-weight: bold; text-align: center; vertical-align: bottom;"/><td style="font-weight: bold; text-align: center; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">Action</td><td style="font-weight: bold; text-align: center; vertical-align: bottom;"/><td style="font-weight: bold; text-align: center; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">Date</td><td style="font-weight: bold; text-align: center; vertical-align: bottom;"/><td style="font-weight: bold; text-align: center; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">Rule 10b5-1*</td><td style="font-weight: bold; text-align: center; vertical-align: bottom;"/><td style="font-weight: bold; text-align: center; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"><ix:nonNumeric contextRef="c36" format="ixt:fixed-false" name="ecd:NonRule10b51ArrAdoptedFlag" id="ixv-12124">Non-Rule 10b5-1</ix:nonNumeric>**</td><td style="font-weight: bold; text-align: center; vertical-align: bottom;"/><td style="font-weight: bold; text-align: center; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">to be Sold</td><td style="font-weight: bold; text-align: center; vertical-align: bottom;"/><td style="font-weight: bold; text-align: center; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">Expiration Date</td></tr><tr><td style="vertical-align: bottom;"><ix:nonNumeric contextRef="c36" name="ecd:TrdArrIndName" id="ixv-12125">Spencer Berthelsen</ix:nonNumeric></td><td style="vertical-align: bottom;"/><td style="vertical-align: bottom; text-align: center;"><ix:nonNumeric contextRef="c36" name="ecd:TrdArrIndTitle" id="ixv-12126">Board Member</ix:nonNumeric></td><td style="vertical-align: bottom;"/><td style="text-align: center; vertical-align: bottom;"><span style="-sec-ix-hidden: hidden-fact-5">Adoption</span></td><td style="vertical-align: bottom;"/><td style="text-align: center; vertical-align: bottom;"><ix:nonNumeric contextRef="c36" name="ecd:TrdArrAdoptionDate" id="ixv-12127">September 12, 2025</ix:nonNumeric></td><td style="vertical-align: bottom;"/><td style="text-align: center; vertical-align: bottom;"><ix:nonNumeric contextRef="c36" format="ixt:fixed-true" name="ecd:Rule10b51ArrAdoptedFlag" id="ixv-12128">X</ix:nonNumeric></td><td style="vertical-align: bottom;"/><td style="vertical-align: bottom;"/><td style="vertical-align: bottom;"/><td style="text-align: center; vertical-align: bottom;"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="ecd:TrdArrSecuritiesAggAvailAmt" scale="0" unitRef="shares" id="ixv-12129">16,000</ix:nonFraction></td><td style="vertical-align: bottom;"/><td style="vertical-align: bottom;">The earlier to occur of (i) <ix:nonNumeric contextRef="c36" name="ecd:TrdArrExpirationDate" id="ixv-12130">July 1, 2026</ix:nonNumeric>, and (ii) Upon the execution of all instructions provided in the plan</td></tr></table></ix:continuation><div>&#160;</div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 10px; margin-top: 0px; margin-bottom: 0px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">52</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-indent: -72pt; padding-left: 72pt;">
    <div style="float: left; width: 72.0pt; white-space: nowrap;">
     <a id="Item_6_-_Exhibits" title="Item 6 - Exhibits"></a><span style="color: #000000; font-weight: bold;">ITEM 6.</span>
    </div>
    <div>
     <span style="color: #000000; font-weight: bold;">EXHIBITS</span>
    </div>
  </div><div>
  </div><div style="margin-left: 72pt;">&#160;
  </div><div>
  </div><div style="text-indent: -18pt; padding-left: 54pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span style="color: #000000;">a.</span>
    </div>
    <div>
     <span style="color: #000000;">Exhibits</span>
    </div>
  </div><div>
  </div><div>&#160;
  </div><div>

  </div><table style="border-spacing: 0px; border-collapse: collapse; font-size: 10pt;">
   <tr style="height: 0px; font-size: 0px;"><td style="width: 8%;">&#160;</td><td style="width: 2%;">&#160;</td><td style="width: 90%;">&#160;</td></tr><tr style="vertical-align: top; height: 25.4pt;">
    <td style="padding : 0px; border-bottom : 1pt solid rgb(0, 0, 0); vertical-align : bottom; ">
     <div style="margin-left: 4.5pt;">
      <span style="font-weight: bold;">Exhibit Number</span>
     </div>
    </td>
    <td style="padding : 0px; vertical-align : bottom; ">&#160;</td>
    <td style="padding: 0px; border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom; text-align: center;">


      <span style="font-weight: bold;">Description of Document</span></td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px; text-align: justify;">&#160;</td>
   </tr>



   <tr style="vertical-align: top;">
    <td style="padding-top: 0px; padding-right: 0px; padding-bottom: 0px;">
     <div>
      <span style="color: rgb(0, 0, 255);"><a href="ex31-1.htm" style="-sec-extract:exhibit">31.1</a></span>
     </div>
    </td>
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px; text-align: justify;">



      Certification by Chief Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as amended.
     &#160;
     </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-top: 0px; padding-right: 0px; padding-bottom: 0px;">
     <div>
      <span style="color: rgb(0, 0, 255);"><a href="ex31-2.htm" style="-sec-extract:exhibit">31.2</a></span>
     </div>
    </td>
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px; text-align: justify;">


      Certification by Chief Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as amended.
     </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-top: 0px; padding-right: 0px; padding-bottom: 0px;">
     <div>
      <span style="color: rgb(0, 0, 255);"><a href="ex32-1.htm" style="-sec-extract:exhibit">32.1</a></span>*
     </div>
    </td>
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px; text-align: justify;">


      Certification Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
     </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-top: 0px; padding-right: 0px; padding-bottom: 0px;">
     <div>
      101
     </div>
    </td>
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px; text-align: justify;">


      The following financial statements from the Ionis Pharmaceuticals, Inc. Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, formatted in Inline Extensible Business Reporting Language (iXBRL): (i) condensed consolidated balance sheets, (ii) condensed consolidated statements of operations, (iii) condensed consolidated statements of comprehensive income (loss), (iv) condensed consolidated statements of stockholders&#8217; equity, (v) condensed consolidated statements of cash flows and (vi) notes to condensed consolidated financial statements (detail tagged).
     </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px;">&#160;</td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding-top: 0px; padding-right: 0px; padding-bottom: 0px;">
     <div>
      104
     </div>
    </td>
    <td style="padding: 0px;">&#160;</td>
    <td style="padding: 0px; text-align: justify;">


      Cover Page Interactive Data File (formatted in iXBRL and included in exhibit 101).
     </td>
   </tr>
  </table><div>&#160;
  </div><div>
  </div><div style="text-indent: -18pt; text-align: justify; padding-left: 18pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <span>*</span>
    </div>
    <div>
     <span style="color: #000000;">This certification is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.</span>
    </div>
  </div><div>
  </div><div>&#160;
  </div><div>

  </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 10px; margin-top: 0px; margin-bottom: 0px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">53</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
<div class="header" style="text-align: left;"><a href="#tableOfContents0">Index</a></div></div><div style="text-align: center;">
   <a id="Signatures" title="Signatures"></a><span style="color: #000000; font-weight: bold;">SIGNATURES</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.</span>
  </div><div>
  </div><div>&#160;
  </div><div>
  </div><table style="border-spacing: 0px; border-collapse: collapse; width: 100%; font-size: 10pt;">
   <tr style="vertical-align: top;">
    <td style="padding: 0; width: 27.58%; border-bottom: 1pt solid #000000; vertical-align: bottom;">
     <div style="text-align: center;">
      <span style="color: #000000; font-weight: bold;">Signatures</span>
     </div>
    </td>
    <td style="padding: 0; width: 2.2%; vertical-align: bottom;">
     <div>
      <span style="color: #000000;">&#160;</span>
     </div>
    </td>
    <td style="padding: 0; width: 50.36%; border-bottom: 1pt solid #000000; vertical-align: bottom;">
     <div style="text-align: center;">
      <span style="color: #000000; font-weight: bold;">Title</span>
     </div>
    </td>
    <td style="padding: 0; width: 2.16%; vertical-align: bottom;">
     <div>
      <span style="color: #000000;">&#160;</span>
     </div>
    </td>
    <td style="padding: 0; width: 17.7%; border-bottom: 1pt solid #000000; vertical-align: bottom;">
     <div style="text-align: center;">
      <span style="color: #000000; font-weight: bold;">Date</span>
     </div>
    </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding: 0; width: 27.58%;">
     <div>
      <span style="color: #000000;">&#160;</span>
     </div>
    </td>
    <td style="padding: 0; width: 2.2%; vertical-align: bottom;">
     <div>
      <span style="color: #000000;">&#160;</span>
     </div>
    </td>
    <td style="padding: 0; width: 50.36%;">
     <div>
      <span style="color: #000000;">&#160;</span>
     </div>
    </td>
    <td style="padding: 0; width: 2.16%; vertical-align: bottom;">
     <div>
      <span style="color: #000000;">&#160;</span>
     </div>
    </td>
    <td style="padding: 0; width: 17.7%;">
     <div style="text-align: center;">
      <span style="color: #000000;">&#160;</span>
     </div>
    </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding: 0; width: 27.58%; border-bottom: 1pt solid #000000;">
     <div>
      <span style="color: #000000;">/s/ BRETT P. MONIA</span>
     </div>
    </td>
    <td rowspan="2" style="padding: 0; width: 2.2%; vertical-align: bottom;">
     <div>
      <span style="color: #000000;">&#160;</span>
     </div>
    </td>
    <td style="padding: 0; width: 50.36%;">
     <div>
      <span style="color: #000000;">Director and Chief Executive Officer</span>
     </div>
    </td>
    <td rowspan="2" style="padding: 0; width: 2.16%; vertical-align: bottom;">
     <div>
      <span style="color: #000000;">&#160;</span>
     </div>
    </td>
    <td style="padding: 0; width: 17.7%; vertical-align: bottom;">&#160;
    </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding: 0; width: 27.58%;">
     <div>
      <span style="color: #000000;">Brett P. Monia, Ph.D.</span>
     </div>
    </td>
    <td style="padding: 0; width: 50.36%;">
     <div>
      <span style="color: #000000;">(Principal executive officer)</span>
     </div>
    </td>
    <td style="padding: 0; width: 17.7%; vertical-align: bottom;">
     <div style="text-align: center;">
      <span style="color: #000000;">October 29, 2025</span>
     </div>
    </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding: 0; width: 27.58%;">
     <div>
      <span style="color: #000000;">&#160;</span>
     </div>
    </td>
    <td style="padding: 0; width: 2.2%; vertical-align: bottom;">
     <div>
      <span style="color: #000000;">&#160;</span>
     </div>
    </td>
    <td style="padding: 0; width: 50.36%;">
     <div>
      <span style="color: #000000;">&#160;</span>
     </div>
    </td>
    <td style="padding: 0; width: 2.16%; vertical-align: bottom;">
     <div>
      <span style="color: #000000;">&#160;</span>
     </div>
    </td>
    <td style="padding: 0; width: 17.7%; vertical-align: bottom;">
     <div style="text-align: center;">
      <span style="color: #000000;">&#160;</span>
     </div>
    </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding: 0; width: 27.58%; border-bottom: 1pt solid #000000;">
     <div>
      <span style="color: #000000;">/s/ ELIZABETH L. HOUGEN</span>
     </div>
    </td>
    <td rowspan="2" style="padding: 0; width: 2.2%; vertical-align: bottom;">
     <div>
      <span style="color: #000000;">&#160;</span>
     </div>
    </td>
    <td style="padding: 0; width: 50.36%;">
     <div>
      <span style="color: #000000;">Executive Vice President, Finance and Chief Financial Officer</span>
     </div>
    </td>
    <td rowspan="2" style="padding: 0; width: 2.16%; vertical-align: bottom;">
     <div>
      <span style="color: #000000;">&#160;</span>
     </div>
    </td>
    <td style="padding: 0; width: 17.7%; vertical-align: bottom;">&#160;
    </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding: 0; width: 27.58%;">
     <div>
      <span style="color: #000000;">Elizabeth L. Hougen</span>
     </div>
    </td>
    <td style="padding: 0; width: 50.36%;">
     <div>
      <span style="color: #000000;">(Principal financial and accounting officer)</span>
     </div>
    </td>
    <td style="padding: 0; width: 17.7%; vertical-align: bottom;">
     <div style="text-align: center;">
      <span style="color: #000000;">October 29, 2025</span>
     </div>
    </td>
   </tr>
  </table><div>
  </div><div>&#160;
  </div><div>
  </div><div>&#160;
  </div><div>

 </div><div style="width: 100%; font-family: TimesNewRoman, &quot;Times New Roman&quot;, Times, Baskerville, Georgia, serif; font-size: 10px; margin-top: 0px; margin-bottom: 0px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="text-align: center;">54</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 2px; color: black; background-color: black;"/></div>
</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonFraction contextRef="c0" decimals="INF" id="hidden-fact-0" name="us-gaap:NumberOfOperatingSegments" unitRef="Segment">1</ix:nonFraction>
<ix:nonNumeric contextRef="c0" id="hidden-fact-1" name="ions:MaximumContractMaturityPeriodRange3">P3Y6M</ix:nonNumeric>
<ix:nonNumeric contextRef="c250" id="hidden-fact-2" name="us-gaap:DebtInstrumentMaturityDate">2028-06-30</ix:nonNumeric>
<ix:nonNumeric contextRef="c251" id="hidden-fact-3" name="us-gaap:DebtInstrumentMaturityDate">2026-04-30</ix:nonNumeric>
<ix:nonFraction contextRef="c0" decimals="INF" id="hidden-fact-4" name="us-gaap:NumberOfReportableSegments" unitRef="pure">1</ix:nonFraction>
<ix:nonNumeric contextRef="c36" id="hidden-fact-5" name="ecd:TrdArrDuration">P293D</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey" id="ixv-12139">0000874015</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag" id="ixv-12140">false</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalPeriodFocus" id="ixv-12141">Q3</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:CurrentFiscalYearEndDate" id="ixv-12142">--12-31</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="ions-20250930.xsd" xlink:type="simple"/></ix:references>
<ix:resources xmlns="http://www.xbrl.org/2003/instance"><ix:relationship xmlns="" fromRefs="ix_0_fact ix_1_fact ix_2_fact ix_3_fact" toRefs="ix_0_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_4_fact ix_5_fact" toRefs="ix_1_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_6_fact ix_7_fact" toRefs="ix_2_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_8_fact ix_9_fact ix_10_fact ix_11_fact ix_12_fact ix_13_fact" toRefs="ix_3_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_14_fact ix_15_fact ix_16_fact" toRefs="ix_4_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_17_fact ix_18_fact ix_19_fact ix_20_fact ix_21_fact ix_22_fact ix_23_fact ix_24_fact ix_25_fact ix_26_fact ix_27_fact ix_28_fact ix_29_fact ix_30_fact ix_31_fact ix_32_fact ix_33_fact ix_34_fact ix_35_fact ix_36_fact ix_37_fact ix_38_fact ix_39_fact ix_40_fact" toRefs="ix_5_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_41_fact ix_42_fact ix_43_fact" toRefs="ix_6_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_44_fact ix_45_fact ix_46_fact ix_47_fact ix_48_fact ix_49_fact" toRefs="ix_7_footnote"/>
<xbrli:context xmlns="" id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-10-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes0PercentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes0PercentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes175PercentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes175PercentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:OtherCommercialMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:OtherCommercialMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:OtherCommercialMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:OtherCommercialMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:CommercialMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:CommercialMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:CommercialMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:CommercialMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:CollaborativeAgreementRevenueMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:CollaborativeAgreementRevenueMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:CollaborativeAgreementRevenueMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:CollaborativeAgreementRevenueMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:WainuaJointDevelopmentRevenueMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:WainuaJointDevelopmentRevenueMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:WainuaJointDevelopmentRevenueMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:WainuaJointDevelopmentRevenueMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:AstraZenecaCollaborationWainuaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:AstraZenecaCollaborationWainuaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c87">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:AstraZenecaCollaborationWainuaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c88">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:TryngolzaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c89">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:TryngolzaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c90">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:TryngolzaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c91">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:TryngolzaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c92">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:SpinrazaRoyaltiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c93">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:SpinrazaRoyaltiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c94">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:SpinrazaRoyaltiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c95">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:SpinrazaRoyaltiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c96">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:WainusRoyaltiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c97">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:WainusRoyaltiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c98">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:WainusRoyaltiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c99">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:WainusRoyaltiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c100">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:OtherRoyaltiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c101">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:OtherRoyaltiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c102">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:OtherRoyaltiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c103">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:OtherRoyaltiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c104">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:AstraZenecaCollaborationsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c105">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:AstraZenecaCollaborationWAINUAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c106">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:AstraZenecaCollaborationCardiovascularRenalAndMetabolicDiseasesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c107">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:AstraZenecaCollaborationCardiovascularRenalAndMetabolicDiseasesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-04-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c108">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:AstraZenecaCollaborationsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c109">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:OnoCollaborationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c110">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:OnoCollaborationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-03-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c111">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:OnoCollaborationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c112">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentServicesForSapablursenMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:OnoCollaborationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c113">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:LicenseOfSapablursenMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:OnoCollaborationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c114">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentServicesForSapablursenMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:OnoCollaborationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-04-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c115">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:LicenseOfSapablursenMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:OnoCollaborationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-04-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c116">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:OnoCollaborationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c117">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:AstraZenecaCollaborationsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c118">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:AstraZenecaCollaborationsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c119">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:AstraZenecaCollaborationsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c120">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:AstraZenecaCollaborationsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c121">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:AstraZenecaCollaborationsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c122">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:AstraZenecaCollaborationsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c123">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:AstraZenecaCollaborationsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c124">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:AstraZenecaCollaborationsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c125">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:OnoCollaborationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c126">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:OnoCollaborationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c127">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:OnoCollaborationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c128">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:OnoCollaborationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c129">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes175PercentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c130">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes0PercentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c131">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes0125PercentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c132">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ions:EquitySecuritiesPubliclyTradedCompaniesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c133">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ions:EquitySecuritiesPrivateCompaniesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c134">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ions:EquitySecuritiesPrivateCompaniesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c135">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ions:EquitySecuritiesPrivateCompaniesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-04-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c136">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c137">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c138">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c139">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c140">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c141">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ions:EquitySecuritiesPubliclyTradedCompaniesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c142">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ions:EquitySecuritiesPrivateCompaniesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c143">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c144">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c145">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c146">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c147">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c148">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ions:EquitySecuritiesPubliclyTradedCompaniesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c149">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ions:EquitySecuritiesPrivateCompaniesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c150">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c151">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c152">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c153">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes175PercentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c154">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes0PercentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c155">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes175PercentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c156">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes0PercentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c157">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c158">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c159">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c160">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c161">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c162">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c163">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c164">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c165">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c166">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c167">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c168">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c169">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c170">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c171">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c172">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c173">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c174">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c175">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ions:EquitySecuritiesPubliclyTradedCompaniesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c176">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ions:EquitySecuritiesPubliclyTradedCompaniesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c177">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ions:EquitySecuritiesPubliclyTradedCompaniesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c178">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c179">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c180">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c181">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c182">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c183">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c184">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c185">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c186">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c187">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c188">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c189">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c190">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c191">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c192">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c193">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c194">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c195">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c196">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ions:EquitySecuritiesPubliclyTradedCompaniesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c197">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ions:EquitySecuritiesPubliclyTradedCompaniesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c198">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ions:EquitySecuritiesPubliclyTradedCompaniesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c199">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c200">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c201">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c202">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c203">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c204">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c205">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c206">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c207">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c208">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c209">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c210">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c211">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">ions:GrantedIn2025Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c212">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">ions:GrantedIn2024Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c213">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">ions:GrantedIn2024Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c214">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">ions:GrantedIn2025Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c215">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">ions:GrantedIn2024Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c216">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">ions:GrantedIn2025Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c217">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">ions:GrantedIn2024Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c218">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">ions:GrantedIn2025Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c219">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c220">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c221">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c222">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c223">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c224">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c225">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ions:ResearchDevelopmentAndPatentExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c226">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ions:ResearchDevelopmentAndPatentExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c227">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ions:ResearchDevelopmentAndPatentExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c228">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ions:ResearchDevelopmentAndPatentExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c229">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c230">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c231">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c232">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c233">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">ions:ShareBasedPaymentArrangementBoardOfDirectorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c234">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">ions:ShareBasedPaymentArrangementBoardOfDirectorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c235">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c236">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c237">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c238">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c239">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:SpinrazaMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c240">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:SpinrazaMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c241">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:SpinrazaMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c242">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:PelacarsenMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c243">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c244">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c245">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c246">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c247">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes175PercentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c248">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes0PercentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c249">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes0PercentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c250">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes175PercentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c251">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes0PercentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c252">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c253">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ions:HeadquartersLocationInCarlsbadCaliforniaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c254">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ions:HeadquartersLocationInCarlsbadCaliforniaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c255">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c256">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:IonisOperationsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c257">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:IonisOperationsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c258">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:IonisOperationsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c259">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:IonisOperationsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:unit xmlns="" id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
<!-- [WMV6][7xOYuPW5bZoivWJyAtdv6ikF61m3qnQDav8i6PuIVNy1a65MQxDkpcfMs7FVf8qsWbP2QjulQYD+8ngdBC1sh2grphygxvCRxPjeV5umCmiBU3Q/4xccurokPgcySYmvCSldshfbvClfNee/nldcs7FPGrbe12aMZhDa62RjI9uviMYhw/Yk/6CfgTHy1GGpmNie2lgu7fFPiN8A1vnsMwYA4Owehe9+Hps85p+nHfm0u+aHQkI+0ObniQexCmY3cxqEs/QgDkdXwrojOn0ryj+GYHEM/u2qdjWovK4qQFmQZrpRrmcqJFvG8aW4VXVAievJug==] CSR-->
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit xmlns="" id="Segment">
  <xbrli:measure>ions:Segment</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="Component">
  <xbrli:measure>ions:Component</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="PerformanceObligation">
  <xbrli:measure>ions:PerformanceObligation</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="Agreement">
  <xbrli:measure>ions:Agreement</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="Company">
  <xbrli:measure>ions:Company</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="Investment">
  <xbrli:measure>ions:Investment</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="Option">
  <xbrli:measure>ions:Option</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="Lot">
  <xbrli:measure>ions:Lot</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>
</div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>2
<FILENAME>ions-20250930.xsd
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION - SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Wed Oct 29 20:43:09 UTC 2025 -->
<xs:schema elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:ions="http://ionis.com/20250930" targetNamespace="http://ionis.com/20250930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="ions-20250930_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="ions-20250930_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="ions-20250930_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="ions-20250930_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://ionis.com/role/ConsolidatedBalanceSheet" id="ions_r_ConsolidatedBalanceSheet">
        <link:definition>995301 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ionis.com/role/ConsolidatedBalanceSheet_Parentheticals" id="ions_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>995302 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ionis.com/role/ConsolidatedIncomeStatement" id="ions_r_ConsolidatedIncomeStatement">
        <link:definition>995303 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ionis.com/role/ConsolidatedComprehensiveIncome" id="ions_r_ConsolidatedComprehensiveIncome">
        <link:definition>995304 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ionis.com/role/ShareholdersEquityType2or3" id="ions_r_ShareholdersEquityType2or3">
        <link:definition>995305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ionis.com/role/ConsolidatedCashFlow" id="ions_r_ConsolidatedCashFlow">
        <link:definition>995306 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ionis.com/role/OrganizationandBasisofPresentation" id="ions_r_OrganizationandBasisofPresentation">
        <link:definition>995307 - Disclosure - Organization and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ionis.com/role/SignificantAccountingPolicies" id="ions_r_SignificantAccountingPolicies">
        <link:definition>995308 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ionis.com/role/SupplementalFinancialData" id="ions_r_SupplementalFinancialData">
        <link:definition>995309 - Disclosure - Supplemental Financial Data</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ionis.com/role/Revenues" id="ions_r_Revenues">
        <link:definition>995310 - Disclosure - Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ionis.com/role/CollaborativeArrangementsandLicensingAgreements" id="ions_r_CollaborativeArrangementsandLicensingAgreements">
        <link:definition>995311 - Disclosure - Collaborative Arrangements and Licensing Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ionis.com/role/BasicandDilutedNetLossPerShare" id="ions_r_BasicandDilutedNetLossPerShare">
        <link:definition>995312 - Disclosure - Basic and Diluted Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ionis.com/role/Investments" id="ions_r_Investments">
        <link:definition>995313 - Disclosure - Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ionis.com/role/FairValueMeasurements" id="ions_r_FairValueMeasurements">
        <link:definition>995314 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ionis.com/role/StockbasedCompensationExpense" id="ions_r_StockbasedCompensationExpense">
        <link:definition>995315 - Disclosure - Stock-based Compensation Expense</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ionis.com/role/IncomeTaxes" id="ions_r_IncomeTaxes">
        <link:definition>995316 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ionis.com/role/LiabilityRelatedtoSaleofFutureRoyalties" id="ions_r_LiabilityRelatedtoSaleofFutureRoyalties">
        <link:definition>995317 - Disclosure - Liability Related to Sale of Future Royalties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ionis.com/role/ConvertibleDebt" id="ions_r_ConvertibleDebt">
        <link:definition>995318 - Disclosure - Convertible Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ionis.com/role/OperatingLeases" id="ions_r_OperatingLeases">
        <link:definition>995319 - Disclosure - Operating Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ionis.com/role/LegalProceedings" id="ions_r_LegalProceedings">
        <link:definition>995320 - Disclosure - Legal Proceedings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ionis.com/role/SegmentInformation" id="ions_r_SegmentInformation">
        <link:definition>995321 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ionis.com/role/AccountingPoliciesByPolicy" id="ions_r_AccountingPoliciesByPolicy">
        <link:definition>996000 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ionis.com/role/SupplementalFinancialDataTables" id="ions_r_SupplementalFinancialDataTables">
        <link:definition>996001 - Disclosure - Supplemental Financial Data (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ionis.com/role/RevenuesTables" id="ions_r_RevenuesTables">
        <link:definition>996002 - Disclosure - Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ionis.com/role/CollaborativeArrangementsandLicensingAgreementsTables" id="ions_r_CollaborativeArrangementsandLicensingAgreementsTables">
        <link:definition>996003 - Disclosure - Collaborative Arrangements and Licensing Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ionis.com/role/InvestmentsTables" id="ions_r_InvestmentsTables">
        <link:definition>996004 - Disclosure - Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ionis.com/role/FairValueMeasurementsTables" id="ions_r_FairValueMeasurementsTables">
        <link:definition>996005 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ionis.com/role/StockbasedCompensationExpenseTables" id="ions_r_StockbasedCompensationExpenseTables">
        <link:definition>996006 - Disclosure - Stock-based Compensation Expense (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ionis.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesTables" id="ions_r_LiabilityRelatedtoSaleofFutureRoyaltiesTables">
        <link:definition>996007 - Disclosure - Liability Related to Sale of Future Royalties (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ionis.com/role/ConvertibleDebtTables" id="ions_r_ConvertibleDebtTables">
        <link:definition>996008 - Disclosure - Convertible Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ionis.com/role/SegmentInformationTables" id="ions_r_SegmentInformationTables">
        <link:definition>996009 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ionis.com/role/OrganizationandBasisofPresentationDetails" id="ions_r_OrganizationandBasisofPresentationDetails">
        <link:definition>996010 - Disclosure - Organization and Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ionis.com/role/InventoriesTable" id="ions_r_InventoriesTable">
        <link:definition>996011 - Disclosure - Supplemental Financial Data - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ionis.com/role/AccruedLiabilitiesTable" id="ions_r_AccruedLiabilitiesTable">
        <link:definition>996012 - Disclosure - Supplemental Financial Data - Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ionis.com/role/RevenuesDetails" id="ions_r_RevenuesDetails">
        <link:definition>996013 - Disclosure - Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ionis.com/role/RevenuesTable" id="ions_r_RevenuesTable">
        <link:definition>996014 - Disclosure - Revenues - Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ionis.com/role/CollaborativeArrangementsandLicensingAgreementsDetailsAstraZeneca" id="ions_r_CollaborativeArrangementsandLicensingAgreementsDetailsAstraZeneca">
        <link:definition>996015 - Disclosure - Collaborative Arrangements and Licensing Agreements - AstraZeneca (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ionis.com/role/RevenuefromCollaborativeRelationshipwithAstraZenecaTable" id="ions_r_RevenuefromCollaborativeRelationshipwithAstraZenecaTable">
        <link:definition>996016 - Disclosure - Collaborative Arrangements and Licensing Agreements - Revenue from Collaborative Relationship with AstraZeneca (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ionis.com/role/CollaborativeArrangementsandLicensingAgreementsDetailsOno" id="ions_r_CollaborativeArrangementsandLicensingAgreementsDetailsOno">
        <link:definition>996017 - Disclosure - Collaborative Arrangements and Licensing Agreements - Ono (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ionis.com/role/RevenuefromCollaborativeRelationshipwithOnoTable" id="ions_r_RevenuefromCollaborativeRelationshipwithOnoTable">
        <link:definition>996018 - Disclosure - Collaborative Arrangements and Licensing Agreements - Revenue from Collaborative Relationship with Ono (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ionis.com/role/BasicandDilutedNetLossPerShareDetails" id="ions_r_BasicandDilutedNetLossPerShareDetails">
        <link:definition>996019 - Disclosure - Basic and Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ionis.com/role/InvestmentsDetails" id="ions_r_InvestmentsDetails">
        <link:definition>996020 - Disclosure - Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ionis.com/role/InvestmentsDetailsContractMaturityofAvailableforSaleSecurities" id="ions_r_InvestmentsDetailsContractMaturityofAvailableforSaleSecurities">
        <link:definition>996021 - Disclosure - Investments - Contract Maturity of Available-for-Sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ionis.com/role/SummaryofInvestmentsTable" id="ions_r_SummaryofInvestmentsTable">
        <link:definition>996022 - Disclosure - Investments - Summary of Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ionis.com/role/TemporarilyImpairedInvestmentsTable" id="ions_r_TemporarilyImpairedInvestmentsTable">
        <link:definition>996023 - Disclosure - Investments - Temporarily Impaired Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ionis.com/role/FairValueMeasurementsDetails" id="ions_r_FairValueMeasurementsDetails">
        <link:definition>996024 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ionis.com/role/FairValueMeasurementsTable" id="ions_r_FairValueMeasurementsTable">
        <link:definition>996025 - Disclosure - Fair Value Measurements - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ionis.com/role/StockbasedCompensationExpenseDetails" id="ions_r_StockbasedCompensationExpenseDetails">
        <link:definition>996026 - Disclosure - Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ionis.com/role/StockbasedCompensationExpenseTable" id="ions_r_StockbasedCompensationExpenseTable">
        <link:definition>996027 - Disclosure - Stock-based Compensation Expense - Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ionis.com/role/WeightedAverageAssumptionsforStockOptionsTable" id="ions_r_WeightedAverageAssumptionsforStockOptionsTable">
        <link:definition>996028 - Disclosure - Stock-based Compensation Expense - Weighted-Average Assumptions for Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ionis.com/role/WeightedAverageAssumptionsforESPPTable" id="ions_r_WeightedAverageAssumptionsforESPPTable">
        <link:definition>996029 - Disclosure - Stock-based Compensation Expense - Weighted-Average Assumptions for ESPP (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ionis.com/role/IncomeTaxesDetails" id="ions_r_IncomeTaxesDetails">
        <link:definition>996030 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ionis.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesDetails" id="ions_r_LiabilityRelatedtoSaleofFutureRoyaltiesDetails">
        <link:definition>996031 - Disclosure - Liability Related to Sale of Future Royalties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ionis.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesTable" id="ions_r_LiabilityRelatedtoSaleofFutureRoyaltiesTable">
        <link:definition>996032 - Disclosure - Liability Related to Sale of Future Royalties - Liability Related to Sale of Future Royalties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ionis.com/role/ConvertibleDebtDetails" id="ions_r_ConvertibleDebtDetails">
        <link:definition>996033 - Disclosure - Convertible Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ionis.com/role/175NotesTable" id="ions_r_175NotesTable">
        <link:definition>996034 - Disclosure - Convertible Debt - 1.75% Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ionis.com/role/0NotesTable" id="ions_r_0NotesTable">
        <link:definition>996035 - Disclosure - Convertible Debt - 0% Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ionis.com/role/OperatingLeasesDetails" id="ions_r_OperatingLeasesDetails">
        <link:definition>996036 - Disclosure - Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ionis.com/role/SegmentInformationDetails" id="ions_r_SegmentInformationDetails">
        <link:definition>996037 - Disclosure - Segment Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ionis.com/role/SegmentInformationTable" id="ions_r_SegmentInformationTable">
        <link:definition>996038 - Disclosure - Segment Information - Segment Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ionis.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ionis.com/role/AdditionalCalculations" id="ions_r_AdditionalCalculations">
        <link:definition>996039 - Disclosure - AdditionalCalculations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2025" schemaLocation="https://xbrl.sec.gov/sic/2025/sic-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd-sub/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei-sub/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-sub-2025.xsd"/>
  <xs:element name="ReportedAsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ions_ReportedAsAbstract"/>
  <xs:element name="LiabilityRelatedToSaleOfFutureRoyaltiesNetNoncurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ions_LiabilityRelatedToSaleOfFutureRoyaltiesNetNoncurrent"/>
  <xs:element name="ResearchDevelopmentAndPatentExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ions_ResearchDevelopmentAndPatentExpense"/>
  <xs:element name="InterestExpenseAndAmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ions_InterestExpenseAndAmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties"/>
  <xs:element name="RoyaltyPayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ions_RoyaltyPayments"/>
  <xs:element name="InterestExpenseRelatedToSaleOfFutureRoyalties" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ions_InterestExpenseRelatedToSaleOfFutureRoyalties"/>
  <xs:element name="CapitalAndPatentExpendituresIncurredButNotYetPaid" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ions_CapitalAndPatentExpendituresIncurredButNotYetPaid"/>
  <xs:element name="ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ions_ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock"/>
  <xs:element name="InventoryRawMaterialsNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ions_InventoryRawMaterialsNet"/>
  <xs:element name="InventoryWorkInProcessNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ions_InventoryWorkInProcessNet"/>
  <xs:element name="InventoryFinishedGoodsNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ions_InventoryFinishedGoodsNet"/>
  <xs:element name="InventoryCurrentAndNoncurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ions_InventoryCurrentAndNoncurrent"/>
  <xs:element name="AccruedClinicalExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ions_AccruedClinicalExpenses"/>
  <xs:element name="AccruedInLicensingFeesCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ions_AccruedInLicensingFeesCurrent"/>
  <xs:element name="AccruedCommercialExpensesCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ions_AccruedCommercialExpensesCurrent"/>
  <xs:element name="DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent"/>
  <xs:element name="DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent"/>
  <xs:element name="DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent"/>
  <xs:element name="DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent"/>
  <xs:element name="EquitySecuritiesFvNiAccumulatedGrossUnrealizedGain" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ions_EquitySecuritiesFvNiAccumulatedGrossUnrealizedGain"/>
  <xs:element name="EquitySecuritiesFvNiAccumulatedGrossUnrealizedLoss" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ions_EquitySecuritiesFvNiAccumulatedGrossUnrealizedLoss"/>
  <xs:element name="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost"/>
  <xs:element name="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain"/>
  <xs:element name="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss"/>
  <xs:element name="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi"/>
  <xs:element name="LiabilityRelatedToSaleOfFutureRoyaltiesNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ions_LiabilityRelatedToSaleOfFutureRoyaltiesNet"/>
  <xs:element name="AmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ions_AmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties"/>
  <xs:element name="LiabilityRelatedToSaleOfFutureRoyaltiesNetCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ions_LiabilityRelatedToSaleOfFutureRoyaltiesNetCurrent"/>
  <xs:element name="DebtInstrumentConvertibleSharesSubjectToConversion" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="ions_DebtInstrumentConvertibleSharesSubjectToConversion"/>
  <xs:element name="DebtInstrumentConvertibleConversionPriceIncludingCallSpread" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="ions_DebtInstrumentConvertibleConversionPriceIncludingCallSpread"/>
  <xs:element name="DrugDiscoveryExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ions_DrugDiscoveryExpenses"/>
  <xs:element name="DrugDevelopmentExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ions_DrugDevelopmentExpenses"/>
  <xs:element name="MedicalAffairsExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ions_MedicalAffairsExpenses"/>
  <xs:element name="ManufacturingAndDevelopmentChemistryExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ions_ManufacturingAndDevelopmentChemistryExpenses"/>
  <xs:element name="ResearchAndDevelopmentSupportExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ions_ResearchAndDevelopmentSupportExpenses"/>
  <xs:element name="MaximumContractMaturityPeriodRange1" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ions_MaximumContractMaturityPeriodRange1"/>
  <xs:element name="AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="ions_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage"/>
  <xs:element name="MaximumContractMaturityPeriodRange2" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ions_MaximumContractMaturityPeriodRange2"/>
  <xs:element name="AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="ions_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage"/>
  <xs:element name="MaximumContractMaturityPeriodRange3" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ions_MaximumContractMaturityPeriodRange3"/>
  <xs:element name="AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="ions_AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage"/>
  <xs:element name="AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="ions_AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage"/>
  <xs:element name="UpfrontPaymentReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ions_UpfrontPaymentReceived"/>
  <xs:element name="NumberOfMaterialComponents" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="ions_NumberOfMaterialComponents"/>
  <xs:element name="RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations"/>
  <xs:element name="RevenueFromContractWithCustomerTransactionPrice" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ions_RevenueFromContractWithCustomerTransactionPrice"/>
  <xs:element name="PercentageOfCostsAssociatedWithOngoingGlobalPhase3DevelopmentProgramPaidByCollaborationPartner" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ions_PercentageOfCostsAssociatedWithOngoingGlobalPhase3DevelopmentProgramPaidByCollaborationPartner"/>
  <xs:element name="NumberOfCollaborationAgreements" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="ions_NumberOfCollaborationAgreements"/>
  <xs:element name="CumulativePaymentsReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ions_CumulativePaymentsReceived"/>
  <xs:element name="NextPaymentToBeAchieved" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ions_NextPaymentToBeAchieved"/>
  <xs:element name="MaximumAmountOfPaymentsReceivableOverTermOfCollaboration" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ions_MaximumAmountOfPaymentsReceivableOverTermOfCollaboration"/>
  <xs:element name="MaximumAmountOfUpfrontPaymentsOverTermOfCollaboration" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ions_MaximumAmountOfUpfrontPaymentsOverTermOfCollaboration"/>
  <xs:element name="MaximumAmountOfDevelopmentMilestonePaymentsOverTermOfCollaboration" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ions_MaximumAmountOfDevelopmentMilestonePaymentsOverTermOfCollaboration"/>
  <xs:element name="MaximumAmountOfRegulatoryMilestonePaymentsOverTermOfCollaboration" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ions_MaximumAmountOfRegulatoryMilestonePaymentsOverTermOfCollaboration"/>
  <xs:element name="MaximumAmountOfSalesMilestonePaymentsOverTermOfCollaboration" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ions_MaximumAmountOfSalesMilestonePaymentsOverTermOfCollaboration"/>
  <xs:element name="NumberOfPerformanceObligationsIdentified" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ions_NumberOfPerformanceObligationsIdentified"/>
  <xs:element name="AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="ions_AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage"/>
  <xs:element name="NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="ions_NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment"/>
  <xs:element name="NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="ions_NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfUnitsGuaranteedToVest" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfUnitsGuaranteedToVest"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfUnitsGuaranteedToVest" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfUnitsGuaranteedToVest"/>
  <xs:element name="UpfrontRoyaltyPaymentReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ions_UpfrontRoyaltyPaymentReceived"/>
  <xs:element name="MaximumAmountOfPaymentsReceivableForAdditionalMilestones" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ions_MaximumAmountOfPaymentsReceivableForAdditionalMilestones"/>
  <xs:element name="PercentageOfRoyaltyPaymentsPaidOnAnnualSalesOfMedicine" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="ions_PercentageOfRoyaltyPaymentsPaidOnAnnualSalesOfMedicine"/>
  <xs:element name="MaximumAmountOfAnnualSalesOnWhichRoyaltyPaymentsArePaid" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ions_MaximumAmountOfAnnualSalesOnWhichRoyaltyPaymentsArePaid"/>
  <xs:element name="MaximumRoyaltyPaymentsMadeBeforeRoyaltyInterestRevertsBack" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ions_MaximumRoyaltyPaymentsMadeBeforeRoyaltyInterestRevertsBack"/>
  <xs:element name="PaymentsForTransactionCostsRelatedToSaleOfFutureRoyalties" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ions_PaymentsForTransactionCostsRelatedToSaleOfFutureRoyalties"/>
  <xs:element name="CallSpread" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ions_CallSpread"/>
  <xs:element name="DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ions_DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange"/>
  <xs:element name="NumberOfPurchaseAndSaleAgreementsEnteredIntoWithRealEstateInvestor" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ions_NumberOfPurchaseAndSaleAgreementsEnteredIntoWithRealEstateInvestor"/>
  <xs:element name="LesseeOperatingLeaseNumberOfOptionsToExtendLease" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="ions_LesseeOperatingLeaseNumberOfOptionsToExtendLease"/>
  <xs:element name="NumberOfLotsOfUndevelopedLandTransferredToRealEstateInvestor" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ions_NumberOfLotsOfUndevelopedLandTransferredToRealEstateInvestor"/>
  <xs:element name="AstraZenecaCollaborationCardiovascularRenalAndMetabolicDiseasesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ions_AstraZenecaCollaborationCardiovascularRenalAndMetabolicDiseasesMember"/>
  <xs:element name="AstraZenecaCollaborationWAINUAMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ions_AstraZenecaCollaborationWAINUAMember"/>
  <xs:element name="AstraZenecaCollaborationWainuaMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ions_AstraZenecaCollaborationWainuaMember"/>
  <xs:element name="AstraZenecaCollaborationsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ions_AstraZenecaCollaborationsMember"/>
  <xs:element name="CollaborativeAgreementRevenueMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ions_CollaborativeAgreementRevenueMember"/>
  <xs:element name="CommercialMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ions_CommercialMember"/>
  <xs:element name="ConvertibleSeniorNotes0125PercentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ions_ConvertibleSeniorNotes0125PercentMember"/>
  <xs:element name="ConvertibleSeniorNotes0PercentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ions_ConvertibleSeniorNotes0PercentMember"/>
  <xs:element name="ConvertibleSeniorNotes175PercentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ions_ConvertibleSeniorNotes175PercentMember"/>
  <xs:element name="EquitySecuritiesPrivateCompaniesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ions_EquitySecuritiesPrivateCompaniesMember"/>
  <xs:element name="EquitySecuritiesPubliclyTradedCompaniesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ions_EquitySecuritiesPubliclyTradedCompaniesMember"/>
  <xs:element name="GrantedIn2024Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ions_GrantedIn2024Member"/>
  <xs:element name="GrantedIn2025Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ions_GrantedIn2025Member"/>
  <xs:element name="HeadquartersLocationInCarlsbadCaliforniaMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ions_HeadquartersLocationInCarlsbadCaliforniaMember"/>
  <xs:element name="IonisOperationsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ions_IonisOperationsMember"/>
  <xs:element name="LicenseOfSapablursenMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ions_LicenseOfSapablursenMember"/>
  <xs:element name="OnoCollaborationMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ions_OnoCollaborationMember"/>
  <xs:element name="OtherCommercialMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ions_OtherCommercialMember"/>
  <xs:element name="OtherRoyaltiesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ions_OtherRoyaltiesMember"/>
  <xs:element name="PelacarsenMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ions_PelacarsenMember"/>
  <xs:element name="ResearchAndDevelopmentRevenueMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ions_ResearchAndDevelopmentRevenueMember"/>
  <xs:element name="ResearchAndDevelopmentServicesForSapablursenMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ions_ResearchAndDevelopmentServicesForSapablursenMember"/>
  <xs:element name="ResearchDevelopmentAndPatentExpensesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ions_ResearchDevelopmentAndPatentExpensesMember"/>
  <xs:element name="RoyaltyPurchaseAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ions_RoyaltyPurchaseAgreementMember"/>
  <xs:element name="ShareBasedPaymentArrangementBoardOfDirectorMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ions_ShareBasedPaymentArrangementBoardOfDirectorMember"/>
  <xs:element name="SpinrazaMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ions_SpinrazaMember"/>
  <xs:element name="SpinrazaRoyaltiesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ions_SpinrazaRoyaltiesMember"/>
  <xs:element name="TryngolzaMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ions_TryngolzaMember"/>
  <xs:element name="WainuaJointDevelopmentRevenueMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ions_WainuaJointDevelopmentRevenueMember"/>
  <xs:element name="WainusRoyaltiesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ions_WainusRoyaltiesMember"/>
  <xs:element name="CollaborativeArrangementsAndLicensingAgreementsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ions_CollaborativeArrangementsAndLicensingAgreementsAbstract"/>
  <xs:element name="ConvertibleNotesDisclosureTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ions_ConvertibleNotesDisclosureTable"/>
  <xs:element name="SupplementalFinancialDataAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ions_SupplementalFinancialDataAbstract"/>
<!-- [WMV6][AoMzrkWUINWrZh7JasjfHeCgum3qwwCsW9IGDSIXUISP48y00M86X9rcSgbHXWQnGN6aT3zosmwZP6GjDp9irUY6HBaKzIusnfxanjB+Wwlt/SyuqdQGMpWkV8FyjPt73SeenFZ5h4/8gHtFgh69WmUsNAN53ROv6pkxgTM2K0DBFHnGr7i5r+7LIiYSqRgFpXpnBXZhzmER/2hYCUWm4HDMTCXBlqTDJ+5WVTKqA086308F0swxLgHy0otIonkWrxhmimbk80gvminAm2yNKYOegxC83rYHiIXbAfltN6sj23tyI8BNHmvuOcC3d0mw9xW/GUT3cA==] CSR-->
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ions_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>3
<FILENAME>ions-20250930_def.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION - DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Wed Oct 29 20:43:09 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_ConsolidatedBalanceSheet" roleURI="http://ionis.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://ionis.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_ConsolidatedIncomeStatement" roleURI="http://ionis.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_ConsolidatedComprehensiveIncome" roleURI="http://ionis.com/role/ConsolidatedComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_ShareholdersEquityType2or3" roleURI="http://ionis.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_ConsolidatedCashFlow" roleURI="http://ionis.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_OrganizationandBasisofPresentation" roleURI="http://ionis.com/role/OrganizationandBasisofPresentation"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_SignificantAccountingPolicies" roleURI="http://ionis.com/role/SignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_SupplementalFinancialData" roleURI="http://ionis.com/role/SupplementalFinancialData"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_Revenues" roleURI="http://ionis.com/role/Revenues"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_CollaborativeArrangementsandLicensingAgreements" roleURI="http://ionis.com/role/CollaborativeArrangementsandLicensingAgreements"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_BasicandDilutedNetLossPerShare" roleURI="http://ionis.com/role/BasicandDilutedNetLossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_Investments" roleURI="http://ionis.com/role/Investments"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_FairValueMeasurements" roleURI="http://ionis.com/role/FairValueMeasurements"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_StockbasedCompensationExpense" roleURI="http://ionis.com/role/StockbasedCompensationExpense"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_IncomeTaxes" roleURI="http://ionis.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_LiabilityRelatedtoSaleofFutureRoyalties" roleURI="http://ionis.com/role/LiabilityRelatedtoSaleofFutureRoyalties"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_ConvertibleDebt" roleURI="http://ionis.com/role/ConvertibleDebt"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_OperatingLeases" roleURI="http://ionis.com/role/OperatingLeases"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_LegalProceedings" roleURI="http://ionis.com/role/LegalProceedings"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_SegmentInformation" roleURI="http://ionis.com/role/SegmentInformation"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_AccountingPoliciesByPolicy" roleURI="http://ionis.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_SupplementalFinancialDataTables" roleURI="http://ionis.com/role/SupplementalFinancialDataTables"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_RevenuesTables" roleURI="http://ionis.com/role/RevenuesTables"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_CollaborativeArrangementsandLicensingAgreementsTables" roleURI="http://ionis.com/role/CollaborativeArrangementsandLicensingAgreementsTables"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_InvestmentsTables" roleURI="http://ionis.com/role/InvestmentsTables"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_FairValueMeasurementsTables" roleURI="http://ionis.com/role/FairValueMeasurementsTables"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_StockbasedCompensationExpenseTables" roleURI="http://ionis.com/role/StockbasedCompensationExpenseTables"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_LiabilityRelatedtoSaleofFutureRoyaltiesTables" roleURI="http://ionis.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesTables"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_ConvertibleDebtTables" roleURI="http://ionis.com/role/ConvertibleDebtTables"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_SegmentInformationTables" roleURI="http://ionis.com/role/SegmentInformationTables"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_InventoriesTable" roleURI="http://ionis.com/role/InventoriesTable"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_AccruedLiabilitiesTable" roleURI="http://ionis.com/role/AccruedLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_RevenuesTable" roleURI="http://ionis.com/role/RevenuesTable"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_RevenuefromCollaborativeRelationshipwithAstraZenecaTable" roleURI="http://ionis.com/role/RevenuefromCollaborativeRelationshipwithAstraZenecaTable"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_RevenuefromCollaborativeRelationshipwithOnoTable" roleURI="http://ionis.com/role/RevenuefromCollaborativeRelationshipwithOnoTable"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_SummaryofInvestmentsTable" roleURI="http://ionis.com/role/SummaryofInvestmentsTable"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_TemporarilyImpairedInvestmentsTable" roleURI="http://ionis.com/role/TemporarilyImpairedInvestmentsTable"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_FairValueMeasurementsTable" roleURI="http://ionis.com/role/FairValueMeasurementsTable"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_StockbasedCompensationExpenseTable" roleURI="http://ionis.com/role/StockbasedCompensationExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_WeightedAverageAssumptionsforStockOptionsTable" roleURI="http://ionis.com/role/WeightedAverageAssumptionsforStockOptionsTable"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_WeightedAverageAssumptionsforESPPTable" roleURI="http://ionis.com/role/WeightedAverageAssumptionsforESPPTable"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_LiabilityRelatedtoSaleofFutureRoyaltiesTable" roleURI="http://ionis.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesTable"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_175NotesTable" roleURI="http://ionis.com/role/175NotesTable"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_0NotesTable" roleURI="http://ionis.com/role/0NotesTable"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_SegmentInformationTable" roleURI="http://ionis.com/role/SegmentInformationTable"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_InvestmentsDetailsContractMaturityofAvailableforSaleSecurities" roleURI="http://ionis.com/role/InvestmentsDetailsContractMaturityofAvailableforSaleSecurities"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_OrganizationandBasisofPresentationDetails" roleURI="http://ionis.com/role/OrganizationandBasisofPresentationDetails"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_RevenuesDetails" roleURI="http://ionis.com/role/RevenuesDetails"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_CollaborativeArrangementsandLicensingAgreementsDetailsAstraZeneca" roleURI="http://ionis.com/role/CollaborativeArrangementsandLicensingAgreementsDetailsAstraZeneca"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_CollaborativeArrangementsandLicensingAgreementsDetailsOno" roleURI="http://ionis.com/role/CollaborativeArrangementsandLicensingAgreementsDetailsOno"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_BasicandDilutedNetLossPerShareDetails" roleURI="http://ionis.com/role/BasicandDilutedNetLossPerShareDetails"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_InvestmentsDetails" roleURI="http://ionis.com/role/InvestmentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_FairValueMeasurementsDetails" roleURI="http://ionis.com/role/FairValueMeasurementsDetails"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_StockbasedCompensationExpenseDetails" roleURI="http://ionis.com/role/StockbasedCompensationExpenseDetails"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_IncomeTaxesDetails" roleURI="http://ionis.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_LiabilityRelatedtoSaleofFutureRoyaltiesDetails" roleURI="http://ionis.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_ConvertibleDebtDetails" roleURI="http://ionis.com/role/ConvertibleDebtDetails"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_OperatingLeasesDetails" roleURI="http://ionis.com/role/OperatingLeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_SegmentInformationDetails" roleURI="http://ionis.com/role/SegmentInformationDetails"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:role="http://ionis.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_ConvertibleSeniorNotes175PercentMember" xlink:href="ions-20250930.xsd#ions_ConvertibleSeniorNotes175PercentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="ions_ConvertibleSeniorNotes175PercentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_ConvertibleSeniorNotes0PercentMember" xlink:href="ions-20250930.xsd#ions_ConvertibleSeniorNotes0PercentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="ions_ConvertibleSeniorNotes0PercentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShortTermInvestments" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryNet" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAssetsCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAssetsNoncurrent" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Assets" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsPayableCurrent" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertibleDebtCurrent" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrent" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertibleDebtNoncurrent" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_LiabilityRelatedToSaleOfFutureRoyaltiesNetNoncurrent" xlink:href="ions-20250930.xsd#ions_LiabilityRelatedToSaleOfFutureRoyaltiesNetNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ions_LiabilityRelatedToSaleOfFutureRoyaltiesNetNoncurrent" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Liabilities" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockValue" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="29" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://ionis.com/role/ConsolidatedBalanceSheet_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_ConvertibleSeniorNotes0PercentMember" xlink:href="ions-20250930.xsd#ions_ConvertibleSeniorNotes0PercentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="ions_ConvertibleSeniorNotes0PercentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_ConvertibleSeniorNotes175PercentMember" xlink:href="ions-20250930.xsd#ions_ConvertibleSeniorNotes175PercentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="ions_ConvertibleSeniorNotes175PercentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://ionis.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RoyaltyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_OtherCommercialMember" xlink:href="ions-20250930.xsd#ions_OtherCommercialMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ions_OtherCommercialMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_CommercialMember" xlink:href="ions-20250930.xsd#ions_CommercialMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ions_CommercialMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_CollaborativeAgreementRevenueMember" xlink:href="ions-20250930.xsd#ions_CollaborativeAgreementRevenueMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ions_CollaborativeAgreementRevenueMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_WainuaJointDevelopmentRevenueMember" xlink:href="ions-20250930.xsd#ions_WainuaJointDevelopmentRevenueMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ions_WainuaJointDevelopmentRevenueMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_ResearchAndDevelopmentRevenueMember" xlink:href="ions-20250930.xsd#ions_ResearchAndDevelopmentRevenueMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ions_ResearchAndDevelopmentRevenueMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_ResearchDevelopmentAndPatentExpense" xlink:href="ions-20250930.xsd#ions_ResearchDevelopmentAndPatentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ions_ResearchDevelopmentAndPatentExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostsAndExpenses" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InvestmentIncomeNet" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpense" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_InterestExpenseAndAmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties" xlink:href="ions-20250930.xsd#ions_InterestExpenseAndAmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ions_InterestExpenseAndAmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainLossOnInvestments" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="17" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://ionis.com/role/ConsolidatedComprehensiveIncome" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://ionis.com/role/ShareholdersEquityType2or3" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://ionis.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_Depreciation" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_RoyaltyPayments" xlink:href="ions-20250930.xsd#ions_RoyaltyPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="ions_RoyaltyPayments" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_InterestExpenseRelatedToSaleOfFutureRoyalties" xlink:href="ions-20250930.xsd#ions_InterestExpenseRelatedToSaleOfFutureRoyalties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="ions_InterestExpenseRelatedToSaleOfFutureRoyalties" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RealizedInvestmentGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_RealizedInvestmentGainsLosses" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerAsset" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherEmployeeRelatedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherEmployeeRelatedLiabilities" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfSecuredDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfSecuredDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_RepaymentsOfSecuredDebt" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_InterestPaidNet" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_CapitalAndPatentExpendituresIncurredButNotYetPaid" xlink:href="ions-20250930.xsd#ions_CapitalAndPatentExpendituresIncurredButNotYetPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="ions_CapitalAndPatentExpendituresIncurredButNotYetPaid" order="35" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://ionis.com/role/OrganizationandBasisofPresentation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://ionis.com/role/SignificantAccountingPolicies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://ionis.com/role/SupplementalFinancialData" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ions_SupplementalFinancialDataAbstract" xlink:href="ions-20250930.xsd#ions_SupplementalFinancialDataAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ions_SupplementalFinancialDataAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://ionis.com/role/Revenues" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://ionis.com/role/CollaborativeArrangementsandLicensingAgreements" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://ionis.com/role/BasicandDilutedNetLossPerShare" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://ionis.com/role/Investments" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentsAbstract" xlink:to="us-gaap_InvestmentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://ionis.com/role/FairValueMeasurements" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://ionis.com/role/StockbasedCompensationExpense" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://ionis.com/role/IncomeTaxes" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://ionis.com/role/LiabilityRelatedtoSaleofFutureRoyalties" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="us-gaap_OtherLiabilitiesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://ionis.com/role/ConvertibleDebt" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <loc xlink:type="locator" xlink:label="ions_ConvertibleNotesDisclosureTable" xlink:href="ions-20250930.xsd#ions_ConvertibleNotesDisclosureTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ions_ConvertibleNotesDisclosureTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://ionis.com/role/OperatingLeases" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://ionis.com/role/LegalProceedings" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LegalMattersAndContingenciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LegalMattersAndContingenciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://ionis.com/role/SegmentInformation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://ionis.com/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CostOfSalesPolicyTextBlock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://ionis.com/role/SupplementalFinancialDataTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ions_SupplementalFinancialDataAbstract" xlink:href="ions-20250930.xsd#ions_SupplementalFinancialDataAbstract"/>
    <loc xlink:type="locator" xlink:label="ions_ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock" xlink:href="ions-20250930.xsd#ions_ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ions_SupplementalFinancialDataAbstract" xlink:to="ions_ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ions_SupplementalFinancialDataAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://ionis.com/role/RevenuesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://ionis.com/role/CollaborativeArrangementsandLicensingAgreementsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_AstraZenecaCollaborationsMember" xlink:href="ions-20250930.xsd#ions_AstraZenecaCollaborationsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ions_AstraZenecaCollaborationsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_OnoCollaborationMember" xlink:href="ions-20250930.xsd#ions_OnoCollaborationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ions_OnoCollaborationMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://ionis.com/role/InvestmentsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentsAbstract" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentsAbstract" xlink:to="us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentsAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://ionis.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://ionis.com/role/StockbasedCompensationExpenseTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://ionis.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncurrentLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://ionis.com/role/ConvertibleDebtTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <loc xlink:type="locator" xlink:label="ions_ConvertibleNotesDisclosureTable" xlink:href="ions-20250930.xsd#ions_ConvertibleNotesDisclosureTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ions_ConvertibleNotesDisclosureTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ions_ConvertibleNotesDisclosureTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_ConvertibleSeniorNotes175PercentMember" xlink:href="ions-20250930.xsd#ions_ConvertibleSeniorNotes175PercentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="ions_ConvertibleSeniorNotes175PercentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_ConvertibleSeniorNotes0PercentMember" xlink:href="ions-20250930.xsd#ions_ConvertibleSeniorNotes0PercentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="ions_ConvertibleSeniorNotes0PercentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ConvertibleDebtTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://ionis.com/role/SegmentInformationTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://ionis.com/role/InventoriesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryCurrentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryCurrentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryCurrentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_InventoryCurrentTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentAssetsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_InventoryRawMaterialsNet" xlink:href="ions-20250930.xsd#ions_InventoryRawMaterialsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryLineItems" xlink:to="ions_InventoryRawMaterialsNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_InventoryWorkInProcessNet" xlink:href="ions-20250930.xsd#ions_InventoryWorkInProcessNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryLineItems" xlink:to="ions_InventoryWorkInProcessNet" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_InventoryFinishedGoodsNet" xlink:href="ions-20250930.xsd#ions_InventoryFinishedGoodsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryLineItems" xlink:to="ions_InventoryFinishedGoodsNet" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_InventoryCurrentAndNoncurrent" xlink:href="ions-20250930.xsd#ions_InventoryCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryLineItems" xlink:to="ions_InventoryCurrentAndNoncurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryNet" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryNoncurrent" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://ionis.com/role/AccruedLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="ions_AccruedClinicalExpenses" xlink:href="ions-20250930.xsd#ions_AccruedClinicalExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="ions_AccruedClinicalExpenses" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_AccruedInLicensingFeesCurrent" xlink:href="ions-20250930.xsd#ions_AccruedInLicensingFeesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="ions_AccruedInLicensingFeesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_AccruedCommercialExpensesCurrent" xlink:href="ions-20250930.xsd#ions_AccruedCommercialExpensesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="ions_AccruedCommercialExpensesCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://ionis.com/role/RevenuesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_TryngolzaMember" xlink:href="ions-20250930.xsd#ions_TryngolzaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ions_TryngolzaMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_SpinrazaRoyaltiesMember" xlink:href="ions-20250930.xsd#ions_SpinrazaRoyaltiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ions_SpinrazaRoyaltiesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_WainusRoyaltiesMember" xlink:href="ions-20250930.xsd#ions_WainusRoyaltiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ions_WainusRoyaltiesMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_OtherRoyaltiesMember" xlink:href="ions-20250930.xsd#ions_OtherRoyaltiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ions_OtherRoyaltiesMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RoyaltyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_OtherCommercialMember" xlink:href="ions-20250930.xsd#ions_OtherCommercialMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ions_OtherCommercialMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_CommercialMember" xlink:href="ions-20250930.xsd#ions_CommercialMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ions_CommercialMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_CollaborativeAgreementRevenueMember" xlink:href="ions-20250930.xsd#ions_CollaborativeAgreementRevenueMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ions_CollaborativeAgreementRevenueMember" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_WainuaJointDevelopmentRevenueMember" xlink:href="ions-20250930.xsd#ions_WainuaJointDevelopmentRevenueMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ions_WainuaJointDevelopmentRevenueMember" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_ResearchAndDevelopmentRevenueMember" xlink:href="ions-20250930.xsd#ions_ResearchAndDevelopmentRevenueMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ions_ResearchAndDevelopmentRevenueMember" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://ionis.com/role/RevenuefromCollaborativeRelationshipwithAstraZenecaTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_RevenueFromContractWithCustomerMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_AstraZenecaCollaborationsMember" xlink:href="ions-20250930.xsd#ions_AstraZenecaCollaborationsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ions_AstraZenecaCollaborationsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://ionis.com/role/RevenuefromCollaborativeRelationshipwithOnoTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_RevenueFromContractWithCustomerMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_OnoCollaborationMember" xlink:href="ions-20250930.xsd#ions_OnoCollaborationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ions_OnoCollaborationMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://ionis.com/role/SummaryofInvestmentsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USStatesAndPoliticalSubdivisionsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_OtherDebtSecuritiesMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_EquitySecuritiesPubliclyTradedCompaniesMember" xlink:href="ions-20250930.xsd#ions_EquitySecuritiesPubliclyTradedCompaniesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="ions_EquitySecuritiesPubliclyTradedCompaniesMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_EquitySecuritiesPrivateCompaniesMember" xlink:href="ions-20250930.xsd#ions_EquitySecuritiesPrivateCompaniesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="ions_EquitySecuritiesPrivateCompaniesMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:href="ions-20250930.xsd#ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:href="ions-20250930.xsd#ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" xlink:href="ions-20250930.xsd#ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" xlink:href="ions-20250930.xsd#ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesFvNiCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiCost" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_EquitySecuritiesFvNiAccumulatedGrossUnrealizedGain" xlink:href="ions-20250930.xsd#ions_EquitySecuritiesFvNiAccumulatedGrossUnrealizedGain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="ions_EquitySecuritiesFvNiAccumulatedGrossUnrealizedGain" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_EquitySecuritiesFvNiAccumulatedGrossUnrealizedLoss" xlink:href="ions-20250930.xsd#ions_EquitySecuritiesFvNiAccumulatedGrossUnrealizedLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="ions_EquitySecuritiesFvNiAccumulatedGrossUnrealizedLoss" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNi" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost" xlink:href="ions-20250930.xsd#ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain" xlink:href="ions-20250930.xsd#ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss" xlink:href="ions-20250930.xsd#ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi" xlink:href="ions-20250930.xsd#ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi" order="19" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://ionis.com/role/TemporarilyImpairedInvestmentsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_OtherDebtSecuritiesMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://ionis.com/role/FairValueMeasurementsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherCurrentAssetsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USStatesAndPoliticalSubdivisionsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_OtherDebtSecuritiesMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_EquitySecuritiesPubliclyTradedCompaniesMember" xlink:href="ions-20250930.xsd#ions_EquitySecuritiesPubliclyTradedCompaniesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="ions_EquitySecuritiesPubliclyTradedCompaniesMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_EquitySecuritiesFvNi" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://ionis.com/role/StockbasedCompensationExpenseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfSalesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_ResearchDevelopmentAndPatentExpensesMember" xlink:href="ions-20250930.xsd#ions_ResearchDevelopmentAndPatentExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="ions_ResearchDevelopmentAndPatentExpensesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://ionis.com/role/WeightedAverageAssumptionsforStockOptionsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GranteeStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_GranteeStatusAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GranteeStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GranteeStatusDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_ShareBasedPaymentArrangementBoardOfDirectorMember" xlink:href="ions-20250930.xsd#ions_ShareBasedPaymentArrangementBoardOfDirectorMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="ions_ShareBasedPaymentArrangementBoardOfDirectorMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://ionis.com/role/WeightedAverageAssumptionsforESPPTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://ionis.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherCurrentLiabilitiesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_RoyaltyPurchaseAgreementMember" xlink:href="ions-20250930.xsd#ions_RoyaltyPurchaseAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ions_RoyaltyPurchaseAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_LiabilityRelatedToSaleOfFutureRoyaltiesNet" xlink:href="ions-20250930.xsd#ions_LiabilityRelatedToSaleOfFutureRoyaltiesNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ions_LiabilityRelatedToSaleOfFutureRoyaltiesNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_RoyaltyPayments" xlink:href="ions-20250930.xsd#ions_RoyaltyPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ions_RoyaltyPayments" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_InterestExpenseRelatedToSaleOfFutureRoyalties" xlink:href="ions-20250930.xsd#ions_InterestExpenseRelatedToSaleOfFutureRoyalties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ions_InterestExpenseRelatedToSaleOfFutureRoyalties" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_AmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties" xlink:href="ions-20250930.xsd#ions_AmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ions_AmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_LiabilityRelatedToSaleOfFutureRoyaltiesNetCurrent" xlink:href="ions-20250930.xsd#ions_LiabilityRelatedToSaleOfFutureRoyaltiesNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ions_LiabilityRelatedToSaleOfFutureRoyaltiesNetCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_LiabilityRelatedToSaleOfFutureRoyaltiesNetNoncurrent" xlink:href="ions-20250930.xsd#ions_LiabilityRelatedToSaleOfFutureRoyaltiesNetNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ions_LiabilityRelatedToSaleOfFutureRoyaltiesNetNoncurrent" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://ionis.com/role/175NotesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_ConvertibleSeniorNotes175PercentMember" xlink:href="ions-20250930.xsd#ions_ConvertibleSeniorNotes175PercentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="ions_ConvertibleSeniorNotes175PercentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_DebtInstrumentConvertibleSharesSubjectToConversion" xlink:href="ions-20250930.xsd#ions_DebtInstrumentConvertibleSharesSubjectToConversion"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ions_DebtInstrumentConvertibleSharesSubjectToConversion" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://ionis.com/role/0NotesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_ConvertibleSeniorNotes0PercentMember" xlink:href="ions-20250930.xsd#ions_ConvertibleSeniorNotes0PercentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="ions_ConvertibleSeniorNotes0PercentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_DebtInstrumentConvertibleConversionPriceIncludingCallSpread" xlink:href="ions-20250930.xsd#ions_DebtInstrumentConvertibleConversionPriceIncludingCallSpread"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ions_DebtInstrumentConvertibleConversionPriceIncludingCallSpread" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_DebtInstrumentConvertibleSharesSubjectToConversion" xlink:href="ions-20250930.xsd#ions_DebtInstrumentConvertibleSharesSubjectToConversion"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ions_DebtInstrumentConvertibleSharesSubjectToConversion" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://ionis.com/role/SegmentInformationTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_IonisOperationsMember" xlink:href="ions-20250930.xsd#ions_IonisOperationsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="ions_IonisOperationsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_DrugDiscoveryExpenses" xlink:href="ions-20250930.xsd#ions_DrugDiscoveryExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="ions_DrugDiscoveryExpenses" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_DrugDevelopmentExpenses" xlink:href="ions-20250930.xsd#ions_DrugDevelopmentExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="ions_DrugDevelopmentExpenses" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_MedicalAffairsExpenses" xlink:href="ions-20250930.xsd#ions_MedicalAffairsExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="ions_MedicalAffairsExpenses" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_ManufacturingAndDevelopmentChemistryExpenses" xlink:href="ions-20250930.xsd#ions_ManufacturingAndDevelopmentChemistryExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="ions_ManufacturingAndDevelopmentChemistryExpenses" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_ResearchAndDevelopmentSupportExpenses" xlink:href="ions-20250930.xsd#ions_ResearchAndDevelopmentSupportExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="ions_ResearchAndDevelopmentSupportExpenses" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingOtherItemAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingOtherItemAmount" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NetIncomeLoss" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://ionis.com/role/InvestmentsDetailsContractMaturityofAvailableforSaleSecurities" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ions_MaximumContractMaturityPeriodRange1" xlink:href="ions-20250930.xsd#ions_MaximumContractMaturityPeriodRange1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentsAbstract" xlink:to="ions_MaximumContractMaturityPeriodRange1" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage" xlink:href="ions-20250930.xsd#ions_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentsAbstract" xlink:to="ions_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_MaximumContractMaturityPeriodRange2" xlink:href="ions-20250930.xsd#ions_MaximumContractMaturityPeriodRange2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentsAbstract" xlink:to="ions_MaximumContractMaturityPeriodRange2" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage" xlink:href="ions-20250930.xsd#ions_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentsAbstract" xlink:to="ions_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_MaximumContractMaturityPeriodRange3" xlink:href="ions-20250930.xsd#ions_MaximumContractMaturityPeriodRange3"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentsAbstract" xlink:to="ions_MaximumContractMaturityPeriodRange3" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage" xlink:href="ions-20250930.xsd#ions_AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentsAbstract" xlink:to="ions_AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage" xlink:href="ions-20250930.xsd#ions_AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentsAbstract" xlink:to="ions_AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://ionis.com/role/OrganizationandBasisofPresentationDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://ionis.com/role/RevenuesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_AstraZenecaCollaborationWainuaMember" xlink:href="ions-20250930.xsd#ions_AstraZenecaCollaborationWainuaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ions_AstraZenecaCollaborationWainuaMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_UpfrontPaymentReceived" xlink:href="ions-20250930.xsd#ions_UpfrontPaymentReceived"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="ions_UpfrontPaymentReceived" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_NumberOfMaterialComponents" xlink:href="ions-20250930.xsd#ions_NumberOfMaterialComponents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="ions_NumberOfMaterialComponents" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" xlink:href="ions-20250930.xsd#ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_RevenueFromContractWithCustomerTransactionPrice" xlink:href="ions-20250930.xsd#ions_RevenueFromContractWithCustomerTransactionPrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="ions_RevenueFromContractWithCustomerTransactionPrice" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_PercentageOfCostsAssociatedWithOngoingGlobalPhase3DevelopmentProgramPaidByCollaborationPartner" xlink:href="ions-20250930.xsd#ions_PercentageOfCostsAssociatedWithOngoingGlobalPhase3DevelopmentProgramPaidByCollaborationPartner"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="ions_PercentageOfCostsAssociatedWithOngoingGlobalPhase3DevelopmentProgramPaidByCollaborationPartner" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://ionis.com/role/CollaborativeArrangementsandLicensingAgreementsDetailsAstraZeneca" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_AstraZenecaCollaborationsMember" xlink:href="ions-20250930.xsd#ions_AstraZenecaCollaborationsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ions_AstraZenecaCollaborationsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_AstraZenecaCollaborationWAINUAMember" xlink:href="ions-20250930.xsd#ions_AstraZenecaCollaborationWAINUAMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ions_AstraZenecaCollaborationWAINUAMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_AstraZenecaCollaborationCardiovascularRenalAndMetabolicDiseasesMember" xlink:href="ions-20250930.xsd#ions_AstraZenecaCollaborationCardiovascularRenalAndMetabolicDiseasesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ions_AstraZenecaCollaborationCardiovascularRenalAndMetabolicDiseasesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_NumberOfCollaborationAgreements" xlink:href="ions-20250930.xsd#ions_NumberOfCollaborationAgreements"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ions_NumberOfCollaborationAgreements" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_CumulativePaymentsReceived" xlink:href="ions-20250930.xsd#ions_CumulativePaymentsReceived"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ions_CumulativePaymentsReceived" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_NextPaymentToBeAchieved" xlink:href="ions-20250930.xsd#ions_NextPaymentToBeAchieved"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ions_NextPaymentToBeAchieved" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://ionis.com/role/CollaborativeArrangementsandLicensingAgreementsDetailsOno" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_ResearchAndDevelopmentServicesForSapablursenMember" xlink:href="ions-20250930.xsd#ions_ResearchAndDevelopmentServicesForSapablursenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ions_ResearchAndDevelopmentServicesForSapablursenMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_LicenseOfSapablursenMember" xlink:href="ions-20250930.xsd#ions_LicenseOfSapablursenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ions_LicenseOfSapablursenMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_OnoCollaborationMember" xlink:href="ions-20250930.xsd#ions_OnoCollaborationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ions_OnoCollaborationMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_MaximumAmountOfPaymentsReceivableOverTermOfCollaboration" xlink:href="ions-20250930.xsd#ions_MaximumAmountOfPaymentsReceivableOverTermOfCollaboration"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ions_MaximumAmountOfPaymentsReceivableOverTermOfCollaboration" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_MaximumAmountOfUpfrontPaymentsOverTermOfCollaboration" xlink:href="ions-20250930.xsd#ions_MaximumAmountOfUpfrontPaymentsOverTermOfCollaboration"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ions_MaximumAmountOfUpfrontPaymentsOverTermOfCollaboration" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_MaximumAmountOfDevelopmentMilestonePaymentsOverTermOfCollaboration" xlink:href="ions-20250930.xsd#ions_MaximumAmountOfDevelopmentMilestonePaymentsOverTermOfCollaboration"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ions_MaximumAmountOfDevelopmentMilestonePaymentsOverTermOfCollaboration" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_MaximumAmountOfRegulatoryMilestonePaymentsOverTermOfCollaboration" xlink:href="ions-20250930.xsd#ions_MaximumAmountOfRegulatoryMilestonePaymentsOverTermOfCollaboration"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ions_MaximumAmountOfRegulatoryMilestonePaymentsOverTermOfCollaboration" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_MaximumAmountOfSalesMilestonePaymentsOverTermOfCollaboration" xlink:href="ions-20250930.xsd#ions_MaximumAmountOfSalesMilestonePaymentsOverTermOfCollaboration"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ions_MaximumAmountOfSalesMilestonePaymentsOverTermOfCollaboration" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_CumulativePaymentsReceived" xlink:href="ions-20250930.xsd#ions_CumulativePaymentsReceived"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ions_CumulativePaymentsReceived" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_NextPaymentToBeAchieved" xlink:href="ions-20250930.xsd#ions_NextPaymentToBeAchieved"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ions_NextPaymentToBeAchieved" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_NumberOfPerformanceObligationsIdentified" xlink:href="ions-20250930.xsd#ions_NumberOfPerformanceObligationsIdentified"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ions_NumberOfPerformanceObligationsIdentified" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_RevenueFromContractWithCustomerTransactionPrice" xlink:href="ions-20250930.xsd#ions_RevenueFromContractWithCustomerTransactionPrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ions_RevenueFromContractWithCustomerTransactionPrice" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://ionis.com/role/BasicandDilutedNetLossPerShareDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_ConvertibleSeniorNotes175PercentMember" xlink:href="ions-20250930.xsd#ions_ConvertibleSeniorNotes175PercentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="ions_ConvertibleSeniorNotes175PercentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_ConvertibleSeniorNotes0PercentMember" xlink:href="ions-20250930.xsd#ions_ConvertibleSeniorNotes0PercentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="ions_ConvertibleSeniorNotes0PercentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_ConvertibleSeniorNotes0125PercentMember" xlink:href="ions-20250930.xsd#ions_ConvertibleSeniorNotes0125PercentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="ions_ConvertibleSeniorNotes0125PercentMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://ionis.com/role/InvestmentsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_EquitySecuritiesPubliclyTradedCompaniesMember" xlink:href="ions-20250930.xsd#ions_EquitySecuritiesPubliclyTradedCompaniesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="ions_EquitySecuritiesPubliclyTradedCompaniesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_EquitySecuritiesPrivateCompaniesMember" xlink:href="ions-20250930.xsd#ions_EquitySecuritiesPrivateCompaniesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="ions_EquitySecuritiesPrivateCompaniesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage" xlink:href="ions-20250930.xsd#ions_AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="ions_AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_MaximumContractMaturityPeriodRange2" xlink:href="ions-20250930.xsd#ions_MaximumContractMaturityPeriodRange2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="ions_MaximumContractMaturityPeriodRange2" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment" xlink:href="ions-20250930.xsd#ions_NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="ions_NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment" xlink:href="ions-20250930.xsd#ions_NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="ions_NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedLoss" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGain" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://ionis.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_DebtInstrumentAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_CashAndCashEquivalentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_ConvertibleSeniorNotes175PercentMember" xlink:href="ions-20250930.xsd#ions_ConvertibleSeniorNotes175PercentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="ions_ConvertibleSeniorNotes175PercentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_ConvertibleSeniorNotes0PercentMember" xlink:href="ions-20250930.xsd#ions_ConvertibleSeniorNotes0PercentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="ions_ConvertibleSeniorNotes0PercentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_NotesPayableFairValueDisclosure" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://ionis.com/role/StockbasedCompensationExpenseDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GranteeStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_GranteeStatusAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GranteeStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GranteeStatusDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardDateAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PerformanceSharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ExecutiveOfficerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="srt_ExecutiveOfficerMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_GrantedIn2025Member" xlink:href="ions-20250930.xsd#ions_GrantedIn2025Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="ions_GrantedIn2025Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_GrantedIn2024Member" xlink:href="ions-20250930.xsd#ions_GrantedIn2024Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="ions_GrantedIn2024Member" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfUnitsGuaranteedToVest" xlink:href="ions-20250930.xsd#ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfUnitsGuaranteedToVest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfUnitsGuaranteedToVest" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfUnitsGuaranteedToVest" xlink:href="ions-20250930.xsd#ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfUnitsGuaranteedToVest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfUnitsGuaranteedToVest" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://ionis.com/role/IncomeTaxesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://ionis.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_SpinrazaMember" xlink:href="ions-20250930.xsd#ions_SpinrazaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ions_SpinrazaMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_PelacarsenMember" xlink:href="ions-20250930.xsd#ions_PelacarsenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ions_PelacarsenMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_RoyaltyPurchaseAgreementMember" xlink:href="ions-20250930.xsd#ions_RoyaltyPurchaseAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ions_RoyaltyPurchaseAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_UpfrontRoyaltyPaymentReceived" xlink:href="ions-20250930.xsd#ions_UpfrontRoyaltyPaymentReceived"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ions_UpfrontRoyaltyPaymentReceived" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_MaximumAmountOfPaymentsReceivableForAdditionalMilestones" xlink:href="ions-20250930.xsd#ions_MaximumAmountOfPaymentsReceivableForAdditionalMilestones"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ions_MaximumAmountOfPaymentsReceivableForAdditionalMilestones" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_PercentageOfRoyaltyPaymentsPaidOnAnnualSalesOfMedicine" xlink:href="ions-20250930.xsd#ions_PercentageOfRoyaltyPaymentsPaidOnAnnualSalesOfMedicine"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ions_PercentageOfRoyaltyPaymentsPaidOnAnnualSalesOfMedicine" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_MaximumAmountOfAnnualSalesOnWhichRoyaltyPaymentsArePaid" xlink:href="ions-20250930.xsd#ions_MaximumAmountOfAnnualSalesOnWhichRoyaltyPaymentsArePaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ions_MaximumAmountOfAnnualSalesOnWhichRoyaltyPaymentsArePaid" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_MaximumRoyaltyPaymentsMadeBeforeRoyaltyInterestRevertsBack" xlink:href="ions-20250930.xsd#ions_MaximumRoyaltyPaymentsMadeBeforeRoyaltyInterestRevertsBack"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ions_MaximumRoyaltyPaymentsMadeBeforeRoyaltyInterestRevertsBack" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_PaymentsForTransactionCostsRelatedToSaleOfFutureRoyalties" xlink:href="ions-20250930.xsd#ions_PaymentsForTransactionCostsRelatedToSaleOfFutureRoyalties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ions_PaymentsForTransactionCostsRelatedToSaleOfFutureRoyalties" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://ionis.com/role/ConvertibleDebtDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_ConvertibleSeniorNotes175PercentMember" xlink:href="ions-20250930.xsd#ions_ConvertibleSeniorNotes175PercentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="ions_ConvertibleSeniorNotes175PercentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_ConvertibleSeniorNotes0PercentMember" xlink:href="ions-20250930.xsd#ions_ConvertibleSeniorNotes0PercentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="ions_ConvertibleSeniorNotes0PercentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_DebtInstrumentConvertibleConversionPriceIncludingCallSpread" xlink:href="ions-20250930.xsd#ions_DebtInstrumentConvertibleConversionPriceIncludingCallSpread"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ions_DebtInstrumentConvertibleConversionPriceIncludingCallSpread" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_CallSpread" xlink:href="ions-20250930.xsd#ions_CallSpread"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ions_CallSpread" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForHedgeFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForHedgeFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_PaymentsForHedgeFinancingActivities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange" xlink:href="ions-20250930.xsd#ions_DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ions_DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://ionis.com/role/OperatingLeasesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_HeadquartersLocationInCarlsbadCaliforniaMember" xlink:href="ions-20250930.xsd#ions_HeadquartersLocationInCarlsbadCaliforniaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="ions_HeadquartersLocationInCarlsbadCaliforniaMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LandMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LandMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_NumberOfPurchaseAndSaleAgreementsEnteredIntoWithRealEstateInvestor" xlink:href="ions-20250930.xsd#ions_NumberOfPurchaseAndSaleAgreementsEnteredIntoWithRealEstateInvestor"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="ions_NumberOfPurchaseAndSaleAgreementsEnteredIntoWithRealEstateInvestor" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_LesseeOperatingLeaseNumberOfOptionsToExtendLease" xlink:href="ions-20250930.xsd#ions_LesseeOperatingLeaseNumberOfOptionsToExtendLease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="ions_LesseeOperatingLeaseNumberOfOptionsToExtendLease" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ions_NumberOfLotsOfUndevelopedLandTransferredToRealEstateInvestor" xlink:href="ions-20250930.xsd#ions_NumberOfLotsOfUndevelopedLandTransferredToRealEstateInvestor"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="ions_NumberOfLotsOfUndevelopedLandTransferredToRealEstateInvestor" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncentiveFromLessor" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncentiveFromLessor"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_IncentiveFromLessor" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleAndLeasebackTransactionGainLossNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleAndLeasebackTransactionGainLossNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_SaleAndLeasebackTransactionGainLossNet" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OtherLiabilities" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://ionis.com/role/SegmentInformationDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfReportableSegments" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingOtherItemCompositionDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemCompositionDescription"/>
<!-- [WMV6][hx0MoLzil4a/Uoi/LREN94a7pNeGl/AtmwSMka5TwzbQ9mafq1//t6ujnvK7K9jRc0MC2iN9ofVMu0OCEgF2yZkofDlPYLztXilIQaaUZM7vy2/ILoOHLxwFtiQy7SRSySNZZTN3GcZ+0fPuiD2rK38kCxjOGw1kqB1yZ55O64ajgZviz0gV8X9iK4cdP6kAHOsZtHKxJc2ZquWKEBkgyN7rl92en9/9q/ABt8FbOluh2/PmDxNQbxLwf4MrHbyWtgVv8G+hTPfpP3hYcwK1RichJvEdzmBzTR59zk3uy75skdTm8DrGUzC4l/4I6Xdh4G/lTYmg] CSR-->
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingOtherItemCompositionDescription" order="1" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>ions-20250930_lab.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION - LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Wed Oct 29 20:43:09 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">CONSOLIDATED BALANCE SHEETS [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&apos; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Balance at</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US">Balance at</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss before income tax benefit (expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">CONSOLIDATED STATEMENTS OF STOCKHOLDERS [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesIssued_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">CONSOLIDATED STATEMENTS OF CASH FLOWS [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents at beginning of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">Cash and cash equivalents at end of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization and Basis of Presentation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Significant Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_SupplementalFinancialDataAbstract" xlink:href="ions-20250930.xsd#ions_SupplementalFinancialDataAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_SupplementalFinancialDataAbstract_lbl" xml:lang="en-US">Supplemental Financial Data [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_SupplementalFinancialDataAbstract" xlink:to="ions_SupplementalFinancialDataAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNetAbstract_lbl" xml:lang="en-US">Inventory [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_InventoryCurrentAndNoncurrent" xlink:href="ions-20250930.xsd#ions_InventoryCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ions_InventoryCurrentAndNoncurrent_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_InventoryCurrentAndNoncurrent" xlink:to="ions_InventoryCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xml:lang="en-US">Statement of Financial Position Location, Balance [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Accrued Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Total accrued liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accrued liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xml:lang="en-US">Revenues [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl0" xml:lang="en-US">Revenue:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="ions_CollaborativeArrangementsAndLicensingAgreementsAbstract" xlink:href="ions-20250930.xsd#ions_CollaborativeArrangementsAndLicensingAgreementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_CollaborativeArrangementsAndLicensingAgreementsAbstract_lbl" xml:lang="en-US">Collaborative Arrangements and Licensing Agreements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_CollaborativeArrangementsAndLicensingAgreementsAbstract" xlink:to="ions_CollaborativeArrangementsAndLicensingAgreementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Basic and Diluted Net Loss Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsAbstract_lbl" xml:lang="en-US">Investments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsAbstract" xlink:to="us-gaap_InvestmentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US">Financial Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_lbl" xml:lang="en-US">Amortized cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_lbl" xml:lang="en-US">Amortized cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xml:lang="en-US">Amortized cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xml:lang="en-US">Gross unrealized gains</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xml:lang="en-US">Gross unrealized losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xml:lang="en-US">Estimated fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl0" xml:lang="en-US">Available-for-sale securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesFvNiCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EquitySecuritiesFvNiCost_lbl" xml:lang="en-US">Amortized cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNiCost" xlink:to="us-gaap_EquitySecuritiesFvNiCost_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost" xlink:href="ions-20250930.xsd#ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost_lbl" xml:lang="en-US">Amortized cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost" xlink:to="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain" xlink:href="ions-20250930.xsd#ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain_lbl" xml:lang="en-US">Gross unrealized gains</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain" xlink:to="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss" xlink:href="ions-20250930.xsd#ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss_lbl" xml:lang="en-US">Gross unrealized losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss" xlink:to="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi" xlink:href="ions-20250930.xsd#ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi_lbl" xml:lang="en-US">Estimated fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi" xlink:to="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl" xml:lang="en-US">Total temporary impairment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_lbl" xml:lang="en-US">Total temporary impairment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Measurements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US">Measurement Frequency [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Stock-based Compensation Expense [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Statement of Income Location, Balance [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_lbl" xml:lang="en-US">Total stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GranteeStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusAxis_lbl" xml:lang="en-US">Grantee Status [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Taxes [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract_lbl" xml:lang="en-US">Liability Related to Sale of Future Royalties [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="us-gaap_OtherLiabilitiesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_LiabilityRelatedToSaleOfFutureRoyaltiesNet" xlink:href="ions-20250930.xsd#ions_LiabilityRelatedToSaleOfFutureRoyaltiesNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ions_LiabilityRelatedToSaleOfFutureRoyaltiesNet_lbl" xml:lang="en-US">Liability related to sale of future royalties, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_LiabilityRelatedToSaleOfFutureRoyaltiesNet" xlink:to="ions_LiabilityRelatedToSaleOfFutureRoyaltiesNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ions_LiabilityRelatedToSaleOfFutureRoyaltiesNet_lbl0" xml:lang="en-US">Liability related to sale of future royalties, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_LiabilityRelatedToSaleOfFutureRoyaltiesNet" xlink:to="ions_LiabilityRelatedToSaleOfFutureRoyaltiesNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Convertible Debt [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US">Operating Leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Legal Proceedings [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">Segment Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xml:lang="en-US">Segments [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermInvestments_lbl" xml:lang="en-US">Short-term investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent_lbl" xml:lang="en-US">Contracts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetNetCurrent" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, plant and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Deposits and other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xml:lang="en-US">Income taxes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebtCurrent_lbl" xml:lang="en-US">0 percent convertible senior notes, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtCurrent" xlink:to="us-gaap_ConvertibleDebtCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Interest rate on convertible senior notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl0" xml:lang="en-US">Interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Current portion of deferred contract revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xml:lang="en-US">Long-term deferred contract revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebtNoncurrent_lbl" xml:lang="en-US">Convertible senior notes, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtNoncurrent" xlink:to="us-gaap_ConvertibleDebtNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_LiabilityRelatedToSaleOfFutureRoyaltiesNetNoncurrent" xlink:href="ions-20250930.xsd#ions_LiabilityRelatedToSaleOfFutureRoyaltiesNetNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_LiabilityRelatedToSaleOfFutureRoyaltiesNetNoncurrent_lbl" xml:lang="en-US">Liability related to sale of future royalties, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_LiabilityRelatedToSaleOfFutureRoyaltiesNetNoncurrent" xlink:to="ions_LiabilityRelatedToSaleOfFutureRoyaltiesNetNoncurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ions_LiabilityRelatedToSaleOfFutureRoyaltiesNetNoncurrent_lbl0" xml:lang="en-US">Liability related to sale of future royalties, net - Non-current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_LiabilityRelatedToSaleOfFutureRoyaltiesNetNoncurrent" xlink:to="ions_LiabilityRelatedToSaleOfFutureRoyaltiesNetNoncurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Long-term lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">Long-term obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; equity:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.001 par value; 300,000,000 shares authorized, 161,137,930 and 157,908,815 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US">Expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US">Cost of sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_ResearchDevelopmentAndPatentExpense" xlink:href="ions-20250930.xsd#ions_ResearchDevelopmentAndPatentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_ResearchDevelopmentAndPatentExpense_lbl" xml:lang="en-US">Research, development and patent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_ResearchDevelopmentAndPatentExpense" xlink:to="ions_ResearchDevelopmentAndPatentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, general and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expense):</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xml:lang="en-US">Investment income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNet" xlink:to="us-gaap_InvestmentIncomeNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainLossOnInvestments_lbl" xml:lang="en-US">Gain (loss) on investments, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnInvestments" xlink:to="us-gaap_GainLossOnInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other income, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic net loss per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Diluted net loss per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Shares used in computing basic net loss per share (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Shares used in computing diluted net loss per share (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US">Unrealized gains on debt securities, net of tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl0" xml:lang="en-US">Change in unrealized gains, net of tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US">Currency translation adjustment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl0" xml:lang="en-US">Foreign currency translation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_lbl" xml:lang="en-US">Issuance of common stock in connection with employee stock plans, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US">Issuance of common stock in connection with employee stock plans, net (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of public common stock, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of public common stock, net (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US">Amortization of right-of-use operating lease assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US">Amortization of debt issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_InterestExpenseRelatedToSaleOfFutureRoyalties" xlink:href="ions-20250930.xsd#ions_InterestExpenseRelatedToSaleOfFutureRoyalties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_InterestExpenseRelatedToSaleOfFutureRoyalties_lbl" xml:lang="en-US">Non-cash interest related to sale of future royalties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_InterestExpenseRelatedToSaleOfFutureRoyalties" xlink:to="ions_InterestExpenseRelatedToSaleOfFutureRoyalties_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ions_InterestExpenseRelatedToSaleOfFutureRoyalties_lbl0" xml:lang="en-US">Interest expense related to sale of future royalties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_InterestExpenseRelatedToSaleOfFutureRoyalties" xlink:to="ions_InterestExpenseRelatedToSaleOfFutureRoyalties_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xml:lang="en-US">Non-cash losses related to other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl" xml:lang="en-US">Income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherEmployeeRelatedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherEmployeeRelatedLiabilities_lbl" xml:lang="en-US">Accrued compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherEmployeeRelatedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xml:lang="en-US">Accrued liabilities and other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Deferred contract revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Investing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl" xml:lang="en-US">Proceeds from sale of short-term investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xml:lang="en-US">Proceeds from issuance of common stock through equity plans, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common stock in public offering, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Effects of exchange rates on cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosures of cash flow information:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Income taxes paid (refunds received), net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Supplemental disclosures of non-cash investing and financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_CapitalAndPatentExpendituresIncurredButNotYetPaid" xlink:href="ions-20250930.xsd#ions_CapitalAndPatentExpendituresIncurredButNotYetPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_CapitalAndPatentExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US">Amounts accrued for capital and patent expenditures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_CapitalAndPatentExpendituresIncurredButNotYetPaid" xlink:to="ions_CapitalAndPatentExpendituresIncurredButNotYetPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_InterestExpenseAndAmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties" xlink:href="ions-20250930.xsd#ions_InterestExpenseAndAmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ions_InterestExpenseAndAmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties_lbl" xml:lang="en-US">Interest expense related to sale of future royalties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_InterestExpenseAndAmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties" xlink:to="ions_InterestExpenseAndAmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax benefit (expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Income tax expense (benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xml:lang="en-US">Amortization of discount on investments, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_RoyaltyPayments" xlink:href="ions-20250930.xsd#ions_RoyaltyPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ions_RoyaltyPayments_lbl" xml:lang="en-US">Non-cash royalty revenue related to sale of royalties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_RoyaltyPayments" xlink:to="ions_RoyaltyPayments_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="ions_RoyaltyPayments_lbl0" xml:lang="en-US">Royalty payments to Royalty Pharma</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_RoyaltyPayments" xlink:to="ions_RoyaltyPayments_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RealizedInvestmentGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RealizedInvestmentGainsLosses_lbl" xml:lang="en-US">Loss (gain) on investments, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RealizedInvestmentGainsLosses" xlink:to="us-gaap_RealizedInvestmentGainsLosses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerAsset_lbl" xml:lang="en-US">Contracts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US">Other current and long-term assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xml:lang="en-US">Purchases of short-term investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Acquisition of licenses and other assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfSecuredDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfSecuredDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfSecuredDebt_lbl" xml:lang="en-US">Principal payments on mortgage debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfSecuredDebt" xlink:to="us-gaap_RepaymentsOfSecuredDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_ConvertibleSeniorNotes0PercentMember" xlink:href="ions-20250930.xsd#ions_ConvertibleSeniorNotes0PercentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_ConvertibleSeniorNotes0PercentMember_lbl" xml:lang="en-US">0 Percent Convertible Senior Notes [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_ConvertibleSeniorNotes0PercentMember" xlink:to="ions_ConvertibleSeniorNotes0PercentMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ions_ConvertibleSeniorNotes0PercentMember_lbl0" xml:lang="en-US">0% Notes [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_ConvertibleSeniorNotes0PercentMember" xlink:to="ions_ConvertibleSeniorNotes0PercentMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="ions_ConvertibleSeniorNotes175PercentMember" xlink:href="ions-20250930.xsd#ions_ConvertibleSeniorNotes175PercentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_ConvertibleSeniorNotes175PercentMember_lbl" xml:lang="en-US">1.75 Percent Convertible Senior Notes [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_ConvertibleSeniorNotes175PercentMember" xlink:to="ions_ConvertibleSeniorNotes175PercentMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ions_ConvertibleSeniorNotes175PercentMember_lbl0" xml:lang="en-US">1.75% Notes [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_ConvertibleSeniorNotes175PercentMember" xlink:to="ions_ConvertibleSeniorNotes175PercentMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US">Product Sales, Net [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RoyaltyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RoyaltyMember_lbl" xml:lang="en-US">Royalty Revenue [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyMember" xlink:to="us-gaap_RoyaltyMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RoyaltyMember_lbl0" xml:lang="en-US">Royalty [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyMember" xlink:to="us-gaap_RoyaltyMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="ions_OtherCommercialMember" xlink:href="ions-20250930.xsd#ions_OtherCommercialMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_OtherCommercialMember_lbl" xml:lang="en-US">Other Commercial Revenue [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_OtherCommercialMember" xlink:to="ions_OtherCommercialMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_CommercialMember" xlink:href="ions-20250930.xsd#ions_CommercialMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_CommercialMember_lbl" xml:lang="en-US">Commercial Revenue [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_CommercialMember" xlink:to="ions_CommercialMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_CollaborativeAgreementRevenueMember" xlink:href="ions-20250930.xsd#ions_CollaborativeAgreementRevenueMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_CollaborativeAgreementRevenueMember_lbl" xml:lang="en-US">Collaborative Agreement Revenue [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_CollaborativeAgreementRevenueMember" xlink:to="ions_CollaborativeAgreementRevenueMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_WainuaJointDevelopmentRevenueMember" xlink:href="ions-20250930.xsd#ions_WainuaJointDevelopmentRevenueMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_WainuaJointDevelopmentRevenueMember_lbl" xml:lang="en-US">WAINUA Joint Development Revenue [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_WainuaJointDevelopmentRevenueMember" xlink:to="ions_WainuaJointDevelopmentRevenueMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_ResearchAndDevelopmentRevenueMember" xlink:href="ions-20250930.xsd#ions_ResearchAndDevelopmentRevenueMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_ResearchAndDevelopmentRevenueMember_lbl" xml:lang="en-US">Research and Development Revenue [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_ResearchAndDevelopmentRevenueMember" xlink:to="ions_ResearchAndDevelopmentRevenueMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">Accumulated Other Comprehensive Loss [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Organization and Basis of Presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Significant Accounting Policies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xml:lang="en-US">Supplemental Financial Data</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock" xlink:href="ions-20250930.xsd#ions_ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock_lbl" xml:lang="en-US">Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock" xlink:to="ions_ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_InventoryRawMaterialsNet" xlink:href="ions-20250930.xsd#ions_InventoryRawMaterialsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_InventoryRawMaterialsNet_lbl" xml:lang="en-US">Raw materials</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_InventoryRawMaterialsNet" xlink:to="ions_InventoryRawMaterialsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_InventoryWorkInProcessNet" xlink:href="ions-20250930.xsd#ions_InventoryWorkInProcessNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_InventoryWorkInProcessNet_lbl" xml:lang="en-US">Work in process</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_InventoryWorkInProcessNet" xlink:to="ions_InventoryWorkInProcessNet_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_InventoryFinishedGoodsNet" xlink:href="ions-20250930.xsd#ions_InventoryFinishedGoodsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_InventoryFinishedGoodsNet_lbl" xml:lang="en-US">Finished goods</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_InventoryFinishedGoodsNet" xlink:to="ions_InventoryFinishedGoodsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_ReportedAsAbstract" xlink:href="ions-20250930.xsd#ions_ReportedAsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_ReportedAsAbstract_lbl" xml:lang="en-US">Reported as:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_ReportedAsAbstract" xlink:to="ions_ReportedAsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNoncurrent_lbl" xml:lang="en-US">Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNoncurrent" xlink:to="us-gaap_InventoryNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_AccruedClinicalExpenses" xlink:href="ions-20250930.xsd#ions_AccruedClinicalExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_AccruedClinicalExpenses_lbl" xml:lang="en-US">Clinical expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_AccruedClinicalExpenses" xlink:to="ions_AccruedClinicalExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_AccruedInLicensingFeesCurrent" xlink:href="ions-20250930.xsd#ions_AccruedInLicensingFeesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_AccruedInLicensingFeesCurrent_lbl" xml:lang="en-US">In-licensing expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_AccruedInLicensingFeesCurrent" xlink:to="ions_AccruedInLicensingFeesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_AccruedCommercialExpensesCurrent" xlink:href="ions-20250930.xsd#ions_AccruedCommercialExpensesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_AccruedCommercialExpensesCurrent_lbl" xml:lang="en-US">Commercial expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_AccruedCommercialExpensesCurrent" xlink:to="ions_AccruedCommercialExpensesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other miscellaneous expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisaggregationOfRevenueAbstract_lbl" xml:lang="en-US">Revenue:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueAbstract" xlink:to="us-gaap_DisaggregationOfRevenueAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US">Collaborative Arrangements and Licensing Agreements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xml:lang="en-US">Revenue from Collaborative Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Concentration percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Basic and Diluted Net Loss Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentTextBlock_lbl" xml:lang="en-US">Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTextBlock" xlink:to="us-gaap_InvestmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xml:lang="en-US">Contract Maturity of Available-for-Sale Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_lbl" xml:lang="en-US">Summary of Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:to="us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_lbl" xml:lang="en-US">Available-for-sale debt securities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:href="ions-20250930.xsd#ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_lbl" xml:lang="en-US">Gross unrealized gains</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:to="ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xml:lang="en-US">Estimated fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" xlink:href="ions-20250930.xsd#ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent_lbl" xml:lang="en-US">Gross unrealized gains</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" xlink:to="ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl" xml:lang="en-US">Estimated fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesFVNIAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFVNIAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquitySecuritiesFVNIAbstract_lbl" xml:lang="en-US">Equity securities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFVNIAbstract" xlink:to="us-gaap_EquitySecuritiesFVNIAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_EquitySecuritiesFvNiAccumulatedGrossUnrealizedGain" xlink:href="ions-20250930.xsd#ions_EquitySecuritiesFvNiAccumulatedGrossUnrealizedGain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_EquitySecuritiesFvNiAccumulatedGrossUnrealizedGain_lbl" xml:lang="en-US">Gross unrealized gains</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_EquitySecuritiesFvNiAccumulatedGrossUnrealizedGain" xlink:to="ions_EquitySecuritiesFvNiAccumulatedGrossUnrealizedGain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquitySecuritiesFvNi_lbl" xml:lang="en-US">Estimated fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNi" xlink:to="us-gaap_EquitySecuritiesFvNi_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EquitySecuritiesFvNi_lbl0" xml:lang="en-US">Equity securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNi" xlink:to="us-gaap_EquitySecuritiesFvNi_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_lbl" xml:lang="en-US">Temporarily Impaired Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_lbl" xml:lang="en-US">Number of investments (in Investment)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl" xml:lang="en-US">Less than 12 months of temporary impairment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl" xml:lang="en-US">More than 12 months of temporary impairment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US">Assets Measured at Fair Value on a Recurring Basis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US">Cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Stock-based Compensation Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Stock-based compensation expense, net of amounts capitalized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_lbl" xml:lang="en-US">Capitalized stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Weighted-Average Assumptions for Stock Options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xml:lang="en-US">Volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Weighted-Average Assumptions for ESPP</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">Liability Related to Sale of Future Royalties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_OtherLiabilitiesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncurrentLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Liability Related to Sale of Future Royalties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:to="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_AmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties" xlink:href="ions-20250930.xsd#ions_AmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_AmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties_lbl" xml:lang="en-US">Amortization of issuance costs related to sale of future royalties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_AmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties" xlink:to="ions_AmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Convertible Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebtTableTextBlock_lbl" xml:lang="en-US">Convertible Senior Notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtTableTextBlock" xlink:to="us-gaap_ConvertibleDebtTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Outstanding principal balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xml:lang="en-US">Unamortized debt issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US">Maturity date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US">Effective interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US">Conversion price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_DebtInstrumentConvertibleSharesSubjectToConversion" xlink:href="ions-20250930.xsd#ions_DebtInstrumentConvertibleSharesSubjectToConversion"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_DebtInstrumentConvertibleSharesSubjectToConversion_lbl" xml:lang="en-US">Total shares of common stock subject to conversion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_DebtInstrumentConvertibleSharesSubjectToConversion" xlink:to="ions_DebtInstrumentConvertibleSharesSubjectToConversion_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_DebtInstrumentConvertibleConversionPriceIncludingCallSpread" xlink:href="ions-20250930.xsd#ions_DebtInstrumentConvertibleConversionPriceIncludingCallSpread"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_DebtInstrumentConvertibleConversionPriceIncludingCallSpread_lbl" xml:lang="en-US">Effective conversion price per share with call spread</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_DebtInstrumentConvertibleConversionPriceIncludingCallSpread" xlink:to="ions_DebtInstrumentConvertibleConversionPriceIncludingCallSpread_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ions_DebtInstrumentConvertibleConversionPriceIncludingCallSpread_lbl0" xml:lang="en-US">Effective conversion price per share with call spread (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_DebtInstrumentConvertibleConversionPriceIncludingCallSpread" xlink:to="ions_DebtInstrumentConvertibleConversionPriceIncludingCallSpread_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">Operating Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LegalMattersAndContingenciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LegalMattersAndContingenciesTextBlock_lbl" xml:lang="en-US">Legal Proceedings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalMattersAndContingenciesTextBlock" xlink:to="us-gaap_LegalMattersAndContingenciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">Segment Information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US">Segment Information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_DrugDiscoveryExpenses" xlink:href="ions-20250930.xsd#ions_DrugDiscoveryExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_DrugDiscoveryExpenses_lbl" xml:lang="en-US">Drug discovery</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_DrugDiscoveryExpenses" xlink:to="ions_DrugDiscoveryExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_DrugDevelopmentExpenses" xlink:href="ions-20250930.xsd#ions_DrugDevelopmentExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_DrugDevelopmentExpenses_lbl" xml:lang="en-US">Drug development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_DrugDevelopmentExpenses" xlink:to="ions_DrugDevelopmentExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_MedicalAffairsExpenses" xlink:href="ions-20250930.xsd#ions_MedicalAffairsExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_MedicalAffairsExpenses_lbl" xml:lang="en-US">Medical affairs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_MedicalAffairsExpenses" xlink:to="ions_MedicalAffairsExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_ManufacturingAndDevelopmentChemistryExpenses" xlink:href="ions-20250930.xsd#ions_ManufacturingAndDevelopmentChemistryExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_ManufacturingAndDevelopmentChemistryExpenses_lbl" xml:lang="en-US">Manufacturing and development chemistry</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_ManufacturingAndDevelopmentChemistryExpenses" xlink:to="ions_ManufacturingAndDevelopmentChemistryExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_ResearchAndDevelopmentSupportExpenses" xlink:href="ions-20250930.xsd#ions_ResearchAndDevelopmentSupportExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_ResearchAndDevelopmentSupportExpenses_lbl" xml:lang="en-US">R&amp;D support</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_ResearchAndDevelopmentSupportExpenses" xlink:to="ions_ResearchAndDevelopmentSupportExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingOtherItemAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingOtherItemAmount_lbl" xml:lang="en-US">Other segment items</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingOtherItemAmount" xlink:to="us-gaap_SegmentReportingOtherItemAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:href="ions-20250930.xsd#ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_lbl" xml:lang="en-US">Gross unrealized losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:to="ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" xlink:href="ions-20250930.xsd#ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_lbl" xml:lang="en-US">Gross unrealized losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" xlink:to="ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_EquitySecuritiesFvNiAccumulatedGrossUnrealizedLoss" xlink:href="ions-20250930.xsd#ions_EquitySecuritiesFvNiAccumulatedGrossUnrealizedLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ions_EquitySecuritiesFvNiAccumulatedGrossUnrealizedLoss_lbl" xml:lang="en-US">Gross unrealized losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_EquitySecuritiesFvNiAccumulatedGrossUnrealizedLoss" xlink:to="ions_EquitySecuritiesFvNiAccumulatedGrossUnrealizedLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl" xml:lang="en-US">Less than 12 months of temporary impairment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl" xml:lang="en-US">More than 12 months of temporary impairment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_LiabilityRelatedToSaleOfFutureRoyaltiesNetCurrent" xlink:href="ions-20250930.xsd#ions_LiabilityRelatedToSaleOfFutureRoyaltiesNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ions_LiabilityRelatedToSaleOfFutureRoyaltiesNetCurrent_lbl" xml:lang="en-US">Less: Current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_LiabilityRelatedToSaleOfFutureRoyaltiesNetCurrent" xlink:to="ions_LiabilityRelatedToSaleOfFutureRoyaltiesNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNoncurrentAssetsMember_lbl" xml:lang="en-US">Deposits and Other Assets [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncurrentAssetsMember" xlink:to="us-gaap_OtherNoncurrentAssetsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_TryngolzaMember" xlink:href="ions-20250930.xsd#ions_TryngolzaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_TryngolzaMember_lbl" xml:lang="en-US">TRYNGOLZA Sales, Net [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_TryngolzaMember" xlink:to="ions_TryngolzaMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_SpinrazaRoyaltiesMember" xlink:href="ions-20250930.xsd#ions_SpinrazaRoyaltiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_SpinrazaRoyaltiesMember_lbl" xml:lang="en-US">SPINRAZA Royalties [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_SpinrazaRoyaltiesMember" xlink:to="ions_SpinrazaRoyaltiesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_WainusRoyaltiesMember" xlink:href="ions-20250930.xsd#ions_WainusRoyaltiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_WainusRoyaltiesMember_lbl" xml:lang="en-US">WAINUA Royalties [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_WainusRoyaltiesMember" xlink:to="ions_WainusRoyaltiesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_OtherRoyaltiesMember" xlink:href="ions-20250930.xsd#ions_OtherRoyaltiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_OtherRoyaltiesMember_lbl" xml:lang="en-US">Other Royalties [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_OtherRoyaltiesMember" xlink:to="ions_OtherRoyaltiesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_AstraZenecaCollaborationsMember" xlink:href="ions-20250930.xsd#ions_AstraZenecaCollaborationsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_AstraZenecaCollaborationsMember_lbl" xml:lang="en-US">AstraZeneca [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_AstraZenecaCollaborationsMember" xlink:to="ions_AstraZenecaCollaborationsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerMember_lbl" xml:lang="en-US">Revenue [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerMember" xlink:to="us-gaap_RevenueFromContractWithCustomerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US">Strategic Partner [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_OnoCollaborationMember" xlink:href="ions-20250930.xsd#ions_OnoCollaborationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_OnoCollaborationMember_lbl" xml:lang="en-US">Ono [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_OnoCollaborationMember" xlink:to="ions_OnoCollaborationMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xml:lang="en-US">Corporate Debt Securities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xml:lang="en-US">Debt Securities Issued by U.S. Government Agencies [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xml:lang="en-US">Debt Securities Issued by the U.S. Treasury [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_USStatesAndPoliticalSubdivisionsMember_lbl" xml:lang="en-US">Debt Securities Issued by States of the U.S. and Political Subdivisions of the States [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:to="us-gaap_USStatesAndPoliticalSubdivisionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherDebtSecuritiesMember_lbl" xml:lang="en-US">Other Municipal Debt Securities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherDebtSecuritiesMember" xlink:to="us-gaap_OtherDebtSecuritiesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_EquitySecuritiesPubliclyTradedCompaniesMember" xlink:href="ions-20250930.xsd#ions_EquitySecuritiesPubliclyTradedCompaniesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_EquitySecuritiesPubliclyTradedCompaniesMember_lbl" xml:lang="en-US">Publicly Traded Equity Securities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_EquitySecuritiesPubliclyTradedCompaniesMember" xlink:to="ions_EquitySecuritiesPubliclyTradedCompaniesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_EquitySecuritiesPrivateCompaniesMember" xlink:href="ions-20250930.xsd#ions_EquitySecuritiesPrivateCompaniesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_EquitySecuritiesPrivateCompaniesMember_lbl" xml:lang="en-US">Privately Held Equity Securities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_EquitySecuritiesPrivateCompaniesMember" xlink:to="ions_EquitySecuritiesPrivateCompaniesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherCurrentAssetsMember_lbl" xml:lang="en-US">Other Current Assets [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsMember" xlink:to="us-gaap_OtherCurrentAssetsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US">Recurring Basis [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Quoted Prices in Active Markets (Level 1) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Significant Other Observable Inputs (Level 2) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfSalesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfSalesMember_lbl" xml:lang="en-US">Cost of Sales [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesMember" xlink:to="us-gaap_CostOfSalesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_ResearchDevelopmentAndPatentExpensesMember" xlink:href="ions-20250930.xsd#ions_ResearchDevelopmentAndPatentExpensesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_ResearchDevelopmentAndPatentExpensesMember_lbl" xml:lang="en-US">Research, Development and Patent Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_ResearchDevelopmentAndPatentExpensesMember" xlink:to="ions_ResearchDevelopmentAndPatentExpensesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US">Selling, General and Administrative Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Stock Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl0" xml:lang="en-US">Stock Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xml:lang="en-US">Employee [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl0" xml:lang="en-US">Employees [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="ions_ShareBasedPaymentArrangementBoardOfDirectorMember" xlink:href="ions-20250930.xsd#ions_ShareBasedPaymentArrangementBoardOfDirectorMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_ShareBasedPaymentArrangementBoardOfDirectorMember_lbl" xml:lang="en-US">Board of Director [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_ShareBasedPaymentArrangementBoardOfDirectorMember" xlink:to="ions_ShareBasedPaymentArrangementBoardOfDirectorMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockMember_lbl" xml:lang="en-US">ESPP [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherCurrentLiabilitiesMember_lbl" xml:lang="en-US">Other Current Liabilities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentLiabilitiesMember" xlink:to="us-gaap_OtherCurrentLiabilitiesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_RoyaltyPurchaseAgreementMember" xlink:href="ions-20250930.xsd#ions_RoyaltyPurchaseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_RoyaltyPurchaseAgreementMember_lbl" xml:lang="en-US">Royalty Purchase Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_RoyaltyPurchaseAgreementMember" xlink:to="ions_RoyaltyPurchaseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_IonisOperationsMember" xlink:href="ions-20250930.xsd#ions_IonisOperationsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_IonisOperationsMember_lbl" xml:lang="en-US">Ionis Operations [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_IonisOperationsMember" xlink:to="ions_IonisOperationsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateAxis_lbl" xml:lang="en-US">Award Date [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_MaximumContractMaturityPeriodRange1" xlink:href="ions-20250930.xsd#ions_MaximumContractMaturityPeriodRange1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_MaximumContractMaturityPeriodRange1_lbl" xml:lang="en-US">Maximum contract maturity period, range 1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_MaximumContractMaturityPeriodRange1" xlink:to="ions_MaximumContractMaturityPeriodRange1_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage" xlink:href="ions-20250930.xsd#ions_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage_lbl" xml:lang="en-US">One year or less</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage" xlink:to="ions_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_MaximumContractMaturityPeriodRange2" xlink:href="ions-20250930.xsd#ions_MaximumContractMaturityPeriodRange2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_MaximumContractMaturityPeriodRange2_lbl" xml:lang="en-US">Maximum contract maturity period, range 2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_MaximumContractMaturityPeriodRange2" xlink:to="ions_MaximumContractMaturityPeriodRange2_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage" xlink:href="ions-20250930.xsd#ions_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage_lbl" xml:lang="en-US">After one year but within two years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage" xlink:to="ions_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_MaximumContractMaturityPeriodRange3" xlink:href="ions-20250930.xsd#ions_MaximumContractMaturityPeriodRange3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_MaximumContractMaturityPeriodRange3_lbl" xml:lang="en-US">Maximum contract maturity period, range 3</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_MaximumContractMaturityPeriodRange3" xlink:to="ions_MaximumContractMaturityPeriodRange3_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage" xlink:href="ions-20250930.xsd#ions_AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage_lbl" xml:lang="en-US">After two years but within three and a half years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage" xlink:to="ions_AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage" xlink:href="ions-20250930.xsd#ions_AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage" xlink:to="ions_AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Number of operating segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_UpfrontPaymentReceived" xlink:href="ions-20250930.xsd#ions_UpfrontPaymentReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_UpfrontPaymentReceived_lbl" xml:lang="en-US">Upfront payment received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_UpfrontPaymentReceived" xlink:to="ions_UpfrontPaymentReceived_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_NumberOfMaterialComponents" xlink:href="ions-20250930.xsd#ions_NumberOfMaterialComponents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_NumberOfMaterialComponents_lbl" xml:lang="en-US">Number of material components (in Component)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_NumberOfMaterialComponents" xlink:to="ions_NumberOfMaterialComponents_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" xlink:href="ions-20250930.xsd#ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations_lbl" xml:lang="en-US">Number of performance obligations (in PerformanceObligation)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" xlink:to="ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_RevenueFromContractWithCustomerTransactionPrice" xlink:href="ions-20250930.xsd#ions_RevenueFromContractWithCustomerTransactionPrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_RevenueFromContractWithCustomerTransactionPrice_lbl" xml:lang="en-US">Transaction price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_RevenueFromContractWithCustomerTransactionPrice" xlink:to="ions_RevenueFromContractWithCustomerTransactionPrice_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_PercentageOfCostsAssociatedWithOngoingGlobalPhase3DevelopmentProgramPaidByCollaborationPartner" xlink:href="ions-20250930.xsd#ions_PercentageOfCostsAssociatedWithOngoingGlobalPhase3DevelopmentProgramPaidByCollaborationPartner"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_PercentageOfCostsAssociatedWithOngoingGlobalPhase3DevelopmentProgramPaidByCollaborationPartner_lbl" xml:lang="en-US">Percentage of costs associated with ongoing global Phase 3 development program paid by AstraZeneca</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_PercentageOfCostsAssociatedWithOngoingGlobalPhase3DevelopmentProgramPaidByCollaborationPartner" xlink:to="ions_PercentageOfCostsAssociatedWithOngoingGlobalPhase3DevelopmentProgramPaidByCollaborationPartner_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_NumberOfCollaborationAgreements" xlink:href="ions-20250930.xsd#ions_NumberOfCollaborationAgreements"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_NumberOfCollaborationAgreements_lbl" xml:lang="en-US">Number of collaboration agreements (in Agreement)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_NumberOfCollaborationAgreements" xlink:to="ions_NumberOfCollaborationAgreements_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_CumulativePaymentsReceived" xlink:href="ions-20250930.xsd#ions_CumulativePaymentsReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_CumulativePaymentsReceived_lbl" xml:lang="en-US">Cumulative payments received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_CumulativePaymentsReceived" xlink:to="ions_CumulativePaymentsReceived_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_NextPaymentToBeAchieved" xlink:href="ions-20250930.xsd#ions_NextPaymentToBeAchieved"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_NextPaymentToBeAchieved_lbl" xml:lang="en-US">Next payment to be achieved</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_NextPaymentToBeAchieved" xlink:to="ions_NextPaymentToBeAchieved_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xml:lang="en-US">Deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_MaximumAmountOfPaymentsReceivableOverTermOfCollaboration" xlink:href="ions-20250930.xsd#ions_MaximumAmountOfPaymentsReceivableOverTermOfCollaboration"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_MaximumAmountOfPaymentsReceivableOverTermOfCollaboration_lbl" xml:lang="en-US">Maximum amount of payments receivable over term of collaboration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_MaximumAmountOfPaymentsReceivableOverTermOfCollaboration" xlink:to="ions_MaximumAmountOfPaymentsReceivableOverTermOfCollaboration_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_MaximumAmountOfUpfrontPaymentsOverTermOfCollaboration" xlink:href="ions-20250930.xsd#ions_MaximumAmountOfUpfrontPaymentsOverTermOfCollaboration"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_MaximumAmountOfUpfrontPaymentsOverTermOfCollaboration_lbl" xml:lang="en-US">Maximum amount of upfront payments over term of collaboration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_MaximumAmountOfUpfrontPaymentsOverTermOfCollaboration" xlink:to="ions_MaximumAmountOfUpfrontPaymentsOverTermOfCollaboration_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_MaximumAmountOfDevelopmentMilestonePaymentsOverTermOfCollaboration" xlink:href="ions-20250930.xsd#ions_MaximumAmountOfDevelopmentMilestonePaymentsOverTermOfCollaboration"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_MaximumAmountOfDevelopmentMilestonePaymentsOverTermOfCollaboration_lbl" xml:lang="en-US">Maximum amount of development milestone payments over term of collaboration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_MaximumAmountOfDevelopmentMilestonePaymentsOverTermOfCollaboration" xlink:to="ions_MaximumAmountOfDevelopmentMilestonePaymentsOverTermOfCollaboration_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_MaximumAmountOfRegulatoryMilestonePaymentsOverTermOfCollaboration" xlink:href="ions-20250930.xsd#ions_MaximumAmountOfRegulatoryMilestonePaymentsOverTermOfCollaboration"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_MaximumAmountOfRegulatoryMilestonePaymentsOverTermOfCollaboration_lbl" xml:lang="en-US">Maximum amount of regulatory milestone payments over term of collaboration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_MaximumAmountOfRegulatoryMilestonePaymentsOverTermOfCollaboration" xlink:to="ions_MaximumAmountOfRegulatoryMilestonePaymentsOverTermOfCollaboration_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_MaximumAmountOfSalesMilestonePaymentsOverTermOfCollaboration" xlink:href="ions-20250930.xsd#ions_MaximumAmountOfSalesMilestonePaymentsOverTermOfCollaboration"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_MaximumAmountOfSalesMilestonePaymentsOverTermOfCollaboration_lbl" xml:lang="en-US">Maximum amount of sales milestone payments over term of collaboration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_MaximumAmountOfSalesMilestonePaymentsOverTermOfCollaboration" xlink:to="ions_MaximumAmountOfSalesMilestonePaymentsOverTermOfCollaboration_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_NumberOfPerformanceObligationsIdentified" xlink:href="ions-20250930.xsd#ions_NumberOfPerformanceObligationsIdentified"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_NumberOfPerformanceObligationsIdentified_lbl" xml:lang="en-US">Number of performance obligations identified (in PerformanceObligation)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_NumberOfPerformanceObligationsIdentified" xlink:to="ions_NumberOfPerformanceObligationsIdentified_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage" xlink:href="ions-20250930.xsd#ions_AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage_lbl" xml:lang="en-US">Percentage of available-for-sale securities with a maturity of less than two years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage" xlink:to="ions_AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment" xlink:href="ions-20250930.xsd#ions_NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment_lbl" xml:lang="en-US">Number of private companies in which there is an equity ownership interest of less than 20% (in Company)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment" xlink:to="ions_NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment" xlink:href="ions-20250930.xsd#ions_NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment_lbl" xml:lang="en-US">Number of public companies in which there is an equity ownership interest of less than 20% (in Company)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment" xlink:to="ions_NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedLoss_lbl" xml:lang="en-US">Unrealized loss on equity securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_lbl" xml:lang="en-US">Unrealized net gain on equity securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGain_lbl" xml:lang="en-US">Unrealized gain on equity securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesPayableFairValueDisclosure_lbl" xml:lang="en-US">Convertible notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableFairValueDisclosure" xlink:to="us-gaap_NotesPayableFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Unrecognized compensation expense related to non-vested stock options (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US">Unrecognized compensation cost related to non-vested units (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Weighted average period for recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average grant date fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Vesting period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfUnitsGuaranteedToVest" xlink:href="ions-20250930.xsd#ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfUnitsGuaranteedToVest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfUnitsGuaranteedToVest_lbl" xml:lang="en-US">Number of units guaranteed to vest (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfUnitsGuaranteedToVest" xlink:to="ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfUnitsGuaranteedToVest_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfUnitsGuaranteedToVest" xlink:href="ions-20250930.xsd#ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfUnitsGuaranteedToVest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfUnitsGuaranteedToVest_lbl" xml:lang="en-US">Percentage of units guaranteed to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfUnitsGuaranteedToVest" xlink:to="ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfUnitsGuaranteedToVest_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_UpfrontRoyaltyPaymentReceived" xlink:href="ions-20250930.xsd#ions_UpfrontRoyaltyPaymentReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_UpfrontRoyaltyPaymentReceived_lbl" xml:lang="en-US">Upfront payment received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_UpfrontRoyaltyPaymentReceived" xlink:to="ions_UpfrontRoyaltyPaymentReceived_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_MaximumAmountOfPaymentsReceivableForAdditionalMilestones" xlink:href="ions-20250930.xsd#ions_MaximumAmountOfPaymentsReceivableForAdditionalMilestones"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_MaximumAmountOfPaymentsReceivableForAdditionalMilestones_lbl" xml:lang="en-US">Maximum amount of payments receivable for additional milestones</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_MaximumAmountOfPaymentsReceivableForAdditionalMilestones" xlink:to="ions_MaximumAmountOfPaymentsReceivableForAdditionalMilestones_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_PercentageOfRoyaltyPaymentsPaidOnAnnualSalesOfMedicine" xlink:href="ions-20250930.xsd#ions_PercentageOfRoyaltyPaymentsPaidOnAnnualSalesOfMedicine"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_PercentageOfRoyaltyPaymentsPaidOnAnnualSalesOfMedicine_lbl" xml:lang="en-US">Percentage of royalty payments paid on annual sales of medicine</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_PercentageOfRoyaltyPaymentsPaidOnAnnualSalesOfMedicine" xlink:to="ions_PercentageOfRoyaltyPaymentsPaidOnAnnualSalesOfMedicine_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_MaximumAmountOfAnnualSalesOnWhichRoyaltyPaymentsArePaid" xlink:href="ions-20250930.xsd#ions_MaximumAmountOfAnnualSalesOnWhichRoyaltyPaymentsArePaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_MaximumAmountOfAnnualSalesOnWhichRoyaltyPaymentsArePaid_lbl" xml:lang="en-US">Maximum amount of annual sales on which royalty payments are paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_MaximumAmountOfAnnualSalesOnWhichRoyaltyPaymentsArePaid" xlink:to="ions_MaximumAmountOfAnnualSalesOnWhichRoyaltyPaymentsArePaid_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_MaximumRoyaltyPaymentsMadeBeforeRoyaltyInterestRevertsBack" xlink:href="ions-20250930.xsd#ions_MaximumRoyaltyPaymentsMadeBeforeRoyaltyInterestRevertsBack"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_MaximumRoyaltyPaymentsMadeBeforeRoyaltyInterestRevertsBack_lbl" xml:lang="en-US">Maximum royalty payments made before royalty interest reverts back</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_MaximumRoyaltyPaymentsMadeBeforeRoyaltyInterestRevertsBack" xlink:to="ions_MaximumRoyaltyPaymentsMadeBeforeRoyaltyInterestRevertsBack_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_PaymentsForTransactionCostsRelatedToSaleOfFutureRoyalties" xlink:href="ions-20250930.xsd#ions_PaymentsForTransactionCostsRelatedToSaleOfFutureRoyalties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_PaymentsForTransactionCostsRelatedToSaleOfFutureRoyalties_lbl" xml:lang="en-US">Transaction costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_PaymentsForTransactionCostsRelatedToSaleOfFutureRoyalties" xlink:to="ions_PaymentsForTransactionCostsRelatedToSaleOfFutureRoyalties_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Face amount of offering (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_CallSpread" xlink:href="ions-20250930.xsd#ions_CallSpread"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_CallSpread_lbl" xml:lang="en-US">Cost of call spread (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_CallSpread" xlink:to="ions_CallSpread_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForHedgeFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForHedgeFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForHedgeFinancingActivities_lbl" xml:lang="en-US">Purchase of note hedges (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForHedgeFinancingActivities" xlink:to="us-gaap_PaymentsForHedgeFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Proceeds from issuance of warrants (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange" xlink:href="ions-20250930.xsd#ions_DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange_lbl" xml:lang="en-US">Percentage of principal amount used as purchase price upon occurrence of fundamental change</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange" xlink:to="ions_DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_NumberOfPurchaseAndSaleAgreementsEnteredIntoWithRealEstateInvestor" xlink:href="ions-20250930.xsd#ions_NumberOfPurchaseAndSaleAgreementsEnteredIntoWithRealEstateInvestor"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_NumberOfPurchaseAndSaleAgreementsEnteredIntoWithRealEstateInvestor_lbl" xml:lang="en-US">Number of purchase and sale agreements entered into with real estate investor (in Agreement)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_NumberOfPurchaseAndSaleAgreementsEnteredIntoWithRealEstateInvestor" xlink:to="ions_NumberOfPurchaseAndSaleAgreementsEnteredIntoWithRealEstateInvestor_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Proceeds from sale of real estate assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US">Initial term of lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_LesseeOperatingLeaseNumberOfOptionsToExtendLease" xlink:href="ions-20250930.xsd#ions_LesseeOperatingLeaseNumberOfOptionsToExtendLease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_LesseeOperatingLeaseNumberOfOptionsToExtendLease_lbl" xml:lang="en-US">Number of options to extend lease (in Option)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_LesseeOperatingLeaseNumberOfOptionsToExtendLease" xlink:to="ions_LesseeOperatingLeaseNumberOfOptionsToExtendLease_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US">Term of lease extension</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_NumberOfLotsOfUndevelopedLandTransferredToRealEstateInvestor" xlink:href="ions-20250930.xsd#ions_NumberOfLotsOfUndevelopedLandTransferredToRealEstateInvestor"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_NumberOfLotsOfUndevelopedLandTransferredToRealEstateInvestor_lbl" xml:lang="en-US">Number of lots of undeveloped land transferred to real estate investor (in Lot)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_NumberOfLotsOfUndevelopedLandTransferredToRealEstateInvestor" xlink:to="ions_NumberOfLotsOfUndevelopedLandTransferredToRealEstateInvestor_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Lease payments to be made over initial term of lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncentiveFromLessor" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncentiveFromLessor"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncentiveFromLessor_lbl" xml:lang="en-US">Reimbursements from lessor for tenant improvements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncentiveFromLessor" xlink:to="us-gaap_IncentiveFromLessor_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleAndLeasebackTransactionGainLossNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleAndLeasebackTransactionGainLossNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleAndLeasebackTransactionGainLossNet_lbl" xml:lang="en-US">Gain on sale-leaseback transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleAndLeasebackTransactionGainLossNet" xlink:to="us-gaap_SaleAndLeasebackTransactionGainLossNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilities_lbl" xml:lang="en-US">Financial liability for sale-leaseback transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilities" xlink:to="us-gaap_OtherLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US">Number of reportable segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingOtherItemCompositionDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemCompositionDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingOtherItemCompositionDescription_lbl" xml:lang="en-US">Segment Reporting, Other Segment Item, Composition, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingOtherItemCompositionDescription" xlink:to="us-gaap_SegmentReportingOtherItemCompositionDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Consolidation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl" xml:lang="en-US">Cost of Sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Standards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Basic and Diluted Net Loss Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_AstraZenecaCollaborationWainuaMember" xlink:href="ions-20250930.xsd#ions_AstraZenecaCollaborationWainuaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_AstraZenecaCollaborationWainuaMember_lbl" xml:lang="en-US">WAINUA (Eplontersen) Collaboration with AstraZeneca [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_AstraZenecaCollaborationWainuaMember" xlink:to="ions_AstraZenecaCollaborationWainuaMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_AstraZenecaCollaborationWAINUAMember" xlink:href="ions-20250930.xsd#ions_AstraZenecaCollaborationWAINUAMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_AstraZenecaCollaborationWAINUAMember_lbl" xml:lang="en-US">WAINUA [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_AstraZenecaCollaborationWAINUAMember" xlink:to="ions_AstraZenecaCollaborationWAINUAMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_AstraZenecaCollaborationCardiovascularRenalAndMetabolicDiseasesMember" xlink:href="ions-20250930.xsd#ions_AstraZenecaCollaborationCardiovascularRenalAndMetabolicDiseasesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_AstraZenecaCollaborationCardiovascularRenalAndMetabolicDiseasesMember_lbl" xml:lang="en-US">Cardiovascular, Renal and Metabolic Diseases [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_AstraZenecaCollaborationCardiovascularRenalAndMetabolicDiseasesMember" xlink:to="ions_AstraZenecaCollaborationCardiovascularRenalAndMetabolicDiseasesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_ResearchAndDevelopmentServicesForSapablursenMember" xlink:href="ions-20250930.xsd#ions_ResearchAndDevelopmentServicesForSapablursenMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_ResearchAndDevelopmentServicesForSapablursenMember_lbl" xml:lang="en-US">R&amp;D Services for Sapablursen [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_ResearchAndDevelopmentServicesForSapablursenMember" xlink:to="ions_ResearchAndDevelopmentServicesForSapablursenMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_LicenseOfSapablursenMember" xlink:href="ions-20250930.xsd#ions_LicenseOfSapablursenMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_LicenseOfSapablursenMember_lbl" xml:lang="en-US">License of Sapablursen [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_LicenseOfSapablursenMember" xlink:to="ions_LicenseOfSapablursenMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_ConvertibleSeniorNotes0125PercentMember" xlink:href="ions-20250930.xsd#ions_ConvertibleSeniorNotes0125PercentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_ConvertibleSeniorNotes0125PercentMember_lbl" xml:lang="en-US">0.125% Notes [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_ConvertibleSeniorNotes0125PercentMember" xlink:to="ions_ConvertibleSeniorNotes0125PercentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsMember_lbl" xml:lang="en-US">Cash and Cash Equivalents [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsMember" xlink:to="us-gaap_CashAndCashEquivalentsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">RSUs [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PerformanceSharesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PerformanceSharesMember_lbl" xml:lang="en-US">PRSUs [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_lbl" xml:lang="en-US">Non-employee Directors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_GrantedIn2025Member" xlink:href="ions-20250930.xsd#ions_GrantedIn2025Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_GrantedIn2025Member_lbl" xml:lang="en-US">Granted in 2025 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_GrantedIn2025Member" xlink:to="ions_GrantedIn2025Member_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_GrantedIn2024Member" xlink:href="ions-20250930.xsd#ions_GrantedIn2024Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_GrantedIn2024Member_lbl" xml:lang="en-US">Granted in 2024 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_GrantedIn2024Member" xlink:to="ions_GrantedIn2024Member_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ExecutiveOfficerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ExecutiveOfficerMember_lbl" xml:lang="en-US">Executive Officers [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ExecutiveOfficerMember" xlink:to="srt_ExecutiveOfficerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_SpinrazaMember" xlink:href="ions-20250930.xsd#ions_SpinrazaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_SpinrazaMember_lbl" xml:lang="en-US">SPINRAZA [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_SpinrazaMember" xlink:to="ions_SpinrazaMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_PelacarsenMember" xlink:href="ions-20250930.xsd#ions_PelacarsenMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_PelacarsenMember_lbl" xml:lang="en-US">Pelacarsen [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_PelacarsenMember" xlink:to="ions_PelacarsenMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_HeadquartersLocationInCarlsbadCaliforniaMember" xlink:href="ions-20250930.xsd#ions_HeadquartersLocationInCarlsbadCaliforniaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ions_HeadquartersLocationInCarlsbadCaliforniaMember_lbl" xml:lang="en-US">Headquarters Location in Carlsbad, California [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_HeadquartersLocationInCarlsbadCaliforniaMember" xlink:to="ions_HeadquartersLocationInCarlsbadCaliforniaMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LandMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LandMember_lbl" xml:lang="en-US">Undeveloped Land in Carlsbad, California [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandMember" xlink:to="us-gaap_LandMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Product and Service [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangements and Licensing Agreements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ions_ConvertibleNotesDisclosureTable" xlink:href="ions-20250930.xsd#ions_ConvertibleNotesDisclosureTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_ConvertibleNotesDisclosureTable_lbl" xml:lang="en-US">Convertible Notes Disclosure [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_ConvertibleNotesDisclosureTable" xlink:to="ions_ConvertibleNotesDisclosureTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US">Convertible Debt [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xml:lang="en-US">Statement of Financial Position Location, Balance [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryCurrentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryCurrentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryCurrentTable_lbl" xml:lang="en-US">Inventory, Current [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryCurrentTable" xlink:to="us-gaap_InventoryCurrentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryLineItems_lbl" xml:lang="en-US">Inventory [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xml:lang="en-US">Disaggregation of Revenue [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xml:lang="en-US">Revenues [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xml:lang="en-US">Concentration Risk Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xml:lang="en-US">Concentration Risk Benchmark [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US">Financial Instruments [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_lbl" xml:lang="en-US">Debt Securities, Trading, and Equity Securities, FV-NI [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:to="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_lbl" xml:lang="en-US">Investments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xml:lang="en-US">Investments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US">Measurement Frequency [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US">Fair Value Measurements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Statement of Income Location, Balance [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Stock-based Compensation Expense [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GranteeStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusDomain_lbl" xml:lang="en-US">Grantee Status [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_GranteeStatusDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Award Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Stock-based Compensation Expense [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl0" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl0" xml:lang="en-US">Royalty Revenue Monetization [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentDomain_lbl" xml:lang="en-US">Segments [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentDomain" xlink:to="us-gaap_SegmentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xml:lang="en-US">Segment Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl" xml:lang="en-US">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicLineItems_lbl" xml:lang="en-US">Basic and Diluted Net Loss Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_EarningsPerShareBasicLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl0" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl0"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateDomain_lbl" xml:lang="en-US">Award Date [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateDomain" xlink:to="us-gaap_AwardDateDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US">Lessee, Lease, Description [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US">Operating Leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_AccruedClinicalExpenses_lbl0" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_AccruedClinicalExpenses" xlink:to="ions_AccruedClinicalExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_AccruedCommercialExpensesCurrent_lbl0" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for commercial expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_AccruedCommercialExpensesCurrent" xlink:to="ions_AccruedCommercialExpensesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_AccruedInLicensingFeesCurrent_lbl0" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for in-licensing fees under collaboration agreements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_AccruedInLicensingFeesCurrent" xlink:to="ions_AccruedInLicensingFeesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_AmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties_lbl0" xml:lang="en-US">Amount of amortization expense attributable to the sale of future royalties.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_AmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties" xlink:to="ions_AmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage_lbl0" xml:lang="en-US">The percentage of available-for-sale debt securities that mature beyond one year but within two years of the balance sheet date.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage" xlink:to="ions_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage_lbl0" xml:lang="en-US">The percentage of available-for-sale debt securities that mature beyond two years but within three and one-half years of the balance sheet date.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage" xlink:to="ions_AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage_lbl0" xml:lang="en-US">The aggregate percentage of all available-for-sale debt securities, regardless of maturity.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage" xlink:to="ions_AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage_lbl0" xml:lang="en-US">The percentage of available-for-sale debt securities that mature within one year of the balance sheet date.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage" xlink:to="ions_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage_lbl0" xml:lang="en-US">The percentage of available-for-sale debt securities that mature within two years of the balance sheet date.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage" xlink:to="ions_AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_CallSpread_lbl0" xml:lang="en-US">The net cash outflow from payments for hedge transactions and proceeds from the issuance of warrants. The call spread transaction was entered into to minimize the impact of potential economic dilution upon conversion of the 0.125% notes issued.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_CallSpread" xlink:to="ions_CallSpread_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_CapitalAndPatentExpendituresIncurredButNotYetPaid_lbl0" xml:lang="en-US">Future cash outflow to pay for purchases of fixed assets and patents that have occurred.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_CapitalAndPatentExpendituresIncurredButNotYetPaid" xlink:to="ions_CapitalAndPatentExpendituresIncurredButNotYetPaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_CumulativePaymentsReceived_lbl0" xml:lang="en-US">Cumulative amount of payments received under the collaboration agreement as of the end of the reporting period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_CumulativePaymentsReceived" xlink:to="ions_CumulativePaymentsReceived_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_DebtInstrumentConvertibleConversionPriceIncludingCallSpread_lbl1" xml:lang="en-US">The computed conversion price per share of the debt instrument based on the conversion feature embedded in the debt instrument and the impact of the purchased hedges in the call spread transaction.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_DebtInstrumentConvertibleConversionPriceIncludingCallSpread" xlink:to="ions_DebtInstrumentConvertibleConversionPriceIncludingCallSpread_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange_lbl0" xml:lang="en-US">The percentage of the principal amount of the notes to be purchased, plus accrued and unpaid interest, upon the occurrence of certain fundamental changes, as set forth in the indenture governing the convertible notes.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange" xlink:to="ions_DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_DebtInstrumentConvertibleSharesSubjectToConversion_lbl0" xml:lang="en-US">The number of shares of common stock subject to conversion if the debt was converted to equity.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_DebtInstrumentConvertibleSharesSubjectToConversion" xlink:to="ions_DebtInstrumentConvertibleSharesSubjectToConversion_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_lbl0" xml:lang="en-US">Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:to="ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent_lbl0" xml:lang="en-US">Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" xlink:to="ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_lbl0" xml:lang="en-US">Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:to="ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_lbl0" xml:lang="en-US">Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" xlink:to="ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi_lbl0" xml:lang="en-US">Total of (1) investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and (2) amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi" xlink:to="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost_lbl0" xml:lang="en-US">Total of (1) amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and (2) cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost" xlink:to="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain_lbl0" xml:lang="en-US">Total of (1) unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and (2) unrealized gain on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain" xlink:to="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss_lbl0" xml:lang="en-US">Total of (1) unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and (2) unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss" xlink:to="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_DrugDevelopmentExpenses_lbl0" xml:lang="en-US">Expenses related to drug development, including expenses for marketed medicines and those in Phase 3 development.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_DrugDevelopmentExpenses" xlink:to="ions_DrugDevelopmentExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_DrugDiscoveryExpenses_lbl0" xml:lang="en-US">Expenses related to drug discovery research and advancing the Company&apos;s core technology.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_DrugDiscoveryExpenses" xlink:to="ions_DrugDiscoveryExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_EquitySecuritiesFvNiAccumulatedGrossUnrealizedGain_lbl0" xml:lang="en-US">Accumulated amount of unrealized gain on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_EquitySecuritiesFvNiAccumulatedGrossUnrealizedGain" xlink:to="ions_EquitySecuritiesFvNiAccumulatedGrossUnrealizedGain_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_EquitySecuritiesFvNiAccumulatedGrossUnrealizedLoss_lbl0" xml:lang="en-US">Accumulated amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_EquitySecuritiesFvNiAccumulatedGrossUnrealizedLoss" xlink:to="ions_EquitySecuritiesFvNiAccumulatedGrossUnrealizedLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_InterestExpenseAndAmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties_lbl0" xml:lang="en-US">Amount of interest expense using the effective interest rate method and amortization of issuance costs related to the sale of future royalties.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_InterestExpenseAndAmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties" xlink:to="ions_InterestExpenseAndAmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_InterestExpenseRelatedToSaleOfFutureRoyalties_lbl1" xml:lang="en-US">Amount of interest expense using the effective interest rate method related to the sale of future royalties.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_InterestExpenseRelatedToSaleOfFutureRoyalties" xlink:to="ions_InterestExpenseRelatedToSaleOfFutureRoyalties_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_InventoryCurrentAndNoncurrent_lbl0" xml:lang="en-US">Amount of inventory after valuation and LIFO reserves.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_InventoryCurrentAndNoncurrent" xlink:to="ions_InventoryCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_InventoryFinishedGoodsNet_lbl0" xml:lang="en-US">Carrying amount, as of the balance sheet date, of merchandise or goods held by the company that are readily available for sale.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_InventoryFinishedGoodsNet" xlink:to="ions_InventoryFinishedGoodsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_InventoryRawMaterialsNet_lbl0" xml:lang="en-US">Amount, as of the balance sheet date, of unprocessed items to be consumed in the manufacturing or production process.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_InventoryRawMaterialsNet" xlink:to="ions_InventoryRawMaterialsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_InventoryWorkInProcessNet_lbl0" xml:lang="en-US">Carrying amount, as of the balance sheet date, of merchandise or goods which are partially completed.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_InventoryWorkInProcessNet" xlink:to="ions_InventoryWorkInProcessNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_LesseeOperatingLeaseNumberOfOptionsToExtendLease_lbl0" xml:lang="en-US">The number of options to extend the lease under the lessee&apos;s operating lease.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_LesseeOperatingLeaseNumberOfOptionsToExtendLease" xlink:to="ions_LesseeOperatingLeaseNumberOfOptionsToExtendLease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_LiabilityRelatedToSaleOfFutureRoyaltiesNet_lbl1" xml:lang="en-US">Amount, after accumulated amortization, of the unamortized liability related to the sale of future royalties, pursuant to a royalty purchase agreement, that the Company is entitled to receive under collaboration agreements with Biogen and Novartis. The balance will be amortized over the estimated life of the arrangement using the effective interest rate method.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_LiabilityRelatedToSaleOfFutureRoyaltiesNet" xlink:to="ions_LiabilityRelatedToSaleOfFutureRoyaltiesNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_LiabilityRelatedToSaleOfFutureRoyaltiesNetCurrent_lbl0" xml:lang="en-US">Amount, after accumulated amortization, of the unamortized liability related to the sale of future royalties, pursuant to a royalty purchase agreement, that the Company is entitled to receive under collaboration agreements with Biogen and Novartis. The balance will be amortized over the estimated life of the arrangement using the effective interest rate method. Used to reflect the current portion of the liability (due within one year or within the normal operating cycle if longer).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_LiabilityRelatedToSaleOfFutureRoyaltiesNetCurrent" xlink:to="ions_LiabilityRelatedToSaleOfFutureRoyaltiesNetCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_LiabilityRelatedToSaleOfFutureRoyaltiesNetNoncurrent_lbl1" xml:lang="en-US">Amount, after accumulated amortization, of the unamortized liability related to the sale of future royalties, pursuant to a royalty purchase agreement, that the Company is entitled to receive under collaboration agreements with Biogen and Novartis. The balance will be amortized over the estimated life of the arrangement using the effective interest rate method. Used to reflect the noncurrent portion of the liability (due after one year or beyond the operating cycle if longer).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_LiabilityRelatedToSaleOfFutureRoyaltiesNetNoncurrent" xlink:to="ions_LiabilityRelatedToSaleOfFutureRoyaltiesNetNoncurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_ManufacturingAndDevelopmentChemistryExpenses_lbl0" xml:lang="en-US">Expenses related to manufacturing and development chemistry for providing drug supplies to drug development and our collaboration partners, including personnel costs, specialized chemicals for oligonucleotide manufacturing, validation batches to support regulatory approvals, laboratory supplies and outside services.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_ManufacturingAndDevelopmentChemistryExpenses" xlink:to="ions_ManufacturingAndDevelopmentChemistryExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_MaximumAmountOfAnnualSalesOnWhichRoyaltyPaymentsArePaid_lbl0" xml:lang="en-US">The maximum amount of annual sales on which royalty payments are paid under the royalty purchase agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_MaximumAmountOfAnnualSalesOnWhichRoyaltyPaymentsArePaid" xlink:to="ions_MaximumAmountOfAnnualSalesOnWhichRoyaltyPaymentsArePaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_MaximumAmountOfDevelopmentMilestonePaymentsOverTermOfCollaboration_lbl0" xml:lang="en-US">The maximum amount of development milestone payments to be received over the term of the collaboration.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_MaximumAmountOfDevelopmentMilestonePaymentsOverTermOfCollaboration" xlink:to="ions_MaximumAmountOfDevelopmentMilestonePaymentsOverTermOfCollaboration_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_MaximumAmountOfPaymentsReceivableForAdditionalMilestones_lbl0" xml:lang="en-US">The maximum amount of payments receivable for additional milestones under the royalty purchase agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_MaximumAmountOfPaymentsReceivableForAdditionalMilestones" xlink:to="ions_MaximumAmountOfPaymentsReceivableForAdditionalMilestones_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_MaximumAmountOfPaymentsReceivableOverTermOfCollaboration_lbl0" xml:lang="en-US">The maximum amount of payments the Company is eligible to receive over the term of the collaboration.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_MaximumAmountOfPaymentsReceivableOverTermOfCollaboration" xlink:to="ions_MaximumAmountOfPaymentsReceivableOverTermOfCollaboration_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_MaximumAmountOfRegulatoryMilestonePaymentsOverTermOfCollaboration_lbl0" xml:lang="en-US">The maximum amount of regulatory milestone payments to be received over the term of the collaboration.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_MaximumAmountOfRegulatoryMilestonePaymentsOverTermOfCollaboration" xlink:to="ions_MaximumAmountOfRegulatoryMilestonePaymentsOverTermOfCollaboration_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_MaximumAmountOfSalesMilestonePaymentsOverTermOfCollaboration_lbl0" xml:lang="en-US">The maximum amount of sales milestone payments to be received over the term of the collaboration.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_MaximumAmountOfSalesMilestonePaymentsOverTermOfCollaboration" xlink:to="ions_MaximumAmountOfSalesMilestonePaymentsOverTermOfCollaboration_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_MaximumAmountOfUpfrontPaymentsOverTermOfCollaboration_lbl0" xml:lang="en-US">The maximum amount of upfront payments to be received over the term of the collaboration.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_MaximumAmountOfUpfrontPaymentsOverTermOfCollaboration" xlink:to="ions_MaximumAmountOfUpfrontPaymentsOverTermOfCollaboration_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_MaximumContractMaturityPeriodRange1_lbl0" xml:lang="en-US">The maximum contract maturity period for the first range of available-for-sale securities, in &apos;PnYnMnDTnHnMnS&apos; format, for example, &apos;P1Y5M13D&apos; represents the reported fact of one year, five months, and thirteen days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_MaximumContractMaturityPeriodRange1" xlink:to="ions_MaximumContractMaturityPeriodRange1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_MaximumContractMaturityPeriodRange2_lbl0" xml:lang="en-US">The maximum contract maturity period for the second range of available-for-sale securities, in &apos;PnYnMnDTnHnMnS&apos; format, for example, &apos;P1Y5M13D&apos; represents the reported fact of one year, five months, and thirteen days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_MaximumContractMaturityPeriodRange2" xlink:to="ions_MaximumContractMaturityPeriodRange2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_MaximumContractMaturityPeriodRange3_lbl0" xml:lang="en-US">The maximum contract maturity period for the third range of available-for-sale securities, in &apos;PnYnMnDTnHnMnS&apos; format, for example, &apos;P1Y5M13D&apos; represents the reported fact of one year, five months, and thirteen days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_MaximumContractMaturityPeriodRange3" xlink:to="ions_MaximumContractMaturityPeriodRange3_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_MaximumRoyaltyPaymentsMadeBeforeRoyaltyInterestRevertsBack_lbl0" xml:lang="en-US">Maximum royalty payments under the royalty purchase agreement made before royalty interest reverts back to the Company.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_MaximumRoyaltyPaymentsMadeBeforeRoyaltyInterestRevertsBack" xlink:to="ions_MaximumRoyaltyPaymentsMadeBeforeRoyaltyInterestRevertsBack_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_MedicalAffairsExpenses_lbl0" xml:lang="en-US">Expenses related to medical affairs for funding and coordinating investigator-sponsored trials, communicating scientific and clinical information to healthcare providers, medical professionals and patients, and managing publications.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_MedicalAffairsExpenses" xlink:to="ions_MedicalAffairsExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_NextPaymentToBeAchieved_lbl0" xml:lang="en-US">The next payment to be achieved under the collaboration agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_NextPaymentToBeAchieved" xlink:to="ions_NextPaymentToBeAchieved_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_NumberOfCollaborationAgreements_lbl0" xml:lang="en-US">The number of collaboration agreements with the collaboration partner.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_NumberOfCollaborationAgreements" xlink:to="ions_NumberOfCollaborationAgreements_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_NumberOfLotsOfUndevelopedLandTransferredToRealEstateInvestor_lbl0" xml:lang="en-US">Number of lots of undeveloped land adjacent to the Company&apos;s headquarters transferred to real estate investor.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_NumberOfLotsOfUndevelopedLandTransferredToRealEstateInvestor" xlink:to="ions_NumberOfLotsOfUndevelopedLandTransferredToRealEstateInvestor_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_NumberOfMaterialComponents_lbl0" xml:lang="en-US">The number of material components identified in the collaboration agreement under Accounting Standards Codification (ASC) 808, Collaborative Arrangements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_NumberOfMaterialComponents" xlink:to="ions_NumberOfMaterialComponents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_NumberOfPerformanceObligationsIdentified_lbl0" xml:lang="en-US">The number of performance obligations identified under the collaboration agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_NumberOfPerformanceObligationsIdentified" xlink:to="ions_NumberOfPerformanceObligationsIdentified_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment_lbl0" xml:lang="en-US">Number of privately-held companies, in which the entity has an equity ownership interest of less than 20%, with which it conducts business. These are accounted for under the cost method.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment" xlink:to="ions_NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment_lbl0" xml:lang="en-US">Number of publicly-held companies, in which the entity has an equity ownership interest of less than 20%, with which it conducts business. These are accounted for at fair value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment" xlink:to="ions_NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_NumberOfPurchaseAndSaleAgreementsEnteredIntoWithRealEstateInvestor_lbl0" xml:lang="en-US">Number of purchase and sale agreements entered into with a real estate investor.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_NumberOfPurchaseAndSaleAgreementsEnteredIntoWithRealEstateInvestor" xlink:to="ions_NumberOfPurchaseAndSaleAgreementsEnteredIntoWithRealEstateInvestor_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_PaymentsForTransactionCostsRelatedToSaleOfFutureRoyalties_lbl0" xml:lang="en-US">The cash outflow paid to third parties for transaction costs in connection with a monetization transaction of future SPINRAZA and pelacarsen royalties the Company is entitled to under collaboration and licensing agreements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_PaymentsForTransactionCostsRelatedToSaleOfFutureRoyalties" xlink:to="ions_PaymentsForTransactionCostsRelatedToSaleOfFutureRoyalties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_PercentageOfCostsAssociatedWithOngoingGlobalPhase3DevelopmentProgramPaidByCollaborationPartner_lbl0" xml:lang="en-US">Percentage of costs associated with the ongoing global Phase 3 development program paid by a collaboration partner under the collaboration agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_PercentageOfCostsAssociatedWithOngoingGlobalPhase3DevelopmentProgramPaidByCollaborationPartner" xlink:to="ions_PercentageOfCostsAssociatedWithOngoingGlobalPhase3DevelopmentProgramPaidByCollaborationPartner_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_PercentageOfRoyaltyPaymentsPaidOnAnnualSalesOfMedicine_lbl0" xml:lang="en-US">The percentage of royalty payments paid on annual sales of medicine.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_PercentageOfRoyaltyPaymentsPaidOnAnnualSalesOfMedicine" xlink:to="ions_PercentageOfRoyaltyPaymentsPaidOnAnnualSalesOfMedicine_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_ResearchAndDevelopmentSupportExpenses_lbl0" xml:lang="en-US">Expenses related to research and development support such as rent, repair and maintenance for buildings and equipment, utilities, depreciation of laboratory equipment and facilities, amortization of intellectual property, information technology costs, procurement costs and waste disposal costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_ResearchAndDevelopmentSupportExpenses" xlink:to="ions_ResearchAndDevelopmentSupportExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_ResearchDevelopmentAndPatentExpense_lbl0" xml:lang="en-US">The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity&apos;s use, during the reporting period charged to research and development projects. Also includes charges for amortization and write-downs of capitalized patent costs, as well as legal fees for patent litigation and patent defense.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_ResearchDevelopmentAndPatentExpense" xlink:to="ions_ResearchDevelopmentAndPatentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations_lbl0" xml:lang="en-US">The number of separate performance obligations under the collaboration agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" xlink:to="ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_RevenueFromContractWithCustomerTransactionPrice_lbl0" xml:lang="en-US">The amount of consideration the Company earned or is eligible to earn under the collaboration agreement, including any variable consideration.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_RevenueFromContractWithCustomerTransactionPrice" xlink:to="ions_RevenueFromContractWithCustomerTransactionPrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_RoyaltyPayments_lbl1" xml:lang="en-US">The amount of royalty payments made during the period under a royalty purchase agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_RoyaltyPayments" xlink:to="ions_RoyaltyPayments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process, and inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle including inventoried costs relating to long-term contracts or programs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock" xlink:to="ions_ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfUnitsGuaranteedToVest_lbl0" xml:lang="en-US">Number of units guaranteed to vest under share-based payment arrangement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfUnitsGuaranteedToVest" xlink:to="ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfUnitsGuaranteedToVest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfUnitsGuaranteedToVest_lbl0" xml:lang="en-US">Percentage of units guaranteed to vest under share-based payment arrangement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfUnitsGuaranteedToVest" xlink:to="ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfUnitsGuaranteedToVest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_UpfrontPaymentReceived_lbl0" xml:lang="en-US">The amount of upfront payments received during the period under the collaboration agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_UpfrontPaymentReceived" xlink:to="ions_UpfrontPaymentReceived_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_UpfrontRoyaltyPaymentReceived_lbl0" xml:lang="en-US">The amount of upfront payments received during the period under the royalty purchase agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_UpfrontRoyaltyPaymentReceived" xlink:to="ions_UpfrontRoyaltyPaymentReceived_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_AstraZenecaCollaborationCardiovascularRenalAndMetabolicDiseasesMember_lbl0" xml:lang="en-US">Collaboration agreement entered into with AstraZeneca PLC in July 2015 to discover and develop antisense therapies for treating cardiovascular and metabolic diseases primarily focused on targets in the kidney and renal diseases.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_AstraZenecaCollaborationCardiovascularRenalAndMetabolicDiseasesMember" xlink:to="ions_AstraZenecaCollaborationCardiovascularRenalAndMetabolicDiseasesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_AstraZenecaCollaborationWAINUAMember_lbl0" xml:lang="en-US">Collaboration agreement entered into with AstraZeneca PLC in December 2021 to develop and commercialize WAINUA. WAINUA (eplontersen), formerly known as IONIS-TTR-L and AKCEA-TTR-L, is a ligand-conjugated (LICA) investigational antisense medicine designed to reduce the production of transthyretin, or TTR protein, to treat all types of TTR amyloidosis (ATTR), a systemic, progressive and fatal disease.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_AstraZenecaCollaborationWAINUAMember" xlink:to="ions_AstraZenecaCollaborationWAINUAMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_AstraZenecaCollaborationWainuaMember_lbl0" xml:lang="en-US">Collaboration agreement entered into with AstraZeneca PLC in December 2021 to develop and commercialize WAINUA. WAINUA (eplontersen), formerly known as IONIS-TTR-L and AKCEA-TTR-L, is a ligand-conjugated (LICA) investigational antisense medicine designed to reduce the production of transthyretin, or TTR protein, to treat all types of TTR amyloidosis (ATTR), a systemic, progressive and fatal disease.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_AstraZenecaCollaborationWainuaMember" xlink:to="ions_AstraZenecaCollaborationWainuaMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_AstraZenecaCollaborationsMember_lbl0" xml:lang="en-US">Collaboration agreements entered into with AstraZeneca PLC.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_AstraZenecaCollaborationsMember" xlink:to="ions_AstraZenecaCollaborationsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_CollaborativeAgreementRevenueMember_lbl0" xml:lang="en-US">Revenue from research and development services performed under a collaborative agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_CollaborativeAgreementRevenueMember" xlink:to="ions_CollaborativeAgreementRevenueMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_CommercialMember_lbl0" xml:lang="en-US">Revenue from the sale of medicines commercially as well as licensing and royalty revenues from other medicines, including SPINRAZA..</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_CommercialMember" xlink:to="ions_CommercialMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_ConvertibleSeniorNotes0125PercentMember_lbl0" xml:lang="en-US">0.125 percent convertible senior notes due December 2024.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_ConvertibleSeniorNotes0125PercentMember" xlink:to="ions_ConvertibleSeniorNotes0125PercentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_ConvertibleSeniorNotes0PercentMember_lbl1" xml:lang="en-US">0 percent convertible senior notes due April 2026.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_ConvertibleSeniorNotes0PercentMember" xlink:to="ions_ConvertibleSeniorNotes0PercentMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_ConvertibleSeniorNotes175PercentMember_lbl1" xml:lang="en-US">1.75 percent convertible senior notes due June 2028.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_ConvertibleSeniorNotes175PercentMember" xlink:to="ions_ConvertibleSeniorNotes175PercentMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_EquitySecuritiesPrivateCompaniesMember_lbl0" xml:lang="en-US">Ownership interest or right to acquire or dispose of ownership interest in private corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_EquitySecuritiesPrivateCompaniesMember" xlink:to="ions_EquitySecuritiesPrivateCompaniesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_EquitySecuritiesPubliclyTradedCompaniesMember_lbl0" xml:lang="en-US">Ownership interest or right to acquire or dispose of ownership interest in publicly traded corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_EquitySecuritiesPubliclyTradedCompaniesMember" xlink:to="ions_EquitySecuritiesPubliclyTradedCompaniesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_GrantedIn2024Member_lbl0" xml:lang="en-US">Awards granted in 2024.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_GrantedIn2024Member" xlink:to="ions_GrantedIn2024Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_GrantedIn2025Member_lbl0" xml:lang="en-US">Awards granted in 2025.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_GrantedIn2025Member" xlink:to="ions_GrantedIn2025Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_HeadquartersLocationInCarlsbadCaliforniaMember_lbl0" xml:lang="en-US">Headquarters location located in Carlsbad, California.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_HeadquartersLocationInCarlsbadCaliforniaMember" xlink:to="ions_HeadquartersLocationInCarlsbadCaliforniaMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_IonisOperationsMember_lbl0" xml:lang="en-US">Operations focused on the research, development and commercialization of RNA-targeted medicines to bring better futures to people with serious diseases.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_IonisOperationsMember" xlink:to="ions_IonisOperationsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_LicenseOfSapablursenMember_lbl0" xml:lang="en-US">License of sapablursen, an investigational RNA-targeted medicine for polycythemia vera (PV), a rare and potentially life-threatening hematologic disease.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_LicenseOfSapablursenMember" xlink:to="ions_LicenseOfSapablursenMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_OnoCollaborationMember_lbl0" xml:lang="en-US">Collaboration agreement entered into with Ono Pharmaceutical, Ltd (Ono) in March 2025 to develop and commercialize sapablursen, an investigational RNA-targeted medicine for the potential treatment of polycythemia vera, a rare and potentially life-threatening hematologic disease.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_OnoCollaborationMember" xlink:to="ions_OnoCollaborationMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_OtherCommercialMember_lbl0" xml:lang="en-US">Revenue from the sale of other medicines commercially as well as licensing and royalty revenue from other medicines, including TEGSEDI and WAYLIVRA.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_OtherCommercialMember" xlink:to="ions_OtherCommercialMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_OtherRoyaltiesMember_lbl0" xml:lang="en-US">Revenue from other royalties excluding SPINRAZA and WAINUA.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_OtherRoyaltiesMember" xlink:to="ions_OtherRoyaltiesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_PelacarsenMember_lbl0" xml:lang="en-US">Pelacarsen, also known as IONIS-APO(a)-L, AKCEA-APO(a)-L, and TQJ230, is an investigational antisense medicine designed to reduce apolipoprotein(a) in the liver in patients suffering from high levels of the lipoprotein Lp(a).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_PelacarsenMember" xlink:to="ions_PelacarsenMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_ResearchAndDevelopmentRevenueMember_lbl0" xml:lang="en-US">Revenue from research and development services.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_ResearchAndDevelopmentRevenueMember" xlink:to="ions_ResearchAndDevelopmentRevenueMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_ResearchAndDevelopmentServicesForSapablursenMember_lbl0" xml:lang="en-US">Research and development (R&amp;D) services for sapablursen, an investigational RNA-targeted medicine for polycythemia vera (PV), a rare and potentially life-threatening hematologic disease.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_ResearchAndDevelopmentServicesForSapablursenMember" xlink:to="ions_ResearchAndDevelopmentServicesForSapablursenMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_ResearchDevelopmentAndPatentExpensesMember_lbl0" xml:lang="en-US">Primary financial statement caption encompassing research, development and patent expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_ResearchDevelopmentAndPatentExpensesMember" xlink:to="ions_ResearchDevelopmentAndPatentExpensesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_RoyaltyPurchaseAgreementMember_lbl0" xml:lang="en-US">In January 2023, the Company entered into a royalty purchase agreement with Royalty Pharma to monetize a portion of future SPINRAZA and pelacarsen royalties the Company is entitled to under arrangements with Biogen and Novartis, respectively.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_RoyaltyPurchaseAgreementMember" xlink:to="ions_RoyaltyPurchaseAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_ShareBasedPaymentArrangementBoardOfDirectorMember_lbl0" xml:lang="en-US">An arrangement whereby a member of the Board of Directors is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement, as a form of compensation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_ShareBasedPaymentArrangementBoardOfDirectorMember" xlink:to="ions_ShareBasedPaymentArrangementBoardOfDirectorMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_SpinrazaMember_lbl0" xml:lang="en-US">Nusinersen, marketed as Spinraza, is a medicine used in treating spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_SpinrazaMember" xlink:to="ions_SpinrazaMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_SpinrazaRoyaltiesMember_lbl0" xml:lang="en-US">Royalty revenues from the sale of SPINRAZA (nusinersen).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_SpinrazaRoyaltiesMember" xlink:to="ions_SpinrazaRoyaltiesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_TryngolzaMember_lbl0" xml:lang="en-US">TRYNGOLZA (olezarsen) is a medicine for the treatment of familial chylomicronemia syndrome, or FCS.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_TryngolzaMember" xlink:to="ions_TryngolzaMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_WainuaJointDevelopmentRevenueMember_lbl0" xml:lang="en-US">Joint development revenue for WAINUA (eplontersen).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_WainuaJointDevelopmentRevenueMember" xlink:to="ions_WainuaJointDevelopmentRevenueMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_WainusRoyaltiesMember_lbl0" xml:lang="en-US">Royalty revenues from the sale of WAINUA (eplontersen).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_WainusRoyaltiesMember" xlink:to="ions_WainusRoyaltiesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ions_ConvertibleNotesDisclosureTable_lbl0" xml:lang="en-US">Disclosure of information about convertible notes.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_ConvertibleNotesDisclosureTable" xlink:to="ions_ConvertibleNotesDisclosureTable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_CapitalAndPatentExpendituresIncurredButNotYetPaid_lbl1" xml:lang="en-US">Capital And Patent Expenditures Incurred But Not Yet Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_CapitalAndPatentExpendituresIncurredButNotYetPaid" xlink:to="ions_CapitalAndPatentExpendituresIncurredButNotYetPaid_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl0" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_ResearchDevelopmentAndPatentExpense_lbl1" xml:lang="en-US">Research Development And Patent Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_ResearchDevelopmentAndPatentExpense" xlink:to="ions_ResearchDevelopmentAndPatentExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_TryngolzaMember_lbl1" xml:lang="en-US">Tryngolza Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_TryngolzaMember" xlink:to="ions_TryngolzaMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl1" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtNoncurrent_lbl0" xml:lang="en-US">Convertible Debt, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtNoncurrent" xlink:to="us-gaap_ConvertibleDebtNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_ResearchAndDevelopmentRevenueMember_lbl1" xml:lang="en-US">Research And Development Revenue Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_ResearchAndDevelopmentRevenueMember" xlink:to="ions_ResearchAndDevelopmentRevenueMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl0" xml:lang="en-US">Other Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl0" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_InventoryRawMaterialsNet_lbl1" xml:lang="en-US">Inventory Raw Materials Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_InventoryRawMaterialsNet" xlink:to="ions_InventoryRawMaterialsNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl0" xml:lang="en-US">Lessee, Lease, Description [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent_lbl0" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetNetCurrent" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange_lbl1" xml:lang="en-US">Debt Instrument Convertible Percentage Of Principal Amount Used As Purchase Price Upon Occurrence Of Fundamental Change</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange" xlink:to="ions_DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentAssetsMember_lbl0" xml:lang="en-US">Other Current Assets [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsMember" xlink:to="us-gaap_OtherCurrentAssetsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_ResearchAndDevelopmentServicesForSapablursenMember_lbl1" xml:lang="en-US">Research And Development Services For Sapablursen Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_ResearchAndDevelopmentServicesForSapablursenMember" xlink:to="ions_ResearchAndDevelopmentServicesForSapablursenMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RealizedInvestmentGainsLosses_lbl0" xml:lang="en-US">Realized Investment Gains (Losses)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RealizedInvestmentGainsLosses" xlink:to="us-gaap_RealizedInvestmentGainsLosses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl0" xml:lang="en-US">Other Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl0" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncentiveFromLessor_lbl0" xml:lang="en-US">Incentive from Lessor</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncentiveFromLessor" xlink:to="us-gaap_IncentiveFromLessor_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_MaximumAmountOfUpfrontPaymentsOverTermOfCollaboration_lbl1" xml:lang="en-US">Maximum Amount Of Upfront Payments Over Term Of Collaboration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_MaximumAmountOfUpfrontPaymentsOverTermOfCollaboration" xlink:to="ions_MaximumAmountOfUpfrontPaymentsOverTermOfCollaboration_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl0" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_CommercialMember_lbl1" xml:lang="en-US">Commercial Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_CommercialMember" xlink:to="ions_CommercialMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_InventoryFinishedGoodsNet_lbl1" xml:lang="en-US">Inventory Finished Goods Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_InventoryFinishedGoodsNet" xlink:to="ions_InventoryFinishedGoodsNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_AmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties_lbl1" xml:lang="en-US">Amortization Of Issuance Costs Related To Sale Of Future Royalties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_AmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties" xlink:to="ions_AmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_RoyaltyPurchaseAgreementMember_lbl1" xml:lang="en-US">Royalty Purchase Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_RoyaltyPurchaseAgreementMember" xlink:to="ions_RoyaltyPurchaseAgreementMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl0" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_AccruedClinicalExpenses_lbl1" xml:lang="en-US">Accrued Clinical Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_AccruedClinicalExpenses" xlink:to="ions_AccruedClinicalExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl0" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl0" xml:lang="en-US">Debt Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_CallSpread_lbl1" xml:lang="en-US">Call Spread</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_CallSpread" xlink:to="ions_CallSpread_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentTextBlock_lbl0" xml:lang="en-US">Investment [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTextBlock" xlink:to="us-gaap_InvestmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_MaximumAmountOfDevelopmentMilestonePaymentsOverTermOfCollaboration_lbl1" xml:lang="en-US">Maximum Amount Of Development Milestone Payments Over Term Of Collaboration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_MaximumAmountOfDevelopmentMilestonePaymentsOverTermOfCollaboration" xlink:to="ions_MaximumAmountOfDevelopmentMilestonePaymentsOverTermOfCollaboration_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_ManufacturingAndDevelopmentChemistryExpenses_lbl1" xml:lang="en-US">Manufacturing And Development Chemistry Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_ManufacturingAndDevelopmentChemistryExpenses" xlink:to="ions_ManufacturingAndDevelopmentChemistryExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_lbl0" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, before Forfeiture</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl1" xml:lang="en-US">Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilities_lbl0" xml:lang="en-US">Other Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilities" xlink:to="us-gaap_OtherLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_CollaborativeAgreementRevenueMember_lbl1" xml:lang="en-US">Collaborative Agreement Revenue Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_CollaborativeAgreementRevenueMember" xlink:to="ions_CollaborativeAgreementRevenueMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl1" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_EquitySecuritiesPubliclyTradedCompaniesMember_lbl1" xml:lang="en-US">Equity Securities Publicly Traded Companies Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_EquitySecuritiesPubliclyTradedCompaniesMember" xlink:to="ions_EquitySecuritiesPubliclyTradedCompaniesMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_lbl0" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl0" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl0" xml:lang="en-US">Accrued Income Taxes, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_AstraZenecaCollaborationWainuaMember_lbl1" xml:lang="en-US">Astra Zeneca Collaboration Wainua Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_AstraZenecaCollaborationWainuaMember" xlink:to="ions_AstraZenecaCollaborationWainuaMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl0" xml:lang="en-US">Costs and Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_OtherCommercialMember_lbl1" xml:lang="en-US">Other Commercial Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_OtherCommercialMember" xlink:to="ions_OtherCommercialMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicLineItems_lbl0" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_EarningsPerShareBasicLineItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_UpfrontPaymentReceived_lbl1" xml:lang="en-US">Upfront Payment Received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_UpfrontPaymentReceived" xlink:to="ions_UpfrontPaymentReceived_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_DrugDevelopmentExpenses_lbl1" xml:lang="en-US">Drug Development Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_DrugDevelopmentExpenses" xlink:to="ions_DrugDevelopmentExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl0" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_NumberOfCollaborationAgreements_lbl1" xml:lang="en-US">Number Of Collaboration Agreements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_NumberOfCollaborationAgreements" xlink:to="ions_NumberOfCollaborationAgreements_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncurrentAssetsMember_lbl0" xml:lang="en-US">Other Noncurrent Assets [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncurrentAssetsMember" xlink:to="us-gaap_OtherNoncurrentAssetsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Other Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_MaximumContractMaturityPeriodRange3_lbl1" xml:lang="en-US">Maximum Contract Maturity Period Range3</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_MaximumContractMaturityPeriodRange3" xlink:to="ions_MaximumContractMaturityPeriodRange3_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_MaximumContractMaturityPeriodRange1_lbl1" xml:lang="en-US">Maximum Contract Maturity Period Range1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_MaximumContractMaturityPeriodRange1" xlink:to="ions_MaximumContractMaturityPeriodRange1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_MaximumContractMaturityPeriodRange2_lbl1" xml:lang="en-US">Maximum Contract Maturity Period Range2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_MaximumContractMaturityPeriodRange2" xlink:to="ions_MaximumContractMaturityPeriodRange2_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent_lbl1" xml:lang="en-US">Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" xlink:to="ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl0" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PerformanceSharesMember_lbl0" xml:lang="en-US">Performance Shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost_lbl1" xml:lang="en-US">Debt Securities Available For Sale And Equity Securities Fv Ni Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost" xlink:to="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_OnoCollaborationMember_lbl1" xml:lang="en-US">Ono Collaboration Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_OnoCollaborationMember" xlink:to="ions_OnoCollaborationMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfUnitsGuaranteedToVest_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Number Of Units Guaranteed To Vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfUnitsGuaranteedToVest" xlink:to="ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfUnitsGuaranteedToVest_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl0" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl0" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_AstraZenecaCollaborationsMember_lbl1" xml:lang="en-US">Astra Zeneca Collaborations Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_AstraZenecaCollaborationsMember" xlink:to="ions_AstraZenecaCollaborationsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnInvestments_lbl0" xml:lang="en-US">Gain (Loss) on Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnInvestments" xlink:to="us-gaap_GainLossOnInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage_lbl1" xml:lang="en-US">Available For Sale Securities Debt Maturities After Two Through Three And One Half Years Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage" xlink:to="ions_AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_lbl0" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_PaymentsForTransactionCostsRelatedToSaleOfFutureRoyalties_lbl1" xml:lang="en-US">Payments For Transaction Costs Related To Sale Of Future Royalties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_PaymentsForTransactionCostsRelatedToSaleOfFutureRoyalties" xlink:to="ions_PaymentsForTransactionCostsRelatedToSaleOfFutureRoyalties_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyMember_lbl1" xml:lang="en-US">Royalty [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyMember" xlink:to="us-gaap_RoyaltyMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleAndLeasebackTransactionGainLossNet_lbl0" xml:lang="en-US">Sale and Leaseback Transaction, Gain (Loss), Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleAndLeasebackTransactionGainLossNet" xlink:to="us-gaap_SaleAndLeasebackTransactionGainLossNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_LesseeOperatingLeaseNumberOfOptionsToExtendLease_lbl1" xml:lang="en-US">Lessee Operating Lease Number Of Options To Extend Lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_LesseeOperatingLeaseNumberOfOptionsToExtendLease" xlink:to="ions_LesseeOperatingLeaseNumberOfOptionsToExtendLease_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl0" xml:lang="en-US">Debt Securities, Available-for-Sale, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_GrantedIn2025Member_lbl1" xml:lang="en-US">Granted In2025 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_GrantedIn2025Member" xlink:to="ions_GrantedIn2025Member_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_EquitySecuritiesPrivateCompaniesMember_lbl1" xml:lang="en-US">Equity Securities Private Companies Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_EquitySecuritiesPrivateCompaniesMember" xlink:to="ions_EquitySecuritiesPrivateCompaniesMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Nonemployee [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl0" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock_lbl0" xml:lang="en-US">Other Liabilities Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_OtherLiabilitiesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage_lbl1" xml:lang="en-US">Available For Sale Securities Debt Maturities After One Through Two Years Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage" xlink:to="ions_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Other Noncurrent Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:to="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_MaximumAmountOfAnnualSalesOnWhichRoyaltyPaymentsArePaid_lbl1" xml:lang="en-US">Maximum Amount Of Annual Sales On Which Royalty Payments Are Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_MaximumAmountOfAnnualSalesOnWhichRoyaltyPaymentsArePaid" xlink:to="ions_MaximumAmountOfAnnualSalesOnWhichRoyaltyPaymentsArePaid_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage_lbl1" xml:lang="en-US">Available For Sale Securities Debt Maturities Within One Year Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage" xlink:to="ions_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_RoyaltyPayments_lbl2" xml:lang="en-US">Royalty Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_RoyaltyPayments" xlink:to="ions_RoyaltyPayments_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_MaximumAmountOfPaymentsReceivableForAdditionalMilestones_lbl1" xml:lang="en-US">Maximum Amount Of Payments Receivable For Additional Milestones</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_MaximumAmountOfPaymentsReceivableForAdditionalMilestones" xlink:to="ions_MaximumAmountOfPaymentsReceivableForAdditionalMilestones_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_GrantedIn2024Member_lbl1" xml:lang="en-US">Granted In2024 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_GrantedIn2024Member" xlink:to="ions_GrantedIn2024Member_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl0" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Periodic Reduction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl0" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_AstraZenecaCollaborationCardiovascularRenalAndMetabolicDiseasesMember_lbl1" xml:lang="en-US">Astra Zeneca Collaboration Cardiovascular Renal And Metabolic Diseases Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_AstraZenecaCollaborationCardiovascularRenalAndMetabolicDiseasesMember" xlink:to="ions_AstraZenecaCollaborationCardiovascularRenalAndMetabolicDiseasesMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US">Equity, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_LiabilityRelatedToSaleOfFutureRoyaltiesNetCurrent_lbl1" xml:lang="en-US">Liability Related To Sale Of Future Royalties Net Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_LiabilityRelatedToSaleOfFutureRoyaltiesNetCurrent" xlink:to="ions_LiabilityRelatedToSaleOfFutureRoyaltiesNetCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_PercentageOfRoyaltyPaymentsPaidOnAnnualSalesOfMedicine_lbl1" xml:lang="en-US">Percentage Of Royalty Payments Paid On Annual Sales Of Medicine</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_PercentageOfRoyaltyPaymentsPaidOnAnnualSalesOfMedicine" xlink:to="ions_PercentageOfRoyaltyPaymentsPaidOnAnnualSalesOfMedicine_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquitySecuritiesFvNiCost_lbl0" xml:lang="en-US">Equity Securities, FV-NI, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNiCost" xlink:to="us-gaap_EquitySecuritiesFvNiCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_AccruedCommercialExpensesCurrent_lbl1" xml:lang="en-US">Accrued Commercial Expenses Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_AccruedCommercialExpensesCurrent" xlink:to="ions_AccruedCommercialExpensesCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl0" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl0" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LandMember_lbl0" xml:lang="en-US">Land [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandMember" xlink:to="us-gaap_LandMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeNet_lbl0" xml:lang="en-US">Investment Income, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNet" xlink:to="us-gaap_InvestmentIncomeNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl0" xml:lang="en-US">Impairment of Intangible Assets, Finite-Lived</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl0" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl0" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_EquitySecuritiesFvNiAccumulatedGrossUnrealizedLoss_lbl1" xml:lang="en-US">Equity Securities Fv Ni Accumulated Gross Unrealized Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_EquitySecuritiesFvNiAccumulatedGrossUnrealizedLoss" xlink:to="ions_EquitySecuritiesFvNiAccumulatedGrossUnrealizedLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl0" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpenses_lbl0" xml:lang="en-US">Costs and Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl0" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquitySecuritiesFvNi_lbl1" xml:lang="en-US">Equity Securities, FV-NI, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNi" xlink:to="us-gaap_EquitySecuritiesFvNi_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage_lbl1" xml:lang="en-US">Available For Sale Securities Debt Maturities Total Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage" xlink:to="ions_AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash and Cash Equivalent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment_lbl1" xml:lang="en-US">Number Of Publicly Held Companies In Which Entity Has Equity Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment" xlink:to="ions_NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_UpfrontRoyaltyPaymentReceived_lbl1" xml:lang="en-US">Upfront Royalty Payment Received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_UpfrontRoyaltyPaymentReceived" xlink:to="ions_UpfrontRoyaltyPaymentReceived_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl0" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_MedicalAffairsExpenses_lbl1" xml:lang="en-US">Medical Affairs Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_MedicalAffairsExpenses" xlink:to="ions_MedicalAffairsExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtTableTextBlock_lbl0" xml:lang="en-US">Convertible Debt [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtTableTextBlock" xlink:to="us-gaap_ConvertibleDebtTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_AccruedInLicensingFeesCurrent_lbl1" xml:lang="en-US">Accrued In Licensing Fees Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_AccruedInLicensingFeesCurrent" xlink:to="ions_AccruedInLicensingFeesCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl0" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsMember_lbl0" xml:lang="en-US">Cash and Cash Equivalents [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsMember" xlink:to="us-gaap_CashAndCashEquivalentsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl0" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_MaximumAmountOfPaymentsReceivableOverTermOfCollaboration_lbl1" xml:lang="en-US">Maximum Amount Of Payments Receivable Over Term Of Collaboration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_MaximumAmountOfPaymentsReceivableOverTermOfCollaboration" xlink:to="ions_MaximumAmountOfPaymentsReceivableOverTermOfCollaboration_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl0" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_SpinrazaRoyaltiesMember_lbl1" xml:lang="en-US">Spinraza Royalties Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_SpinrazaRoyaltiesMember" xlink:to="ions_SpinrazaRoyaltiesMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_EquitySecuritiesFvNiAccumulatedGrossUnrealizedGain_lbl1" xml:lang="en-US">Equity Securities Fv Ni Accumulated Gross Unrealized Gain</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_EquitySecuritiesFvNiAccumulatedGrossUnrealizedGain" xlink:to="ions_EquitySecuritiesFvNiAccumulatedGrossUnrealizedGain_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_NumberOfMaterialComponents_lbl1" xml:lang="en-US">Number Of Material Components</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_NumberOfMaterialComponents" xlink:to="ions_NumberOfMaterialComponents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_lbl0" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfReportableSegments_lbl0" xml:lang="en-US">Number of Reportable Segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl0" xml:lang="en-US">Inventory, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_lbl0" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl0" xml:lang="en-US">Income Taxes Paid, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl0" xml:lang="en-US">Number of Operating Segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl0" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl0" xml:lang="en-US">Proceeds from Issuance of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl0" xml:lang="en-US">Amortization of Debt Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductMember_lbl0" xml:lang="en-US">Product [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForHedgeFinancingActivities_lbl0" xml:lang="en-US">Payments for Hedge, Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForHedgeFinancingActivities" xlink:to="us-gaap_PaymentsForHedgeFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl0" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_DebtInstrumentConvertibleConversionPriceIncludingCallSpread_lbl2" xml:lang="en-US">Debt Instrument Convertible Conversion Price Including Call Spread</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_DebtInstrumentConvertibleConversionPriceIncludingCallSpread" xlink:to="ions_DebtInstrumentConvertibleConversionPriceIncludingCallSpread_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueAbstract_lbl0" xml:lang="en-US">Disaggregation of Revenue [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueAbstract" xlink:to="us-gaap_DisaggregationOfRevenueAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl0" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_InterestExpenseAndAmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties_lbl1" xml:lang="en-US">Interest Expense And Amortization Of Issuance Costs Related To Sale Of Future Royalties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_InterestExpenseAndAmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties" xlink:to="ions_InterestExpenseAndAmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment_lbl1" xml:lang="en-US">Number Of Privately Held Companies In Which Entity Has Equity Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment" xlink:to="ions_NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_USStatesAndPoliticalSubdivisionsMember_lbl0" xml:lang="en-US">US States and Political Subdivisions Debt Securities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:to="us-gaap_USStatesAndPoliticalSubdivisionsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl0" xml:lang="en-US">US Treasury Securities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_lbl1" xml:lang="en-US">Debt Securities Available For Sale Accumulated Gross Unrealized Loss Before Tax Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:to="ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl0" xml:lang="en-US">Cost of Product and Service Sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_lbl0" xml:lang="en-US">Debt and Equity Securities, FV-NI [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl0" xml:lang="en-US">Corporate Debt Securities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl1" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl0" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl0" xml:lang="en-US">Amortization of Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Leases [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_DrugDiscoveryExpenses_lbl1" xml:lang="en-US">Drug Discovery Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_DrugDiscoveryExpenses" xlink:to="ions_DrugDiscoveryExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl0" xml:lang="en-US">Segment Reporting Information [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl0" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquitySecuritiesFVNIAbstract_lbl0" xml:lang="en-US">Equity Securities, FV-NI [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFVNIAbstract" xlink:to="us-gaap_EquitySecuritiesFVNIAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_PelacarsenMember_lbl1" xml:lang="en-US">Pelacarsen Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_PelacarsenMember" xlink:to="ions_PelacarsenMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl0" xml:lang="en-US">Earnings Per Share, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableFairValueDisclosure_lbl0" xml:lang="en-US">Notes Payable, Fair Value Disclosure</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableFairValueDisclosure" xlink:to="us-gaap_NotesPayableFairValueDisclosure_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl1" xml:lang="en-US">Debt Securities, Available-for-Sale</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl0" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl0" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_InventoryCurrentAndNoncurrent_lbl1" xml:lang="en-US">Inventory Current And Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_InventoryCurrentAndNoncurrent" xlink:to="ions_InventoryCurrentAndNoncurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtCurrent_lbl0" xml:lang="en-US">Convertible Debt, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtCurrent" xlink:to="us-gaap_ConvertibleDebtCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations_lbl1" xml:lang="en-US">Revenue From Contract With Customer Number Of Separate Performance Obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" xlink:to="ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_ResearchDevelopmentAndPatentExpensesMember_lbl1" xml:lang="en-US">Research Development And Patent Expenses Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_ResearchDevelopmentAndPatentExpensesMember" xlink:to="ions_ResearchDevelopmentAndPatentExpensesMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl0" xml:lang="en-US">Assets, Fair Value Disclosure</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl0" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_OtherRoyaltiesMember_lbl1" xml:lang="en-US">Other Royalties Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_OtherRoyaltiesMember" xlink:to="ions_OtherRoyaltiesMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl0" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl0" xml:lang="en-US">Debt Instrument [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl0" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl0" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl0" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_lbl0" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl0" xml:lang="en-US">Accounts Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl0" xml:lang="en-US">Fair Value, Recurring [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl0" xml:lang="en-US">Debt Issuance Costs, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_LiabilityRelatedToSaleOfFutureRoyaltiesNet_lbl2" xml:lang="en-US">Liability Related To Sale Of Future Royalties Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_LiabilityRelatedToSaleOfFutureRoyaltiesNet" xlink:to="ions_LiabilityRelatedToSaleOfFutureRoyaltiesNet_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_ResearchAndDevelopmentSupportExpenses_lbl1" xml:lang="en-US">Research And Development Support Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_ResearchAndDevelopmentSupportExpenses" xlink:to="ions_ResearchAndDevelopmentSupportExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_MaximumRoyaltyPaymentsMadeBeforeRoyaltyInterestRevertsBack_lbl1" xml:lang="en-US">Maximum Royalty Payments Made Before Royalty Interest Reverts Back</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_MaximumRoyaltyPaymentsMadeBeforeRoyaltyInterestRevertsBack" xlink:to="ions_MaximumRoyaltyPaymentsMadeBeforeRoyaltyInterestRevertsBack_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_ConvertibleSeniorNotes175PercentMember_lbl2" xml:lang="en-US">Convertible Senior Notes175 Percent Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_ConvertibleSeniorNotes175PercentMember" xlink:to="ions_ConvertibleSeniorNotes175PercentMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesMember_lbl0" xml:lang="en-US">Cost of Sales [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesMember" xlink:to="us-gaap_CostOfSalesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl0" xml:lang="en-US">Employee-related Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentLiabilitiesMember_lbl0" xml:lang="en-US">Other Current Liabilities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentLiabilitiesMember" xlink:to="us-gaap_OtherCurrentLiabilitiesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_ReportedAsAbstract_lbl0" xml:lang="en-US">Reported As Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_ReportedAsAbstract" xlink:to="ions_ReportedAsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_NextPaymentToBeAchieved_lbl1" xml:lang="en-US">Next Payment To Be Achieved</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_NextPaymentToBeAchieved" xlink:to="ions_NextPaymentToBeAchieved_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl0" xml:lang="en-US">Long-Term Debt, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiability_lbl0" xml:lang="en-US">Contract with Customer, Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_lbl0" xml:lang="en-US">Unrealized Gain (Loss) on Investments [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:to="us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl0" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherEmployeeRelatedLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Other Employee-Related Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherEmployeeRelatedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingOtherItemAmount_lbl0" xml:lang="en-US">Segment Reporting, Other Segment Item, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingOtherItemAmount" xlink:to="us-gaap_SegmentReportingOtherItemAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi_lbl1" xml:lang="en-US">Debt Securities Available For Sale And Equity Securities Fv Ni</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi" xlink:to="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_InterestExpenseRelatedToSaleOfFutureRoyalties_lbl2" xml:lang="en-US">Interest Expense Related To Sale Of Future Royalties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_InterestExpenseRelatedToSaleOfFutureRoyalties" xlink:to="ions_InterestExpenseRelatedToSaleOfFutureRoyalties_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_LicenseOfSapablursenMember_lbl1" xml:lang="en-US">License Of Sapablursen Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_LicenseOfSapablursenMember" xlink:to="ions_LicenseOfSapablursenMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl0" xml:lang="en-US">Increase (Decrease) in Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfSecuredDebt_lbl0" xml:lang="en-US">Repayments of Secured Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfSecuredDebt" xlink:to="us-gaap_RepaymentsOfSecuredDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl0" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedLoss_lbl0" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherDebtSecuritiesMember_lbl0" xml:lang="en-US">Other Debt Obligations [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherDebtSecuritiesMember" xlink:to="us-gaap_OtherDebtSecuritiesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl1" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl0" xml:lang="en-US">Interest Expense, Operating and Nonoperating</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl0" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_IonisOperationsMember_lbl1" xml:lang="en-US">Ionis Operations Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_IonisOperationsMember" xlink:to="ions_IonisOperationsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_lbl1" xml:lang="en-US">Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:to="ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl0" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_NumberOfPurchaseAndSaleAgreementsEnteredIntoWithRealEstateInvestor_lbl1" xml:lang="en-US">Number Of Purchase And Sale Agreements Entered Into With Real Estate Investor</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_NumberOfPurchaseAndSaleAgreementsEnteredIntoWithRealEstateInvestor" xlink:to="ions_NumberOfPurchaseAndSaleAgreementsEnteredIntoWithRealEstateInvestor_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl0" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LegalMattersAndContingenciesTextBlock_lbl0" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalMattersAndContingenciesTextBlock" xlink:to="us-gaap_LegalMattersAndContingenciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl0" xml:lang="en-US">Other Liabilities, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">Selling, General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl0" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_ShareBasedPaymentArrangementBoardOfDirectorMember_lbl1" xml:lang="en-US">Share Based Payment Arrangement Board Of Director Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_ShareBasedPaymentArrangementBoardOfDirectorMember" xlink:to="ions_ShareBasedPaymentArrangementBoardOfDirectorMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ExecutiveOfficerMember_lbl0" xml:lang="en-US">Executive Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ExecutiveOfficerMember" xlink:to="srt_ExecutiveOfficerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl0" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_lbl0" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockMember_lbl0" xml:lang="en-US">Employee Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_DebtInstrumentConvertibleSharesSubjectToConversion_lbl1" xml:lang="en-US">Debt Instrument Convertible Shares Subject To Conversion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_DebtInstrumentConvertibleSharesSubjectToConversion" xlink:to="ions_DebtInstrumentConvertibleSharesSubjectToConversion_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl0" xml:lang="en-US">Other Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNoncurrent_lbl0" xml:lang="en-US">Inventory, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNoncurrent" xlink:to="us-gaap_InventoryNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl0" xml:lang="en-US">Disaggregation of Revenue [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_WainusRoyaltiesMember_lbl1" xml:lang="en-US">Wainus Royalties Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_WainusRoyaltiesMember" xlink:to="ions_WainusRoyaltiesMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_SpinrazaMember_lbl1" xml:lang="en-US">Spinraza Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_SpinrazaMember" xlink:to="ions_SpinrazaMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl0" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_NumberOfLotsOfUndevelopedLandTransferredToRealEstateInvestor_lbl1" xml:lang="en-US">Number Of Lots Of Undeveloped Land Transferred To Real Estate Investor</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_NumberOfLotsOfUndevelopedLandTransferredToRealEstateInvestor" xlink:to="ions_NumberOfLotsOfUndevelopedLandTransferredToRealEstateInvestor_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_MaximumAmountOfSalesMilestonePaymentsOverTermOfCollaboration_lbl1" xml:lang="en-US">Maximum Amount Of Sales Milestone Payments Over Term Of Collaboration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_MaximumAmountOfSalesMilestonePaymentsOverTermOfCollaboration" xlink:to="ions_MaximumAmountOfSalesMilestonePaymentsOverTermOfCollaboration_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Other Current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage_lbl1" xml:lang="en-US">Available For Sale Securities Debt Maturities Within Two Years Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage" xlink:to="ions_AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_HeadquartersLocationInCarlsbadCaliforniaMember_lbl1" xml:lang="en-US">Headquarters Location In Carlsbad California Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_HeadquartersLocationInCarlsbadCaliforniaMember" xlink:to="ions_HeadquartersLocationInCarlsbadCaliforniaMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGain_lbl0" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGain_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_LiabilityRelatedToSaleOfFutureRoyaltiesNetNoncurrent_lbl2" xml:lang="en-US">Liability Related To Sale Of Future Royalties Net Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_LiabilityRelatedToSaleOfFutureRoyaltiesNetNoncurrent" xlink:to="ions_LiabilityRelatedToSaleOfFutureRoyaltiesNetNoncurrent_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl0" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain_lbl1" xml:lang="en-US">Debt Securities Available For Sale And Equity Securities Fv Ni Gross Unrealized Gain</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain" xlink:to="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl0" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl0" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_ConvertibleSeniorNotes0125PercentMember_lbl1" xml:lang="en-US">Convertible Senior Notes0125 Percent Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_ConvertibleSeniorNotes0125PercentMember" xlink:to="ions_ConvertibleSeniorNotes0125PercentMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl0" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl0" xml:lang="en-US">Earnings Per Share [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl0" xml:lang="en-US">Concentration Risk, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_lbl1" xml:lang="en-US">Debt Securities Available For Sale Accumulated Gross Unrealized Loss Before Tax Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" xlink:to="ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_MaximumAmountOfRegulatoryMilestonePaymentsOverTermOfCollaboration_lbl1" xml:lang="en-US">Maximum Amount Of Regulatory Milestone Payments Over Term Of Collaboration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_MaximumAmountOfRegulatoryMilestonePaymentsOverTermOfCollaboration" xlink:to="ions_MaximumAmountOfRegulatoryMilestonePaymentsOverTermOfCollaboration_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl0" xml:lang="en-US">Contract with Customer, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_NumberOfPerformanceObligationsIdentified_lbl1" xml:lang="en-US">Number Of Performance Obligations Identified</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_NumberOfPerformanceObligationsIdentified" xlink:to="ions_NumberOfPerformanceObligationsIdentified_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryLineItems_lbl0" xml:lang="en-US">Inventory [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryLineItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_RevenueFromContractWithCustomerTransactionPrice_lbl1" xml:lang="en-US">Revenue From Contract With Customer Transaction Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_RevenueFromContractWithCustomerTransactionPrice" xlink:to="ions_RevenueFromContractWithCustomerTransactionPrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Inventory Current And Noncurrent Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock" xlink:to="ions_ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfUnitsGuaranteedToVest_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Units Guaranteed To Vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfUnitsGuaranteedToVest" xlink:to="ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfUnitsGuaranteedToVest_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl0" xml:lang="en-US">Other Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_ConvertibleSeniorNotes0PercentMember_lbl2" xml:lang="en-US">Convertible Senior Notes0 Percent Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_ConvertibleSeniorNotes0PercentMember" xlink:to="ions_ConvertibleSeniorNotes0PercentMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl0" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_InventoryWorkInProcessNet_lbl1" xml:lang="en-US">Inventory Work In Process Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_InventoryWorkInProcessNet" xlink:to="ions_InventoryWorkInProcessNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermInvestments_lbl0" xml:lang="en-US">Short-Term Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl0" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl0" xml:lang="en-US">Debt Instrument, Face Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerMember_lbl0" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerMember" xlink:to="us-gaap_RevenueFromContractWithCustomerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerAsset_lbl0" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl0" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_lbl0" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_PercentageOfCostsAssociatedWithOngoingGlobalPhase3DevelopmentProgramPaidByCollaborationPartner_lbl1" xml:lang="en-US">Percentage Of Costs Associated With Ongoing Global Phase3 Development Program Paid By Collaboration Partner</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_PercentageOfCostsAssociatedWithOngoingGlobalPhase3DevelopmentProgramPaidByCollaborationPartner" xlink:to="ions_PercentageOfCostsAssociatedWithOngoingGlobalPhase3DevelopmentProgramPaidByCollaborationPartner_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl1" xml:lang="en-US">Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl0" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_AstraZenecaCollaborationWAINUAMember_lbl1" xml:lang="en-US">Astra Zeneca Collaboration WAINUAMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_AstraZenecaCollaborationWAINUAMember" xlink:to="ions_AstraZenecaCollaborationWAINUAMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl0" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl0" xml:lang="en-US">Payments to Acquire Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl0" xml:lang="en-US">Customer Concentration Risk [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_CumulativePaymentsReceived_lbl1" xml:lang="en-US">Cumulative Payments Received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_CumulativePaymentsReceived" xlink:to="ions_CumulativePaymentsReceived_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl0" xml:lang="en-US">Debt Instrument, Maturity Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl1" xml:lang="en-US">Share-Based Payment Arrangement, Employee [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingOtherItemCompositionDescription_lbl0" xml:lang="en-US">Segment Reporting, Other Segment Item, Composition, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingOtherItemCompositionDescription" xlink:to="us-gaap_SegmentReportingOtherItemCompositionDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl0" xml:lang="en-US">US Government Agencies Debt Securities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Amount Capitalized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss_lbl1" xml:lang="en-US">Debt Securities Available For Sale And Equity Securities Fv Ni Gross Unrealized Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss" xlink:to="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl0" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ions_WainuaJointDevelopmentRevenueMember_lbl1" xml:lang="en-US">Wainua Joint Development Revenue Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ions_WainuaJointDevelopmentRevenueMember" xlink:to="ions_WainuaJointDevelopmentRevenueMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl0" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
<!-- [WMV6][Ig/PUQrOU873PNQkzBDfHepJ4dT1zlxHAuE56C4XLN3Ug3v9jPEEyFC5efXHdnSv7wjOKX5u/as+CPDYlBDTHfOahd7nIcFwVugdnfZRtXZGkvTycgATjvWzWMsnGCYbEPUOl/JJmmwuAPibA2p5Mw5OYA7AIQtXC1L1m/yIVbDNzETHA9kSHdS3XFJnMG+uif9oJ53EzXOj9fU+3j3TMhtu2ooSAXmuLUPwGHqUBOrwEGV9x1WtFzdivSNcKsHBL5Z976b7F5JN/QNUpGopZC6duzLddpNbxAAjLMG0mH+grL9ynt61sHG312T8+qmrZZGHHic4] CSR-->
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl0"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>ions-20250930_pre.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION - PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Wed Oct 29 20:43:09 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_ConsolidatedBalanceSheet" roleURI="http://ionis.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://ionis.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_ConsolidatedIncomeStatement" roleURI="http://ionis.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_ConsolidatedComprehensiveIncome" roleURI="http://ionis.com/role/ConsolidatedComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_ShareholdersEquityType2or3" roleURI="http://ionis.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_ConsolidatedCashFlow" roleURI="http://ionis.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_OrganizationandBasisofPresentation" roleURI="http://ionis.com/role/OrganizationandBasisofPresentation"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_SignificantAccountingPolicies" roleURI="http://ionis.com/role/SignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_SupplementalFinancialData" roleURI="http://ionis.com/role/SupplementalFinancialData"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_Revenues" roleURI="http://ionis.com/role/Revenues"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_CollaborativeArrangementsandLicensingAgreements" roleURI="http://ionis.com/role/CollaborativeArrangementsandLicensingAgreements"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_BasicandDilutedNetLossPerShare" roleURI="http://ionis.com/role/BasicandDilutedNetLossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_Investments" roleURI="http://ionis.com/role/Investments"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_FairValueMeasurements" roleURI="http://ionis.com/role/FairValueMeasurements"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_StockbasedCompensationExpense" roleURI="http://ionis.com/role/StockbasedCompensationExpense"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_IncomeTaxes" roleURI="http://ionis.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_LiabilityRelatedtoSaleofFutureRoyalties" roleURI="http://ionis.com/role/LiabilityRelatedtoSaleofFutureRoyalties"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_ConvertibleDebt" roleURI="http://ionis.com/role/ConvertibleDebt"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_OperatingLeases" roleURI="http://ionis.com/role/OperatingLeases"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_LegalProceedings" roleURI="http://ionis.com/role/LegalProceedings"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_SegmentInformation" roleURI="http://ionis.com/role/SegmentInformation"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_AccountingPoliciesByPolicy" roleURI="http://ionis.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_SupplementalFinancialDataTables" roleURI="http://ionis.com/role/SupplementalFinancialDataTables"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_RevenuesTables" roleURI="http://ionis.com/role/RevenuesTables"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_CollaborativeArrangementsandLicensingAgreementsTables" roleURI="http://ionis.com/role/CollaborativeArrangementsandLicensingAgreementsTables"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_InvestmentsTables" roleURI="http://ionis.com/role/InvestmentsTables"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_FairValueMeasurementsTables" roleURI="http://ionis.com/role/FairValueMeasurementsTables"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_StockbasedCompensationExpenseTables" roleURI="http://ionis.com/role/StockbasedCompensationExpenseTables"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_LiabilityRelatedtoSaleofFutureRoyaltiesTables" roleURI="http://ionis.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesTables"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_ConvertibleDebtTables" roleURI="http://ionis.com/role/ConvertibleDebtTables"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_SegmentInformationTables" roleURI="http://ionis.com/role/SegmentInformationTables"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_InventoriesTable" roleURI="http://ionis.com/role/InventoriesTable"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_AccruedLiabilitiesTable" roleURI="http://ionis.com/role/AccruedLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_RevenuesTable" roleURI="http://ionis.com/role/RevenuesTable"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_RevenuefromCollaborativeRelationshipwithAstraZenecaTable" roleURI="http://ionis.com/role/RevenuefromCollaborativeRelationshipwithAstraZenecaTable"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_RevenuefromCollaborativeRelationshipwithOnoTable" roleURI="http://ionis.com/role/RevenuefromCollaborativeRelationshipwithOnoTable"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_SummaryofInvestmentsTable" roleURI="http://ionis.com/role/SummaryofInvestmentsTable"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_TemporarilyImpairedInvestmentsTable" roleURI="http://ionis.com/role/TemporarilyImpairedInvestmentsTable"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_FairValueMeasurementsTable" roleURI="http://ionis.com/role/FairValueMeasurementsTable"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_StockbasedCompensationExpenseTable" roleURI="http://ionis.com/role/StockbasedCompensationExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_WeightedAverageAssumptionsforStockOptionsTable" roleURI="http://ionis.com/role/WeightedAverageAssumptionsforStockOptionsTable"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_WeightedAverageAssumptionsforESPPTable" roleURI="http://ionis.com/role/WeightedAverageAssumptionsforESPPTable"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_LiabilityRelatedtoSaleofFutureRoyaltiesTable" roleURI="http://ionis.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesTable"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_175NotesTable" roleURI="http://ionis.com/role/175NotesTable"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_0NotesTable" roleURI="http://ionis.com/role/0NotesTable"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_SegmentInformationTable" roleURI="http://ionis.com/role/SegmentInformationTable"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_InvestmentsDetailsContractMaturityofAvailableforSaleSecurities" roleURI="http://ionis.com/role/InvestmentsDetailsContractMaturityofAvailableforSaleSecurities"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_OrganizationandBasisofPresentationDetails" roleURI="http://ionis.com/role/OrganizationandBasisofPresentationDetails"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_RevenuesDetails" roleURI="http://ionis.com/role/RevenuesDetails"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_CollaborativeArrangementsandLicensingAgreementsDetailsAstraZeneca" roleURI="http://ionis.com/role/CollaborativeArrangementsandLicensingAgreementsDetailsAstraZeneca"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_CollaborativeArrangementsandLicensingAgreementsDetailsOno" roleURI="http://ionis.com/role/CollaborativeArrangementsandLicensingAgreementsDetailsOno"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_BasicandDilutedNetLossPerShareDetails" roleURI="http://ionis.com/role/BasicandDilutedNetLossPerShareDetails"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_InvestmentsDetails" roleURI="http://ionis.com/role/InvestmentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_FairValueMeasurementsDetails" roleURI="http://ionis.com/role/FairValueMeasurementsDetails"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_StockbasedCompensationExpenseDetails" roleURI="http://ionis.com/role/StockbasedCompensationExpenseDetails"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_IncomeTaxesDetails" roleURI="http://ionis.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_LiabilityRelatedtoSaleofFutureRoyaltiesDetails" roleURI="http://ionis.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_ConvertibleDebtDetails" roleURI="http://ionis.com/role/ConvertibleDebtDetails"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_OperatingLeasesDetails" roleURI="http://ionis.com/role/OperatingLeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_SegmentInformationDetails" roleURI="http://ionis.com/role/SegmentInformationDetails"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#cover" roleURI="http://xbrl.sec.gov/dei/role/document/Cover"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#ai" roleURI="http://xbrl.sec.gov/dei/role/document/AuditInformation"/>
  <presentationLink xlink:role="http://ionis.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ConvertibleSeniorNotes175PercentMember" xlink:href="ions-20250930.xsd#ions_ConvertibleSeniorNotes175PercentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="ConvertibleSeniorNotes175PercentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConvertibleSeniorNotes0PercentMember" xlink:href="ions-20250930.xsd#ions_ConvertibleSeniorNotes0PercentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="ConvertibleSeniorNotes0PercentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_AssetsCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_Assets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ConvertibleDebtCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_ConvertibleDebtNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LiabilityRelatedToSaleOfFutureRoyaltiesNetNoncurrent" xlink:href="ions-20250930.xsd#ions_LiabilityRelatedToSaleOfFutureRoyaltiesNetNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="LiabilityRelatedToSaleOfFutureRoyaltiesNetNoncurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_Liabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://ionis.com/role/ConsolidatedBalanceSheet_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ConvertibleSeniorNotes0PercentMember" xlink:href="ions-20250930.xsd#ions_ConvertibleSeniorNotes0PercentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="ConvertibleSeniorNotes0PercentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConvertibleSeniorNotes175PercentMember" xlink:href="ions-20250930.xsd#ions_ConvertibleSeniorNotes175PercentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="ConvertibleSeniorNotes175PercentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://ionis.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="us-gaap_ProductMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RoyaltyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="us-gaap_RoyaltyMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherCommercialMember" xlink:href="ions-20250930.xsd#ions_OtherCommercialMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="OtherCommercialMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommercialMember" xlink:href="ions-20250930.xsd#ions_CommercialMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="CommercialMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CollaborativeAgreementRevenueMember" xlink:href="ions-20250930.xsd#ions_CollaborativeAgreementRevenueMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="CollaborativeAgreementRevenueMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WainuaJointDevelopmentRevenueMember" xlink:href="ions-20250930.xsd#ions_WainuaJointDevelopmentRevenueMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="WainuaJointDevelopmentRevenueMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ResearchAndDevelopmentRevenueMember" xlink:href="ions-20250930.xsd#ions_ResearchAndDevelopmentRevenueMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="ResearchAndDevelopmentRevenueMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostsAndExpensesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ResearchDevelopmentAndPatentExpense" xlink:href="ions-20250930.xsd#ions_ResearchDevelopmentAndPatentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="ResearchDevelopmentAndPatentExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_CostsAndExpenses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="InterestExpenseAndAmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties" xlink:href="ions-20250930.xsd#ions_InterestExpenseAndAmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="InterestExpenseAndAmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_GainLossOnInvestments" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://ionis.com/role/ConsolidatedComprehensiveIncome" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://ionis.com/role/ShareholdersEquityType2or3" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="4.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_0" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued_0" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://ionis.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RoyaltyPayments" xlink:href="ions-20250930.xsd#ions_RoyaltyPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="RoyaltyPayments" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="InterestExpenseRelatedToSaleOfFutureRoyalties" xlink:href="ions-20250930.xsd#ions_InterestExpenseRelatedToSaleOfFutureRoyalties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="InterestExpenseRelatedToSaleOfFutureRoyalties" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RealizedInvestmentGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_RealizedInvestmentGainsLosses" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerAsset" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherEmployeeRelatedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherEmployeeRelatedLiabilities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfSecuredDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfSecuredDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfSecuredDebt" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepaymentsOfSecuredDebt" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CapitalAndPatentExpendituresIncurredButNotYetPaid" xlink:href="ions-20250930.xsd#ions_CapitalAndPatentExpendituresIncurredButNotYetPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="CapitalAndPatentExpendituresIncurredButNotYetPaid" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://ionis.com/role/OrganizationandBasisofPresentation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://ionis.com/role/SignificantAccountingPolicies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://ionis.com/role/SupplementalFinancialData" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="SupplementalFinancialDataAbstract" xlink:href="ions-20250930.xsd#ions_SupplementalFinancialDataAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalFinancialDataAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://ionis.com/role/Revenues" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://ionis.com/role/CollaborativeArrangementsandLicensingAgreements" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="CollaborativeArrangementsAndLicensingAgreementsAbstract" xlink:href="ions-20250930.xsd#ions_CollaborativeArrangementsAndLicensingAgreementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndLicensingAgreementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://ionis.com/role/BasicandDilutedNetLossPerShare" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://ionis.com/role/Investments" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAbstract" xlink:to="us-gaap_InvestmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://ionis.com/role/FairValueMeasurements" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://ionis.com/role/StockbasedCompensationExpense" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://ionis.com/role/IncomeTaxes" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://ionis.com/role/LiabilityRelatedtoSaleofFutureRoyalties" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="us-gaap_OtherLiabilitiesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://ionis.com/role/ConvertibleDebt" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="ConvertibleNotesDisclosureTable" xlink:href="ions-20250930.xsd#ions_ConvertibleNotesDisclosureTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="ConvertibleNotesDisclosureTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesDisclosureTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://ionis.com/role/OperatingLeases" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://ionis.com/role/LegalProceedings" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LegalMattersAndContingenciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LegalMattersAndContingenciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://ionis.com/role/SegmentInformation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://ionis.com/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CostOfSalesPolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://ionis.com/role/SupplementalFinancialDataTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="SupplementalFinancialDataAbstract" xlink:href="ions-20250930.xsd#ions_SupplementalFinancialDataAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock" xlink:href="ions-20250930.xsd#ions_ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalFinancialDataAbstract" xlink:to="ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalFinancialDataAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://ionis.com/role/RevenuesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://ionis.com/role/CollaborativeArrangementsandLicensingAgreementsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="CollaborativeArrangementsAndLicensingAgreementsAbstract" xlink:href="ions-20250930.xsd#ions_CollaborativeArrangementsAndLicensingAgreementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndLicensingAgreementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AstraZenecaCollaborationsMember" xlink:href="ions-20250930.xsd#ions_AstraZenecaCollaborationsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="AstraZenecaCollaborationsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OnoCollaborationMember" xlink:href="ions-20250930.xsd#ions_OnoCollaborationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="OnoCollaborationMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://ionis.com/role/InvestmentsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAbstract" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAbstract" xlink:to="us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://ionis.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://ionis.com/role/StockbasedCompensationExpenseTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://ionis.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncurrentLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://ionis.com/role/ConvertibleDebtTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="ConvertibleNotesDisclosureTable" xlink:href="ions-20250930.xsd#ions_ConvertibleNotesDisclosureTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="ConvertibleNotesDisclosureTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesDisclosureTable" xlink:to="us-gaap_DebtInstrumentAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ConvertibleSeniorNotes175PercentMember" xlink:href="ions-20250930.xsd#ions_ConvertibleSeniorNotes175PercentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="ConvertibleSeniorNotes175PercentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ConvertibleSeniorNotes0PercentMember" xlink:href="ions-20250930.xsd#ions_ConvertibleSeniorNotes0PercentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="ConvertibleSeniorNotes0PercentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesDisclosureTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ConvertibleDebtTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://ionis.com/role/SegmentInformationTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://ionis.com/role/InventoriesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryCurrentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryCurrentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryCurrentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryCurrentTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_OtherNoncurrentAssetsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryCurrentTable" xlink:to="us-gaap_InventoryLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InventoryRawMaterialsNet" xlink:href="ions-20250930.xsd#ions_InventoryRawMaterialsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems" xlink:to="InventoryRawMaterialsNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InventoryWorkInProcessNet" xlink:href="ions-20250930.xsd#ions_InventoryWorkInProcessNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems" xlink:to="InventoryWorkInProcessNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InventoryFinishedGoodsNet" xlink:href="ions-20250930.xsd#ions_InventoryFinishedGoodsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems" xlink:to="InventoryFinishedGoodsNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InventoryCurrentAndNoncurrent" xlink:href="ions-20250930.xsd#ions_InventoryCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryFinishedGoodsNet" xlink:to="InventoryCurrentAndNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ReportedAsAbstract" xlink:href="ions-20250930.xsd#ions_ReportedAsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems" xlink:to="ReportedAsAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReportedAsAbstract" xlink:to="us-gaap_InventoryNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReportedAsAbstract" xlink:to="us-gaap_InventoryNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://ionis.com/role/AccruedLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="AccruedClinicalExpenses" xlink:href="ions-20250930.xsd#ions_AccruedClinicalExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="AccruedClinicalExpenses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccruedInLicensingFeesCurrent" xlink:href="ions-20250930.xsd#ions_AccruedInLicensingFeesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="AccruedInLicensingFeesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccruedCommercialExpensesCurrent" xlink:href="ions-20250930.xsd#ions_AccruedCommercialExpensesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="AccruedCommercialExpensesCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://ionis.com/role/RevenuesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TryngolzaMember" xlink:href="ions-20250930.xsd#ions_TryngolzaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="TryngolzaMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="us-gaap_ProductMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SpinrazaRoyaltiesMember" xlink:href="ions-20250930.xsd#ions_SpinrazaRoyaltiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="SpinrazaRoyaltiesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WainusRoyaltiesMember" xlink:href="ions-20250930.xsd#ions_WainusRoyaltiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="WainusRoyaltiesMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherRoyaltiesMember" xlink:href="ions-20250930.xsd#ions_OtherRoyaltiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="OtherRoyaltiesMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RoyaltyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="us-gaap_RoyaltyMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherCommercialMember" xlink:href="ions-20250930.xsd#ions_OtherCommercialMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="OtherCommercialMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommercialMember" xlink:href="ions-20250930.xsd#ions_CommercialMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="CommercialMember" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CollaborativeAgreementRevenueMember" xlink:href="ions-20250930.xsd#ions_CollaborativeAgreementRevenueMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="CollaborativeAgreementRevenueMember" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WainuaJointDevelopmentRevenueMember" xlink:href="ions-20250930.xsd#ions_WainuaJointDevelopmentRevenueMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="WainuaJointDevelopmentRevenueMember" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ResearchAndDevelopmentRevenueMember" xlink:href="ions-20250930.xsd#ions_ResearchAndDevelopmentRevenueMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="ResearchAndDevelopmentRevenueMember" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://ionis.com/role/RevenuefromCollaborativeRelationshipwithAstraZenecaTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="CollaborativeArrangementsAndLicensingAgreementsAbstract" xlink:href="ions-20250930.xsd#ions_CollaborativeArrangementsAndLicensingAgreementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndLicensingAgreementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AstraZenecaCollaborationsMember" xlink:href="ions-20250930.xsd#ions_AstraZenecaCollaborationsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="AstraZenecaCollaborationsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_RevenueFromContractWithCustomerMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://ionis.com/role/RevenuefromCollaborativeRelationshipwithOnoTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="CollaborativeArrangementsAndLicensingAgreementsAbstract" xlink:href="ions-20250930.xsd#ions_CollaborativeArrangementsAndLicensingAgreementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndLicensingAgreementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="OnoCollaborationMember" xlink:href="ions-20250930.xsd#ions_OnoCollaborationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="OnoCollaborationMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_RevenueFromContractWithCustomerMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://ionis.com/role/SummaryofInvestmentsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAbstract" xlink:to="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_USTreasurySecuritiesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_USStatesAndPoliticalSubdivisionsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_OtherDebtSecuritiesMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EquitySecuritiesPubliclyTradedCompaniesMember" xlink:href="ions-20250930.xsd#ions_EquitySecuritiesPubliclyTradedCompaniesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="EquitySecuritiesPubliclyTradedCompaniesMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EquitySecuritiesPrivateCompaniesMember" xlink:href="ions-20250930.xsd#ions_EquitySecuritiesPrivateCompaniesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="EquitySecuritiesPrivateCompaniesMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:to="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:href="ions-20250930.xsd#ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:href="ions-20250930.xsd#ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" xlink:href="ions-20250930.xsd#ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" xlink:href="ions-20250930.xsd#ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesFvNiCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiCost" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="EquitySecuritiesFvNiAccumulatedGrossUnrealizedGain" xlink:href="ions-20250930.xsd#ions_EquitySecuritiesFvNiAccumulatedGrossUnrealizedGain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="EquitySecuritiesFvNiAccumulatedGrossUnrealizedGain" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EquitySecuritiesFvNiAccumulatedGrossUnrealizedLoss" xlink:href="ions-20250930.xsd#ions_EquitySecuritiesFvNiAccumulatedGrossUnrealizedLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="EquitySecuritiesFvNiAccumulatedGrossUnrealizedLoss" order="14.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNi" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost" xlink:href="ions-20250930.xsd#ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain" xlink:href="ions-20250930.xsd#ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss" xlink:href="ions-20250930.xsd#ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss" order="18.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <loc xlink:type="locator" xlink:label="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi" xlink:href="ions-20250930.xsd#ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://ionis.com/role/TemporarilyImpairedInvestmentsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_USTreasurySecuritiesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_OtherDebtSecuritiesMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://ionis.com/role/FairValueMeasurementsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel2Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_USTreasurySecuritiesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_USStatesAndPoliticalSubdivisionsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_OtherDebtSecuritiesMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EquitySecuritiesPubliclyTradedCompaniesMember" xlink:href="ions-20250930.xsd#ions_EquitySecuritiesPubliclyTradedCompaniesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="EquitySecuritiesPubliclyTradedCompaniesMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_OtherCurrentAssetsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_EquitySecuritiesFvNi" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://ionis.com/role/StockbasedCompensationExpenseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfSalesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_CostOfSalesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ResearchDevelopmentAndPatentExpensesMember" xlink:href="ions-20250930.xsd#ions_ResearchDevelopmentAndPatentExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="ResearchDevelopmentAndPatentExpensesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://ionis.com/role/WeightedAverageAssumptionsforStockOptionsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GranteeStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_GranteeStatusAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentArrangementBoardOfDirectorMember" xlink:href="ions-20250930.xsd#ions_ShareBasedPaymentArrangementBoardOfDirectorMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="ShareBasedPaymentArrangementBoardOfDirectorMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://ionis.com/role/WeightedAverageAssumptionsforESPPTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://ionis.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="RoyaltyPurchaseAgreementMember" xlink:href="ions-20250930.xsd#ions_RoyaltyPurchaseAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="RoyaltyPurchaseAgreementMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_OtherCurrentLiabilitiesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="LiabilityRelatedToSaleOfFutureRoyaltiesNet" xlink:href="ions-20250930.xsd#ions_LiabilityRelatedToSaleOfFutureRoyaltiesNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="LiabilityRelatedToSaleOfFutureRoyaltiesNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="RoyaltyPayments" xlink:href="ions-20250930.xsd#ions_RoyaltyPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="RoyaltyPayments" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <loc xlink:type="locator" xlink:label="InterestExpenseRelatedToSaleOfFutureRoyalties" xlink:href="ions-20250930.xsd#ions_InterestExpenseRelatedToSaleOfFutureRoyalties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="InterestExpenseRelatedToSaleOfFutureRoyalties" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="AmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties" xlink:href="ions-20250930.xsd#ions_AmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="AmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LiabilityRelatedToSaleOfFutureRoyaltiesNet_0" xlink:href="ions-20250930.xsd#ions_LiabilityRelatedToSaleOfFutureRoyaltiesNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="LiabilityRelatedToSaleOfFutureRoyaltiesNet_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="LiabilityRelatedToSaleOfFutureRoyaltiesNetCurrent" xlink:href="ions-20250930.xsd#ions_LiabilityRelatedToSaleOfFutureRoyaltiesNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="LiabilityRelatedToSaleOfFutureRoyaltiesNetCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="LiabilityRelatedToSaleOfFutureRoyaltiesNetNoncurrent" xlink:href="ions-20250930.xsd#ions_LiabilityRelatedToSaleOfFutureRoyaltiesNetNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="LiabilityRelatedToSaleOfFutureRoyaltiesNetNoncurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://ionis.com/role/175NotesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ConvertibleSeniorNotes175PercentMember" xlink:href="ions-20250930.xsd#ions_ConvertibleSeniorNotes175PercentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="ConvertibleSeniorNotes175PercentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtInstrumentConvertibleSharesSubjectToConversion" xlink:href="ions-20250930.xsd#ions_DebtInstrumentConvertibleSharesSubjectToConversion"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="DebtInstrumentConvertibleSharesSubjectToConversion" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://ionis.com/role/0NotesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ConvertibleSeniorNotes0PercentMember" xlink:href="ions-20250930.xsd#ions_ConvertibleSeniorNotes0PercentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="ConvertibleSeniorNotes0PercentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtInstrumentConvertibleConversionPriceIncludingCallSpread" xlink:href="ions-20250930.xsd#ions_DebtInstrumentConvertibleConversionPriceIncludingCallSpread"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="DebtInstrumentConvertibleConversionPriceIncludingCallSpread" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtInstrumentConvertibleSharesSubjectToConversion" xlink:href="ions-20250930.xsd#ions_DebtInstrumentConvertibleSharesSubjectToConversion"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="DebtInstrumentConvertibleSharesSubjectToConversion" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://ionis.com/role/SegmentInformationTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="IonisOperationsMember" xlink:href="ions-20250930.xsd#ions_IonisOperationsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="IonisOperationsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_SegmentReportingInformationLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DrugDiscoveryExpenses" xlink:href="ions-20250930.xsd#ions_DrugDiscoveryExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="DrugDiscoveryExpenses" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DrugDevelopmentExpenses" xlink:href="ions-20250930.xsd#ions_DrugDevelopmentExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="DrugDevelopmentExpenses" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MedicalAffairsExpenses" xlink:href="ions-20250930.xsd#ions_MedicalAffairsExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="MedicalAffairsExpenses" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ManufacturingAndDevelopmentChemistryExpenses" xlink:href="ions-20250930.xsd#ions_ManufacturingAndDevelopmentChemistryExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="ManufacturingAndDevelopmentChemistryExpenses" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ResearchAndDevelopmentSupportExpenses" xlink:href="ions-20250930.xsd#ions_ResearchAndDevelopmentSupportExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="ResearchAndDevelopmentSupportExpenses" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingOtherItemAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingOtherItemAmount" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NetIncomeLoss" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://ionis.com/role/InvestmentsDetailsContractMaturityofAvailableforSaleSecurities" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="MaximumContractMaturityPeriodRange1" xlink:href="ions-20250930.xsd#ions_MaximumContractMaturityPeriodRange1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAbstract" xlink:to="MaximumContractMaturityPeriodRange1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage" xlink:href="ions-20250930.xsd#ions_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAbstract" xlink:to="AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MaximumContractMaturityPeriodRange2" xlink:href="ions-20250930.xsd#ions_MaximumContractMaturityPeriodRange2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAbstract" xlink:to="MaximumContractMaturityPeriodRange2" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage" xlink:href="ions-20250930.xsd#ions_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAbstract" xlink:to="AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MaximumContractMaturityPeriodRange3" xlink:href="ions-20250930.xsd#ions_MaximumContractMaturityPeriodRange3"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAbstract" xlink:to="MaximumContractMaturityPeriodRange3" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage" xlink:href="ions-20250930.xsd#ions_AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAbstract" xlink:to="AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage" xlink:href="ions-20250930.xsd#ions_AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAbstract" xlink:to="AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://ionis.com/role/OrganizationandBasisofPresentationDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://ionis.com/role/RevenuesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AstraZenecaCollaborationWainuaMember" xlink:href="ions-20250930.xsd#ions_AstraZenecaCollaborationWainuaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="AstraZenecaCollaborationWainuaMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UpfrontPaymentReceived" xlink:href="ions-20250930.xsd#ions_UpfrontPaymentReceived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="UpfrontPaymentReceived" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfMaterialComponents" xlink:href="ions-20250930.xsd#ions_NumberOfMaterialComponents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="NumberOfMaterialComponents" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" xlink:href="ions-20250930.xsd#ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RevenueFromContractWithCustomerTransactionPrice" xlink:href="ions-20250930.xsd#ions_RevenueFromContractWithCustomerTransactionPrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="RevenueFromContractWithCustomerTransactionPrice" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfCostsAssociatedWithOngoingGlobalPhase3DevelopmentProgramPaidByCollaborationPartner" xlink:href="ions-20250930.xsd#ions_PercentageOfCostsAssociatedWithOngoingGlobalPhase3DevelopmentProgramPaidByCollaborationPartner"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="PercentageOfCostsAssociatedWithOngoingGlobalPhase3DevelopmentProgramPaidByCollaborationPartner" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://ionis.com/role/CollaborativeArrangementsandLicensingAgreementsDetailsAstraZeneca" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="CollaborativeArrangementsAndLicensingAgreementsAbstract" xlink:href="ions-20250930.xsd#ions_CollaborativeArrangementsAndLicensingAgreementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndLicensingAgreementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AstraZenecaCollaborationsMember" xlink:href="ions-20250930.xsd#ions_AstraZenecaCollaborationsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="AstraZenecaCollaborationsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AstraZenecaCollaborationWAINUAMember" xlink:href="ions-20250930.xsd#ions_AstraZenecaCollaborationWAINUAMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="AstraZenecaCollaborationWAINUAMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AstraZenecaCollaborationCardiovascularRenalAndMetabolicDiseasesMember" xlink:href="ions-20250930.xsd#ions_AstraZenecaCollaborationCardiovascularRenalAndMetabolicDiseasesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="AstraZenecaCollaborationCardiovascularRenalAndMetabolicDiseasesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfCollaborationAgreements" xlink:href="ions-20250930.xsd#ions_NumberOfCollaborationAgreements"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="NumberOfCollaborationAgreements" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CumulativePaymentsReceived" xlink:href="ions-20250930.xsd#ions_CumulativePaymentsReceived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="CumulativePaymentsReceived" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NextPaymentToBeAchieved" xlink:href="ions-20250930.xsd#ions_NextPaymentToBeAchieved"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="NextPaymentToBeAchieved" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://ionis.com/role/CollaborativeArrangementsandLicensingAgreementsDetailsOno" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="CollaborativeArrangementsAndLicensingAgreementsAbstract" xlink:href="ions-20250930.xsd#ions_CollaborativeArrangementsAndLicensingAgreementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndLicensingAgreementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="OnoCollaborationMember" xlink:href="ions-20250930.xsd#ions_OnoCollaborationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="OnoCollaborationMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ResearchAndDevelopmentServicesForSapablursenMember" xlink:href="ions-20250930.xsd#ions_ResearchAndDevelopmentServicesForSapablursenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="ResearchAndDevelopmentServicesForSapablursenMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LicenseOfSapablursenMember" xlink:href="ions-20250930.xsd#ions_LicenseOfSapablursenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="LicenseOfSapablursenMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MaximumAmountOfPaymentsReceivableOverTermOfCollaboration" xlink:href="ions-20250930.xsd#ions_MaximumAmountOfPaymentsReceivableOverTermOfCollaboration"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MaximumAmountOfPaymentsReceivableOverTermOfCollaboration" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MaximumAmountOfUpfrontPaymentsOverTermOfCollaboration" xlink:href="ions-20250930.xsd#ions_MaximumAmountOfUpfrontPaymentsOverTermOfCollaboration"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MaximumAmountOfUpfrontPaymentsOverTermOfCollaboration" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MaximumAmountOfDevelopmentMilestonePaymentsOverTermOfCollaboration" xlink:href="ions-20250930.xsd#ions_MaximumAmountOfDevelopmentMilestonePaymentsOverTermOfCollaboration"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MaximumAmountOfDevelopmentMilestonePaymentsOverTermOfCollaboration" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MaximumAmountOfRegulatoryMilestonePaymentsOverTermOfCollaboration" xlink:href="ions-20250930.xsd#ions_MaximumAmountOfRegulatoryMilestonePaymentsOverTermOfCollaboration"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MaximumAmountOfRegulatoryMilestonePaymentsOverTermOfCollaboration" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MaximumAmountOfSalesMilestonePaymentsOverTermOfCollaboration" xlink:href="ions-20250930.xsd#ions_MaximumAmountOfSalesMilestonePaymentsOverTermOfCollaboration"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MaximumAmountOfSalesMilestonePaymentsOverTermOfCollaboration" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CumulativePaymentsReceived" xlink:href="ions-20250930.xsd#ions_CumulativePaymentsReceived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="CumulativePaymentsReceived" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NextPaymentToBeAchieved" xlink:href="ions-20250930.xsd#ions_NextPaymentToBeAchieved"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="NextPaymentToBeAchieved" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfPerformanceObligationsIdentified" xlink:href="ions-20250930.xsd#ions_NumberOfPerformanceObligationsIdentified"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="NumberOfPerformanceObligationsIdentified" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RevenueFromContractWithCustomerTransactionPrice" xlink:href="ions-20250930.xsd#ions_RevenueFromContractWithCustomerTransactionPrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="RevenueFromContractWithCustomerTransactionPrice" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://ionis.com/role/BasicandDilutedNetLossPerShareDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_DebtInstrumentAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ConvertibleSeniorNotes175PercentMember" xlink:href="ions-20250930.xsd#ions_ConvertibleSeniorNotes175PercentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="ConvertibleSeniorNotes175PercentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ConvertibleSeniorNotes0PercentMember" xlink:href="ions-20250930.xsd#ions_ConvertibleSeniorNotes0PercentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="ConvertibleSeniorNotes0PercentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ConvertibleSeniorNotes0125PercentMember" xlink:href="ions-20250930.xsd#ions_ConvertibleSeniorNotes0125PercentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="ConvertibleSeniorNotes0125PercentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_EarningsPerShareBasicLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://ionis.com/role/InvestmentsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAbstract" xlink:to="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="EquitySecuritiesPubliclyTradedCompaniesMember" xlink:href="ions-20250930.xsd#ions_EquitySecuritiesPubliclyTradedCompaniesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="EquitySecuritiesPubliclyTradedCompaniesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EquitySecuritiesPrivateCompaniesMember" xlink:href="ions-20250930.xsd#ions_EquitySecuritiesPrivateCompaniesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="EquitySecuritiesPrivateCompaniesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:to="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage" xlink:href="ions-20250930.xsd#ions_AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MaximumContractMaturityPeriodRange2" xlink:href="ions-20250930.xsd#ions_MaximumContractMaturityPeriodRange2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="MaximumContractMaturityPeriodRange2" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment" xlink:href="ions-20250930.xsd#ions_NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment" xlink:href="ions-20250930.xsd#ions_NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedLoss" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGain" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://ionis.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_USTreasurySecuritiesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_CashAndCashEquivalentsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_DebtInstrumentAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ConvertibleSeniorNotes175PercentMember" xlink:href="ions-20250930.xsd#ions_ConvertibleSeniorNotes175PercentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="ConvertibleSeniorNotes175PercentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ConvertibleSeniorNotes0PercentMember" xlink:href="ions-20250930.xsd#ions_ConvertibleSeniorNotes0PercentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="ConvertibleSeniorNotes0PercentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_NotesPayableFairValueDisclosure" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://ionis.com/role/StockbasedCompensationExpenseDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PerformanceSharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_PerformanceSharesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GranteeStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_GranteeStatusAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GranteeStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ExecutiveOfficerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="srt_ExecutiveOfficerMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardDateAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="GrantedIn2025Member" xlink:href="ions-20250930.xsd#ions_GrantedIn2025Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="GrantedIn2025Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GrantedIn2024Member" xlink:href="ions-20250930.xsd#ions_GrantedIn2024Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="GrantedIn2024Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfUnitsGuaranteedToVest" xlink:href="ions-20250930.xsd#ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfUnitsGuaranteedToVest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfUnitsGuaranteedToVest" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfUnitsGuaranteedToVest" xlink:href="ions-20250930.xsd#ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfUnitsGuaranteedToVest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfUnitsGuaranteedToVest" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://ionis.com/role/IncomeTaxesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://ionis.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="RoyaltyPurchaseAgreementMember" xlink:href="ions-20250930.xsd#ions_RoyaltyPurchaseAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="RoyaltyPurchaseAgreementMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SpinrazaMember" xlink:href="ions-20250930.xsd#ions_SpinrazaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="SpinrazaMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PelacarsenMember" xlink:href="ions-20250930.xsd#ions_PelacarsenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="PelacarsenMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="UpfrontRoyaltyPaymentReceived" xlink:href="ions-20250930.xsd#ions_UpfrontRoyaltyPaymentReceived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="UpfrontRoyaltyPaymentReceived" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MaximumAmountOfPaymentsReceivableForAdditionalMilestones" xlink:href="ions-20250930.xsd#ions_MaximumAmountOfPaymentsReceivableForAdditionalMilestones"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MaximumAmountOfPaymentsReceivableForAdditionalMilestones" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfRoyaltyPaymentsPaidOnAnnualSalesOfMedicine" xlink:href="ions-20250930.xsd#ions_PercentageOfRoyaltyPaymentsPaidOnAnnualSalesOfMedicine"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="PercentageOfRoyaltyPaymentsPaidOnAnnualSalesOfMedicine" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MaximumAmountOfAnnualSalesOnWhichRoyaltyPaymentsArePaid" xlink:href="ions-20250930.xsd#ions_MaximumAmountOfAnnualSalesOnWhichRoyaltyPaymentsArePaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MaximumAmountOfAnnualSalesOnWhichRoyaltyPaymentsArePaid" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MaximumRoyaltyPaymentsMadeBeforeRoyaltyInterestRevertsBack" xlink:href="ions-20250930.xsd#ions_MaximumRoyaltyPaymentsMadeBeforeRoyaltyInterestRevertsBack"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MaximumRoyaltyPaymentsMadeBeforeRoyaltyInterestRevertsBack" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentsForTransactionCostsRelatedToSaleOfFutureRoyalties" xlink:href="ions-20250930.xsd#ions_PaymentsForTransactionCostsRelatedToSaleOfFutureRoyalties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="PaymentsForTransactionCostsRelatedToSaleOfFutureRoyalties" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://ionis.com/role/ConvertibleDebtDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ConvertibleSeniorNotes175PercentMember" xlink:href="ions-20250930.xsd#ions_ConvertibleSeniorNotes175PercentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="ConvertibleSeniorNotes175PercentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ConvertibleSeniorNotes0PercentMember" xlink:href="ions-20250930.xsd#ions_ConvertibleSeniorNotes0PercentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="ConvertibleSeniorNotes0PercentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtInstrumentConvertibleConversionPriceIncludingCallSpread" xlink:href="ions-20250930.xsd#ions_DebtInstrumentConvertibleConversionPriceIncludingCallSpread"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="DebtInstrumentConvertibleConversionPriceIncludingCallSpread" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="CallSpread" xlink:href="ions-20250930.xsd#ions_CallSpread"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="CallSpread" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForHedgeFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForHedgeFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_PaymentsForHedgeFinancingActivities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange" xlink:href="ions-20250930.xsd#ions_DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://ionis.com/role/OperatingLeasesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="HeadquartersLocationInCarlsbadCaliforniaMember" xlink:href="ions-20250930.xsd#ions_HeadquartersLocationInCarlsbadCaliforniaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="HeadquartersLocationInCarlsbadCaliforniaMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LandMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LandMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfPurchaseAndSaleAgreementsEnteredIntoWithRealEstateInvestor" xlink:href="ions-20250930.xsd#ions_NumberOfPurchaseAndSaleAgreementsEnteredIntoWithRealEstateInvestor"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="NumberOfPurchaseAndSaleAgreementsEnteredIntoWithRealEstateInvestor" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LesseeOperatingLeaseNumberOfOptionsToExtendLease" xlink:href="ions-20250930.xsd#ions_LesseeOperatingLeaseNumberOfOptionsToExtendLease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseNumberOfOptionsToExtendLease" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfLotsOfUndevelopedLandTransferredToRealEstateInvestor" xlink:href="ions-20250930.xsd#ions_NumberOfLotsOfUndevelopedLandTransferredToRealEstateInvestor"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="NumberOfLotsOfUndevelopedLandTransferredToRealEstateInvestor" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncentiveFromLessor" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncentiveFromLessor"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_IncentiveFromLessor" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleAndLeasebackTransactionGainLossNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleAndLeasebackTransactionGainLossNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_SaleAndLeasebackTransactionGainLossNet" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OtherLiabilities" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://ionis.com/role/SegmentInformationDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfReportableSegments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingOtherItemCompositionDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemCompositionDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingOtherItemCompositionDescription" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/dei/role/document/Cover" xlink:type="extended"/>
<!-- [WMV6][+QmqS5fyeDIxRagsOcoyzna99HZkpjfCZakjl6ajcpAXXNnKBthZq9+UgkiaBy7ghPUEzePFLTdmNrF/Aug8ilvVBnfQLr45d1ezVcayPLaZrsZrH5R+hTsuvElo25bklFklLs1D2kKYRt3STatpAPbJTPluWApybJeyS0E2LuuupVBxPsNyDLIVos2dwUiQBshvv4zaQmJkr+yrexmsIqwkGeYiFR9eK9Dw+1BSeLEuBR6VA1pHmxtpHGWAeQkE7z2N5shhKfcT5+J+c22+wD6rhCecuaP7uA22pMcYaJ1K59nGfsG4kwF/UYwvp9MhBidkKrZEug==] CSR-->
  <presentationLink xlink:role="http://xbrl.sec.gov/dei/role/document/AuditInformation" xlink:type="extended"/>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>ions-20250930_cal.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION - CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Wed Oct 29 20:43:09 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_ConsolidatedBalanceSheet" roleURI="http://ionis.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_ConsolidatedIncomeStatement" roleURI="http://ionis.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_ConsolidatedComprehensiveIncome" roleURI="http://ionis.com/role/ConsolidatedComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_ConsolidatedCashFlow" roleURI="http://ionis.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_InventoriesTable" roleURI="http://ionis.com/role/InventoriesTable"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_AccruedLiabilitiesTable" roleURI="http://ionis.com/role/AccruedLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_SummaryofInvestmentsTable" roleURI="http://ionis.com/role/SummaryofInvestmentsTable"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_StockbasedCompensationExpenseTable" roleURI="http://ionis.com/role/StockbasedCompensationExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_SegmentInformationTable" roleURI="http://ionis.com/role/SegmentInformationTable"/>
  <roleRef xlink:type="simple" xlink:href="ions-20250930.xsd#ions_r_AdditionalCalculations" roleURI="http://ionis.com/role/AdditionalCalculations"/>
  <calculationLink xlink:role="http://ionis.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ShortTermInvestments" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ConvertibleDebtCurrent" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_ConvertibleDebtNoncurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ions_LiabilityRelatedToSaleOfFutureRoyaltiesNetNoncurrent" xlink:href="ions-20250930.xsd#ions_LiabilityRelatedToSaleOfFutureRoyaltiesNetNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="ions_LiabilityRelatedToSaleOfFutureRoyaltiesNetNoncurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://ionis.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpenses"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ions_ResearchDevelopmentAndPatentExpense" xlink:href="ions-20250930.xsd#ions_ResearchDevelopmentAndPatentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="ions_ResearchDevelopmentAndPatentExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_CostsAndExpenses" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_InvestmentIncomeNet" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_GainLossOnInvestments" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_InterestExpense" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ions_InterestExpenseAndAmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties" xlink:href="ions-20250930.xsd#ions_InterestExpenseAndAmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="ions_InterestExpenseAndAmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://ionis.com/role/ConsolidatedComprehensiveIncome" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://ionis.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="ions_InterestExpenseRelatedToSaleOfFutureRoyalties" xlink:href="ions-20250930.xsd#ions_InterestExpenseRelatedToSaleOfFutureRoyalties"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="ions_InterestExpenseRelatedToSaleOfFutureRoyalties" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" order="10" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherEmployeeRelatedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherEmployeeRelatedLiabilities" order="11" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" order="12" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="13" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="14" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ions_RoyaltyPayments" xlink:href="ions-20250930.xsd#ions_RoyaltyPayments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="ions_RoyaltyPayments" order="15" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RealizedInvestmentGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_RealizedInvestmentGainsLosses" order="16" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerAsset" order="17" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="18" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="19" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfSecuredDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfSecuredDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfSecuredDebt" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="4" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://ionis.com/role/InventoriesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ions_InventoryCurrentAndNoncurrent" xlink:href="ions-20250930.xsd#ions_InventoryCurrentAndNoncurrent"/>
    <loc xlink:type="locator" xlink:label="ions_InventoryRawMaterialsNet" xlink:href="ions-20250930.xsd#ions_InventoryRawMaterialsNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ions_InventoryCurrentAndNoncurrent" xlink:to="ions_InventoryRawMaterialsNet" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ions_InventoryWorkInProcessNet" xlink:href="ions-20250930.xsd#ions_InventoryWorkInProcessNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ions_InventoryCurrentAndNoncurrent" xlink:to="ions_InventoryWorkInProcessNet" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ions_InventoryFinishedGoodsNet" xlink:href="ions-20250930.xsd#ions_InventoryFinishedGoodsNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ions_InventoryCurrentAndNoncurrent" xlink:to="ions_InventoryFinishedGoodsNet" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://ionis.com/role/AccruedLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="ions_AccruedClinicalExpenses" xlink:href="ions-20250930.xsd#ions_AccruedClinicalExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="ions_AccruedClinicalExpenses" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ions_AccruedInLicensingFeesCurrent" xlink:href="ions-20250930.xsd#ions_AccruedInLicensingFeesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="ions_AccruedInLicensingFeesCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ions_AccruedCommercialExpensesCurrent" xlink:href="ions-20250930.xsd#ions_AccruedCommercialExpensesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="ions_AccruedCommercialExpensesCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="4" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://ionis.com/role/SummaryofInvestmentsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <loc xlink:type="locator" xlink:label="ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:href="ions-20250930.xsd#ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" xlink:href="ions-20250930.xsd#ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <loc xlink:type="locator" xlink:label="ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:href="ions-20250930.xsd#ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" xlink:href="ions-20250930.xsd#ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost" xlink:href="ions-20250930.xsd#ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesFvNiCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost" xlink:to="us-gaap_EquitySecuritiesFvNiCost" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain" xlink:href="ions-20250930.xsd#ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ions_EquitySecuritiesFvNiAccumulatedGrossUnrealizedGain" xlink:href="ions-20250930.xsd#ions_EquitySecuritiesFvNiAccumulatedGrossUnrealizedGain"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain" xlink:to="ions_EquitySecuritiesFvNiAccumulatedGrossUnrealizedGain" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss" xlink:href="ions-20250930.xsd#ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ions_EquitySecuritiesFvNiAccumulatedGrossUnrealizedLoss" xlink:href="ions-20250930.xsd#ions_EquitySecuritiesFvNiAccumulatedGrossUnrealizedLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss" xlink:to="ions_EquitySecuritiesFvNiAccumulatedGrossUnrealizedLoss" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi" xlink:href="ions-20250930.xsd#ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi" xlink:to="us-gaap_EquitySecuritiesFvNi" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://ionis.com/role/StockbasedCompensationExpenseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://ionis.com/role/SegmentInformationTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ions_DrugDiscoveryExpenses" xlink:href="ions-20250930.xsd#ions_DrugDiscoveryExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="ions_DrugDiscoveryExpenses" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ions_DrugDevelopmentExpenses" xlink:href="ions-20250930.xsd#ions_DrugDevelopmentExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="ions_DrugDevelopmentExpenses" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ions_MedicalAffairsExpenses" xlink:href="ions-20250930.xsd#ions_MedicalAffairsExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="ions_MedicalAffairsExpenses" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ions_ManufacturingAndDevelopmentChemistryExpenses" xlink:href="ions-20250930.xsd#ions_ManufacturingAndDevelopmentChemistryExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="ions_ManufacturingAndDevelopmentChemistryExpenses" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ions_ResearchAndDevelopmentSupportExpenses" xlink:href="ions-20250930.xsd#ions_ResearchAndDevelopmentSupportExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="ions_ResearchAndDevelopmentSupportExpenses" order="7" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="8" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingOtherItemAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_SegmentReportingOtherItemAmount" order="9" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://ionis.com/role/AdditionalCalculations" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ions_AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage" xlink:href="ions-20250930.xsd#ions_AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage"/>
    <loc xlink:type="locator" xlink:label="ions_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage" xlink:href="ions-20250930.xsd#ions_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ions_AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage" xlink:to="ions_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ions_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage" xlink:href="ions-20250930.xsd#ions_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ions_AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage" xlink:to="ions_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ions_AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage" xlink:href="ions-20250930.xsd#ions_AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ions_AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage" xlink:to="ions_AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ions_InventoryCurrentAndNoncurrent" xlink:href="ions-20250930.xsd#ions_InventoryCurrentAndNoncurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ions_InventoryCurrentAndNoncurrent" xlink:to="us-gaap_InventoryNet" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ions_InventoryCurrentAndNoncurrent" xlink:to="us-gaap_InventoryNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_EquitySecuritiesFvNi" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <loc xlink:type="locator" xlink:label="ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:href="ions-20250930.xsd#ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:to="ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:href="ions-20250930.xsd#ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:to="ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent"/>
    <loc xlink:type="locator" xlink:label="ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" xlink:href="ions-20250930.xsd#ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:to="ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" xlink:href="ions-20250930.xsd#ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:to="ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesFvNiCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <loc xlink:type="locator" xlink:label="ions_EquitySecuritiesFvNiAccumulatedGrossUnrealizedLoss" xlink:href="ions-20250930.xsd#ions_EquitySecuritiesFvNiAccumulatedGrossUnrealizedLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EquitySecuritiesFvNiCost" xlink:to="ions_EquitySecuritiesFvNiAccumulatedGrossUnrealizedLoss" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EquitySecuritiesFvNiCost" xlink:to="us-gaap_EquitySecuritiesFvNi" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ions_EquitySecuritiesFvNiAccumulatedGrossUnrealizedGain" xlink:href="ions-20250930.xsd#ions_EquitySecuritiesFvNiAccumulatedGrossUnrealizedGain"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EquitySecuritiesFvNiCost" xlink:to="ions_EquitySecuritiesFvNiAccumulatedGrossUnrealizedGain" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost" xlink:href="ions-20250930.xsd#ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost"/>
    <loc xlink:type="locator" xlink:label="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss" xlink:href="ions-20250930.xsd#ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost" xlink:to="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi" xlink:href="ions-20250930.xsd#ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost" xlink:to="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain" xlink:href="ions-20250930.xsd#ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain"/>
<!-- [WMV6][tCEy75ipknyGxhGyRkRPSgkB61pw17wznjVfXiZP+ENTMLA3K8EgqsXbVsMgoo1nB7DsFCTA5qHq7KnpIn/SxBXpN722oDJ9HiWDEyjzYMcSZW2nYSXs2fyK9AO5G65h6WJYaShc2fQro+jNXrw2Na7IGc1Ti/j7o+vfPECSRnT949sEcjPxXkNhoTiuFwNqKNbszrH7tfxUgL2uqkFOALPINGDJ13krg4txMe14mt5yoIM/SqaFW4zvfLkMp6MA5MtjPjjB0vFcdStNi9FHofqZ3aE8wxrPJBTiaKh6dT9fcCJgVkltbUXACFvgYlGDX5dKrq7WTg==] CSR-->
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost" xlink:to="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain" order="3" weight="-1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!-- Created by CompSci Resources, LLC on Mon Jul 28 02:03:31 UTC 2025 --><html>
 <head><meta content="text/html; charset=ASCII">
  <title></title>
 </head>
 <body style="font-family: Times New Roman; font-size: 10pt;">
  <div style="text-align: right;">
   <font style="font-weight: bold;">EXHIBIT 31.1</font>
  </div>
  <div>&#xa0;
  </div>
  <div style="text-align: center;">
   <font>CERTIFICATION</font>
  </div>
  <div>&#xa0;
  </div>
  <div style="text-align: justify;">
   <font>I, Brett P. Monia, certify that:</font>
  </div>
  <div>&#xa0;
  </div>
  <div style="text-indent: -18pt; text-align: justify; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <font>1.</font>
    </div>
    <div>
     <font>I have reviewed this Quarterly Report on Form 10-Q of Ionis Pharmaceuticals, Inc.;</font>
    </div>
  </div>
  <div style="margin-left: 36pt;">&#xa0;
  </div>
  <div style="text-indent: -18pt; text-align: justify; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <font>2.</font>
    </div>
    <div>
     <font>Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;</font>
    </div>
  </div>
  <div style="margin-left: 36pt;">&#xa0;
  </div>
  <div style="text-indent: -18pt; text-align: justify; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <font>3.</font>
    </div>
    <div>
     <font>Based on my knowledge, the condensed consolidated financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, condensed consolidated results of operations and condensed consolidated cash flows of the registrant as of, and for, the periods presented in this quarterly report;</font>
    </div>
  </div>
  <div style="margin-left: 36pt;">&#xa0;
  </div>
  <div style="text-indent: -18pt; text-align: justify; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <font>4.</font>
    </div>
    <div>
     <font>The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font>
    </div>
  </div>
  <div>&#xa0;
  </div>
  <div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <font>a)</font>
    </div>
    <div>
     <font>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font>
    </div>
  </div>
  <div style="margin-left: 54pt;">&#xa0;
  </div>
  <div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <font>b)</font>
    </div>
    <div>
     <font>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font>
    </div>
  </div>
  <div style="margin-left: 54pt;">&#xa0;
  </div>
  <div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <font>c)</font>
    </div>
    <div>
     <font>Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font>
    </div>
  </div>
  <div style="margin-left: 54pt;">&#xa0;
  </div>
  <div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <font>d)</font>
    </div>
    <div>
     <font>Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font>
    </div>
  </div>
  <div>&#xa0;
  </div>
  <div style="text-indent: -18pt; text-align: justify; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <font>5.</font>
    </div>
    <div>
     <font>The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font>
    </div>
  </div>
  <div>&#xa0;
  </div>
  <div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <font>a)</font>
    </div>
    <div>
     <font>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font>
    </div>
  </div>
  <div style="margin-left: 54pt;">&#xa0;
  </div>
  <div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <font>b)</font>
    </div>
    <div>
     <font>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font>
    </div>
  </div>
  <div style="text-align: justify;">
   <font>&#xa0;</font>
  </div>
  <div>
   <font>&#xa0;</font>
  </div>
  <table style="font-size: 10pt; border-spacing: 0px; border-collapse: collapse;">
   <tr style="vertical-align: top;">
    <td style="padding: 0; width: 144.4pt;">
     <div>
      <font>Dated: October 29, 2025</font>
     </div>
    </td>
    <td style="padding: 0; width: 378.9pt;">
     <div>
      <font>&#xa0;</font>
     </div>
    </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding: 0; width: 144.4pt;">
     <div>
      <font>&#xa0;</font>
     </div>
    </td>
    <td style="padding: 0; width: 378.9pt;">
     <div>
      <font>&#xa0;</font>
     </div>
    </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding: 0; width: 144.4pt; border-bottom: 1pt solid #000000;">
     <div>
      <font>/s/ BRETT P. MONIA</font>
     </div>
    </td>
    <td style="padding: 0; width: 378.9pt;">
     <div>
      <font>&#xa0;</font>
     </div>
    </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding: 0; width: 144.4pt;">
     <div>
      <font>Brett P. Monia, Ph.D.</font>
     </div>
    </td>
    <td style="padding: 0; width: 378.9pt;">
     <div>
      <font>&#xa0;</font>
     </div>
    </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding: 0; width: 144.4pt;">
     <div>
      <font>Chief Executive Officer</font>
     </div>
    </td>
    <td style="padding: 0; width: 378.9pt;">
     <div>
      <font>&#xa0;</font>
     </div>
    </td>
   </tr>
  </table>
  <div style="text-align: justify;">&#xa0;
  </div>
  <div style="text-align: justify;">&#xa0;
  </div>
 </body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!-- Created by CompSci Resources, LLC on Mon Jul 28 02:03:31 UTC 2025 --><html>
 <head><meta content="text/html; charset=ASCII">
  <title></title>
 </head>
 <body style="font-family: Times New Roman; font-size: 10pt;">
  <div style="text-align: right;">
   <font style="font-weight: bold;">EXHIBIT 31.2</font>
  </div>
  <div style="text-align: center;">&#xa0;
  </div>
  <div style="text-align: center;">
   <font>CERTIFICATION</font>
  </div>
  <div>&#xa0;
  </div>
  <div style="text-align: justify;">
   <font>I, Elizabeth L. Hougen, certify that:</font>
  </div>
  <div>&#xa0;
  </div>
  <div style="text-indent: -18pt; text-align: justify; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <font>1.</font>
    </div>
    <div>
     <font>I have reviewed this Quarterly Report on Form 10-Q of Ionis Pharmaceuticals, Inc.;</font>
    </div>
  </div>
  <div>&#xa0;
  </div>
  <div style="text-indent: -18pt; text-align: justify; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <font>2.</font>
    </div>
    <div>
     <font>Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;</font>
    </div>
  </div>
  <div style="margin-left: 36pt;">&#xa0;
  </div>
  <div style="text-indent: -18pt; text-align: justify; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <font>3.</font>
    </div>
    <div>
     <font>Based on my knowledge, the condensed consolidated financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, condensed consolidated results of operations and condensed consolidated cash flows of the registrant as of, and for, the periods presented in this quarterly report;</font>
    </div>
  </div>
  <div style="margin-left: 36pt;">&#xa0;
  </div>
  <div style="text-indent: -18pt; text-align: justify; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <font>4.</font>
    </div>
    <div>
     <font>The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font>
    </div>
  </div>
  <div>&#xa0;
  </div>
  <div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <font>a)</font>
    </div>
    <div>
     <font>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font>
    </div>
  </div>
  <div style="margin-left: 54pt;">&#xa0;
  </div>
  <div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <font>b)</font>
    </div>
    <div>
     <font>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font>
    </div>
  </div>
  <div style="margin-left: 54pt;">&#xa0;
  </div>
  <div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <font>c)</font>
    </div>
    <div>
     <font>Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font>
    </div>
  </div>
  <div style="margin-left: 54pt;">&#xa0;
  </div>
  <div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <font>d)</font>
    </div>
    <div>
     <font>Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font>
    </div>
  </div>
  <div>&#xa0;
  </div>
  <div style="text-indent: -18pt; text-align: justify; padding-left: 36pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <font>5.</font>
    </div>
    <div>
     <font>The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font>
    </div>
  </div>
  <div>&#xa0;
  </div>
  <div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <font>a)</font>
    </div>
    <div>
     <font>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font>
    </div>
  </div>
  <div style="margin-left: 54pt;">&#xa0;
  </div>
  <div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <font>b)</font>
    </div>
    <div>
     <font>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font>
    </div>
  </div>
  <div style="text-align: justify;">&#xa0;
  </div>
  <div>&#xa0;
  </div>
  <table style="font-size: 10pt; border-spacing: 0px; border-collapse: collapse;">
   <tr style="vertical-align: top;">
    <td style="padding: 0; width: 143.65pt;">
     <div>
      <font>Dated: October 29, 2025</font>
     </div>
    </td>
    <td style="padding: 0; width: 379.65pt;">
     <div>
      <font>&#xa0;</font>
     </div>
    </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding: 0; width: 143.65pt;">
     <div>
      <font>&#xa0;</font>
     </div>
    </td>
    <td style="padding: 0; width: 379.65pt;">
     <div>
      <font>&#xa0;</font>
     </div>
    </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding: 0; width: 143.65pt; border-bottom: 1pt solid #000000;">
     <div>
      <font>/s/ ELIZABETH L. HOUGEN</font>
     </div>
    </td>
    <td style="padding: 0; width: 379.65pt;">
     <div>
      <font>&#xa0;</font>
     </div>
    </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding: 0; width: 143.65pt;">
     <div>
      <font>Elizabeth L. Hougen</font>
     </div>
    </td>
    <td style="padding: 0; width: 379.65pt;">
     <div>
      <font>&#xa0;</font>
     </div>
    </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding: 0; width: 143.65pt;">
     <div>
      <font>Chief Financial Officer</font>
     </div>
    </td>
    <td style="padding: 0; width: 379.65pt;">
     <div>
      <font>&#xa0;</font>
     </div>
    </td>
   </tr>
  </table>
  <div>&#xa0;
  </div>
  <div>&#xa0;
  </div>
 </body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>9
<FILENAME>ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!-- Created by CompSci Resources, LLC on Mon Jul 28 02:03:31 UTC 2025 --><html>
 <head><meta content="text/html; charset=ASCII">
  <title></title>
 </head>
 <body style="font-family: Times New Roman; font-size: 10pt;">
  <div style="text-align: right;">
   <font style="font-weight: bold;">Exhibit 32.1</font>
  </div>
  <div style="text-align: center;">&#xa0;
  </div>
  <div style="text-align: center;">
   <font>CERTIFICATION</font>
  </div>
  <div>&#xa0;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <font>Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Brett P. Monia, the Chief Executive Officer of Ionis Pharmaceuticals, Inc., (the &#x201c;Company&#x201d;), and Elizabeth L. Hougen, the Chief Financial Officer of the Company, each hereby certifies that, to the best of his or her knowledge:</font>
  </div>
  <div>&#xa0;
  </div>
  <div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <font>1.</font>
    </div>
    <div>
     <font>The Company&#x2019;s Quarterly Report on Form 10-Q for the period ended September 30, 2025, to which this Certification is attached as Exhibit 32.1 (the &#x201c;Periodic Report&#x201d;), fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended; and</font>
    </div>
  </div>
  <div style="text-align: justify; margin-left: 54pt;">&#xa0;
  </div>
  <div style="text-indent: -18pt; text-align: justify; padding-left: 54pt;">
    <div style="float: left; width: 18.0pt; white-space: nowrap;">
     <font>2.</font>
    </div>
    <div>
     <font>The information contained in the Periodic Report fairly presents, in all material respects, the financial condition of the Company at the end of the period covered by the Periodic Report and the results of operations of the Company for the period covered by the Periodic Report.</font>
    </div>
  </div>
  <div>&#xa0;
  </div>
  <div>&#xa0;
  </div>

  <table style="font-size: 10pt; border-spacing: 0px; border-collapse: collapse; width: 100%;">
   <tr style="height: 0px; font-size: 0px;"><td style="width: 25%;">&#xa0;</td><td style="width: 25%;">&#xa0;</td><td style="width: 25%;">&#xa0;</td><td style="width: 25%;">&#xa0;</td></tr><tr style="vertical-align: top;">
    <td style="padding: 0px;">
     <div>
      <font>Dated: October 29, 2025</font>
     </div>
    </td>
    <td style="padding: 0px;">
     <div>
      <font>&#xa0;</font>
     </div>
    </td>
    <td style="padding: 0px;">
     <div>
      <font>&#xa0;</font>
     </div>
    </td>
    <td style="padding: 0px;">&#xa0;
    </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding: 0px;">
     <div>
      <font>&#xa0;</font>
     </div>
    </td>
    <td style="padding: 0px;">
     <div>
      <font>&#xa0;</font>
     </div>
    </td>
    <td style="padding: 0px;">
     <div>
      <font>&#xa0;</font>
     </div>
    </td>
    <td style="padding: 0px;">&#xa0;
    </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding: 0px; border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom;">
     <div>
      <font>/s/ BRETT P. MONIA</font>
     </div>
    </td>
    <td style="padding: 0px;">
     <div>
      <font>&#xa0;</font>
     </div>
    </td>
    <td style="padding: 0px; border-bottom: 1pt solid rgb(0, 0, 0);">
     <div>
      <font>/s/ ELIZABETH L. HOUGEN</font>
     </div>
    </td>
    <td style="padding: 0px;">&#xa0;
    </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding: 0px;">
     <div>
      <font>Brett P. Monia, Ph.D.</font>
     </div>
    </td>
    <td style="padding: 0px;">
     <div>
      <font>&#xa0;</font>
     </div>
    </td>
    <td style="padding: 0px;">
     <div>
      <font>Elizabeth L. Hougen</font>
     </div>
    </td>
    <td style="padding: 0px;">&#xa0;
    </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding: 0px;">
     <div>
      <font>Chief Executive Officer</font>
     </div>
    </td>
    <td style="padding: 0px;">
     <div>
      <font>&#xa0;</font>
     </div>
    </td>
    <td style="padding: 0px;">
     <div>
      <font>Chief Financial Officer</font>
     </div>
    </td>
    <td style="padding: 0px;">&#xa0;
    </td>
   </tr>
  </table><div>&#xa0;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <font>A signed original of this written statement required by Section 906 has been provided to Ionis Pharmaceuticals, Inc. and will be retained by Ionis Pharmaceuticals, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font>
  </div>
  <div>&#xa0;
  </div>
  <div>&#xa0;
  </div>
 </body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Oct. 23, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Ionis Pharmaceuticals, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000874015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-19125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0336973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityContactPersonnelLineItems', window );"><strong>Entity Contact Personnel [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2855 Gazelle Court<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Carlsbad<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPhoneFaxNumbersLineItems', window );"><strong>Entity Phone Fax Numbers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">931-9200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $.001 Par Value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IONS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">161,974,393<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityContactPersonnelLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityContactPersonnelLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPhoneFaxNumbersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPhoneFaxNumbersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 338,341<span></span>
</td>
<td class="nump">$ 242,077<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">1,901,830<span></span>
</td>
<td class="nump">2,055,579<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contracts receivable</a></td>
<td class="nump">24,608<span></span>
</td>
<td class="nump">92,188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">10,470<span></span>
</td>
<td class="nump">12,512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">243,744<span></span>
</td>
<td class="nump">217,934<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">2,518,993<span></span>
</td>
<td class="nump">2,620,290<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">106,117<span></span>
</td>
<td class="nump">94,251<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">241,993<span></span>
</td>
<td class="nump">161,856<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Deposits and other assets</a></td>
<td class="nump">165,988<span></span>
</td>
<td class="nump">127,278<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">3,033,091<span></span>
</td>
<td class="nump">3,003,675<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">14,326<span></span>
</td>
<td class="nump">42,964<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">57,019<span></span>
</td>
<td class="nump">69,614<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">99,310<span></span>
</td>
<td class="nump">108,438<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable</a></td>
<td class="nump">101<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">0 percent convertible senior notes, net</a></td>
<td class="nump">630,911<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current portion of deferred contract revenue</a></td>
<td class="nump">76,986<span></span>
</td>
<td class="nump">78,989<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">24,803<span></span>
</td>
<td class="nump">9,279<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">903,456<span></span>
</td>
<td class="nump">309,318<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term deferred contract revenue</a></td>
<td class="nump">107,906<span></span>
</td>
<td class="nump">156,504<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_LiabilityRelatedToSaleOfFutureRoyaltiesNetNoncurrent', window );">Liability related to sale of future royalties, net</a></td>
<td class="nump">545,182<span></span>
</td>
<td class="nump">542,212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term lease liabilities</a></td>
<td class="nump">262,672<span></span>
</td>
<td class="nump">161,805<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Long-term obligations</a></td>
<td class="nump">28,785<span></span>
</td>
<td class="nump">51,924<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">2,415,124<span></span>
</td>
<td class="nump">2,415,324<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 300,000,000 shares authorized, 161,137,930 and 157,908,815 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively</a></td>
<td class="nump">161<span></span>
</td>
<td class="nump">158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">3,045,585<span></span>
</td>
<td class="nump">2,868,812<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="num">(25,978)<span></span>
</td>
<td class="num">(30,811)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(2,401,801)<span></span>
</td>
<td class="num">(2,249,808)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">617,967<span></span>
</td>
<td class="nump">588,351<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">3,033,091<span></span>
</td>
<td class="nump">3,003,675<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes175PercentMember', window );">1.75 Percent Convertible Senior Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible senior notes, net</a></td>
<td class="nump">567,123<span></span>
</td>
<td class="nump">565,026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes0PercentMember', window );">0 Percent Convertible Senior Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible senior notes, net</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 628,535<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_LiabilityRelatedToSaleOfFutureRoyaltiesNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of the unamortized liability related to the sale of future royalties, pursuant to a royalty purchase agreement, that the Company is entitled to receive under collaboration agreements with Biogen and Novartis. The balance will be amortized over the estimated life of the arrangement using the effective interest rate method. Used to reflect the noncurrent portion of the liability (due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_LiabilityRelatedToSaleOfFutureRoyaltiesNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes175PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes175PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes0PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes0PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in Shares)</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in Shares)</a></td>
<td class="nump">161,137,930<span></span>
</td>
<td class="nump">157,908,815<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in Shares)</a></td>
<td class="nump">161,137,930<span></span>
</td>
<td class="nump">157,908,815<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes0PercentMember', window );">0 Percent Convertible Senior Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on convertible senior notes</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes175PercentMember', window );">1.75 Percent Convertible Senior Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on convertible senior notes</a></td>
<td class="nump">1.75%<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes0PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes0PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes175PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes175PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 156,719<span></span>
</td>
<td class="nump">$ 133,814<span></span>
</td>
<td class="nump">$ 740,381<span></span>
</td>
<td class="nump">$ 478,562<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">2,338<span></span>
</td>
<td class="nump">1,071<span></span>
</td>
<td class="nump">7,952<span></span>
</td>
<td class="nump">7,385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_ResearchDevelopmentAndPatentExpense', window );">Research, development and patent</a></td>
<td class="nump">217,754<span></span>
</td>
<td class="nump">219,761<span></span>
</td>
<td class="nump">635,973<span></span>
</td>
<td class="nump">656,040<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">96,809<span></span>
</td>
<td class="nump">61,638<span></span>
</td>
<td class="nump">263,681<span></span>
</td>
<td class="nump">179,395<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">316,901<span></span>
</td>
<td class="nump">282,470<span></span>
</td>
<td class="nump">907,606<span></span>
</td>
<td class="nump">842,820<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(160,182)<span></span>
</td>
<td class="num">(148,656)<span></span>
</td>
<td class="num">(167,225)<span></span>
</td>
<td class="num">(364,258)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Investment income</a></td>
<td class="nump">23,682<span></span>
</td>
<td class="nump">26,228<span></span>
</td>
<td class="nump">73,035<span></span>
</td>
<td class="nump">78,112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(4,212)<span></span>
</td>
<td class="num">(4,161)<span></span>
</td>
<td class="num">(12,434)<span></span>
</td>
<td class="num">(12,803)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_InterestExpenseAndAmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties', window );">Interest expense related to sale of future royalties</a></td>
<td class="num">(17,952)<span></span>
</td>
<td class="num">(18,533)<span></span>
</td>
<td class="num">(55,422)<span></span>
</td>
<td class="num">(54,788)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Gain (loss) on investments, net</a></td>
<td class="nump">29,908<span></span>
</td>
<td class="nump">879<span></span>
</td>
<td class="nump">9,432<span></span>
</td>
<td class="num">(321)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">363<span></span>
</td>
<td class="nump">142<span></span>
</td>
<td class="nump">929<span></span>
</td>
<td class="nump">1,029<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax benefit (expense)</a></td>
<td class="num">(128,393)<span></span>
</td>
<td class="num">(144,101)<span></span>
</td>
<td class="num">(151,685)<span></span>
</td>
<td class="num">(353,029)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="num">(213)<span></span>
</td>
<td class="nump">3,621<span></span>
</td>
<td class="num">(308)<span></span>
</td>
<td class="nump">3,481<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (128,606)<span></span>
</td>
<td class="num">$ (140,480)<span></span>
</td>
<td class="num">$ (151,993)<span></span>
</td>
<td class="num">$ (349,548)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per share (in Dollars per share)</a></td>
<td class="num">$ (0.8)<span></span>
</td>
<td class="num">$ (0.95)<span></span>
</td>
<td class="num">$ (0.95)<span></span>
</td>
<td class="num">$ (2.38)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per share (in Dollars per share)</a></td>
<td class="num">$ (0.8)<span></span>
</td>
<td class="num">$ (0.95)<span></span>
</td>
<td class="num">$ (0.95)<span></span>
</td>
<td class="num">$ (2.38)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used in computing basic net loss per share (in Shares)</a></td>
<td class="nump">159,765<span></span>
</td>
<td class="nump">148,593<span></span>
</td>
<td class="nump">159,216<span></span>
</td>
<td class="nump">146,703<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in computing diluted net loss per share (in Shares)</a></td>
<td class="nump">159,765<span></span>
</td>
<td class="nump">148,593<span></span>
</td>
<td class="nump">159,216<span></span>
</td>
<td class="nump">146,703<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product Sales, Net [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 31,792<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 57,353<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">75,694<span></span>
</td>
<td class="nump">66,807<span></span>
</td>
<td class="nump">209,811<span></span>
</td>
<td class="nump">180,036<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ions_OtherCommercialMember', window );">Other Commercial Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">8,112<span></span>
</td>
<td class="nump">8,924<span></span>
</td>
<td class="nump">27,359<span></span>
</td>
<td class="nump">27,324<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ions_CommercialMember', window );">Commercial Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">115,598<span></span>
</td>
<td class="nump">75,731<span></span>
</td>
<td class="nump">294,523<span></span>
</td>
<td class="nump">207,360<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ions_CollaborativeAgreementRevenueMember', window );">Collaborative Agreement Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">31,436<span></span>
</td>
<td class="nump">44,883<span></span>
</td>
<td class="nump">413,387<span></span>
</td>
<td class="nump">235,753<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ions_WainuaJointDevelopmentRevenueMember', window );">WAINUA Joint Development Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">9,685<span></span>
</td>
<td class="nump">13,200<span></span>
</td>
<td class="nump">32,471<span></span>
</td>
<td class="nump">35,449<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ions_ResearchAndDevelopmentRevenueMember', window );">Research and Development Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 41,121<span></span>
</td>
<td class="nump">$ 58,083<span></span>
</td>
<td class="nump">$ 445,858<span></span>
</td>
<td class="nump">$ 271,202<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_InterestExpenseAndAmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense using the effective interest rate method and amortization of issuance costs related to the sale of future royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_InterestExpenseAndAmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_ResearchDevelopmentAndPatentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects. Also includes charges for amortization and write-downs of capitalized patent costs, as well as legal fees for patent litigation and patent defense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_ResearchDevelopmentAndPatentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ions_OtherCommercialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ions_OtherCommercialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ions_CommercialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ions_CommercialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ions_CollaborativeAgreementRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ions_CollaborativeAgreementRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ions_WainuaJointDevelopmentRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ions_WainuaJointDevelopmentRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ions_ResearchAndDevelopmentRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ions_ResearchAndDevelopmentRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (128,606)<span></span>
</td>
<td class="num">$ (140,480)<span></span>
</td>
<td class="num">$ (151,993)<span></span>
</td>
<td class="num">$ (349,548)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gains on debt securities, net of tax</a></td>
<td class="nump">2,091<span></span>
</td>
<td class="nump">10,315<span></span>
</td>
<td class="nump">4,088<span></span>
</td>
<td class="nump">8,259<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Currency translation adjustment</a></td>
<td class="num">(82)<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="nump">745<span></span>
</td>
<td class="nump">213<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (126,597)<span></span>
</td>
<td class="num">$ (129,815)<span></span>
</td>
<td class="num">$ (147,160)<span></span>
</td>
<td class="num">$ (341,076)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481839/830-10-45-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482014/830-20-35-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid in Capital [Member]</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at at Dec. 31, 2023</a></td>
<td class="nump">$ 144<span></span>
</td>
<td class="nump">$ 2,215,098<span></span>
</td>
<td class="num">$ (32,645)<span></span>
</td>
<td class="num">$ (1,795,911)<span></span>
</td>
<td class="nump">$ 386,686<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in Shares) at Dec. 31, 2023</a></td>
<td class="nump">144,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(349,548)<span></span>
</td>
<td class="num">(349,548)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Change in unrealized gains, net of tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,259<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">213<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">213<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Issuance of common stock in connection with employee stock plans, net</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">33,205<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">33,207<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock in connection with employee stock plans, net (in Shares)</a></td>
<td class="nump">1,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of public common stock, net</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">489,081<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">489,093<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of public common stock, net (in Shares)</a></td>
<td class="nump">11,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">94,558<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">94,558<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at at Sep. 30, 2024</a></td>
<td class="nump">$ 158<span></span>
</td>
<td class="nump">2,831,942<span></span>
</td>
<td class="num">(24,173)<span></span>
</td>
<td class="num">(2,145,459)<span></span>
</td>
<td class="nump">662,468<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in Shares) at Sep. 30, 2024</a></td>
<td class="nump">157,813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at at Jun. 30, 2024</a></td>
<td class="nump">$ 146<span></span>
</td>
<td class="nump">2,303,369<span></span>
</td>
<td class="num">(34,838)<span></span>
</td>
<td class="num">(2,004,979)<span></span>
</td>
<td class="nump">263,698<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in Shares) at Jun. 30, 2024</a></td>
<td class="nump">146,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(140,480)<span></span>
</td>
<td class="num">(140,480)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Change in unrealized gains, net of tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,315<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,315<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Issuance of common stock in connection with employee stock plans, net</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">7,002<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock in connection with employee stock plans, net (in Shares)</a></td>
<td class="nump">288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of public common stock, net</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">489,081<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">489,093<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of public common stock, net (in Shares)</a></td>
<td class="nump">11,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">32,490<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">32,490<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at at Sep. 30, 2024</a></td>
<td class="nump">$ 158<span></span>
</td>
<td class="nump">2,831,942<span></span>
</td>
<td class="num">(24,173)<span></span>
</td>
<td class="num">(2,145,459)<span></span>
</td>
<td class="nump">662,468<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in Shares) at Sep. 30, 2024</a></td>
<td class="nump">157,813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at at Dec. 31, 2024</a></td>
<td class="nump">$ 158<span></span>
</td>
<td class="nump">2,868,812<span></span>
</td>
<td class="num">(30,811)<span></span>
</td>
<td class="num">(2,249,808)<span></span>
</td>
<td class="nump">588,351<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in Shares) at Dec. 31, 2024</a></td>
<td class="nump">157,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(151,993)<span></span>
</td>
<td class="num">(151,993)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Change in unrealized gains, net of tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,088<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,088<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">745<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">745<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Issuance of common stock in connection with employee stock plans, net</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">84,784<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">84,787<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock in connection with employee stock plans, net (in Shares)</a></td>
<td class="nump">3,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">91,989<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">91,989<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at at Sep. 30, 2025</a></td>
<td class="nump">$ 161<span></span>
</td>
<td class="nump">3,045,585<span></span>
</td>
<td class="num">(25,978)<span></span>
</td>
<td class="num">(2,401,801)<span></span>
</td>
<td class="nump">617,967<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in Shares) at Sep. 30, 2025</a></td>
<td class="nump">161,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at at Jun. 30, 2025</a></td>
<td class="nump">$ 159<span></span>
</td>
<td class="nump">2,932,747<span></span>
</td>
<td class="num">(27,987)<span></span>
</td>
<td class="num">(2,273,195)<span></span>
</td>
<td class="nump">631,724<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in Shares) at Jun. 30, 2025</a></td>
<td class="nump">159,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(128,606)<span></span>
</td>
<td class="num">(128,606)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Change in unrealized gains, net of tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,091<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,091<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(82)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(82)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Issuance of common stock in connection with employee stock plans, net</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">81,257<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">81,259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock in connection with employee stock plans, net (in Shares)</a></td>
<td class="nump">1,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">31,581<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">31,581<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at at Sep. 30, 2025</a></td>
<td class="nump">$ 161<span></span>
</td>
<td class="nump">$ 3,045,585<span></span>
</td>
<td class="num">$ (25,978)<span></span>
</td>
<td class="num">$ (2,401,801)<span></span>
</td>
<td class="nump">$ 617,967<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in Shares) at Sep. 30, 2025</a></td>
<td class="nump">161,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481839/830-10-45-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482014/830-20-35-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (151,993)<span></span>
</td>
<td class="num">$ (349,548)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">6,749<span></span>
</td>
<td class="nump">7,374<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right-of-use operating lease assets</a></td>
<td class="nump">6,803<span></span>
</td>
<td class="nump">7,472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of other assets</a></td>
<td class="nump">1,801<span></span>
</td>
<td class="nump">1,877<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of discount on investments, net</a></td>
<td class="num">(18,063)<span></span>
</td>
<td class="num">(28,283)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">4,940<span></span>
</td>
<td class="nump">5,016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_RoyaltyPayments', window );">Non-cash royalty revenue related to sale of royalties</a></td>
<td class="num">(38,478)<span></span>
</td>
<td class="num">(30,422)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_InterestExpenseRelatedToSaleOfFutureRoyalties', window );">Non-cash interest related to sale of future royalties</a></td>
<td class="nump">54,964<span></span>
</td>
<td class="nump">54,330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">90,554<span></span>
</td>
<td class="nump">94,052<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RealizedInvestmentGainsLosses', window );">Loss (gain) on investments, net</a></td>
<td class="num">(9,437)<span></span>
</td>
<td class="nump">320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Non-cash losses related to other assets</a></td>
<td class="num">(3,643)<span></span>
</td>
<td class="nump">1,009<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset', window );">Contracts receivable</a></td>
<td class="nump">67,580<span></span>
</td>
<td class="nump">79,850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(14,600)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other current and long-term assets</a></td>
<td class="num">(123,489)<span></span>
</td>
<td class="num">(8,155)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(29,116)<span></span>
</td>
<td class="num">(19,215)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income taxes</a></td>
<td class="nump">67<span></span>
</td>
<td class="num">(2,110)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherEmployeeRelatedLiabilities', window );">Accrued compensation</a></td>
<td class="num">(12,595)<span></span>
</td>
<td class="num">(27,169)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Accrued liabilities and other current liabilities</a></td>
<td class="nump">87,683<span></span>
</td>
<td class="num">(28,661)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred contract revenue</a></td>
<td class="num">(50,601)<span></span>
</td>
<td class="num">(142,518)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(130,874)<span></span>
</td>
<td class="num">(384,808)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of short-term investments</a></td>
<td class="num">(1,126,595)<span></span>
</td>
<td class="num">(1,519,227)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from sale of short-term investments</a></td>
<td class="nump">1,302,751<span></span>
</td>
<td class="nump">1,339,284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(30,152)<span></span>
</td>
<td class="num">(19,783)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquisition of licenses and other assets, net</a></td>
<td class="num">(4,275)<span></span>
</td>
<td class="num">(2,514)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">141,729<span></span>
</td>
<td class="num">(202,240)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from issuance of common stock through equity plans, net</a></td>
<td class="nump">84,787<span></span>
</td>
<td class="nump">33,207<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock in public offering, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">489,093<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfSecuredDebt', window );">Principal payments on mortgage debt</a></td>
<td class="num">(123)<span></span>
</td>
<td class="num">(126)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">84,664<span></span>
</td>
<td class="nump">522,174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effects of exchange rates on cash</a></td>
<td class="nump">745<span></span>
</td>
<td class="nump">213<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">96,264<span></span>
</td>
<td class="num">(64,661)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">242,077<span></span>
</td>
<td class="nump">399,266<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">338,341<span></span>
</td>
<td class="nump">334,605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">5,399<span></span>
</td>
<td class="nump">5,714<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes paid (refunds received), net</a></td>
<td class="num">(661)<span></span>
</td>
<td class="nump">2,072<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosures of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for lease obligations</a></td>
<td class="nump">86,939<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_CapitalAndPatentExpendituresIncurredButNotYetPaid', window );">Amounts accrued for capital and patent expenditures</a></td>
<td class="nump">$ 478<span></span>
</td>
<td class="nump">$ 2,240<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_CapitalAndPatentExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets and patents that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_CapitalAndPatentExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_InterestExpenseRelatedToSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense using the effective interest rate method related to the sale of future royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_InterestExpenseRelatedToSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_RoyaltyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of royalty payments made during the period under a royalty purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_RoyaltyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in employer-related costs classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedInvestmentGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedInvestmentGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization and Basis of Presentation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Basis of Presentation</a></td>
<td class="text"><div style="text-align: justify;">
   <span style="color: #000000; font-weight: bold;">1.&#160;&#160;Organization and Basis of Presentation</span>
  </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span style="font-weight: bold;">Organization and Business Activity</span>
  </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span>We incorporated in California on January 10, 1989. In conjunction with our initial public offering, we reorganized as a Delaware corporation in April 1991. We are a fully integrated commercial-stage biotechnology company and a leader in the discovery and development of RNA-targeted therapeutics. </span></div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000; font-weight: bold;">Basis of Presentation</span>
  </div>
  <div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span style="color: #000000;">We prepared the unaudited interim condensed consolidated financial statements for the three and nine months ended September 30, 2025 and 2024 on the same basis as the audited financial statements for the year ended December 31, 2024. We included all normal recurring adjustments in the financial statements, which we considered necessary for a fair presentation of our financial position at such dates and our operating results and cash flows for those periods. Our operating results for the interim periods may not be indicative of what our operating results will be for the entire year. For more complete financial information, these financial statements, and notes thereto, should be read in conjunction with the audited financial statements for the year ended December 31, 2024 included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission, or SEC. </span> </div>
  <div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span style="color: #000000;">In our condensed consolidated financial statements, we included the accounts of Ionis Pharmaceuticals, Inc. and the consolidated results of our wholly owned subsidiary, Akcea Therapeutics, Inc. and its wholly owned subsidiaries (&#8220;we&#8221;, &#8220;us&#8221; or &#8220;our&#8221;).</span> </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span>We operate as a </span><span style="color: #000000;">single </span><span>segment, Ionis operations, because our chief operating decision maker, or CODM, reviews operating results on an aggregate basis and manages our operations as a </span><span style="color: #000000;"><span style="-sec-ix-hidden: hidden-fact-0">single</span> </span><span>operating segment. Refer to Note 15, </span><span style="font-style: italic;">Segment Information</span><span>, for further details on our segment information.</span> </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span style="color: #000000; font-weight: bold;">Use of Estimates</span> </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">We prepare our condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States, or </span><span>U.S., that require us to make estimates and assumptions that affect the amounts reported in our condensed consolidated financial statements and accompanying notes. Actual results could differ from our estimates.</span>
  </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480922/205-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481034/205-10-S45-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text"><div>
   <span style="color: #000000; font-weight: bold;">2.&#160;&#160;Significant Accounting Policies</span>
  </div>
  <div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">Below, we have included our accounting policies for revenue recognition related to product sales, net and cost of sales as a result of our launch of TRYNGOLZA and DAWNZERA in the U.S. Our other significant accounting policies have not changed substantially from those included in our Annual Report on Form 10-K for the year ended December 31, 2024.</span>
  </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span style="color: #000000; font-weight: bold; font-style: italic;">Revenue Recognition</span> </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000; font-style: italic;">Product Sales, Net</span>
  </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">We recognize revenue from product sales when the customer obtains control of our product in the amount of the transaction price, which is the amount that reflects the consideration which we expect to receive. We estimate reserves for variable consideration related to applicable discounts, rebates, chargebacks and other allowances included in our agreements with customers, payors and other third parties. We include the amount of variable consideration in the transaction price to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If actual results vary significantly from our estimates, we adjust our estimates in the period that we become aware of such variances.</span>
  </div><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"> <span style="color: #000000; font-weight: bold; font-style: italic;">Cost of Sales</span> </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span>Our cost of sales is comprised of costs related to our commercial revenue, including manufacturing costs, transportation and freight costs and indirect overhead costs associated with the manufacturing and distribution of our products. We also may include certain period costs related to manufacturing services and inventory adjustments in cost of sales.</span>
  </div>
  <div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span>Cost of sales for a newly launched product, such as TRYNGOLZA or DAWNZERA, does not include the full cost of manufacturing until we manufacture and sell additional inventory after exhausting pre-launch inventory, which we previously recorded as research and development, or R&amp;D, expense.</span>
  </div>
  <div>&#160;
  </div>
  <div style="text-indent: 36pt;"> <span style="color: #000000; font-weight: bold;">Recent Accounting Standards</span> </div>
  <div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">In November 2023, the Financial Accounting Standards Board, or FASB, issued Accounting Standard Update, or ASU, 2023-07, which provides updated guidance on segment reporting. The guidance requires public companies to disclose significant expenses that are regularly provided to the CODM, other segment items for each reportable segment and measures of segment profit or loss used by the CODM for allocating resources. In addition, the updated guidance requires public companies with a single reportable segment to provide all disclosures required under Accounting Standards Codification, or ASC, Topic 280, </span><span style="color: #000000; font-style: italic;">Segment Reporting</span><span style="color: #000000;">, and public companies to include in interim reports all disclosures related to a reportable segment&#8217;s profit or loss and assets that are currently required in annual reports. We adopted the reporting requirements in our 2024 Annual Report on Form 10-K and began providing the interim reporting requirements in our Quarterly Report on Form 10-Q for the first quarter of 2025. Refer to Note 15, </span><span style="color: #000000; font-style: italic;">Segment Information</span><span style="color: #000000;">, for further details on our segment information.</span>
  </div>
  <div style="text-align: justify;">&#160;</div>
  <div style="text-indent: 36pt; line-height: 1.15; text-align: justify;">In July 2025, the FASB issued ASU 2025-05, which amended the guidance in ASC 326 to simplify the estimation of credit losses on accounts receivable and contract assets from revenue transactions. The amended guidance allows companies to elect a practical expedient to assume that conditions as of the balance sheet date will remain unchanged for the remaining life of the asset when estimating the expected credit losses of the asset. This update is effective for annual periods beginning after December 15, 2025 and interim periods within those annual periods. Early adoption of this guidance is permitted. Companies that elect the practical expedient are required to apply the amendments prospectively. We are currently assessing the impact and timing of adopting this update.</div><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;">&#160;</div><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"><span style="letter-spacing: normal; text-align: justify; text-indent: 48px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">In September 2025, the FASB issued ASU 2025-06, which amended and simplified the existing guidance for software costs. The amended guidance removes references to software development stages and allows companies to begin capitalizing software costs when management has authorized and committed to funding the software project and it is probable that the project will be completed with the software performing the intended function.&#160;This update is effective for annual periods beginning after December 15, 2027 and interim periods within those annual periods. Early adoption of this guidance is permitted at the beginning of an annual reporting period. The guidance may be applied on a prospective or retrospective basis. We expect to early adopt this update on January 1, 2026 on a prospective basis.</span></div><div style="text-align: justify;">&#160;</div><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"><span style="letter-spacing: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">In September&#160;2025, the FASB issued ASU 2025-07, which clarifies that share-based non-cash consideration received from a customer in exchange for goods or services under a revenue contract is subject to the guidance on non-cash consideration under ASC 606.&#160;This update is effective for annual periods beginning after December 15, 2026 and interim periods within those annual periods. Early adoption of this guidance is permitted. The guidance may be applied on a prospective or modified retrospective basis. We are currently assessing the impact and timing of adopting this update.</span></div><div style="text-align: justify;">&#160;</div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">We do not expect any recently issued accounting standards other than the standards mentioned above and those included in our Annual Report on Form 10-K for the year ended December 31, 2024 to have a material impact to our financial results.</span>
  </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Financial Data<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_SupplementalFinancialDataAbstract', window );"><strong>Supplemental Financial Data [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Supplemental Financial Data</a></td>
<td class="text"><div style="text-align: justify;">
   <span style="color: #000000; font-weight: bold;">3. Supplemental Financial Data</span>
  </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-align: justify; margin-left: 36pt;">
   <span style="color: #000000; font-weight: bold;">Inventories</span>
  </div>
  <div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span style="color: #000000;">Our inventories consisted of the following (in thousands): </span> </div>

  <div style="text-align: justify; color: #000000;">&#160;</div>
  <table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td></tr><tr style="height: 0px; font-size: 0px;"><td></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td></tr><tr><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Supplemental Financial Data - B4"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">September 30, 2025</td><td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Supplemental Financial Data - B4"></td><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Supplemental Financial Data - D4"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">December 31, 2024</td><td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Supplemental Financial Data - D4"></td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Raw materials</td><td style="text-align: left; width: 1%;" title="Note 3. Supplemental Financial Data - B5">$</td><td style="text-align: right; width: 9%;">424</td><td style="text-align: left; width: 1%;" title="Note 3. Supplemental Financial Data - B5">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 3. Supplemental Financial Data - D5">$</td><td style="text-align: right; width: 9%;">5,557</td><td style="text-align: left; width: 1%;" title="Note 3. Supplemental Financial Data - D5">&#160;</td></tr><tr><td>Work in process</td><td style="text-align: left; width: 1%;" title="Note 3. Supplemental Financial Data - B6">&#160;</td><td style="text-align: right; width: 9%;">26,139</td><td style="text-align: left; width: 1%;" title="Note 3. Supplemental Financial Data - B6">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 3. Supplemental Financial Data - D6">&#160;</td><td style="text-align: right; width: 9%;">6,679</td><td style="text-align: left; width: 1%;" title="Note 3. Supplemental Financial Data - D6">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Finished goods</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Supplemental Financial Data - B7">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">549</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 3. Supplemental Financial Data - B7">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Supplemental Financial Data - D7">$</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">276</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 3. Supplemental Financial Data - D7">&#160;</td></tr><tr><td style="padding-left: 20px;">Total</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Supplemental Financial Data - B8">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">27,112</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 3. Supplemental Financial Data - B8">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Supplemental Financial Data - D8">&#160;</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">12,512</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 3. Supplemental Financial Data - D8">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Reported as:</td><td style="text-align: left; border-width: initial; border-style: none; border-color: initial; width: 1%;" title="Note 3. Supplemental Financial Data - B8">&#160;</td><td style="text-align: right; border-width: initial; border-style: none; border-color: initial; width: 9%;"></td><td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;" title="Note 3. Supplemental Financial Data - B8">&#160;</td><td>&#160;</td><td style="text-align: left; border-width: initial; border-style: none; border-color: initial; width: 1%;" title="Note 3. Supplemental Financial Data - D8">&#160;</td><td style="text-align: right; border-width: initial; border-style: none; border-color: initial; width: 9%;"></td><td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;" title="Note 3. Supplemental Financial Data - D8">&#160;</td></tr><tr><td style="padding-left: 10px;">Inventories</td><td style="text-align: left; border-width: initial; border-style: none; border-color: initial; width: 1%;" title="Note 3. Supplemental Financial Data - B8">$</td><td style="text-align: right; border-width: initial; border-style: none; border-color: initial; width: 9%;">10,470</td><td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;" title="Note 3. Supplemental Financial Data - B8">&#160;</td><td>&#160;</td><td style="text-align: left; border-width: initial; border-style: none; border-color: initial; width: 1%;" title="Note 3. Supplemental Financial Data - D8">$</td><td style="text-align: right; border-width: initial; border-style: none; border-color: initial; width: 9%;">12,512</td><td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;" title="Note 3. Supplemental Financial Data - D8">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 10px;">Deposits and other assets</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Supplemental Financial Data - B8">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">16,642</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 3. Supplemental Financial Data - B8">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Supplemental Financial Data - D8">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"> - </td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 3. Supplemental Financial Data - D8">&#160;</td></tr><tr><td style="padding-left: 20px;">Total</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Supplemental Financial Data - B8">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">27,112</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 3. Supplemental Financial Data - B8">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Supplemental Financial Data - D8">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">12,512</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 3. Supplemental Financial Data - D8">&#160;</td></tr></table><div>&#160;</div>
  <div style="text-indent: 36pt; line-height: 1.15; text-align: justify;">We classify inventories as non-current assets when we expect  the inventories to remain on hand beyond one year. We include non-current inventories in deposits and other assets in our condensed consolidated balance sheets. The amount reported as deposits and other assets  as of September 30, 2025  consists of work in process inventory.</div><div>&#160;</div><div style="text-indent: 36pt;">
   <span style="font-weight: bold;">Accrued Liabilities</span>
  </div>
  <div>&#160;
  </div>
  <div style="text-indent: 36pt;"> <span>Our accrued liabilities consisted of the following (in thousands):</span> </div>


  <div>&#160;</div>

  <table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td></tr><tr><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Accrued Liabilities - B4"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">September 30, 2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 3. Accrued Liabilities - B4"></td><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Accrued Liabilities - D4"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">December 31, 2024</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 3. Accrued Liabilities - D4"></td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Clinical expenses</td><td style="text-align: left; width: 1%;" title="Note 3. Accrued Liabilities - B5">$</td><td style="text-align: right; width: 9%;">54,842</td><td style="text-align: left; width: 1%;" title="Note 3. Accrued Liabilities - B5">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 3. Accrued Liabilities - D5">$</td><td style="text-align: right; width: 9%;">77,436</td><td style="text-align: left; width: 1%;" title="Note 3. Accrued Liabilities - D5">&#160;</td></tr><tr><td>In-licensing expenses</td><td style="text-align: left; width: 1%;" title="Note 3. Accrued Liabilities - B6">&#160;</td><td style="text-align: right; width: 9%;">7,770</td><td style="text-align: left; width: 1%;" title="Note 3. Accrued Liabilities - B6">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 3. Accrued Liabilities - D6">&#160;</td><td style="text-align: right; width: 9%;">7,951</td><td style="text-align: left; width: 1%;" title="Note 3. Accrued Liabilities - D6">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Commercial expenses</td><td style="text-align: left; width: 1%;" title="Note 3. Accrued Liabilities - B7">&#160;</td><td style="text-align: right; width: 9%;">15,017</td><td style="text-align: left; width: 1%;" title="Note 3. Accrued Liabilities - B7">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 3. Accrued Liabilities - D7">&#160;</td><td style="text-align: right; width: 9%;">3,589</td><td style="text-align: left; width: 1%;" title="Note 3. Accrued Liabilities - D7">&#160;</td></tr><tr><td>Other miscellaneous expenses</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Accrued Liabilities - B8">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">21,681</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 3. Accrued Liabilities - B8">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Accrued Liabilities - D8">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">19,462</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 3. Accrued Liabilities - D8">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 20px;">Total accrued liabilities</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Accrued Liabilities - B9">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">99,310</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 3. Accrued Liabilities - B9">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Accrued Liabilities - D9">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">108,438</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 3. Accrued Liabilities - D9">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_SupplementalFinancialDataAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_SupplementalFinancialDataAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/210/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenues</a></td>
<td class="text"><div>
   <span style="font-weight: bold;">4. Revenues</span>
  </div>
  <div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span>During the three and nine months ended September 30, 2025 and 2024, our revenues consisted of the following (in thousands):</span> </div>

  <div>&#160;</div>
  <table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold;">Three Months Ended</td><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold;">Nine Months Ended</td></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td></tr><tr><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - B4"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - B4"></td><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - D4"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - D4"></td><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - F4"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - F4"></td><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - H4"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - H4"></td></tr><tr><td>Revenue:</td><td style="width: 1%;" title="Note 4. Revenues - B5"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 4. Revenues - B5"></td><td>&#160;</td><td style="width: 1%;" title="Note 4. Revenues - D5"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 4. Revenues - D5"></td><td>&#160;</td><td style="width: 1%;" title="Note 4. Revenues - F5"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 4. Revenues - F5"></td><td>&#160;</td><td style="width: 1%;" title="Note 4. Revenues - H5"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 4. Revenues - H5"></td></tr><tr><td style="padding-left: 10px;">Commercial revenue:</td><td style="width: 1%;" title="Note 4. Revenues - B6"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 4. Revenues - B6"></td><td>&#160;</td><td style="width: 1%;" title="Note 4. Revenues - D6"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 4. Revenues - D6"></td><td>&#160;</td><td style="width: 1%;" title="Note 4. Revenues - F6"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 4. Revenues - F6"></td><td>&#160;</td><td style="width: 1%;" title="Note 4. Revenues - H6"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 4. Revenues - H6"></td></tr><tr><td style="padding-left: 20px;">Product sales, net:</td><td style="width: 1%;" title="Note 4. Revenues - B7"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 4. Revenues - B7"></td><td>&#160;</td><td style="width: 1%;" title="Note 4. Revenues - D7"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 4. Revenues - D7"></td><td>&#160;</td><td style="width: 1%;" title="Note 4. Revenues - F7"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 4. Revenues - F7"></td><td>&#160;</td><td style="width: 1%;" title="Note 4. Revenues - H7"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 4. Revenues - H7"></td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 30px;">TRYNGOLZA sales, net</td><td style="text-align: left; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none; width: 1%;" title="Note 4. Revenues - B8">$</td><td style="text-align: right; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none; width: 9%;">31,792</td><td style="text-align: left; width: 1%; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none;" title="Note 4. Revenues - B8">&#160;</td><td>&#160;</td><td style="text-align: left; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none; width: 1%;" title="Note 4. Revenues - D8">$</td><td style="text-align: right; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none; width: 9%;"> - </td><td style="text-align: left; width: 1%; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none;" title="Note 4. Revenues - D8">&#160;</td><td>&#160;</td><td style="text-align: left; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none; width: 1%;" title="Note 4. Revenues - F8">$</td><td style="text-align: right; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none; width: 9%;">57,353</td><td style="text-align: left; width: 1%; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none;" title="Note 4. Revenues - F8">&#160;</td><td>&#160;</td><td style="text-align: left; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none; width: 1%;" title="Note 4. Revenues - H8">$</td><td style="text-align: right; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none; width: 9%;"> - </td><td style="text-align: left; width: 1%; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none;" title="Note 4. Revenues - H8">&#160;</td></tr><tr><td style="padding-left: 30px;">Total product sales, net</td><td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;" title="Note 4. Revenues - B9">&#160;</td><td style="text-align: right; width: 9%; border-width: initial; border-style: none; border-color: initial;">31,792</td><td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;" title="Note 4. Revenues - B9">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;" title="Note 4. Revenues - D9">&#160;</td><td style="text-align: right; width: 9%; border-width: initial; border-style: none; border-color: initial;"> - </td><td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;" title="Note 4. Revenues - D9">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;" title="Note 4. Revenues - F9">&#160;</td><td style="text-align: right; width: 9%; border-width: initial; border-style: none; border-color: initial;">57,353</td><td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;" title="Note 4. Revenues - F9">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;" title="Note 4. Revenues - H9">&#160;</td><td style="text-align: right; width: 9%; border-width: initial; border-style: none; border-color: initial;"> - </td><td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;" title="Note 4. Revenues - H9">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 20px;">Royalty revenue:</td><td style="width: 1%;" title="Note 4. Revenues - B10"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 4. Revenues - B10"></td><td>&#160;</td><td style="width: 1%;" title="Note 4. Revenues - D10"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 4. Revenues - D10"></td><td>&#160;</td><td style="width: 1%;" title="Note 4. Revenues - F10"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 4. Revenues - F10"></td><td>&#160;</td><td style="width: 1%;" title="Note 4. Revenues - H10"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 4. Revenues - H10"></td></tr><tr><td style="padding-left: 30px;">SPINRAZA royalties</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - B11">&#160;</td><td style="text-align: right; width: 9%;">55,896</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - B11">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - D11">&#160;</td><td style="text-align: right; width: 9%;">57,208</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - D11">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - F11">&#160;</td><td style="text-align: right; width: 9%;">158,243</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - F11">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - H11">&#160;</td><td style="text-align: right; width: 9%;">152,406</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - H11">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 30px;">WAINUA royalties</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - B12">&#160;</td><td style="text-align: right; width: 9%;">13,320</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - B12">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - D12">&#160;</td><td style="text-align: right; width: 9%;">5,371</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - D12">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - F12">&#160;</td><td style="text-align: right; width: 9%;">33,107</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - F12">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - H12">&#160;</td><td style="text-align: right; width: 9%;">10,278</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - H12">&#160;</td></tr><tr><td style="padding-left: 30px;">Other royalties</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 4. Revenues - B13">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; width: 9%;">6,478</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - B13">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 4. Revenues - D13">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; width: 9%;">4,228</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - D13">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 4. Revenues - F13">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; width: 9%;">18,461</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - F13">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 4. Revenues - H13">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-right: none; width: 9%;">17,352</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - H13">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 50px;">Total royalty revenue</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - B14">&#160;</td><td style="text-align: right; width: 9%;">75,694</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - B14">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - D14">&#160;</td><td style="text-align: right; width: 9%;">66,807</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - D14">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - F14">&#160;</td><td style="text-align: right; width: 9%;">209,811</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - F14">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - H14">&#160;</td><td style="text-align: right; width: 9%;">180,036</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - H14">&#160;</td></tr><tr><td style="padding-left: 20px;">Other commercial revenue</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - B15"></td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"> 8,112 </td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - B15"></td><td>&#160;</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - D15"></td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"> 8,924 </td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - D15"></td><td>&#160;</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - F15"></td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"> 27,359 </td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - F15"></td><td>&#160;</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - H15"></td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"> 27,324 </td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - H15"></td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 70px;">Total commercial revenue</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - B19">&#160;</td><td style="text-align: right; width: 9%;">115,598</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - B19">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - D19">&#160;</td><td style="text-align: right; width: 9%;">75,731</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - D19">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - F19">&#160;</td><td style="text-align: right; width: 9%;">294,523</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - F19">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - H19">&#160;</td><td style="text-align: right; width: 9%;">207,360</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - H19">&#160;</td></tr><tr><td style="padding-left: 10px;">Research and development revenue:</td><td style="width: 1%;" title="Note 4. Revenues - B20"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 4. Revenues - B20"></td><td>&#160;</td><td style="width: 1%;" title="Note 4. Revenues - D20"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 4. Revenues - D20"></td><td>&#160;</td><td style="width: 1%;" title="Note 4. Revenues - F20"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 4. Revenues - F20"></td><td>&#160;</td><td style="width: 1%;" title="Note 4. Revenues - H20"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 4. Revenues - H20"></td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 30px;">Collaborative agreement revenue</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - B21">&#160;</td><td style="text-align: right; width: 9%;">31,436</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - B21">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - D21">&#160;</td><td style="text-align: right; width: 9%;">44,883</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - D21">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - F21">&#160;</td><td style="text-align: right; width: 9%;">413,387</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - F21">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - H21">&#160;</td><td style="text-align: right; width: 9%;">235,753</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - H21">&#160;</td></tr><tr><td style="padding-left: 30px;">WAINUA joint development revenue</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - B22">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">9,685</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - B22">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - D22">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">13,200</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - D22">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - F22">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">32,471</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - F22">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - H22">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">35,449</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - H22">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 70px;">Total research and development revenue</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - B23">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">41,121</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - B23">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - D23">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">58,083</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - D23">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - F23">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">445,858</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - F23">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - H23">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">271,202</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - H23">&#160;</td></tr><tr><td style="padding-left: 90px;">Total revenue  </td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - B24">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">156,719</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - B24">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - D24">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">133,814</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - D24">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - F24">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">740,381</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - F24">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - H24">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">478,562</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - H24">&#160;</td></tr></table><div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span style="font-weight: bold; text-decoration: underline;">Revenue Sources </span>
  </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span>The following are sources of revenue and when we typically recognize revenue.</span>
  </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span style="font-style: italic;">Commercial Revenue </span>
  </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span>In December 2024, the U.S. Food and Drug Administration, or FDA, approved TRYNGOLZA (olezarsen) for the treatment of familial chylomicronemia syndrome, or FCS. Following the approval, we launched TRYNGOLZA and began earning revenue from TRYNGOLZA sales. </span>
  </div>
  <div style="text-align: justify;">&#160;</div>
  <div style="text-indent: 36pt; line-height: 1.15; text-align: justify;">In August 2025, the FDA approved DAWNZERA (donidalorsen) for prophylaxis to prevent attacks of hereditary angioedema, or HAE, in adult and pediatric patients 12 years of age and older. Our launch of DAWNZERA is currently underway.</div><div style="text-align: justify;">&#160;</div><div style="text-indent: 36pt; text-align: justify;">
   <span>We earn royalty payments primarily on net sales of SPINRAZA, WAINUA and QALSODY.</span>
  </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span>We earn commercial revenue from TEGSEDI and WAYLIVRA sales under our distribution agreements with Swedish Orphan Biovitrum AB, or Sobi. In addition, we receive royalties from PTC Therapeutics International Limited, or PTC, for TEGSEDI and WAYLIVRA sales. Refer to Part IV, Item 15, Note 4, </span><span style="font-style: italic;">Collaborative Arrangements and Licensing Agreements</span><span>, of our audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2024 for details on our commercialization partnerships with Sobi and PTC.</span>
  </div>
  <div style="text-align: justify;">&#160;</div>
  <div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"><span style="letter-spacing: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">Under our distribution agreements with Sobi, we concluded that our performance obligation is to provide services to Sobi over the term of the agreement, which includes supplying finished goods inventory to Sobi. We are also responsible for maintaining the marketing authorization for TEGSEDI and WAYLIVRA in major markets and for leading the global commercial strategy for each medicine. We view this performance obligation as a series of distinct activities that are substantially the same. Therefore, we recognize as revenue the price Sobi pays us for the inventory when we deliver the finished goods inventory to Sobi. We also recognize distribution fee revenue based on Sobi&#8217;s net sales of TEGSEDI and WAYLIVRA. Under our agreements with Sobi, Sobi does not generally have a right of return.</span></div><div style="text-align: justify;">&#160;</div><div style="text-indent: 36pt; text-align: justify;">
   <span style="font-style: italic;">Research and development revenue under collaboration agreements</span>
  </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span>We enter into collaboration agreements to license and sell our technology on an exclusive or non-exclusive basis. Our collaboration agreements typically contain multiple elements, or performance obligations, including technology licenses or options to obtain technology licenses, R&amp;D services and manufacturing services.</span>
  </div><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;">
   For R&amp;D services that we recognize over time, we measure our progress using an input method. The input methods we use are based on the effort we expend or costs we incur toward the satisfaction of our performance obligation. We estimate the amount of effort we expend, including the time we estimate it will take us to complete the activities, or costs we incur in a given period, relative to the estimated total effort or costs to satisfy the performance obligation. This results in a percentage that we multiply by the transaction price to determine the amount of revenue we recognize each period. This approach requires us to make numerous estimates that may involve judgement. If our estimates or judgements change over the course of the collaboration, they may affect the timing and amount of revenue that we recognize in the current and future periods.
  </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span style="font-style: italic; text-decoration: underline;">Upfront payments:</span><span> When we enter into a collaboration agreement and receive an upfront payment, we record the entire upfront payment as deferred revenue if our only performance obligation is for R&amp;D services we will provide in the future. We amortize the upfront payment into revenue as we perform the R&amp;D services. If part or all of the upfront payment is a license fee, we recognize as revenue the portion related to the license when we deliver the license to our partner because our partner has full use of the license and we do not have any additional performance obligations related to the license after delivery.</span>
  </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span style="font-style: italic; text-decoration: underline;">Milestone payments:</span><span> We consider milestone payments to be variable consideration and include them in the transaction price when it is probable. We typically include milestone payments for R&amp;D services in the transaction price when they are achieved. We include these milestone payments when they are achieved because there is considerable uncertainty in the research and development processes that trigger these payments. Similarly, we include regulatory milestone payments in the transaction price once the medicine is approved by the applicable regulatory agency. We will recognize sales-based milestone payments in the period in which we achieve the milestone under the sales-based royalty exception allowed under accounting rules.</span>
  </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span>We recognize milestone payments that relate to an ongoing performance obligation over our period of performance. For example, when we achieve a milestone payment from a partner for advancing a clinical study under a collaboration agreement, we add the milestone payment to the transaction price if the milestone relates to an ongoing R&amp;D services performance obligation and recognize revenue related to the milestone payment over our estimated period of performance. If we have partially completed our performance obligation, then we record a cumulative-effect adjustment in the period we add the milestone payment to the transaction price.</span>
  </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span>Conversely, we recognize in full those milestone payments that we earn based on our partners&#8217; activities when our partner achieves the milestone event and we do not have a remaining performance obligation.</span>
  </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span style="font-style: italic; text-decoration: underline;">License fees:</span><span> We recognize as revenue the total amount we determine to be the relative stand-alone selling price of a license when we deliver the license to our partner because our partner has full use of the license and we do not have any additional performance obligations related to the license after delivery.</span>
  </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span style="font-style: italic;">WAINUA (Eplontersen) Collaboration with AstraZeneca</span>
  </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span>In 2021, we entered into a joint development and commercialization agreement with AstraZeneca to develop and commercialize WAINUA for the treatment of transthyretin amyloidosis, or ATTR. Under the terms of the agreement, we received a $200 million upfront payment in 2021.</span> </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span>We evaluated our WAINUA collaboration under ASC Topic 808, </span><span style="font-style: italic;">Collaborative Arrangements</span><span>, or ASC 808, and identified four material components: (i) the license we granted to AstraZeneca in 2021, (ii) the co-development activities that we and AstraZeneca are performing, (iii) the co-commercialization activities that we and AstraZeneca are performing and (iv) the co-medical affairs activities that we and AstraZeneca are performing.</span> </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span>We determined that we had a vendor-customer relationship within the scope of ASC Topic 606, </span><span style="font-style: italic;">Revenue from Contracts with Customers</span><span>, or ASC 606, for the license we granted to AstraZeneca and as a result we had one performance obligation. For our sole performance obligation, we determined the transaction price was the $200 million upfront payment we received. We recognized the upfront payment in full in 2021 because we did not have any remaining performance obligations after we delivered the license to AstraZeneca.</span> </div><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;">We also concluded that the co-development activities, the co-commercialization activities and the co-medical affairs activities are within the scope of ASC 808 because we and AstraZeneca are active participants exposed to the risks and benefits of the activities under the collaboration and therefore do not have a vendor-customer relationship. AstraZeneca is currently responsible for 55 percent of the costs associated with the ongoing global Phase 3 development program. Because we are leading the Phase 3 development program, we made an accounting policy election to recognize as non-customer revenue the cost-share funding from AstraZeneca, net of our share of AstraZeneca&#8217;s development expenses, in the same period we incur the related development expenses. As AstraZeneca is responsible for the majority of the commercial and medical affairs costs in the U.S. and all costs associated with bringing WAINUA to market outside the U.S., we made an accounting policy election to recognize cost-share funding we receive from AstraZeneca related to commercial and medical affairs activities as reductions of our selling, general and administrative, or SG&amp;A, expense and R&amp;D expense, respectively. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Arrangements and Licensing Agreements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Licensing Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative Arrangements and Licensing Agreements</a></td>
<td class="text"><div>
   <span style="color: #000000; font-weight: bold;">5.  Collaborative Arrangements and Licensing Agreements</span>
  </div>
  <div>&#160;
  </div>
  <div style="text-indent: 36pt; font-family: Calibri; font-size: 11pt; color: rgb(0, 0, 0); text-align: justify;">
   <span style="font-family: Times New Roman; font-size: 10.0pt;">Below, we have included our AstraZeneca and Ono collaborations, which were the only collaborations that had either substantive changes or were new from those included in Part IV, Item 15, Note 4, </span><span style="font-family: Times New Roman; font-size: 10.0pt; font-style: italic;">Collaborative Arrangements and Licensing Agreements</span><span style="font-family: Times New Roman; font-size: 10.0pt;">, of our audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2024. </span>
  </div>
  <div>&#160;</div>
  <div>&#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160;<b>AstraZeneca</b></div><div>&#160;</div><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;">We have two collaborations with AstraZeneca: one focused on the joint development and commercialization of WAINUA and one focused on the treatment of cardiovascular, renal and metabolic diseases. From inception through September 30, 2025, we have received more than $960 million from these collaborations.</div><div>&#160;</div><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;">In the second quarter of 2025, we earned a $30 million milestone payment under our cardiovascular, renal and metabolic diseases collaboration when AstraZeneca initiated the Phase 2b study of opemalirsen (formerly ION532), an investigational medicine designed to reduce the production of apolipoprotein L1, or APOL1, for the treatment of APOL1-mediated kidney disease. We recognized this milestone payment as R&amp;D revenue in full in the second quarter of 2025 because we did not have any remaining performance obligations related to the milestone payment. We will achieve the next payment of $20 million if AstraZeneca advances a medicine under this collaboration.</div><div>&#160;</div><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;">During the three and nine months ended September 30, 2025 and 2024, we earned the following revenue from our relationship with AstraZeneca (in thousands, except percentage amounts):</div><div>&#160;</div><table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold;">Three Months Ended</td><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold;">Nine Months Ended</td></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td></tr><tr><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 5. Collaborations - B6"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 5. Collaborations - B6"></td><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 5. Collaborations - D6"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 5. Collaborations - D6"></td><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 5. Collaborations - F6"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 5. Collaborations - F6"></td><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 5. Collaborations - H6"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 5. Collaborations - H6"></td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Revenue from our relationship with AstraZeneca</td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - B7">$</td><td style="text-align: right; width: 9%;">27,128</td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - B7">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - D7">$</td><td style="text-align: right; width: 9%;">19,461</td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - D7">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - F7">$</td><td style="text-align: right; width: 9%;">101,705</td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - F7">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - H7">$</td><td style="text-align: right; width: 9%;">47,106</td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - H7">&#160;</td></tr><tr><td>Percentage of total revenue</td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - B8">&#160;</td><td style="text-align: right; width: 9%;">17</td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - B8">%</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - D8">&#160;</td><td style="text-align: right; width: 9%;">15</td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - D8">%</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - F8">&#160;</td><td style="text-align: right; width: 9%;">14</td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - F8">%</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - H8">&#160;</td><td style="text-align: right; width: 9%;">10</td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - H8">%</td></tr></table><div>&#160;</div><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;">&#160;We did not have any deferred revenue from our relationship with AstraZeneca at September 30, 2025 and December 31, 2024.</div><div>&#160;</div><div style="text-indent: 36pt;">
   <span style="color: #000000; font-weight: bold; font-style: italic;">Ono</span>
  </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">In March 2025, we entered into an agreement with Ono Pharmaceutical Co., Ltd., or Ono, to develop and commercialize sapablursen, an investigational RNA-targeted medicine for the potential treatment of polycythemia vera, or PV, a rare and potentially life-threatening hematologic disease. We are responsible for completing the ongoing Phase 2 IMPRSSION study, while Ono will be solely responsible for subsequent development, regulatory filings and commercialization of sapablursen.</span>
  </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span style="color: #000000;">Over the term of this collaboration, we are eligible to receive up to $940 million, which is comprised of a $280 million upfront payment, a $20 million development milestone payment, up to $20 million in regulatory milestone payments and up to $620 million in sales milestone payments. In addition, we are eligible to receive royalties in the mid-teen percentage range on net sales. From inception through September 30, 2025, we received more than $280 million from this collaboration, which includes the upfront payment and reimbursements for additional R&amp;D services. We will achieve the next payment of $20 million if Ono initiates a pivotal clinical trial under this collaboration.</span>&#160;</div>


  <div style="text-indent: 36pt; text-align: justify;">&#160;</div><div style="text-indent: 36pt; text-align: justify;">At inception, we identified two performance obligations under this agreement, comprised of our license of sapablursen to Ono and R&amp;D services for sapablursen. We determined the transaction price to be the $280 million upfront payment we received <span style="letter-spacing: normal; text-indent: 48px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">when this transaction received clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, or HSR Act,&#160;</span>in the second quarter of 2025. We allocated the transaction price based on the estimated stand-alone selling price of each performance obligation as follows:</div><div style="text-indent: 36pt; text-align: justify;">&#160;</div><div style="text-indent: 36pt; text-align: justify;">&#9679;&#160;&#160;&#160;&#160;$278 million for the license of sapablursen; and</div><div style="text-indent: 36pt; text-align: justify;">&#9679;&#160; &#160; $2 million for the R&amp;D services for sapablursen.</div><div style="text-indent: 36pt; text-align: justify;">&#160;</div><div style="text-indent: 36pt; text-align: justify;">We recognized $278 million of R&amp;D revenue for the license of sapablursen in the second quarter of 2025 because we completed the performance obligation when we delivered the license to Ono. We recognized revenue for our R&amp;D services performance obligation as we performed services based on our effort to satisfy our performance obligation relative to our total effort expected to satisfy our performance obligation. In the second quarter of 2025, we completed our R&amp;D services performance obligation and recognized $2 million of R&amp;D revenue.</div><div style="text-indent: 36pt; text-align: justify;">&#160;</div><div style="text-indent: 36pt; text-align: justify;">During&#160;<span style="letter-spacing: normal; text-indent: 48px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">the three and nine months ended September 30, 2025&#160;and 2024, we earned the following revenue from our relationship with Ono&#160;(in thousands, except percentage amounts):</span></div><div style="text-indent: 36pt; text-align: justify;">&#160;</div><table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td></tr><tr><td>&#160;</td><td style="width: 1%;" title="Note 5. Collaborations - Ono - B2"></td><td style="text-align: center; font-weight: bold; width: 9%;">Three Months Ended</td><td style="width: 1%;" title="Note 5. Collaborations - Ono - B2"></td><td>&#160;</td><td style="width: 1%;" title="Note 5. Collaborations - Ono - D2"></td><td style="text-align: center; font-weight: bold; width: 9%;">Nine Months Ended</td><td style="width: 1%;" title="Note 5. Collaborations - Ono - D2"></td></tr><tr><td>&#160;</td><td style="border-left: none; border-right: none; border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 5. Collaborations - Ono - B3"></td><td style="text-align: center; font-weight: bold; border-top: none; border-left: none; border-right: none; border-bottom: 1px solid black; width: 9%;">September 30, 2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 5. Collaborations - Ono - B3"></td><td>&#160;</td><td style="border-bottom: 1px solid black; border-left: none; border-right: none; border-top: none; width: 1%;" title="Note 5. Collaborations - Ono - D3"></td><td style="text-align: center; font-weight: bold; border-left: none; border-right: none; border-bottom: 1px solid black; border-top: none; width: 9%;">September 30, 2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 5. Collaborations - Ono - D3"></td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Revenue from our relationship with Ono</td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - Ono - B4">$</td><td style="text-align: right; width: 9%;">2,979</td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - Ono - B4">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - Ono - D4">$</td><td style="text-align: right; width: 9%;">282,979</td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - Ono - D4">&#160;</td></tr><tr><td>Percentage of total revenue</td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - Ono - B5">&#160;</td><td style="text-align: right; width: 9%;">2</td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - Ono - B5">%</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - Ono - D5">&#160;</td><td style="text-align: right; width: 9%;">38</td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - Ono - D5">%</td></tr></table><div style="text-indent: 36pt; text-align: justify;">&#160;</div><div style="text-indent: 36pt; text-align: justify;"><span style="letter-spacing: normal; text-indent: 48px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">Our condensed consolidated balance sheet at September 30, 2025 included deferred revenue of $2.9 million from our relationship with Ono. We did not have any deferred revenue from our relationship with Ono at&#160;December 31, 2024.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basic and Diluted Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Basic and Diluted Net Loss Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Basic and Diluted Net Loss Per Share</a></td>
<td class="text"><div>
   <span style="color: #000000; font-weight: bold;">6. Basic and Diluted Net Loss Per Share</span>
  </div>
  <div style="font-size: 8pt;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span style="color: #000000; font-weight: bold;">Basic net loss&#160;per share</span> </div>
  <div style="text-align: justify; font-size: 8pt;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">We calculated our basic net loss per share for the three and nine months ended September 30, 2025 and 2024 by dividing our net loss&#160;by our weighted-average number of common shares outstanding during the period.</span>
  </div><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;">
   <span style="color: #000000; font-weight: bold;">Diluted net loss&#160;per share</span>
  </div>


  <div style="text-indent: 36pt; text-align: justify;">&#160;</div><div style="text-indent: 36pt; text-align: justify;"><span style="color: #000000;">For the three and&#160;nine months ended&#160;September 30, 2025 and 2024, we incurred a net loss; therefore, we did not include dilutive common equivalent shares in the computation of diluted net loss per share because the effect would have been anti-dilutive. Common stock from the following would have had an anti-dilutive effect on net loss per share:</span>
  </div><div>&#160;
  </div>
  <div style="text-indent: -18pt; padding-left: 54pt;">

    <div> <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;1.75 percent convertible senior notes, or 1.75% Notes;</span> </div>
  </div>
  <div style="text-indent: -18pt; padding-left: 54pt;">

    <div> <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;0 percent convertible senior notes, or 0% Notes;</span> </div>
  </div>
  <div style="text-indent: -18pt; padding-left: 54pt;">

    <div> <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;Note hedges related to the 0% Notes;</span> </div>
  </div>
  <div style="text-indent: -18pt; padding-left: 54pt;">

    <div>
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;Dilutive stock options; </span>
    </div>
  </div>
  <div style="text-indent: -18pt; padding-left: 54pt;">

    <div>
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;Unvested restricted stock units, or RSUs; </span>
    </div>
  </div>
  <div style="text-indent: -18pt; padding-left: 54pt;">

    <div>
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;Unvested performance restricted stock units, or PRSUs; and</span>
    </div>
  </div>
  <div style="text-indent: -18pt; padding-left: 54pt;">

    <div>
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;Employee Stock Purchase Plan, or ESPP.</span>
    </div>
  </div>
  <div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span>For the three and nine months ended September 30, 2024, common stock underlying the 0.125 percent</span><span style="color: #000000;"> convertible senior notes, or 0.125% Notes</span><span>, and n</span><span style="color: #000000;">ote hedges related to the 0.125% Notes </span><span>would also have had an anti-dilutive effect on net loss per share.</span> </div>
  <div style="text-align: justify;">&#160;
  </div>

  <div style="text-indent: 36pt; text-align: justify;"> As of&#160;September 30, 2025<span style="letter-spacing: normal; text-indent: 48px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">, we had warrants related to our 0% Notes outstanding.</span> As of September 30, 2024,&#160;we had warrants related to our 0% and 0.125% Notes outstanding. We will include the shares issuable under these warrants in our calculation of diluted earnings per share when the average market price per share of our common stock for the reporting period exceeds the strike price of the warrants. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAbstract', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTextBlock', window );">Investments</a></td>
<td class="text"><div>
   <span style="color: #000000; font-weight: bold;">7.&#160;&#160;Investments</span>
  </div>
  <div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span style="color: #000000;">The following table summarizes the contract maturity of the available-for-sale securities we held as of September 30, 2025:</span> </div>
  <div>&#160;</div>
  <div>&#160;</div><table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="background-color: rgb(204, 238, 255);"><td>One year or less </td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B4">&#160;</td><td style="width: 9%; text-align: right;">67</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B4">%</td></tr><tr><td>After one year but within two years </td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B5">&#160;</td><td style="width: 9%; text-align: right;">29</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B5">%</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>After two years but within <span style="-sec-ix-hidden: hidden-fact-1">three and a half years</span></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B6">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">4</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B6">%</td></tr><tr><td>Total </td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B7">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">100</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B7">%</td></tr></table>
  <div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span style="color: #000000;">As illustrated above, at September 30, 2025, 96 percent of our available-for-sale securities had a maturity of less than two years.</span> </div>
  <div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">All of our available-for-sale debt securities are available to us for use in our current operations. As a result, we categorize all of these securities as current assets even though the stated maturity of some individual securities may be one year or more beyond the balance sheet date.</span>
  </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">We invest in debt securities</span><span> with strong credit ratings and an investment grade rating at or above A-1, P-1 or F-1 by Standard &amp; Poor&#8217;s, Moody&#8217;s or Fitch, respectively. </span>
  </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span style="color: #000000;">At September 30, 2025, we had an equity ownership interest of less than 20 percent in seven private companies and three public companies with which we conduct business. </span> </div><div> <span style="color: #000000;">The following is a summary of our investments (in thousands):</span> </div>

  <div>&#160;</div><table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td></tr><tr><td>&#160;</td><td style="width: 1%;" title="Note 7. Investments - B9"></td><td style="font-weight: bold; text-align: center; width: 9%;">Amortized</td><td style="width: 1%;" title="Note 7. Investments - B9"></td><td>&#160;</td><td colspan="7" style="font-weight: bold; text-align: center; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">Gross Unrealized</td><td>&#160;</td><td style="width: 1%;" title="Note 7. Investments - H9"></td><td style="font-weight: bold; text-align: center; width: 9%;">Estimated</td><td style="width: 1%;" title="Note 7. Investments - H9"></td></tr><tr><td style="font-weight: bold; text-align: left;">September 30, 2025</td><td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - B10"></td><td style="font-weight: bold; text-align: center; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">Cost</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B10"></td><td>&#160;</td><td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - D10"></td><td style="font-weight: bold; text-align: center; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">Gains</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D10"></td><td>&#160;</td><td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - F10"></td><td style="font-weight: bold; text-align: center; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">Losses</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F10"></td><td>&#160;</td><td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - H10"></td><td style="font-weight: bold; text-align: center; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">Fair Value</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H10"></td></tr><tr><td style="text-decoration: underline;">Available-for-sale debt securities:</td><td style="width: 1%;" title="Note 7. Investments - B11"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 7. Investments - B11"></td><td>&#160;</td><td style="width: 1%;" title="Note 7. Investments - D11"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 7. Investments - D11"></td><td>&#160;</td><td style="width: 1%;" title="Note 7. Investments - F11"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 7. Investments - F11"></td><td>&#160;</td><td style="width: 1%;" title="Note 7. Investments - H11"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 7. Investments - H11"></td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="vertical-align: bottom;">Corporate debt securities (1)</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B12">$</td><td style="width: 9%; text-align: right; vertical-align: bottom;">639,937</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B12">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D12">$</td><td style="width: 9%; text-align: right; vertical-align: bottom;">815</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D12">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F12">$</td><td style="width: 9%; text-align: right; vertical-align: bottom;">(69</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F12">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H12">$</td><td style="width: 9%; text-align: right; vertical-align: bottom;">640,683</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H12">&#160;</td></tr><tr><td style="vertical-align: bottom;">Debt securities issued by U.S. government agencies</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B13">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;">73,905</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B13">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D13">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;">66</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D13">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F13">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;">(16</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F13">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H13">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;">73,955</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H13">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="vertical-align: bottom;">Debt securities issued by the U.S. Treasury (1)</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B14">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;">562,662</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B14">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D14">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;">384</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D14">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F14">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;">(61</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F14">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H14">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;">562,985</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H14">&#160;</td></tr><tr><td style="vertical-align: bottom;">Debt securities issued by states of the U.S. and political subdivisions of&#160;the states</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - B15">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;">5,151</td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B15">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - D15">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;">11</td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D15">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - F15">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"> - </td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F15">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - H15">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;">5,162</td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H15">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="vertical-align: bottom; padding-left: 20px;">Total debt securities with a maturity of one year&#160;or less</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - B16">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;">1,281,655</td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B16">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - D16">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;">1,276</td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D16">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - F16">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;">(146</td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F16">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - H16">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;">1,282,785</td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H16">&#160;</td></tr><tr><td style="vertical-align: bottom;">Corporate debt securities</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B17">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;">415,818</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B17">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D17">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;">1,688</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D17">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F17">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;">(121</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F17">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H17">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;">417,385</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H17">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="vertical-align: bottom;">Debt securities issued by U.S. government agencies</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B18">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;">76,548</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B18">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D18">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;">147</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D18">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F18">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;">(60</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F18">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H18">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;">76,635</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H18">&#160;</td></tr><tr><td style="vertical-align: bottom;">Debt securities issued by the U.S. Treasury  </td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B19">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;">204,656</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B19">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D19">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;">493</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D19">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F19">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;">(49</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F19">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H19">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;">205,100</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H19">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="vertical-align: bottom;">Debt securities issued by states of the U.S. and political subdivisions of&#160;the states</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B20">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;">1,117</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B20">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D20">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;">5</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D20">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F20">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;"> - </td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F20">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H20">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;">1,122</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H20">&#160;</td></tr><tr><td style="vertical-align: bottom;">Other municipal debt securities</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - B21">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;">698</td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B21">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - D21">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"> - </td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D21">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - F21">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"> - </td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F21">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - H21">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;">698</td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H21">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="vertical-align: bottom; padding-left: 20px;">Total debt securities with a maturity of more than one year</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - B22">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;">698,837</td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B22">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - D22">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;">2,333</td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D22">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - F22">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;">(230</td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F22">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - H22">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;">700,940</td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H22">&#160;</td></tr><tr><td style="vertical-align: bottom; padding-left: 40px;">Total available-for-sale debt securities</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - B23">$</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;">1,980,492</td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B23">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - D23">$</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;">3,609</td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D23">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - F23">$</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;">(376</td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F23">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - H23">$</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;">1,983,725</td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H23">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="text-decoration: underline; vertical-align: bottom;">Equity securities:</td><td style="width: 1%;" title="Note 7. Investments - B25"></td><td style="vertical-align: bottom; width: 9%;">&#160;</td><td style="width: 1%;" title="Note 7. Investments - B25"></td><td>&#160;</td><td style="width: 1%;" title="Note 7. Investments - D25"></td><td style="vertical-align: bottom; width: 9%;">&#160;</td><td style="width: 1%;" title="Note 7. Investments - D25"></td><td>&#160;</td><td style="width: 1%;" title="Note 7. Investments - F25"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 7. Investments - F25"></td><td>&#160;</td><td style="width: 1%;" title="Note 7. Investments - H25"></td><td style="vertical-align: bottom; width: 9%;">&#160;</td><td style="width: 1%;" title="Note 7. Investments - H25"></td></tr><tr><td style="vertical-align: bottom;">Publicly traded equity securities included in other current assets (2)</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B26">$</td><td style="width: 9%; text-align: right; vertical-align: bottom;">11,897</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B26">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D26">$</td><td style="width: 9%; text-align: right; vertical-align: bottom;">40</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D26">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F26">$</td><td style="width: 9%; text-align: right; vertical-align: bottom;">(8,681</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F26">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H26">$</td><td style="width: 9%; text-align: right; vertical-align: bottom;">3,256</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H26">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="vertical-align: bottom;">Privately held equity securities included in deposits and&#160;other assets (3)</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; vertical-align: bottom;" title="Note 7. Investments - B27">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;">4,905</td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B27">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;" title="Note 7. Investments - D27">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;">54,395</td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D27">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;" title="Note 7. Investments - F27">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;">(7,090</td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F27">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;" title="Note 7. Investments - H27">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;">52,210</td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H27">&#160;</td></tr><tr><td style="vertical-align: bottom; padding-left: 20px;">Total equity securities  </td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;" title="Note 7. Investments - B28">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;">16,802</td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B28">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;" title="Note 7. Investments - D28">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;">54,435</td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D28">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;" title="Note 7. Investments - F28">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;">(15,771</td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F28">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;" title="Note 7. Investments - H28">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-right: none; vertical-align: bottom;">55,466</td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H28">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="vertical-align: bottom; padding-left: 40px;">Total available-for-sale debt and equity securities</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - B29">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;">1,997,294</td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B29">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - D29">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;">58,044</td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D29">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - F29">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;">(16,147</td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F29">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - H29">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;">2,039,191</td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H29">&#160;</td></tr></table><table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td></tr><tr><td>&#160;</td><td style="text-align: center; font-weight: bold; width: 1%;" title="Note 7. Investments - B30"></td><td style="text-align: center; font-weight: bold; width: 9%;">Amortized</td><td style="width: 1%;" title="Note 7. Investments - B30"></td><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">Gross Unrealized</td><td>&#160;</td><td style="text-align: center; font-weight: bold; width: 1%;" title="Note 7. Investments - H30"></td><td style="text-align: center; font-weight: bold; width: 9%;">Estimated</td><td style="width: 1%;" title="Note 7. Investments - H30"></td></tr><tr><td style="font-weight: bold;">December 31, 2024</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - B31"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">Cost</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B31"></td><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - D31"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">Gains</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D31"></td><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - F31"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">Losses</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F31"></td><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - H31"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">Fair Value</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H31"></td></tr><tr><td style="text-decoration: underline;">Available-for-sale debt securities:</td><td style="width: 1%;" title="Note 7. Investments - B32"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 7. Investments - B32"></td><td>&#160;</td><td style="width: 1%;" title="Note 7. Investments - D32"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 7. Investments - D32"></td><td>&#160;</td><td style="width: 1%;" title="Note 7. Investments - F32"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 7. Investments - F32"></td><td>&#160;</td><td style="width: 1%;" title="Note 7. Investments - H32"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 7. Investments - H32"></td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Corporate debt securities (1)</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B33">$</td><td style="width: 9%; text-align: right;">593,810</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B33">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - D33">$</td><td style="width: 9%; text-align: right;">487</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - D33">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - F33">$</td><td style="width: 9%; text-align: right;">(240</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - F33">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - H33">$</td><td style="width: 9%; text-align: right;">594,057</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - H33">&#160;</td></tr><tr><td>Debt securities issued by U.S. government agencies</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B34">&#160;</td><td style="width: 9%; text-align: right;">143,647</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B34">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - D34">&#160;</td><td style="width: 9%; text-align: right;">287</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - D34">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - F34">&#160;</td><td style="width: 9%; text-align: right;">(39</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - F34">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - H34">&#160;</td><td style="width: 9%; text-align: right;">143,895</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - H34">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Debt securities issued by the U.S. Treasury (1)</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B35">&#160;</td><td style="width: 9%; text-align: right;">657,285</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B35">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - D35">&#160;</td><td style="width: 9%; text-align: right;">825</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - D35">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - F35">&#160;</td><td style="width: 9%; text-align: right;">(120</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - F35">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - H35">&#160;</td><td style="width: 9%; text-align: right;">657,990</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - H35">&#160;</td></tr><tr><td>Debt securities issued by states of the U.S. and political subdivisions of&#160;the states</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B36">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">7,516</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B36">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D36">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">8</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D36">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F36">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"> - </td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F36">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H36">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">7,524</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H36">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 20px;">Total debt securities with a maturity of one year&#160;or less</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B37">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">1,402,258</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B37">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D37">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">1,607</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D37">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F37">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">(399</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F37">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H37">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">1,403,466</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H37">&#160;</td></tr><tr><td>Corporate debt securities</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B38">&#160;</td><td style="width: 9%; text-align: right;">439,561</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B38">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - D38">&#160;</td><td style="width: 9%; text-align: right;">723</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - D38">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - F38">&#160;</td><td style="width: 9%; text-align: right;">(2,275</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - F38">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - H38">&#160;</td><td style="width: 9%; text-align: right;">438,009</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - H38">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Debt securities issued by U.S. government agencies</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B39">&#160;</td><td style="width: 9%; text-align: right;">65,255</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B39">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - D39">&#160;</td><td style="width: 9%; text-align: right;">137</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - D39">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - F39">&#160;</td><td style="width: 9%; text-align: right;">(289</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - F39">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - H39">&#160;</td><td style="width: 9%; text-align: right;">65,103</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - H39">&#160;</td></tr><tr><td>Debt securities issued by the U.S. Treasury  </td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B40">&#160;</td><td style="width: 9%; text-align: right;">149,086</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B40">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - D40">&#160;</td><td style="width: 9%; text-align: right;">124</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - D40">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - F40">&#160;</td><td style="width: 9%; text-align: right;">(476</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - F40">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - H40">&#160;</td><td style="width: 9%; text-align: right;">148,734</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - H40">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Other municipal debt securities</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B41">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">698</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B41">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D41">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"> - </td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D41">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F41">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">(2</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F41">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H41">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">696</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H41">&#160;</td></tr><tr><td style="padding-left: 20px;">Total debt securities with a maturity of more than one year</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none;" title="Note 7. Investments - B42">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;">654,600</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B42">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - D42">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;">984</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D42">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - F42">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;">(3,042</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F42">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - H42">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;">652,542</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H42">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 40px;">Total available-for-sale debt securities</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - B43">$</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;">2,056,858</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B43">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - D43">$</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;">2,591</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D43">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - F43">$</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;">(3,441</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F43">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - H43">$</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-right: none;">2,056,008</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H43">&#160;</td></tr><tr><td style="text-decoration: underline;">Equity securities:</td><td style="width: 1%;" title="Note 7. Investments - B44"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 7. Investments - B44"></td><td>&#160;</td><td style="width: 1%;" title="Note 7. Investments - D44"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 7. Investments - D44"></td><td>&#160;</td><td style="width: 1%;" title="Note 7. Investments - F44"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 7. Investments - F44"></td><td>&#160;</td><td style="width: 1%;" title="Note 7. Investments - H44"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 7. Investments - H44"></td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Publicly traded equity securities included in other current assets (2)</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B45">$</td><td style="width: 9%; text-align: right;">11,897</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B45">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - D45">$</td><td style="width: 9%; text-align: right;">26</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - D45">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - F45">$</td><td style="width: 9%; text-align: right;">(6,660</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - F45">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - H45">$</td><td style="width: 9%; text-align: right;">5,263</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - H45">&#160;</td></tr><tr><td>Privately held equity securities included in deposits and&#160;other assets (3)</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none;" title="Note 7. Investments - B46">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;">23,115</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B46">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - D46">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;">25,001</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D46">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - F46">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;">(7,093</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F46">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - H46">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;">41,023</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H46">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 20px;">Total equity securities  </td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - B47">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;">35,012</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B47">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - D47">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;">25,027</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D47">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - F47">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;">(13,753</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F47">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - H47">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-right: none;">46,286</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H47">&#160;</td></tr><tr><td style="padding-left: 40px;">Total available-for-sale debt and equity securities</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B48">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">2,091,870</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B48">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D48">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">27,618</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D48">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F48">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">(17,194</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F48">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H48">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">2,102,294</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H48">&#160;</td></tr></table><div style="text-align: justify;">&#160;</div><div style="text-indent: -18pt; text-align: justify; padding-left: 18pt;">

    <div> <span style="color: #000000;">(1)&#160;&#160;&#160;Includes investments classified as cash equivalents in our condensed consolidated balance sheets.</span> </div>
  </div>
  <div style="margin-left: 18pt;">&#160;
  </div>
  <div style="text-indent: -18pt; text-align: justify; padding-left: 18pt;">

    <div> <span style="color: #000000;">(2)&#160;&#160;Our publicly traded equity securities are included in other current assets. We recognize publicly traded equity securities at fair value. In the nine months ended September 30, 2025, we recorded a $2.0 million net unrealized loss in our condensed consolidated statements of operations related to changes in the fair value of our investments in publicly traded companies.</span> </div>
  </div>
  <div style="margin-left: 18pt;">&#160;
  </div>
  <div style="text-indent: -18pt; text-align: justify; padding-left: 18pt;">

    <div> <span style="color: #000000;">(3)&#160; Our privately held equity securities are included in deposits and other assets. We recognize our privately held equity securities at</span><span> cost minus impairments, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer, which are Level 3 inputs</span><span style="color: #000000;">. In the nine months ended September 30, 2025, the amortized cost of our privately held equity securities increased $11.2 million. In the third quarter of 2025, we recorded a $29.4 million unrealized gain related to our investment in a privately held company due to an observable price change in an orderly transaction for a similar investment of the investee. This increase was partially offset by a loss of $18.2 million related to an impairment of our investment in another privately held company that we recorded in the second quarter of 2025.</span></div>
  </div>
  <div style="text-align: justify; margin-left: 18pt;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span style="color: #000000;">The following is a summary of our investments we consider to be temporarily impaired at September 30, 2025 (in thousands, except for number of investments): </span> </div>

  <div>&#160;</div>
  <table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td></tr><tr><td>&#160;</td><td style="width: 1%;" title="Note 7. Investments - B52"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 7. Investments - B52"></td><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">Less than 12 Months of Temporary Impairment</td><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">More than 12 Months of Temporary Impairment</td><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">Total Temporary Impairment</td></tr><tr><td>&#160;</td><td style="width: 1%;" title="Note 7. Investments - B53"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">Number&#160;of Investments</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B53"></td><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - D53"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">Estimated Fair&#160;Value</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D53"></td><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - F53"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">Unrealized Losses</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F53"></td><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - H53"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">Estimated Fair&#160;Value</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H53"></td><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - J53"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">Unrealized Losses</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - J53"></td><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - L53"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">Estimated Fair&#160;Value</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - L53"></td><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - N53"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">Unrealized Losses</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - N53"></td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Corporate debt securities  </td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B54">&#160;</td><td style="width: 9%; text-align: right;">105</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B54">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - D54">$</td><td style="width: 9%; text-align: right;">179,031</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - D54">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - F54">$</td><td style="width: 9%; text-align: right;">(127</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - F54">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - H54">$</td><td style="width: 9%; text-align: right;">55,955</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - H54">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - J54">$</td><td style="width: 9%; text-align: right;">(63</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - J54">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - L54">$</td><td style="width: 9%; text-align: right;">234,986</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - L54">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - N54">$</td><td style="width: 9%; text-align: right;">(190</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - N54">)&#160;</td></tr><tr><td>Debt securities issued by&#160;U.S. government agencies</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B55">&#160;</td><td style="width: 9%; text-align: right;">43</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B55">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - D55">&#160;</td><td style="width: 9%; text-align: right;">71,369</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - D55">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - F55">&#160;</td><td style="width: 9%; text-align: right;">(60</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - F55">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - H55">&#160;</td><td style="width: 9%; text-align: right;">17,286</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - H55">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - J55">&#160;</td><td style="width: 9%; text-align: right;">(16</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - J55">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - L55">&#160;</td><td style="width: 9%; text-align: right;">88,655</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - L55">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - N55">&#160;</td><td style="width: 9%; text-align: right;">(76</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - N55">)&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Debt securities issued by the U.S. Treasury  </td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B56">&#160;</td><td style="width: 9%; text-align: right;">25</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B56">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - D56">&#160;</td><td style="width: 9%; text-align: right;">141,191</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - D56">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - F56">&#160;</td><td style="width: 9%; text-align: right;">(74</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - F56">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - H56">&#160;</td><td style="width: 9%; text-align: right;">46,285</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - H56">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - J56">&#160;</td><td style="width: 9%; text-align: right;">(36</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - J56">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - L56">&#160;</td><td style="width: 9%; text-align: right;">187,476</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - L56">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - N56">&#160;</td><td style="width: 9%; text-align: right;">(110</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - N56">)&#160;</td></tr><tr><td>Other municipal debt securities</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B58">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">1</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B58">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D58">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">698</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D58">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F58">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"> - </td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F58">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H58">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"> - </td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H58">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - J58">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"> - </td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - J58">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - L58">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">698</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - L58">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - N58">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"> - </td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - N58">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Total temporarily impaired&#160;debt securities</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B59">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">174</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B59">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D59">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">392,289</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D59">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F59">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">(261</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F59">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H59">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">119,526</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H59">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - J59">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">(115</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - J59">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - L59">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">511,815</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - L59">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - N59">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">(376</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - N59">)&#160;</td></tr></table><div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span>We believe that the decline in value of these securities is temporary and is primarily related to the change in market interest rates since purchase rather than underlying credit deterioration for any of the issuers. We believe it is more likely than not that we will be able to hold our debt securities with declines in value to maturity. Therefore, we intend to hold these securities to maturity and anticipate full recovery of our debt securities&#8217; amortized cost basis at maturity.</span>
  </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 321<br> -Publisher FASB<br> -URI https://asc.fasb.org/321/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 325<br> -Publisher FASB<br> -URI https://asc.fasb.org/325/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div>
   <span style="color: #000000; font-weight: bold;">8.&#160;&#160;Fair Value Measurements</span>
  </div>
  <div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span style="color: #000000;">The following tables present the major security types we held at September 30, 2025 and December 31, 2024 that we regularly measure and carry at fair value. The following tables segregate each security type by the level within the fair value hierarchy of the valuation techniques we utilized to determine the respective security&#8217;s fair value (in thousands):</span> </div>


  <div>&#160;</div>
  <table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td></tr><tr><td>&#160;</td><td style="width: 1%;" title="Note 8. Fair Value Measurements - B3"></td><td style="vertical-align: bottom; text-align: center; font-weight: bold; width: 9%;">At</td><td style="width: 1%;" title="Note 8. Fair Value Measurements - B3"></td><td>&#160;</td><td style="width: 1%;" title="Note 8. Fair Value Measurements - D3"></td><td style="text-align: center; font-weight: bold; vertical-align: bottom; width: 9%;">Quoted&#160;Prices&#160;in Active&#160;Markets</td><td style="width: 1%;" title="Note 8. Fair Value Measurements - D3"></td><td>&#160;</td><td style="width: 1%;" title="Note 8. Fair Value Measurements - F3"></td><td style="text-align: center; font-weight: bold; width: 9%;">Significant&#160;Other Observable Inputs</td><td style="width: 1%;" title="Note 8. Fair Value Measurements - F3"></td></tr><tr><td>&#160;</td><td style="border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 8. Fair Value Measurements - B4"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; width: 9%;">September 30, 2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - B4"></td><td>&#160;</td><td style="border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 8. Fair Value Measurements - D4"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; width: 9%;">(Level 1)</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - D4"></td><td>&#160;</td><td style="border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 8. Fair Value Measurements - F4"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; width: 9%;">(Level 2)</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - F4"></td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Cash equivalents (1)  </td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B5">$</td><td style="text-align: right; width: 9%;">167,298</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B5">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D5">$</td><td style="text-align: right; width: 9%;">167,298</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D5">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F5">$</td><td style="text-align: right; width: 9%;"> - </td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F5">&#160;</td></tr><tr><td>Corporate debt securities (2)  </td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B6">&#160;</td><td style="text-align: right; width: 9%;">1,058,068</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B6">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D6">&#160;</td><td style="text-align: right; width: 9%;"> - </td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D6">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F6">&#160;</td><td style="text-align: right; width: 9%;">1,058,068</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F6">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Debt securities issued by U.S. government agencies (3)  </td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B7">&#160;</td><td style="text-align: right; width: 9%;">150,590</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B7">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D7">&#160;</td><td style="text-align: right; width: 9%;"> - </td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D7">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F7">&#160;</td><td style="text-align: right; width: 9%;">150,590</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F7">&#160;</td></tr><tr><td>Debt securities issued by the U.S. Treasury (4)</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B8">&#160;</td><td style="text-align: right; width: 9%;">768,085</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B8">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D8">&#160;</td><td style="text-align: right; width: 9%;">768,085</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D8">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F8">&#160;</td><td style="text-align: right; width: 9%;"> - </td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F8">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Debt securities issued by states of the U.S. and political subdivisions of the states (5)</td><td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - B9">&#160;</td><td style="text-align: right; vertical-align: bottom; width: 9%;">6,284</td><td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - B9">&#160;</td><td>&#160;</td><td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - D9">&#160;</td><td style="text-align: right; vertical-align: bottom; width: 9%;"> - </td><td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - D9">&#160;</td><td>&#160;</td><td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - F9">&#160;</td><td style="text-align: right; vertical-align: bottom; width: 9%;">6,284</td><td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - F9">&#160;</td></tr><tr><td>Other municipal debt securities (5)</td><td style="text-align: left; border-width: initial; border-style: none; border-color: initial; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - B10">&#160;</td><td style="text-align: right; border-width: initial; border-style: none; border-color: initial; vertical-align: bottom; width: 9%;">698</td><td style="text-align: left; vertical-align: bottom; border-width: initial; border-style: none; border-color: initial; width: 1%;" title="Note 8. Fair Value Measurements - B10">&#160;</td><td>&#160;</td><td style="text-align: left; border-width: initial; border-style: none; border-color: initial; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - D10">&#160;</td><td style="text-align: right; border-width: initial; border-style: none; border-color: initial; vertical-align: bottom; width: 9%;"> - </td><td style="text-align: left; vertical-align: bottom; border-width: initial; border-style: none; border-color: initial; width: 1%;" title="Note 8. Fair Value Measurements - D10">&#160;</td><td>&#160;</td><td style="text-align: left; border-width: initial; border-style: none; border-color: initial; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - F10">&#160;</td><td style="text-align: right; border-width: initial; border-style: none; border-color: initial; vertical-align: bottom; width: 9%;">698</td><td style="text-align: left; vertical-align: bottom; border-width: initial; border-style: none; border-color: initial; width: 1%;" title="Note 8. Fair Value Measurements - F10">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Publicly traded equity securities included in other current assets (6)</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - B10">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; vertical-align: bottom; width: 9%;">3,256</td><td style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - B10">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - D10">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; vertical-align: bottom; width: 9%;">3,256</td><td style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - D10">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - F10">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-right: none; vertical-align: bottom; width: 9%;"> - </td><td style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - F10">&#160;</td></tr><tr><td style="padding-left: 20px;">Total  </td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 8. Fair Value Measurements - B11">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">2,154,279</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - B11">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 8. Fair Value Measurements - D11">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">938,639</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - D11">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 8. Fair Value Measurements - F11">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">1,215,640</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - F11">&#160;</td></tr></table><div>&#160;</div>
  <table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td></tr><tr><td>&#160;</td><td style="width: 1%;" title="Note 8. Fair Value Measurements - B13"></td><td style="vertical-align: bottom; text-align: center; font-weight: bold; width: 9%;">At</td><td style="width: 1%;" title="Note 8. Fair Value Measurements - B13"></td><td>&#160;</td><td style="width: 1%;" title="Note 8. Fair Value Measurements - D13"></td><td style="text-align: center; font-weight: bold; vertical-align: bottom; width: 9%;">Quoted&#160;Prices&#160;in Active&#160;Markets</td><td style="width: 1%;" title="Note 8. Fair Value Measurements - D13"></td><td>&#160;</td><td style="width: 1%;" title="Note 8. Fair Value Measurements - F13"></td><td style="text-align: center; font-weight: bold; width: 9%;">Significant&#160;Other Observable Inputs</td><td style="width: 1%;" title="Note 8. Fair Value Measurements - F13"></td></tr><tr><td>&#160;</td><td style="border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 8. Fair Value Measurements - B14"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; width: 9%;">December 31, 2024</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - B14"></td><td>&#160;</td><td style="border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 8. Fair Value Measurements - D14"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; width: 9%;">(Level 1)</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - D14"></td><td>&#160;</td><td style="border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 8. Fair Value Measurements - F14"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; width: 9%;">(Level 2)</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - F14"></td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Cash equivalents (1) </td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B15">$</td><td style="text-align: right; width: 9%;">180,445</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B15">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D15">$</td><td style="text-align: right; width: 9%;">180,445</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D15">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F15">$</td><td style="text-align: right; width: 9%;">-</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F15">&#160;</td></tr><tr><td>Corporate debt securities (5)</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B16">&#160;</td><td style="text-align: right; width: 9%;">1,032,066</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B16">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D16">&#160;</td><td style="text-align: right; width: 9%;">-</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D16">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F16">&#160;</td><td style="text-align: right; width: 9%;">1,032,066</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F16">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Debt securities issued by U.S. government agencies (5)</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B17">&#160;</td><td style="text-align: right; width: 9%;">208,998</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B17">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D17">&#160;</td><td style="text-align: right; width: 9%;">-</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D17">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F17">&#160;</td><td style="text-align: right; width: 9%;">208,998</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F17">&#160;</td></tr><tr><td>Debt securities issued by the U.S. Treasury (5)</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B18">&#160;</td><td style="text-align: right; width: 9%;">806,724</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B18">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D18">&#160;</td><td style="text-align: right; width: 9%;">806,724</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D18">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F18">&#160;</td><td style="text-align: right; width: 9%;">-</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F18">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Debt securities issued by states of the U.S. and political subdivisions of the states (5)</td><td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - B19">&#160;</td><td style="text-align: right; vertical-align: bottom; width: 9%;">7,524</td><td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - B19">&#160;</td><td>&#160;</td><td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - D19">&#160;</td><td style="text-align: right; vertical-align: bottom; width: 9%;">-</td><td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - D19">&#160;</td><td>&#160;</td><td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - F19">&#160;</td><td style="text-align: right; vertical-align: bottom; width: 9%;">7,524</td><td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - F19">&#160;</td></tr><tr><td>Other municipal debt securities (5)</td><td style="text-align: left; vertical-align: bottom; border-width: initial; border-style: none; border-color: initial; width: 1%;" title="Note 8. Fair Value Measurements - B20">&#160;</td><td style="text-align: right; vertical-align: bottom; border-width: initial; border-style: none; border-color: initial; width: 9%;">696</td><td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - B20">&#160;</td><td>&#160;</td><td style="text-align: left; vertical-align: bottom; border-width: initial; border-style: none; border-color: initial; width: 1%;" title="Note 8. Fair Value Measurements - D20">&#160;</td><td style="text-align: right; vertical-align: bottom; border-width: initial; border-style: none; border-color: initial; width: 9%;">-</td><td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - D20">&#160;</td><td>&#160;</td><td style="text-align: left; vertical-align: bottom; border-width: initial; border-style: none; border-color: initial; width: 1%;" title="Note 8. Fair Value Measurements - F20">&#160;</td><td style="text-align: right; vertical-align: bottom; border-width: initial; border-style: none; border-color: initial; width: 9%;">696</td><td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - F20">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Publicly traded equity securities included in other current assets (6)</td><td style="text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 8. Fair Value Measurements - B20">&#160;</td><td style="text-align: right; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; width: 9%;">5,263</td><td style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - B20">&#160;</td><td>&#160;</td><td style="text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 8. Fair Value Measurements - D20">&#160;</td><td style="text-align: right; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; width: 9%;">5,263</td><td style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - D20">&#160;</td><td>&#160;</td><td style="text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 8. Fair Value Measurements - F20">&#160;</td><td style="text-align: right; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-right: none; width: 9%;">-</td><td style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - F20">&#160;</td></tr><tr><td style="padding-left: 20px;">Total </td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 8. Fair Value Measurements - B21">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">2,241,716</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - B21">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 8. Fair Value Measurements - D21">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">992,432</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - D21">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 8. Fair Value Measurements - F21">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">1,249,284</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - F21">&#160;</td></tr></table><div style="text-align: justify; margin-left: 18pt;">&#160;
  </div>
  <div style="text-align: justify;"> <span style="color: #000000;">The following footnotes reference lines in our condensed consolidated balance sheets:</span></div>
  <div style="text-align: justify;">&#160;</div><div style="text-align: justify;">(1)&#160; &#160; Included in cash and cash equivalents.</div><div style="text-align: justify;">&#160;</div><div style="text-align: justify;">(2)&#160;&#160;&#160;&#160;$39.9 million was included in cash and cash equivalents, with the difference included in short-term investments.</div><div style="text-align: justify;">&#160;</div><div style="text-align: justify;">(3)&#160; &#160; $6.0 million was included in cash and cash equivalents, with the difference i<span style="letter-spacing: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">ncluded in short-term investments.</span></div><div style="text-align: justify;">&#160;</div><div style="text-align: justify;">(4)&#160; &#160; <span style="letter-spacing: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">$36.0 million was included in cash and cash equivalents, with the difference included in short-term investments.</span></div><div style="text-align: justify;">&#160;</div><div style="text-align: justify;">(5)&#160; &#160; Included in short-term investments.</div><div style="text-align: justify;">&#160;</div><div style="text-align: justify;">(6)&#160; &#160; Included in other current assets.</div>
  <div style="text-indent: -18pt; text-align: justify; padding-left: 18pt;">


  &#160;</div>








  <div style="text-indent: 36pt;"><span style="color: #000000; font-style: italic;">Convertible Notes</span>
  </div><div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span style="color: #000000;">Our 1.75% Notes and 0% Notes had a fair value of $794.5 million and $777.0 million at September 30, 2025, respectively. Our 1.75% Notes and 0% Notes had a fair value of $569.3 million and $612.8 million at December 31, 2024, respectively. We determine the fair value of our notes based on quoted market prices for these notes, which are Level 2 measurements because the notes do not trade regularly.</span> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation Expense<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-based Compensation Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based Compensation Expense</a></td>
<td class="text"><div>
   <span style="color: #000000; font-weight: bold;">9. Stock-based Compensation Expense</span>
  </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span style="color: #000000;">The following table summarizes stock-based compensation expense for the three and nine months ended September 30, 2025 and 2024 (in thousands):</span> </div>
  <div style="text-indent: 36pt; text-align: justify;">&#160;</div>
  <table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold;">Three Months Ended</td><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold;">Nine Months Ended</td></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td></tr><tr><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 9. Stock-based Compensation Expense - B5"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none;" title="Note 9. Stock-based Compensation Expense - B5"></td><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 9. Stock-based Compensation Expense - D5"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none;" title="Note 9. Stock-based Compensation Expense - D5"></td><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 9. Stock-based Compensation Expense - F5"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none;" title="Note 9. Stock-based Compensation Expense - F5"></td><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 9. Stock-based Compensation Expense - H5"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="width: 1%;" title="Note 9. Stock-based Compensation Expense - H5"></td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Cost of sales</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B6">$</td><td style="width: 9%; text-align: right;">145</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B6">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D6">$</td><td style="width: 9%; text-align: right;">159</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D6">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - F6">$</td><td style="width: 9%; text-align: right;">855</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - F6">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - H6">$</td><td style="width: 9%; text-align: right;">609</td><td style="width: 1%; text-align: left; border-width: initial; border-style: none; border-color: initial;" title="Note 9. Stock-based Compensation Expense - H6">&#160;</td></tr><tr><td>Research, development and patent expense</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B7">&#160;</td><td style="width: 9%; text-align: right;">20,757</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B7">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D7">&#160;</td><td style="width: 9%; text-align: right;">22,120</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D7">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - F7">&#160;</td><td style="width: 9%; text-align: right;">60,597</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - F7">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - H7">&#160;</td><td style="width: 9%; text-align: right;">67,111</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - H7">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Selling, general and administrative expense</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - B8">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">10,244</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 9. Stock-based Compensation Expense - B8">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - D8">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">9,705</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 9. Stock-based Compensation Expense - D8">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - F8">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">29,102</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 9. Stock-based Compensation Expense - F8">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - H8">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">26,332</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 9. Stock-based Compensation Expense - H8">&#160;</td></tr><tr><td style="padding-left: 20px;">Stock-based compensation expense, net of amounts capitalized</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - B9">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">31,146</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 9. Stock-based Compensation Expense - B9">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - D9">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">31,984</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 9. Stock-based Compensation Expense - D9">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - F9">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">90,554</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 9. Stock-based Compensation Expense - F9">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - H9">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">94,052</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 9. Stock-based Compensation Expense - H9">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Capitalized stock-based compensation expense</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - B10">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">435</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - B10">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - D10">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">506</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 9. Stock-based Compensation Expense - D10">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - F10">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">1,435</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 9. Stock-based Compensation Expense - F10">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - H10">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">506</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 9. Stock-based Compensation Expense - H10">&#160;</td></tr><tr><td style="padding-left: 20px;">Total stock-based compensation expense</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - B11">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">31,581</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - B11">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - D11">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">32,490</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - D11">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - F11">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">91,989</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - F11">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - H11">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">94,558</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - H11">&#160;</td></tr></table><div style="text-indent: 36pt; text-align: justify;">&#160;</div>

  <div style="text-indent: 36pt; text-align: justify;"> <span style="color: #000000;">As of September 30, 2025, total unrecognized estimated stock-based compensation expense related to non-vested stock options, RSUs and PRSUs was $37.2 million, $88.1 million and $13.0 million, respectively. Our actual expenses will likely differ from these estimates because we will adjust our unrecognized stock-based compensation expense for future forfeitures, including any PRSUs that do not vest. We expect to recognize the cost of stock-based compensation expense related to our non-vested stock options, RSUs and PRSUs over a weighted average amortization period of 1.2 years, 1.5 years and 1.4 years, respectively.</span> </div>
  <div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">Refer to Part IV, Item 15, Note 1, </span><span style="color: #000000; font-style: italic;">Organization and Significant Accounting Policies</span><span style="color: #000000;">, of our audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2024 for further details on how we determine the fair value of stock options granted, RSUs, PRSUs and stock purchase rights under the ESPP.</span>
  </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">For the nine months ended  September 30, 2025 and 2024, we used the following weighted-average assumptions in our Black-Scholes calculations:</span>
  </div>
  <div>&#160;
  </div>
  <div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"> <span style="color: #000000; font-style: italic;">Employee Stock Options:</span></div>


  <div style="text-indent: 36pt;">&#160;</div><table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold;">Nine Months Ended</td></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td></tr><tr><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 9. Stock-based Compensation Expense - B17"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - B17"></td><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 9. Stock-based Compensation Expense - D17"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - D17"></td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Risk-free interest rate </td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B18">&#160;</td><td style="width: 9%; text-align: right;">4.4</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B18">%</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D18">&#160;</td><td style="width: 9%; text-align: right;">4.1</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D18">%</td></tr><tr><td>Dividend yield </td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B19">&#160;</td><td style="width: 9%; text-align: right;">0.0</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B19">%</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D19">&#160;</td><td style="width: 9%; text-align: right;">0.0</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D19">%</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Volatility </td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B20">&#160;</td><td style="width: 9%; text-align: right;">42.1</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B20">%</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D20">&#160;</td><td style="width: 9%; text-align: right;">43.8</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D20">%</td></tr><tr><td>Expected life</td><td style="width: 1%;" title="Note 9. Stock-based Compensation Expense - B21"></td><td style="text-align: right; width: 9%;">6.3 years</td><td style="width: 1%;" title="Note 9. Stock-based Compensation Expense - B21"></td><td>&#160;</td><td style="width: 1%;" title="Note 9. Stock-based Compensation Expense - D21"></td><td style="text-align: right; width: 9%;">6.3 years</td><td style="width: 1%;" title="Note 9. Stock-based Compensation Expense - D21"></td></tr></table><div>&#160;</div><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"><i>Board of Director Stock Options:</i></div><div>&#160;</div><table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold;">Nine Months Ended</td></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td></tr><tr><td>&#160;</td><td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 9. Stock-based Compensation Expense - B35"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 9. Stock-based Compensation Expense - B35"></td><td>&#160;</td><td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 9. Stock-based Compensation Expense - D35"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 9. Stock-based Compensation Expense - D35"></td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Risk-free interest rate </td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B36">&#160;</td><td style="width: 9%; text-align: right;">4.0</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B36">%</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D36">&#160;</td><td style="width: 9%; text-align: right;">4.5</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D36">%</td></tr><tr><td>Dividend yield </td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B37">&#160;</td><td style="width: 9%; text-align: right;">0.0</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B37">%</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D37">&#160;</td><td style="width: 9%; text-align: right;">0.0</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D37">%</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Volatility </td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B38">&#160;</td><td style="width: 9%; text-align: right;">43.0</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B38">%</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D38">&#160;</td><td style="width: 9%; text-align: right;">49.8</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D38">%</td></tr><tr><td>Expected life</td><td style="width: 1%;" title="Note 9. Stock-based Compensation Expense - B39"></td><td style="text-align: right; width: 9%;">7.4 years</td><td style="width: 1%;" title="Note 9. Stock-based Compensation Expense - B39"></td><td>&#160;</td><td style="width: 1%;" title="Note 9. Stock-based Compensation Expense - D39"></td><td style="text-align: right; width: 9%;">7.5 years</td><td style="width: 1%;" title="Note 9. Stock-based Compensation Expense - D39"></td></tr></table><div>&#160;</div><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"> <span style="color: #000000; font-style: italic;">ESPP:</span></div>



  <div style="text-indent: 36pt; text-align: justify;">&#160;</div><table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold;">Nine Months Ended</td></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td></tr><tr><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 9. Stock-based Compensation Expense - B26"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - B26"></td><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 9. Stock-based Compensation Expense - D26"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - D26"></td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Risk-free interest rate </td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B27">&#160;</td><td style="width: 9%; text-align: right;">4.2</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B27">%</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D27">&#160;</td><td style="width: 9%; text-align: right;">5.2</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D27">%</td></tr><tr><td>Dividend yield </td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B28">&#160;</td><td style="width: 9%; text-align: right;">0.0</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B28">%</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D28">&#160;</td><td style="width: 9%; text-align: right;">0.0</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D28">%</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Volatility </td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B29">&#160;</td><td style="width: 9%; text-align: right;">48.2</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B29">%</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D29">&#160;</td><td style="width: 9%; text-align: right;">37.8</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D29">%</td></tr><tr><td>Expected life</td><td style="width: 1%;" title="Note 9. Stock-based Compensation Expense - B30"></td><td style="text-align: right; width: 9%;">6 months</td><td style="width: 1%;" title="Note 9. Stock-based Compensation Expense - B30"></td><td>&#160;</td><td style="width: 1%;" title="Note 9. Stock-based Compensation Expense - D30"></td><td style="text-align: right; width: 9%;">6 months</td><td style="width: 1%;" title="Note 9. Stock-based Compensation Expense - D30"></td></tr></table><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"><i>Stock Options:</i></div>
  <div style="text-indent: 36pt; line-height: 1.15; text-align: justify;">&#160;</div><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"><span style="letter-spacing: normal; text-align: justify; text-indent: 48px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">The weighted-average grant date fair value of stock options granted to employees for the&#160;</span><span style="cursor: pointer; letter-spacing: normal; text-align: justify; text-indent: 48px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;">nine months ended&#160;September 30, 2025</span><span style="letter-spacing: normal; text-align: justify; text-indent: 48px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">&#160;and&#160;</span><span style="cursor: pointer; letter-spacing: normal; text-align: justify; text-indent: 48px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;">2024</span><span style="letter-spacing: normal; text-align: justify; text-indent: 48px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">&#160;was $17.21 and $24.73 per share, respectively.&#160;<span style="text-decoration-thickness: initial; float: none; display: inline !important;">The weighted-average grant date fair value of stock options granted to non-employee directors for the&#160;</span><span style="cursor: pointer; text-decoration-thickness: initial;">nine months ended&#160;September 30, 2025</span><span style="text-decoration-thickness: initial; float: none; display: inline !important;">&#160;and&#160;</span><span style="cursor: pointer; text-decoration-thickness: initial;">2024</span><span style="text-decoration-thickness: initial; float: none; display: inline !important;">&#160;was $20.86 and $27.47 per share, respectively.</span></span></div><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;">&#160;</div><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"><span style="color: #000000; font-style: italic;">RSUs:</span>
  </div><div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span style="color: #000000;">The weighted-average grant date fair value of RSUs granted to employees for the nine months ended September 30, 2025 and 2024 was $33.78 and $52.08 per share, respectively. </span> </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt;">
   <span style="color: #000000; font-style: italic;">PRSUs:</span>
  </div>
  <div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span>Under the terms of the PRSUs we granted in 2025 and 2024, the PRSUs may vest at the end of the three-year performance period based on our relative total shareholder return, or TSR, as compared to a peer group of companies and as measured at the end of the performance period. Under the terms of the grants, no number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of each performance period may be anywhere from zero to 200 percent of the target number depending on our relative TSR.</span> </div>
  <div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span>The weighted-average grant date fair value of PRSUs we granted to our executive officers for the nine months ended September 30, 2025 and 2024 was $48.81 and $78.41 per share, respectively.</span> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="text-indent: -36pt; padding-left: 36pt;">
   <span style="color: #000000; font-weight: bold;">10.&#160;&#160;Income Taxes</span>
  </div>
  <div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span style="color: #000000;">We recorded nominal income tax expense for the three and nine months ended September 30, 2025 compared to income tax benefit of $3.6 million and $3.5 million for the same periods in 2024.</span></div>
  <div style="text-align: justify;">&#160;</div>
  <div style="text-indent: 36pt; line-height: 1.15; text-align: justify;">The benefit for the three and nine months ended September 30, 2024 was primarily related to the 2023 tax return position for the royalty purchase agreement with Royalty Pharma that we finalized during the third quarter of 2024.</div><div style="text-align: justify;">&#160;</div><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;">In July 2025, the One Big Beautiful Bill Act, or OBBBA, was signed into law, introducing significant changes to U.S. federal tax law. The new law restores current expensing of domestic R&amp;D costs and allows us to accelerate the deduction for a significant amount of such costs we capitalized since 2022.
 The tax law changes from the OBBBA did not have a material effect on our tax expense for the three and nine months ended September 30, 2025.</div><div style="text-align: justify;">&#160;</div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">We continue to maintain a full valuation allowance on all of our net deferred tax assets.</span>
  </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liability Related to Sale of Future Royalties<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Liability Related to Sale of Future Royalties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureTextBlock', window );">Liability Related to Sale of Future Royalties</a></td>
<td class="text"><div>
   <span style="font-weight: bold;">11. Liability Related to Sale of Future Royalties</span>
  </div>
  <div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span style="color: #000000;">In 2023, we entered into a royalty purchase agreement with Royalty Pharma Investments, or Royalty Pharma, to monetize a portion of our future SPINRAZA and pelacarsen royalties we are entitled to under our arrangements with Biogen and Novartis, respectively. As a result, we received an upfront payment of $500 million and we are eligible to receive up to $625 million in additional milestone payments. Under the terms of the agreement, Royalty Pharma will receive 25 percent of our SPINRAZA royalty payments from 2023 through 2027, increasing to 45 percent of royalty payments in 2028, on up to $1.5 billion in annual sales. In addition, Royalty Pharma will receive 25 percent of any future royalty payments on pelacarsen, our medicine in development to treat patients with elevated lipoprotein(a)-driven cardiovascular disease. Royalty Pharma&#8217;s royalty interest in SPINRAZA will revert to us after total SPINRAZA royalty payments to Royalty Pharma reach either $475 million or $550 million, depending on the timing and occurrence of FDA approval of pelacarsen.</span> </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span style="color: #000000;">We recorded the upfront payment of $500 million as a liability related to the sale of future royalties, net of transaction costs of $10.4 million, which we are amortizing over the estimated life of the arrangement using the effective interest rate method. We recognize royalty revenue in the period in which the counterparty sells the related product and recognizes the related revenue. We record royalty payments made to Royalty Pharma as a reduction of the liability.</span> </div>
  <div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span style="color: #000000;">We determine the effective interest rate used to record interest expense under this agreement based on an estimate of future royalty payments to Royalty Pharma. As of September 30, 2025 and 2024, the estimated effective interest rate under the agreement was 12.4 percent and 13.5 percent, respectively.</span> </div><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"> <span style="color: #000000;">The following table sets forth information on our liability related to sale of future royalties (in thousands):</span> </div>

  <div style="text-align: justify;">&#160;</div><table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="background-color: rgb(204, 238, 255);"><td>Liability related to sale of future royalties, net as of December 31, 2024</td><td style="width: 1%; text-align: left;" title="Note 11. Liability Related to Sale of Future Royalties - B4">$</td><td style="width: 9%; text-align: right;">542,212</td><td style="width: 1%; text-align: left;" title="Note 11. Liability Related to Sale of Future Royalties - B4">&#160;</td></tr><tr><td>Royalty payments to Royalty Pharma</td><td style="width: 1%; text-align: left;" title="Note 11. Liability Related to Sale of Future Royalties - B5">&#160;</td><td style="width: 9%; text-align: right;">(38,478</td><td style="width: 1%; text-align: left;" title="Note 11. Liability Related to Sale of Future Royalties - B5">)&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Interest expense related to sale of future royalties</td><td style="width: 1%; text-align: left;" title="Note 11. Liability Related to Sale of Future Royalties - B6">&#160;</td><td style="width: 9%; text-align: right;">54,964</td><td style="width: 1%; text-align: left;" title="Note 11. Liability Related to Sale of Future Royalties - B6">&#160;</td></tr><tr><td>Amortization of issuance costs related to sale of future royalties</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none;" title="Note 11. Liability Related to Sale of Future Royalties - B7">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;">458</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 11. Liability Related to Sale of Future Royalties - B7">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Liability related to sale of future royalties, net as of September 30, 2025</td><td style="width: 1%; text-align: left;" title="Note 11. Liability Related to Sale of Future Royalties - B8">$</td><td style="width: 9%; text-align: right;">559,156</td><td style="width: 1%; text-align: left;" title="Note 11. Liability Related to Sale of Future Royalties - B8">&#160;</td></tr><tr><td>Less: Current portion (1)</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 11. Liability Related to Sale of Future Royalties - B9">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-right: none;">(13,974</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 11. Liability Related to Sale of Future Royalties - B9">)&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Liability related to sale of future royalties, net as of September 30, 2025 &#8211; Non-current</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 11. Liability Related to Sale of Future Royalties - B10">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">545,182</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 11. Liability Related to Sale of Future Royalties - B10">&#160;</td></tr></table>
  <div>&#160;
  </div>
  <div style="text-indent: -18pt; text-align: justify; padding-left: 18pt;">

    <div>
     <span style="color: #000000;">(1)&#160; &#160;Included in other current liabilities in our condensed consolidated balance sheet.</span>
    </div>
  </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">There are numerous factors, most of which are not within our control, that could materially impact the amount and timing of royalty payments from Biogen and Novartis, and result in changes to our estimate of future royalty payments to Royalty Pharma. Such factors include, but are not limited to, the commercial sales of SPINRAZA, the regulatory approval and commercial sales of pelacarsen, competing products or other significant events. </span>
  </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Debt [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Convertible Debt</a></td>
<td class="text"><div>
   <span style="font-weight: bold;">12. Convertible Debt</span>
  </div>
  <div style="font-size: 9pt;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span style="color: #000000; font-style: italic;">1.75 Percent Convertible Senior Notes</span> </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span style="font-family: Times;">In 2023, we completed a $575.0 million offering of our 1.75% Notes. </span> </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span>At September 30, 2025, we had the following 1.75% Notes outstanding (in millions except interest rate and price per share data):</span> </div>
  <div style="text-align: justify; color: #000000;">&#160;
  </div>

  <div>&#160;</div>
  <table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td></tr><tr><td>&#160;</td><td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 12. Convertible Debt - B4"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">1.75% Notes</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 12. Convertible Debt - B4"></td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Outstanding principal balance</td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B5">$</td><td style="text-align: right; width: 9%;">575.0</td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B5">&#160;</td></tr><tr><td>Unamortized debt issuance costs</td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B6">$</td><td style="text-align: right; width: 9%;">7.9</td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B6">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Maturity date</td><td style="width: 1%;" title="Note 12. Convertible Debt - B7"></td><td style="text-align: right; width: 9%;"><div style="-sec-ix-hidden: hidden-fact-2">June 2028</div></td><td style="width: 1%;" title="Note 12. Convertible Debt - B7"></td></tr><tr><td>Interest rate</td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B8">&#160;</td><td style="text-align: right; width: 9%;">1.75</td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B8">%</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Effective interest rate</td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B9">$</td><td style="text-align: right; width: 9%;">2.30</td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B9">%</td></tr><tr><td>Conversion price per share</td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B10">&#160;</td><td style="text-align: right; width: 9%;">53.73</td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B10">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Total shares of common stock subject to conversion</td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B11">&#160;</td><td style="text-align: right; width: 9%;">10.7</td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B11">&#160;</td></tr></table><div>&#160;</div><div style="text-indent: 36pt; text-align: justify;"> <span style="color: #000000; font-style: italic;">0 Percent Convertible Senior Notes and Call Spread</span><span style="color: #000000; font-weight: bold; font-style: italic;">&#160;</span> </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span>In 2021, we completed a $632.5 million offering of our 0% Notes. </span></div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span>At September 30, 2025, we had the following </span><span style="font-family: Times;">0%</span><span> Notes outstanding (in millions except interest rate and price per share data):</span> </div>
  <div style="text-align: justify; color: #000000;">&#160;</div>
  <div style="text-align: justify; color: #000000;">&#160;</div>
  <table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td></tr><tr><td>&#160;</td><td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 12. Convertible Debt - B15"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">0% Notes</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 12. Convertible Debt - B15"></td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Outstanding principal balance</td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B16">$</td><td style="text-align: right; width: 9%;">632.5</td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B16">&#160;</td></tr><tr><td>Unamortized debt issuance costs</td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B17">$</td><td style="text-align: right; width: 9%;">1.6</td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B17">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Maturity date</td><td style="width: 1%;" title="Note 12. Convertible Debt - B18"></td><td style="text-align: right; width: 9%;"><div style="-sec-ix-hidden: hidden-fact-3">April 2026</div></td><td style="width: 1%;" title="Note 12. Convertible Debt - B18"></td></tr><tr><td>Interest rate</td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B19">&#160;</td><td style="text-align: right; width: 9%;">0</td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B19">%</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Effective interest rate</td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B20">&#160;</td><td style="text-align: right; width: 9%;">0.50</td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B20">%</td></tr><tr><td>Conversion price per share</td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B21">$</td><td style="text-align: right; width: 9%;">57.84</td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B21">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Effective conversion price per share with call spread</td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B22">$</td><td style="text-align: right; width: 9%;">76.39</td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B22">&#160;</td></tr><tr><td>Total shares of common stock subject to conversion</td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B23">&#160;</td><td style="text-align: right; width: 9%;">10.9</td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B23">&#160;</td></tr></table><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"> In conjunction with the 2021 offering, we entered into a call spread transaction, which was comprised of purchasing note hedges and selling warrants, to minimize the impact of potential economic dilution upon conversion of our <span style="font-family: Times;">0%</span> Notes by increasing the effective conversion price on our <span style="font-family: Times;">0%</span>&#160;Notes. We increased our effective conversion price to $76.39 with the same number of underlying shares as our <span style="font-family: Times;">0% </span>Notes. The call spread cost us $46.9 million, of which $136.7 million was for the note hedge purchase, offset by $89.8 million we received for selling the warrants. Similar to our <span style="font-family: Times;">0%</span> Notes, our note hedges are subject to adjustment. Additionally, our note hedges are exercisable upon conversion of the <span style="font-family: Times;">0%</span>&#160;Notes. The note hedges will expire upon maturity of the <span style="font-family: Times;">0%</span> Notes, or April 2026. The warrants will expire in July 2026. The note hedges and warrants are separate transactions and are not part of the terms of our <span style="font-family: Times;">0%</span> Notes. The holders of the <span style="font-family: Times;">0%</span> Notes do not have any rights with respect to the note hedges and warrants. </div>
  <div style="text-align: justify; color: #000000;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span>We recorded the amount we paid for the note hedges and the amount we received for the warrants in additional paid-in capital in our condensed consolidated balance sheets. Refer to Part IV, Item 15, Note 1, </span><span style="font-style: italic;">Organization and Significant Accounting Policies</span><span>, of our audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2024 for our Call Spread accounting policy. We reassess our ability to continue to classify the note hedges and warrants in shareholders&#8217; equity at each reporting period.</span>
  </div>
  <div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span style="font-style: italic;">Other Terms of Convertible Senior Notes</span>
  </div>
  <div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span style="color: #000000;">The 1.75% and 0% Notes are convertible under certain conditions, at the option of the note holders. We can settle conversions of the notes, at our election, in cash, shares of our common stock or a combination of both. We may not redeem the notes prior to maturity, and we do not have to provide a sinking fund for them. Holders of the notes may require us to purchase some or all of their notes upon the occurrence of certain fundamental changes, as set forth in the indentures governing the notes, at a purchase price equal to 100 percent of the principal amount of the notes to be purchased, plus any accrued and unpaid interest.</span> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Operating Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Operating Leases</a></td>
<td class="text"><div><span style="font-weight: 700; letter-spacing: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">13. Operating Leases</span></div><div>&#160;</div><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;">In 2022, we concurrently entered into two purchase and sale agreements with a real estate investor. In the same period, we closed the first transaction in which we sold the facilities at our headquarters in Carlsbad, California, which includes our primary R&amp;D facility, for a purchase price of $263.4 million. In connection with this transaction, we leased back our headquarters facilities for an initial lease term of 15 years with options to extend the lease for two additional terms of five years each.
</div><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;">&#160;</div><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;">In 2023, we closed the second transaction and transferred legal ownership of two lots of undeveloped land adjacent to our headquarters to the real estate investor for a purchase price of $33.0 million. In connection with this transaction, we entered into a build-to-suit lease agreement with the same real estate investor to lease a new R&amp;D facility. The lessor developed and constructed a new building composed of R&amp;D and office space. We are designing and constructing tenant improvements to customize the facility&#8217;s interior space.
</div><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;">&#160;</div><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;">The lease commenced in September 2025 when the lessor completed constructing the structure of the new facility. The initial lease term for this facility is 15 years with options to extend the lease for 2 additional terms of five years each. We determined at lease inception that it was not reasonably certain that we would exercise any of the options to extend the lease. We estimated our lease payments over the initial term to total approximately $230 million. In addition, we expect to receive reimbursements totaling $41.2 million from the lessor for tenant improvements that we own.
</div><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;">&#160;</div><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;">Since the building was under construction and unavailable to lease, we were unable to complete the sale-leaseback evaluation under ASC Topic 842, Leases, in 2023. As a result, the land remained in our consolidated balance sheets and we accounted for the proceeds as a financial liability. In September 2025, we reassessed the transaction under the sale-leaseback accounting guidance when the facility became available for lease commencement. We determined the transaction qualified as a sale-leaseback transaction upon lease commencement. As a result, we de-recognized the land and recorded a net gain of $4.2 million that we reported within operating loss in our condensed consolidated statements of operations. In addition, we recorded a financial liability of $19.6 million, which reflects the difference in the fair value of the land as of the lease commencement date compared to the purchase price of the land in 2023. W<span style="letter-spacing: normal; text-align: justify; text-indent: 48px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">e reported the current portion of the financial liability in other current liabilities and the non-current portion of the financial liability in long-term obligations in our condensed consolidated balance sheets. We recognize interest expense related to the financial liability based on our incremental borrowing rate at the commencement of the lease. We allocate payments to the lessor between the financial liability and lease expense.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal Proceedings<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Legal Proceedings [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Legal Proceedings</a></td>
<td class="text"><div>
   <span style="font-weight: bold;">14. Legal Proceedings</span>
  </div>
  <div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">From time to time, we are involved in legal proceedings arising in the ordinary course of our business. Periodically, we evaluate the status of each legal matter and assess our potential financial exposure. If we consider the potential loss from any legal proceeding to be probable and we can reasonably estimate the amount, we accrue a liability for the estimated loss. The outcome of any proceeding is not determinable in advance. Therefore, we are required to use significant judgment to determine the probability of a loss and whether the amount of the loss is reasonably estimable. Our assessment of a potential liability and the amount of accruals we recorded are based only on the information available to us at the time. As additional information becomes available, we reassess the potential liability related to the legal proceeding and may revise our estimates.</span>
  </div>
  <div style="text-align: justify;">&#160;
  </div>

  <div style="text-indent: 36pt; text-align: justify;">
   On September 10, 2025, Arrowhead Pharmaceuticals, Inc., or Arrowhead, filed a lawsuit in the District of Delaware seeking a declaratory judgment that our patent US9,593,333 is invalid or not infringed by use of Arrowhead&#8217;s ApoCIII inhibitor plozasiran.  On September 11, 2025, we filed suit in the Central District of California asserting infringement of that same patent by Arrowhead&#8217;s announced intention to commercialize plozasiran in November 2025. On October 8, 2025, we filed a motion to dismiss, or in the alternative, transfer Arrowhead&#8217;s Delaware suit in favor of the case we brought in the Central District of California.  At present, both lawsuits remain pending.   </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text"><div>
   <span style="font-weight: bold;">15. Segment Information</span>
  </div>
  <div>&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;"> <span>We operate as a <span style="-sec-ix-hidden: hidden-fact-4">single</span> operating segment, Ionis operations, focused on the research, development and commercialization of our RNA-targeted medicines to bring better futures to people with serious diseases. The CODM, our Chief Executive Officer, manages our company, reviews operating results, assesses performance and allocates resources on an aggregate basis using consolidated net income or loss as the key measure of segment profit or loss. As such, results of our operations are reported on a consolidated basis for purposes of management and segment reporting.</span> </div>
  <div style="text-align: justify;">&#160;
  </div>
  <div style="text-indent: 36pt; text-align: justify;">
   <span>Ionis operations derives its revenues from commercial and R&amp;D revenue sources. Refer to Note 4, </span><span style="font-style: italic;">Revenues</span><span>, for further details on our sources of revenue.</span>
  </div><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"> The following table sets forth information on segment profit or loss, including significant segment expenses (in thousands): </div>
  <div style="text-align: justify;">&#160;</div>

  <table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold;">Three Months Ended</td><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold;">Nine Months Ended</td></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td></tr><tr><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 14. Segment Information - B5"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - B5"></td><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 14. Segment Information - D5"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - D5"></td><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 14. Segment Information - F5"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - F5"></td><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 14. Segment Information - H5"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - H5"></td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Revenue</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B6">$</td><td style="width: 9%; text-align: right;">156,719</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B6">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D6">$</td><td style="width: 9%; text-align: right;">133,814</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D6">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F6">$</td><td style="width: 9%; text-align: right;">740,381</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F6">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H6">$</td><td style="width: 9%; text-align: right;">478,562</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H6">&#160;</td></tr><tr><td>&#160;</td><td style="width: 1%;" title="Note 14. Segment Information - B7"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 14. Segment Information - B7"></td><td>&#160;</td><td style="width: 1%;" title="Note 14. Segment Information - D7"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 14. Segment Information - D7"></td><td>&#160;</td><td style="width: 1%;" title="Note 14. Segment Information - F7"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 14. Segment Information - F7"></td><td>&#160;</td><td style="width: 1%;" title="Note 14. Segment Information - H7"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 14. Segment Information - H7"></td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Less:</td><td style="width: 1%;" title="Note 14. Segment Information - B8"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 14. Segment Information - B8"></td><td>&#160;</td><td style="width: 1%;" title="Note 14. Segment Information - D8"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 14. Segment Information - D8"></td><td>&#160;</td><td style="width: 1%;" title="Note 14. Segment Information - F8"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 14. Segment Information - F8"></td><td>&#160;</td><td style="width: 1%;" title="Note 14. Segment Information - H8"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 14. Segment Information - H8"></td></tr><tr><td style="padding-left: 10px;">Cost of sales</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B9">&#160;</td><td style="width: 9%; text-align: right;">2,193</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B9">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D9">&#160;</td><td style="width: 9%; text-align: right;">912</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D9">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F9">&#160;</td><td style="width: 9%; text-align: right;">7,097</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F9">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H9">&#160;</td><td style="width: 9%; text-align: right;">6,815</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H9">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 10px;">Drug discovery</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B10">&#160;</td><td style="width: 9%; text-align: right;">28,412</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B10">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D10">&#160;</td><td style="width: 9%; text-align: right;">25,790</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D10">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F10">&#160;</td><td style="width: 9%; text-align: right;">85,656</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F10">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H10">&#160;</td><td style="width: 9%; text-align: right;">80,652</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H10">&#160;</td></tr><tr><td style="padding-left: 10px;">Drug development</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B11">&#160;</td><td style="width: 9%; text-align: right;">120,828</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B11">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D11">&#160;</td><td style="width: 9%; text-align: right;">132,201</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D11">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F11">&#160;</td><td style="width: 9%; text-align: right;">351,463</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F11">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H11">&#160;</td><td style="width: 9%; text-align: right;">392,151</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H11">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 10px;">Medical affairs</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B12">&#160;</td><td style="width: 9%; text-align: right;">8,874</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B12">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D12">&#160;</td><td style="width: 9%; text-align: right;">5,511</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D12">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F12">&#160;</td><td style="width: 9%; text-align: right;">22,342</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F12">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H12">&#160;</td><td style="width: 9%; text-align: right;">17,279</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H12">&#160;</td></tr><tr><td style="padding-left: 10px;">Manufacturing and development chemistry</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B13">&#160;</td><td style="width: 9%; text-align: right;">15,790</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B13">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D13">&#160;</td><td style="width: 9%; text-align: right;">14,087</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D13">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F13">&#160;</td><td style="width: 9%; text-align: right;">51,616</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F13">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H13">&#160;</td><td style="width: 9%; text-align: right;">39,723</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H13">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 10px;">R&amp;D support</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B14">&#160;</td><td style="width: 9%; text-align: right;">23,092</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B14">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D14">&#160;</td><td style="width: 9%; text-align: right;">20,052</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D14">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F14">&#160;</td><td style="width: 9%; text-align: right;">64,252</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F14">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H14">&#160;</td><td style="width: 9%; text-align: right;">59,065</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H14">&#160;</td></tr><tr><td style="padding-left: 10px;">Selling, general and administrative</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B15">&#160;</td><td style="width: 9%; text-align: right;">86,565</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B15">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D15">&#160;</td><td style="width: 9%; text-align: right;">51,933</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D15">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F15">&#160;</td><td style="width: 9%; text-align: right;">234,626</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F15">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H15">&#160;</td><td style="width: 9%; text-align: right;">153,083</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H15">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 10px;">Other segment items (1)</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - B16">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">(429</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - B16">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - D16">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">23,808</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - D16">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - F16">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">75,322</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - F16">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - H16">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">79,342</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - H16">&#160;</td></tr><tr><td>Consolidated net loss</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - B17">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">(128,606</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - B17">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - D17">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">(140,480</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - D17">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - F17">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">(151,993</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - F17">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - H17">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">(349,548</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - H17">)&#160;</td></tr></table><div style="text-align: justify; margin-left: 18pt;">&#160;
  </div>
  <div style="text-indent: -18pt; text-align: justify; padding-left: 18pt;">

    <div style="text-align: justify;"> <span style="color: #000000;">(1)&#160; Other segment items include stock-based compensation expense, investment income, interest expense, gain or loss on investments, other income or expense and income tax expense or benefit.</span> </div>
  </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (128,606)<span></span>
</td>
<td class="num">$ (140,480)<span></span>
</td>
<td class="num">$ (151,993)<span></span>
</td>
<td class="num">$ (349,548)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2025 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text"><div style="text-indent: 36pt; text-align: justify;"> <span style="color: #000000;">During the quarter ended September 30, 2025, our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act), or Section 16 officers and directors, adopted or terminated contracts, instructions or written plans for the purchase or sale of our securities as noted in the table below.</span></div><div>*&#160; &#160; &#160;&#160;&#160;Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.</div><div>**&#160; &#160; "Non-Rule 10b5-1 trading arrangement" as defined in item 408(c) of Regulation S-K under the Exchange Act.</div><table cellpadding="0" class="worksheetTable" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td style="width: 8%;"></td><td style="width: 1%;"></td><td style="width: 7%;"></td><td style="width: 1%;"></td><td style="width: 7%;"></td><td style="width: 1%;"></td><td style="width: 8%;"></td><td style="width: 1%;"></td><td style="width: 7%;"></td><td style="width: 1%;"></td><td style="width: 8%;"></td><td style="width: 1%;"></td><td style="width: 8%;"></td><td style="width: 1%;"></td><td style="width: 40%;"></td></tr><tr><td style="font-weight: bold; text-align: center;"></td><td style="font-weight: bold; text-align: center;"></td><td style="font-weight: bold; text-align: center;"></td><td style="font-weight: bold; text-align: center;"></td><td style="font-weight: bold; text-align: center;"></td><td style="font-weight: bold; text-align: center;"></td><td style="font-weight: bold; text-align: center;"></td><td style="font-weight: bold; text-align: center;"></td><td colspan="3" style="font-weight: bold; text-align: center; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">Trading Arrangement</td><td style="font-weight: bold; text-align: center;"></td><td style="font-weight: bold; text-align: center;">Total Shares</td><td style="font-weight: bold; text-align: center;"></td><td style="font-weight: bold; text-align: center;"></td></tr><tr><td style="font-weight: bold; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; text-align: left;">Name</td><td style="font-weight: bold; text-align: center; vertical-align: bottom;"></td><td style="font-weight: bold; text-align: center; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">Title</td><td style="font-weight: bold; text-align: center; vertical-align: bottom;"></td><td style="font-weight: bold; text-align: center; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">Action</td><td style="font-weight: bold; text-align: center; vertical-align: bottom;"></td><td style="font-weight: bold; text-align: center; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">Date</td><td style="font-weight: bold; text-align: center; vertical-align: bottom;"></td><td style="font-weight: bold; text-align: center; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">Rule 10b5-1*</td><td style="font-weight: bold; text-align: center; vertical-align: bottom;"></td><td style="font-weight: bold; text-align: center; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">Non-Rule 10b5-1**</td><td style="font-weight: bold; text-align: center; vertical-align: bottom;"></td><td style="font-weight: bold; text-align: center; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">to be Sold</td><td style="font-weight: bold; text-align: center; vertical-align: bottom;"></td><td style="font-weight: bold; text-align: center; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">Expiration Date</td></tr><tr><td style="vertical-align: bottom;">Spencer Berthelsen</td><td style="vertical-align: bottom;"></td><td style="vertical-align: bottom; text-align: center;">Board Member</td><td style="vertical-align: bottom;"></td><td style="text-align: center; vertical-align: bottom;"><span style="-sec-ix-hidden: hidden-fact-5">Adoption</span></td><td style="vertical-align: bottom;"></td><td style="text-align: center; vertical-align: bottom;">September 12, 2025</td><td style="vertical-align: bottom;"></td><td style="text-align: center; vertical-align: bottom;">X</td><td style="vertical-align: bottom;"></td><td style="vertical-align: bottom;"></td><td style="vertical-align: bottom;"></td><td style="text-align: center; vertical-align: bottom;">16,000</td><td style="vertical-align: bottom;"></td><td style="vertical-align: bottom;">The earlier to occur of (i) July 1, 2026, and (ii) Upon the execution of all instructions provided in the plan</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Spencer Berthelsen<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Board Member<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">September 12, 2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">July 1, 2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">293 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">16,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrSecuritiesAggAvailAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrSecuritiesAggAvailAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="text-indent: 36pt; text-align: justify;"> <span style="color: #000000;">We prepared the unaudited interim condensed consolidated financial statements for the three and nine months ended September 30, 2025 and 2024 on the same basis as the audited financial statements for the year ended December 31, 2024. We included all normal recurring adjustments in the financial statements, which we considered necessary for a fair presentation of our financial position at such dates and our operating results and cash flows for those periods. Our operating results for the interim periods may not be indicative of what our operating results will be for the entire year. For more complete financial information, these financial statements, and notes thereto, should be read in conjunction with the audited financial statements for the year ended December 31, 2024 included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission, or SEC. </span> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation</a></td>
<td class="text"><div style="text-indent: 36pt; text-align: justify;"> <span style="color: #000000;">In our condensed consolidated financial statements, we included the accounts of Ionis Pharmaceuticals, Inc. and the consolidated results of our wholly owned subsidiary, Akcea Therapeutics, Inc. and its wholly owned subsidiaries (&#8220;we&#8221;, &#8220;us&#8221; or &#8220;our&#8221;).</span> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="text-indent: 36pt; text-align: justify;"> <span>We operate as a </span><span style="color: #000000;">single </span><span>segment, Ionis operations, because our chief operating decision maker, or CODM, reviews operating results on an aggregate basis and manages our operations as a </span><span style="color: #000000;"><span style="-sec-ix-hidden: hidden-fact-0">single</span> </span><span>operating segment. Refer to Note 15, </span><span style="font-style: italic;">Segment Information</span><span>, for further details on our segment information.</span> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="text-indent: 36pt; text-align: justify;"> <span style="color: #000000; font-weight: bold;">Use of Estimates</span> </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">We prepare our condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States, or </span><span>U.S., that require us to make estimates and assumptions that affect the amounts reported in our condensed consolidated financial statements and accompanying notes. Actual results could differ from our estimates.</span>
  </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="text-indent: 36pt; text-align: justify;"> <span style="color: #000000; font-weight: bold; font-style: italic;">Revenue Recognition</span> </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000; font-style: italic;">Product Sales, Net</span>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">We recognize revenue from product sales when the customer obtains control of our product in the amount of the transaction price, which is the amount that reflects the consideration which we expect to receive. We estimate reserves for variable consideration related to applicable discounts, rebates, chargebacks and other allowances included in our agreements with customers, payors and other third parties. We include the amount of variable consideration in the transaction price to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If actual results vary significantly from our estimates, we adjust our estimates in the period that we become aware of such variances.</span>
  </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Sales</a></td>
<td class="text"><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"> <span style="color: #000000; font-weight: bold; font-style: italic;">Cost of Sales</span> </div><div style="text-indent: 36pt; text-align: justify;">
   <span>Our cost of sales is comprised of costs related to our commercial revenue, including manufacturing costs, transportation and freight costs and indirect overhead costs associated with the manufacturing and distribution of our products. We also may include certain period costs related to manufacturing services and inventory adjustments in cost of sales.</span>
  </div><div style="text-indent: 36pt; text-align: justify;">
   <span>Cost of sales for a newly launched product, such as TRYNGOLZA or DAWNZERA, does not include the full cost of manufacturing until we manufacture and sell additional inventory after exhausting pre-launch inventory, which we previously recorded as research and development, or R&amp;D, expense.</span>
  </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Standards</a></td>
<td class="text"><div style="text-indent: 36pt;"> <span style="color: #000000; font-weight: bold;">Recent Accounting Standards</span> </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">In November 2023, the Financial Accounting Standards Board, or FASB, issued Accounting Standard Update, or ASU, 2023-07, which provides updated guidance on segment reporting. The guidance requires public companies to disclose significant expenses that are regularly provided to the CODM, other segment items for each reportable segment and measures of segment profit or loss used by the CODM for allocating resources. In addition, the updated guidance requires public companies with a single reportable segment to provide all disclosures required under Accounting Standards Codification, or ASC, Topic 280, </span><span style="color: #000000; font-style: italic;">Segment Reporting</span><span style="color: #000000;">, and public companies to include in interim reports all disclosures related to a reportable segment&#8217;s profit or loss and assets that are currently required in annual reports. We adopted the reporting requirements in our 2024 Annual Report on Form 10-K and began providing the interim reporting requirements in our Quarterly Report on Form 10-Q for the first quarter of 2025. Refer to Note 15, </span><span style="color: #000000; font-style: italic;">Segment Information</span><span style="color: #000000;">, for further details on our segment information.</span>
  </div><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;">In July 2025, the FASB issued ASU 2025-05, which amended the guidance in ASC 326 to simplify the estimation of credit losses on accounts receivable and contract assets from revenue transactions. The amended guidance allows companies to elect a practical expedient to assume that conditions as of the balance sheet date will remain unchanged for the remaining life of the asset when estimating the expected credit losses of the asset. This update is effective for annual periods beginning after December 15, 2025 and interim periods within those annual periods. Early adoption of this guidance is permitted. Companies that elect the practical expedient are required to apply the amendments prospectively. We are currently assessing the impact and timing of adopting this update.</div><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"><span style="letter-spacing: normal; text-align: justify; text-indent: 48px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">In September 2025, the FASB issued ASU 2025-06, which amended and simplified the existing guidance for software costs. The amended guidance removes references to software development stages and allows companies to begin capitalizing software costs when management has authorized and committed to funding the software project and it is probable that the project will be completed with the software performing the intended function.&#160;This update is effective for annual periods beginning after December 15, 2027 and interim periods within those annual periods. Early adoption of this guidance is permitted at the beginning of an annual reporting period. The guidance may be applied on a prospective or retrospective basis. We expect to early adopt this update on January 1, 2026 on a prospective basis.</span></div><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"><span style="letter-spacing: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">In September&#160;2025, the FASB issued ASU 2025-07, which clarifies that share-based non-cash consideration received from a customer in exchange for goods or services under a revenue contract is subject to the guidance on non-cash consideration under ASC 606.&#160;This update is effective for annual periods beginning after December 15, 2026 and interim periods within those annual periods. Early adoption of this guidance is permitted. The guidance may be applied on a prospective or modified retrospective basis. We are currently assessing the impact and timing of adopting this update.</span></div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">We do not expect any recently issued accounting standards other than the standards mentioned above and those included in our Annual Report on Form 10-K for the year ended December 31, 2024 to have a material impact to our financial results.</span>
  </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Net Loss Per Share</a></td>
<td class="text"><div style="text-indent: 36pt; text-align: justify;"> <span style="color: #000000; font-weight: bold;">Basic net loss&#160;per share</span> </div><div style="text-indent: 36pt; text-align: justify;">
   <span style="color: #000000;">We calculated our basic net loss per share for the three and nine months ended September 30, 2025 and 2024 by dividing our net loss&#160;by our weighted-average number of common shares outstanding during the period.</span>
  </div><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;">
   <span style="color: #000000; font-weight: bold;">Diluted net loss&#160;per share</span>
  </div><div style="text-indent: 36pt; text-align: justify;"><span style="color: #000000;">For the three and&#160;nine months ended&#160;September 30, 2025 and 2024, we incurred a net loss; therefore, we did not include dilutive common equivalent shares in the computation of diluted net loss per share because the effect would have been anti-dilutive. Common stock from the following would have had an anti-dilutive effect on net loss per share:</span>
  </div><div> <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;1.75 percent convertible senior notes, or 1.75% Notes;</span> </div><div> <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;0 percent convertible senior notes, or 0% Notes;</span> </div><div> <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;Note hedges related to the 0% Notes;</span> </div><div>
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;Dilutive stock options; </span>
    </div><div>
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;Unvested restricted stock units, or RSUs; </span>
    </div><div>
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;Unvested performance restricted stock units, or PRSUs; and</span>
    </div><div>
     <span style="color: #000000;">&#9679;&#160;&#160;&#160;&#160;Employee Stock Purchase Plan, or ESPP.</span>
    </div><div style="text-indent: 36pt; text-align: justify;"> <span>For the three and nine months ended September 30, 2024, common stock underlying the 0.125 percent</span><span style="color: #000000;"> convertible senior notes, or 0.125% Notes</span><span>, and n</span><span style="color: #000000;">ote hedges related to the 0.125% Notes </span><span>would also have had an anti-dilutive effect on net loss per share.</span> </div><div style="text-indent: 36pt; text-align: justify;"> As of&#160;September 30, 2025<span style="letter-spacing: normal; text-indent: 48px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">, we had warrants related to our 0% Notes outstanding.</span> As of September 30, 2024,&#160;we had warrants related to our 0% and 0.125% Notes outstanding. We will include the shares issuable under these warrants in our calculation of diluted earnings per share when the average market price per share of our common stock for the reporting period exceeds the strike price of the warrants. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 705<br> -Publisher FASB<br> -URI https://asc.fasb.org/705/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Financial Data (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_SupplementalFinancialDataAbstract', window );"><strong>Supplemental Financial Data [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock', window );">Inventories</a></td>
<td class="text"><div style="text-indent: 36pt; text-align: justify;"> <span style="color: #000000;">Our inventories consisted of the following (in thousands): </span> </div>

  <div style="text-align: justify; color: #000000;">&#160;</div>
  <table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td></tr><tr style="height: 0px; font-size: 0px;"><td></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td></tr><tr><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Supplemental Financial Data - B4"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">September 30, 2025</td><td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Supplemental Financial Data - B4"></td><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Supplemental Financial Data - D4"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">December 31, 2024</td><td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Supplemental Financial Data - D4"></td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Raw materials</td><td style="text-align: left; width: 1%;" title="Note 3. Supplemental Financial Data - B5">$</td><td style="text-align: right; width: 9%;">424</td><td style="text-align: left; width: 1%;" title="Note 3. Supplemental Financial Data - B5">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 3. Supplemental Financial Data - D5">$</td><td style="text-align: right; width: 9%;">5,557</td><td style="text-align: left; width: 1%;" title="Note 3. Supplemental Financial Data - D5">&#160;</td></tr><tr><td>Work in process</td><td style="text-align: left; width: 1%;" title="Note 3. Supplemental Financial Data - B6">&#160;</td><td style="text-align: right; width: 9%;">26,139</td><td style="text-align: left; width: 1%;" title="Note 3. Supplemental Financial Data - B6">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 3. Supplemental Financial Data - D6">&#160;</td><td style="text-align: right; width: 9%;">6,679</td><td style="text-align: left; width: 1%;" title="Note 3. Supplemental Financial Data - D6">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Finished goods</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Supplemental Financial Data - B7">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">549</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 3. Supplemental Financial Data - B7">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Supplemental Financial Data - D7">$</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">276</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 3. Supplemental Financial Data - D7">&#160;</td></tr><tr><td style="padding-left: 20px;">Total</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Supplemental Financial Data - B8">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">27,112</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 3. Supplemental Financial Data - B8">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Supplemental Financial Data - D8">&#160;</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">12,512</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 3. Supplemental Financial Data - D8">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Reported as:</td><td style="text-align: left; border-width: initial; border-style: none; border-color: initial; width: 1%;" title="Note 3. Supplemental Financial Data - B8">&#160;</td><td style="text-align: right; border-width: initial; border-style: none; border-color: initial; width: 9%;"></td><td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;" title="Note 3. Supplemental Financial Data - B8">&#160;</td><td>&#160;</td><td style="text-align: left; border-width: initial; border-style: none; border-color: initial; width: 1%;" title="Note 3. Supplemental Financial Data - D8">&#160;</td><td style="text-align: right; border-width: initial; border-style: none; border-color: initial; width: 9%;"></td><td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;" title="Note 3. Supplemental Financial Data - D8">&#160;</td></tr><tr><td style="padding-left: 10px;">Inventories</td><td style="text-align: left; border-width: initial; border-style: none; border-color: initial; width: 1%;" title="Note 3. Supplemental Financial Data - B8">$</td><td style="text-align: right; border-width: initial; border-style: none; border-color: initial; width: 9%;">10,470</td><td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;" title="Note 3. Supplemental Financial Data - B8">&#160;</td><td>&#160;</td><td style="text-align: left; border-width: initial; border-style: none; border-color: initial; width: 1%;" title="Note 3. Supplemental Financial Data - D8">$</td><td style="text-align: right; border-width: initial; border-style: none; border-color: initial; width: 9%;">12,512</td><td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;" title="Note 3. Supplemental Financial Data - D8">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 10px;">Deposits and other assets</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Supplemental Financial Data - B8">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">16,642</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 3. Supplemental Financial Data - B8">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Supplemental Financial Data - D8">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"> - </td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 3. Supplemental Financial Data - D8">&#160;</td></tr><tr><td style="padding-left: 20px;">Total</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Supplemental Financial Data - B8">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">27,112</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 3. Supplemental Financial Data - B8">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Supplemental Financial Data - D8">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">12,512</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 3. Supplemental Financial Data - D8">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued Liabilities</a></td>
<td class="text"><div style="text-indent: 36pt;"> <span>Our accrued liabilities consisted of the following (in thousands):</span> </div>


  <div>&#160;</div>

  <table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td></tr><tr><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Accrued Liabilities - B4"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">September 30, 2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 3. Accrued Liabilities - B4"></td><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Accrued Liabilities - D4"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">December 31, 2024</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 3. Accrued Liabilities - D4"></td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Clinical expenses</td><td style="text-align: left; width: 1%;" title="Note 3. Accrued Liabilities - B5">$</td><td style="text-align: right; width: 9%;">54,842</td><td style="text-align: left; width: 1%;" title="Note 3. Accrued Liabilities - B5">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 3. Accrued Liabilities - D5">$</td><td style="text-align: right; width: 9%;">77,436</td><td style="text-align: left; width: 1%;" title="Note 3. Accrued Liabilities - D5">&#160;</td></tr><tr><td>In-licensing expenses</td><td style="text-align: left; width: 1%;" title="Note 3. Accrued Liabilities - B6">&#160;</td><td style="text-align: right; width: 9%;">7,770</td><td style="text-align: left; width: 1%;" title="Note 3. Accrued Liabilities - B6">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 3. Accrued Liabilities - D6">&#160;</td><td style="text-align: right; width: 9%;">7,951</td><td style="text-align: left; width: 1%;" title="Note 3. Accrued Liabilities - D6">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Commercial expenses</td><td style="text-align: left; width: 1%;" title="Note 3. Accrued Liabilities - B7">&#160;</td><td style="text-align: right; width: 9%;">15,017</td><td style="text-align: left; width: 1%;" title="Note 3. Accrued Liabilities - B7">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 3. Accrued Liabilities - D7">&#160;</td><td style="text-align: right; width: 9%;">3,589</td><td style="text-align: left; width: 1%;" title="Note 3. Accrued Liabilities - D7">&#160;</td></tr><tr><td>Other miscellaneous expenses</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Accrued Liabilities - B8">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">21,681</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 3. Accrued Liabilities - B8">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Accrued Liabilities - D8">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">19,462</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 3. Accrued Liabilities - D8">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 20px;">Total accrued liabilities</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Accrued Liabilities - B9">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">99,310</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 3. Accrued Liabilities - B9">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Accrued Liabilities - D9">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">108,438</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 3. Accrued Liabilities - D9">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process, and inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle including inventoried costs relating to long-term contracts or programs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_SupplementalFinancialDataAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_SupplementalFinancialDataAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Revenues</a></td>
<td class="text"><div style="text-indent: 36pt; text-align: justify;"> <span>During the three and nine months ended September 30, 2025 and 2024, our revenues consisted of the following (in thousands):</span> </div>

  <div>&#160;</div>
  <table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold;">Three Months Ended</td><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold;">Nine Months Ended</td></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td></tr><tr><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - B4"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - B4"></td><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - D4"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - D4"></td><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - F4"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - F4"></td><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - H4"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - H4"></td></tr><tr><td>Revenue:</td><td style="width: 1%;" title="Note 4. Revenues - B5"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 4. Revenues - B5"></td><td>&#160;</td><td style="width: 1%;" title="Note 4. Revenues - D5"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 4. Revenues - D5"></td><td>&#160;</td><td style="width: 1%;" title="Note 4. Revenues - F5"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 4. Revenues - F5"></td><td>&#160;</td><td style="width: 1%;" title="Note 4. Revenues - H5"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 4. Revenues - H5"></td></tr><tr><td style="padding-left: 10px;">Commercial revenue:</td><td style="width: 1%;" title="Note 4. Revenues - B6"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 4. Revenues - B6"></td><td>&#160;</td><td style="width: 1%;" title="Note 4. Revenues - D6"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 4. Revenues - D6"></td><td>&#160;</td><td style="width: 1%;" title="Note 4. Revenues - F6"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 4. Revenues - F6"></td><td>&#160;</td><td style="width: 1%;" title="Note 4. Revenues - H6"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 4. Revenues - H6"></td></tr><tr><td style="padding-left: 20px;">Product sales, net:</td><td style="width: 1%;" title="Note 4. Revenues - B7"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 4. Revenues - B7"></td><td>&#160;</td><td style="width: 1%;" title="Note 4. Revenues - D7"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 4. Revenues - D7"></td><td>&#160;</td><td style="width: 1%;" title="Note 4. Revenues - F7"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 4. Revenues - F7"></td><td>&#160;</td><td style="width: 1%;" title="Note 4. Revenues - H7"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 4. Revenues - H7"></td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 30px;">TRYNGOLZA sales, net</td><td style="text-align: left; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none; width: 1%;" title="Note 4. Revenues - B8">$</td><td style="text-align: right; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none; width: 9%;">31,792</td><td style="text-align: left; width: 1%; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none;" title="Note 4. Revenues - B8">&#160;</td><td>&#160;</td><td style="text-align: left; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none; width: 1%;" title="Note 4. Revenues - D8">$</td><td style="text-align: right; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none; width: 9%;"> - </td><td style="text-align: left; width: 1%; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none;" title="Note 4. Revenues - D8">&#160;</td><td>&#160;</td><td style="text-align: left; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none; width: 1%;" title="Note 4. Revenues - F8">$</td><td style="text-align: right; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none; width: 9%;">57,353</td><td style="text-align: left; width: 1%; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none;" title="Note 4. Revenues - F8">&#160;</td><td>&#160;</td><td style="text-align: left; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none; width: 1%;" title="Note 4. Revenues - H8">$</td><td style="text-align: right; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none; width: 9%;"> - </td><td style="text-align: left; width: 1%; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none;" title="Note 4. Revenues - H8">&#160;</td></tr><tr><td style="padding-left: 30px;">Total product sales, net</td><td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;" title="Note 4. Revenues - B9">&#160;</td><td style="text-align: right; width: 9%; border-width: initial; border-style: none; border-color: initial;">31,792</td><td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;" title="Note 4. Revenues - B9">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;" title="Note 4. Revenues - D9">&#160;</td><td style="text-align: right; width: 9%; border-width: initial; border-style: none; border-color: initial;"> - </td><td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;" title="Note 4. Revenues - D9">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;" title="Note 4. Revenues - F9">&#160;</td><td style="text-align: right; width: 9%; border-width: initial; border-style: none; border-color: initial;">57,353</td><td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;" title="Note 4. Revenues - F9">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;" title="Note 4. Revenues - H9">&#160;</td><td style="text-align: right; width: 9%; border-width: initial; border-style: none; border-color: initial;"> - </td><td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;" title="Note 4. Revenues - H9">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 20px;">Royalty revenue:</td><td style="width: 1%;" title="Note 4. Revenues - B10"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 4. Revenues - B10"></td><td>&#160;</td><td style="width: 1%;" title="Note 4. Revenues - D10"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 4. Revenues - D10"></td><td>&#160;</td><td style="width: 1%;" title="Note 4. Revenues - F10"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 4. Revenues - F10"></td><td>&#160;</td><td style="width: 1%;" title="Note 4. Revenues - H10"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 4. Revenues - H10"></td></tr><tr><td style="padding-left: 30px;">SPINRAZA royalties</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - B11">&#160;</td><td style="text-align: right; width: 9%;">55,896</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - B11">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - D11">&#160;</td><td style="text-align: right; width: 9%;">57,208</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - D11">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - F11">&#160;</td><td style="text-align: right; width: 9%;">158,243</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - F11">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - H11">&#160;</td><td style="text-align: right; width: 9%;">152,406</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - H11">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 30px;">WAINUA royalties</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - B12">&#160;</td><td style="text-align: right; width: 9%;">13,320</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - B12">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - D12">&#160;</td><td style="text-align: right; width: 9%;">5,371</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - D12">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - F12">&#160;</td><td style="text-align: right; width: 9%;">33,107</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - F12">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - H12">&#160;</td><td style="text-align: right; width: 9%;">10,278</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - H12">&#160;</td></tr><tr><td style="padding-left: 30px;">Other royalties</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 4. Revenues - B13">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; width: 9%;">6,478</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - B13">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 4. Revenues - D13">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; width: 9%;">4,228</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - D13">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 4. Revenues - F13">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; width: 9%;">18,461</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - F13">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 4. Revenues - H13">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-right: none; width: 9%;">17,352</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - H13">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 50px;">Total royalty revenue</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - B14">&#160;</td><td style="text-align: right; width: 9%;">75,694</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - B14">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - D14">&#160;</td><td style="text-align: right; width: 9%;">66,807</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - D14">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - F14">&#160;</td><td style="text-align: right; width: 9%;">209,811</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - F14">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - H14">&#160;</td><td style="text-align: right; width: 9%;">180,036</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - H14">&#160;</td></tr><tr><td style="padding-left: 20px;">Other commercial revenue</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - B15"></td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"> 8,112 </td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - B15"></td><td>&#160;</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - D15"></td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"> 8,924 </td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - D15"></td><td>&#160;</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - F15"></td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"> 27,359 </td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - F15"></td><td>&#160;</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - H15"></td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"> 27,324 </td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - H15"></td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 70px;">Total commercial revenue</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - B19">&#160;</td><td style="text-align: right; width: 9%;">115,598</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - B19">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - D19">&#160;</td><td style="text-align: right; width: 9%;">75,731</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - D19">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - F19">&#160;</td><td style="text-align: right; width: 9%;">294,523</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - F19">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - H19">&#160;</td><td style="text-align: right; width: 9%;">207,360</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - H19">&#160;</td></tr><tr><td style="padding-left: 10px;">Research and development revenue:</td><td style="width: 1%;" title="Note 4. Revenues - B20"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 4. Revenues - B20"></td><td>&#160;</td><td style="width: 1%;" title="Note 4. Revenues - D20"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 4. Revenues - D20"></td><td>&#160;</td><td style="width: 1%;" title="Note 4. Revenues - F20"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 4. Revenues - F20"></td><td>&#160;</td><td style="width: 1%;" title="Note 4. Revenues - H20"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 4. Revenues - H20"></td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 30px;">Collaborative agreement revenue</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - B21">&#160;</td><td style="text-align: right; width: 9%;">31,436</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - B21">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - D21">&#160;</td><td style="text-align: right; width: 9%;">44,883</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - D21">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - F21">&#160;</td><td style="text-align: right; width: 9%;">413,387</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - F21">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - H21">&#160;</td><td style="text-align: right; width: 9%;">235,753</td><td style="text-align: left; width: 1%;" title="Note 4. Revenues - H21">&#160;</td></tr><tr><td style="padding-left: 30px;">WAINUA joint development revenue</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - B22">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">9,685</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - B22">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - D22">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">13,200</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - D22">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - F22">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">32,471</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - F22">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - H22">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">35,449</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - H22">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 70px;">Total research and development revenue</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - B23">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">41,121</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - B23">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - D23">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">58,083</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - D23">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - F23">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">445,858</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - F23">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - H23">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">271,202</td><td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - H23">&#160;</td></tr><tr><td style="padding-left: 90px;">Total revenue  </td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - B24">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">156,719</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - B24">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - D24">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">133,814</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - D24">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - F24">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">740,381</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - F24">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - H24">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">478,562</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - H24">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Arrangements and Licensing Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_AstraZenecaCollaborationsMember', window );">AstraZeneca [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Licensing Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Revenue from Collaborative Agreement</a></td>
<td class="text"><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;">During the three and nine months ended September 30, 2025 and 2024, we earned the following revenue from our relationship with AstraZeneca (in thousands, except percentage amounts):</div><div>&#160;</div><table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold;">Three Months Ended</td><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold;">Nine Months Ended</td></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td></tr><tr><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 5. Collaborations - B6"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 5. Collaborations - B6"></td><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 5. Collaborations - D6"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 5. Collaborations - D6"></td><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 5. Collaborations - F6"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 5. Collaborations - F6"></td><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 5. Collaborations - H6"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 5. Collaborations - H6"></td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Revenue from our relationship with AstraZeneca</td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - B7">$</td><td style="text-align: right; width: 9%;">27,128</td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - B7">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - D7">$</td><td style="text-align: right; width: 9%;">19,461</td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - D7">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - F7">$</td><td style="text-align: right; width: 9%;">101,705</td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - F7">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - H7">$</td><td style="text-align: right; width: 9%;">47,106</td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - H7">&#160;</td></tr><tr><td>Percentage of total revenue</td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - B8">&#160;</td><td style="text-align: right; width: 9%;">17</td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - B8">%</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - D8">&#160;</td><td style="text-align: right; width: 9%;">15</td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - D8">%</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - F8">&#160;</td><td style="text-align: right; width: 9%;">14</td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - F8">%</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - H8">&#160;</td><td style="text-align: right; width: 9%;">10</td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - H8">%</td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_OnoCollaborationMember', window );">Ono [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Licensing Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Revenue from Collaborative Agreement</a></td>
<td class="text"><div style="text-indent: 36pt; text-align: justify;">During&#160;<span style="letter-spacing: normal; text-indent: 48px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">the three and nine months ended September 30, 2025&#160;and 2024, we earned the following revenue from our relationship with Ono&#160;(in thousands, except percentage amounts):</span></div><div style="text-indent: 36pt; text-align: justify;">&#160;</div><table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td></tr><tr><td>&#160;</td><td style="width: 1%;" title="Note 5. Collaborations - Ono - B2"></td><td style="text-align: center; font-weight: bold; width: 9%;">Three Months Ended</td><td style="width: 1%;" title="Note 5. Collaborations - Ono - B2"></td><td>&#160;</td><td style="width: 1%;" title="Note 5. Collaborations - Ono - D2"></td><td style="text-align: center; font-weight: bold; width: 9%;">Nine Months Ended</td><td style="width: 1%;" title="Note 5. Collaborations - Ono - D2"></td></tr><tr><td>&#160;</td><td style="border-left: none; border-right: none; border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 5. Collaborations - Ono - B3"></td><td style="text-align: center; font-weight: bold; border-top: none; border-left: none; border-right: none; border-bottom: 1px solid black; width: 9%;">September 30, 2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 5. Collaborations - Ono - B3"></td><td>&#160;</td><td style="border-bottom: 1px solid black; border-left: none; border-right: none; border-top: none; width: 1%;" title="Note 5. Collaborations - Ono - D3"></td><td style="text-align: center; font-weight: bold; border-left: none; border-right: none; border-bottom: 1px solid black; border-top: none; width: 9%;">September 30, 2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 5. Collaborations - Ono - D3"></td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Revenue from our relationship with Ono</td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - Ono - B4">$</td><td style="text-align: right; width: 9%;">2,979</td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - Ono - B4">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - Ono - D4">$</td><td style="text-align: right; width: 9%;">282,979</td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - Ono - D4">&#160;</td></tr><tr><td>Percentage of total revenue</td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - Ono - B5">&#160;</td><td style="text-align: right; width: 9%;">2</td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - Ono - B5">%</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - Ono - D5">&#160;</td><td style="text-align: right; width: 9%;">38</td><td style="text-align: left; width: 1%;" title="Note 5. Collaborations - Ono - D5">%</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ions_AstraZenecaCollaborationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ions_AstraZenecaCollaborationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ions_OnoCollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ions_OnoCollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAbstract', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Contract Maturity of Available-for-Sale Securities</a></td>
<td class="text"><div style="text-indent: 36pt; text-align: justify;"> <span style="color: #000000;">The following table summarizes the contract maturity of the available-for-sale securities we held as of September 30, 2025:</span> </div>
  <div>&#160;</div>
  <div>&#160;</div><table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="background-color: rgb(204, 238, 255);"><td>One year or less </td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B4">&#160;</td><td style="width: 9%; text-align: right;">67</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B4">%</td></tr><tr><td>After one year but within two years </td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B5">&#160;</td><td style="width: 9%; text-align: right;">29</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B5">%</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>After two years but within <span style="-sec-ix-hidden: hidden-fact-1">three and a half years</span></td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B6">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">4</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B6">%</td></tr><tr><td>Total </td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B7">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">100</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B7">%</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock', window );">Summary of Investments</a></td>
<td class="text"><div> <span style="color: #000000;">The following is a summary of our investments (in thousands):</span> </div>

  <div>&#160;</div><table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td></tr><tr><td>&#160;</td><td style="width: 1%;" title="Note 7. Investments - B9"></td><td style="font-weight: bold; text-align: center; width: 9%;">Amortized</td><td style="width: 1%;" title="Note 7. Investments - B9"></td><td>&#160;</td><td colspan="7" style="font-weight: bold; text-align: center; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">Gross Unrealized</td><td>&#160;</td><td style="width: 1%;" title="Note 7. Investments - H9"></td><td style="font-weight: bold; text-align: center; width: 9%;">Estimated</td><td style="width: 1%;" title="Note 7. Investments - H9"></td></tr><tr><td style="font-weight: bold; text-align: left;">September 30, 2025</td><td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - B10"></td><td style="font-weight: bold; text-align: center; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">Cost</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B10"></td><td>&#160;</td><td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - D10"></td><td style="font-weight: bold; text-align: center; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">Gains</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D10"></td><td>&#160;</td><td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - F10"></td><td style="font-weight: bold; text-align: center; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">Losses</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F10"></td><td>&#160;</td><td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - H10"></td><td style="font-weight: bold; text-align: center; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">Fair Value</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H10"></td></tr><tr><td style="text-decoration: underline;">Available-for-sale debt securities:</td><td style="width: 1%;" title="Note 7. Investments - B11"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 7. Investments - B11"></td><td>&#160;</td><td style="width: 1%;" title="Note 7. Investments - D11"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 7. Investments - D11"></td><td>&#160;</td><td style="width: 1%;" title="Note 7. Investments - F11"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 7. Investments - F11"></td><td>&#160;</td><td style="width: 1%;" title="Note 7. Investments - H11"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 7. Investments - H11"></td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="vertical-align: bottom;">Corporate debt securities (1)</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B12">$</td><td style="width: 9%; text-align: right; vertical-align: bottom;">639,937</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B12">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D12">$</td><td style="width: 9%; text-align: right; vertical-align: bottom;">815</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D12">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F12">$</td><td style="width: 9%; text-align: right; vertical-align: bottom;">(69</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F12">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H12">$</td><td style="width: 9%; text-align: right; vertical-align: bottom;">640,683</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H12">&#160;</td></tr><tr><td style="vertical-align: bottom;">Debt securities issued by U.S. government agencies</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B13">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;">73,905</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B13">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D13">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;">66</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D13">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F13">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;">(16</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F13">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H13">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;">73,955</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H13">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="vertical-align: bottom;">Debt securities issued by the U.S. Treasury (1)</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B14">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;">562,662</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B14">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D14">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;">384</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D14">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F14">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;">(61</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F14">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H14">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;">562,985</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H14">&#160;</td></tr><tr><td style="vertical-align: bottom;">Debt securities issued by states of the U.S. and political subdivisions of&#160;the states</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - B15">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;">5,151</td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B15">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - D15">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;">11</td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D15">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - F15">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"> - </td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F15">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - H15">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;">5,162</td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H15">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="vertical-align: bottom; padding-left: 20px;">Total debt securities with a maturity of one year&#160;or less</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - B16">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;">1,281,655</td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B16">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - D16">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;">1,276</td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D16">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - F16">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;">(146</td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F16">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - H16">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;">1,282,785</td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H16">&#160;</td></tr><tr><td style="vertical-align: bottom;">Corporate debt securities</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B17">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;">415,818</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B17">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D17">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;">1,688</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D17">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F17">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;">(121</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F17">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H17">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;">417,385</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H17">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="vertical-align: bottom;">Debt securities issued by U.S. government agencies</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B18">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;">76,548</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B18">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D18">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;">147</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D18">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F18">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;">(60</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F18">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H18">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;">76,635</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H18">&#160;</td></tr><tr><td style="vertical-align: bottom;">Debt securities issued by the U.S. Treasury  </td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B19">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;">204,656</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B19">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D19">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;">493</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D19">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F19">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;">(49</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F19">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H19">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;">205,100</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H19">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="vertical-align: bottom;">Debt securities issued by states of the U.S. and political subdivisions of&#160;the states</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B20">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;">1,117</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B20">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D20">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;">5</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D20">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F20">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;"> - </td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F20">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H20">&#160;</td><td style="width: 9%; text-align: right; vertical-align: bottom;">1,122</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H20">&#160;</td></tr><tr><td style="vertical-align: bottom;">Other municipal debt securities</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - B21">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;">698</td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B21">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - D21">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"> - </td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D21">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - F21">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"> - </td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F21">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - H21">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;">698</td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H21">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="vertical-align: bottom; padding-left: 20px;">Total debt securities with a maturity of more than one year</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - B22">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;">698,837</td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B22">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - D22">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;">2,333</td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D22">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - F22">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;">(230</td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F22">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - H22">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;">700,940</td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H22">&#160;</td></tr><tr><td style="vertical-align: bottom; padding-left: 40px;">Total available-for-sale debt securities</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - B23">$</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;">1,980,492</td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B23">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - D23">$</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;">3,609</td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D23">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - F23">$</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;">(376</td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F23">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - H23">$</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;">1,983,725</td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H23">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="text-decoration: underline; vertical-align: bottom;">Equity securities:</td><td style="width: 1%;" title="Note 7. Investments - B25"></td><td style="vertical-align: bottom; width: 9%;">&#160;</td><td style="width: 1%;" title="Note 7. Investments - B25"></td><td>&#160;</td><td style="width: 1%;" title="Note 7. Investments - D25"></td><td style="vertical-align: bottom; width: 9%;">&#160;</td><td style="width: 1%;" title="Note 7. Investments - D25"></td><td>&#160;</td><td style="width: 1%;" title="Note 7. Investments - F25"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 7. Investments - F25"></td><td>&#160;</td><td style="width: 1%;" title="Note 7. Investments - H25"></td><td style="vertical-align: bottom; width: 9%;">&#160;</td><td style="width: 1%;" title="Note 7. Investments - H25"></td></tr><tr><td style="vertical-align: bottom;">Publicly traded equity securities included in other current assets (2)</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B26">$</td><td style="width: 9%; text-align: right; vertical-align: bottom;">11,897</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B26">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D26">$</td><td style="width: 9%; text-align: right; vertical-align: bottom;">40</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D26">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F26">$</td><td style="width: 9%; text-align: right; vertical-align: bottom;">(8,681</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F26">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H26">$</td><td style="width: 9%; text-align: right; vertical-align: bottom;">3,256</td><td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H26">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="vertical-align: bottom;">Privately held equity securities included in deposits and&#160;other assets (3)</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; vertical-align: bottom;" title="Note 7. Investments - B27">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;">4,905</td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B27">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;" title="Note 7. Investments - D27">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;">54,395</td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D27">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;" title="Note 7. Investments - F27">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;">(7,090</td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F27">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;" title="Note 7. Investments - H27">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;">52,210</td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H27">&#160;</td></tr><tr><td style="vertical-align: bottom; padding-left: 20px;">Total equity securities  </td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;" title="Note 7. Investments - B28">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;">16,802</td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B28">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;" title="Note 7. Investments - D28">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;">54,435</td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D28">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;" title="Note 7. Investments - F28">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;">(15,771</td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F28">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;" title="Note 7. Investments - H28">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-right: none; vertical-align: bottom;">55,466</td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H28">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="vertical-align: bottom; padding-left: 40px;">Total available-for-sale debt and equity securities</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - B29">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;">1,997,294</td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B29">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - D29">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;">58,044</td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D29">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - F29">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;">(16,147</td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F29">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - H29">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;">2,039,191</td><td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H29">&#160;</td></tr></table><table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td></tr><tr><td>&#160;</td><td style="text-align: center; font-weight: bold; width: 1%;" title="Note 7. Investments - B30"></td><td style="text-align: center; font-weight: bold; width: 9%;">Amortized</td><td style="width: 1%;" title="Note 7. Investments - B30"></td><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">Gross Unrealized</td><td>&#160;</td><td style="text-align: center; font-weight: bold; width: 1%;" title="Note 7. Investments - H30"></td><td style="text-align: center; font-weight: bold; width: 9%;">Estimated</td><td style="width: 1%;" title="Note 7. Investments - H30"></td></tr><tr><td style="font-weight: bold;">December 31, 2024</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - B31"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">Cost</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B31"></td><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - D31"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">Gains</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D31"></td><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - F31"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">Losses</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F31"></td><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - H31"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">Fair Value</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H31"></td></tr><tr><td style="text-decoration: underline;">Available-for-sale debt securities:</td><td style="width: 1%;" title="Note 7. Investments - B32"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 7. Investments - B32"></td><td>&#160;</td><td style="width: 1%;" title="Note 7. Investments - D32"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 7. Investments - D32"></td><td>&#160;</td><td style="width: 1%;" title="Note 7. Investments - F32"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 7. Investments - F32"></td><td>&#160;</td><td style="width: 1%;" title="Note 7. Investments - H32"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 7. Investments - H32"></td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Corporate debt securities (1)</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B33">$</td><td style="width: 9%; text-align: right;">593,810</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B33">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - D33">$</td><td style="width: 9%; text-align: right;">487</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - D33">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - F33">$</td><td style="width: 9%; text-align: right;">(240</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - F33">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - H33">$</td><td style="width: 9%; text-align: right;">594,057</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - H33">&#160;</td></tr><tr><td>Debt securities issued by U.S. government agencies</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B34">&#160;</td><td style="width: 9%; text-align: right;">143,647</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B34">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - D34">&#160;</td><td style="width: 9%; text-align: right;">287</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - D34">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - F34">&#160;</td><td style="width: 9%; text-align: right;">(39</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - F34">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - H34">&#160;</td><td style="width: 9%; text-align: right;">143,895</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - H34">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Debt securities issued by the U.S. Treasury (1)</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B35">&#160;</td><td style="width: 9%; text-align: right;">657,285</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B35">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - D35">&#160;</td><td style="width: 9%; text-align: right;">825</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - D35">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - F35">&#160;</td><td style="width: 9%; text-align: right;">(120</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - F35">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - H35">&#160;</td><td style="width: 9%; text-align: right;">657,990</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - H35">&#160;</td></tr><tr><td>Debt securities issued by states of the U.S. and political subdivisions of&#160;the states</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B36">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">7,516</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B36">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D36">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">8</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D36">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F36">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"> - </td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F36">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H36">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">7,524</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H36">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 20px;">Total debt securities with a maturity of one year&#160;or less</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B37">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">1,402,258</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B37">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D37">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">1,607</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D37">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F37">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">(399</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F37">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H37">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">1,403,466</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H37">&#160;</td></tr><tr><td>Corporate debt securities</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B38">&#160;</td><td style="width: 9%; text-align: right;">439,561</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B38">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - D38">&#160;</td><td style="width: 9%; text-align: right;">723</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - D38">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - F38">&#160;</td><td style="width: 9%; text-align: right;">(2,275</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - F38">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - H38">&#160;</td><td style="width: 9%; text-align: right;">438,009</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - H38">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Debt securities issued by U.S. government agencies</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B39">&#160;</td><td style="width: 9%; text-align: right;">65,255</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B39">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - D39">&#160;</td><td style="width: 9%; text-align: right;">137</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - D39">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - F39">&#160;</td><td style="width: 9%; text-align: right;">(289</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - F39">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - H39">&#160;</td><td style="width: 9%; text-align: right;">65,103</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - H39">&#160;</td></tr><tr><td>Debt securities issued by the U.S. Treasury  </td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B40">&#160;</td><td style="width: 9%; text-align: right;">149,086</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B40">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - D40">&#160;</td><td style="width: 9%; text-align: right;">124</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - D40">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - F40">&#160;</td><td style="width: 9%; text-align: right;">(476</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - F40">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - H40">&#160;</td><td style="width: 9%; text-align: right;">148,734</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - H40">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Other municipal debt securities</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B41">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">698</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B41">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D41">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"> - </td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D41">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F41">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">(2</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F41">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H41">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">696</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H41">&#160;</td></tr><tr><td style="padding-left: 20px;">Total debt securities with a maturity of more than one year</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none;" title="Note 7. Investments - B42">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;">654,600</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B42">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - D42">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;">984</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D42">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - F42">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;">(3,042</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F42">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - H42">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;">652,542</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H42">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 40px;">Total available-for-sale debt securities</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - B43">$</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;">2,056,858</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B43">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - D43">$</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;">2,591</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D43">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - F43">$</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;">(3,441</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F43">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - H43">$</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-right: none;">2,056,008</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H43">&#160;</td></tr><tr><td style="text-decoration: underline;">Equity securities:</td><td style="width: 1%;" title="Note 7. Investments - B44"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 7. Investments - B44"></td><td>&#160;</td><td style="width: 1%;" title="Note 7. Investments - D44"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 7. Investments - D44"></td><td>&#160;</td><td style="width: 1%;" title="Note 7. Investments - F44"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 7. Investments - F44"></td><td>&#160;</td><td style="width: 1%;" title="Note 7. Investments - H44"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 7. Investments - H44"></td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Publicly traded equity securities included in other current assets (2)</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B45">$</td><td style="width: 9%; text-align: right;">11,897</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B45">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - D45">$</td><td style="width: 9%; text-align: right;">26</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - D45">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - F45">$</td><td style="width: 9%; text-align: right;">(6,660</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - F45">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - H45">$</td><td style="width: 9%; text-align: right;">5,263</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - H45">&#160;</td></tr><tr><td>Privately held equity securities included in deposits and&#160;other assets (3)</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none;" title="Note 7. Investments - B46">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;">23,115</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B46">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - D46">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;">25,001</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D46">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - F46">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;">(7,093</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F46">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - H46">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;">41,023</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H46">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 20px;">Total equity securities  </td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - B47">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;">35,012</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B47">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - D47">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;">25,027</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D47">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - F47">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;">(13,753</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F47">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - H47">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-right: none;">46,286</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H47">&#160;</td></tr><tr><td style="padding-left: 40px;">Total available-for-sale debt and equity securities</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B48">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">2,091,870</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B48">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D48">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">27,618</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D48">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F48">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">(17,194</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F48">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H48">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">2,102,294</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H48">&#160;</td></tr></table><div style="text-align: justify;">&#160;</div><div style="text-indent: -18pt; text-align: justify; padding-left: 18pt;">

    <div> <span style="color: #000000;">(1)&#160;&#160;&#160;Includes investments classified as cash equivalents in our condensed consolidated balance sheets.</span> </div>
  </div>
  <div style="margin-left: 18pt;">&#160;
  </div>
  <div style="text-indent: -18pt; text-align: justify; padding-left: 18pt;">

    <div> <span style="color: #000000;">(2)&#160;&#160;Our publicly traded equity securities are included in other current assets. We recognize publicly traded equity securities at fair value. In the nine months ended September 30, 2025, we recorded a $2.0 million net unrealized loss in our condensed consolidated statements of operations related to changes in the fair value of our investments in publicly traded companies.</span> </div>
  </div>
  <div style="margin-left: 18pt;">&#160;
  </div>
  <div style="text-indent: -18pt; text-align: justify; padding-left: 18pt;">

    <div> <span style="color: #000000;">(3)&#160; Our privately held equity securities are included in deposits and other assets. We recognize our privately held equity securities at</span><span> cost minus impairments, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer, which are Level 3 inputs</span><span style="color: #000000;">. In the nine months ended September 30, 2025, the amortized cost of our privately held equity securities increased $11.2 million. In the third quarter of 2025, we recorded a $29.4 million unrealized gain related to our investment in a privately held company due to an observable price change in an orderly transaction for a similar investment of the investee. This increase was partially offset by a loss of $18.2 million related to an impairment of our investment in another privately held company that we recorded in the second quarter of 2025.</span></div>
  </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Temporarily Impaired Investments</a></td>
<td class="text"><div style="text-indent: 36pt; text-align: justify;"> <span style="color: #000000;">The following is a summary of our investments we consider to be temporarily impaired at September 30, 2025 (in thousands, except for number of investments): </span> </div>

  <div>&#160;</div>
  <table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td></tr><tr><td>&#160;</td><td style="width: 1%;" title="Note 7. Investments - B52"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 7. Investments - B52"></td><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">Less than 12 Months of Temporary Impairment</td><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">More than 12 Months of Temporary Impairment</td><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">Total Temporary Impairment</td></tr><tr><td>&#160;</td><td style="width: 1%;" title="Note 7. Investments - B53"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">Number&#160;of Investments</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B53"></td><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - D53"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">Estimated Fair&#160;Value</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D53"></td><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - F53"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">Unrealized Losses</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F53"></td><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - H53"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">Estimated Fair&#160;Value</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H53"></td><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - J53"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">Unrealized Losses</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - J53"></td><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - L53"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">Estimated Fair&#160;Value</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - L53"></td><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - N53"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">Unrealized Losses</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - N53"></td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Corporate debt securities  </td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B54">&#160;</td><td style="width: 9%; text-align: right;">105</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B54">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - D54">$</td><td style="width: 9%; text-align: right;">179,031</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - D54">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - F54">$</td><td style="width: 9%; text-align: right;">(127</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - F54">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - H54">$</td><td style="width: 9%; text-align: right;">55,955</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - H54">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - J54">$</td><td style="width: 9%; text-align: right;">(63</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - J54">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - L54">$</td><td style="width: 9%; text-align: right;">234,986</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - L54">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - N54">$</td><td style="width: 9%; text-align: right;">(190</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - N54">)&#160;</td></tr><tr><td>Debt securities issued by&#160;U.S. government agencies</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B55">&#160;</td><td style="width: 9%; text-align: right;">43</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B55">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - D55">&#160;</td><td style="width: 9%; text-align: right;">71,369</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - D55">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - F55">&#160;</td><td style="width: 9%; text-align: right;">(60</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - F55">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - H55">&#160;</td><td style="width: 9%; text-align: right;">17,286</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - H55">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - J55">&#160;</td><td style="width: 9%; text-align: right;">(16</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - J55">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - L55">&#160;</td><td style="width: 9%; text-align: right;">88,655</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - L55">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - N55">&#160;</td><td style="width: 9%; text-align: right;">(76</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - N55">)&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Debt securities issued by the U.S. Treasury  </td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B56">&#160;</td><td style="width: 9%; text-align: right;">25</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - B56">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - D56">&#160;</td><td style="width: 9%; text-align: right;">141,191</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - D56">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - F56">&#160;</td><td style="width: 9%; text-align: right;">(74</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - F56">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - H56">&#160;</td><td style="width: 9%; text-align: right;">46,285</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - H56">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - J56">&#160;</td><td style="width: 9%; text-align: right;">(36</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - J56">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - L56">&#160;</td><td style="width: 9%; text-align: right;">187,476</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - L56">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - N56">&#160;</td><td style="width: 9%; text-align: right;">(110</td><td style="width: 1%; text-align: left;" title="Note 7. Investments - N56">)&#160;</td></tr><tr><td>Other municipal debt securities</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B58">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">1</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B58">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D58">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">698</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D58">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F58">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"> - </td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F58">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H58">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"> - </td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H58">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - J58">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"> - </td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - J58">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - L58">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">698</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - L58">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - N58">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"> - </td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - N58">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Total temporarily impaired&#160;debt securities</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B59">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">174</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B59">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D59">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">392,289</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D59">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F59">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">(261</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F59">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H59">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">119,526</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H59">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - J59">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">(115</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - J59">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - L59">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">511,815</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - L59">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - N59">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">(376</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - N59">)&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of unrealized gains and losses on investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Assets Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="text-indent: 36pt; text-align: justify;"> <span style="color: #000000;">The following tables present the major security types we held at September 30, 2025 and December 31, 2024 that we regularly measure and carry at fair value. The following tables segregate each security type by the level within the fair value hierarchy of the valuation techniques we utilized to determine the respective security&#8217;s fair value (in thousands):</span> </div>


  <div>&#160;</div>
  <table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td></tr><tr><td>&#160;</td><td style="width: 1%;" title="Note 8. Fair Value Measurements - B3"></td><td style="vertical-align: bottom; text-align: center; font-weight: bold; width: 9%;">At</td><td style="width: 1%;" title="Note 8. Fair Value Measurements - B3"></td><td>&#160;</td><td style="width: 1%;" title="Note 8. Fair Value Measurements - D3"></td><td style="text-align: center; font-weight: bold; vertical-align: bottom; width: 9%;">Quoted&#160;Prices&#160;in Active&#160;Markets</td><td style="width: 1%;" title="Note 8. Fair Value Measurements - D3"></td><td>&#160;</td><td style="width: 1%;" title="Note 8. Fair Value Measurements - F3"></td><td style="text-align: center; font-weight: bold; width: 9%;">Significant&#160;Other Observable Inputs</td><td style="width: 1%;" title="Note 8. Fair Value Measurements - F3"></td></tr><tr><td>&#160;</td><td style="border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 8. Fair Value Measurements - B4"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; width: 9%;">September 30, 2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - B4"></td><td>&#160;</td><td style="border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 8. Fair Value Measurements - D4"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; width: 9%;">(Level 1)</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - D4"></td><td>&#160;</td><td style="border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 8. Fair Value Measurements - F4"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; width: 9%;">(Level 2)</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - F4"></td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Cash equivalents (1)  </td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B5">$</td><td style="text-align: right; width: 9%;">167,298</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B5">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D5">$</td><td style="text-align: right; width: 9%;">167,298</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D5">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F5">$</td><td style="text-align: right; width: 9%;"> - </td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F5">&#160;</td></tr><tr><td>Corporate debt securities (2)  </td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B6">&#160;</td><td style="text-align: right; width: 9%;">1,058,068</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B6">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D6">&#160;</td><td style="text-align: right; width: 9%;"> - </td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D6">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F6">&#160;</td><td style="text-align: right; width: 9%;">1,058,068</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F6">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Debt securities issued by U.S. government agencies (3)  </td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B7">&#160;</td><td style="text-align: right; width: 9%;">150,590</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B7">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D7">&#160;</td><td style="text-align: right; width: 9%;"> - </td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D7">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F7">&#160;</td><td style="text-align: right; width: 9%;">150,590</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F7">&#160;</td></tr><tr><td>Debt securities issued by the U.S. Treasury (4)</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B8">&#160;</td><td style="text-align: right; width: 9%;">768,085</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B8">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D8">&#160;</td><td style="text-align: right; width: 9%;">768,085</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D8">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F8">&#160;</td><td style="text-align: right; width: 9%;"> - </td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F8">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Debt securities issued by states of the U.S. and political subdivisions of the states (5)</td><td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - B9">&#160;</td><td style="text-align: right; vertical-align: bottom; width: 9%;">6,284</td><td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - B9">&#160;</td><td>&#160;</td><td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - D9">&#160;</td><td style="text-align: right; vertical-align: bottom; width: 9%;"> - </td><td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - D9">&#160;</td><td>&#160;</td><td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - F9">&#160;</td><td style="text-align: right; vertical-align: bottom; width: 9%;">6,284</td><td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - F9">&#160;</td></tr><tr><td>Other municipal debt securities (5)</td><td style="text-align: left; border-width: initial; border-style: none; border-color: initial; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - B10">&#160;</td><td style="text-align: right; border-width: initial; border-style: none; border-color: initial; vertical-align: bottom; width: 9%;">698</td><td style="text-align: left; vertical-align: bottom; border-width: initial; border-style: none; border-color: initial; width: 1%;" title="Note 8. Fair Value Measurements - B10">&#160;</td><td>&#160;</td><td style="text-align: left; border-width: initial; border-style: none; border-color: initial; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - D10">&#160;</td><td style="text-align: right; border-width: initial; border-style: none; border-color: initial; vertical-align: bottom; width: 9%;"> - </td><td style="text-align: left; vertical-align: bottom; border-width: initial; border-style: none; border-color: initial; width: 1%;" title="Note 8. Fair Value Measurements - D10">&#160;</td><td>&#160;</td><td style="text-align: left; border-width: initial; border-style: none; border-color: initial; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - F10">&#160;</td><td style="text-align: right; border-width: initial; border-style: none; border-color: initial; vertical-align: bottom; width: 9%;">698</td><td style="text-align: left; vertical-align: bottom; border-width: initial; border-style: none; border-color: initial; width: 1%;" title="Note 8. Fair Value Measurements - F10">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Publicly traded equity securities included in other current assets (6)</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - B10">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; vertical-align: bottom; width: 9%;">3,256</td><td style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - B10">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - D10">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; vertical-align: bottom; width: 9%;">3,256</td><td style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - D10">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 1px solid black; border-top: none; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - F10">&#160;</td><td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-right: none; vertical-align: bottom; width: 9%;"> - </td><td style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - F10">&#160;</td></tr><tr><td style="padding-left: 20px;">Total  </td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 8. Fair Value Measurements - B11">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">2,154,279</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - B11">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 8. Fair Value Measurements - D11">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">938,639</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - D11">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 8. Fair Value Measurements - F11">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">1,215,640</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - F11">&#160;</td></tr></table><div>&#160;</div>
  <table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td></tr><tr><td>&#160;</td><td style="width: 1%;" title="Note 8. Fair Value Measurements - B13"></td><td style="vertical-align: bottom; text-align: center; font-weight: bold; width: 9%;">At</td><td style="width: 1%;" title="Note 8. Fair Value Measurements - B13"></td><td>&#160;</td><td style="width: 1%;" title="Note 8. Fair Value Measurements - D13"></td><td style="text-align: center; font-weight: bold; vertical-align: bottom; width: 9%;">Quoted&#160;Prices&#160;in Active&#160;Markets</td><td style="width: 1%;" title="Note 8. Fair Value Measurements - D13"></td><td>&#160;</td><td style="width: 1%;" title="Note 8. Fair Value Measurements - F13"></td><td style="text-align: center; font-weight: bold; width: 9%;">Significant&#160;Other Observable Inputs</td><td style="width: 1%;" title="Note 8. Fair Value Measurements - F13"></td></tr><tr><td>&#160;</td><td style="border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 8. Fair Value Measurements - B14"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; width: 9%;">December 31, 2024</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - B14"></td><td>&#160;</td><td style="border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 8. Fair Value Measurements - D14"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; width: 9%;">(Level 1)</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - D14"></td><td>&#160;</td><td style="border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 8. Fair Value Measurements - F14"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; width: 9%;">(Level 2)</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - F14"></td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Cash equivalents (1) </td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B15">$</td><td style="text-align: right; width: 9%;">180,445</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B15">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D15">$</td><td style="text-align: right; width: 9%;">180,445</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D15">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F15">$</td><td style="text-align: right; width: 9%;">-</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F15">&#160;</td></tr><tr><td>Corporate debt securities (5)</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B16">&#160;</td><td style="text-align: right; width: 9%;">1,032,066</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B16">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D16">&#160;</td><td style="text-align: right; width: 9%;">-</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D16">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F16">&#160;</td><td style="text-align: right; width: 9%;">1,032,066</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F16">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Debt securities issued by U.S. government agencies (5)</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B17">&#160;</td><td style="text-align: right; width: 9%;">208,998</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B17">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D17">&#160;</td><td style="text-align: right; width: 9%;">-</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D17">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F17">&#160;</td><td style="text-align: right; width: 9%;">208,998</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F17">&#160;</td></tr><tr><td>Debt securities issued by the U.S. Treasury (5)</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B18">&#160;</td><td style="text-align: right; width: 9%;">806,724</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B18">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D18">&#160;</td><td style="text-align: right; width: 9%;">806,724</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D18">&#160;</td><td>&#160;</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F18">&#160;</td><td style="text-align: right; width: 9%;">-</td><td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F18">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Debt securities issued by states of the U.S. and political subdivisions of the states (5)</td><td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - B19">&#160;</td><td style="text-align: right; vertical-align: bottom; width: 9%;">7,524</td><td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - B19">&#160;</td><td>&#160;</td><td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - D19">&#160;</td><td style="text-align: right; vertical-align: bottom; width: 9%;">-</td><td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - D19">&#160;</td><td>&#160;</td><td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - F19">&#160;</td><td style="text-align: right; vertical-align: bottom; width: 9%;">7,524</td><td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - F19">&#160;</td></tr><tr><td>Other municipal debt securities (5)</td><td style="text-align: left; vertical-align: bottom; border-width: initial; border-style: none; border-color: initial; width: 1%;" title="Note 8. Fair Value Measurements - B20">&#160;</td><td style="text-align: right; vertical-align: bottom; border-width: initial; border-style: none; border-color: initial; width: 9%;">696</td><td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - B20">&#160;</td><td>&#160;</td><td style="text-align: left; vertical-align: bottom; border-width: initial; border-style: none; border-color: initial; width: 1%;" title="Note 8. Fair Value Measurements - D20">&#160;</td><td style="text-align: right; vertical-align: bottom; border-width: initial; border-style: none; border-color: initial; width: 9%;">-</td><td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - D20">&#160;</td><td>&#160;</td><td style="text-align: left; vertical-align: bottom; border-width: initial; border-style: none; border-color: initial; width: 1%;" title="Note 8. Fair Value Measurements - F20">&#160;</td><td style="text-align: right; vertical-align: bottom; border-width: initial; border-style: none; border-color: initial; width: 9%;">696</td><td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - F20">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Publicly traded equity securities included in other current assets (6)</td><td style="text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 8. Fair Value Measurements - B20">&#160;</td><td style="text-align: right; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; width: 9%;">5,263</td><td style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - B20">&#160;</td><td>&#160;</td><td style="text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 8. Fair Value Measurements - D20">&#160;</td><td style="text-align: right; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; width: 9%;">5,263</td><td style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - D20">&#160;</td><td>&#160;</td><td style="text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 8. Fair Value Measurements - F20">&#160;</td><td style="text-align: right; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-right: none; width: 9%;">-</td><td style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - F20">&#160;</td></tr><tr><td style="padding-left: 20px;">Total </td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 8. Fair Value Measurements - B21">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">2,241,716</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - B21">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 8. Fair Value Measurements - D21">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">992,432</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - D21">&#160;</td><td>&#160;</td><td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 8. Fair Value Measurements - F21">$</td><td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;">1,249,284</td><td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - F21">&#160;</td></tr></table><div style="text-align: justify; margin-left: 18pt;">&#160;
  </div>
  <div style="text-align: justify;"> <span style="color: #000000;">The following footnotes reference lines in our condensed consolidated balance sheets:</span></div>
  <div style="text-align: justify;">&#160;</div><div style="text-align: justify;">(1)&#160; &#160; Included in cash and cash equivalents.</div><div style="text-align: justify;">&#160;</div><div style="text-align: justify;">(2)&#160;&#160;&#160;&#160;$39.9 million was included in cash and cash equivalents, with the difference included in short-term investments.</div><div style="text-align: justify;">&#160;</div><div style="text-align: justify;">(3)&#160; &#160; $6.0 million was included in cash and cash equivalents, with the difference i<span style="letter-spacing: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">ncluded in short-term investments.</span></div><div style="text-align: justify;">&#160;</div><div style="text-align: justify;">(4)&#160; &#160; <span style="letter-spacing: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">$36.0 million was included in cash and cash equivalents, with the difference included in short-term investments.</span></div><div style="text-align: justify;">&#160;</div><div style="text-align: justify;">(5)&#160; &#160; Included in short-term investments.</div><div style="text-align: justify;">&#160;</div><div style="text-align: justify;">(6)&#160; &#160; Included in other current assets.</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation Expense (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-based Compensation Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-Based Compensation Expense</a></td>
<td class="text"><div style="text-indent: 36pt; text-align: justify;"> <span style="color: #000000;">The following table summarizes stock-based compensation expense for the three and nine months ended September 30, 2025 and 2024 (in thousands):</span> </div>
  <div style="text-indent: 36pt; text-align: justify;">&#160;</div>
  <table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold;">Three Months Ended</td><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold;">Nine Months Ended</td></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td></tr><tr><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 9. Stock-based Compensation Expense - B5"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none;" title="Note 9. Stock-based Compensation Expense - B5"></td><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 9. Stock-based Compensation Expense - D5"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none;" title="Note 9. Stock-based Compensation Expense - D5"></td><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 9. Stock-based Compensation Expense - F5"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none;" title="Note 9. Stock-based Compensation Expense - F5"></td><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 9. Stock-based Compensation Expense - H5"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="width: 1%;" title="Note 9. Stock-based Compensation Expense - H5"></td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Cost of sales</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B6">$</td><td style="width: 9%; text-align: right;">145</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B6">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D6">$</td><td style="width: 9%; text-align: right;">159</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D6">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - F6">$</td><td style="width: 9%; text-align: right;">855</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - F6">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - H6">$</td><td style="width: 9%; text-align: right;">609</td><td style="width: 1%; text-align: left; border-width: initial; border-style: none; border-color: initial;" title="Note 9. Stock-based Compensation Expense - H6">&#160;</td></tr><tr><td>Research, development and patent expense</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B7">&#160;</td><td style="width: 9%; text-align: right;">20,757</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B7">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D7">&#160;</td><td style="width: 9%; text-align: right;">22,120</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D7">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - F7">&#160;</td><td style="width: 9%; text-align: right;">60,597</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - F7">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - H7">&#160;</td><td style="width: 9%; text-align: right;">67,111</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - H7">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Selling, general and administrative expense</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - B8">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">10,244</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 9. Stock-based Compensation Expense - B8">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - D8">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">9,705</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 9. Stock-based Compensation Expense - D8">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - F8">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">29,102</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 9. Stock-based Compensation Expense - F8">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - H8">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">26,332</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 9. Stock-based Compensation Expense - H8">&#160;</td></tr><tr><td style="padding-left: 20px;">Stock-based compensation expense, net of amounts capitalized</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - B9">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">31,146</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 9. Stock-based Compensation Expense - B9">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - D9">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">31,984</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 9. Stock-based Compensation Expense - D9">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - F9">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">90,554</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 9. Stock-based Compensation Expense - F9">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - H9">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">94,052</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 9. Stock-based Compensation Expense - H9">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Capitalized stock-based compensation expense</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - B10">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">435</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - B10">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - D10">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">506</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 9. Stock-based Compensation Expense - D10">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - F10">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">1,435</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 9. Stock-based Compensation Expense - F10">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - H10">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">506</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 9. Stock-based Compensation Expense - H10">&#160;</td></tr><tr><td style="padding-left: 20px;">Total stock-based compensation expense</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - B11">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">31,581</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - B11">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - D11">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">32,490</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - D11">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - F11">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">91,989</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - F11">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - H11">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">94,558</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - H11">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Weighted-Average Assumptions for Stock Options</a></td>
<td class="text"><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"> <span style="color: #000000; font-style: italic;">Employee Stock Options:</span></div>


  <div style="text-indent: 36pt;">&#160;</div><table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold;">Nine Months Ended</td></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td></tr><tr><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 9. Stock-based Compensation Expense - B17"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - B17"></td><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 9. Stock-based Compensation Expense - D17"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - D17"></td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Risk-free interest rate </td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B18">&#160;</td><td style="width: 9%; text-align: right;">4.4</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B18">%</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D18">&#160;</td><td style="width: 9%; text-align: right;">4.1</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D18">%</td></tr><tr><td>Dividend yield </td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B19">&#160;</td><td style="width: 9%; text-align: right;">0.0</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B19">%</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D19">&#160;</td><td style="width: 9%; text-align: right;">0.0</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D19">%</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Volatility </td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B20">&#160;</td><td style="width: 9%; text-align: right;">42.1</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B20">%</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D20">&#160;</td><td style="width: 9%; text-align: right;">43.8</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D20">%</td></tr><tr><td>Expected life</td><td style="width: 1%;" title="Note 9. Stock-based Compensation Expense - B21"></td><td style="text-align: right; width: 9%;">6.3 years</td><td style="width: 1%;" title="Note 9. Stock-based Compensation Expense - B21"></td><td>&#160;</td><td style="width: 1%;" title="Note 9. Stock-based Compensation Expense - D21"></td><td style="text-align: right; width: 9%;">6.3 years</td><td style="width: 1%;" title="Note 9. Stock-based Compensation Expense - D21"></td></tr></table><div>&#160;</div><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"><i>Board of Director Stock Options:</i></div><div>&#160;</div><table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold;">Nine Months Ended</td></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td></tr><tr><td>&#160;</td><td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 9. Stock-based Compensation Expense - B35"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 9. Stock-based Compensation Expense - B35"></td><td>&#160;</td><td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 9. Stock-based Compensation Expense - D35"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 9. Stock-based Compensation Expense - D35"></td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Risk-free interest rate </td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B36">&#160;</td><td style="width: 9%; text-align: right;">4.0</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B36">%</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D36">&#160;</td><td style="width: 9%; text-align: right;">4.5</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D36">%</td></tr><tr><td>Dividend yield </td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B37">&#160;</td><td style="width: 9%; text-align: right;">0.0</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B37">%</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D37">&#160;</td><td style="width: 9%; text-align: right;">0.0</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D37">%</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Volatility </td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B38">&#160;</td><td style="width: 9%; text-align: right;">43.0</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B38">%</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D38">&#160;</td><td style="width: 9%; text-align: right;">49.8</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D38">%</td></tr><tr><td>Expected life</td><td style="width: 1%;" title="Note 9. Stock-based Compensation Expense - B39"></td><td style="text-align: right; width: 9%;">7.4 years</td><td style="width: 1%;" title="Note 9. Stock-based Compensation Expense - B39"></td><td>&#160;</td><td style="width: 1%;" title="Note 9. Stock-based Compensation Expense - D39"></td><td style="text-align: right; width: 9%;">7.5 years</td><td style="width: 1%;" title="Note 9. Stock-based Compensation Expense - D39"></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Weighted-Average Assumptions for ESPP</a></td>
<td class="text"><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"> <span style="color: #000000; font-style: italic;">ESPP:</span></div>



  <div style="text-indent: 36pt; text-align: justify;">&#160;</div><table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold;">Nine Months Ended</td></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td></tr><tr><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 9. Stock-based Compensation Expense - B26"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - B26"></td><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 9. Stock-based Compensation Expense - D26"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - D26"></td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Risk-free interest rate </td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B27">&#160;</td><td style="width: 9%; text-align: right;">4.2</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B27">%</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D27">&#160;</td><td style="width: 9%; text-align: right;">5.2</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D27">%</td></tr><tr><td>Dividend yield </td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B28">&#160;</td><td style="width: 9%; text-align: right;">0.0</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B28">%</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D28">&#160;</td><td style="width: 9%; text-align: right;">0.0</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D28">%</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Volatility </td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B29">&#160;</td><td style="width: 9%; text-align: right;">48.2</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B29">%</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D29">&#160;</td><td style="width: 9%; text-align: right;">37.8</td><td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D29">%</td></tr><tr><td>Expected life</td><td style="width: 1%;" title="Note 9. Stock-based Compensation Expense - B30"></td><td style="text-align: right; width: 9%;">6 months</td><td style="width: 1%;" title="Note 9. Stock-based Compensation Expense - B30"></td><td>&#160;</td><td style="width: 1%;" title="Note 9. Stock-based Compensation Expense - D30"></td><td style="text-align: right; width: 9%;">6 months</td><td style="width: 1%;" title="Note 9. Stock-based Compensation Expense - D30"></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718-50/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liability Related to Sale of Future Royalties (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Liability Related to Sale of Future Royalties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock', window );">Liability Related to Sale of Future Royalties</a></td>
<td class="text"><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"> <span style="color: #000000;">The following table sets forth information on our liability related to sale of future royalties (in thousands):</span> </div>

  <div style="text-align: justify;">&#160;</div><table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="background-color: rgb(204, 238, 255);"><td>Liability related to sale of future royalties, net as of December 31, 2024</td><td style="width: 1%; text-align: left;" title="Note 11. Liability Related to Sale of Future Royalties - B4">$</td><td style="width: 9%; text-align: right;">542,212</td><td style="width: 1%; text-align: left;" title="Note 11. Liability Related to Sale of Future Royalties - B4">&#160;</td></tr><tr><td>Royalty payments to Royalty Pharma</td><td style="width: 1%; text-align: left;" title="Note 11. Liability Related to Sale of Future Royalties - B5">&#160;</td><td style="width: 9%; text-align: right;">(38,478</td><td style="width: 1%; text-align: left;" title="Note 11. Liability Related to Sale of Future Royalties - B5">)&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Interest expense related to sale of future royalties</td><td style="width: 1%; text-align: left;" title="Note 11. Liability Related to Sale of Future Royalties - B6">&#160;</td><td style="width: 9%; text-align: right;">54,964</td><td style="width: 1%; text-align: left;" title="Note 11. Liability Related to Sale of Future Royalties - B6">&#160;</td></tr><tr><td>Amortization of issuance costs related to sale of future royalties</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none;" title="Note 11. Liability Related to Sale of Future Royalties - B7">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;">458</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 11. Liability Related to Sale of Future Royalties - B7">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Liability related to sale of future royalties, net as of September 30, 2025</td><td style="width: 1%; text-align: left;" title="Note 11. Liability Related to Sale of Future Royalties - B8">$</td><td style="width: 9%; text-align: right;">559,156</td><td style="width: 1%; text-align: left;" title="Note 11. Liability Related to Sale of Future Royalties - B8">&#160;</td></tr><tr><td>Less: Current portion (1)</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 11. Liability Related to Sale of Future Royalties - B9">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-right: none;">(13,974</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 11. Liability Related to Sale of Future Royalties - B9">)&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Liability related to sale of future royalties, net as of September 30, 2025 &#8211; Non-current</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 11. Liability Related to Sale of Future Royalties - B10">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">545,182</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 11. Liability Related to Sale of Future Royalties - B10">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other noncurrent liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes175PercentMember', window );">1.75% Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Debt [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Convertible Senior Notes</a></td>
<td class="text"><div style="text-indent: 36pt; text-align: justify;"> <span>At September 30, 2025, we had the following 1.75% Notes outstanding (in millions except interest rate and price per share data):</span> </div>
  <div style="text-align: justify; color: #000000;">&#160;
  </div>

  <div>&#160;</div>
  <table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td></tr><tr><td>&#160;</td><td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 12. Convertible Debt - B4"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">1.75% Notes</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 12. Convertible Debt - B4"></td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Outstanding principal balance</td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B5">$</td><td style="text-align: right; width: 9%;">575.0</td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B5">&#160;</td></tr><tr><td>Unamortized debt issuance costs</td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B6">$</td><td style="text-align: right; width: 9%;">7.9</td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B6">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Maturity date</td><td style="width: 1%;" title="Note 12. Convertible Debt - B7"></td><td style="text-align: right; width: 9%;"><div style="-sec-ix-hidden: hidden-fact-2">June 2028</div></td><td style="width: 1%;" title="Note 12. Convertible Debt - B7"></td></tr><tr><td>Interest rate</td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B8">&#160;</td><td style="text-align: right; width: 9%;">1.75</td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B8">%</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Effective interest rate</td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B9">$</td><td style="text-align: right; width: 9%;">2.30</td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B9">%</td></tr><tr><td>Conversion price per share</td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B10">&#160;</td><td style="text-align: right; width: 9%;">53.73</td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B10">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Total shares of common stock subject to conversion</td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B11">&#160;</td><td style="text-align: right; width: 9%;">10.7</td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B11">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes0PercentMember', window );">0% Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Debt [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Convertible Senior Notes</a></td>
<td class="text"><div style="text-indent: 36pt; text-align: justify;"> <span>At September 30, 2025, we had the following </span><span style="font-family: Times;">0%</span><span> Notes outstanding (in millions except interest rate and price per share data):</span> </div>
  <div style="text-align: justify; color: #000000;">&#160;</div>
  <div style="text-align: justify; color: #000000;">&#160;</div>
  <table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td></tr><tr><td>&#160;</td><td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 12. Convertible Debt - B15"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">0% Notes</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 12. Convertible Debt - B15"></td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Outstanding principal balance</td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B16">$</td><td style="text-align: right; width: 9%;">632.5</td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B16">&#160;</td></tr><tr><td>Unamortized debt issuance costs</td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B17">$</td><td style="text-align: right; width: 9%;">1.6</td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B17">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Maturity date</td><td style="width: 1%;" title="Note 12. Convertible Debt - B18"></td><td style="text-align: right; width: 9%;"><div style="-sec-ix-hidden: hidden-fact-3">April 2026</div></td><td style="width: 1%;" title="Note 12. Convertible Debt - B18"></td></tr><tr><td>Interest rate</td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B19">&#160;</td><td style="text-align: right; width: 9%;">0</td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B19">%</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Effective interest rate</td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B20">&#160;</td><td style="text-align: right; width: 9%;">0.50</td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B20">%</td></tr><tr><td>Conversion price per share</td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B21">$</td><td style="text-align: right; width: 9%;">57.84</td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B21">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Effective conversion price per share with call spread</td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B22">$</td><td style="text-align: right; width: 9%;">76.39</td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B22">&#160;</td></tr><tr><td>Total shares of common stock subject to conversion</td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B23">&#160;</td><td style="text-align: right; width: 9%;">10.9</td><td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B23">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes175PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes175PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes0PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes0PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"> The following table sets forth information on segment profit or loss, including significant segment expenses (in thousands): </div>
  <div style="text-align: justify;">&#160;</div>

  <table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"><tr style="height: 0px; font-size: 0px;"><td></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 1%;"></td><td style="width: 9%;"></td><td style="width: 1%;"></td></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold;">Three Months Ended</td><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold;">Nine Months Ended</td></tr><tr><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td><td>&#160;</td><td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">September 30,</td></tr><tr><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 14. Segment Information - B5"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - B5"></td><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 14. Segment Information - D5"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - D5"></td><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 14. Segment Information - F5"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2025</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - F5"></td><td>&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 14. Segment Information - H5"></td><td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;">2024</td><td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - H5"></td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Revenue</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B6">$</td><td style="width: 9%; text-align: right;">156,719</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B6">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D6">$</td><td style="width: 9%; text-align: right;">133,814</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D6">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F6">$</td><td style="width: 9%; text-align: right;">740,381</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F6">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H6">$</td><td style="width: 9%; text-align: right;">478,562</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H6">&#160;</td></tr><tr><td>&#160;</td><td style="width: 1%;" title="Note 14. Segment Information - B7"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 14. Segment Information - B7"></td><td>&#160;</td><td style="width: 1%;" title="Note 14. Segment Information - D7"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 14. Segment Information - D7"></td><td>&#160;</td><td style="width: 1%;" title="Note 14. Segment Information - F7"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 14. Segment Information - F7"></td><td>&#160;</td><td style="width: 1%;" title="Note 14. Segment Information - H7"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 14. Segment Information - H7"></td></tr><tr style="background-color: rgb(204, 238, 255);"><td>Less:</td><td style="width: 1%;" title="Note 14. Segment Information - B8"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 14. Segment Information - B8"></td><td>&#160;</td><td style="width: 1%;" title="Note 14. Segment Information - D8"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 14. Segment Information - D8"></td><td>&#160;</td><td style="width: 1%;" title="Note 14. Segment Information - F8"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 14. Segment Information - F8"></td><td>&#160;</td><td style="width: 1%;" title="Note 14. Segment Information - H8"></td><td style="width: 9%;">&#160;</td><td style="width: 1%;" title="Note 14. Segment Information - H8"></td></tr><tr><td style="padding-left: 10px;">Cost of sales</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B9">&#160;</td><td style="width: 9%; text-align: right;">2,193</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B9">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D9">&#160;</td><td style="width: 9%; text-align: right;">912</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D9">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F9">&#160;</td><td style="width: 9%; text-align: right;">7,097</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F9">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H9">&#160;</td><td style="width: 9%; text-align: right;">6,815</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H9">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 10px;">Drug discovery</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B10">&#160;</td><td style="width: 9%; text-align: right;">28,412</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B10">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D10">&#160;</td><td style="width: 9%; text-align: right;">25,790</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D10">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F10">&#160;</td><td style="width: 9%; text-align: right;">85,656</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F10">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H10">&#160;</td><td style="width: 9%; text-align: right;">80,652</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H10">&#160;</td></tr><tr><td style="padding-left: 10px;">Drug development</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B11">&#160;</td><td style="width: 9%; text-align: right;">120,828</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B11">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D11">&#160;</td><td style="width: 9%; text-align: right;">132,201</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D11">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F11">&#160;</td><td style="width: 9%; text-align: right;">351,463</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F11">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H11">&#160;</td><td style="width: 9%; text-align: right;">392,151</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H11">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 10px;">Medical affairs</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B12">&#160;</td><td style="width: 9%; text-align: right;">8,874</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B12">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D12">&#160;</td><td style="width: 9%; text-align: right;">5,511</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D12">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F12">&#160;</td><td style="width: 9%; text-align: right;">22,342</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F12">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H12">&#160;</td><td style="width: 9%; text-align: right;">17,279</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H12">&#160;</td></tr><tr><td style="padding-left: 10px;">Manufacturing and development chemistry</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B13">&#160;</td><td style="width: 9%; text-align: right;">15,790</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B13">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D13">&#160;</td><td style="width: 9%; text-align: right;">14,087</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D13">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F13">&#160;</td><td style="width: 9%; text-align: right;">51,616</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F13">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H13">&#160;</td><td style="width: 9%; text-align: right;">39,723</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H13">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 10px;">R&amp;D support</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B14">&#160;</td><td style="width: 9%; text-align: right;">23,092</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B14">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D14">&#160;</td><td style="width: 9%; text-align: right;">20,052</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D14">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F14">&#160;</td><td style="width: 9%; text-align: right;">64,252</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F14">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H14">&#160;</td><td style="width: 9%; text-align: right;">59,065</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H14">&#160;</td></tr><tr><td style="padding-left: 10px;">Selling, general and administrative</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B15">&#160;</td><td style="width: 9%; text-align: right;">86,565</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B15">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D15">&#160;</td><td style="width: 9%; text-align: right;">51,933</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D15">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F15">&#160;</td><td style="width: 9%; text-align: right;">234,626</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F15">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H15">&#160;</td><td style="width: 9%; text-align: right;">153,083</td><td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H15">&#160;</td></tr><tr style="background-color: rgb(204, 238, 255);"><td style="padding-left: 10px;">Other segment items (1)</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - B16">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">(429</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - B16">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - D16">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">23,808</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - D16">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - F16">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">75,322</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - F16">&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - H16">&#160;</td><td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;">79,342</td><td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - H16">&#160;</td></tr><tr><td>Consolidated net loss</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - B17">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">(128,606</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - B17">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - D17">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">(140,480</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - D17">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - F17">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">(151,993</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - F17">)&#160;</td><td>&#160;</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - H17">$</td><td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;">(349,548</td><td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - H17">)&#160;</td></tr></table><div style="text-align: justify; margin-left: 18pt;">&#160;
  </div>
  <div style="text-indent: -18pt; text-align: justify; padding-left: 18pt;">

    <div style="text-align: justify;"> <span style="color: #000000;">(1)&#160; Other segment items include stock-based compensation expense, investment income, interest expense, gain or loss on investments, other income or expense and income tax expense or benefit.</span> </div>
  </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2025 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization and Basis of Presentation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Supplemental Financial Data - Inventories (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_InventoryRawMaterialsNet', window );">Raw materials</a></td>
<td class="nump">$ 424<span></span>
</td>
<td class="nump">$ 5,557<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_InventoryWorkInProcessNet', window );">Work in process</a></td>
<td class="nump">26,139<span></span>
</td>
<td class="nump">6,679<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_InventoryFinishedGoodsNet', window );">Finished goods</a></td>
<td class="nump">549<span></span>
</td>
<td class="nump">276<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_InventoryCurrentAndNoncurrent', window );">Total</a></td>
<td class="nump">27,112<span></span>
</td>
<td class="nump">12,512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_ReportedAsAbstract', window );"><strong>Reported as:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">10,470<span></span>
</td>
<td class="nump">12,512<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Deposits and Other Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_ReportedAsAbstract', window );"><strong>Reported as:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventories</a></td>
<td class="nump">$ 16,642<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_InventoryCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of inventory after valuation and LIFO reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_InventoryCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_InventoryFinishedGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, as of the balance sheet date, of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_InventoryFinishedGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_InventoryRawMaterialsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, as of the balance sheet date, of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_InventoryRawMaterialsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_InventoryWorkInProcessNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, as of the balance sheet date, of merchandise or goods which are partially completed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_InventoryWorkInProcessNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_ReportedAsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_ReportedAsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Supplemental Financial Data - Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_AccruedClinicalExpenses', window );">Clinical expenses</a></td>
<td class="nump">$ 54,842<span></span>
</td>
<td class="nump">$ 77,436<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_AccruedInLicensingFeesCurrent', window );">In-licensing expenses</a></td>
<td class="nump">7,770<span></span>
</td>
<td class="nump">7,951<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_AccruedCommercialExpensesCurrent', window );">Commercial expenses</a></td>
<td class="nump">15,017<span></span>
</td>
<td class="nump">3,589<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other miscellaneous expenses</a></td>
<td class="nump">21,681<span></span>
</td>
<td class="nump">19,462<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 99,310<span></span>
</td>
<td class="nump">$ 108,438<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_AccruedClinicalExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_AccruedClinicalExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_AccruedCommercialExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for commercial expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_AccruedCommercialExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_AccruedInLicensingFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for in-licensing fees under collaboration agreements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_AccruedInLicensingFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Details) - WAINUA (Eplontersen) Collaboration with AstraZeneca [Member]<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>Component </div>
<div>PerformanceObligation</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_UpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_NumberOfMaterialComponents', window );">Number of material components (in Component) | Component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations', window );">Number of performance obligations (in PerformanceObligation) | PerformanceObligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_RevenueFromContractWithCustomerTransactionPrice', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_PercentageOfCostsAssociatedWithOngoingGlobalPhase3DevelopmentProgramPaidByCollaborationPartner', window );">Percentage of costs associated with ongoing global Phase 3 development program paid by AstraZeneca</a></td>
<td class="nump">55.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_NumberOfMaterialComponents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of material components identified in the collaboration agreement under Accounting Standards Codification (ASC) 808, Collaborative Arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_NumberOfMaterialComponents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_PercentageOfCostsAssociatedWithOngoingGlobalPhase3DevelopmentProgramPaidByCollaborationPartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of costs associated with the ongoing global Phase 3 development program paid by a collaboration partner under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_PercentageOfCostsAssociatedWithOngoingGlobalPhase3DevelopmentProgramPaidByCollaborationPartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of separate performance obligations under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_RevenueFromContractWithCustomerTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration the Company earned or is eligible to earn under the collaboration agreement, including any variable consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_RevenueFromContractWithCustomerTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_UpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of upfront payments received during the period under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_UpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ions_AstraZenecaCollaborationWainuaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ions_AstraZenecaCollaborationWainuaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Revenues (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 156,719<span></span>
</td>
<td class="nump">$ 133,814<span></span>
</td>
<td class="nump">$ 740,381<span></span>
</td>
<td class="nump">$ 478,562<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ions_TryngolzaMember', window );">TRYNGOLZA Sales, Net [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">31,792<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">57,353<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product Sales, Net [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">31,792<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">57,353<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ions_SpinrazaRoyaltiesMember', window );">SPINRAZA Royalties [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">55,896<span></span>
</td>
<td class="nump">57,208<span></span>
</td>
<td class="nump">158,243<span></span>
</td>
<td class="nump">152,406<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ions_WainusRoyaltiesMember', window );">WAINUA Royalties [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">13,320<span></span>
</td>
<td class="nump">5,371<span></span>
</td>
<td class="nump">33,107<span></span>
</td>
<td class="nump">10,278<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ions_OtherRoyaltiesMember', window );">Other Royalties [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">6,478<span></span>
</td>
<td class="nump">4,228<span></span>
</td>
<td class="nump">18,461<span></span>
</td>
<td class="nump">17,352<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">75,694<span></span>
</td>
<td class="nump">66,807<span></span>
</td>
<td class="nump">209,811<span></span>
</td>
<td class="nump">180,036<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ions_OtherCommercialMember', window );">Other Commercial Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">8,112<span></span>
</td>
<td class="nump">8,924<span></span>
</td>
<td class="nump">27,359<span></span>
</td>
<td class="nump">27,324<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ions_CommercialMember', window );">Commercial Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">115,598<span></span>
</td>
<td class="nump">75,731<span></span>
</td>
<td class="nump">294,523<span></span>
</td>
<td class="nump">207,360<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ions_CollaborativeAgreementRevenueMember', window );">Collaborative Agreement Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">31,436<span></span>
</td>
<td class="nump">44,883<span></span>
</td>
<td class="nump">413,387<span></span>
</td>
<td class="nump">235,753<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ions_WainuaJointDevelopmentRevenueMember', window );">WAINUA Joint Development Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">9,685<span></span>
</td>
<td class="nump">13,200<span></span>
</td>
<td class="nump">32,471<span></span>
</td>
<td class="nump">35,449<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ions_ResearchAndDevelopmentRevenueMember', window );">Research and Development Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 41,121<span></span>
</td>
<td class="nump">$ 58,083<span></span>
</td>
<td class="nump">$ 445,858<span></span>
</td>
<td class="nump">$ 271,202<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ions_TryngolzaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ions_TryngolzaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ions_SpinrazaRoyaltiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ions_SpinrazaRoyaltiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ions_WainusRoyaltiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ions_WainusRoyaltiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ions_OtherRoyaltiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ions_OtherRoyaltiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ions_OtherCommercialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ions_OtherCommercialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ions_CommercialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ions_CommercialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ions_CollaborativeAgreementRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ions_CollaborativeAgreementRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ions_WainuaJointDevelopmentRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ions_WainuaJointDevelopmentRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ions_ResearchAndDevelopmentRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ions_ResearchAndDevelopmentRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Arrangements and Licensing Agreements - AstraZeneca (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($) </div>
<div>Agreement</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($) </div>
<div>Agreement</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_AstraZenecaCollaborationsMember', window );">AstraZeneca [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Licensing Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_NumberOfCollaborationAgreements', window );">Number of collaboration agreements (in Agreement) | Agreement</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_CumulativePaymentsReceived', window );">Cumulative payments received</a></td>
<td class="nump">$ 960,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 960,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">27,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,461<span></span>
</td>
<td class="nump">101,705<span></span>
</td>
<td class="nump">$ 47,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_AstraZenecaCollaborationWAINUAMember', window );">WAINUA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Licensing Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_NumberOfCollaborationAgreements', window );">Number of collaboration agreements (in Agreement) | Agreement</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_AstraZenecaCollaborationCardiovascularRenalAndMetabolicDiseasesMember', window );">Cardiovascular, Renal and Metabolic Diseases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Licensing Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_NumberOfCollaborationAgreements', window );">Number of collaboration agreements (in Agreement) | Agreement</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_NextPaymentToBeAchieved', window );">Next payment to be achieved</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_CumulativePaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cumulative amount of payments received under the collaboration agreement as of the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_CumulativePaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_NextPaymentToBeAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The next payment to be achieved under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_NextPaymentToBeAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_NumberOfCollaborationAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of collaboration agreements with the collaboration partner.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_NumberOfCollaborationAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ions_AstraZenecaCollaborationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ions_AstraZenecaCollaborationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ions_AstraZenecaCollaborationWAINUAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ions_AstraZenecaCollaborationWAINUAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ions_AstraZenecaCollaborationCardiovascularRenalAndMetabolicDiseasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ions_AstraZenecaCollaborationCardiovascularRenalAndMetabolicDiseasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Arrangements and Licensing Agreements - Revenue from Collaborative Relationship with AstraZeneca (Details) - AstraZeneca [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Licensing Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 27,128<span></span>
</td>
<td class="nump">$ 19,461<span></span>
</td>
<td class="nump">$ 101,705<span></span>
</td>
<td class="nump">$ 47,106<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_AstraZenecaCollaborationsMember', window );">Revenue [Member] | Strategic Partner [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Licensing Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration percentage</a></td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ions_AstraZenecaCollaborationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ions_AstraZenecaCollaborationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Arrangements and Licensing Agreements - Ono (Details) - Ono [Member]<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>PerformanceObligation</div>
</th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Licensing Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_MaximumAmountOfPaymentsReceivableOverTermOfCollaboration', window );">Maximum amount of payments receivable over term of collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 940,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 940,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_MaximumAmountOfUpfrontPaymentsOverTermOfCollaboration', window );">Maximum amount of upfront payments over term of collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">280,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">280,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_MaximumAmountOfDevelopmentMilestonePaymentsOverTermOfCollaboration', window );">Maximum amount of development milestone payments over term of collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_MaximumAmountOfRegulatoryMilestonePaymentsOverTermOfCollaboration', window );">Maximum amount of regulatory milestone payments over term of collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_MaximumAmountOfSalesMilestonePaymentsOverTermOfCollaboration', window );">Maximum amount of sales milestone payments over term of collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">620,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">620,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_CumulativePaymentsReceived', window );">Cumulative payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">280,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">280,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_NextPaymentToBeAchieved', window );">Next payment to be achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_NumberOfPerformanceObligationsIdentified', window );">Number of performance obligations identified (in PerformanceObligation) | PerformanceObligation</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_RevenueFromContractWithCustomerTransactionPrice', window );">Transaction price</a></td>
<td class="nump">$ 280,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">282,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_OnoCollaborationMember', window );">R&amp;D Services for Sapablursen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Licensing Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_RevenueFromContractWithCustomerTransactionPrice', window );">Transaction price</a></td>
<td class="nump">278,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 278,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_OnoCollaborationMember', window );">License of Sapablursen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Licensing Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_RevenueFromContractWithCustomerTransactionPrice', window );">Transaction price</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_CumulativePaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cumulative amount of payments received under the collaboration agreement as of the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_CumulativePaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_MaximumAmountOfDevelopmentMilestonePaymentsOverTermOfCollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of development milestone payments to be received over the term of the collaboration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_MaximumAmountOfDevelopmentMilestonePaymentsOverTermOfCollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_MaximumAmountOfPaymentsReceivableOverTermOfCollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of payments the Company is eligible to receive over the term of the collaboration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_MaximumAmountOfPaymentsReceivableOverTermOfCollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_MaximumAmountOfRegulatoryMilestonePaymentsOverTermOfCollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of regulatory milestone payments to be received over the term of the collaboration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_MaximumAmountOfRegulatoryMilestonePaymentsOverTermOfCollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_MaximumAmountOfSalesMilestonePaymentsOverTermOfCollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of sales milestone payments to be received over the term of the collaboration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_MaximumAmountOfSalesMilestonePaymentsOverTermOfCollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_MaximumAmountOfUpfrontPaymentsOverTermOfCollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of upfront payments to be received over the term of the collaboration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_MaximumAmountOfUpfrontPaymentsOverTermOfCollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_NextPaymentToBeAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The next payment to be achieved under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_NextPaymentToBeAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_NumberOfPerformanceObligationsIdentified">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of performance obligations identified under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_NumberOfPerformanceObligationsIdentified</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_RevenueFromContractWithCustomerTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration the Company earned or is eligible to earn under the collaboration agreement, including any variable consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_RevenueFromContractWithCustomerTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ions_OnoCollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ions_OnoCollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ions_ResearchAndDevelopmentServicesForSapablursenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ions_ResearchAndDevelopmentServicesForSapablursenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ions_LicenseOfSapablursenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ions_LicenseOfSapablursenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Arrangements and Licensing Agreements - Revenue from Collaborative Relationship with Ono (Details) - Ono [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Licensing Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 2,979<span></span>
</td>
<td class="nump">$ 282,979<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_OnoCollaborationMember', window );">Revenue [Member] | Strategic Partner [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Licensing Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration percentage</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">38.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ions_OnoCollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ions_OnoCollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basic and Diluted Net Loss Per Share (Details)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes175PercentMember', window );">1.75% Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Basic and Diluted Net Loss Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on convertible senior notes</a></td>
<td class="nump">1.75%<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes0PercentMember', window );">0% Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Basic and Diluted Net Loss Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on convertible senior notes</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes0125PercentMember', window );">0.125% Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Basic and Diluted Net Loss Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.125%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes175PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes175PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes0PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes0PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes0125PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes0125PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($) </div>
<div>Company</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($) </div>
<div>Company</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage', window );">Percentage of available-for-sale securities with a maturity of less than two years</a></td>
<td class="nump">96.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_MaximumContractMaturityPeriodRange2', window );">Maximum contract maturity period, range 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment', window );">Number of private companies in which there is an equity ownership interest of less than 20% (in Company) | Company</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment', window );">Number of public companies in which there is an equity ownership interest of less than 20% (in Company) | Company</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=ions_EquitySecuritiesPubliclyTradedCompaniesMember', window );">Publicly Traded Equity Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss', window );">Unrealized loss on equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=ions_EquitySecuritiesPrivateCompaniesMember', window );">Privately Held Equity Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss', window );">Unrealized loss on equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized net gain on equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGain', window );">Unrealized gain on equity securities</a></td>
<td class="nump">$ 29.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of available-for-sale debt securities that mature within two years of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_MaximumContractMaturityPeriodRange2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum contract maturity period for the second range of available-for-sale securities, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_MaximumContractMaturityPeriodRange2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of privately-held companies, in which the entity has an equity ownership interest of less than 20%, with which it conducts business. These are accounted for under the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of publicly-held companies, in which the entity has an equity ownership interest of less than 20%, with which it conducts business. These are accounted for at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=ions_EquitySecuritiesPubliclyTradedCompaniesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=ions_EquitySecuritiesPubliclyTradedCompaniesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=ions_EquitySecuritiesPrivateCompaniesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=ions_EquitySecuritiesPrivateCompaniesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments - Contract Maturity of Available-for-Sale Securities (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAbstract', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_MaximumContractMaturityPeriodRange1', window );">Maximum contract maturity period, range 1</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage', window );">One year or less</a></td>
<td class="nump">67.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_MaximumContractMaturityPeriodRange2', window );">Maximum contract maturity period, range 2</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage', window );">After one year but within two years</a></td>
<td class="nump">29.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_MaximumContractMaturityPeriodRange3', window );">Maximum contract maturity period, range 3</a></td>
<td class="text">3 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage', window );">After two years but within three and a half years</a></td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage', window );">Total</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of available-for-sale debt securities that mature beyond one year but within two years of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of available-for-sale debt securities that mature beyond two years but within three and one-half years of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate percentage of all available-for-sale debt securities, regardless of maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of available-for-sale debt securities that mature within one year of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_MaximumContractMaturityPeriodRange1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum contract maturity period for the first range of available-for-sale securities, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_MaximumContractMaturityPeriodRange1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_MaximumContractMaturityPeriodRange2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum contract maturity period for the second range of available-for-sale securities, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_MaximumContractMaturityPeriodRange2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_MaximumContractMaturityPeriodRange3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum contract maturity period for the third range of available-for-sale securities, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_MaximumContractMaturityPeriodRange3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Investments - Summary of Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Amortized cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,281,655<span></span>
</td>
<td class="nump">$ 1,402,258<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent', window );">Gross unrealized gains</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,276<span></span>
</td>
<td class="nump">1,607<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent', window );">Gross unrealized losses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(146)<span></span>
</td>
<td class="num">(399)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,282,785<span></span>
</td>
<td class="nump">1,403,466<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent', window );">Amortized cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">698,837<span></span>
</td>
<td class="nump">654,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent', window );">Gross unrealized gains</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,333<span></span>
</td>
<td class="nump">984<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent', window );">Gross unrealized losses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(230)<span></span>
</td>
<td class="num">(3,042)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">700,940<span></span>
</td>
<td class="nump">652,542<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,980,492<span></span>
</td>
<td class="nump">2,056,858<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,609<span></span>
</td>
<td class="nump">2,591<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(376)<span></span>
</td>
<td class="num">(3,441)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,983,725<span></span>
</td>
<td class="nump">2,056,008<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCost', window );">Amortized cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16,802<span></span>
</td>
<td class="nump">35,012<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_EquitySecuritiesFvNiAccumulatedGrossUnrealizedGain', window );">Gross unrealized gains</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">54,435<span></span>
</td>
<td class="nump">25,027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_EquitySecuritiesFvNiAccumulatedGrossUnrealizedLoss', window );">Gross unrealized losses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(15,771)<span></span>
</td>
<td class="num">(13,753)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">55,466<span></span>
</td>
<td class="nump">46,286<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost', window );">Amortized cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,997,294<span></span>
</td>
<td class="nump">2,091,870<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain', window );">Gross unrealized gains</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">58,044<span></span>
</td>
<td class="nump">27,618<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss', window );">Gross unrealized losses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(16,147)<span></span>
</td>
<td class="num">(17,194)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi', window );">Estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,039,191<span></span>
</td>
<td class="nump">2,102,294<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Amortized cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">639,937<span></span>
</td>
<td class="nump">593,810<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent', window );">Gross unrealized gains</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">815<span></span>
</td>
<td class="nump">487<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent', window );">Gross unrealized losses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(69)<span></span>
</td>
<td class="num">(240)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">640,683<span></span>
</td>
<td class="nump">594,057<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent', window );">Amortized cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">415,818<span></span>
</td>
<td class="nump">439,561<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent', window );">Gross unrealized gains</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,688<span></span>
</td>
<td class="nump">723<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent', window );">Gross unrealized losses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(121)<span></span>
</td>
<td class="num">(2,275)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">417,385<span></span>
</td>
<td class="nump">438,009<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Debt Securities Issued by U.S. Government Agencies [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Amortized cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">73,905<span></span>
</td>
<td class="nump">143,647<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent', window );">Gross unrealized gains</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">66<span></span>
</td>
<td class="nump">287<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent', window );">Gross unrealized losses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(16)<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">73,955<span></span>
</td>
<td class="nump">143,895<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent', window );">Amortized cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">76,548<span></span>
</td>
<td class="nump">65,255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent', window );">Gross unrealized gains</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">147<span></span>
</td>
<td class="nump">137<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent', window );">Gross unrealized losses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(60)<span></span>
</td>
<td class="num">(289)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">76,635<span></span>
</td>
<td class="nump">65,103<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">Debt Securities Issued by the U.S. Treasury [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Amortized cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">562,662<span></span>
</td>
<td class="nump">657,285<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent', window );">Gross unrealized gains</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">384<span></span>
</td>
<td class="nump">825<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent', window );">Gross unrealized losses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(61)<span></span>
</td>
<td class="num">(120)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">562,985<span></span>
</td>
<td class="nump">657,990<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent', window );">Amortized cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">204,656<span></span>
</td>
<td class="nump">149,086<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent', window );">Gross unrealized gains</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">493<span></span>
</td>
<td class="nump">124<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent', window );">Gross unrealized losses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(49)<span></span>
</td>
<td class="num">(476)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">205,100<span></span>
</td>
<td class="nump">148,734<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember', window );">Debt Securities Issued by States of the U.S. and Political Subdivisions of the States [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Amortized cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,151<span></span>
</td>
<td class="nump">7,516<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent', window );">Gross unrealized gains</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent', window );">Gross unrealized losses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,162<span></span>
</td>
<td class="nump">7,524<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent', window );">Amortized cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent', window );">Gross unrealized gains</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent', window );">Gross unrealized losses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_OtherDebtSecuritiesMember', window );">Other Municipal Debt Securities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent', window );">Amortized cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">698<span></span>
</td>
<td class="nump">698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent', window );">Gross unrealized gains</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent', window );">Gross unrealized losses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">698<span></span>
</td>
<td class="nump">696<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=ions_EquitySecuritiesPubliclyTradedCompaniesMember', window );">Publicly Traded Equity Securities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCost', window );">Amortized cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">11,897<span></span>
</td>
<td class="nump">11,897<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_EquitySecuritiesFvNiAccumulatedGrossUnrealizedGain', window );">Gross unrealized gains</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">40<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_EquitySecuritiesFvNiAccumulatedGrossUnrealizedLoss', window );">Gross unrealized losses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(8,681)<span></span>
</td>
<td class="num">(6,660)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,256<span></span>
</td>
<td class="nump">5,263<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=ions_EquitySecuritiesPrivateCompaniesMember', window );">Privately Held Equity Securities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCost', window );">Amortized cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">4,905<span></span>
</td>
<td class="nump">23,115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_EquitySecuritiesFvNiAccumulatedGrossUnrealizedGain', window );">Gross unrealized gains</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">54,395<span></span>
</td>
<td class="nump">25,001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_EquitySecuritiesFvNiAccumulatedGrossUnrealizedLoss', window );">Gross unrealized losses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(7,090)<span></span>
</td>
<td class="num">(7,093)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 52,210<span></span>
</td>
<td class="nump">$ 41,023<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Includes investments classified as cash equivalents in our condensed consolidated balance sheets.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Our publicly traded equity securities are included in other current assets. We recognize publicly traded equity securities at fair value. In the nine months ended September 30, 2025, we recorded a $2.0 million net unrealized loss in our condensed consolidated statements of operations related to changes in the fair value of our investments in publicly traded companies.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Our privately held equity securities are included in deposits and other assets. We recognize our privately held equity securities at<span> cost minus impairments, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer, which are Level 3 inputs</span><span style="color: #000000;">. In the nine months ended September 30, 2025, the amortized cost of our privately held equity securities increased $11.2 million. In the third quarter of 2025, we recorded a $29.4 million unrealized gain related to our investment in a privately held company due to an observable price change in an orderly transaction for a similar investment of the investee. This increase was partially offset by a loss of $18.2 million related to an impairment of our investment in another privately held company that we recorded in the second quarter of 2025.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of (1) investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and (2) amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of (1) amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and (2) cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of (1) unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and (2) unrealized gain on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of (1) unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and (2) unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_EquitySecuritiesFvNiAccumulatedGrossUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of unrealized gain on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_EquitySecuritiesFvNiAccumulatedGrossUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_EquitySecuritiesFvNiAccumulatedGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_EquitySecuritiesFvNiAccumulatedGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_OtherDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_OtherDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=ions_EquitySecuritiesPubliclyTradedCompaniesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=ions_EquitySecuritiesPubliclyTradedCompaniesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=ions_EquitySecuritiesPrivateCompaniesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=ions_EquitySecuritiesPrivateCompaniesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Temporarily Impaired Investments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($) </div>
<div>Investment</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">Number of investments (in Investment) | Investment</a></td>
<td class="nump">174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months of temporary impairment</a></td>
<td class="nump">$ 392,289<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months of temporary impairment</a></td>
<td class="num">(261)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">More than 12 months of temporary impairment</a></td>
<td class="nump">119,526<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">More than 12 months of temporary impairment</a></td>
<td class="num">(115)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total temporary impairment</a></td>
<td class="nump">511,815<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total temporary impairment</a></td>
<td class="num">$ (376)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">Number of investments (in Investment) | Investment</a></td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months of temporary impairment</a></td>
<td class="nump">$ 179,031<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months of temporary impairment</a></td>
<td class="num">(127)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">More than 12 months of temporary impairment</a></td>
<td class="nump">55,955<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">More than 12 months of temporary impairment</a></td>
<td class="num">(63)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total temporary impairment</a></td>
<td class="nump">234,986<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total temporary impairment</a></td>
<td class="num">$ (190)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Debt Securities Issued by U.S. Government Agencies [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">Number of investments (in Investment) | Investment</a></td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months of temporary impairment</a></td>
<td class="nump">$ 71,369<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months of temporary impairment</a></td>
<td class="num">(60)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">More than 12 months of temporary impairment</a></td>
<td class="nump">17,286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">More than 12 months of temporary impairment</a></td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total temporary impairment</a></td>
<td class="nump">88,655<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total temporary impairment</a></td>
<td class="num">$ (76)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">Debt Securities Issued by the U.S. Treasury [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">Number of investments (in Investment) | Investment</a></td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months of temporary impairment</a></td>
<td class="nump">$ 141,191<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months of temporary impairment</a></td>
<td class="num">(74)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">More than 12 months of temporary impairment</a></td>
<td class="nump">46,285<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">More than 12 months of temporary impairment</a></td>
<td class="num">(36)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total temporary impairment</a></td>
<td class="nump">187,476<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total temporary impairment</a></td>
<td class="num">$ (110)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_OtherDebtSecuritiesMember', window );">Other Municipal Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">Number of investments (in Investment) | Investment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months of temporary impairment</a></td>
<td class="nump">$ 698<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months of temporary impairment</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">More than 12 months of temporary impairment</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">More than 12 months of temporary impairment</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total temporary impairment</a></td>
<td class="nump">698<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total temporary impairment</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_OtherDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_OtherDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2"><div>Sep. 30, 2025</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,983,725<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 2,056,008<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes175PercentMember', window );">1.75% Notes [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on convertible senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.75%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1.75%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1.75%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes0PercentMember', window );">0% Notes [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on convertible senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis [Member] | Corporate Debt Securities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,058,068<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 1,032,066<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis [Member] | Corporate Debt Securities [Member] | Cash and Cash Equivalents [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">39,900<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis [Member] | Debt Securities Issued by U.S. Government Agencies [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">150,590<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">208,998<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis [Member] | Debt Securities Issued by U.S. Government Agencies [Member] | Cash and Cash Equivalents [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis [Member] | Debt Securities Issued by the U.S. Treasury [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">768,085<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">806,724<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis [Member] | Debt Securities Issued by the U.S. Treasury [Member] | Cash and Cash Equivalents [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">36,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis [Member] | Significant Other Observable Inputs (Level 2) [Member] | 1.75% Notes [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Convertible notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">794,500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">569,300<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis [Member] | Significant Other Observable Inputs (Level 2) [Member] | 0% Notes [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Convertible notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">777,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">612,800<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis [Member] | Significant Other Observable Inputs (Level 2) [Member] | Corporate Debt Securities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,058,068<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,032,066<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis [Member] | Significant Other Observable Inputs (Level 2) [Member] | Debt Securities Issued by U.S. Government Agencies [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">150,590<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">208,998<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis [Member] | Significant Other Observable Inputs (Level 2) [Member] | Debt Securities Issued by the U.S. Treasury [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">$39.9 million was included in cash and cash equivalents, with the difference included in short-term investments.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Included in short-term investments.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="letter-spacing: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">$36.0 million was included in cash and cash equivalents, with the difference included in short-term investments.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes175PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes175PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes0PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes0PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Fair Value Measurements (Details) - Recurring Basis [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2"><div>Sep. 30, 2025</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 167,298<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 180,445<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,154,279<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,241,716<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate Debt Securities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,058,068<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">1,032,066<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Debt Securities Issued by U.S. Government Agencies [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">150,590<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">208,998<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Debt Securities Issued by the U.S. Treasury [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">768,085<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">806,724<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Debt Securities Issued by States of the U.S. and Political Subdivisions of the States [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">6,284<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">7,524<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Other Municipal Debt Securities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">698<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">696<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Publicly Traded Equity Securities [Member] | Other Current Assets [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">3,256<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,263<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Quoted Prices in Active Markets (Level 1) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">167,298<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">180,445<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">938,639<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">992,432<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Quoted Prices in Active Markets (Level 1) [Member] | Corporate Debt Securities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Quoted Prices in Active Markets (Level 1) [Member] | Debt Securities Issued by U.S. Government Agencies [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Quoted Prices in Active Markets (Level 1) [Member] | Debt Securities Issued by the U.S. Treasury [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">768,085<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">806,724<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Quoted Prices in Active Markets (Level 1) [Member] | Debt Securities Issued by States of the U.S. and Political Subdivisions of the States [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Quoted Prices in Active Markets (Level 1) [Member] | Other Municipal Debt Securities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Quoted Prices in Active Markets (Level 1) [Member] | Publicly Traded Equity Securities [Member] | Other Current Assets [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">3,256<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,263<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Other Observable Inputs (Level 2) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,215,640<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,249,284<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Other Observable Inputs (Level 2) [Member] | Corporate Debt Securities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,058,068<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">1,032,066<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Other Observable Inputs (Level 2) [Member] | Debt Securities Issued by U.S. Government Agencies [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">150,590<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">208,998<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Other Observable Inputs (Level 2) [Member] | Debt Securities Issued by the U.S. Treasury [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Other Observable Inputs (Level 2) [Member] | Debt Securities Issued by States of the U.S. and Political Subdivisions of the States [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">6,284<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">7,524<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Other Observable Inputs (Level 2) [Member] | Other Municipal Debt Securities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">698<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">696<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Other Observable Inputs (Level 2) [Member] | Publicly Traded Equity Securities [Member] | Other Current Assets [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Included in cash and cash equivalents.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">$39.9 million was included in cash and cash equivalents, with the difference included in short-term investments.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Included in short-term investments.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><span style="letter-spacing: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">$36.0 million was included in cash and cash equivalents, with the difference included in short-term investments.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top">Included in other current assets.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_OtherDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_OtherDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=ions_EquitySecuritiesPubliclyTradedCompaniesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=ions_EquitySecuritiesPubliclyTradedCompaniesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation Expense (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based Compensation Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense related to non-vested stock options (in Dollars)</a></td>
<td class="nump">$ 37.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period for recognition</a></td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member] | Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based Compensation Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value</a></td>
<td class="nump">$ 17.21<span></span>
</td>
<td class="nump">$ 24.73<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member] | Non-employee Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based Compensation Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value</a></td>
<td class="nump">$ 20.86<span></span>
</td>
<td class="nump">27.47<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based Compensation Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost related to non-vested units (in Dollars)</a></td>
<td class="nump">$ 88.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period for recognition</a></td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs [Member] | Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based Compensation Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value</a></td>
<td class="nump">$ 33.78<span></span>
</td>
<td class="nump">52.08<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PRSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based Compensation Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost related to non-vested units (in Dollars)</a></td>
<td class="nump">$ 13.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period for recognition</a></td>
<td class="text">1 year 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PRSUs [Member] | Granted in 2025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based Compensation Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PRSUs [Member] | Granted in 2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based Compensation Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PRSUs [Member] | Granted in 2024 [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based Compensation Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfUnitsGuaranteedToVest', window );">Percentage of units guaranteed to vest</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PRSUs [Member] | Granted in 2024 [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based Compensation Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfUnitsGuaranteedToVest', window );">Percentage of units guaranteed to vest</a></td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PRSUs [Member] | Executive Officers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based Compensation Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value</a></td>
<td class="nump">$ 48.81<span></span>
</td>
<td class="nump">$ 78.41<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PRSUs [Member] | Executive Officers [Member] | Granted in 2025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based Compensation Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfUnitsGuaranteedToVest', window );">Number of units guaranteed to vest (in Shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PRSUs [Member] | Executive Officers [Member] | Granted in 2025 [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based Compensation Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfUnitsGuaranteedToVest', window );">Percentage of units guaranteed to vest</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PRSUs [Member] | Executive Officers [Member] | Granted in 2025 [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based Compensation Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfUnitsGuaranteedToVest', window );">Percentage of units guaranteed to vest</a></td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PRSUs [Member] | Executive Officers [Member] | Granted in 2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based Compensation Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfUnitsGuaranteedToVest', window );">Number of units guaranteed to vest (in Shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfUnitsGuaranteedToVest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of units guaranteed to vest under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfUnitsGuaranteedToVest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfUnitsGuaranteedToVest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of units guaranteed to vest under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfUnitsGuaranteedToVest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=ions_GrantedIn2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=ions_GrantedIn2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=ions_GrantedIn2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=ions_GrantedIn2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=srt_ExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=srt_ExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation Expense - Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based Compensation Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense, net of amounts capitalized</a></td>
<td class="nump">$ 31,146<span></span>
</td>
<td class="nump">$ 31,984<span></span>
</td>
<td class="nump">$ 90,554<span></span>
</td>
<td class="nump">$ 94,052<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Capitalized stock-based compensation expense</a></td>
<td class="nump">435<span></span>
</td>
<td class="nump">506<span></span>
</td>
<td class="nump">1,435<span></span>
</td>
<td class="nump">506<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1', window );">Total stock-based compensation expense</a></td>
<td class="nump">31,581<span></span>
</td>
<td class="nump">32,490<span></span>
</td>
<td class="nump">91,989<span></span>
</td>
<td class="nump">94,558<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based Compensation Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense, net of amounts capitalized</a></td>
<td class="nump">145<span></span>
</td>
<td class="nump">159<span></span>
</td>
<td class="nump">855<span></span>
</td>
<td class="nump">609<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=ions_ResearchDevelopmentAndPatentExpensesMember', window );">Research, Development and Patent Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based Compensation Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense, net of amounts capitalized</a></td>
<td class="nump">20,757<span></span>
</td>
<td class="nump">22,120<span></span>
</td>
<td class="nump">60,597<span></span>
</td>
<td class="nump">67,111<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based Compensation Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense, net of amounts capitalized</a></td>
<td class="nump">$ 10,244<span></span>
</td>
<td class="nump">$ 9,705<span></span>
</td>
<td class="nump">$ 29,102<span></span>
</td>
<td class="nump">$ 26,332<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost expensed and capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=ions_ResearchDevelopmentAndPatentExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=ions_ResearchDevelopmentAndPatentExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation Expense - Weighted-Average Assumptions for Stock Options (Details) - Stock Option [Member]<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based Compensation Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Volatility</a></td>
<td class="nump">42.10%<span></span>
</td>
<td class="nump">43.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">6 years 3 months 18 days<span></span>
</td>
<td class="text">6 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Board of Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based Compensation Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Volatility</a></td>
<td class="nump">43.00%<span></span>
</td>
<td class="nump">49.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">7 years 4 months 24 days<span></span>
</td>
<td class="text">7 years 6 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=ions_ShareBasedPaymentArrangementBoardOfDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=ions_ShareBasedPaymentArrangementBoardOfDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation Expense - Weighted-Average Assumptions for ESPP (Details) - ESPP [Member]<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based Compensation Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.20%<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Volatility</a></td>
<td class="nump">48.20%<span></span>
</td>
<td class="nump">37.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">$ 213<span></span>
</td>
<td class="num">$ (3,621)<span></span>
</td>
<td class="nump">$ 308<span></span>
</td>
<td class="num">$ (3,481)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liability Related to Sale of Future Royalties (Details) - Royalty Purchase Agreement [Member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Royalty Revenue Monetization [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_UpfrontRoyaltyPaymentReceived', window );">Upfront payment received</a></td>
<td class="nump">$ 500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_MaximumAmountOfPaymentsReceivableForAdditionalMilestones', window );">Maximum amount of payments receivable for additional milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 625.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_PaymentsForTransactionCostsRelatedToSaleOfFutureRoyalties', window );">Transaction costs</a></td>
<td class="nump">$ 10.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.40%<span></span>
</td>
<td class="nump">13.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_RoyaltyPurchaseAgreementMember', window );">SPINRAZA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Royalty Revenue Monetization [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_MaximumAmountOfAnnualSalesOnWhichRoyaltyPaymentsArePaid', window );">Maximum amount of annual sales on which royalty payments are paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_RoyaltyPurchaseAgreementMember', window );">SPINRAZA [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Royalty Revenue Monetization [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_PercentageOfRoyaltyPaymentsPaidOnAnnualSalesOfMedicine', window );">Percentage of royalty payments paid on annual sales of medicine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_MaximumRoyaltyPaymentsMadeBeforeRoyaltyInterestRevertsBack', window );">Maximum royalty payments made before royalty interest reverts back</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 475.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_RoyaltyPurchaseAgreementMember', window );">SPINRAZA [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Royalty Revenue Monetization [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_PercentageOfRoyaltyPaymentsPaidOnAnnualSalesOfMedicine', window );">Percentage of royalty payments paid on annual sales of medicine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_MaximumRoyaltyPaymentsMadeBeforeRoyaltyInterestRevertsBack', window );">Maximum royalty payments made before royalty interest reverts back</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 550.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_RoyaltyPurchaseAgreementMember', window );">Pelacarsen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Royalty Revenue Monetization [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_PercentageOfRoyaltyPaymentsPaidOnAnnualSalesOfMedicine', window );">Percentage of royalty payments paid on annual sales of medicine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_MaximumAmountOfAnnualSalesOnWhichRoyaltyPaymentsArePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of annual sales on which royalty payments are paid under the royalty purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_MaximumAmountOfAnnualSalesOnWhichRoyaltyPaymentsArePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_MaximumAmountOfPaymentsReceivableForAdditionalMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of payments receivable for additional milestones under the royalty purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_MaximumAmountOfPaymentsReceivableForAdditionalMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_MaximumRoyaltyPaymentsMadeBeforeRoyaltyInterestRevertsBack">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum royalty payments under the royalty purchase agreement made before royalty interest reverts back to the Company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_MaximumRoyaltyPaymentsMadeBeforeRoyaltyInterestRevertsBack</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_PaymentsForTransactionCostsRelatedToSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties for transaction costs in connection with a monetization transaction of future SPINRAZA and pelacarsen royalties the Company is entitled to under collaboration and licensing agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_PaymentsForTransactionCostsRelatedToSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_PercentageOfRoyaltyPaymentsPaidOnAnnualSalesOfMedicine">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of royalty payments paid on annual sales of medicine.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_PercentageOfRoyaltyPaymentsPaidOnAnnualSalesOfMedicine</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_UpfrontRoyaltyPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of upfront payments received during the period under the royalty purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_UpfrontRoyaltyPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ions_RoyaltyPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ions_RoyaltyPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ions_SpinrazaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ions_SpinrazaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ions_PelacarsenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ions_PelacarsenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liability Related to Sale of Future Royalties - Liability Related to Sale of Future Royalties (Details) - Royalty Purchase Agreement [Member]<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Royalty Revenue Monetization [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_LiabilityRelatedToSaleOfFutureRoyaltiesNet', window );">Liability related to sale of future royalties, net</a></td>
<td class="nump">$ 542,212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_RoyaltyPayments', window );">Royalty payments to Royalty Pharma</a></td>
<td class="num">(38,478)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_InterestExpenseRelatedToSaleOfFutureRoyalties', window );">Interest expense related to sale of future royalties</a></td>
<td class="nump">54,964<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_AmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties', window );">Amortization of issuance costs related to sale of future royalties</a></td>
<td class="nump">458<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_LiabilityRelatedToSaleOfFutureRoyaltiesNet', window );">Liability related to sale of future royalties, net</a></td>
<td class="nump">559,156<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_LiabilityRelatedToSaleOfFutureRoyaltiesNetNoncurrent', window );">Liability related to sale of future royalties, net - Non-current</a></td>
<td class="nump">545,182<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_RoyaltyPurchaseAgreementMember', window );">Other Current Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Royalty Revenue Monetization [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_LiabilityRelatedToSaleOfFutureRoyaltiesNetCurrent', window );">Less: Current portion</a></td>
<td class="num">$ (13,974)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_AmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to the sale of future royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_AmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_InterestExpenseRelatedToSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense using the effective interest rate method related to the sale of future royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_InterestExpenseRelatedToSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_LiabilityRelatedToSaleOfFutureRoyaltiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of the unamortized liability related to the sale of future royalties, pursuant to a royalty purchase agreement, that the Company is entitled to receive under collaboration agreements with Biogen and Novartis. The balance will be amortized over the estimated life of the arrangement using the effective interest rate method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_LiabilityRelatedToSaleOfFutureRoyaltiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_LiabilityRelatedToSaleOfFutureRoyaltiesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of the unamortized liability related to the sale of future royalties, pursuant to a royalty purchase agreement, that the Company is entitled to receive under collaboration agreements with Biogen and Novartis. The balance will be amortized over the estimated life of the arrangement using the effective interest rate method. Used to reflect the current portion of the liability (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_LiabilityRelatedToSaleOfFutureRoyaltiesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_LiabilityRelatedToSaleOfFutureRoyaltiesNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of the unamortized liability related to the sale of future royalties, pursuant to a royalty purchase agreement, that the Company is entitled to receive under collaboration agreements with Biogen and Novartis. The balance will be amortized over the estimated life of the arrangement using the effective interest rate method. Used to reflect the noncurrent portion of the liability (due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_LiabilityRelatedToSaleOfFutureRoyaltiesNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_RoyaltyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of royalty payments made during the period under a royalty purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_RoyaltyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ions_RoyaltyPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ions_RoyaltyPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes175PercentMember', window );">1.75% Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Debt [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount of offering (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 575.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange', window );">Percentage of principal amount used as purchase price upon occurrence of fundamental change</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes0PercentMember', window );">0% Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Debt [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount of offering (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 632.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_DebtInstrumentConvertibleConversionPriceIncludingCallSpread', window );">Effective conversion price per share with call spread (in Dollars per share)</a></td>
<td class="nump">$ 76.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_CallSpread', window );">Cost of call spread (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForHedgeFinancingActivities', window );">Purchase of note hedges (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of warrants (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 89.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange', window );">Percentage of principal amount used as purchase price upon occurrence of fundamental change</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_CallSpread">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net cash outflow from payments for hedge transactions and proceeds from the issuance of warrants. The call spread transaction was entered into to minimize the impact of potential economic dilution upon conversion of the 0.125% notes issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_CallSpread</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_DebtInstrumentConvertibleConversionPriceIncludingCallSpread">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The computed conversion price per share of the debt instrument based on the conversion feature embedded in the debt instrument and the impact of the purchased hedges in the call spread transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_DebtInstrumentConvertibleConversionPriceIncludingCallSpread</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of the principal amount of the notes to be purchased, plus accrued and unpaid interest, upon the occurrence of certain fundamental changes, as set forth in the indenture governing the convertible notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForHedgeFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a financial contract that meets the hedge criteria as either cash flow hedge, fair value hedge or hedge of net investment in foreign operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForHedgeFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes175PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes175PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes0PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes0PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt - 1.75% Notes (Details) - 1.75% Notes [Member] - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Debt [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Outstanding principal balance</a></td>
<td class="nump">$ 575.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized debt issuance costs</a></td>
<td class="nump">$ 7.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">Jun. 30,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="nump">1.75%<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">2.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price per share</a></td>
<td class="nump">$ 53.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_DebtInstrumentConvertibleSharesSubjectToConversion', window );">Total shares of common stock subject to conversion</a></td>
<td class="nump">10.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_DebtInstrumentConvertibleSharesSubjectToConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares of common stock subject to conversion if the debt was converted to equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_DebtInstrumentConvertibleSharesSubjectToConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes175PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes175PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt - 0% Notes (Details) - 0% Notes [Member] - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Debt [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Outstanding principal balance</a></td>
<td class="nump">$ 632.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized debt issuance costs</a></td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">Apr. 30,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price per share</a></td>
<td class="nump">$ 57.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_DebtInstrumentConvertibleConversionPriceIncludingCallSpread', window );">Effective conversion price per share with call spread</a></td>
<td class="nump">$ 76.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_DebtInstrumentConvertibleSharesSubjectToConversion', window );">Total shares of common stock subject to conversion</a></td>
<td class="nump">10.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_DebtInstrumentConvertibleConversionPriceIncludingCallSpread">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The computed conversion price per share of the debt instrument based on the conversion feature embedded in the debt instrument and the impact of the purchased hedges in the call spread transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_DebtInstrumentConvertibleConversionPriceIncludingCallSpread</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_DebtInstrumentConvertibleSharesSubjectToConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares of common stock subject to conversion if the debt was converted to equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_DebtInstrumentConvertibleSharesSubjectToConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes0PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes0PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($) </div>
<div>Option</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>Lot</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>Agreement</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Operating Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_NumberOfPurchaseAndSaleAgreementsEnteredIntoWithRealEstateInvestor', window );">Number of purchase and sale agreements entered into with real estate investor (in Agreement) | Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleAndLeasebackTransactionGainLossNet', window );">Gain on sale-leaseback transaction</a></td>
<td class="nump">$ 4.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Financial liability for sale-leaseback transaction</a></td>
<td class="nump">$ 19.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ions_HeadquartersLocationInCarlsbadCaliforniaMember', window );">Headquarters Location in Carlsbad, California [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Operating Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of real estate assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 263.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Initial term of lease</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_LesseeOperatingLeaseNumberOfOptionsToExtendLease', window );">Number of options to extend lease (in Option) | Option</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Term of lease extension</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Lease payments to be made over initial term of lease</a></td>
<td class="nump">$ 230.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncentiveFromLessor', window );">Reimbursements from lessor for tenant improvements</a></td>
<td class="nump">$ 41.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Undeveloped Land in Carlsbad, California [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Operating Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of real estate assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_NumberOfLotsOfUndevelopedLandTransferredToRealEstateInvestor', window );">Number of lots of undeveloped land transferred to real estate investor (in Lot) | Lot</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_LesseeOperatingLeaseNumberOfOptionsToExtendLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of options to extend the lease under the lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_LesseeOperatingLeaseNumberOfOptionsToExtendLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_NumberOfLotsOfUndevelopedLandTransferredToRealEstateInvestor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of lots of undeveloped land adjacent to the Company's headquarters transferred to real estate investor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_NumberOfLotsOfUndevelopedLandTransferredToRealEstateInvestor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_NumberOfPurchaseAndSaleAgreementsEnteredIntoWithRealEstateInvestor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of purchase and sale agreements entered into with a real estate investor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_NumberOfPurchaseAndSaleAgreementsEnteredIntoWithRealEstateInvestor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncentiveFromLessor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of incentive received by lessee from lessor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481178/840-20-25-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481475/840-20-55-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481178/840-20-25-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 5<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479924/842-10-30-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncentiveFromLessor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleAndLeasebackTransactionGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale and leaseback transaction from transfer of asset accounted for as sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479741/842-40-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (s)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleAndLeasebackTransactionGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ions_HeadquartersLocationInCarlsbadCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ions_HeadquartersLocationInCarlsbadCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherItemCompositionDescription', window );">Segment Reporting, Other Segment Item, Composition, Description</a></td>
<td class="text">Other segment items include stock-based compensation expense, investment income, interest expense, gain or loss on investments, other income or expense and income tax expense or benefit.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingOtherItemCompositionDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of composition of other segment item not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingOtherItemCompositionDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Segment Information (Details) - Ionis Operations [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 156,719<span></span>
</td>
<td class="nump">$ 133,814<span></span>
</td>
<td class="nump">$ 740,381<span></span>
</td>
<td class="nump">$ 478,562<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">2,193<span></span>
</td>
<td class="nump">912<span></span>
</td>
<td class="nump">7,097<span></span>
</td>
<td class="nump">6,815<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_DrugDiscoveryExpenses', window );">Drug discovery</a></td>
<td class="nump">28,412<span></span>
</td>
<td class="nump">25,790<span></span>
</td>
<td class="nump">85,656<span></span>
</td>
<td class="nump">80,652<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_DrugDevelopmentExpenses', window );">Drug development</a></td>
<td class="nump">120,828<span></span>
</td>
<td class="nump">132,201<span></span>
</td>
<td class="nump">351,463<span></span>
</td>
<td class="nump">392,151<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_MedicalAffairsExpenses', window );">Medical affairs</a></td>
<td class="nump">8,874<span></span>
</td>
<td class="nump">5,511<span></span>
</td>
<td class="nump">22,342<span></span>
</td>
<td class="nump">17,279<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_ManufacturingAndDevelopmentChemistryExpenses', window );">Manufacturing and development chemistry</a></td>
<td class="nump">15,790<span></span>
</td>
<td class="nump">14,087<span></span>
</td>
<td class="nump">51,616<span></span>
</td>
<td class="nump">39,723<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ions_ResearchAndDevelopmentSupportExpenses', window );">R&amp;D support</a></td>
<td class="nump">23,092<span></span>
</td>
<td class="nump">20,052<span></span>
</td>
<td class="nump">64,252<span></span>
</td>
<td class="nump">59,065<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">86,565<span></span>
</td>
<td class="nump">51,933<span></span>
</td>
<td class="nump">234,626<span></span>
</td>
<td class="nump">153,083<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherItemAmount', window );">Other segment items</a></td>
<td class="num">(429)<span></span>
</td>
<td class="nump">23,808<span></span>
</td>
<td class="nump">75,322<span></span>
</td>
<td class="nump">79,342<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (128,606)<span></span>
</td>
<td class="num">$ (140,480)<span></span>
</td>
<td class="num">$ (151,993)<span></span>
</td>
<td class="num">$ (349,548)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_DrugDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses related to drug development, including expenses for marketed medicines and those in Phase 3 development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_DrugDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_DrugDiscoveryExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses related to drug discovery research and advancing the Company's core technology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_DrugDiscoveryExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_ManufacturingAndDevelopmentChemistryExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses related to manufacturing and development chemistry for providing drug supplies to drug development and our collaboration partners, including personnel costs, specialized chemicals for oligonucleotide manufacturing, validation batches to support regulatory approvals, laboratory supplies and outside services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_ManufacturingAndDevelopmentChemistryExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_MedicalAffairsExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses related to medical affairs for funding and coordinating investigator-sponsored trials, communicating scientific and clinical information to healthcare providers, medical professionals and patients, and managing publications.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_MedicalAffairsExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_ResearchAndDevelopmentSupportExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses related to research and development support such as rent, repair and maintenance for buildings and equipment, utilities, depreciation of laboratory equipment and facilities, amortization of intellectual property, information technology costs, procurement costs and waste disposal costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_ResearchAndDevelopmentSupportExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingOtherItemAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingOtherItemAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ions_IonisOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ions_IonisOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>260</ContextCount>
  <ElementCount>294</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>62</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>12</UnitCount>
  <MyReports>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995100 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/dei/role/document/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995301 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ionis.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995302 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ionis.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>995303 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ionis.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>995304 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ionis.com/role/ConsolidatedComprehensiveIncome</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>995305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ionis.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995306 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ionis.com/role/ConsolidatedCashFlow</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995307 - Disclosure - Organization and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ionis.com/role/OrganizationandBasisofPresentation</Role>
      <ShortName>Organization and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995308 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ionis.com/role/SignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995309 - Disclosure - Supplemental Financial Data</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ionis.com/role/SupplementalFinancialData</Role>
      <ShortName>Supplemental Financial Data</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995310 - Disclosure - Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ionis.com/role/Revenues</Role>
      <ShortName>Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995311 - Disclosure - Collaborative Arrangements and Licensing Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ionis.com/role/CollaborativeArrangementsandLicensingAgreements</Role>
      <ShortName>Collaborative Arrangements and Licensing Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995312 - Disclosure - Basic and Diluted Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ionis.com/role/BasicandDilutedNetLossPerShare</Role>
      <ShortName>Basic and Diluted Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995313 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ionis.com/role/Investments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995314 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ionis.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995315 - Disclosure - Stock-based Compensation Expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ionis.com/role/StockbasedCompensationExpense</Role>
      <ShortName>Stock-based Compensation Expense</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995316 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ionis.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995317 - Disclosure - Liability Related to Sale of Future Royalties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ionis.com/role/LiabilityRelatedtoSaleofFutureRoyalties</Role>
      <ShortName>Liability Related to Sale of Future Royalties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995318 - Disclosure - Convertible Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ionis.com/role/ConvertibleDebt</Role>
      <ShortName>Convertible Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995319 - Disclosure - Operating Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ionis.com/role/OperatingLeases</Role>
      <ShortName>Operating Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995320 - Disclosure - Legal Proceedings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ionis.com/role/LegalProceedings</Role>
      <ShortName>Legal Proceedings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995321 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ionis.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>996000 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ionis.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://ionis.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>996001 - Disclosure - Supplemental Financial Data (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ionis.com/role/SupplementalFinancialDataTables</Role>
      <ShortName>Supplemental Financial Data (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ionis.com/role/SupplementalFinancialData</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>996002 - Disclosure - Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ionis.com/role/RevenuesTables</Role>
      <ShortName>Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ionis.com/role/Revenues</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>996003 - Disclosure - Collaborative Arrangements and Licensing Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ionis.com/role/CollaborativeArrangementsandLicensingAgreementsTables</Role>
      <ShortName>Collaborative Arrangements and Licensing Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ionis.com/role/CollaborativeArrangementsandLicensingAgreements</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>996004 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ionis.com/role/InvestmentsTables</Role>
      <ShortName>Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ionis.com/role/Investments</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>996005 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ionis.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ionis.com/role/FairValueMeasurements</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>996006 - Disclosure - Stock-based Compensation Expense (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ionis.com/role/StockbasedCompensationExpenseTables</Role>
      <ShortName>Stock-based Compensation Expense (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ionis.com/role/StockbasedCompensationExpense</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>996007 - Disclosure - Liability Related to Sale of Future Royalties (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ionis.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesTables</Role>
      <ShortName>Liability Related to Sale of Future Royalties (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ionis.com/role/LiabilityRelatedtoSaleofFutureRoyalties</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>996008 - Disclosure - Convertible Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ionis.com/role/ConvertibleDebtTables</Role>
      <ShortName>Convertible Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ionis.com/role/ConvertibleDebt</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>996009 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ionis.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ionis.com/role/SegmentInformation</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>996010 - Disclosure - Organization and Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ionis.com/role/OrganizationandBasisofPresentationDetails</Role>
      <ShortName>Organization and Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ionis.com/role/OrganizationandBasisofPresentation</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>996011 - Disclosure - Supplemental Financial Data - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ionis.com/role/InventoriesTable</Role>
      <ShortName>Supplemental Financial Data - Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>996012 - Disclosure - Supplemental Financial Data - Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ionis.com/role/AccruedLiabilitiesTable</Role>
      <ShortName>Supplemental Financial Data - Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>996013 - Disclosure - Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ionis.com/role/RevenuesDetails</Role>
      <ShortName>Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ionis.com/role/RevenuesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>996014 - Disclosure - Revenues - Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ionis.com/role/RevenuesTable</Role>
      <ShortName>Revenues - Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>996015 - Disclosure - Collaborative Arrangements and Licensing Agreements - AstraZeneca (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ionis.com/role/CollaborativeArrangementsandLicensingAgreementsDetailsAstraZeneca</Role>
      <ShortName>Collaborative Arrangements and Licensing Agreements - AstraZeneca (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>996016 - Disclosure - Collaborative Arrangements and Licensing Agreements - Revenue from Collaborative Relationship with AstraZeneca (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ionis.com/role/RevenuefromCollaborativeRelationshipwithAstraZenecaTable</Role>
      <ShortName>Collaborative Arrangements and Licensing Agreements - Revenue from Collaborative Relationship with AstraZeneca (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>996017 - Disclosure - Collaborative Arrangements and Licensing Agreements - Ono (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ionis.com/role/CollaborativeArrangementsandLicensingAgreementsDetailsOno</Role>
      <ShortName>Collaborative Arrangements and Licensing Agreements - Ono (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ionis.com/role/CollaborativeArrangementsandLicensingAgreementsTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>996018 - Disclosure - Collaborative Arrangements and Licensing Agreements - Revenue from Collaborative Relationship with Ono (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ionis.com/role/RevenuefromCollaborativeRelationshipwithOnoTable</Role>
      <ShortName>Collaborative Arrangements and Licensing Agreements - Revenue from Collaborative Relationship with Ono (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>996019 - Disclosure - Basic and Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ionis.com/role/BasicandDilutedNetLossPerShareDetails</Role>
      <ShortName>Basic and Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ionis.com/role/BasicandDilutedNetLossPerShare</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>996020 - Disclosure - Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ionis.com/role/InvestmentsDetails</Role>
      <ShortName>Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ionis.com/role/InvestmentsTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>996021 - Disclosure - Investments - Contract Maturity of Available-for-Sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ionis.com/role/InvestmentsDetailsContractMaturityofAvailableforSaleSecurities</Role>
      <ShortName>Investments - Contract Maturity of Available-for-Sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>996022 - Disclosure - Investments - Summary of Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ionis.com/role/SummaryofInvestmentsTable</Role>
      <ShortName>Investments - Summary of Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>996023 - Disclosure - Investments - Temporarily Impaired Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ionis.com/role/TemporarilyImpairedInvestmentsTable</Role>
      <ShortName>Investments - Temporarily Impaired Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>996024 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ionis.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ionis.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>996025 - Disclosure - Fair Value Measurements - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ionis.com/role/FairValueMeasurementsTable</Role>
      <ShortName>Fair Value Measurements - Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>996026 - Disclosure - Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ionis.com/role/StockbasedCompensationExpenseDetails</Role>
      <ShortName>Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ionis.com/role/StockbasedCompensationExpenseTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>996027 - Disclosure - Stock-based Compensation Expense - Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ionis.com/role/StockbasedCompensationExpenseTable</Role>
      <ShortName>Stock-based Compensation Expense - Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>996028 - Disclosure - Stock-based Compensation Expense - Weighted-Average Assumptions for Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ionis.com/role/WeightedAverageAssumptionsforStockOptionsTable</Role>
      <ShortName>Stock-based Compensation Expense - Weighted-Average Assumptions for Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>996029 - Disclosure - Stock-based Compensation Expense - Weighted-Average Assumptions for ESPP (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ionis.com/role/WeightedAverageAssumptionsforESPPTable</Role>
      <ShortName>Stock-based Compensation Expense - Weighted-Average Assumptions for ESPP (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>996030 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ionis.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ionis.com/role/IncomeTaxes</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>996031 - Disclosure - Liability Related to Sale of Future Royalties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ionis.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesDetails</Role>
      <ShortName>Liability Related to Sale of Future Royalties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ionis.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>996032 - Disclosure - Liability Related to Sale of Future Royalties - Liability Related to Sale of Future Royalties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ionis.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesTable</Role>
      <ShortName>Liability Related to Sale of Future Royalties - Liability Related to Sale of Future Royalties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>996033 - Disclosure - Convertible Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ionis.com/role/ConvertibleDebtDetails</Role>
      <ShortName>Convertible Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ionis.com/role/ConvertibleDebtTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>996034 - Disclosure - Convertible Debt - 1.75% Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://ionis.com/role/175NotesTable</Role>
      <ShortName>Convertible Debt - 1.75% Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>996035 - Disclosure - Convertible Debt - 0% Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://ionis.com/role/0NotesTable</Role>
      <ShortName>Convertible Debt - 0% Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>996036 - Disclosure - Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ionis.com/role/OperatingLeasesDetails</Role>
      <ShortName>Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ionis.com/role/OperatingLeases</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>996037 - Disclosure - Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ionis.com/role/SegmentInformationDetails</Role>
      <ShortName>Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ionis.com/role/SegmentInformationTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>996038 - Disclosure - Segment Information - Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ionis.com/role/SegmentInformationTable</Role>
      <ShortName>Segment Information - Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="form10q.htm">form10q.htm</File>
    <File>ions-20250930.xsd</File>
    <File>ions-20250930_cal.xml</File>
    <File>ions-20250930_def.xml</File>
    <File>ions-20250930_lab.xml</File>
    <File>ions-20250930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="839">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="9">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>80
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form10q.htm": {
   "nsprefix": "ions",
   "nsuri": "http://ionis.com/20250930",
   "dts": {
    "inline": {
     "local": [
      "form10q.htm"
     ]
    },
    "schema": {
     "local": [
      "ions-20250930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025_def.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025_lab.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025_pre.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-sub-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd",
      "https://xbrl.sec.gov/sic/2025/sic-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "ions-20250930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ions-20250930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "ions-20250930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ions-20250930_pre.xml"
     ]
    }
   },
   "keyStandard": 223,
   "keyCustom": 71,
   "axisStandard": 17,
   "axisCustom": 0,
   "memberStandard": 32,
   "memberCustom": 30,
   "hidden": {
    "total": 10,
    "http://fasb.org/us-gaap/2025": 4,
    "http://xbrl.sec.gov/dei/2025": 4,
    "http://ionis.com/20250930": 1,
    "http://xbrl.sec.gov/ecd/2025": 1
   },
   "contextCount": 260,
   "entityCount": 1,
   "segmentCount": 62,
   "elementCount": 677,
   "unitCount": 12,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 839,
    "http://xbrl.sec.gov/dei/2025": 29,
    "http://xbrl.sec.gov/ecd/2025": 9
   },
   "report": {
    "R1": {
     "role": "http://xbrl.sec.gov/dei/role/document/Cover",
     "longName": "995100 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://ionis.com/role/ConsolidatedBalanceSheet",
     "longName": "995301 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://ionis.com/role/ConsolidatedBalanceSheet_Parentheticals",
     "longName": "995302 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals)",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://ionis.com/role/ConsolidatedIncomeStatement",
     "longName": "995303 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c36",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c36",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://ionis.com/role/ConsolidatedComprehensiveIncome",
     "longName": "995304 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c36",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c36",
      "name": "us-gaap:ComprehensiveIncomeNetOfTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://ionis.com/role/ShareholdersEquityType2or3",
     "longName": "995305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c66",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c66",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://ionis.com/role/ConsolidatedCashFlow",
     "longName": "995306 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://ionis.com/role/OrganizationandBasisofPresentation",
     "longName": "995307 - Disclosure - Organization and Basis of Presentation",
     "shortName": "Organization and Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://ionis.com/role/SignificantAccountingPolicies",
     "longName": "995308 - Disclosure - Significant Accounting Policies",
     "shortName": "Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://ionis.com/role/SupplementalFinancialData",
     "longName": "995309 - Disclosure - Supplemental Financial Data",
     "shortName": "Supplemental Financial Data",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://ionis.com/role/Revenues",
     "longName": "995310 - Disclosure - Revenues",
     "shortName": "Revenues",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://ionis.com/role/CollaborativeArrangementsandLicensingAgreements",
     "longName": "995311 - Disclosure - Collaborative Arrangements and Licensing Agreements",
     "shortName": "Collaborative Arrangements and Licensing Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://ionis.com/role/BasicandDilutedNetLossPerShare",
     "longName": "995312 - Disclosure - Basic and Diluted Net Loss Per Share",
     "shortName": "Basic and Diluted Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://ionis.com/role/Investments",
     "longName": "995313 - Disclosure - Investments",
     "shortName": "Investments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:InvestmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:InvestmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://ionis.com/role/FairValueMeasurements",
     "longName": "995314 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://ionis.com/role/StockbasedCompensationExpense",
     "longName": "995315 - Disclosure - Stock-based Compensation Expense",
     "shortName": "Stock-based Compensation Expense",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://ionis.com/role/IncomeTaxes",
     "longName": "995316 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://ionis.com/role/LiabilityRelatedtoSaleofFutureRoyalties",
     "longName": "995317 - Disclosure - Liability Related to Sale of Future Royalties",
     "shortName": "Liability Related to Sale of Future Royalties",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://ionis.com/role/ConvertibleDebt",
     "longName": "995318 - Disclosure - Convertible Debt",
     "shortName": "Convertible Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://ionis.com/role/OperatingLeases",
     "longName": "995319 - Disclosure - Operating Leases",
     "shortName": "Operating Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://ionis.com/role/LegalProceedings",
     "longName": "995320 - Disclosure - Legal Proceedings",
     "shortName": "Legal Proceedings",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://ionis.com/role/SegmentInformation",
     "longName": "995321 - Disclosure - Segment Information",
     "shortName": "Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c36",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R24": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c36",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c36",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://ionis.com/role/AccountingPoliciesByPolicy",
     "longName": "996000 - Disclosure - Accounting Policies, by Policy (Policies)",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://ionis.com/role/SupplementalFinancialDataTables",
     "longName": "996001 - Disclosure - Supplemental Financial Data (Tables)",
     "shortName": "Supplemental Financial Data (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ions:ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ions:ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://ionis.com/role/RevenuesTables",
     "longName": "996002 - Disclosure - Revenues (Tables)",
     "shortName": "Revenues (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://ionis.com/role/CollaborativeArrangementsandLicensingAgreementsTables",
     "longName": "996003 - Disclosure - Collaborative Arrangements and Licensing Agreements (Tables)",
     "shortName": "Collaborative Arrangements and Licensing Agreements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c117",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c117",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://ionis.com/role/InvestmentsTables",
     "longName": "996004 - Disclosure - Investments (Tables)",
     "shortName": "Investments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InvestmentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InvestmentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://ionis.com/role/FairValueMeasurementsTables",
     "longName": "996005 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://ionis.com/role/StockbasedCompensationExpenseTables",
     "longName": "996006 - Disclosure - Stock-based Compensation Expense (Tables)",
     "shortName": "Stock-based Compensation Expense (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://ionis.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesTables",
     "longName": "996007 - Disclosure - Liability Related to Sale of Future Royalties (Tables)",
     "shortName": "Liability Related to Sale of Future Royalties (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://ionis.com/role/ConvertibleDebtTables",
     "longName": "996008 - Disclosure - Convertible Debt (Tables)",
     "shortName": "Convertible Debt (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c250",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c250",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://ionis.com/role/SegmentInformationTables",
     "longName": "996009 - Disclosure - Segment Information (Tables)",
     "shortName": "Segment Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://ionis.com/role/OrganizationandBasisofPresentationDetails",
     "longName": "996010 - Disclosure - Organization and Basis of Presentation (Details)",
     "shortName": "Organization and Basis of Presentation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R36": {
     "role": "http://ionis.com/role/InventoriesTable",
     "longName": "996011 - Disclosure - Supplemental Financial Data - Inventories (Details)",
     "shortName": "Supplemental Financial Data - Inventories (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ions:InventoryRawMaterialsNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ions:ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "ions:InventoryRawMaterialsNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ions:ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://ionis.com/role/AccruedLiabilitiesTable",
     "longName": "996012 - Disclosure - Supplemental Financial Data - Accrued Liabilities (Details)",
     "shortName": "Supplemental Financial Data - Accrued Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ions:AccruedClinicalExpenses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "ions:AccruedClinicalExpenses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://ionis.com/role/RevenuesDetails",
     "longName": "996013 - Disclosure - Revenues (Details)",
     "shortName": "Revenues (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c85",
      "name": "ions:UpfrontPaymentReceived",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c85",
      "name": "ions:UpfrontPaymentReceived",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://ionis.com/role/RevenuesTable",
     "longName": "996014 - Disclosure - Revenues - Revenues (Details)",
     "shortName": "Revenues - Revenues (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c36",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c88",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://ionis.com/role/CollaborativeArrangementsandLicensingAgreementsDetailsAstraZeneca",
     "longName": "996015 - Disclosure - Collaborative Arrangements and Licensing Agreements - AstraZeneca (Details)",
     "shortName": "Collaborative Arrangements and Licensing Agreements - AstraZeneca (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c104",
      "name": "ions:NumberOfCollaborationAgreements",
      "unitRef": "Agreement",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c108",
      "name": "us-gaap:ContractWithCustomerLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "us-gaap:ContractWithCustomerLiability",
       "div",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://ionis.com/role/RevenuefromCollaborativeRelationshipwithAstraZenecaTable",
     "longName": "996016 - Disclosure - Collaborative Arrangements and Licensing Agreements - Revenue from Collaborative Relationship with AstraZeneca (Details)",
     "shortName": "Collaborative Arrangements and Licensing Agreements - Revenue from Collaborative Relationship with AstraZeneca (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c118",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c121",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://ionis.com/role/CollaborativeArrangementsandLicensingAgreementsDetailsOno",
     "longName": "996017 - Disclosure - Collaborative Arrangements and Licensing Agreements - Ono (Details)",
     "shortName": "Collaborative Arrangements and Licensing Agreements - Ono (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c109",
      "name": "ions:MaximumAmountOfPaymentsReceivableOverTermOfCollaboration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c110",
      "name": "ions:NumberOfPerformanceObligationsIdentified",
      "unitRef": "PerformanceObligation",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://ionis.com/role/RevenuefromCollaborativeRelationshipwithOnoTable",
     "longName": "996018 - Disclosure - Collaborative Arrangements and Licensing Agreements - Revenue from Collaborative Relationship with Ono (Details)",
     "shortName": "Collaborative Arrangements and Licensing Agreements - Revenue from Collaborative Relationship with Ono (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c126",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c127",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://ionis.com/role/BasicandDilutedNetLossPerShareDetails",
     "longName": "996019 - Disclosure - Basic and Diluted Net Loss Per Share (Details)",
     "shortName": "Basic and Diluted Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c131",
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:DebtInstrumentInterestRateStatedPercentage",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://ionis.com/role/InvestmentsDetails",
     "longName": "996020 - Disclosure - Investments (Details)",
     "shortName": "Investments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ions:AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "us-gaap:InvestmentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c132",
      "name": "us-gaap:EquitySecuritiesFvNiUnrealizedLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "link:footnote",
       "span",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://ionis.com/role/InvestmentsDetailsContractMaturityofAvailableforSaleSecurities",
     "longName": "996021 - Disclosure - Investments - Contract Maturity of Available-for-Sale Securities (Details)",
     "shortName": "Investments - Contract Maturity of Available-for-Sale Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ions:MaximumContractMaturityPeriodRange1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "us-gaap:InvestmentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ions:MaximumContractMaturityPeriodRange1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "us-gaap:InvestmentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://ionis.com/role/SummaryofInvestmentsTable",
     "longName": "996022 - Disclosure - Investments - Summary of Investments (Details)",
     "shortName": "Investments - Summary of Investments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://ionis.com/role/TemporarilyImpairedInvestmentsTable",
     "longName": "996023 - Disclosure - Investments - Temporarily Impaired Investments (Details)",
     "shortName": "Investments - Temporarily Impaired Investments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions",
      "unitRef": "Investment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions",
      "unitRef": "Investment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://ionis.com/role/FairValueMeasurementsDetails",
     "longName": "996024 - Disclosure - Fair Value Measurements (Details)",
     "shortName": "Fair Value Measurements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c150",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "link:footnote",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://ionis.com/role/FairValueMeasurementsTable",
     "longName": "996025 - Disclosure - Fair Value Measurements - Fair Value Measurements (Details)",
     "shortName": "Fair Value Measurements - Fair Value Measurements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c157",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c157",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://ionis.com/role/StockbasedCompensationExpenseDetails",
     "longName": "996026 - Disclosure - Stock-based Compensation Expense (Details)",
     "shortName": "Stock-based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c199",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c199",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://ionis.com/role/StockbasedCompensationExpenseTable",
     "longName": "996027 - Disclosure - Stock-based Compensation Expense - Stock-based Compensation Expense (Details)",
     "shortName": "Stock-based Compensation Expense - Stock-based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c36",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c36",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://ionis.com/role/WeightedAverageAssumptionsforStockOptionsTable",
     "longName": "996028 - Disclosure - Stock-based Compensation Expense - Weighted-Average Assumptions for Stock Options (Details)",
     "shortName": "Stock-based Compensation Expense - Weighted-Average Assumptions for Stock Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c205",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c205",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://ionis.com/role/WeightedAverageAssumptionsforESPPTable",
     "longName": "996029 - Disclosure - Stock-based Compensation Expense - Weighted-Average Assumptions for ESPP (Details)",
     "shortName": "Stock-based Compensation Expense - Weighted-Average Assumptions for ESPP (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c235",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c235",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://ionis.com/role/IncomeTaxesDetails",
     "longName": "996030 - Disclosure - Income Taxes (Details)",
     "shortName": "Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c36",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R56": {
     "role": "http://ionis.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesDetails",
     "longName": "996031 - Disclosure - Liability Related to Sale of Future Royalties (Details)",
     "shortName": "Liability Related to Sale of Future Royalties (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c237",
      "name": "ions:UpfrontRoyaltyPaymentReceived",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "us-gaap:OtherLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c237",
      "name": "ions:UpfrontRoyaltyPaymentReceived",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "us-gaap:OtherLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://ionis.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesTable",
     "longName": "996032 - Disclosure - Liability Related to Sale of Future Royalties - Liability Related to Sale of Future Royalties (Details)",
     "shortName": "Liability Related to Sale of Future Royalties - Liability Related to Sale of Future Royalties (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c244",
      "name": "ions:LiabilityRelatedToSaleOfFutureRoyaltiesNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c244",
      "name": "ions:LiabilityRelatedToSaleOfFutureRoyaltiesNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://ionis.com/role/ConvertibleDebtDetails",
     "longName": "996033 - Disclosure - Convertible Debt (Details)",
     "shortName": "Convertible Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c247",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://ionis.com/role/175NotesTable",
     "longName": "996034 - Disclosure - Convertible Debt - 1.75% Notes (Details)",
     "shortName": "Convertible Debt - 1.75% Notes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://ionis.com/role/0NotesTable",
     "longName": "996035 - Disclosure - Convertible Debt - 0% Notes (Details)",
     "shortName": "Convertible Debt - 0% Notes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://ionis.com/role/OperatingLeasesDetails",
     "longName": "996036 - Disclosure - Operating Leases (Details)",
     "shortName": "Operating Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c252",
      "name": "ions:NumberOfPurchaseAndSaleAgreementsEnteredIntoWithRealEstateInvestor",
      "unitRef": "Agreement",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c252",
      "name": "ions:NumberOfPurchaseAndSaleAgreementsEnteredIntoWithRealEstateInvestor",
      "unitRef": "Agreement",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://ionis.com/role/SegmentInformationDetails",
     "longName": "996037 - Disclosure - Segment Information (Details)",
     "shortName": "Segment Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SegmentReportingOtherItemCompositionDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SegmentReportingOtherItemCompositionDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://ionis.com/role/SegmentInformationTable",
     "longName": "996038 - Disclosure - Segment Information - Segment Information (Details)",
     "shortName": "Segment Information - Segment Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c256",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c256",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r805"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Amortization of discount on investments, net",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "ions_AccruedClinicalExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "AccruedClinicalExpenses",
     "crdr": "credit",
     "calculation": {
      "http://ionis.com/role/AccruedLiabilitiesTable": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ionis.com/role/AccruedLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Clinical Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ions_AccruedCommercialExpensesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "AccruedCommercialExpensesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://ionis.com/role/AccruedLiabilitiesTable": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://ionis.com/role/AccruedLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for commercial expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Commercial Expenses Current"
       }
      }
     },
     "auth_ref": []
    },
    "ions_AccruedInLicensingFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "AccruedInLicensingFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://ionis.com/role/AccruedLiabilitiesTable": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ionis.com/role/AccruedLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "In-licensing expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for in-licensing fees under collaboration agreements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued In Licensing Fees Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedIncomeTaxesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes payable",
        "label": "Accrued Income Taxes, Current",
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r77"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://ionis.com/role/AccruedLiabilitiesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ionis.com/role/AccruedLiabilitiesTable",
      "http://ionis.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total accrued liabilities",
        "terseLabel": "Accrued liabilities",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive income",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r12",
      "r46",
      "r118",
      "r608",
      "r648",
      "r649",
      "r1098"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://ionis.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Loss [Member]",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r7",
      "r12",
      "r492",
      "r495",
      "r558",
      "r644",
      "r645",
      "r966",
      "r967",
      "r968",
      "r1020",
      "r1021",
      "r1022",
      "r1023"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://ionis.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid in Capital [Member]",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r660",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1099",
      "r1166"
     ]
    },
    "dei_AdditionalSecurities462b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AdditionalSecurities462b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities. 462(b)"
       }
      }
     },
     "auth_ref": [
      "r940"
     ]
    },
    "dei_AdditionalSecurities462bFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AdditionalSecurities462bFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities, 462(b), File Number"
       }
      }
     },
     "auth_ref": [
      "r940"
     ]
    },
    "dei_AdditionalSecuritiesEffective413b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AdditionalSecuritiesEffective413b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities Effective, 413(b)"
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://ionis.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r400"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://ionis.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r847",
      "r858",
      "r874",
      "r909"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r850",
      "r861",
      "r877",
      "r912"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r932"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r851",
      "r862",
      "r878",
      "r904",
      "r913",
      "r917",
      "r925"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/StockbasedCompensationExpenseTable": {
       "parentTag": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ionis.com/role/StockbasedCompensationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense, net of amounts capitalized",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r431",
      "r438",
      "r439"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AmortizationOfFinancingCosts",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of debt issuance costs",
        "label": "Amortization of Debt Issuance Costs",
        "documentation": "Amount of amortization expense attributable to debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r343",
      "r1012",
      "r1116"
     ]
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of other assets",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r135",
      "r291",
      "r292",
      "r729",
      "r733",
      "r734",
      "r736",
      "r738"
     ]
    },
    "ions_AmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "AmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties",
     "crdr": "debit",
     "presentation": [
      "http://ionis.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of issuance costs related to sale of future royalties",
        "documentation": "Amount of amortization expense attributable to the sale of future royalties.",
        "label": "Amortization Of Issuance Costs Related To Sale Of Future Royalties"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r854"
     ]
    },
    "dei_ApproximateDateOfCommencementOfProposedSaleToThePublic": {
     "xbrltype": "dateOrAsapItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Approximate Date of Commencement of Proposed Sale to Public",
        "documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r88",
      "r115",
      "r147",
      "r149",
      "r150",
      "r183",
      "r194",
      "r220",
      "r224",
      "r267",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r470",
      "r472",
      "r530",
      "r597",
      "r598",
      "r605",
      "r684",
      "r752",
      "r753",
      "r766",
      "r805",
      "r812",
      "r813",
      "r826",
      "r1058",
      "r1059",
      "r1119"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://ionis.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r121",
      "r147",
      "r149",
      "r150",
      "r267",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r470",
      "r472",
      "r530",
      "r805",
      "r1058",
      "r1059",
      "r1119"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://ionis.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/AdditionalCalculations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ionis.com/role/FairValueMeasurementsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r506",
      "r507",
      "r792"
     ]
    },
    "ions_AstraZenecaCollaborationCardiovascularRenalAndMetabolicDiseasesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "AstraZenecaCollaborationCardiovascularRenalAndMetabolicDiseasesMember",
     "presentation": [
      "http://ionis.com/role/CollaborativeArrangementsandLicensingAgreementsDetailsAstraZeneca"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cardiovascular, Renal and Metabolic Diseases [Member]",
        "documentation": "Collaboration agreement entered into with AstraZeneca PLC in July 2015 to discover and develop antisense therapies for treating cardiovascular and metabolic diseases primarily focused on targets in the kidney and renal diseases.",
        "label": "Astra Zeneca Collaboration Cardiovascular Renal And Metabolic Diseases Member"
       }
      }
     },
     "auth_ref": []
    },
    "ions_AstraZenecaCollaborationWAINUAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "AstraZenecaCollaborationWAINUAMember",
     "presentation": [
      "http://ionis.com/role/CollaborativeArrangementsandLicensingAgreementsDetailsAstraZeneca"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "WAINUA [Member]",
        "documentation": "Collaboration agreement entered into with AstraZeneca PLC in December 2021 to develop and commercialize WAINUA. WAINUA (eplontersen), formerly known as IONIS-TTR-L and AKCEA-TTR-L, is a ligand-conjugated (LICA) investigational antisense medicine designed to reduce the production of transthyretin, or TTR protein, to treat all types of TTR amyloidosis (ATTR), a systemic, progressive and fatal disease.",
        "label": "Astra Zeneca Collaboration WAINUAMember"
       }
      }
     },
     "auth_ref": []
    },
    "ions_AstraZenecaCollaborationWainuaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "AstraZenecaCollaborationWainuaMember",
     "presentation": [
      "http://ionis.com/role/RevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "WAINUA (Eplontersen) Collaboration with AstraZeneca [Member]",
        "documentation": "Collaboration agreement entered into with AstraZeneca PLC in December 2021 to develop and commercialize WAINUA. WAINUA (eplontersen), formerly known as IONIS-TTR-L and AKCEA-TTR-L, is a ligand-conjugated (LICA) investigational antisense medicine designed to reduce the production of transthyretin, or TTR protein, to treat all types of TTR amyloidosis (ATTR), a systemic, progressive and fatal disease.",
        "label": "Astra Zeneca Collaboration Wainua Member"
       }
      }
     },
     "auth_ref": []
    },
    "ions_AstraZenecaCollaborationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "AstraZenecaCollaborationsMember",
     "presentation": [
      "http://ionis.com/role/CollaborativeArrangementsandLicensingAgreementsDetailsAstraZeneca",
      "http://ionis.com/role/CollaborativeArrangementsandLicensingAgreementsTables",
      "http://ionis.com/role/RevenuefromCollaborativeRelationshipwithAstraZenecaTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AstraZeneca [Member]",
        "documentation": "Collaboration agreements entered into with AstraZeneca PLC.",
        "label": "Astra Zeneca Collaborations Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r854"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r839",
      "r842",
      "r854"
     ]
    },
    "dei_AuditorLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorLocation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r839",
      "r842",
      "r854"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r839",
      "r842",
      "r854"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r936"
     ]
    },
    "dei_AuditorTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://ionis.com/role/SummaryofInvestmentsTable": {
       "parentTag": "ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain",
       "weight": 1.0,
       "order": 1.0
      },
      "http://ionis.com/role/AdditionalCalculations": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://ionis.com/role/SummaryofInvestmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross unrealized gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r239"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/SummaryofInvestmentsTable": {
       "parentTag": "ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://ionis.com/role/AdditionalCalculations": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ionis.com/role/SummaryofInvestmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Gross unrealized losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r240"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/SummaryofInvestmentsTable": {
       "parentTag": "ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost",
       "weight": 1.0,
       "order": 1.0
      },
      "http://ionis.com/role/AdditionalCalculations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ionis.com/role/SummaryofInvestmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortized cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r236",
      "r275",
      "r604"
     ]
    },
    "ions_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage",
     "calculation": {
      "http://ionis.com/role/AdditionalCalculations": {
       "parentTag": "ions_AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ionis.com/role/InvestmentsDetailsContractMaturityofAvailableforSaleSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "After one year but within two years",
        "documentation": "The percentage of available-for-sale debt securities that mature beyond one year but within two years of the balance sheet date.",
        "label": "Available For Sale Securities Debt Maturities After One Through Two Years Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ions_AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage",
     "calculation": {
      "http://ionis.com/role/AdditionalCalculations": {
       "parentTag": "ions_AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://ionis.com/role/InvestmentsDetailsContractMaturityofAvailableforSaleSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "After two years but within three and a half years",
        "documentation": "The percentage of available-for-sale debt securities that mature beyond two years but within three and one-half years of the balance sheet date.",
        "label": "Available For Sale Securities Debt Maturities After Two Through Three And One Half Years Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ions_AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage",
     "calculation": {
      "http://ionis.com/role/AdditionalCalculations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ionis.com/role/InvestmentsDetailsContractMaturityofAvailableforSaleSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "documentation": "The aggregate percentage of all available-for-sale debt securities, regardless of maturity.",
        "label": "Available For Sale Securities Debt Maturities Total Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ions_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage",
     "calculation": {
      "http://ionis.com/role/AdditionalCalculations": {
       "parentTag": "ions_AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ionis.com/role/InvestmentsDetailsContractMaturityofAvailableforSaleSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "One year or less",
        "documentation": "The percentage of available-for-sale debt securities that mature within one year of the balance sheet date.",
        "label": "Available For Sale Securities Debt Maturities Within One Year Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ions_AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage",
     "presentation": [
      "http://ionis.com/role/InvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of available-for-sale securities with a maturity of less than two years",
        "documentation": "The percentage of available-for-sale debt securities that mature within two years of the balance sheet date.",
        "label": "Available For Sale Securities Debt Maturities Within Two Years Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/SummaryofInvestmentsTable": {
       "parentTag": "ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi",
       "weight": 1.0,
       "order": 1.0
      },
      "http://ionis.com/role/AdditionalCalculations": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ionis.com/role/FairValueMeasurementsDetails",
      "http://ionis.com/role/FairValueMeasurementsTable",
      "http://ionis.com/role/SummaryofInvestmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Estimated fair value",
        "terseLabel": "Available-for-sale securities",
        "label": "Debt Securities, Available-for-Sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r275",
      "r506",
      "r525",
      "r526",
      "r527",
      "r528",
      "r594",
      "r727",
      "r792",
      "r795",
      "r802",
      "r1038",
      "r1103",
      "r1104",
      "r1105"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/SummaryofInvestmentsTable": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://ionis.com/role/AdditionalCalculations": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ionis.com/role/SummaryofInvestmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated fair value",
        "label": "Debt Securities, Available-for-Sale, Current",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r275"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/SummaryofInvestmentsTable": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://ionis.com/role/AdditionalCalculations": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ionis.com/role/SummaryofInvestmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated fair value",
        "label": "Debt Securities, Available-for-Sale, Noncurrent",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r234",
      "r275"
     ]
    },
    "us-gaap_AwardDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardDateAxis",
     "presentation": [
      "http://ionis.com/role/StockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Date [Axis]",
        "documentation": "Information by date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092"
     ]
    },
    "us-gaap_AwardDateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardDateDomain",
     "presentation": [
      "http://ionis.com/role/StockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Date [Domain]",
        "documentation": "Date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://ionis.com/role/StockbasedCompensationExpenseDetails",
      "http://ionis.com/role/WeightedAverageAssumptionsforESPPTable",
      "http://ionis.com/role/WeightedAverageAssumptionsforStockOptionsTable",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://ionis.com/role/FairValueMeasurementsDetails",
      "http://ionis.com/role/FairValueMeasurementsTable",
      "http://ionis.com/role/InventoriesTable",
      "http://ionis.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position Location, Balance [Axis]",
        "documentation": "Information by location in statement of financial position where disaggregated cumulative balance is reported."
       }
      }
     },
     "auth_ref": [
      "r302",
      "r474",
      "r476",
      "r477",
      "r478",
      "r479",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r529",
      "r789",
      "r790",
      "r952",
      "r1131"
     ]
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://ionis.com/role/FairValueMeasurementsDetails",
      "http://ionis.com/role/FairValueMeasurementsTable",
      "http://ionis.com/role/InventoriesTable",
      "http://ionis.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position Location, Balance [Domain]",
        "documentation": "Location in statement of financial position where disaggregated cumulative balance is reported."
       }
      }
     },
     "auth_ref": [
      "r302",
      "r474",
      "r476",
      "r477",
      "r478",
      "r479",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r529",
      "r789",
      "r790",
      "r952",
      "r1131"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://ionis.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r1013"
     ]
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r842",
      "r854"
     ]
    },
    "ions_CallSpread": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "CallSpread",
     "crdr": "credit",
     "presentation": [
      "http://ionis.com/role/ConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of call spread (in Dollars)",
        "documentation": "The net cash outflow from payments for hedge transactions and proceeds from the issuance of warrants. The call spread transaction was entered into to minimize the impact of potential economic dilution upon conversion of the 0.125% notes issued.",
        "label": "Call Spread"
       }
      }
     },
     "auth_ref": []
    },
    "ions_CapitalAndPatentExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "CapitalAndPatentExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://ionis.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amounts accrued for capital and patent expenditures",
        "documentation": "Future cash outflow to pay for purchases of fixed assets and patents that have occurred.",
        "label": "Capital And Patent Expenditures Incurred But Not Yet Paid"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalent",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r112",
      "r730"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/AdditionalCalculations": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ionis.com/role/FairValueMeasurementsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r526",
      "r527",
      "r528",
      "r1101",
      "r1102"
     ]
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsMember",
     "presentation": [
      "http://ionis.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Member]",
        "label": "Cash and Cash Equivalents [Member]",
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://ionis.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r62",
      "r144"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedCashFlow": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash and cash equivalents",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r62"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://ionis.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosures of non-cash investing and financing activities:",
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "ions_CollaborativeAgreementRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "CollaborativeAgreementRevenueMember",
     "presentation": [
      "http://ionis.com/role/ConsolidatedIncomeStatement",
      "http://ionis.com/role/RevenuesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Agreement Revenue [Member]",
        "documentation": "Revenue from research and development services performed under a collaborative agreement.",
        "label": "Collaborative Agreement Revenue Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://ionis.com/role/CollaborativeArrangementsandLicensingAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangements and Licensing Agreements",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r467",
      "r468"
     ]
    },
    "ions_CollaborativeArrangementsAndLicensingAgreementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "CollaborativeArrangementsAndLicensingAgreementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangements and Licensing Agreements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://ionis.com/role/CollaborativeArrangementsandLicensingAgreements",
      "http://ionis.com/role/CollaborativeArrangementsandLicensingAgreementsDetailsAstraZeneca",
      "http://ionis.com/role/CollaborativeArrangementsandLicensingAgreementsDetailsOno",
      "http://ionis.com/role/CollaborativeArrangementsandLicensingAgreementsTables",
      "http://ionis.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesDetails",
      "http://ionis.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesTable",
      "http://ionis.com/role/RevenuefromCollaborativeRelationshipwithAstraZenecaTable",
      "http://ionis.com/role/RevenuefromCollaborativeRelationshipwithOnoTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangements and Licensing Agreements [Abstract]",
        "label": "Royalty Revenue Monetization [Abstract]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "ions_CommercialMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "CommercialMember",
     "presentation": [
      "http://ionis.com/role/ConsolidatedIncomeStatement",
      "http://ionis.com/role/RevenuesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial Revenue [Member]",
        "documentation": "Revenue from the sale of medicines commercially as well as licensing and royalty revenues from other medicines, including SPINRAZA..",
        "label": "Commercial Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Proceedings [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://ionis.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock [Member]",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r816",
      "r817",
      "r818",
      "r820",
      "r821",
      "r822",
      "r823",
      "r1020",
      "r1021",
      "r1023",
      "r1099",
      "r1162",
      "r1166"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://ionis.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in Dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://ionis.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in Shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r672"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://ionis.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in Shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://ionis.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding (in Shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r38",
      "r672",
      "r690",
      "r1166",
      "r1167"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.001 par value; 300,000,000 shares authorized, 161,137,930 and 157,908,815 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r353",
      "r358",
      "r607",
      "r805"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedComprehensiveIncome": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r125",
      "r127",
      "r131",
      "r595",
      "r616",
      "r617"
     ]
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://ionis.com/role/RevenuefromCollaborativeRelationshipwithAstraZenecaTable",
      "http://ionis.com/role/RevenuefromCollaborativeRelationshipwithOnoTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r231",
      "r652",
      "r653",
      "r722",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://ionis.com/role/RevenuefromCollaborativeRelationshipwithAstraZenecaTable",
      "http://ionis.com/role/RevenuefromCollaborativeRelationshipwithOnoTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r231",
      "r652",
      "r653",
      "r722",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://ionis.com/role/RevenuefromCollaborativeRelationshipwithAstraZenecaTable",
      "http://ionis.com/role/RevenuefromCollaborativeRelationshipwithOnoTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r231",
      "r652",
      "r653",
      "r722",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://ionis.com/role/RevenuefromCollaborativeRelationshipwithAstraZenecaTable",
      "http://ionis.com/role/RevenuefromCollaborativeRelationshipwithOnoTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration percentage",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r231",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://ionis.com/role/RevenuefromCollaborativeRelationshipwithAstraZenecaTable",
      "http://ionis.com/role/RevenuefromCollaborativeRelationshipwithOnoTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r231",
      "r652",
      "r653",
      "r722",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://ionis.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r740"
     ]
    },
    "dei_ContactPersonnelEmailAddress": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContactPersonnelEmailAddress",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Email Address",
        "documentation": "Email address of contact personnel."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelFaxNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContactPersonnelFaxNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Fax Number",
        "documentation": "Fax Number of contact personnel."
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContainedFileInformationFileDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Description",
        "documentation": "The description of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContainedFileInformationFileName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Name",
        "documentation": "The name of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContainedFileInformationFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Number",
        "documentation": "The SEC Document Number of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileType": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContainedFileInformationFileType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Type",
        "documentation": "The type or format of the contained file (usually XBRL but may be used for other types such as HTML, Word, PDF, GIF/JPG, etc.)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerAssetNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerAssetNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contracts receivable",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current."
       }
      }
     },
     "auth_ref": [
      "r362",
      "r364",
      "r366",
      "r385"
     ]
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://ionis.com/role/CollaborativeArrangementsandLicensingAgreementsDetailsAstraZeneca",
      "http://ionis.com/role/CollaborativeArrangementsandLicensingAgreementsDetailsOno"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Contract with Customer, Liability",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r362",
      "r363",
      "r366",
      "r385"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of deferred contract revenue",
        "label": "Contract with Customer, Liability, Current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r362",
      "r363",
      "r366",
      "r385"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term deferred contract revenue",
        "label": "Contract with Customer, Liability, Noncurrent",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r362",
      "r363",
      "r366",
      "r385"
     ]
    },
    "us-gaap_ConvertibleDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertibleDebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "0 percent convertible senior notes, net",
        "label": "Convertible Debt, Current",
        "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_ConvertibleDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertibleDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible senior notes, net",
        "label": "Convertible Debt, Noncurrent",
        "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_ConvertibleDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertibleDebtTableTextBlock",
     "presentation": [
      "http://ionis.com/role/ConvertibleDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Senior Notes",
        "label": "Convertible Debt [Table Text Block]",
        "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount."
       }
      }
     },
     "auth_ref": []
    },
    "ions_ConvertibleNotesDisclosureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "ConvertibleNotesDisclosureTable",
     "presentation": [
      "http://ionis.com/role/ConvertibleDebt",
      "http://ionis.com/role/ConvertibleDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Notes Disclosure [Table]",
        "documentation": "Disclosure of information about convertible notes."
       }
      }
     },
     "auth_ref": []
    },
    "ions_ConvertibleSeniorNotes0125PercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "ConvertibleSeniorNotes0125PercentMember",
     "presentation": [
      "http://ionis.com/role/BasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "0.125% Notes [Member]",
        "documentation": "0.125 percent convertible senior notes due December 2024.",
        "label": "Convertible Senior Notes0125 Percent Member"
       }
      }
     },
     "auth_ref": []
    },
    "ions_ConvertibleSeniorNotes0PercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "ConvertibleSeniorNotes0PercentMember",
     "presentation": [
      "http://ionis.com/role/0NotesTable",
      "http://ionis.com/role/BasicandDilutedNetLossPerShareDetails",
      "http://ionis.com/role/ConsolidatedBalanceSheet",
      "http://ionis.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://ionis.com/role/ConvertibleDebtDetails",
      "http://ionis.com/role/ConvertibleDebtTables",
      "http://ionis.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "0 Percent Convertible Senior Notes [Member]",
        "verboseLabel": "0% Notes [Member]",
        "documentation": "0 percent convertible senior notes due April 2026.",
        "label": "Convertible Senior Notes0 Percent Member"
       }
      }
     },
     "auth_ref": []
    },
    "ions_ConvertibleSeniorNotes175PercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "ConvertibleSeniorNotes175PercentMember",
     "presentation": [
      "http://ionis.com/role/175NotesTable",
      "http://ionis.com/role/BasicandDilutedNetLossPerShareDetails",
      "http://ionis.com/role/ConsolidatedBalanceSheet",
      "http://ionis.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://ionis.com/role/ConvertibleDebtDetails",
      "http://ionis.com/role/ConvertibleDebtTables",
      "http://ionis.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "1.75 Percent Convertible Senior Notes [Member]",
        "verboseLabel": "1.75% Notes [Member]",
        "documentation": "1.75 percent convertible senior notes due June 2028.",
        "label": "Convertible Senior Notes175 Percent Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://ionis.com/role/FairValueMeasurementsDetails",
      "http://ionis.com/role/FairValueMeasurementsTable",
      "http://ionis.com/role/SummaryofInvestmentsTable",
      "http://ionis.com/role/TemporarilyImpairedInvestmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate Debt Securities [Member]",
        "label": "Corporate Debt Securities [Member]",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r776",
      "r778",
      "r780",
      "r792",
      "r806",
      "r814",
      "r1159"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 1.0
      },
      "http://ionis.com/role/SegmentInformationTable": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedIncomeStatement",
      "http://ionis.com/role/SegmentInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of sales",
        "label": "Cost of Product and Service Sold",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r49",
      "r592",
      "r734",
      "r739",
      "r788",
      "r1006"
     ]
    },
    "us-gaap_CostOfSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostOfSalesMember",
     "presentation": [
      "http://ionis.com/role/StockbasedCompensationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of Sales [Member]",
        "label": "Cost of Sales [Member]",
        "documentation": "Primary financial statement caption encompassing cost of sales."
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostOfSalesPolicyTextBlock",
     "presentation": [
      "http://ionis.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of Sales",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered."
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "us-gaap_CostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Costs and Expenses",
        "documentation": "Total costs of sales and operating expenses for the period."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostsAndExpensesAbstract",
     "presentation": [
      "http://ionis.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expenses:",
        "label": "Costs and Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "ions_CumulativePaymentsReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "CumulativePaymentsReceived",
     "crdr": "debit",
     "presentation": [
      "http://ionis.com/role/CollaborativeArrangementsandLicensingAgreementsDetailsAstraZeneca",
      "http://ionis.com/role/CollaborativeArrangementsandLicensingAgreementsDetailsOno"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cumulative payments received",
        "documentation": "Cumulative amount of payments received under the collaboration agreement as of the end of the reporting period.",
        "label": "Cumulative Payments Received"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://ionis.com/role/RevenuefromCollaborativeRelationshipwithAstraZenecaTable",
      "http://ionis.com/role/RevenuefromCollaborativeRelationshipwithOnoTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Strategic Partner [Member]",
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r1026"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://ionis.com/role/ConvertibleDebt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Debt",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r147",
      "r148",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r310",
      "r311",
      "r321",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r337",
      "r344",
      "r345",
      "r347",
      "r490",
      "r544"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://ionis.com/role/0NotesTable",
      "http://ionis.com/role/175NotesTable",
      "http://ionis.com/role/BasicandDilutedNetLossPerShareDetails",
      "http://ionis.com/role/ConsolidatedBalanceSheet",
      "http://ionis.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://ionis.com/role/ConvertibleDebtDetails",
      "http://ionis.com/role/ConvertibleDebtTables",
      "http://ionis.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r29",
      "r30",
      "r76",
      "r79",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r328",
      "r333",
      "r334",
      "r335",
      "r336",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r803",
      "r1014",
      "r1015",
      "r1016",
      "r1019",
      "r1052",
      "r1053",
      "r1054",
      "r1115",
      "r1117",
      "r1127"
     ]
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "presentation": [
      "http://ionis.com/role/0NotesTable",
      "http://ionis.com/role/175NotesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding principal balance",
        "label": "Long-Term Debt, Gross",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r79",
      "r348"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "presentation": [
      "http://ionis.com/role/0NotesTable",
      "http://ionis.com/role/175NotesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion price per share",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "documentation": "The price per share of the conversion feature embedded in the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r324"
     ]
    },
    "ions_DebtInstrumentConvertibleConversionPriceIncludingCallSpread": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "DebtInstrumentConvertibleConversionPriceIncludingCallSpread",
     "presentation": [
      "http://ionis.com/role/0NotesTable",
      "http://ionis.com/role/ConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective conversion price per share with call spread",
        "verboseLabel": "Effective conversion price per share with call spread (in Dollars per share)",
        "documentation": "The computed conversion price per share of the debt instrument based on the conversion feature embedded in the debt instrument and the impact of the purchased hedges in the call spread transaction.",
        "label": "Debt Instrument Convertible Conversion Price Including Call Spread"
       }
      }
     },
     "auth_ref": []
    },
    "ions_DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange": {
     "xbrltype": "percentItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange",
     "presentation": [
      "http://ionis.com/role/ConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of principal amount used as purchase price upon occurrence of fundamental change",
        "documentation": "The percentage of the principal amount of the notes to be purchased, plus accrued and unpaid interest, upon the occurrence of certain fundamental changes, as set forth in the indenture governing the convertible notes.",
        "label": "Debt Instrument Convertible Percentage Of Principal Amount Used As Purchase Price Upon Occurrence Of Fundamental Change"
       }
      }
     },
     "auth_ref": []
    },
    "ions_DebtInstrumentConvertibleSharesSubjectToConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "DebtInstrumentConvertibleSharesSubjectToConversion",
     "presentation": [
      "http://ionis.com/role/0NotesTable",
      "http://ionis.com/role/175NotesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total shares of common stock subject to conversion",
        "documentation": "The number of shares of common stock subject to conversion if the debt was converted to equity.",
        "label": "Debt Instrument Convertible Shares Subject To Conversion"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://ionis.com/role/ConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Face amount of offering (in Dollars)",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r322",
      "r544",
      "r545",
      "r762",
      "r763",
      "r803"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://ionis.com/role/0NotesTable",
      "http://ionis.com/role/175NotesTable",
      "http://ionis.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective interest rate",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r349",
      "r544",
      "r545",
      "r803"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://ionis.com/role/0NotesTable",
      "http://ionis.com/role/175NotesTable",
      "http://ionis.com/role/BasicandDilutedNetLossPerShareDetails",
      "http://ionis.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://ionis.com/role/ConvertibleDebtDetails",
      "http://ionis.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate on convertible senior notes",
        "verboseLabel": "Interest rate",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r323"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://ionis.com/role/0NotesTable",
      "http://ionis.com/role/175NotesTable",
      "http://ionis.com/role/ConvertibleDebt",
      "http://ionis.com/role/ConvertibleDebtDetails",
      "http://ionis.com/role/ConvertibleDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Debt [Abstract]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r328",
      "r333",
      "r334",
      "r335",
      "r336",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r346",
      "r490",
      "r600",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r803",
      "r1014",
      "r1015",
      "r1016",
      "r1019",
      "r1115",
      "r1117"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentMaturityDate",
     "presentation": [
      "http://ionis.com/role/0NotesTable",
      "http://ionis.com/role/175NotesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturity date",
        "label": "Debt Instrument, Maturity Date",
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r761",
      "r1104",
      "r1105"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://ionis.com/role/ConsolidatedBalanceSheet",
      "http://ionis.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://ionis.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r328",
      "r333",
      "r334",
      "r335",
      "r336",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r803",
      "r1014",
      "r1015",
      "r1016",
      "r1019",
      "r1052",
      "r1053",
      "r1054",
      "r1115",
      "r1117",
      "r1127"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://ionis.com/role/0NotesTable",
      "http://ionis.com/role/175NotesTable",
      "http://ionis.com/role/ConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r23",
      "r24",
      "r27",
      "r70",
      "r71",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r328",
      "r333",
      "r334",
      "r335",
      "r336",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r346",
      "r490",
      "r600",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r803",
      "r1014",
      "r1015",
      "r1016",
      "r1019",
      "r1115",
      "r1117"
     ]
    },
    "ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent",
     "crdr": "credit",
     "calculation": {
      "http://ionis.com/role/SummaryofInvestmentsTable": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://ionis.com/role/AdditionalCalculations": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://ionis.com/role/SummaryofInvestmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross unrealized gains",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Current"
       }
      }
     },
     "auth_ref": []
    },
    "ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://ionis.com/role/SummaryofInvestmentsTable": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
       "weight": 1.0,
       "order": 2.0
      },
      "http://ionis.com/role/AdditionalCalculations": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://ionis.com/role/SummaryofInvestmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross unrealized gains",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/SummaryofInvestmentsTable": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://ionis.com/role/AdditionalCalculations": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ionis.com/role/SummaryofInvestmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gross unrealized losses",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities Available For Sale Accumulated Gross Unrealized Loss Before Tax Current"
       }
      }
     },
     "auth_ref": []
    },
    "ions_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/AdditionalCalculations": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://ionis.com/role/SummaryofInvestmentsTable": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ionis.com/role/SummaryofInvestmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gross unrealized losses",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities Available For Sale Accumulated Gross Unrealized Loss Before Tax Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/SummaryofInvestmentsTable": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 1.0
      },
      "http://ionis.com/role/AdditionalCalculations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ionis.com/role/SummaryofInvestmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortized cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Current",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r275",
      "r1040"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/SummaryofInvestmentsTable": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      },
      "http://ionis.com/role/AdditionalCalculations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ionis.com/role/SummaryofInvestmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortized cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Noncurrent",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r275",
      "r1040"
     ]
    },
    "ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/AdditionalCalculations": {
       "parentTag": "ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost",
       "weight": 1.0,
       "order": 2.0
      },
      "http://ionis.com/role/SummaryofInvestmentsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ionis.com/role/SummaryofInvestmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Estimated fair value",
        "documentation": "Total of (1) investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and (2) amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Debt Securities Available For Sale And Equity Securities Fv Ni"
       }
      }
     },
     "auth_ref": []
    },
    "ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/SummaryofInvestmentsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://ionis.com/role/AdditionalCalculations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ionis.com/role/SummaryofInvestmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortized cost",
        "documentation": "Total of (1) amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and (2) cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Debt Securities Available For Sale And Equity Securities Fv Ni Cost"
       }
      }
     },
     "auth_ref": []
    },
    "ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain",
     "crdr": "credit",
     "calculation": {
      "http://ionis.com/role/AdditionalCalculations": {
       "parentTag": "ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost",
       "weight": -1.0,
       "order": 3.0
      },
      "http://ionis.com/role/SummaryofInvestmentsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ionis.com/role/SummaryofInvestmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross unrealized gains",
        "documentation": "Total of (1) unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and (2) unrealized gain on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Debt Securities Available For Sale And Equity Securities Fv Ni Gross Unrealized Gain"
       }
      }
     },
     "auth_ref": []
    },
    "ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/AdditionalCalculations": {
       "parentTag": "ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost",
       "weight": 1.0,
       "order": 1.0
      },
      "http://ionis.com/role/SummaryofInvestmentsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ionis.com/role/SummaryofInvestmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Gross unrealized losses",
        "documentation": "Total of (1) unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and (2) unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Debt Securities Available For Sale And Equity Securities Fv Ni Gross Unrealized Loss"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/AdditionalCalculations": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ionis.com/role/TemporarilyImpairedInvestmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "More than 12 months of temporary impairment",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r279",
      "r759"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/AdditionalCalculations": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ionis.com/role/TemporarilyImpairedInvestmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "More than 12 months of temporary impairment",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r279"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/AdditionalCalculations": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ionis.com/role/TemporarilyImpairedInvestmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less than 12 months of temporary impairment",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r279",
      "r759"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/AdditionalCalculations": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ionis.com/role/TemporarilyImpairedInvestmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less than 12 months of temporary impairment",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r279"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions",
     "presentation": [
      "http://ionis.com/role/TemporarilyImpairedInvestmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of investments (in Investment)",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions",
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without an allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r1049"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://ionis.com/role/TemporarilyImpairedInvestmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/AdditionalCalculations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ionis.com/role/TemporarilyImpairedInvestmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total temporary impairment",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r277",
      "r759"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/AdditionalCalculations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ionis.com/role/TemporarilyImpairedInvestmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total temporary impairment",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r278"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "presentation": [
      "http://ionis.com/role/InvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporarily Impaired Investments",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r759",
      "r1047"
     ]
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredFinanceCostsNet",
     "crdr": "debit",
     "presentation": [
      "http://ionis.com/role/0NotesTable",
      "http://ionis.com/role/175NotesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unamortized debt issuance costs",
        "label": "Debt Issuance Costs, Net",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r1061",
      "r1114",
      "r1115",
      "r1117"
     ]
    },
    "dei_DelayedOrContinuousOffering": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DelayedOrContinuousOffering",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Delayed or Continuous Offering"
       }
      }
     },
     "auth_ref": [
      "r866",
      "r867",
      "r881"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r22",
      "r134",
      "r733",
      "r734",
      "r736",
      "r738"
     ]
    },
    "us-gaap_DisaggregationOfRevenueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisaggregationOfRevenueAbstract",
     "presentation": [
      "http://ionis.com/role/RevenuesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue:",
        "label": "Disaggregation of Revenue [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://ionis.com/role/RevenuesDetails",
      "http://ionis.com/role/RevenuesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues [Abstract]",
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r383",
      "r384",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://ionis.com/role/RevenuesDetails",
      "http://ionis.com/role/RevenuesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r383",
      "r384",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://ionis.com/role/RevenuesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r1062"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://ionis.com/role/StockbasedCompensationExpense"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based Compensation Expense",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r402",
      "r433",
      "r434",
      "r436",
      "r782"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based Compensation Expense [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DividendOrInterestReinvestmentPlanOnly": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DividendOrInterestReinvestmentPlanOnly",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend or Interest Reinvestment Plan Only"
       }
      }
     },
     "auth_ref": [
      "r866",
      "r867",
      "r881"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r839",
      "r842",
      "r854"
     ]
    },
    "dei_DocumentCopyrightInformation": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentCopyrightInformation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Copyright Information",
        "documentation": "The copyright information for the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentCreationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentCreationDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Creation Date",
        "documentation": "The date the document was made available and submitted, in YYYY-MM-DD format. The date of submission, date of acceptance by the recipient, and the document effective date are all potentially different."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Description",
        "documentation": "The description of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document [Domain]",
        "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentEffectiveDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentEffectiveDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Effective Date",
        "documentation": "The date when a document, upon receipt and acceptance, becomes officially effective, in YYYY-MM-DD format. Usually it is a system-assigned date time value, but it may be declared by the submitter in some cases."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r839",
      "r842",
      "r854",
      "r905"
     ]
    },
    "dei_DocumentFinStmtRestatementRecoveryAnalysisFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFinStmtRestatementRecoveryAnalysisFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Restatement Recovery Analysis [Flag]",
        "documentation": "Indicates whether any of the financial statement periods include restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to \u00a7240.10D-1(b)."
       }
      }
     },
     "auth_ref": [
      "r839",
      "r842",
      "r854",
      "r905"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationDocumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationDocumentAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information, Document [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Text Block]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Name",
        "documentation": "Name of the document as assigned by the filer, corresponding to SEC document naming convention standards. Examples appear in the &lt;FILENAME> field of EDGAR filings, such as 'htm_25911.htm', 'exhibit1.htm', 'v105727_8k.txt'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "dei_DocumentSubtitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentSubtitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Subtitle",
        "documentation": "The subtitle given to the document resource by the creator or publisher. An example is 'A New Period of Growth'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentSynopsis": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentSynopsis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Synopsis",
        "documentation": "A synopsis or description of the document provided by the creator or publisher. Examples are 'This is the 2006 annual report for Company. During this period we saw revenue grow by 10% and earnings per share grow by 15% over the prior period'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Title",
        "documentation": "The name or title given to the document resource by the creator or publisher. An example is '2002 Annual Report'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r882"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentVersion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentVersion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Version",
        "documentation": "The version identifier of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "ions_DrugDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "DrugDevelopmentExpenses",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/SegmentInformationTable": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://ionis.com/role/SegmentInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Drug development",
        "documentation": "Expenses related to drug development, including expenses for marketed medicines and those in Phase 3 development.",
        "label": "Drug Development Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ions_DrugDiscoveryExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "DrugDiscoveryExpenses",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/SegmentInformationTable": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://ionis.com/role/SegmentInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Drug discovery",
        "documentation": "Expenses related to drug discovery research and advancing the Company's core technology.",
        "label": "Drug Discovery Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic and Diluted Net Loss Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://ionis.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic net loss per share (in Dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r132",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r170",
      "r172",
      "r175",
      "r176",
      "r177",
      "r182",
      "r351",
      "r437",
      "r461",
      "r466",
      "r503",
      "r504",
      "r596",
      "r618",
      "r743"
     ]
    },
    "us-gaap_EarningsPerShareBasicLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasicLineItems",
     "presentation": [
      "http://ionis.com/role/BasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic and Diluted Net Loss Per Share [Abstract]",
        "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r173",
      "r175",
      "r177"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://ionis.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted net loss per share (in Dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r132",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r172",
      "r175",
      "r176",
      "r177",
      "r182",
      "r351",
      "r437",
      "r461",
      "r466",
      "r503",
      "r504",
      "r596",
      "r618",
      "r743"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://ionis.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic and Diluted Net Loss Per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r18",
      "r179"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://ionis.com/role/BasicandDilutedNetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic and Diluted Net Loss Per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r178",
      "r180",
      "r181"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effects of exchange rates on cash",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation",
        "documentation": "Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r1113"
     ]
    },
    "dei_EffectiveAfter60Days486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveAfter60Days486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective after 60 Days, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "dei_EffectiveOnDate486a": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveOnDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "dei_EffectiveOnDate486b": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveOnDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r945"
     ]
    },
    "dei_EffectiveOnSetDate486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveOnSetDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "dei_EffectiveOnSetDate486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveOnSetDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r945"
     ]
    },
    "dei_EffectiveUponFiling462e": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveUponFiling462e",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Upon Filing, 462(e)"
       }
      }
     },
     "auth_ref": [
      "r943"
     ]
    },
    "dei_EffectiveUponFiling486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveUponFiling486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective upon Filing, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r945"
     ]
    },
    "dei_EffectiveWhenDeclaredSection8c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveWhenDeclaredSection8c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective when Declared, Section 8(c)"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/StockbasedCompensationExpenseTable": {
       "parentTag": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ionis.com/role/StockbasedCompensationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Amount Capitalized",
        "documentation": "Amount of cost capitalized for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://ionis.com/role/StockbasedCompensationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based Compensation Expense [Abstract]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r1093"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://ionis.com/role/StockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average period for recognition",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://ionis.com/role/StockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation cost related to non-vested units (in Dollars)",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r1094"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://ionis.com/role/StockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation expense related to non-vested stock options (in Dollars)",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1094"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://ionis.com/role/WeightedAverageAssumptionsforESPPTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ESPP [Member]",
        "label": "Employee Stock [Member]",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://ionis.com/role/StockbasedCompensationExpenseDetails",
      "http://ionis.com/role/WeightedAverageAssumptionsforStockOptionsTable",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock Option [Member]",
        "netLabel": "Stock Options [Member]",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092"
     ]
    },
    "dei_EntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitiesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entities [Table]",
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAccountingStandard": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Accounting Standard",
        "documentation": "The standardized abbreviation of the accounting standard used by the entity. This can either be US GAAP as promulgated by the FASB or IFRS as promulgated by the IASB. Example: 'US GAAP', 'IFRS'. This is distinct from the Document Accounting Standard element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Description",
        "documentation": "Description of the kind of address for the entity, if needed to distinguish more finely among mailing, principal, legal, accounting, contact or other addresses."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressesLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Table]",
        "documentation": "Container of address information for the entity"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityContactPersonnelLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityContactPersonnelLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Contact Personnel [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r946"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "dei_EntityHomeCountryISOCode": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityHomeCountryISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Home Country ISO Code",
        "documentation": "ISO 3166-1 alpha-2 country code for the Entity's home country. If home country is different from country of legal incorporation, then also provide country of legal incorporation in the 'Entity Incorporation, State Country Code' element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationDateOfIncorporation": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationDateOfIncorporation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, Date of Incorporation",
        "documentation": "Date when an entity was incorporated"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information, Former Legal or Registered Name",
        "documentation": "Former Legal or Registered Name of an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r935"
     ]
    },
    "dei_EntityInvCompanyType": {
     "xbrltype": "invCompanyType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInvCompanyType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Inv Company Type",
        "documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product)."
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "dei_EntityLegalForm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityLegalForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Legal Form",
        "documentation": "The details of the entity's legal form. Examples are partnership, limited liability company, trust, etc."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDepositoryReceiptRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingDepositoryReceiptRatio",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Depository Receipt Ratio",
        "documentation": "The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Description",
        "documentation": "Description of the kind of listing the entity has on the exchange, if necessary to further describe different instruments that are already distinguished by Entity, Exchange and Security."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingForeign": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingForeign",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Foreign",
        "documentation": "Yes or No value indicating whether this is a listing that is a foreign listing or depository receipt."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingParValuePerShare",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Par Value Per Share",
        "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingPrimary": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingPrimary",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Primary",
        "documentation": "Yes or No value indicating whether a listing of an instrument on an exchange is primary for the entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingSecurityTradingCurrency": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingSecurityTradingCurrency",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Security Trading Currency",
        "documentation": "The three character ISO 4217 code for the currency in which the security is quoted. Example: 'USD'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsExchangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingsExchangeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings, Exchange [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingsLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingsTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Table]",
        "documentation": "Container for exchange listing information for an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityNumberOfEmployees": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityNumberOfEmployees",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Number of Employees",
        "documentation": "Number of persons employed by the Entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPhoneFaxNumbersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPhoneFaxNumbersLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Phone Fax Numbers [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r854"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "dei_EntityReportingCurrencyISOCode": {
     "xbrltype": "currencyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityReportingCurrencyISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Reporting Currency ISO Code",
        "documentation": "The three character ISO 4217 code for the currency used for reporting purposes. Example: 'USD'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "dei_EntityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Text Block]",
        "documentation": "Container to serve as parent of six Entity related Table concepts."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r888"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://ionis.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r102",
      "r103",
      "r104",
      "r128",
      "r129",
      "r130",
      "r153",
      "r154",
      "r155",
      "r157",
      "r164",
      "r166",
      "r168",
      "r184",
      "r268",
      "r269",
      "r294",
      "r350",
      "r361",
      "r437",
      "r451",
      "r452",
      "r458",
      "r459",
      "r460",
      "r462",
      "r465",
      "r466",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r502",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r546",
      "r548",
      "r558",
      "r614",
      "r644",
      "r645",
      "r646",
      "r660",
      "r709"
     ]
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquitySecuritiesFvNi",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/SummaryofInvestmentsTable": {
       "parentTag": "ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi",
       "weight": 1.0,
       "order": 2.0
      },
      "http://ionis.com/role/AdditionalCalculations": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://ionis.com/role/FairValueMeasurementsTable",
      "http://ionis.com/role/SummaryofInvestmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated fair value",
        "verboseLabel": "Equity securities",
        "label": "Equity Securities, FV-NI, Current",
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r525",
      "r732"
     ]
    },
    "ions_EquitySecuritiesFvNiAccumulatedGrossUnrealizedGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "EquitySecuritiesFvNiAccumulatedGrossUnrealizedGain",
     "crdr": "credit",
     "calculation": {
      "http://ionis.com/role/SummaryofInvestmentsTable": {
       "parentTag": "ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain",
       "weight": 1.0,
       "order": 2.0
      },
      "http://ionis.com/role/AdditionalCalculations": {
       "parentTag": "us-gaap_EquitySecuritiesFvNiCost",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://ionis.com/role/SummaryofInvestmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross unrealized gains",
        "documentation": "Accumulated amount of unrealized gain on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities Fv Ni Accumulated Gross Unrealized Gain"
       }
      }
     },
     "auth_ref": []
    },
    "ions_EquitySecuritiesFvNiAccumulatedGrossUnrealizedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "EquitySecuritiesFvNiAccumulatedGrossUnrealizedLoss",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/AdditionalCalculations": {
       "parentTag": "us-gaap_EquitySecuritiesFvNiCost",
       "weight": 1.0,
       "order": 1.0
      },
      "http://ionis.com/role/SummaryofInvestmentsTable": {
       "parentTag": "ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ionis.com/role/SummaryofInvestmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gross unrealized losses",
        "documentation": "Accumulated amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities Fv Ni Accumulated Gross Unrealized Loss"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquitySecuritiesFvNiCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquitySecuritiesFvNiCost",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/SummaryofInvestmentsTable": {
       "parentTag": "ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost",
       "weight": 1.0,
       "order": 2.0
      },
      "http://ionis.com/role/AdditionalCalculations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ionis.com/role/SummaryofInvestmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortized cost",
        "label": "Equity Securities, FV-NI, Cost",
        "documentation": "Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value."
       }
      }
     },
     "auth_ref": [
      "r604"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquitySecuritiesFvNiUnrealizedGain",
     "crdr": "credit",
     "presentation": [
      "http://ionis.com/role/InvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gain on equity securities",
        "label": "Equity Securities, FV-NI, Unrealized Gain",
        "documentation": "Amount of unrealized gain on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r266"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://ionis.com/role/InvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized net gain on equity securities",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r620",
      "r1045"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquitySecuritiesFvNiUnrealizedLoss",
     "crdr": "debit",
     "presentation": [
      "http://ionis.com/role/InvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized loss on equity securities",
        "label": "Equity Securities, FV-NI, Unrealized Loss",
        "documentation": "Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r266"
     ]
    },
    "ions_EquitySecuritiesPrivateCompaniesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "EquitySecuritiesPrivateCompaniesMember",
     "presentation": [
      "http://ionis.com/role/InvestmentsDetails",
      "http://ionis.com/role/SummaryofInvestmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Privately Held Equity Securities [Member]",
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in private corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.",
        "label": "Equity Securities Private Companies Member"
       }
      }
     },
     "auth_ref": []
    },
    "ions_EquitySecuritiesPubliclyTradedCompaniesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "EquitySecuritiesPubliclyTradedCompaniesMember",
     "presentation": [
      "http://ionis.com/role/FairValueMeasurementsTable",
      "http://ionis.com/role/InvestmentsDetails",
      "http://ionis.com/role/SummaryofInvestmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Publicly Traded Equity Securities [Member]",
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in publicly traded corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.",
        "label": "Equity Securities Publicly Traded Companies Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r898"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r847",
      "r858",
      "r874",
      "r909"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r844",
      "r855",
      "r871",
      "r906"
     ]
    },
    "dei_ExchangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ExchangeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchange [Domain]",
        "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "srt_ExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ExecutiveOfficerMember",
     "presentation": [
      "http://ionis.com/role/StockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Officers [Member]",
        "label": "Executive Officer [Member]"
       }
      }
     },
     "auth_ref": [
      "r1036"
     ]
    },
    "dei_ExhibitsOnly462d": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ExhibitsOnly462d",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d)"
       }
      }
     },
     "auth_ref": [
      "r942"
     ]
    },
    "dei_ExhibitsOnly462dFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ExhibitsOnly462dFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d), File Number"
       }
      }
     },
     "auth_ref": [
      "r942"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://ionis.com/role/FairValueMeasurementsDetails",
      "http://ionis.com/role/FairValueMeasurementsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements [Abstract]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r506",
      "r507",
      "r517",
      "r792"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://ionis.com/role/FairValueMeasurementsDetails",
      "http://ionis.com/role/FairValueMeasurementsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r506",
      "r507",
      "r517",
      "r792"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://ionis.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets Measured at Fair Value on a Recurring Basis",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1101",
      "r1102"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://ionis.com/role/FairValueMeasurementsDetails",
      "http://ionis.com/role/FairValueMeasurementsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r505",
      "r507",
      "r508",
      "r509",
      "r510",
      "r516",
      "r517",
      "r519",
      "r526",
      "r562",
      "r563",
      "r564",
      "r727",
      "r762",
      "r763",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r792",
      "r795",
      "r802"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://ionis.com/role/FairValueMeasurementsDetails",
      "http://ionis.com/role/FairValueMeasurementsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r506",
      "r507",
      "r508",
      "r510",
      "r792",
      "r1104",
      "r1107"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://ionis.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r508",
      "r512",
      "r514",
      "r515",
      "r516",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r593",
      "r792",
      "r796"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://ionis.com/role/FairValueMeasurementsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Quoted Prices in Active Markets (Level 1) [Member]",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r388",
      "r393",
      "r394",
      "r507",
      "r517",
      "r526",
      "r562",
      "r727",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r792",
      "r802"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://ionis.com/role/FairValueMeasurementsDetails",
      "http://ionis.com/role/FairValueMeasurementsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Other Observable Inputs (Level 2) [Member]",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r388",
      "r393",
      "r394",
      "r396",
      "r507",
      "r508",
      "r517",
      "r526",
      "r563",
      "r727",
      "r762",
      "r763",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r792",
      "r802"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://ionis.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r506",
      "r507",
      "r508",
      "r510",
      "r792",
      "r1104",
      "r1107"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://ionis.com/role/FairValueMeasurementsDetails",
      "http://ionis.com/role/FairValueMeasurementsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r505",
      "r507",
      "r508",
      "r509",
      "r510",
      "r516",
      "r517",
      "r519",
      "r526",
      "r562",
      "r563",
      "r564",
      "r727",
      "r762",
      "r763",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r792",
      "r795",
      "r802"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://ionis.com/role/FairValueMeasurementsDetails",
      "http://ionis.com/role/FairValueMeasurementsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recurring Basis [Member]",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r792",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1107"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://ionis.com/role/FairValueMeasurementsDetails",
      "http://ionis.com/role/FairValueMeasurementsTable",
      "http://ionis.com/role/InvestmentsDetails",
      "http://ionis.com/role/SummaryofInvestmentsTable",
      "http://ionis.com/role/TemporarilyImpairedInvestmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r276",
      "r280",
      "r281",
      "r346",
      "r360",
      "r490",
      "r501",
      "r524",
      "r529",
      "r532",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r603",
      "r615",
      "r759",
      "r792",
      "r793",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r806",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1100",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r851",
      "r862",
      "r878",
      "r913"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r851",
      "r862",
      "r878",
      "r913"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r851",
      "r862",
      "r878",
      "r913"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r851",
      "r862",
      "r878",
      "r913"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r851",
      "r862",
      "r878",
      "r913"
     ]
    },
    "dei_FormerAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "FormerAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Address [Member]",
        "documentation": "Former address for entity"
       }
      }
     },
     "auth_ref": [
      "r841",
      "r865"
     ]
    },
    "dei_FormerFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "FormerFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Fiscal Year End Date",
        "documentation": "Former end date of previous fiscal years"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "us-gaap_GainLossOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainLossOnInvestments",
     "crdr": "credit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain (loss) on investments, net",
        "label": "Gain (Loss) on Investments",
        "documentation": "Amount of realized and unrealized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r56",
      "r948"
     ]
    },
    "ions_GrantedIn2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "GrantedIn2024Member",
     "presentation": [
      "http://ionis.com/role/StockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted in 2024 [Member]",
        "documentation": "Awards granted in 2024.",
        "label": "Granted In2024 Member"
       }
      }
     },
     "auth_ref": []
    },
    "ions_GrantedIn2025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "GrantedIn2025Member",
     "presentation": [
      "http://ionis.com/role/StockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted in 2025 [Member]",
        "documentation": "Awards granted in 2025.",
        "label": "Granted In2025 Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GranteeStatusAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GranteeStatusAxis",
     "presentation": [
      "http://ionis.com/role/StockbasedCompensationExpenseDetails",
      "http://ionis.com/role/WeightedAverageAssumptionsforStockOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grantee Status [Axis]",
        "documentation": "Information by status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r399",
      "r401",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429"
     ]
    },
    "us-gaap_GranteeStatusDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GranteeStatusDomain",
     "presentation": [
      "http://ionis.com/role/StockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grantee Status [Domain]",
        "documentation": "Status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r399",
      "r401",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429"
     ]
    },
    "ions_HeadquartersLocationInCarlsbadCaliforniaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "HeadquartersLocationInCarlsbadCaliforniaMember",
     "presentation": [
      "http://ionis.com/role/OperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Headquarters Location in Carlsbad, California [Member]",
        "documentation": "Headquarters location located in Carlsbad, California.",
        "label": "Headquarters Location In Carlsbad California Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r839",
      "r842",
      "r854"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash losses related to other assets",
        "label": "Impairment of Intangible Assets, Finite-Lived",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r1012",
      "r1050"
     ]
    },
    "us-gaap_IncentiveFromLessor": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncentiveFromLessor",
     "crdr": "credit",
     "presentation": [
      "http://ionis.com/role/OperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reimbursements from lessor for tenant improvements",
        "label": "Incentive from Lessor",
        "documentation": "Amount of incentive received by lessee from lessor."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r94",
      "r95",
      "r949"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before income tax benefit (expense)",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r83",
      "r87",
      "r597",
      "r599",
      "r612",
      "r735",
      "r737",
      "r739",
      "r746",
      "r752",
      "r1024",
      "r1032",
      "r1033",
      "r1034",
      "r1035"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://ionis.com/role/StockbasedCompensationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r295",
      "r302",
      "r303",
      "r475",
      "r480",
      "r481",
      "r489",
      "r511",
      "r513",
      "r518",
      "r531",
      "r532",
      "r533",
      "r641",
      "r643",
      "r694",
      "r725",
      "r727",
      "r784",
      "r785",
      "r790",
      "r791",
      "r794",
      "r802",
      "r1096",
      "r1097",
      "r1132"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://ionis.com/role/StockbasedCompensationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r302",
      "r303",
      "r475",
      "r480",
      "r481",
      "r489",
      "r511",
      "r513",
      "r518",
      "r531",
      "r532",
      "r533",
      "r641",
      "r643",
      "r694",
      "r725",
      "r727",
      "r784",
      "r785",
      "r790",
      "r791",
      "r794",
      "r802",
      "r1096",
      "r1097",
      "r1132"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://ionis.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r151",
      "r441",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r453",
      "r455",
      "r456",
      "r457",
      "r602",
      "r651",
      "r659",
      "r783"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedIncomeStatement",
      "http://ionis.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income tax benefit (expense)",
        "terseLabel": "Income tax expense (benefit)",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r99",
      "r147",
      "r167",
      "r168",
      "r183",
      "r202",
      "r224",
      "r442",
      "r443",
      "r454",
      "r621",
      "r735",
      "r737",
      "r739",
      "r783"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://ionis.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes paid (refunds received), net",
        "label": "Income Taxes Paid, Net",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r143",
      "r449",
      "r450"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInContractWithCustomerAsset",
     "crdr": "credit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Contracts receivable",
        "label": "Increase (Decrease) in Contract with Customer, Asset",
        "documentation": "Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time."
       }
      }
     },
     "auth_ref": [
      "r1011"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred contract revenue",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r591",
      "r1011"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventories",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://ionis.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherCurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued liabilities and other current liabilities",
        "label": "Increase (Decrease) in Other Current Liabilities",
        "documentation": "Amount of increase (decrease) in current liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r1011"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherEmployeeRelatedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherEmployeeRelatedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation",
        "label": "Increase (Decrease) in Other Employee-Related Liabilities",
        "documentation": "Amount of increase (decrease) in employer-related costs classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "crdr": "credit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other current and long-term assets",
        "label": "Increase (Decrease) in Other Operating Assets",
        "documentation": "Amount of increase (decrease) in operating assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r851",
      "r862",
      "r878",
      "r904",
      "r913",
      "r917",
      "r925"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r843",
      "r929"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r843",
      "r929"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r843",
      "r929"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest Expense, Operating and Nonoperating",
        "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r194",
      "r198",
      "r204",
      "r224",
      "r543",
      "r752",
      "r753",
      "r1165"
     ]
    },
    "ions_InterestExpenseAndAmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "InterestExpenseAndAmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense related to sale of future royalties",
        "documentation": "Amount of interest expense using the effective interest rate method and amortization of issuance costs related to the sale of future royalties.",
        "label": "Interest Expense And Amortization Of Issuance Costs Related To Sale Of Future Royalties"
       }
      }
     },
     "auth_ref": []
    },
    "ions_InterestExpenseRelatedToSaleOfFutureRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "InterestExpenseRelatedToSaleOfFutureRoyalties",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedCashFlow",
      "http://ionis.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash interest related to sale of future royalties",
        "verboseLabel": "Interest expense related to sale of future royalties",
        "documentation": "Amount of interest expense using the effective interest rate method related to the sale of future royalties.",
        "label": "Interest Expense Related To Sale Of Future Royalties"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://ionis.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest paid",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activity",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r140",
      "r142"
     ]
    },
    "ions_InventoryCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "InventoryCurrentAndNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/InventoriesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://ionis.com/role/AdditionalCalculations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ionis.com/role/InventoriesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "documentation": "Amount of inventory after valuation and LIFO reserves.",
        "label": "Inventory Current And Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryCurrentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryCurrentTable",
     "presentation": [
      "http://ionis.com/role/InventoriesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Current [Table]",
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "ions_InventoryFinishedGoodsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "InventoryFinishedGoodsNet",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/InventoriesTable": {
       "parentTag": "ions_InventoryCurrentAndNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://ionis.com/role/InventoriesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finished goods",
        "documentation": "Carrying amount, as of the balance sheet date, of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory Finished Goods Net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryLineItems",
     "presentation": [
      "http://ionis.com/role/InventoriesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory [Abstract]",
        "label": "Inventory [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/AdditionalCalculations": {
       "parentTag": "ions_InventoryCurrentAndNoncurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://ionis.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedBalanceSheet",
      "http://ionis.com/role/InventoriesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r731",
      "r805"
     ]
    },
    "us-gaap_InventoryNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/AdditionalCalculations": {
       "parentTag": "ions_InventoryCurrentAndNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ionis.com/role/InventoriesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "label": "Inventory, Noncurrent",
        "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle."
       }
      }
     },
     "auth_ref": [
      "r964"
     ]
    },
    "ions_InventoryRawMaterialsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "InventoryRawMaterialsNet",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/InventoriesTable": {
       "parentTag": "ions_InventoryCurrentAndNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ionis.com/role/InventoriesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Raw materials",
        "documentation": "Amount, as of the balance sheet date, of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory Raw Materials Net"
       }
      }
     },
     "auth_ref": []
    },
    "ions_InventoryWorkInProcessNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "InventoryWorkInProcessNet",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/InventoriesTable": {
       "parentTag": "ions_InventoryCurrentAndNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ionis.com/role/InventoriesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Work in process",
        "documentation": "Carrying amount, as of the balance sheet date, of merchandise or goods which are partially completed.",
        "label": "Inventory Work In Process Net"
       }
      }
     },
     "auth_ref": []
    },
    "dei_InvestmentCompanyActFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "InvestmentCompanyActFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act File Number"
       }
      }
     },
     "auth_ref": [
      "r867",
      "r868",
      "r869",
      "r870"
     ]
    },
    "dei_InvestmentCompanyActRegistration": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "InvestmentCompanyActRegistration",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act Registration"
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "InvestmentCompanyRegistrationAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment"
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "InvestmentCompanyRegistrationAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment Number"
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "us-gaap_InvestmentIncomeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentIncomeNet",
     "crdr": "credit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment income",
        "label": "Investment Income, Net",
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r53",
      "r55"
     ]
    },
    "us-gaap_InvestmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentTextBlock",
     "presentation": [
      "http://ionis.com/role/Investments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "label": "Investment [Text Block]",
        "documentation": "The entire disclosure for investment."
       }
      }
     },
     "auth_ref": [
      "r953",
      "r954",
      "r1037"
     ]
    },
    "us-gaap_InvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "presentation": [
      "http://ionis.com/role/InvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract Maturity of Available-for-Sale Securities",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments."
       }
      }
     },
     "auth_ref": []
    },
    "ions_IonisOperationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "IonisOperationsMember",
     "presentation": [
      "http://ionis.com/role/SegmentInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ionis Operations [Member]",
        "documentation": "Operations focused on the research, development and commercialization of RNA-targeted medicines to bring better futures to people with serious diseases.",
        "label": "Ionis Operations Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LandMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LandMember",
     "presentation": [
      "http://ionis.com/role/OperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Undeveloped Land in Carlsbad, California [Member]",
        "label": "Land [Member]",
        "documentation": "Part of earth's surface not covered by water."
       }
      }
     },
     "auth_ref": [
      "r1062",
      "r1063"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityIdentifier": {
     "xbrltype": "legalEntityIdentifierItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LegalEntityIdentifier",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity Identifier",
        "documentation": "A globally unique ISO 17442 value to identify entities, commonly abbreviated as LEI."
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LegalMattersAndContingenciesTextBlock",
     "presentation": [
      "http://ionis.com/role/LegalProceedings"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal Proceedings",
        "label": "Legal Matters and Contingencies [Text Block]",
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://ionis.com/role/OperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Leases [Abstract]",
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r551",
      "r556"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://ionis.com/role/OperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r551",
      "r556"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "presentation": [
      "http://ionis.com/role/OperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease payments to be made over initial term of lease",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r554",
      "r1015",
      "r1019",
      "r1127"
     ]
    },
    "ions_LesseeOperatingLeaseNumberOfOptionsToExtendLease": {
     "xbrltype": "integerItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "LesseeOperatingLeaseNumberOfOptionsToExtendLease",
     "presentation": [
      "http://ionis.com/role/OperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of options to extend lease (in Option)",
        "documentation": "The number of options to extend the lease under the lessee's operating lease.",
        "label": "Lessee Operating Lease Number Of Options To Extend Lease"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://ionis.com/role/OperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term of lease extension",
        "label": "Lessee, Operating Lease, Renewal Term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1118"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://ionis.com/role/OperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial term of lease",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1118"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://ionis.com/role/OperatingLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r547"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r29",
      "r30",
      "r31",
      "r33",
      "r34",
      "r35",
      "r36",
      "r147",
      "r149",
      "r150",
      "r267",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r471",
      "r472",
      "r473",
      "r530",
      "r671",
      "r745",
      "r766",
      "r826",
      "r1058",
      "r1119",
      "r1120"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r80",
      "r610",
      "r805",
      "r812",
      "r813",
      "r1014",
      "r1018",
      "r1046",
      "r1112"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://ionis.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r111",
      "r147",
      "r149",
      "r150",
      "r267",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r471",
      "r472",
      "r473",
      "r530",
      "r805",
      "r1058",
      "r1119",
      "r1120"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://ionis.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ions_LiabilityRelatedToSaleOfFutureRoyaltiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "LiabilityRelatedToSaleOfFutureRoyaltiesNet",
     "crdr": "credit",
     "presentation": [
      "http://ionis.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Liability related to sale of future royalties, net",
        "periodEndLabel": "Liability related to sale of future royalties, net",
        "documentation": "Amount, after accumulated amortization, of the unamortized liability related to the sale of future royalties, pursuant to a royalty purchase agreement, that the Company is entitled to receive under collaboration agreements with Biogen and Novartis. The balance will be amortized over the estimated life of the arrangement using the effective interest rate method.",
        "label": "Liability Related To Sale Of Future Royalties Net"
       }
      }
     },
     "auth_ref": []
    },
    "ions_LiabilityRelatedToSaleOfFutureRoyaltiesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "LiabilityRelatedToSaleOfFutureRoyaltiesNetCurrent",
     "crdr": "credit",
     "presentation": [
      "http://ionis.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Current portion",
        "documentation": "Amount, after accumulated amortization, of the unamortized liability related to the sale of future royalties, pursuant to a royalty purchase agreement, that the Company is entitled to receive under collaboration agreements with Biogen and Novartis. The balance will be amortized over the estimated life of the arrangement using the effective interest rate method. Used to reflect the current portion of the liability (due within one year or within the normal operating cycle if longer).",
        "label": "Liability Related To Sale Of Future Royalties Net Current"
       }
      }
     },
     "auth_ref": []
    },
    "ions_LiabilityRelatedToSaleOfFutureRoyaltiesNetNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "LiabilityRelatedToSaleOfFutureRoyaltiesNetNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedBalanceSheet",
      "http://ionis.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability related to sale of future royalties, net",
        "verboseLabel": "Liability related to sale of future royalties, net - Non-current",
        "documentation": "Amount, after accumulated amortization, of the unamortized liability related to the sale of future royalties, pursuant to a royalty purchase agreement, that the Company is entitled to receive under collaboration agreements with Biogen and Novartis. The balance will be amortized over the estimated life of the arrangement using the effective interest rate method. Used to reflect the noncurrent portion of the liability (due after one year or beyond the operating cycle if longer).",
        "label": "Liability Related To Sale Of Future Royalties Net Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "ions_LicenseOfSapablursenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "LicenseOfSapablursenMember",
     "presentation": [
      "http://ionis.com/role/CollaborativeArrangementsandLicensingAgreementsDetailsOno"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License of Sapablursen [Member]",
        "documentation": "License of sapablursen, an investigational RNA-targeted medicine for polycythemia vera (PV), a rare and potentially life-threatening hematologic disease.",
        "label": "License Of Sapablursen Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "ions_ManufacturingAndDevelopmentChemistryExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "ManufacturingAndDevelopmentChemistryExpenses",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/SegmentInformationTable": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://ionis.com/role/SegmentInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Manufacturing and development chemistry",
        "documentation": "Expenses related to manufacturing and development chemistry for providing drug supplies to drug development and our collaboration partners, including personnel costs, specialized chemicals for oligonucleotide manufacturing, validation batches to support regulatory approvals, laboratory supplies and outside services.",
        "label": "Manufacturing And Development Chemistry Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ions_MaximumAmountOfAnnualSalesOnWhichRoyaltyPaymentsArePaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "MaximumAmountOfAnnualSalesOnWhichRoyaltyPaymentsArePaid",
     "crdr": "credit",
     "presentation": [
      "http://ionis.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum amount of annual sales on which royalty payments are paid",
        "documentation": "The maximum amount of annual sales on which royalty payments are paid under the royalty purchase agreement.",
        "label": "Maximum Amount Of Annual Sales On Which Royalty Payments Are Paid"
       }
      }
     },
     "auth_ref": []
    },
    "ions_MaximumAmountOfDevelopmentMilestonePaymentsOverTermOfCollaboration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "MaximumAmountOfDevelopmentMilestonePaymentsOverTermOfCollaboration",
     "crdr": "debit",
     "presentation": [
      "http://ionis.com/role/CollaborativeArrangementsandLicensingAgreementsDetailsOno"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum amount of development milestone payments over term of collaboration",
        "documentation": "The maximum amount of development milestone payments to be received over the term of the collaboration.",
        "label": "Maximum Amount Of Development Milestone Payments Over Term Of Collaboration"
       }
      }
     },
     "auth_ref": []
    },
    "ions_MaximumAmountOfPaymentsReceivableForAdditionalMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "MaximumAmountOfPaymentsReceivableForAdditionalMilestones",
     "crdr": "debit",
     "presentation": [
      "http://ionis.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum amount of payments receivable for additional milestones",
        "documentation": "The maximum amount of payments receivable for additional milestones under the royalty purchase agreement.",
        "label": "Maximum Amount Of Payments Receivable For Additional Milestones"
       }
      }
     },
     "auth_ref": []
    },
    "ions_MaximumAmountOfPaymentsReceivableOverTermOfCollaboration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "MaximumAmountOfPaymentsReceivableOverTermOfCollaboration",
     "crdr": "debit",
     "presentation": [
      "http://ionis.com/role/CollaborativeArrangementsandLicensingAgreementsDetailsOno"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum amount of payments receivable over term of collaboration",
        "documentation": "The maximum amount of payments the Company is eligible to receive over the term of the collaboration.",
        "label": "Maximum Amount Of Payments Receivable Over Term Of Collaboration"
       }
      }
     },
     "auth_ref": []
    },
    "ions_MaximumAmountOfRegulatoryMilestonePaymentsOverTermOfCollaboration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "MaximumAmountOfRegulatoryMilestonePaymentsOverTermOfCollaboration",
     "crdr": "debit",
     "presentation": [
      "http://ionis.com/role/CollaborativeArrangementsandLicensingAgreementsDetailsOno"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum amount of regulatory milestone payments over term of collaboration",
        "documentation": "The maximum amount of regulatory milestone payments to be received over the term of the collaboration.",
        "label": "Maximum Amount Of Regulatory Milestone Payments Over Term Of Collaboration"
       }
      }
     },
     "auth_ref": []
    },
    "ions_MaximumAmountOfSalesMilestonePaymentsOverTermOfCollaboration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "MaximumAmountOfSalesMilestonePaymentsOverTermOfCollaboration",
     "crdr": "debit",
     "presentation": [
      "http://ionis.com/role/CollaborativeArrangementsandLicensingAgreementsDetailsOno"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum amount of sales milestone payments over term of collaboration",
        "documentation": "The maximum amount of sales milestone payments to be received over the term of the collaboration.",
        "label": "Maximum Amount Of Sales Milestone Payments Over Term Of Collaboration"
       }
      }
     },
     "auth_ref": []
    },
    "ions_MaximumAmountOfUpfrontPaymentsOverTermOfCollaboration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "MaximumAmountOfUpfrontPaymentsOverTermOfCollaboration",
     "crdr": "debit",
     "presentation": [
      "http://ionis.com/role/CollaborativeArrangementsandLicensingAgreementsDetailsOno"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum amount of upfront payments over term of collaboration",
        "documentation": "The maximum amount of upfront payments to be received over the term of the collaboration.",
        "label": "Maximum Amount Of Upfront Payments Over Term Of Collaboration"
       }
      }
     },
     "auth_ref": []
    },
    "ions_MaximumContractMaturityPeriodRange1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "MaximumContractMaturityPeriodRange1",
     "presentation": [
      "http://ionis.com/role/InvestmentsDetailsContractMaturityofAvailableforSaleSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum contract maturity period, range 1",
        "documentation": "The maximum contract maturity period for the first range of available-for-sale securities, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Maximum Contract Maturity Period Range1"
       }
      }
     },
     "auth_ref": []
    },
    "ions_MaximumContractMaturityPeriodRange2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "MaximumContractMaturityPeriodRange2",
     "presentation": [
      "http://ionis.com/role/InvestmentsDetails",
      "http://ionis.com/role/InvestmentsDetailsContractMaturityofAvailableforSaleSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum contract maturity period, range 2",
        "documentation": "The maximum contract maturity period for the second range of available-for-sale securities, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Maximum Contract Maturity Period Range2"
       }
      }
     },
     "auth_ref": []
    },
    "ions_MaximumContractMaturityPeriodRange3": {
     "xbrltype": "durationItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "MaximumContractMaturityPeriodRange3",
     "presentation": [
      "http://ionis.com/role/InvestmentsDetailsContractMaturityofAvailableforSaleSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum contract maturity period, range 3",
        "documentation": "The maximum contract maturity period for the third range of available-for-sale securities, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Maximum Contract Maturity Period Range3"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://ionis.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesDetails",
      "http://ionis.com/role/StockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum [Member]",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r189",
      "r306",
      "r307",
      "r308",
      "r309",
      "r397",
      "r426",
      "r427",
      "r428",
      "r440",
      "r510",
      "r590",
      "r640",
      "r642",
      "r650",
      "r663",
      "r664",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r718",
      "r719",
      "r720",
      "r721",
      "r723",
      "r724",
      "r758",
      "r767",
      "r781",
      "r784",
      "r786",
      "r787",
      "r795",
      "r796",
      "r800",
      "r801",
      "r808",
      "r1060",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126"
     ]
    },
    "ions_MaximumRoyaltyPaymentsMadeBeforeRoyaltyInterestRevertsBack": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "MaximumRoyaltyPaymentsMadeBeforeRoyaltyInterestRevertsBack",
     "crdr": "credit",
     "presentation": [
      "http://ionis.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum royalty payments made before royalty interest reverts back",
        "documentation": "Maximum royalty payments under the royalty purchase agreement made before royalty interest reverts back to the Company.",
        "label": "Maximum Royalty Payments Made Before Royalty Interest Reverts Back"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "ions_MedicalAffairsExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "MedicalAffairsExpenses",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/SegmentInformationTable": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://ionis.com/role/SegmentInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medical affairs",
        "documentation": "Expenses related to medical affairs for funding and coordinating investigator-sponsored trials, communicating scientific and clinical information to healthcare providers, medical professionals and patients, and managing publications.",
        "label": "Medical Affairs Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://ionis.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesDetails",
      "http://ionis.com/role/StockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum [Member]",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r189",
      "r306",
      "r307",
      "r308",
      "r309",
      "r397",
      "r426",
      "r427",
      "r428",
      "r440",
      "r510",
      "r590",
      "r640",
      "r642",
      "r650",
      "r663",
      "r664",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r718",
      "r719",
      "r720",
      "r721",
      "r723",
      "r724",
      "r758",
      "r767",
      "r781",
      "r784",
      "r786",
      "r787",
      "r795",
      "r796",
      "r800",
      "r808",
      "r1060",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "dei_NameChangeEventDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NameChangeEventDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event Date [Axis]",
        "documentation": "For a sequence of name change event related facts, use this typed dimension to distinguish them. The axis members are restricted to be a valid for xml schema 'date' or 'datetime' data type."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NameChangeEventLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Line Items]",
        "documentation": "Line items represent concepts included in a table. Name change event line item concepts are used for information qualified by domain members of axes in the Name Change Event table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NameChangeEventTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Table]",
        "documentation": "For a set of related facts in a sequence of name change events, use this table when the events occurred within a single reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://ionis.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing activities:",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) investing activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://ionis.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investing activities:",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://ionis.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r63",
      "r64"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://ionis.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating activities:",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedComprehensiveIncome": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://ionis.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://ionis.com/role/ConsolidatedIncomeStatement": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://ionis.com/role/SegmentInformationTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedCashFlow",
      "http://ionis.com/role/ConsolidatedComprehensiveIncome",
      "http://ionis.com/role/ConsolidatedIncomeStatement",
      "http://ionis.com/role/SegmentInformationTable",
      "http://ionis.com/role/ShareholdersEquityType2or3",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss",
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r64",
      "r84",
      "r104",
      "r109",
      "r124",
      "r126",
      "r130",
      "r147",
      "r149",
      "r150",
      "r152",
      "r156",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r167",
      "r168",
      "r174",
      "r267",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r351",
      "r354",
      "r356",
      "r359",
      "r437",
      "r461",
      "r466",
      "r504",
      "r530",
      "r613",
      "r691",
      "r707",
      "r708",
      "r735",
      "r737",
      "r739",
      "r824",
      "r1058"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://ionis.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Standards",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NewEffectiveDateForPreviousFiling": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NewEffectiveDateForPreviousFiling",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Effective Date for Previous Filing"
       }
      }
     },
     "auth_ref": [
      "r867",
      "r868",
      "r869",
      "r870"
     ]
    },
    "ions_NextPaymentToBeAchieved": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "NextPaymentToBeAchieved",
     "crdr": "debit",
     "presentation": [
      "http://ionis.com/role/CollaborativeArrangementsandLicensingAgreementsDetailsAstraZeneca",
      "http://ionis.com/role/CollaborativeArrangementsandLicensingAgreementsDetailsOno"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Next payment to be achieved",
        "documentation": "The next payment to be achieved under the collaboration agreement.",
        "label": "Next Payment To Be Achieved"
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoSubstantiveChanges462c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoSubstantiveChanges462c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c)"
       }
      }
     },
     "auth_ref": [
      "r941"
     ]
    },
    "dei_NoSubstantiveChanges462cFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoSubstantiveChanges462cFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c), File Number"
       }
      }
     },
     "auth_ref": [
      "r941"
     ]
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r851",
      "r862",
      "r878",
      "r904",
      "r913"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://ionis.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense):",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesPayableFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NotesPayableFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://ionis.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible notes",
        "label": "Notes Payable, Fair Value Disclosure",
        "documentation": "Fair value portion of notes payable."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r29",
      "r30",
      "r1102",
      "r1106",
      "r1108",
      "r1109",
      "r1110",
      "r1111"
     ]
    },
    "ions_NumberOfCollaborationAgreements": {
     "xbrltype": "integerItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "NumberOfCollaborationAgreements",
     "presentation": [
      "http://ionis.com/role/CollaborativeArrangementsandLicensingAgreementsDetailsAstraZeneca"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of collaboration agreements (in Agreement)",
        "documentation": "The number of collaboration agreements with the collaboration partner.",
        "label": "Number Of Collaboration Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "ions_NumberOfLotsOfUndevelopedLandTransferredToRealEstateInvestor": {
     "xbrltype": "integerItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "NumberOfLotsOfUndevelopedLandTransferredToRealEstateInvestor",
     "presentation": [
      "http://ionis.com/role/OperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of lots of undeveloped land transferred to real estate investor (in Lot)",
        "documentation": "Number of lots of undeveloped land adjacent to the Company's headquarters transferred to real estate investor.",
        "label": "Number Of Lots Of Undeveloped Land Transferred To Real Estate Investor"
       }
      }
     },
     "auth_ref": []
    },
    "ions_NumberOfMaterialComponents": {
     "xbrltype": "integerItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "NumberOfMaterialComponents",
     "presentation": [
      "http://ionis.com/role/RevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of material components (in Component)",
        "documentation": "The number of material components identified in the collaboration agreement under Accounting Standards Codification (ASC) 808, Collaborative Arrangements.",
        "label": "Number Of Material Components"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://ionis.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r753",
      "r1031"
     ]
    },
    "ions_NumberOfPerformanceObligationsIdentified": {
     "xbrltype": "integerItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "NumberOfPerformanceObligationsIdentified",
     "presentation": [
      "http://ionis.com/role/CollaborativeArrangementsandLicensingAgreementsDetailsOno"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of performance obligations identified (in PerformanceObligation)",
        "documentation": "The number of performance obligations identified under the collaboration agreement.",
        "label": "Number Of Performance Obligations Identified"
       }
      }
     },
     "auth_ref": []
    },
    "ions_NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment": {
     "xbrltype": "integerItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment",
     "presentation": [
      "http://ionis.com/role/InvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of private companies in which there is an equity ownership interest of less than 20% (in Company)",
        "documentation": "Number of privately-held companies, in which the entity has an equity ownership interest of less than 20%, with which it conducts business. These are accounted for under the cost method.",
        "label": "Number Of Privately Held Companies In Which Entity Has Equity Investment"
       }
      }
     },
     "auth_ref": []
    },
    "ions_NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment": {
     "xbrltype": "integerItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment",
     "presentation": [
      "http://ionis.com/role/InvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of public companies in which there is an equity ownership interest of less than 20% (in Company)",
        "documentation": "Number of publicly-held companies, in which the entity has an equity ownership interest of less than 20%, with which it conducts business. These are accounted for at fair value.",
        "label": "Number Of Publicly Held Companies In Which Entity Has Equity Investment"
       }
      }
     },
     "auth_ref": []
    },
    "ions_NumberOfPurchaseAndSaleAgreementsEnteredIntoWithRealEstateInvestor": {
     "xbrltype": "integerItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "NumberOfPurchaseAndSaleAgreementsEnteredIntoWithRealEstateInvestor",
     "presentation": [
      "http://ionis.com/role/OperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of purchase and sale agreements entered into with real estate investor (in Agreement)",
        "documentation": "Number of purchase and sale agreements entered into with a real estate investor.",
        "label": "Number Of Purchase And Sale Agreements Entered Into With Real Estate Investor"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://ionis.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r747",
      "r757",
      "r1031"
     ]
    },
    "ions_OnoCollaborationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "OnoCollaborationMember",
     "presentation": [
      "http://ionis.com/role/CollaborativeArrangementsandLicensingAgreementsDetailsOno",
      "http://ionis.com/role/CollaborativeArrangementsandLicensingAgreementsTables",
      "http://ionis.com/role/RevenuefromCollaborativeRelationshipwithOnoTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ono [Member]",
        "documentation": "Collaboration agreement entered into with Ono Pharmaceutical, Ltd (Ono) in March 2025 to develop and commercialize sapablursen, an investigational RNA-targeted medicine for the potential treatment of polycythemia vera, a rare and potentially life-threatening hematologic disease.",
        "label": "Ono Collaboration Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r735",
      "r739",
      "r746",
      "r1024",
      "r1032",
      "r1033",
      "r1034",
      "r1035"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term lease liabilities",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r550"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r549"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of right-of-use operating lease assets",
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r1012"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Basis of Presentation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://ionis.com/role/OrganizationandBasisofPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization and Basis of Presentation",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r105",
      "r106",
      "r107",
      "r654",
      "r655"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://ionis.com/role/AccruedLiabilitiesTable": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://ionis.com/role/AccruedLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other miscellaneous expenses",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "dei_OtherAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Address [Member]",
        "documentation": "Other address for entity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r805"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deposits and other assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "ions_OtherCommercialMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "OtherCommercialMember",
     "presentation": [
      "http://ionis.com/role/ConsolidatedIncomeStatement",
      "http://ionis.com/role/RevenuesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commercial Revenue [Member]",
        "documentation": "Revenue from the sale of other medicines commercially as well as licensing and royalty revenue from other medicines, including TEGSEDI and WAYLIVRA.",
        "label": "Other Commercial Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedComprehensiveIncome": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedComprehensiveIncome",
      "http://ionis.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency translation adjustment",
        "verboseLabel": "Foreign currency translation",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax",
        "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r44",
      "r45",
      "r46",
      "r534",
      "r535",
      "r536"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedComprehensiveIncome": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedComprehensiveIncome",
      "http://ionis.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gains on debt securities, net of tax",
        "verboseLabel": "Change in unrealized gains, net of tax",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r123",
      "r265"
     ]
    },
    "us-gaap_OtherCurrentAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCurrentAssetsMember",
     "presentation": [
      "http://ionis.com/role/FairValueMeasurementsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Current Assets [Member]",
        "label": "Other Current Assets [Member]",
        "documentation": "Primary financial statement caption encompassing other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCurrentLiabilitiesMember",
     "presentation": [
      "http://ionis.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Current Liabilities [Member]",
        "label": "Other Current Liabilities [Member]",
        "documentation": "Primary financial statement caption encompassing other current liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherDebtSecuritiesMember",
     "presentation": [
      "http://ionis.com/role/FairValueMeasurementsTable",
      "http://ionis.com/role/SummaryofInvestmentsTable",
      "http://ionis.com/role/TemporarilyImpairedInvestmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Municipal Debt Securities [Member]",
        "label": "Other Debt Obligations [Member]",
        "documentation": "Investments in debt securities classified as other."
       }
      }
     },
     "auth_ref": [
      "r1048",
      "r1064",
      "r1065"
     ]
    },
    "us-gaap_OtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ionis.com/role/OperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial liability for sale-leaseback transaction",
        "label": "Other Liabilities",
        "documentation": "Amount of liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r606",
      "r667",
      "r668",
      "r766",
      "r812",
      "r813",
      "r826",
      "r1129",
      "r1163"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current liabilities",
        "label": "Other Liabilities, Current",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r805"
     ]
    },
    "us-gaap_OtherLiabilitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLiabilitiesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability Related to Sale of Future Royalties [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://ionis.com/role/LiabilityRelatedtoSaleofFutureRoyalties"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability Related to Sale of Future Royalties",
        "label": "Other Liabilities Disclosure [Text Block]",
        "documentation": "The entire disclosure for other liabilities."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r34",
      "r1051"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term obligations",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNoncurrentAssetsMember",
     "presentation": [
      "http://ionis.com/role/InventoriesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deposits and Other Assets [Member]",
        "label": "Other Noncurrent Assets [Member]",
        "documentation": "Primary financial statement caption encompassing other noncurrent assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNoncurrentLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNoncurrentLiabilitiesTableTextBlock",
     "presentation": [
      "http://ionis.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability Related to Sale of Future Royalties",
        "label": "Other Noncurrent Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of other noncurrent liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income, net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r788"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "ions_OtherRoyaltiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "OtherRoyaltiesMember",
     "presentation": [
      "http://ionis.com/role/RevenuesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Royalties [Member]",
        "documentation": "Revenue from other royalties excluding SPINRAZA and WAINUA.",
        "label": "Other Royalties Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r849",
      "r860",
      "r876",
      "r911"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r852",
      "r863",
      "r879",
      "r914"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r852",
      "r863",
      "r879",
      "r914"
     ]
    },
    "dei_ParentEntityLegalName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ParentEntityLegalName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parent Entity Legal Name",
        "documentation": "If the entity which the financial information concerns is a subsidiary of another company, then provide to full legal name of the parent entity"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "us-gaap_PaymentsForHedgeFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForHedgeFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://ionis.com/role/ConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase of note hedges (in Dollars)",
        "label": "Payments for Hedge, Financing Activities",
        "documentation": "The cash outflow for a financial contract that meets the hedge criteria as either cash flow hedge, fair value hedge or hedge of net investment in foreign operations."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r950"
     ]
    },
    "ions_PaymentsForTransactionCostsRelatedToSaleOfFutureRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "PaymentsForTransactionCostsRelatedToSaleOfFutureRoyalties",
     "crdr": "credit",
     "presentation": [
      "http://ionis.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transaction costs",
        "documentation": "The cash outflow paid to third parties for transaction costs in connection with a monetization transaction of future SPINRAZA and pelacarsen royalties the Company is entitled to under collaboration and licensing agreements.",
        "label": "Payments For Transaction Costs Related To Sale Of Future Royalties"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "crdr": "credit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of short-term investments",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r136",
      "r233"
     ]
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Acquisition of licenses and other assets, net",
        "label": "Payments to Acquire Intangible Assets",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property, plant and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "ions_PelacarsenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "PelacarsenMember",
     "presentation": [
      "http://ionis.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pelacarsen [Member]",
        "documentation": "Pelacarsen, also known as IONIS-APO(a)-L, AKCEA-APO(a)-L, and TQJ230, is an investigational antisense medicine designed to reduce apolipoprotein(a) in the liver in patients suffering from high levels of the lipoprotein Lp(a).",
        "label": "Pelacarsen Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "ions_PercentageOfCostsAssociatedWithOngoingGlobalPhase3DevelopmentProgramPaidByCollaborationPartner": {
     "xbrltype": "percentItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "PercentageOfCostsAssociatedWithOngoingGlobalPhase3DevelopmentProgramPaidByCollaborationPartner",
     "presentation": [
      "http://ionis.com/role/RevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of costs associated with ongoing global Phase 3 development program paid by AstraZeneca",
        "documentation": "Percentage of costs associated with the ongoing global Phase 3 development program paid by a collaboration partner under the collaboration agreement.",
        "label": "Percentage Of Costs Associated With Ongoing Global Phase3 Development Program Paid By Collaboration Partner"
       }
      }
     },
     "auth_ref": []
    },
    "ions_PercentageOfRoyaltyPaymentsPaidOnAnnualSalesOfMedicine": {
     "xbrltype": "percentItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "PercentageOfRoyaltyPaymentsPaidOnAnnualSalesOfMedicine",
     "presentation": [
      "http://ionis.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of royalty payments paid on annual sales of medicine",
        "documentation": "The percentage of royalty payments paid on annual sales of medicine.",
        "label": "Percentage Of Royalty Payments Paid On Annual Sales Of Medicine"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PerformanceSharesMember",
     "presentation": [
      "http://ionis.com/role/StockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PRSUs [Member]",
        "label": "Performance Shares [Member]",
        "documentation": "Share-based payment arrangement awarded for meeting performance target."
       }
      }
     },
     "auth_ref": [
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092"
     ]
    },
    "dei_PhoneFaxNumberDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PhoneFaxNumberDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Phone Fax Number Description",
        "documentation": "Description of Phone or Fax Number"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r888"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "dei_PostEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PostEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "dei_PostEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PostEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "dei_PreEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "dei_PreEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock in public offering, net",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock through equity plans, net",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised",
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r9"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://ionis.com/role/ConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of warrants (in Dollars)",
        "label": "Proceeds from Issuance of Warrants",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of short-term investments",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r137",
      "r1039"
     ]
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://ionis.com/role/OperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of real estate assets",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_ProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProductMember",
     "presentation": [
      "http://ionis.com/role/ConsolidatedIncomeStatement",
      "http://ionis.com/role/RevenuesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product Sales, Net [Member]",
        "label": "Product [Member]",
        "documentation": "Article or substance produced by nature, labor or machinery."
       }
      }
     },
     "auth_ref": [
      "r734",
      "r739",
      "r768",
      "r769"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://ionis.com/role/CollaborativeArrangementsandLicensingAgreementsDetailsOno",
      "http://ionis.com/role/ConsolidatedIncomeStatement",
      "http://ionis.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesDetails",
      "http://ionis.com/role/RevenuesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r228",
      "r592",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r728",
      "r734",
      "r737",
      "r739",
      "r768",
      "r769",
      "r807",
      "r808",
      "r809",
      "r811",
      "r815",
      "r951",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1056",
      "r1057",
      "r1130",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1160",
      "r1161"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://ionis.com/role/CollaborativeArrangementsandLicensingAgreementsDetailsOno",
      "http://ionis.com/role/ConsolidatedIncomeStatement",
      "http://ionis.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesDetails",
      "http://ionis.com/role/RevenuesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r228",
      "r592",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r728",
      "r734",
      "r737",
      "r739",
      "r768",
      "r769",
      "r807",
      "r808",
      "r809",
      "r811",
      "r815",
      "r951",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1056",
      "r1057",
      "r1130",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1160",
      "r1161"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://ionis.com/role/OperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r555"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r555",
      "r601",
      "r611",
      "r805"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://ionis.com/role/OperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r555"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://ionis.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesDetails",
      "http://ionis.com/role/StockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r189",
      "r306",
      "r307",
      "r308",
      "r309",
      "r387",
      "r397",
      "r426",
      "r427",
      "r428",
      "r436",
      "r440",
      "r510",
      "r565",
      "r574",
      "r590",
      "r640",
      "r642",
      "r650",
      "r663",
      "r664",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r718",
      "r719",
      "r720",
      "r721",
      "r723",
      "r724",
      "r758",
      "r767",
      "r781",
      "r784",
      "r786",
      "r787",
      "r795",
      "r796",
      "r800",
      "r801",
      "r808",
      "r818",
      "r1055",
      "r1060",
      "r1104",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://ionis.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesDetails",
      "http://ionis.com/role/StockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r189",
      "r306",
      "r307",
      "r308",
      "r309",
      "r387",
      "r397",
      "r426",
      "r427",
      "r428",
      "r436",
      "r440",
      "r510",
      "r565",
      "r574",
      "r590",
      "r640",
      "r642",
      "r650",
      "r663",
      "r664",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r718",
      "r719",
      "r720",
      "r721",
      "r723",
      "r724",
      "r758",
      "r767",
      "r781",
      "r784",
      "r786",
      "r787",
      "r795",
      "r796",
      "r800",
      "r801",
      "r808",
      "r818",
      "r1055",
      "r1060",
      "r1104",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126"
     ]
    },
    "us-gaap_RealizedInvestmentGainsLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RealizedInvestmentGainsLosses",
     "crdr": "credit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss (gain) on investments, net",
        "label": "Realized Investment Gains (Losses)",
        "documentation": "Amount of realized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r844",
      "r855",
      "r871",
      "r906"
     ]
    },
    "dei_RegistrationStatementAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "RegistrationStatementAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration Statement Amendment Number",
        "documentation": "Amendment number to registration statement under the Investment Company Act of 1940."
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "us-gaap_RepaymentsOfSecuredDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RepaymentsOfSecuredDebt",
     "crdr": "credit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Principal payments on mortgage debt",
        "label": "Repayments of Secured Debt",
        "documentation": "The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "ions_ReportedAsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "ReportedAsAbstract",
     "presentation": [
      "http://ionis.com/role/InventoriesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reported as:",
        "label": "Reported As Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ions_ResearchAndDevelopmentRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "ResearchAndDevelopmentRevenueMember",
     "presentation": [
      "http://ionis.com/role/ConsolidatedIncomeStatement",
      "http://ionis.com/role/RevenuesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Revenue [Member]",
        "documentation": "Revenue from research and development services.",
        "label": "Research And Development Revenue Member"
       }
      }
     },
     "auth_ref": []
    },
    "ions_ResearchAndDevelopmentServicesForSapablursenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "ResearchAndDevelopmentServicesForSapablursenMember",
     "presentation": [
      "http://ionis.com/role/CollaborativeArrangementsandLicensingAgreementsDetailsOno"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "R&amp;D Services for Sapablursen [Member]",
        "documentation": "Research and development (R&amp;D) services for sapablursen, an investigational RNA-targeted medicine for polycythemia vera (PV), a rare and potentially life-threatening hematologic disease.",
        "label": "Research And Development Services For Sapablursen Member"
       }
      }
     },
     "auth_ref": []
    },
    "ions_ResearchAndDevelopmentSupportExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "ResearchAndDevelopmentSupportExpenses",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/SegmentInformationTable": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://ionis.com/role/SegmentInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "R&amp;D support",
        "documentation": "Expenses related to research and development support such as rent, repair and maintenance for buildings and equipment, utilities, depreciation of laboratory equipment and facilities, amortization of intellectual property, information technology costs, procurement costs and waste disposal costs.",
        "label": "Research And Development Support Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ions_ResearchDevelopmentAndPatentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "ResearchDevelopmentAndPatentExpense",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research, development and patent",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects. Also includes charges for amortization and write-downs of capitalized patent costs, as well as legal fees for patent litigation and patent defense.",
        "label": "Research Development And Patent Expense"
       }
      }
     },
     "auth_ref": []
    },
    "ions_ResearchDevelopmentAndPatentExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "ResearchDevelopmentAndPatentExpensesMember",
     "presentation": [
      "http://ionis.com/role/StockbasedCompensationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research, Development and Patent Expense [Member]",
        "documentation": "Primary financial statement caption encompassing research, development and patent expenses.",
        "label": "Research Development And Patent Expenses Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r845",
      "r856",
      "r872",
      "r907"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r846",
      "r857",
      "r873",
      "r908"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r853",
      "r864",
      "r880",
      "r915"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://ionis.com/role/StockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSUs [Member]",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r72",
      "r609",
      "r647",
      "r649",
      "r658",
      "r673",
      "r805"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://ionis.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit [Member]",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r153",
      "r154",
      "r155",
      "r157",
      "r164",
      "r166",
      "r168",
      "r268",
      "r269",
      "r294",
      "r350",
      "r437",
      "r451",
      "r452",
      "r458",
      "r459",
      "r460",
      "r462",
      "r465",
      "r466",
      "r491",
      "r493",
      "r494",
      "r496",
      "r502",
      "r546",
      "r548",
      "r644",
      "r646",
      "r660",
      "r1166"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "presentation": [
      "http://ionis.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://ionis.com/role/SegmentInformationTable": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ionis.com/role/CollaborativeArrangementsandLicensingAgreementsDetailsAstraZeneca",
      "http://ionis.com/role/CollaborativeArrangementsandLicensingAgreementsDetailsOno",
      "http://ionis.com/role/ConsolidatedIncomeStatement",
      "http://ionis.com/role/RevenuefromCollaborativeRelationshipwithAstraZenecaTable",
      "http://ionis.com/role/RevenuefromCollaborativeRelationshipwithOnoTable",
      "http://ionis.com/role/RevenuesTable",
      "http://ionis.com/role/SegmentInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r86",
      "r183",
      "r195",
      "r196",
      "r218",
      "r224",
      "r228",
      "r230",
      "r231",
      "r382",
      "r383",
      "r384",
      "r592",
      "r735",
      "r739"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerMember",
     "presentation": [
      "http://ionis.com/role/RevenuefromCollaborativeRelationshipwithAstraZenecaTable",
      "http://ionis.com/role/RevenuefromCollaborativeRelationshipwithOnoTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue [Member]",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r1026",
      "r1027"
     ]
    },
    "ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations": {
     "xbrltype": "integerItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations",
     "presentation": [
      "http://ionis.com/role/RevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of performance obligations (in PerformanceObligation)",
        "documentation": "The number of separate performance obligations under the collaboration agreement.",
        "label": "Revenue From Contract With Customer Number Of Separate Performance Obligations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://ionis.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r726"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://ionis.com/role/Revenues"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues",
        "label": "Revenue from Contract with Customer [Text Block]",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r365",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r384",
      "r386"
     ]
    },
    "ions_RevenueFromContractWithCustomerTransactionPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "RevenueFromContractWithCustomerTransactionPrice",
     "crdr": "credit",
     "presentation": [
      "http://ionis.com/role/CollaborativeArrangementsandLicensingAgreementsDetailsOno",
      "http://ionis.com/role/RevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transaction price",
        "documentation": "The amount of consideration the Company earned or is eligible to earn under the collaboration agreement, including any variable consideration.",
        "label": "Revenue From Contract With Customer Transaction Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://ionis.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets obtained in exchange for lease obligations",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r553",
      "r804"
     ]
    },
    "us-gaap_RoyaltyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RoyaltyMember",
     "presentation": [
      "http://ionis.com/role/ConsolidatedIncomeStatement",
      "http://ionis.com/role/RevenuesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty Revenue [Member]",
        "verboseLabel": "Royalty [Member]",
        "label": "Royalty [Member]",
        "documentation": "Money for usage-based right to asset."
       }
      }
     },
     "auth_ref": [
      "r1062",
      "r1063"
     ]
    },
    "ions_RoyaltyPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "RoyaltyPayments",
     "crdr": "credit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedCashFlow",
      "http://ionis.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Non-cash royalty revenue related to sale of royalties",
        "negatedTerseLabel": "Royalty payments to Royalty Pharma",
        "documentation": "The amount of royalty payments made during the period under a royalty purchase agreement.",
        "label": "Royalty Payments"
       }
      }
     },
     "auth_ref": []
    },
    "ions_RoyaltyPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "RoyaltyPurchaseAgreementMember",
     "presentation": [
      "http://ionis.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesDetails",
      "http://ionis.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty Purchase Agreement [Member]",
        "documentation": "In January 2023, the Company entered into a royalty purchase agreement with Royalty Pharma to monetize a portion of future SPINRAZA and pelacarsen royalties the Company is entitled to under arrangements with Biogen and Novartis, respectively.",
        "label": "Royalty Purchase Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "us-gaap_SaleAndLeasebackTransactionGainLossNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleAndLeasebackTransactionGainLossNet",
     "crdr": "credit",
     "presentation": [
      "http://ionis.com/role/OperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain on sale-leaseback transaction",
        "label": "Sale and Leaseback Transaction, Gain (Loss), Net",
        "documentation": "Amount of gain (loss) on sale and leaseback transaction from transfer of asset accounted for as sale."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r552",
      "r557",
      "r804"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://ionis.com/role/SupplementalFinancialDataTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Liabilities",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://ionis.com/role/TemporarilyImpairedInvestmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments [Abstract]",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://ionis.com/role/CollaborativeArrangementsandLicensingAgreements",
      "http://ionis.com/role/CollaborativeArrangementsandLicensingAgreementsDetailsAstraZeneca",
      "http://ionis.com/role/CollaborativeArrangementsandLicensingAgreementsDetailsOno",
      "http://ionis.com/role/CollaborativeArrangementsandLicensingAgreementsTables",
      "http://ionis.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesDetails",
      "http://ionis.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesTable",
      "http://ionis.com/role/RevenuefromCollaborativeRelationshipwithAstraZenecaTable",
      "http://ionis.com/role/RevenuefromCollaborativeRelationshipwithOnoTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable",
     "presentation": [
      "http://ionis.com/role/BasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]",
        "documentation": "Disclosure of information about basic earnings per share by class of stock. Includes, but is not limited to, two-class method."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r173",
      "r175",
      "r177"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://ionis.com/role/StockbasedCompensationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://ionis.com/role/StockbasedCompensationExpenseTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "ions_ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock",
     "presentation": [
      "http://ionis.com/role/SupplementalFinancialDataTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process, and inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle including inventoried costs relating to long-term contracts or programs.",
        "label": "Schedule Of Inventory Current And Noncurrent Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://ionis.com/role/SegmentInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r21"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://ionis.com/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r21"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://ionis.com/role/StockbasedCompensationExpenseDetails",
      "http://ionis.com/role/WeightedAverageAssumptionsforESPPTable",
      "http://ionis.com/role/WeightedAverageAssumptionsforStockOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r399",
      "r401",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r436"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://ionis.com/role/StockbasedCompensationExpenseTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Assumptions for ESPP",
        "label": "Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r1095"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://ionis.com/role/StockbasedCompensationExpenseTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Assumptions for Stock Options",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems",
     "presentation": [
      "http://ionis.com/role/InvestmentsDetails",
      "http://ionis.com/role/SummaryofInvestmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments [Abstract]",
        "label": "Debt and Equity Securities, FV-NI [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r524"
     ]
    },
    "us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable",
     "presentation": [
      "http://ionis.com/role/InvestmentsDetails",
      "http://ionis.com/role/SummaryofInvestmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Trading, and Equity Securities, FV-NI [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r524"
     ]
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "presentation": [
      "http://ionis.com/role/CollaborativeArrangementsandLicensingAgreementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from Collaborative Agreement",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark."
       }
      }
     },
     "auth_ref": [
      "r1025",
      "r1030"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://ionis.com/role/SegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r183",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r207",
      "r209",
      "r210",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r228",
      "r229",
      "r231",
      "r747",
      "r750",
      "r751",
      "r752",
      "r754",
      "r756",
      "r757"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://ionis.com/role/SegmentInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information [Abstract]",
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingOtherItemAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingOtherItemAmount",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/SegmentInformationTable": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://ionis.com/role/SegmentInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other segment items",
        "label": "Segment Reporting, Other Segment Item, Amount",
        "documentation": "Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss)."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r209",
      "r210",
      "r224",
      "r752"
     ]
    },
    "us-gaap_SegmentReportingOtherItemCompositionDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingOtherItemCompositionDescription",
     "presentation": [
      "http://ionis.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting, Other Segment Item, Composition, Description",
        "label": "Segment Reporting, Other Segment Item, Composition, Description",
        "documentation": "Description of composition of other segment item not separately disclosed."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r209",
      "r210",
      "r224",
      "r752"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://ionis.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r227",
      "r230",
      "r748",
      "r749",
      "r755"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 3.0
      },
      "http://ionis.com/role/SegmentInformationTable": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedIncomeStatement",
      "http://ionis.com/role/SegmentInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative",
        "label": "Selling, General and Administrative Expense",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r734",
      "r735",
      "r736",
      "r739",
      "r1006"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://ionis.com/role/StockbasedCompensationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, General and Administrative Expense [Member]",
        "label": "Selling, General and Administrative Expenses [Member]",
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r784",
      "r785"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://ionis.com/role/StockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r782"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://ionis.com/role/WeightedAverageAssumptionsforESPPTable",
      "http://ionis.com/role/WeightedAverageAssumptionsforStockOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://ionis.com/role/WeightedAverageAssumptionsforESPPTable",
      "http://ionis.com/role/WeightedAverageAssumptionsforStockOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "presentation": [
      "http://ionis.com/role/WeightedAverageAssumptionsforESPPTable",
      "http://ionis.com/role/WeightedAverageAssumptionsforStockOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r426"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://ionis.com/role/StockbasedCompensationExpenseDetails",
      "http://ionis.com/role/WeightedAverageAssumptionsforESPPTable",
      "http://ionis.com/role/WeightedAverageAssumptionsforStockOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based Compensation Expense [Abstract]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r399",
      "r401",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r436"
     ]
    },
    "ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfUnitsGuaranteedToVest": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfUnitsGuaranteedToVest",
     "presentation": [
      "http://ionis.com/role/StockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of units guaranteed to vest (in Shares)",
        "documentation": "Number of units guaranteed to vest under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Units Guaranteed To Vest"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://ionis.com/role/StockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average grant date fair value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r420"
     ]
    },
    "ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfUnitsGuaranteedToVest": {
     "xbrltype": "percentItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfUnitsGuaranteedToVest",
     "presentation": [
      "http://ionis.com/role/StockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of units guaranteed to vest",
        "documentation": "Percentage of units guaranteed to vest under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Units Guaranteed To Vest"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429"
     ]
    },
    "ions_ShareBasedPaymentArrangementBoardOfDirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "ShareBasedPaymentArrangementBoardOfDirectorMember",
     "presentation": [
      "http://ionis.com/role/WeightedAverageAssumptionsforStockOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Board of Director [Member]",
        "documentation": "An arrangement whereby a member of the Board of Directors is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement, as a form of compensation.",
        "label": "Share Based Payment Arrangement Board Of Director Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedPaymentArrangementEmployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedPaymentArrangementEmployeeMember",
     "presentation": [
      "http://ionis.com/role/StockbasedCompensationExpenseDetails",
      "http://ionis.com/role/WeightedAverageAssumptionsforStockOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee [Member]",
        "verboseLabel": "Employees [Member]",
        "label": "Share-Based Payment Arrangement, Employee [Member]",
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires."
       }
      }
     },
     "auth_ref": [
      "r401",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429"
     ]
    },
    "us-gaap_ShareBasedPaymentArrangementNonemployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedPaymentArrangementNonemployeeMember",
     "presentation": [
      "http://ionis.com/role/StockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-employee Directors [Member]",
        "label": "Share-Based Payment Arrangement, Nonemployee [Member]",
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires."
       }
      }
     },
     "auth_ref": [
      "r399",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/StockbasedCompensationExpenseTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ionis.com/role/StockbasedCompensationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount",
        "documentation": "Amount of cost expensed and capitalized for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://ionis.com/role/WeightedAverageAssumptionsforESPPTable",
      "http://ionis.com/role/WeightedAverageAssumptionsforStockOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected life",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesIssued",
     "presentation": [
      "http://ionis.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance (in Shares)",
        "periodEndLabel": "Balance (in Shares)",
        "label": "Shares, Issued",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term investments",
        "label": "Short-Term Investments",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r82",
      "r965"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://ionis.com/role/SignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r146"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "ions_SpinrazaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "SpinrazaMember",
     "presentation": [
      "http://ionis.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SPINRAZA [Member]",
        "documentation": "Nusinersen, marketed as Spinraza, is a medicine used in treating spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease.",
        "label": "Spinraza Member"
       }
      }
     },
     "auth_ref": []
    },
    "ions_SpinrazaRoyaltiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "SpinrazaRoyaltiesMember",
     "presentation": [
      "http://ionis.com/role/RevenuesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SPINRAZA Royalties [Member]",
        "documentation": "Royalty revenues from the sale of SPINRAZA (nusinersen).",
        "label": "Spinraza Royalties Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://ionis.com/role/SegmentInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r86",
      "r87",
      "r88",
      "r108",
      "r183",
      "r191",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r205",
      "r206",
      "r208",
      "r209",
      "r210",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r224",
      "r225",
      "r226",
      "r231",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r293",
      "r296",
      "r304",
      "r305",
      "r463",
      "r464",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r749",
      "r752",
      "r753",
      "r760",
      "r810",
      "r1130",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1160",
      "r1161"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://ionis.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r38",
      "r41",
      "r42",
      "r102",
      "r103",
      "r104",
      "r128",
      "r129",
      "r130",
      "r153",
      "r154",
      "r155",
      "r157",
      "r164",
      "r166",
      "r168",
      "r184",
      "r268",
      "r269",
      "r294",
      "r350",
      "r361",
      "r437",
      "r451",
      "r452",
      "r458",
      "r459",
      "r460",
      "r462",
      "r465",
      "r466",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r502",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r546",
      "r548",
      "r558",
      "r614",
      "r644",
      "r645",
      "r646",
      "r660",
      "r709"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://ionis.com/role/ConsolidatedBalanceSheet",
      "http://ionis.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://ionis.com/role/ConsolidatedIncomeStatement",
      "http://ionis.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r154",
      "r155",
      "r184",
      "r352",
      "r353",
      "r355",
      "r357",
      "r548",
      "r592",
      "r656",
      "r661",
      "r662",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r672",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r692",
      "r693",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r709",
      "r737",
      "r739",
      "r819",
      "r1164"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF CASH FLOWS [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED BALANCE SHEETS [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://ionis.com/role/ConsolidatedBalanceSheet",
      "http://ionis.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://ionis.com/role/ConsolidatedIncomeStatement",
      "http://ionis.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r154",
      "r155",
      "r184",
      "r232",
      "r352",
      "r353",
      "r355",
      "r357",
      "r548",
      "r592",
      "r656",
      "r661",
      "r662",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r672",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r692",
      "r693",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r709",
      "r737",
      "r739",
      "r819",
      "r1164"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r848",
      "r859",
      "r875",
      "r910"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": [
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://ionis.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of public common stock, net (in Shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r37",
      "r38",
      "r72",
      "r657",
      "r709",
      "r717"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://ionis.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in connection with employee stock plans, net (in Shares)",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r37",
      "r38",
      "r72"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://ionis.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of public common stock, net",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r37",
      "r38",
      "r72",
      "r660",
      "r709",
      "r717",
      "r825"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensationGross",
     "crdr": "credit",
     "presentation": [
      "http://ionis.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in connection with employee stock plans, net",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, before Forfeiture",
        "documentation": "Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r1066"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://ionis.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ionis.com/role/ConsolidatedBalanceSheet",
      "http://ionis.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders' equity",
        "periodStartLabel": "Balance at",
        "periodEndLabel": "Balance at",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r41",
      "r42",
      "r65",
      "r674",
      "r690",
      "r710",
      "r711",
      "r805",
      "r826",
      "r1014",
      "r1017",
      "r1018",
      "r1046",
      "r1112",
      "r1166"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://ionis.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "presentation": [
      "http://ionis.com/role/SupplementalFinancialData"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental Financial Data",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity."
       }
      }
     },
     "auth_ref": [
      "r963"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://ionis.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosures of cash flow information:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ions_SupplementalFinancialDataAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "SupplementalFinancialDataAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Financial Data [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://ionis.com/role/FairValueMeasurementsDetails",
      "http://ionis.com/role/FairValueMeasurementsTable",
      "http://ionis.com/role/InvestmentsDetails",
      "http://ionis.com/role/SummaryofInvestmentsTable",
      "http://ionis.com/role/TemporarilyImpairedInvestmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r346",
      "r360",
      "r490",
      "r501",
      "r524",
      "r529",
      "r532",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r603",
      "r615",
      "r792",
      "r793",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r806",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1100",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r927"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r927"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "ions_TryngolzaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "TryngolzaMember",
     "presentation": [
      "http://ionis.com/role/RevenuesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TRYNGOLZA Sales, Net [Member]",
        "documentation": "TRYNGOLZA (olezarsen) is a medicine for the treatment of familial chylomicronemia syndrome, or FCS.",
        "label": "Tryngolza Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://ionis.com/role/CollaborativeArrangementsandLicensingAgreementsDetailsAstraZeneca",
      "http://ionis.com/role/CollaborativeArrangementsandLicensingAgreementsDetailsOno",
      "http://ionis.com/role/CollaborativeArrangementsandLicensingAgreementsTables",
      "http://ionis.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesDetails",
      "http://ionis.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesTable",
      "http://ionis.com/role/RevenuefromCollaborativeRelationshipwithAstraZenecaTable",
      "http://ionis.com/role/RevenuefromCollaborativeRelationshipwithOnoTable",
      "http://ionis.com/role/RevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "presentation": [
      "http://ionis.com/role/FairValueMeasurementsDetails",
      "http://ionis.com/role/FairValueMeasurementsTable",
      "http://ionis.com/role/SummaryofInvestmentsTable",
      "http://ionis.com/role/TemporarilyImpairedInvestmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities Issued by U.S. Government Agencies [Member]",
        "label": "US Government Agencies Debt Securities [Member]",
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)."
       }
      }
     },
     "auth_ref": [
      "r741",
      "r742",
      "r776",
      "r778",
      "r1128"
     ]
    },
    "us-gaap_USStatesAndPoliticalSubdivisionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "USStatesAndPoliticalSubdivisionsMember",
     "presentation": [
      "http://ionis.com/role/FairValueMeasurementsTable",
      "http://ionis.com/role/SummaryofInvestmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities Issued by States of the U.S. and Political Subdivisions of the States [Member]",
        "label": "US States and Political Subdivisions Debt Securities [Member]",
        "documentation": "Bonds or similar securities issued by state, city, or local US governments or the agencies operated by state, city, or local governments. Debt securities issued by state governments may include bond issuances of US state authorities including, for example, but not limited to, housing authorities, dormitory authorities, and general obligations while debt securities issued by political subdivisions of US states would include, for example, debt issuances by county, borough, city, or municipal governments."
       }
      }
     },
     "auth_ref": [
      "r776",
      "r778",
      "r806",
      "r814",
      "r1159"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://ionis.com/role/FairValueMeasurementsDetails",
      "http://ionis.com/role/FairValueMeasurementsTable",
      "http://ionis.com/role/SummaryofInvestmentsTable",
      "http://ionis.com/role/TemporarilyImpairedInvestmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities Issued by the U.S. Treasury [Member]",
        "label": "US Treasury Securities [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r741",
      "r742",
      "r776",
      "r778",
      "r780",
      "r792",
      "r1128"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrealizedGainLossOnInvestmentsTableTextBlock",
     "presentation": [
      "http://ionis.com/role/InvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Investments",
        "label": "Unrealized Gain (Loss) on Investments [Table Text Block]",
        "documentation": "Tabular disclosure of unrealized gains and losses on investments."
       }
      }
     },
     "auth_ref": []
    },
    "ions_UpfrontPaymentReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "UpfrontPaymentReceived",
     "crdr": "debit",
     "presentation": [
      "http://ionis.com/role/RevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront payment received",
        "documentation": "The amount of upfront payments received during the period under the collaboration agreement.",
        "label": "Upfront Payment Received"
       }
      }
     },
     "auth_ref": []
    },
    "ions_UpfrontRoyaltyPaymentReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "UpfrontRoyaltyPaymentReceived",
     "crdr": "debit",
     "presentation": [
      "http://ionis.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront payment received",
        "documentation": "The amount of upfront payments received during the period under the royalty purchase agreement.",
        "label": "Upfront Royalty Payment Received"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://ionis.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r98",
      "r185",
      "r187",
      "r188",
      "r189",
      "r597",
      "r599",
      "r744"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "ions_WainuaJointDevelopmentRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "WainuaJointDevelopmentRevenueMember",
     "presentation": [
      "http://ionis.com/role/ConsolidatedIncomeStatement",
      "http://ionis.com/role/RevenuesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "WAINUA Joint Development Revenue [Member]",
        "documentation": "Joint development revenue for WAINUA (eplontersen).",
        "label": "Wainua Joint Development Revenue Member"
       }
      }
     },
     "auth_ref": []
    },
    "ions_WainusRoyaltiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ionis.com/20250930",
     "localname": "WainusRoyaltiesMember",
     "presentation": [
      "http://ionis.com/role/RevenuesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "WAINUA Royalties [Member]",
        "documentation": "Royalty revenues from the sale of WAINUA (eplontersen).",
        "label": "Wainus Royalties Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://ionis.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares used in computing diluted net loss per share (in Shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r177"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://ionis.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares used in computing basic net loss per share (in Shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r177"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r939"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-5"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-7"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481178/840-20-25-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481178/840-20-25-6"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481475/840-20-55-3"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/808/tableOfContent"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481034/205-10-S45-5"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-3"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(s)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-27"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-2"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-4"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-5"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-3"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-11"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-7"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EE",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EE",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EE",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EE",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EEE",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EEE"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EEE",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EEE"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EEE",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EEE"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-9"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-3"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-12"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479741/842-40-50-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(d)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "181",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-181"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "Global LEI Foundation"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "249",
   "Section": "308",
   "Subsection": "a"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Number": "249",
   "Section": "308"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form F-3"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-3"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-4"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-6"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form S-3"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Investment Company Act",
   "Number": "270"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "313"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "413",
   "Subsection": "b"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "b"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "c"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "d"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "e"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "a"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "b"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Section": "8",
   "Subsection": "c"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479924/842-10-30-5"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "SubTopic": "310",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "321",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/321/tableOfContent"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "325",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/325/tableOfContent"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "705",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/705/tableOfContent"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/210/tableOfContent"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(r)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(s)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(t)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(u)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-4"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405/tableOfContent"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718-50/tableOfContent"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>81
<FILENAME>0000874015-25-000266-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000874015-25-000266-xbrl.zip
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M@A.K @J-JAP'[JJ["'R;$ N"W:!/\==R6 V2>P3 R5<"L#4/W,)A>P9I#4=
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MEW)8!9('!,#A%P*P,0]<PV%S!FD,1T!XHF)&F70FDTR5T@&AW(0Q]*2-:Q@
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M,I 69,!(N$=%OM:4+7R3Z,R\L6Y>!<,#V$Q3Y3T%S*W3&QH461Z,%;P+%C:
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M[$90Q^X7;OD2+<1Y<&MG:*),*H]-TO60>>\P\GDRG['EBEMN6>U"1"IN.,/
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M(#6X[X-I>LL)*Y>KA0\[W<%V,K,\^R<&Q&$@^4AWDQ@"I\K/@%#T\U8]DNU
MUN[!!V.&=?C^@!4']3!##GTN7!G#;RS9@P7O@KL(NPO75T;'=[0W:P Q5_O5
MTC*68Q.^]IKM</3H*+A#87?H'%&VX;:QQ(Y#S @R/]I13FC'TSI^(K94B,6S
MY7, ;&BV]H)V;=C8DG!!_06!B^A=)6UX\%3*<&J9%@TWO^FZN%8,PO%N!'(4
MZJ4"]0$5^PGJ4H(:8ST.G0**S2?ZAP_QA,#>^"KY;+L,X#[1"5 >9\)+#_#Z
M3X!7 ^#[EL"7ES&!&A@&=;#\\T8 H__GTO1>4MM[%HN;PKJ'.FYPOHWXC_)#
M'WXH[4=5D,9/!?G;*,B%X4[_N)S9SV[2&0.^0-@7XE2AX@K0^HGYOP'F;VR/
MNIAD C]P3W8/[N.B'!'((OQ?K[;#3HO;]D_<B@R<J;P"9]>&93PR)*U.S?=,
M=[3TJX:B7>Q:QNS%-9FI70,0$>HG*. ]=]1=SK87IC_C;^6"$G<32#85_TR1
MS[4]"\+;)]Q1I<^U3O@;&JMR3+$!L:KVTV15'F<7F$T#P_JCN\I_^J/O>N;<
M8!-L^#%9?TQ6'Y</D?6?B*P\(H.I\0][\L=Z:JQU8F?,\B&P\1.!E4?@9_//
MI3G&H!.X:G]<& O3 P.Y:CE7ZZQN8+Y<<,.Z)UWI4*DI/U$I<G&A\5I<\%@:
M#V"=^X?VQ]D??N&&/^Y,]UNM\R_,7@:8LO.FB%JX, O_Q@7,S':7F&-I/-A+
M+RSZ@-^-Q(C*!>J?[J=04.NE [4.H,9<-L>>N<PT?W'L$1TC;%GDDWW P+W^
MX"=Z_W;H39A[QSGY[O;^JG\7S:LK%]STGW"K1%X>-V.I@+'\3!_!<67&D)5W
M0-<5+Y'(I=(:R)^(%8O8;OD@VP7,HLOYQZ4Q\FP'5_WP%PG^^HG4OR=2N6W=
M;,%-!;0-C1EEH:8PRV1UOK#6^6I%ZONR&S'XY-\8/8B(#N=7E_KUS9E=+5\$
MH*[^Q.C?+P+0HQ-C.?/^6"YL"Z!MF;:S@?#@<X*?$__S"+#+:F\W6#2CGA<]
MR;3G%."9-S5'W["8PEO":O[$W<,>>>#S0!RKSX.6J?Y)O]5Y0M-"@9#_,N=8
M*<*PD')4OR.,_*F+/W;@XAH^@>EF0KV76@?_(/X?T>!;637NY^PA%K'UTB&V
M#HB]Q;(-?PPL_R \?*/689=(Y-)/Q/X]$=LH'6(;@-C^]ZGY8'K@V82_E1:?
M/\._:?$)-Z$<?ZNIM5T*CZSWAO!:P_,W"H:#CS?=^Z]W_>&Z!L+I\7 PAO ^
M6ECZ!$4:[N^ZO?YU]^[3,&MU@KWT\2@UM:<CHM^P($D%']9U>566$Y/@_3[,
M,_O1]HM"^XTZ/<<84RQJY&(-*1?S\D:4!!<FY$#S9F(L%M1@!7=-RR_$Z]<%
MQ;9*00U>>P'H>CGVH&!<W6\C:FR0S*ZD)=G_TCW<:2S8BS+1N^\IDC^2\/C-
M\]3&^L?V,Q9X<I</KCDV#>?E'+ZY?CY6Y3%,RR6H>&CUC9D_"%9S!QX<&1$.
M<V=(;-QPG]\?)8Y<^-O$$F#8KYKM?R-%CGM.AO:, H%^Z3#K"1;$U!K1G5=&
MR(&G3*@3E#S>XM3<> G8R,J/X;8Z4@+ZT=3?H33NKX.V-NYY IAF[_NYQR:L
M%2R^H,C/RD'QE8-B[>K:W_Q9*R@)Y#+9='_CEIE 17U'CI0S.4;81II84\U1
MTNR,?7NK[43PQ%^VO8 @:L28'\J\J?IM#L%F>90%LQ@LG\&>KCV)U.6$V#;/
M>=3]C3H9:T<I?96D%>.']UUX2__F?AC[F@PN2DR>7KV>039)G_J+[RABN:3-
M6AC$P_Y2JZLDJ)#!E*'B5:XN;F]Z_9MAOT?@M^'MYT$/I-@C'[J?0:Q],KSJ
M]^\3N'K\"7O%IE![Z<(T"],#_3ZBV'0&:^61L>$9"5I/[IW,-B8TOT;6B,YF
M@=*RZGR!R7RV8:9':=_C7=M%L^+J8^V41=^8&)/,A,&<MS$'[%MMQ%7OJD5+
M71TMP)6FG6([9?O%M->//#^HXH4W'*[_A??'ZJQ+SL@'=?,=N^"+:].U5P(1
MTCL;IV/ST)9C>#UQPXN6[\E.VG$I[C2;^K[9@2W:GLWWEX(K_FR[<<D)?;VH
M6W50!%HF_@FC.8E@\!QV*9E81@'WJBE@/9/&:1SMIIZ);]%A1"H$Y*$@CW74
M]TX\N9\:87,Z'M4ZW>&0N5D9>%(7,:#PJ7EX(H0P_ZE10 >MH BX:W#+VTRC
M;0CA82,_#X40YC]UJR1JPA#\;C@\/%OE.Y2LG@@&QD;X"_8 >S)FK-0"V29U
M)_R0;&9IUCK_?>A1?LQ]P^P<K/:M1JM]GVF)BGTOW;-'PUB\Q=%VK3'^Z*^'
MVO4N#,?!7@.LF?"JYK<6J?F]=,>;!;_;M8X&?-9T9:?8-S_&;6)F#X2R/;['
M6RY:*>2BRS#YZJHD-YN"Y-+;DDO,+!*K:4/LPW<&T\><F-83=;TY5S5K[;,P
MI](U-MY[&.Y@/=ID(E1J'45JRXK4TF11RK7#+K[*)40:>30LNS144"A)KM>E
M>K,M2J5:L2K%>ZK#4V9 -V[RC"@8&0PC\5*_=MG4+QSM[Z8WO5BZL$*A3A==
MKAOJK;IQ)I&_A@95:L@M4:JXPSJ^JBA$,KDF.UZ2T6N=MBHI+5&2V69=TID.
M38SEV0XFV//2+T4NFX*%HWRYH0GE58=Y39;TIK!);9=)?%5)C!#RZ%)Z(31
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M_.(/,E7XO@T>O2YIJJBX!^.4R' 4=TGD\@6R2Z(!X]!5J=W(M]M[A%/B\VV
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M& $)6U2D%5 +!%1O2'597)@SOLA9AJ2@@QQM1#FJGS:6V&P?$7^S1,2V9(#
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M,8R,#8%4&6;E1EQY5\%\%5."Z8ZZU'!&4W:0? Q\F]D+)(A7+I&B"$XF"E_
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MK2I-K?-*W-KH-ES%#JR1/:?(AZB%=($.>.8A4XDG\1JRI+0*Z'2-''Q=3+:
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MG%/5+=:58H1SO2V<[$7$+Z:&]4AQYW"Y56@UKJJJ"$\I6Z4.$9X2C^HG1[V
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MM9,!GL/*^Z15'*L&^(SK]')@G<.&VLF SF'E?])BCU4#>L8X03F SB'-_61
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MBYA-X^NU)G>(9VQT47=8[-[/WL(\)]/0P7QAF [2N[N?<(FGH^C,?-HL#Y(
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M6<G0EWFS84?$&)P-3^>0F6F+,3,#GY\I; F;$5?R8.+UK26SV /; N/P96H
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M4=/.(8&G@)C#PL!LLC96/C<\E56OFX&N/E(+E 4-.WR.#NHX= &_6LRG8#$
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M;FN6_8O%GE@4$^X>C=C. ML$P'R)(,)W3@833-6,.G]/&**,4!#.>1LN(/,
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MV@ZK9,N,M,>Q="UG4^=\24'D4,0:!!@ E,S]ZV_W#  "!$ \!P_&I^[-6GR
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M]*ZU#[>\>$FN^@MDE@^^XX4WW8Q%NE!!.;XLP+5>"N\"2 %>!1,>3WR/Y4:
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M+V7WH\9W/\FV^]!%R$*UEIKYK-J+G:Y:>(8;OC$!3B.:+5A70E1JC:'3A[K
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M-4>K!:MM1N)PT)#1$F%"G49+!Q#0G-&"S<('C11[QS"F3I.E:E2TN^(F+RR
M.J.2+>1+,*9!BZ4#RH*WQ3*E9\5(:<A@F?#(:8U6TN0;BE'TX)MV)T&:G_4Q
MZ/=F:%*.AHW4\<5PH4[SHP,0:,S\&$C@'4T;:2L0PY@ZS8^J4='N:IJ\L, @
M:T-=1J:-FA\=4!:<S0^<A"OWAV+I$485L:")@$FM%3@%#U6Y7R]4:ZIGR8M6
MC.V*\(]&#)LH#VHT;+H @.8,FV%OUDS3M"8Q,6\5)GB6+^2% \<*AOP\J=&@
M:14@&C)HQO2(D!MI(Q%A0)YPRAU8%):P@9TMM&TT4;[+B5OOL(_#&21N28-^
M.^TB#"!/^=PV-9;^'L7,&:0P7O\U)*%B8Z"4;3@]OW+&&!2=@6S,O\M&S8;R
ML']^LA&#HC.0C9N_AFPTXS,,I?,SGR* :6FM+YU*3:<&>U6_71;3=W*DB7XG
MQ;2F0M^\<BI3.14GG.9E-.?J5#)ZH66R</T7EH7&O)TAWN>)BL+GDK\Y?^<<
M!63>'0%I<[%O7@D9@(0H?&Z[F_-YJIG6TC(!N>F.@#1>[YM7"H:]V;C?%Z>#
M\Y*$"&2RW\ <.3*#H".CI@Z,[+*<O</.NCG'+9VQB!V=2D&'Y9UJ:W8V 1OA
M/>1TTA<'T_/J(D;1<G9GS?5W&3@A ]E\E6R",>[-%''4YY-PVIR'<HY",>^$
M4%3OG)25BI!_DDTJ)B 59]:BBZ+G'+V2+@A%XPY)-MA/F96DB&/YS#H/'1\(
MI>]?Z);C)]HGP^##GSN\:*EDL+T\#$\Z3Z+X013*#[SW?K/T4/H&%G]=U>+G
MQXNO<)'SJA9YTP"%W=_,DV5YOWO4M86^%QQ+79*E0(X%1-",A;[#MS1#,&E.
MIAM8$53;)O"[K^1:IL)A'_9Z9B /I"(#X0:Q ^&8PCD< _/G3QIZSLECWR1)
MG$P;JNBHI(=H48>SK?P-!.CCN'G:&<QT[(^P$+61@K/K)ED^KY+E*26H=?$<
M79UL/)=[LXDXFC33F4NNIB%J48^AW:)^2G=GXZV",1VYF88#-\<BS:^&]-[2
MGD$&P'I8$SW-=EB2K6EKL$356+J3#*@UX5D12CXKHA(_IN@Y6;"S7/XU%X5]
M/H_6M6!&%5DP W':/R_O-8;C]41NBI[J9P;0&DPP+)D=B,KTO( ;@X0V W?>
M N"F&9(U(3>[(8G=%<7^]+P2%R@2&@F6%[6ZFD<N!^"6-X5Q<I@LRM)YP3/"
M[L)Y-:$"@:@%G:]17%UH?R<7[%18%]JKQOI)@S>$=YR_-1(G_7-+<JFD76I]
M!O 9XI.K^3NEYN^ 4]O-YLS?3L%VW@+8<DIMYV3\CG%:U5 <C\]K<#4%0J>L
MW]J VXZLC\+V\%@"13L4!Z/SRFV* *"F\MI,6>G8O3!B69>1(P6HNC1W\$N-
M9:A/R^9<U;"'9NH(C64I WXLTQ2LZ5B4IX-:9+0Z3F1!3>6'2N/"</U=&'(*
M0U$O8:S X341^X,S$XSK\Q2,>3<$HYEBVDR2D=T/&="P#Z]A-HU)!H50]8Y(
MXZ)QTPW1:)%D9!.#(;9;Z"M349K6XY'7)@DWQV<$]7!^<I!R,[I59(YF[%1W
MKVSSGW8;8FF+V=NE]NQ_'?]-7_C;WS# [_UY3)=^'RBS@J=>K-2-IN]?"U^T
M#;$_D9?/YD8U1.$??^Y,YPU]48!7!?HR>U%DGQ6%=ZK]E5C/FJX34?B%F-:3
MIHK@!UG:RGVX#9H.?PT\*6&CPOL&(U[P!8_<]#7*+,U8 F7<5^AS7HA'38"A
M[CT<MW1X+9*TST@_0SH$*!"$PP)^AEAO,,[#2'7TV4=0UE\OU!5\Z#5XAT_X
MN+?K@^=).>WQ/43:M;M@&;?@NJ4>B"+^*GN#IE?31= E+'35!N%;$Q5^HQ>W
M>@IF6) JK"V4F!\H8.Y6[U&2 5G]WNP6*/GM[4^J^^1X>!SABPK='P>$?H&?
M?*>;BZ\7B_X?^,$_Y%["E\)V'YYP=T8 ZE]P?=''2>B<XUO #UUWG?"?>_V>
M1X,7T_IJKPEQZ -Z8?(C$75U:P,2O'\=@\\Y@GH6;+LH#C$U16_86W4!*V>X
M[05#%!X:#H!F:_,^N(PK.<"<_*12A#R?S_OZF3\_<)N:8&W$:(BP%GHT]>4!
M&NF5-4H_O*!\/T"K-_S2^.+U/=XJCG<-4@/(-7[NC6.US(D%<@L(SJBM+!S4
M28I]6#7';BK@V ?; >O(*<$Q=Q4QU__1G\:A*PNR>226H$BB(/?E04$B\6)J
M'GF1"E&?]\HI6S'8=\+8;.H.W2-9.0%IGO?7;>8]&C6G@OM-W42?"_/G;68^
M6K,GKW::NL\]%^[?M)G[<U6SA'^I^HZT#P$NX6+LA!-U[&!2IC;:*E' KLC<
MRJC]9Y<N&N>XR.NJ%CGGN,AY58N\X;A(]]F%+_W!8K.V*  1> NOI%QU8:FX
MS-VL)#6O6BE2:R7'UEKEZ!7]/J6[X6PX5<1)R;3K+-0L?3F0*J5-LZSJ'L9I
MK M%U,>]V6!2[E8I"X%Y<W%>A(MII3BULS'4R"H7&R>]F5RRQ#\+A<M?U:5J
M^G9(8][V2[F8A<G0TX'8'W*5NYMCN0M&/9/'\]*!O$_F,[&,#>W"\D2,1<Z$
MME2]/BB4SIG*Z4$]<Q3R,'N"&<0#11R5O+K/3U(>1V6+^-;,>3F10-'R/B]K
M8.6\,"O3#LW:>5GXT)S(O9E2KB]J%BK7<&:V2"QY'IP3A>G22<DJ^KST+.YW
M)A^S.,^>'K5? ,?VSMI7[HD.^8!B6,0=5;B[HZ/A6)0G7'$10U(>9VPK^-;H
M&0L4F)3L3YJ?RCS.V**L3#MC:^=E\3,6^_++G!W382V';(ODDNLA.V;*=%JR
MXT=>>F;S3FT'T&GC)$/_ ,7RJZVI:S0M2[!WCTOM6;,1[O Q]@OX6?9-SN6-
M%5WD1YHF<JYV3,W%2<'PJ(5^]P3;U@REDG60[8% FUJYIYZN?P4 -V0<3<$X
MZB2F8U#1(4S/SPO3/*>BYX'SM(J1Z.V!1(< ?7->@&[ 4IY*U,202U:KMH7_
MI5LJE)M,;KKSR-W>O190Q^Z(N5Y;:[Y*!*G,=2@G8WU*FR(,^K(H#[MIW,2
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MT&A>D$;-=2Z06M:Z0&I)[X)(VZ!VEUW[=&NX=T%M[.MB\X)V\&C>)(]:W[Y
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M#FD7@,&T8)OEEB%X?HS@XRX <3OY]\YVM-7^C;!1K2?-<)<C3;;.&^]AV"_
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M >6A#+ =B4J&KA+-P_:8R5F;^P0?'9?<)PH&H1=-Z@:,;L<6%NJ65D#]YY"
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M50/A]F5-HJWJ:)<_88EQR0S- +'[(G&O5VVO':''AIB.B#O+QL5N38V%G3M
MT-XLTA20;3#:&#!NRQW880[(L)VKQO+<>,SN(?X:[$MOF7[41$"NQZMRSX9?
M4+78MP;K57OD5M$WKT$[^6:>[UKUP^VOX>LV_HP=MO>&8"*,+^681N%9&H2/
MSI4L(Q"!P>58B9)E"PJ.?N.H^:^K 8+"D@7LM1]/\$L7WA$%/\C*?(N<51EV
M5_*LJ)9^171UICTFZ4H>R\^BJ\;G*I1CI/7E)#H@,9.NFIPK629 EO'E8)Q=
M5_EI<X'LN<XX'9FR [$9=Z1Q=&T-ME.Z:^?3Y+2O^"G_(J9+]XDFW1DFQ,C]
MZ;G*RK0W4Y3+<32BG$6%2/VS)(L,J.S-AO)E/X8L22I$B!UV4*UTI7>JCQ?^
M^UCIKW@> UO7[#>_K3_.#:"#H/ /=Q@3\057,XY[Y1\^ME'W=$2+H#KT54QS
M<)]S,GPLQ0]">3&MI4V,RA!(__,O'&=C/#'X26'T2"EA;DEJQSKEWLQ96X1<
M8( ]+=B,R*>+-A;$FTS# MHFFUA 1^& ,+A#OJB0K$T=X6 19V<9H@#Z^<O#
M9U$ C8O3=. #5(.K\#SX%(9*M\AH^IZA$38^ CZ\(2J&*Y<Q@(BNZE)(P""%
MWF'43))2"Y76W7Z:A]7:2OL&A]1_B&5Z?*+QRL), O+"L72W^@V4DOW+3J7B
M099?3&1<K-:*TU=*VC6H-.C@K@;@+YDQ=YW'.MF@OX9L9OI# _O _TT$&%,F
M!IO#X4ZM.OX2G0]%QU'%J!ZB+M9Q H":ZI'@E*F7-<$I5#CN*H43PUHY 8*/
M=Q]P**9QX]35,S!CF JQ43<W-NK-<%49< 9(2B'!^"0)$DRBEM!AG,K@28=W
MATYA/RXU*\; PU_T#@U'M9Z(XVF+)8'%T\%RQX<>G&M\YUVY]E4^7REB=KES
MZL@WLMC1=9NKE;8@%D?G23I/YPG0-*4)6I-BL6+Y7)TG\ IGX\GE((8L*?$7
M+RSQT]&U-4MT"(4MCJ7JZ!/%BT5O#; ^R1?UV^&6/*;:<]3'?DF)<GS!!-DM
MEW2+37*Y<$<E>%+?C:>S_[)%"K!*?[(<7[<N,73S.Z&3,RW4$X:YT0RPK#2V
M.D?]%AK42;4INAM4.C*IF:"3$'CJ(S'(2J,J^K20*:'S..? 5A\);H[.._:K
MP7&J-A +GILX5Q6$ 7Q!Y3(F0IM][.S14.XF-H%IAS$MH?Q->.RUX;==T]AV
M/?S!9;@F.7M<I/+T#SPZ/>@4 B0[[K86$-K2]'UP^"L^"SZA4'PR=U?8FC8=
MH.G_F&7N5=W9'T8AJD_PZZB<P?%PUL)G]_U[4)$;U?5(")T"J=.!N,N=A;8'
M6[AF+84_P1IRF!?CTCI/7+?:H/2M(?QS!U1Q)WW#&N^ HN^T)^$=4<'86.UT
M^ O\JZN%0T,!=^_>O;L2*4T1@S0H!*34U1><X.M8YG*'E^KT36^T)M -CC@;
M2?[;Y<.EL"+@ZH/.0;+#%R\%9+)!7O //&,<T\+QB3O+0BHS=43-MY6P!,&
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M4)5E+!7NDI  GABP?6]$A_X3HD6APN#[-1G!$"D$&'O!54^_!G=A.Z&@!*B
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MDS10'="UG=U\5J+9]4YT2[.YO] ^["7+.[RZC$<I,#W#FJ#YXBIBA3L>8'?
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M\H<Q-!=S$.6$M5*7 E5F>8CPBCUG.U/=,OX091\1LD:XM(5C4_EBI!MA82]
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MUUINI>BTRC0[<;HB@"K?,"F1&33>DL6&*Q08-LYS,O:ZU. P25;YBRTW*PJ
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MWL@\XP]1-UPM1C!C-">8K.1F\"*Y&AU9 P+''LUL6Z1&AE26/*22\A!CAEJ
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M:I<16MT\W#\_/GQZHK#JR^/#S6T/(ZE,<5.%SF%%XD,TQL(RCB;WCR-5'HM
M'L+*XZ)CHN<:K#G0;9_?E_8B;9>$\W+0@8C&AN(53*;];^7*Z\)RX08*3((;
M]%FL\9=C;<E:6(QG+.,F>!S7(MA4V9744)H?8IS"BR.);Y]N;X2M=/FQ.8V#
M!(NPBJ9 3EB=!]"CCT;^W.>I&+)SX"5]"RR+DIOA,08N8W6+CM_<S PV@;E2
M-@&LQ0,:+,K=C,5W81Y8?$>P!2KN!GZ7#![Z?2Q.1'/$CKPP.5?@)Z8ZA2PA
MJT-1\LB,I$7O8[SO&?<B&T@<)3&UC#]XN@&E#V9QQ<.(;T CB FG&5!*L(M
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M.MZ'FE'1\WQ@]U#S'L-/LX1!%D?B1-"Z0=HDQ0K67*(%[JJ4)US1'FNAOF.
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MH8]"&33SCLGT#^(/0W+OF=WZ;N?HT'%7WC(S H0 5G>4!=>JR;E&>TUCPK3
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M3@C<@F#)!X?P&9"!:,KIK]27FTD2; P$<HT,8A ? Z>TV2(B5AW,JKH,$/:
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M;X: H?<$?Z"A#??<DQNG1"E6)$%.^FWEYM :\0ZQ+TO7=BO"J,Z% -XJ3><
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M]'3CI@>90X/  3)[G8^)5AM9]H320HKI7L&]@M*V\$;?C\-S[_/6H&-NKQW
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M(-S^36+I@=$ J>[9ES.CP;)1S'SBY*V:5XG0@&)$!EHP+8LA,A/-775X7C7
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M,O=15(7,;<-6V\W*-9HDCM-K5"H-^62VTTVP'[F6'M'%?1$5V-EFP+C__W"
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MH> (Q]SG&GO%2KHLICX(98$&E$ZV7!!Z$R<ANB4X$Q@,>DS&&+\<9-R>@<A
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M/=S#D(?C)3-X"QQ1U>3XNJ?<;>3\O8N/_* 9ODU)X]:2QNYS+FG4LFP=6WD
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MGT5>IZVNPS(W]CFD:UKB.BQS&U<$-?)(J[').CQ.NJEMX*G]3;+BD<L/;9.
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MU3S#=]6N?+%9E5$/<X=T3=S&E#!^S1QL*Y62BKGV01 6DDS_8!7,-T)X& _
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M72>!_\*A]P0M(V -OTWYV,  "\7B/$1*(++%1R,@22J7#DXH!!<3*"W-9=Z
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M*08+UJ!-*,3%$"6!LP1Y^MCT^9S%D"6&J[CE;-^:0U(T5S&:J20H>(5UK+1
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M$O_]_@I>WB_OS0U'OC1-TVGOAI OI4U"'I FO9N;&\?(H,;81#($^M<_R9B
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M;O%$-MH]$0$G.O6O&@_N#PQ,^#9PU."RP<QZ9[.E''2^KBS5?%? JPE0&ME
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MRA $"";E*X%[*V11W/T^['U)R;>0H5 P!J&]%Q40S+\OLQ21WI.O?+ 0D:S
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MDP;T@-G(0!8W^NQ$B],XC/PE#49A2*-;&IW&09!:X:"[1P)B#W@D1;B,9>]
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M70O3+MX3LJ[8>:(.A3O/]$(-5K^M1 ^IMJV,X)L5]:(=D0P[%"DEX9/2SJI
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ML1/0T1-Q7'[&7_@!]_9N2Q/.Z".T:T$5>I_8JTS9/"X/GOG"),RBU$Z:77/
M(\^^(1&'O1[/Q%A!\UH3BUX$35J3.F<^T-PSH1 R!)E^B=83ER23OWB5X"KK
M+X.ZL\6 >[VI:^B9LQ0\T68/">1<FV9X_;KH2M OYQV\VTEPZJ=A(0-65!7@
M/NU(%7KF7*WU1[4]8?.9/7F/Z >/ 656/'LE/GC9LZNCM5R!A.QKZ:#2I*!@
MO$IF42">P_"X]DP3X/(MES=X)UDUXH5&/P<1FB*\E\#X$OURYL%/L;NCJ^P$
M8K+&;4!J(]RM1%#ZQ2@AK7+VU-;!09[0FZ2_0Y_058!?P E=2<^<J^#.J_/9
MC%H,X_-G:\%L/7K'WF'L<;SX_[C5_L1N9!Z?LL?>Q+&R0B:F]LM_*'QSH_3/
MG'#EA\2]#/QXQ4?*\^3>9*84M;<CI8"%I0,OU*N;>0?HM9%NX-& K5XB+2'<
M]S)GKU8D5TI"8#D^,/*]DME#,S8O- $>BMCJ-;HD;CV*";:D>2X)\$,,T[QR
M7NN,,4&[O'JO-OL>:7(>U/@/-4.UVVP.'"[L >C7G:.*0CDSX!V".R6;X\>T
M;>65EVOH"S\H%WEBA=';8-*C')A6!,_E0.Q"5*Y*RCH^\$I ]B)>6G-C.[S$
MAIN8/(O#/HFC6S_Z%TVT0YGM@LHD]55[P$)=>N5<JW/$P7;$& =SXF4%@\2S
M^73 T)]-&(H,XU(9TUY_#*T:^P*X;3..M.-;$>BF=I&X&YIC]=& P4GWF&L%
MG5_@F( PB;IGC#EQX1VJX.@9M75 Q:_4W0"<B\WM18!' 3ESSYDY%@\/I_G1
MO#T4>P^KX$ $T0'[RR-M[!I NKWCZHB$M04E@9JU79N96BH$E:3CP3=!O%JE
M\XR(N]FH9R0BP@V@;D8)853O H'9U+Q*FY:GA<5/B,N#3M,%I=%64>$)NPIH
M Y:@&@M+,J]$U$-+_AU]HEY<H^GU@XC)PCR 65FTB*/Z9:'J6FT-ZV/M#FFP
M1JTL19:7PZBR=#WT!CGU728#/K]M/]%1$/ +>&*]L5O3M6/QOM;>?#0/*"VU
M0:G:1WHCHP3@F8%YZWN6X.-"3^WP&FGT(BAJNH:9M:!V[":Y$:VQ01GZ"(\@
M6FQ=.#D20PA+1R0"%]O/K03=K_@W=A7(9N\,V.*DQ(-#GR?<T\;N/_:9X\81
MY<Y[WF)E0H,D?0_FOK')*<A&2^6K(QE=0C"Z5M;N@EA;1@S'J!W5Q+92VHB8
M5(>6[(HVC!56D%Y(<+,RD@A70= /8.9K8<EM%02#T9$:]I3#EA5TD1GT"2BC
M%\0)DA[D-Y3P@P!#6C<P"C=\)+&M!=7"$52U+I8PU\,R*-8R?"S*=P/19/J&
M0[LU>:;X7I/^G3;6(+[][2LG6>J%@0!)PX:D#^EV9$!>X(2T*UHBHVW[2\,]
M*<+%VE=ML3%[1X 1J%(O^;;<D9L5"FI0;?)\P VJ;.4M4= ,*S&D-MT\=A?%
M,[5J0)G=(A),K,P:T[P& POW)F<IVW]1TKO7%W4YALE"X6UG"OUFT*5? J!V
M_HAP:;24$ F(9K,\I-F[-Z6RB9"'CSJPRU(0\9+O8ND=C%N(KWCE,8K$E:.@
MP(;.5$/1N):D:75;DMSZ48E/^WY[4=)APQI(^?-"QWH#)[8IA4WOWMK;K2M'
M^&I'!,6P?=K,N48R24Z2@LSZ+*4-UUB5.N*0KHETDNXLKGMJ7M,PI'2'#%B2
MVP#,Z%E9S:RBV#:1ZM!'XC6=$S>KB^<>;^ K$:^M=Z(\#'6:E$?.J6<=PDQ4
M@ZU?9)R0\(9$$0WV .%M AF8)NO%M3A?WBE29#7A $Q/_2MOY@?+^JQ^79G*
M0-S1%9] Y,VQAEZ*P&A/_]Y9$-^0D8%HMB*P@96EE T9\AWZB-C/*3Y9)S^M
M@0^+'J>R)Y4^X]G.PAF9L$1?$FB?4MEEZ2BU!S2LE4*M"2[O:D'UB6/U-&L>
M+@MQRAQBL\G!-&EQ*1:-R-&P<6RL#O\>0CJ>G8>1PZPG\'Y*.XL;#'6K,627
M*(WS7U%R[7$WD2)P<XTWU%BG2E.T,:\\W#J>\9!/B'U\"0'UA6EUM)(9[:K9
M9>YK <O ]]B/5IHO=8A#3!E\GRP1==HV3YN%R+/%96D3M+YLQT:J24R;/5@!
M:Q(?@O*5=KV.-5UY4TR2#]Q;9Y-FLO*"])>$, )1%^&LM;(9Q:1>K]J&>'+9
M(RVJN[))7X4P?1W_ *NV&@&;N$>U*$96H&CSC1A<C>75R U::ZA'+B0UDOD\
MH/.LRT@&#W5SR,$TZ5]H48@L2=##A^X5ZY ;S_VA''DH1Q[*D5]Z.?(]^PX[
MZ[>HC9X=Z(U7#0/I-K=@3P96_$C?L+]RI;<-:>\$,]&V8E%4!/3-32=H@W@?
M>U*-\$WI=(0*1BI"QS,!<M:_28V!:@FHE?TB$Y6I*GGZ8[/WC^,N,!B=Q71&
M8C<Z+(\Y:6$C@LF=;<0-S]^I1RU2T$J"_2KP0C2M8="-IJ>=-LZ'1NH NQD2
MH&//+P%3X(3@4:.1U98L$%%#QA?0QF .^3&=S+(*\HN7$WXY6?/_OV H^VBM
MM70P,+?%#F7Z*O'#0&)CH>5 \TWW>VHY$9ZZ) R=F<,'&>7.CSA)3TVFO)Z1
M"-<[U H5H^F/RFTL=&B-DP[VX 64N,XW:E^RM^0-A<;>[A;!8K@:[#YP6)&:
M.)ECO&IH.X!Y=S3S%L6D>Y0?)F3<=*# ]?\"8M8'<0#E1&.6VB$:WN <F2^I
M[TTZ9SFCF3WV[CC_ \>;)VF_Z*UP9,&;37K1;I C3=W#AUEJ6^8T[9NA<T[K
M0/_Y<N7Z:TJG-'AR>*?LJIG&(S=9+@O06?[<X_HW'2B7X(B?%P"-I\'D7_A6
M.XCLQ'*];E'>ZP$T^DH"NS@XF^NP%/$PC)>K;80 7^Q D'MIG9V@>2?A[,(0
ML<U>X>A.XL!:L&_P\>V=D[<VF)KSG1U>\%IQ5*:>Y?#]F#!,H!?7EFF;*'FH
MA$5IL'UMT"1%4L-=FD!SK8O>AZ%9T]"L":)9TQ9[A#2@"@"(AF9C'I"*&.YZ
M^W;IU)S.TYXCMV1)STK9+"A\*8!!NW)*9>>(Y5',C2*-D$H.1 #!<VUJV6(T
MIZ8=9Z0R9]J<)U/J.7Z0;.>W'S],F!9@\!6R-B27ZE)[N7W=4'78U!(&-NY8
M _H8BB/'>_SH)R]V"2);5J/3$V3/&D5L"E(#RZ0S4[XO8P.].M&N"Z$0JK<-
MN[;.EIVE"_0Z66<?'L UIH1%?QI[Z9+9Q+@A7J":^P& []V;^E>L*W<%@!;*
M?[=<%Z-XJ!K&H:_A8L;L9FE5T .@#$>SZ]IV\.]U%NQ"N(,+P6"=R-+E.+7R
M6>ZK)J*43%$-''=0[N(U@+#L6ZG+>)-X-C%(^E(.RQWP2WD]?XS>RF%8)%?7
M A+ZR)-\$ K1ZB"9K+YHUB,U<8TRO4!W4G([W6C@._+UAD0T<(@;WE*Y=BW"
MAPV/'10; @WOC. /V0#[[ =?KKRD57FH3N&]IXWGR,H2>?^]@3,IRN N&"5"
M=EFY]'U;G<Q[3_>&S/OOW9Q4W(+,5?U_U$A=N4)/%$?UVS=WO&QUA]L39KBK
MVT;2.TG[:DI(-*%L1VZ!7 -2O0=R7TL6V3:3L,W<JQI4U;AYM'NY[\#)]SQ:
M2_<&>+I)%]G*I^P#QR)NEK0>2BEKT;/&VVK*\69;0RZB ;Q!G8&Z\C;MER[H
M!D$5H@M6,-L/6H_N(F)@]%+(..TOES3@O>]R7FMP0+R(X3;IFM(OIHF$J=CB
M]B_$&,,!( 9FU)17XIHL]1H-3M"3[U G7@\9U<PCL9F*V"L3W"H2]$'<LQQQ
M>TI>ET-CT!TR#_,2A39Y!VZ4)\M$V0:8,/$S)3:&0?3')/#MV(K&059%)ALX
M8\\6V,9^V[),N"S:>2\=*9,16,XP,66D F6:3."-9C)@H7R(3(X3%6L;:B'7
M)'4[]*\B"G!^:BTTN3A8.R88"7ZUY@-.-NI]L/;FOON-*"0Y[CYCQ/21VLB;
MV\3>:Z*$=S-\4 *%Y;7-^#*D:2X@",+5>;IRO(!\(YNJ/@4Y%CW;<>+6O[?,
MK5B9RI\9"G&H0^/J)P^? :U&7<'[PL9*$DC);5F'L)4/]D 35[^PS(5361VG
M4-8HZKB\=L<UAH @S9$0/7'>^NQ4Y7GOR:XK"L'[PLZXRBHR-(C:.WH*25DS
M@4J#E,76HOF<B>QRJD3=YG5ZH)&ER)&QX2>XFT=RQI*_^>R]SA@LUU_I<4%F
MG1YP08H<&1<^P7'ACH:4O<N"(=B*"S+K]( +4N20<$IIF2OUHW[.GRTWMGG)
M2QA2]I]]3YZAC1H-#(PVP5%V"6O16,97 !\-F24X%E1STLV&2^G"67UE2!=Z
MS&-4#0WSD8;Y2,-\I&$^TC ?J9:^PWRD83X2/GN'^4@]FH^T/;P*8T?2H2,G
MU+,62Q)\05#.C>#,)P0<1E,WTSWG-WCAX#[H'#!*$6XC.,-Z678'U'-OEX2R
M[4S N0>NA>7X9U3M8K!0LG072.?R@^,PZG8#Z3O6M%MJYQP&"T4+H7*8A]&O
M!4C=4ZV[@E[+J2+-#J=0MU#Q=>DNK[JF1C79A:D\,S?H'G24.V83-).C"1L5
M3(E9361#239K<&7C9#U(P319:"1K@"L$!1#[3@Y#="O>UM@0W2$0U\U)KCA!
M.S";)FN*2N;T+;9)4P1EMIP9F^?U5);RUQD(R8X]'Z>&;0C&#L'8(1@[!&.'
M8.P0C!V"L4,PUK0[:PC&#L'8(1@[!&.'8*SI*,(0C!V"L4,PMGNJ=0C&#L'8
M(1@[!&.'8&Q?@K%CSR^%&56*UZL?-=IQLV7P540-+!_,$'3M5@!N"+H.05>S
M0==IO&1'Q=J?\3;N892\:$-TM5WLD-&)2_246G&0]$-E9$T:?&0?I&-ML.*H
M^GAHFYBJ('$CHRHXF&A!VEI0JF.=2J0_>-/2'-\+QR,>[\M2/4X;2!A$4!#9
MK>'$T=@L1=8+2=D<O=0*17/M/Z-!N.E^P5 <SRJP"/G-*JS^",6C XH:EBDF
MY0!JV!ZET#4H/] L+D@TP=U+T()CU!ME2'90_?[!BINAR3#RK9K$<5S5PC(X
M> 1#[Y:-]5HB(^5&/TPO_2<:>(F4SBE#EX8'X+(T6*-C&+!9+D]\K,&H#]/[
M@)(P#M;H#!<",N=SP>>OF+IHTVX>IM.(:1'^3A.?SP&QB#N-'VWGR0G14MHD
M@9IUM^"S6X[R.",:DQO+ 52W&,Z+UM4UY)48 JD>O3C_,W:B@MZ8Q(^N8[EK
M?B=-QFBMB*?685IMQ1?)3!W*-G95;L_:P'EB>@.$I]5+O4R]JT3,YA;.FD.<
M2BIA]$0<ESN*+OQ@2EPZ6OI!Y'SC8A5&."/,-! PNK=!W:XZU =WL21RV(")
M9<7+V&6":5\&?A@^>,PP=#EJEXQ>)W3F!_2>/*O,AP0%:,X&!Q$'! Y@S(?7
MQ?":_790&:D$^#W+2#4'@(?;;U(]=M#:(EQ&'VDDIB)TDTDQH&>),MEQ[G$*
M1QK:='@]',Q:F:;LBHI9]'4W03.&A4A2,&V+'<GHLUC@, +^9@ERO!U(5D0P
MOVM9$3*B\?J*:6B@G3,:"+R<NZL.]9NG)P'9G#L"7#SP3D@(GBBD#/X%V1KJ
MI&\<WH0B W('W&$%0Q*GOI\IP!QJ'#MU8 $JG7H=$: R3M^[ .UP2&J,.ZI)
M8L@0^0[-#YF&#CJ<W@W<7#S=.OR, ^:L$,Q+V=)B.DK5B+</7W* ]4>/5BA3
M8MG^;T9M@N:\K7$^8G.6GPD(G$V6_2XYFQ(TYRR4$[%.3QQ U[X 5M93,.?7
MX=QXGBUW=NHY[&I6[WVHIRUU<U[79I$<B-^ZYRP8L.]8&FJ/9#CG'!B"TD<U
M&+!!.*I/]3J?W:&$ T\27H);M@U=<R[7#G0'+*F_ITM>,Q0X[OIJN2).0.U#
M%=>+W0=[5 6O+)>!C971B5$S+P,1SXR6*)!78+9\%L50 H_$4.D2> 5)!RIX
M-U^[#,S>H>1]*'GOA. ,)>]#R3NT/3V4O -R>2AY5R/^4/+>3_X:*'D?2I\-
MES[712$1[N"\@:7CQ7Z\XV:;^&'J/:%A>+\@WMMW-^R;B_ VYMB.9_GGT'<\
M;&P[$D)#\0( \!+)3H#%N],BUQF_;2=$3,+V,"]/A32"_>A.Q\1K%]=!VNH8
MV6@F'5[X<ES'P;7OS<'M*F#DOFOQVF=5HXUF7IZZK,R:<!VDK8Z1C16Q\,)7
MC>E!94J 0C>2(E $143TQAI7G!MB-3HFU8P<1M^=A(@41F.&'6 6Q05Q@M^(
M&].;Q'-%99(G]"+..: T_63DV=<.>73<S*62 +?'WAVG8<"S5)(Q$$'^:U+]
MAY5= 8N;]J4; @V,% TXO$R,.D 1O%)* !S;S.6#Y.]PLBXH@HN _AE3SUIC
MY(9(0,3S_4FGB8#OR4K)J:,Z5F))E>;?@$;)%Y&!B.CNE<L$D=\(E9RL(R;*
MM#X)R.#Y&Y*,-)F4@<9&R;R+MEIX\^.O#@W8RR_6U_2)NKB*N YH%W+V#J6,
M:XF/4Q%<:8?OXW$PO2R&W2$-+;%)FG9W#8VQID,JH7$0W5W+[&YH<4Q6RZGT
M(<VZ>RJ[*1D;-HXTI&(?0KT/J=A#*O:0BIVA>4)<!I1.%Y1&U_R;G*#P)X@0
M#%8"=C?.#S%U)5J,0+$3Y3RH 614NS?)<Q-W4%TI8H#@:K>>/T:5* R+,-TD
M24[N:=H6-%4+>!G/56 ,5J4T*Y"]Y.5*0B&EC6ZT]96WBJ,PN:*]16%.'223
M@60M/T[ES;6*A&@V:A74=P=CW+N7RKAW*@4]<,ZDC36$R\$ZD.:J?!3B6HT>
MHSU"8OD$AY++H>02ELM#R:4:\8>2RW[R=Y@R/$P9'J8,OP3F#E.&7P S=2@+
M.@MJ8^R1<,'>C?_#T7DB;NE"=^:$' HS]*&M:VFX';@B8:7$*A ?Q9,[3%(P
MR7WUZ0K@)MIWV? ;G;&UC3_A[>ST-?!5MAC.RV9G#7UE>IL 5R)-(]_Z\DC"
MU$"@7I@$-\Z?^8^TOB))2T,L5ZZ_IC0U?NAT00)ZL@M]Y+I9D&4\8W3VYQZO
MX9K0P/&3F61H%4G0V.E>>;9U<3 8890GX>!HH.<LDD@6MSP2/R'JEG3$\\IC
MZH,F/@&^/&*&3!TDM+"5=)8,ZC8MRD\MP24JE0"9C)(W4P\++38BE3LC(>P2
MK))/=P3G%7@633.WC&;20#),-I]&,_H81N,9OZIA11QWUS<9Z9?2)^6XX1YY
MH./ B=OLCH:4)QF<\=0!?Y7$K#Q[PO#THLP.5O%&*BS7"W8HTPBED]F4NNS/
M\TOJT8"X#/;(7C*"A5' T'ZB=7QJ;^DJP39Z>57>9(IT;78Z:'D<4L.(VM5V
M4X8$M/M!#JC9R-X![B:RQ$=+@H-YQU.R<J*TV<MHZ<<>^%!7)"Q-G@$'D"XT
MYF(ECB08[OG#1D% O'FB4T_6VZ],R#HY"K^2H/1UCO1;Z%,(#C&#R6:'<+8
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M.F']'<.PSF%8IP1_AF&=TL,Z2_VKD2=V[L/JY=C."I(!A\B=I*U>XE]83^+
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MKSS+C6UF+)T2UYVN DKL=EY1B?4-YA:W=H[*D*_92SKXMCOKV_YX,-_V-'5
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MUYH/..W"!9T!,\A)5?:*[=8X"*FG$'_16-9(3:V4.FAJHUA+K,;-H\RRU$?
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MJ"EN[L,V>@(#<+2"FO!7J_-G:L5\=/UX-G,L&H#9]8*%#1Z;#2RIHP:X8N3
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M_5RT_>N_\^'K,H*?%VE34%[J%Q32?W;,*O_B&S^AFG:7G38FN$J3K9F(L\2
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MFY&&=B)!MW2Y+%=T9QK]EB<?R;Y94D&-#)?U%BV]Y^;>URF[YA50/65#!-7
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MP2G*-EZ,FHW:%VP':E,IV+J2E#-G2 8E2A\H7+BIWX?DE_/#.8[]S=9+?YD
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M8]@^> NID-7WI=^B5Q']^C6$4]?R6;M/#*F46*/8KW3" \,<I:IJ9-QT#.;
M+4=-D<8.Y1X^>A)L>;>J)VWJ:U/83 O'G7./A/[(*!*/85O["*F0 (;]C85Y
M@ :JO+6Z?+C<)#=2B;"1T$C* 7-U=-SG91CML]$=:F2C.,F*):9%EE:4_]4$
M2S. TI$T56"JL\'XC/PCAE2W.%@\4T6WQK=[\,U=KEKN%5-HJ7YC.]CZ>A$H
M+1'"W&_VA$(2_"*2[6[/ZG\^J33>L7>. V0:(:..U_[<,]U2)2/E"V1JE[&^
MH]OWINA)85\D!VJ-.Q-W6$.0:"!:R<<A%2\$;AR?XA1[$3CE?I]$,$AUXWG
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M[,QPI-./;1QIT"3!T8^+Z]M/"\2:HEI;E;ZQC:0>DBN1I,L1$R3=8X(I[9
M:1"2=/JQC20-FF3G^KPE>S^:*9)Z2*YR[-7DB.$K9BVUWB27PG;_]D.,6C0H
MCCM)C-B'CN'2*9Y&!@SA_ P!L0@"]B;K11!T?1WG<=J3@$,]EO64%$IR9*_8
M91L$C2#/1-Y,>%1V$>ZC(]!&5$\G&P:X1RY\?[_=LW"6XAZV2_$&QX0>N7A@
MW#10TQ[7=LT=;<KD-7>*]JB\FE<](!:;X/)J;BSZHU"S'EPR#Z*\QSQ9RI67
MQF&\)M-82L6#V-\9Q81H .T2KT(_G(\-72VVIA>%=,J&.^8R77MQ'OQX08]L
M210&/(,C"W\DD+&+!T;F^:B\Z('^AMTM:_FH'O'G[#P:/R?VZ.0Y2/$X]AQD
MELW:,.P><>Z1D'E*U@=Q>R*<"FWU-3()NXWSZX;K.*3:!EPW>055NFSO*$E^
MB,E4BT9S4!>/7'JDR9((5HU1U1H5S5TGT^TEZD8N77VF&+^=UA,PGGL1)&1Y
MV&"<58"?#HY]AG::\KF+.IWDEJ5209=>YKD\LIJ(7);B68LSIFD1'OP-#O:0
M#Z@(93OD92BIRH;,F/R'1PC6D(!48B4TZ]FZ Y@1F3T"&VV;"@<)M#0>FG/%
M,,%:/LB]]_*1G@=2NH9)*]^T-%N:I+'==(XR,F1F9^\%;8O/7":(Z.)]+=F8
M8H*&O@]EGS\FZ2_7,:OB0OI+OM7:]O.#E!+9\Q7]C-7?X1^Z>^WL%$!;_,(I
MFKQ'E3W2?3LD5.%\2)*@O_!;K9T)_Y@2>74_]AE:PW<.$Q-VL+\M>N$$S9XB
M=TF:X6 A*1@I?7EL-;-^8&C3('U8Y!\BKY8[W<'3H8S3M9="X8S,RT;D:*G.
M"2/?:D0C6+^\"(CHD^_"S459(9MFA@'QW :\WU0GR@7/4UTK<Z^Z70R_ NL/
M;-^.KD^<W+;.DG[7VCF]]_:6<N/6VX\;)AM/WO$%_4/H>U&>2%,O':"LK?4M
M2$*(S#LA_ZS(>^KPM-G!_7)'4DW0Z(*9=W@=W[!H\3!>O\>87(AV)[7P)3W8
MO6HJ:9%N0J=1\?5\D* 6R#$>%!,VO'\60"O=?@NH&4!#WHF]?46+GFZG[38^
MG*F*+LFT=(9RU@,.,,Q[H+TO"8$R_.U5/9B+EU0E1<J(CVU(?!S1/^!D3QQC
MJY\T&V^;W0PP3YO*G#*A=K$H1^%4)V/M81W 39<VZ=V;-7<,LKYR;;J;]&"
M*? N0^*MURE>YZ_R^:"3WL?TQK1_%=.B2Q]N3@#72YYUM.E/WM#723+ 1+4?
MNT:S[:K908\:5:XK%6N*3@-.@LJ)9J$']6BK-(7*=/!4/KU+7)^17;CX]*!/
M+SZOZH+G5ROO7U7HGFO?'P,T-&,@^K',W LH-VZ1Y>H"9@5[>KXZ0O++^0'^
M]SU=',EDYST3"FQK2@,:U=H3 5J0).S4:8J! 8 0&4W[<FR(_JT- ]WG&6>\
M-7XSNL)5#.5&P\H)DN?6KYJ@7?F]4_#IR+"I)COF;:P7"W]ZVN'#QIMN[Y:/
MX^!Z*R5&@B'P)_=YA&H8[>%1&1(1L0@=V@5B?;A\]^D48AU+ZLD/>7;F&;.G
M0I!H!"?/SD=$*)Z=!2G$73T[2V1S_.PLFMN@J@HE$RXBCY!P%>+@_%"85/9>
M]-'+(/?XX=++IC5\#"+%@8X:0F]'F1E4M(00F3(9_.DJ24\ASQJJ\L'/![GF
M^!%#W)"IINKQ4YSFY9F@*!/L',NX1LRDR.\WM@.H]R)0&HFPW7HI0[10\SH
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M$"A-&LKZ.$%Y+PRLS7X4H'622,< $<VT.GVY9FJ]N-KNHN2 \0,4'5GN9%Y
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MEJ8#P.A /T1)BB),W"7N'TGF5>Z;$=@UD1I\.Y(:?#M#-?AVH!I\.VLU^-9
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M"&+-GJWOJ$9D:D-XWWP)(3KX=0S??A"08;<''X?X:Q7#U6ZC'\,(4TT?XPE
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M\,$+8^OH*P=U4?E:C[1N(,8X0VOZ=1<89P?%8Y'KP['!G(E4(8QA'8QS4X5
M4S<"== W4_R986^H*KQ-,DSNO .[(!9%T"Y#XM--99_BD6'7-9KM<IX=]$@K
MF=$34)JQC',Q]. X0E-/A(TX38UYCY R':?/H8^KC.UPL,0Q83:VVX0=(W'
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M-2QQ3*$;Q_<,:'5O^T9R3(#,08B_A-,=,"KV"::T-##E %(RH=7!(YRX>8*
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MZ7=Y/MWR2?4$Y5V[-D[I"[:9M57)%W,;!-3&B>F?#Q>L@NXD3QSB,2RB2DB
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MD?W<S!;?:8I_O/KP<'5YS=K^N/CIYOJ'^X5;;2/D7EO><AZ[T#% 39E0I(?
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ML%Y$Z XKTZ'E]_1N_X+*%H@V<1KF)YE&2UVJYVO9.%U5*A#; ZZVNR@Y8/P
MJ0(*[Z\[*@\P$G"C0F4HT%NMQ9#E_5!LXRE&1FQH5(R-8/ 35 Y?-P#-;%%/
MR%NAS6=J45J&Y@TF!.,;<#ZZQ,1/0T;931CCZPQOI06\>+,3Q!K"':ILBGZ&
MQHBU=@J,CIF)A*O%#,L"$I5K8O8LJLPN.N\DK"EWE"T:GR#6O+B@+J(H>2D+
MD5ZD. @S!+>S$W1Q?'UQ<WGIFK[D&J/'-7L[,%RGKF.2I<RCH';/JI=TN*/7
M7S_<>=&")=?_1+7+@I1J!+Q0/^V2>.GS2YG/BH7'@<=\%*(+5D)(MJ,S.T=%
M *K?6&L5/)8K5!*!.!4(R*"HJ6T/0 D"4E!%"S2M48,X.<X\&FWQNW7TL"MH
MR^J(&WGR,DO,K-Z1JX+=]?(&J'@XF,>#KVPN<N.6;-X6'A,&Q"/ULI$4G2':
M&ZIU-P/[M;. +LMOQG!TO*:G1!S4S:'\V>,6O[ _24]F_"#/FR/>'O$.3O*'
MHA-ZB7OA7Q!7KK+]YBH\B/?@DFUW&&[MKLP#8/ F<*:2BZUHA*I6[(6!\"<&
M3%X[]XY1S$KL)-/)!HMOL$Q_<\7=;<SGFQ;_6FC(=[59'4] NE.)9^K.[('7
MW%J=EQN_KCQ>SP_Y'_N9-'@;5/:(:EV>,,>6_ N%M<*-QC-C2H<MHC]_+=NC
MX> ;/K,"Q'#+3A3QJ?FGW%^=?^S6:MRB76P,EDS1UMGPH_<YW.ZW_#ZQ7#5+
MS)$EO80\XG2[7#72$,F.AWEGQ060WNSR_@H#(D'0(X(NX:^-3MT]K!GQH'5(
M',!)JZOJ 2H:X_Q*Z)'-^RAYJ:W\+B^N>G,$[1%T4%>D0@\O1VI3;ZY"-=F'
M31:/).P$NTFB *>$I];MDAC_Z@0MLBP-G_:9E]>YO_/8[5HH+5>'>N'$I =Y
M!1LL'5I"644-82A(^=WQM?B+*!)BRYNF^1+W/HQ#0D\L'Z ^N];38]$"L2:-
MMT=G#X_'LY"_/(KG:RT^@&Y?]"S(D[TN5W =!BO_!92)___+N];GN&TD_Z_@
MOB65<65EQ\FEZK[(DFPK)WFT>L1YU-45-<.1F(Q(+3DC6_[K#XT'"9*-!^?1
MH/>J=F-;(IKH!@'T\]>7T"4>&@9#<AMX%J&8IRZILZV+21#N?$V2"9I,$677
M!0.RTALL<#]JRO$Z8VTJB][J;BE5,D>A%TD$=0IJ/!?MYZ_'Q3[F=@ZD0NO2
MP\)19UDB@"&>@Y(+T4!>3<*6;3B6B!W":VC4SBHF0DT-@H9<<;PHBZ=L#BD^
M$*XYS:<ZW>L0H(9D&JM'@Q-JMJ8#;HIO;B2ZR+>LIL84.;ZJIS4.*E31<NED
M.;AU:P1K3.6+L.3#Y8.M_J92I@OA'LYF)9?_$?\%X"EK$##KA2D?9_IY75<7
M\1[$&>C?<BY&26W<8VC-PK57;6*CU?3&,[%//W,NV$?>YX?R'H+0M%&/[_.X
MBI0! ZO@3]2+&D7**!^XP!TL$Q<5\-/M,)_#'V#H/G$U,5]5=3%@,TOG[0$0
M4N(O!HU6L69#)_9F"&8850:&28L\+0LZ0PG?1:\>S:[&B6Y25[*!E [&&@,C
M9UK9.<*5-9\$2$$^ELLK?K(F#O2.Y9+)1^+B<>B)]CTU'1XH+X8F2#N@#L!R
M'\1-[0_,V.]?!#&"-$8.RGFVY%,K\G1G$1LSJZ>F/BQ^$SV"LX& ?.&<C65.
M>)R=)_EZ 24DD-C2SE4Z G!N;OX\^ZR/%HU>FE=-IF^4Q%GV<(:1!1XJ+>I$
M"#Q72>@Q.(C$N[*H["E>LMY?$I15&ND$K_)HL"CJ&N6W1;E(!7S3"*)$PX5B
M#2%M*E]2<];BXY#W4LO'L8$'J:8RP(,45>4,E\8 ?Y%5EN2X/Y7\)&T'M#8
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M>2!UR4LX%U_YBA;J O>Z?80<S>3PZ(!2+MYZ^D&P/$@W#WXO!6 AMN]V+^A
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MA[&(^M"'R8<:6[33^E/<.\_RO_[;N=M&=2)OYF?VI_IS/-=S")_H[1PN(%(
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MZ/?]%5Z_+^]%A\=7>WK<,;T;JLM=/>62IJK<GNZ-C0X4"4D<4X2:1[GD7_\
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MH<94"?K!A3HU3V?EY:JQ RJ 8_D.53ZD(G+9CF=FJ!5*EHURL@'.(7*RB5R
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M3U'!A-T%*Q+&WC=.P^F<52VRMZ?\UF[OR2;E>T#".R3.@])90S,+I$7G>']
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MFX\8M(*R?9XDV-A8T&S8Q8<^"=NBQ^Q4QWQ 'Q'-/X2J+6-MF O]EXT?%0F
MVE5APJ6-%7I)0+1=NR7-X%)AE@PI!QLG."74"0QCUNFKU%D!*#[&UC1^3@1
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MNC)?1)2P\S0T%Q:R6N&0M5#,Q46#0^)%K \<4#\]8H) >17:X3KA?DQ$[,3
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MSSE%"NEWJ>Q5"U3#,O0>J.X 86#S4@>@2&6) M;@\O"=_AX!-=M-S$I*=?*
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M7+DF"U]WIXWKUPZ (3Y5@%DV0KN$M;E.3%I ]ET:M&VS@>_CRX!N)3%4 M8
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M,S$M,BYH=&U02P$"% ,4    " !YA5U;NGV''L8$  "<$@  "@
M    @ &&#@  97@S,BTQ+FAT;5!+ 0(4 Q0    ( 'F%75M$&\X+J](! .ZJ
M$P +              "  703  !F;W)M,3!Q+FAT;5!+ 0(4 Q0    ( 'F%
M75O>SODXRQ0  #_B   1              "  4CF 0!I;VYS+3(P,C4P.3,P
M+GAS9%!+ 0(4 Q0    ( 'F%75O,7EW<,A,  ,(2 0 5              "
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8;6Q02P4&      D "0 L @  &ST#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>form10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:ions="http://ionis.com/20250930"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ions-20250930.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
        </entity>
        <period>
            <instant>2025-10-23</instant>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes0PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes0PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes175PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes175PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:OtherCommercialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:OtherCommercialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:OtherCommercialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:OtherCommercialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:CommercialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:CommercialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:CommercialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:CommercialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:CollaborativeAgreementRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:CollaborativeAgreementRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:CollaborativeAgreementRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:CollaborativeAgreementRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:WainuaJointDevelopmentRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:WainuaJointDevelopmentRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:WainuaJointDevelopmentRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:WainuaJointDevelopmentRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:AstraZenecaCollaborationWainuaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:AstraZenecaCollaborationWainuaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:AstraZenecaCollaborationWainuaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:TryngolzaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:TryngolzaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:TryngolzaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:TryngolzaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:SpinrazaRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:SpinrazaRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:SpinrazaRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:SpinrazaRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:WainusRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:WainusRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:WainusRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:WainusRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:OtherRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:OtherRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:OtherRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:OtherRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:AstraZenecaCollaborationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:AstraZenecaCollaborationWAINUAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:AstraZenecaCollaborationCardiovascularRenalAndMetabolicDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:AstraZenecaCollaborationCardiovascularRenalAndMetabolicDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:AstraZenecaCollaborationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:OnoCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:OnoCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:OnoCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentServicesForSapablursenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:OnoCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:LicenseOfSapablursenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:OnoCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentServicesForSapablursenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:OnoCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:LicenseOfSapablursenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:OnoCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:OnoCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:AstraZenecaCollaborationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:AstraZenecaCollaborationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:AstraZenecaCollaborationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:AstraZenecaCollaborationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:AstraZenecaCollaborationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:AstraZenecaCollaborationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:AstraZenecaCollaborationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:AstraZenecaCollaborationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:OnoCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:OnoCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:OnoCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:OnoCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes175PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes0PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes0125PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ions:EquitySecuritiesPubliclyTradedCompaniesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ions:EquitySecuritiesPrivateCompaniesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ions:EquitySecuritiesPrivateCompaniesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ions:EquitySecuritiesPrivateCompaniesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ions:EquitySecuritiesPubliclyTradedCompaniesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ions:EquitySecuritiesPrivateCompaniesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ions:EquitySecuritiesPubliclyTradedCompaniesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ions:EquitySecuritiesPrivateCompaniesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes175PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes0PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes175PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes0PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ions:EquitySecuritiesPubliclyTradedCompaniesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ions:EquitySecuritiesPubliclyTradedCompaniesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ions:EquitySecuritiesPubliclyTradedCompaniesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ions:EquitySecuritiesPubliclyTradedCompaniesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ions:EquitySecuritiesPubliclyTradedCompaniesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ions:EquitySecuritiesPubliclyTradedCompaniesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">ions:GrantedIn2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">ions:GrantedIn2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">ions:GrantedIn2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">ions:GrantedIn2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">ions:GrantedIn2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">ions:GrantedIn2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">ions:GrantedIn2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">ions:GrantedIn2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ions:ResearchDevelopmentAndPatentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ions:ResearchDevelopmentAndPatentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ions:ResearchDevelopmentAndPatentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ions:ResearchDevelopmentAndPatentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">ions:ShareBasedPaymentArrangementBoardOfDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">ions:ShareBasedPaymentArrangementBoardOfDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:SpinrazaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:SpinrazaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:SpinrazaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:PelacarsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes175PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes0PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes0PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes175PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes0PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ions:HeadquartersLocationInCarlsbadCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ions:HeadquartersLocationInCarlsbadCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:IonisOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:IonisOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:IonisOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:IonisOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Segment">
        <measure>ions:Segment</measure>
    </unit>
    <unit id="Component">
        <measure>ions:Component</measure>
    </unit>
    <unit id="PerformanceObligation">
        <measure>ions:PerformanceObligation</measure>
    </unit>
    <unit id="Agreement">
        <measure>ions:Agreement</measure>
    </unit>
    <unit id="Company">
        <measure>ions:Company</measure>
    </unit>
    <unit id="Investment">
        <measure>ions:Investment</measure>
    </unit>
    <unit id="Option">
        <measure>ions:Option</measure>
    </unit>
    <unit id="Lot">
        <measure>ions:Lot</measure>
    </unit>
    <dei:DocumentType contextRef="c0" id="ixv-11124">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c0" id="ixv-29">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c0" id="ixv-11125">2025-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c0" id="ixv-11126">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="c0" id="ixv-48">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c0" id="ixv-11127">000-19125</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c0" id="ixv-77">Ionis Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0" id="ixv-89">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c0" id="ixv-96">33-0336973</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c0" id="ixv-11128">2855 Gazelle Court</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c0" id="ixv-11129">Carlsbad</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c0" id="ixv-11130">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c0" id="ixv-120">92010</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c0" id="ixv-11131">760</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c0" id="ixv-11132">931-9200</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c0" id="ixv-172">Common Stock, $.001 Par Value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c0" id="ixv-11133">IONS</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c0" id="ixv-11134">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c0" id="ixv-11135">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c0" id="ixv-11136">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c0" id="ixv-11137">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c0" id="ixv-245">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c0" id="ixv-252">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c0" id="ixv-266">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="c1"
      decimals="INF"
      id="ixv-11138"
      unitRef="shares">161974393</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c2" decimals="-3" id="ixv-11139" unitRef="usd">338341000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c3" decimals="-3" id="ixv-11140" unitRef="usd">242077000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments contextRef="c2" decimals="-3" id="ixv-11141" unitRef="usd">1901830000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments contextRef="c3" decimals="-3" id="ixv-11142" unitRef="usd">2055579000</us-gaap:ShortTermInvestments>
    <us-gaap:ContractWithCustomerAssetNetCurrent contextRef="c2" decimals="-3" id="ixv-11143" unitRef="usd">24608000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent contextRef="c3" decimals="-3" id="ixv-11144" unitRef="usd">92188000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:InventoryNet contextRef="c2" decimals="-3" id="ixv-11145" unitRef="usd">10470000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c3" decimals="-3" id="ixv-11146" unitRef="usd">12512000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent contextRef="c2" decimals="-3" id="ixv-11147" unitRef="usd">243744000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c3" decimals="-3" id="ixv-11148" unitRef="usd">217934000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c2" decimals="-3" id="ixv-11149" unitRef="usd">2518993000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c3" decimals="-3" id="ixv-11150" unitRef="usd">2620290000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c2" decimals="-3" id="ixv-11151" unitRef="usd">106117000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="-3" id="ixv-11152" unitRef="usd">94251000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c2" decimals="-3" id="ixv-11153" unitRef="usd">241993000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c3" decimals="-3" id="ixv-11154" unitRef="usd">161856000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent contextRef="c2" decimals="-3" id="ixv-11155" unitRef="usd">165988000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c3" decimals="-3" id="ixv-11156" unitRef="usd">127278000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c2" decimals="-3" id="ixv-11157" unitRef="usd">3033091000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c3" decimals="-3" id="ixv-11158" unitRef="usd">3003675000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c2" decimals="-3" id="ixv-11159" unitRef="usd">14326000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c3" decimals="-3" id="ixv-11160" unitRef="usd">42964000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c2" decimals="-3" id="ixv-11161" unitRef="usd">57019000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c3" decimals="-3" id="ixv-11162" unitRef="usd">69614000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c2" decimals="-3" id="ixv-11163" unitRef="usd">99310000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c3" decimals="-3" id="ixv-11164" unitRef="usd">108438000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent contextRef="c2" decimals="-3" id="ixv-11165" unitRef="usd">101000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent contextRef="c3" decimals="-3" id="ixv-11166" unitRef="usd">34000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c4" decimals="2" id="ixv-11167" unitRef="pure">0</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c5" decimals="2" id="ixv-11168" unitRef="pure">0</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ConvertibleDebtCurrent contextRef="c2" decimals="-3" id="ixv-11169" unitRef="usd">630911000</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:ConvertibleDebtCurrent contextRef="c3" decimals="-3" id="ixv-11170" unitRef="usd">0</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c2" decimals="-3" id="ixv-11171" unitRef="usd">76986000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c3" decimals="-3" id="ixv-11172" unitRef="usd">78989000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c2" decimals="-3" id="ixv-11173" unitRef="usd">24803000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c3" decimals="-3" id="ixv-11174" unitRef="usd">9279000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c2" decimals="-3" id="ixv-11175" unitRef="usd">903456000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c3" decimals="-3" id="ixv-11176" unitRef="usd">309318000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c2" decimals="-3" id="ixv-11177" unitRef="usd">107906000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c3" decimals="-3" id="ixv-11178" unitRef="usd">156504000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c6" decimals="4" id="ixv-11179" unitRef="pure">0.0175</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c7" decimals="4" id="ixv-11180" unitRef="pure">0.0175</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ConvertibleDebtNoncurrent contextRef="c6" decimals="-3" id="ixv-11181" unitRef="usd">567123000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:ConvertibleDebtNoncurrent contextRef="c7" decimals="-3" id="ixv-11182" unitRef="usd">565026000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c4" decimals="2" id="ixv-11183" unitRef="pure">0</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c5" decimals="2" id="ixv-11184" unitRef="pure">0</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ConvertibleDebtNoncurrent contextRef="c4" decimals="-3" id="ixv-11185" unitRef="usd">0</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:ConvertibleDebtNoncurrent contextRef="c5" decimals="-3" id="ixv-11186" unitRef="usd">628535000</us-gaap:ConvertibleDebtNoncurrent>
    <ions:LiabilityRelatedToSaleOfFutureRoyaltiesNetNoncurrent contextRef="c2" decimals="-3" id="ixv-11187" unitRef="usd">545182000</ions:LiabilityRelatedToSaleOfFutureRoyaltiesNetNoncurrent>
    <ions:LiabilityRelatedToSaleOfFutureRoyaltiesNetNoncurrent contextRef="c3" decimals="-3" id="ixv-11188" unitRef="usd">542212000</ions:LiabilityRelatedToSaleOfFutureRoyaltiesNetNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c2" decimals="-3" id="ixv-11189" unitRef="usd">262672000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c3" decimals="-3" id="ixv-11190" unitRef="usd">161805000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c2" decimals="-3" id="ixv-11191" unitRef="usd">28785000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c3" decimals="-3" id="ixv-11192" unitRef="usd">51924000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c2" decimals="-3" id="ixv-11193" unitRef="usd">2415124000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c3" decimals="-3" id="ixv-11194" unitRef="usd">2415324000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c2"
      decimals="INF"
      id="ixv-11195"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c3"
      decimals="INF"
      id="ixv-11196"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c2"
      decimals="INF"
      id="ixv-11197"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c3"
      decimals="INF"
      id="ixv-11198"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c2"
      decimals="INF"
      id="ixv-11199"
      unitRef="shares">161137930</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c2"
      decimals="INF"
      id="ixv-11200"
      unitRef="shares">161137930</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c3"
      decimals="INF"
      id="ixv-11201"
      unitRef="shares">157908815</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c3"
      decimals="INF"
      id="ixv-11202"
      unitRef="shares">157908815</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c2" decimals="-3" id="ixv-11203" unitRef="usd">161000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c3" decimals="-3" id="ixv-11204" unitRef="usd">158000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c2" decimals="-3" id="ixv-11205" unitRef="usd">3045585000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c3" decimals="-3" id="ixv-11206" unitRef="usd">2868812000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c2" decimals="-3" id="ixv-11207" unitRef="usd">-25978000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c3" decimals="-3" id="ixv-11208" unitRef="usd">-30811000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c2" decimals="-3" id="ixv-11209" unitRef="usd">-2401801000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c3" decimals="-3" id="ixv-11210" unitRef="usd">-2249808000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="-3" id="ixv-11211" unitRef="usd">617967000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="-3" id="ixv-11212" unitRef="usd">588351000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c2" decimals="-3" id="ixv-11213" unitRef="usd">3033091000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c3" decimals="-3" id="ixv-11214" unitRef="usd">3003675000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c8" decimals="-3" id="ixv-11215" unitRef="usd">31792000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c9" decimals="-3" id="ixv-11216" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c10" decimals="-3" id="ixv-11217" unitRef="usd">57353000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c11" decimals="-3" id="ixv-11218" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c12" decimals="-3" id="ixv-11219" unitRef="usd">75694000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c13" decimals="-3" id="ixv-11220" unitRef="usd">66807000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c14" decimals="-3" id="ixv-11221" unitRef="usd">209811000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c15" decimals="-3" id="ixv-11222" unitRef="usd">180036000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c16" decimals="-3" id="ixv-11223" unitRef="usd">8112000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c17" decimals="-3" id="ixv-11224" unitRef="usd">8924000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c18" decimals="-3" id="ixv-11225" unitRef="usd">27359000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c19" decimals="-3" id="ixv-11226" unitRef="usd">27324000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c20" decimals="-3" id="ixv-11227" unitRef="usd">115598000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c21" decimals="-3" id="ixv-11228" unitRef="usd">75731000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c22" decimals="-3" id="ixv-11229" unitRef="usd">294523000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c23" decimals="-3" id="ixv-11230" unitRef="usd">207360000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c24" decimals="-3" id="ixv-11231" unitRef="usd">31436000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c25" decimals="-3" id="ixv-11232" unitRef="usd">44883000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c26" decimals="-3" id="ixv-11233" unitRef="usd">413387000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c27" decimals="-3" id="ixv-11234" unitRef="usd">235753000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c28" decimals="-3" id="ixv-11235" unitRef="usd">9685000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c29" decimals="-3" id="ixv-11236" unitRef="usd">13200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c30" decimals="-3" id="ixv-11237" unitRef="usd">32471000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c31" decimals="-3" id="ixv-11238" unitRef="usd">35449000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c32" decimals="-3" id="ixv-11239" unitRef="usd">41121000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c33" decimals="-3" id="ixv-11240" unitRef="usd">58083000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c34" decimals="-3" id="ixv-11241" unitRef="usd">445858000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c35" decimals="-3" id="ixv-11242" unitRef="usd">271202000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c36" decimals="-3" id="ixv-11243" unitRef="usd">156719000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c37" decimals="-3" id="ixv-11244" unitRef="usd">133814000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c0" decimals="-3" id="ixv-11245" unitRef="usd">740381000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c38" decimals="-3" id="ixv-11246" unitRef="usd">478562000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c36" decimals="-3" id="ixv-11247" unitRef="usd">2338000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c37" decimals="-3" id="ixv-11248" unitRef="usd">1071000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c0" decimals="-3" id="ixv-11249" unitRef="usd">7952000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c38" decimals="-3" id="ixv-11250" unitRef="usd">7385000</us-gaap:CostOfGoodsAndServicesSold>
    <ions:ResearchDevelopmentAndPatentExpense contextRef="c36" decimals="-3" id="ixv-11251" unitRef="usd">217754000</ions:ResearchDevelopmentAndPatentExpense>
    <ions:ResearchDevelopmentAndPatentExpense contextRef="c37" decimals="-3" id="ixv-11252" unitRef="usd">219761000</ions:ResearchDevelopmentAndPatentExpense>
    <ions:ResearchDevelopmentAndPatentExpense contextRef="c0" decimals="-3" id="ixv-11253" unitRef="usd">635973000</ions:ResearchDevelopmentAndPatentExpense>
    <ions:ResearchDevelopmentAndPatentExpense contextRef="c38" decimals="-3" id="ixv-11254" unitRef="usd">656040000</ions:ResearchDevelopmentAndPatentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c36" decimals="-3" id="ixv-11255" unitRef="usd">96809000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c37" decimals="-3" id="ixv-11256" unitRef="usd">61638000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c0" decimals="-3" id="ixv-11257" unitRef="usd">263681000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c38" decimals="-3" id="ixv-11258" unitRef="usd">179395000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses contextRef="c36" decimals="-3" id="ixv-11259" unitRef="usd">316901000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c37" decimals="-3" id="ixv-11260" unitRef="usd">282470000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c0" decimals="-3" id="ixv-11261" unitRef="usd">907606000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c38" decimals="-3" id="ixv-11262" unitRef="usd">842820000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c36" decimals="-3" id="ixv-11263" unitRef="usd">-160182000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c37" decimals="-3" id="ixv-11264" unitRef="usd">-148656000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c0" decimals="-3" id="ixv-11265" unitRef="usd">-167225000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c38" decimals="-3" id="ixv-11266" unitRef="usd">-364258000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeNet contextRef="c36" decimals="-3" id="ixv-11267" unitRef="usd">23682000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet contextRef="c37" decimals="-3" id="ixv-11268" unitRef="usd">26228000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet contextRef="c0" decimals="-3" id="ixv-11269" unitRef="usd">73035000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet contextRef="c38" decimals="-3" id="ixv-11270" unitRef="usd">78112000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InterestExpense contextRef="c36" decimals="-3" id="ixv-11271" unitRef="usd">4212000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c37" decimals="-3" id="ixv-11272" unitRef="usd">4161000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c0" decimals="-3" id="ixv-11273" unitRef="usd">12434000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c38" decimals="-3" id="ixv-11274" unitRef="usd">12803000</us-gaap:InterestExpense>
    <ions:InterestExpenseAndAmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties contextRef="c36" decimals="-3" id="ixv-11275" unitRef="usd">17952000</ions:InterestExpenseAndAmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties>
    <ions:InterestExpenseAndAmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties contextRef="c37" decimals="-3" id="ixv-11276" unitRef="usd">18533000</ions:InterestExpenseAndAmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties>
    <ions:InterestExpenseAndAmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties contextRef="c0" decimals="-3" id="ixv-11277" unitRef="usd">55422000</ions:InterestExpenseAndAmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties>
    <ions:InterestExpenseAndAmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties contextRef="c38" decimals="-3" id="ixv-11278" unitRef="usd">54788000</ions:InterestExpenseAndAmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties>
    <us-gaap:GainLossOnInvestments contextRef="c36" decimals="-3" id="ixv-11279" unitRef="usd">29908000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments contextRef="c37" decimals="-3" id="ixv-11280" unitRef="usd">879000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments contextRef="c0" decimals="-3" id="ixv-11281" unitRef="usd">9432000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments contextRef="c38" decimals="-3" id="ixv-11282" unitRef="usd">-321000</us-gaap:GainLossOnInvestments>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c36" decimals="-3" id="ixv-11283" unitRef="usd">363000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c37" decimals="-3" id="ixv-11284" unitRef="usd">142000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c0" decimals="-3" id="ixv-11285" unitRef="usd">929000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c38" decimals="-3" id="ixv-11286" unitRef="usd">1029000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c36" decimals="-3" id="ixv-11287" unitRef="usd">-128393000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c37" decimals="-3" id="ixv-11288" unitRef="usd">-144101000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c0" decimals="-3" id="ixv-11289" unitRef="usd">-151685000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c38" decimals="-3" id="ixv-11290" unitRef="usd">-353029000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c36" decimals="-3" id="ixv-11291" unitRef="usd">213000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c37" decimals="-3" id="ixv-11292" unitRef="usd">-3621000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c0" decimals="-3" id="ixv-11293" unitRef="usd">308000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c38" decimals="-3" id="ixv-11294" unitRef="usd">-3481000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c36" decimals="-3" id="ixv-11295" unitRef="usd">-128606000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c37" decimals="-3" id="ixv-11296" unitRef="usd">-140480000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-11297" unitRef="usd">-151993000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c38" decimals="-3" id="ixv-11298" unitRef="usd">-349548000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c36"
      decimals="2"
      id="ixv-11299"
      unitRef="usdPershares">-0.8</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c36"
      decimals="2"
      id="ixv-11300"
      unitRef="usdPershares">-0.8</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c37"
      decimals="2"
      id="ixv-11301"
      unitRef="usdPershares">-0.95</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c37"
      decimals="2"
      id="ixv-11302"
      unitRef="usdPershares">-0.95</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c0"
      decimals="2"
      id="ixv-11303"
      unitRef="usdPershares">-0.95</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c0"
      decimals="2"
      id="ixv-11304"
      unitRef="usdPershares">-0.95</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c38"
      decimals="2"
      id="ixv-11305"
      unitRef="usdPershares">-2.38</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c38"
      decimals="2"
      id="ixv-11306"
      unitRef="usdPershares">-2.38</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c36"
      decimals="-3"
      id="ixv-11307"
      unitRef="shares">159765000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c36"
      decimals="-3"
      id="ixv-11308"
      unitRef="shares">159765000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c37"
      decimals="-3"
      id="ixv-11309"
      unitRef="shares">148593000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c37"
      decimals="-3"
      id="ixv-11310"
      unitRef="shares">148593000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c0"
      decimals="-3"
      id="ixv-11311"
      unitRef="shares">159216000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c0"
      decimals="-3"
      id="ixv-11312"
      unitRef="shares">159216000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c38"
      decimals="-3"
      id="ixv-11313"
      unitRef="shares">146703000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c38"
      decimals="-3"
      id="ixv-11314"
      unitRef="shares">146703000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss contextRef="c36" decimals="-3" id="ixv-11315" unitRef="usd">-128606000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c37" decimals="-3" id="ixv-11316" unitRef="usd">-140480000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-11317" unitRef="usd">-151993000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c38" decimals="-3" id="ixv-11318" unitRef="usd">-349548000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c36" decimals="-3" id="ixv-11319" unitRef="usd">2091000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c37" decimals="-3" id="ixv-11320" unitRef="usd">10315000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c0" decimals="-3" id="ixv-11321" unitRef="usd">4088000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c38" decimals="-3" id="ixv-11322" unitRef="usd">8259000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c36" decimals="-3" id="ixv-11323" unitRef="usd">-82000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c37" decimals="-3" id="ixv-11324" unitRef="usd">350000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c0" decimals="-3" id="ixv-11325" unitRef="usd">745000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c38" decimals="-3" id="ixv-11326" unitRef="usd">213000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c36" decimals="-3" id="ixv-11327" unitRef="usd">-126597000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c37" decimals="-3" id="ixv-11328" unitRef="usd">-129815000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c0" decimals="-3" id="ixv-11329" unitRef="usd">-147160000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c38" decimals="-3" id="ixv-11330" unitRef="usd">-341076000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesIssued
      contextRef="c39"
      decimals="-3"
      id="ixv-11331"
      unitRef="shares">146025000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity contextRef="c39" decimals="-3" id="ixv-11332" unitRef="usd">146000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c40" decimals="-3" id="ixv-11333" unitRef="usd">2303369000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c41" decimals="-3" id="ixv-11334" unitRef="usd">-34838000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c42" decimals="-3" id="ixv-11335" unitRef="usd">-2004979000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c43" decimals="-3" id="ixv-11336" unitRef="usd">263698000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c44" decimals="-3" id="ixv-11337" unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c45" decimals="-3" id="ixv-11338" unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c46" decimals="-3" id="ixv-11339" unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c47" decimals="-3" id="ixv-11340" unitRef="usd">-140480000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c37" decimals="-3" id="ixv-11341" unitRef="usd">-140480000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c44" decimals="-3" id="ixv-11342" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c45" decimals="-3" id="ixv-11343" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c46" decimals="-3" id="ixv-11344" unitRef="usd">10315000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c47" decimals="-3" id="ixv-11345" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c37" decimals="-3" id="ixv-11346" unitRef="usd">10315000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c44" decimals="-3" id="ixv-11347" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c45" decimals="-3" id="ixv-11348" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c46" decimals="-3" id="ixv-11349" unitRef="usd">350000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c47" decimals="-3" id="ixv-11350" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c37" decimals="-3" id="ixv-11351" unitRef="usd">350000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c44"
      decimals="-3"
      id="ixv-11352"
      unitRef="shares">288000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross contextRef="c44" decimals="-3" id="ixv-11353" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross contextRef="c45" decimals="-3" id="ixv-11354" unitRef="usd">7002000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross contextRef="c46" decimals="-3" id="ixv-11355" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross contextRef="c47" decimals="-3" id="ixv-11356" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross contextRef="c37" decimals="-3" id="ixv-11357" unitRef="usd">7002000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c44"
      decimals="-3"
      id="ixv-11358"
      unitRef="shares">11500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c44" decimals="-3" id="ixv-11359" unitRef="usd">12000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c45" decimals="-3" id="ixv-11360" unitRef="usd">489081000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c46" decimals="-3" id="ixv-11361" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c47" decimals="-3" id="ixv-11362" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c37" decimals="-3" id="ixv-11363" unitRef="usd">489093000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c44" decimals="-3" id="ixv-11364" unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c45" decimals="-3" id="ixv-11365" unitRef="usd">32490000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c46" decimals="-3" id="ixv-11366" unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c47" decimals="-3" id="ixv-11367" unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c37" decimals="-3" id="ixv-11368" unitRef="usd">32490000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:SharesIssued
      contextRef="c48"
      decimals="-3"
      id="ixv-11369"
      unitRef="shares">157813000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity contextRef="c48" decimals="-3" id="ixv-11370" unitRef="usd">158000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c49" decimals="-3" id="ixv-11371" unitRef="usd">2831942000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c50" decimals="-3" id="ixv-11372" unitRef="usd">-24173000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c51" decimals="-3" id="ixv-11373" unitRef="usd">-2145459000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c52" decimals="-3" id="ixv-11374" unitRef="usd">662468000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="c53"
      decimals="-3"
      id="ixv-11375"
      unitRef="shares">159197000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity contextRef="c53" decimals="-3" id="ixv-11376" unitRef="usd">159000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c54" decimals="-3" id="ixv-11377" unitRef="usd">2932747000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c55" decimals="-3" id="ixv-11378" unitRef="usd">-27987000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c56" decimals="-3" id="ixv-11379" unitRef="usd">-2273195000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c57" decimals="-3" id="ixv-11380" unitRef="usd">631724000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c58" decimals="-3" id="ixv-11381" unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c59" decimals="-3" id="ixv-11382" unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c60" decimals="-3" id="ixv-11383" unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c61" decimals="-3" id="ixv-11384" unitRef="usd">-128606000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c36" decimals="-3" id="ixv-11385" unitRef="usd">-128606000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c58" decimals="-3" id="ixv-11386" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c59" decimals="-3" id="ixv-11387" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c60" decimals="-3" id="ixv-11388" unitRef="usd">2091000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c61" decimals="-3" id="ixv-11389" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c36" decimals="-3" id="ixv-11390" unitRef="usd">2091000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c58" decimals="-3" id="ixv-11391" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c59" decimals="-3" id="ixv-11392" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c60" decimals="-3" id="ixv-11393" unitRef="usd">-82000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c61" decimals="-3" id="ixv-11394" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c36" decimals="-3" id="ixv-11395" unitRef="usd">-82000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c58"
      decimals="-3"
      id="ixv-11396"
      unitRef="shares">1941000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross contextRef="c58" decimals="-3" id="ixv-11397" unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross contextRef="c59" decimals="-3" id="ixv-11398" unitRef="usd">81257000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross contextRef="c60" decimals="-3" id="ixv-11399" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross contextRef="c61" decimals="-3" id="ixv-11400" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross contextRef="c36" decimals="-3" id="ixv-11401" unitRef="usd">81259000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c58" decimals="-3" id="ixv-11402" unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c59" decimals="-3" id="ixv-11403" unitRef="usd">31581000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c60" decimals="-3" id="ixv-11404" unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c61" decimals="-3" id="ixv-11405" unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c36" decimals="-3" id="ixv-11406" unitRef="usd">31581000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:SharesIssued
      contextRef="c62"
      decimals="-3"
      id="ixv-11407"
      unitRef="shares">161138000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity contextRef="c62" decimals="-3" id="ixv-11408" unitRef="usd">161000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c63" decimals="-3" id="ixv-11409" unitRef="usd">3045585000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c64" decimals="-3" id="ixv-11410" unitRef="usd">-25978000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c65" decimals="-3" id="ixv-11411" unitRef="usd">-2401801000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="-3" id="ixv-11412" unitRef="usd">617967000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="c66"
      decimals="-3"
      id="ixv-11413"
      unitRef="shares">144341000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity contextRef="c66" decimals="-3" id="ixv-11414" unitRef="usd">144000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c67" decimals="-3" id="ixv-11415" unitRef="usd">2215098000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c68" decimals="-3" id="ixv-11416" unitRef="usd">-32645000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c69" decimals="-3" id="ixv-11417" unitRef="usd">-1795911000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c70" decimals="-3" id="ixv-11418" unitRef="usd">386686000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c71" decimals="-3" id="ixv-11419" unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c72" decimals="-3" id="ixv-11420" unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c73" decimals="-3" id="ixv-11421" unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c74" decimals="-3" id="ixv-11422" unitRef="usd">-349548000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c38" decimals="-3" id="ixv-11423" unitRef="usd">-349548000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c71" decimals="-3" id="ixv-11424" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c72" decimals="-3" id="ixv-11425" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c73" decimals="-3" id="ixv-11426" unitRef="usd">8259000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c74" decimals="-3" id="ixv-11427" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c38" decimals="-3" id="ixv-11428" unitRef="usd">8259000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c71" decimals="-3" id="ixv-11429" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c72" decimals="-3" id="ixv-11430" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c73" decimals="-3" id="ixv-11431" unitRef="usd">213000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c74" decimals="-3" id="ixv-11432" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c38" decimals="-3" id="ixv-11433" unitRef="usd">213000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c71"
      decimals="-3"
      id="ixv-11434"
      unitRef="shares">1972000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross contextRef="c71" decimals="-3" id="ixv-11435" unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross contextRef="c72" decimals="-3" id="ixv-11436" unitRef="usd">33205000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross contextRef="c73" decimals="-3" id="ixv-11437" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross contextRef="c74" decimals="-3" id="ixv-11438" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross contextRef="c38" decimals="-3" id="ixv-11439" unitRef="usd">33207000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c71"
      decimals="-3"
      id="ixv-11440"
      unitRef="shares">11500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c71" decimals="-3" id="ixv-11441" unitRef="usd">12000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c72" decimals="-3" id="ixv-11442" unitRef="usd">489081000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c73" decimals="-3" id="ixv-11443" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c74" decimals="-3" id="ixv-11444" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c38" decimals="-3" id="ixv-11445" unitRef="usd">489093000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c71" decimals="-3" id="ixv-11446" unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c72" decimals="-3" id="ixv-11447" unitRef="usd">94558000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c73" decimals="-3" id="ixv-11448" unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c74" decimals="-3" id="ixv-11449" unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c38" decimals="-3" id="ixv-11450" unitRef="usd">94558000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:SharesIssued
      contextRef="c48"
      decimals="-3"
      id="ixv-11451"
      unitRef="shares">157813000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity contextRef="c48" decimals="-3" id="ixv-11452" unitRef="usd">158000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c49" decimals="-3" id="ixv-11453" unitRef="usd">2831942000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c50" decimals="-3" id="ixv-11454" unitRef="usd">-24173000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c51" decimals="-3" id="ixv-11455" unitRef="usd">-2145459000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c52" decimals="-3" id="ixv-11456" unitRef="usd">662468000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="c75"
      decimals="-3"
      id="ixv-11457"
      unitRef="shares">157909000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity contextRef="c75" decimals="-3" id="ixv-11458" unitRef="usd">158000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c76" decimals="-3" id="ixv-11459" unitRef="usd">2868812000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c77" decimals="-3" id="ixv-11460" unitRef="usd">-30811000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c78" decimals="-3" id="ixv-11461" unitRef="usd">-2249808000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="-3" id="ixv-11462" unitRef="usd">588351000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c79" decimals="-3" id="ixv-11463" unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c80" decimals="-3" id="ixv-11464" unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c81" decimals="-3" id="ixv-11465" unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c82" decimals="-3" id="ixv-11466" unitRef="usd">-151993000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-11467" unitRef="usd">-151993000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c79" decimals="-3" id="ixv-11468" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c80" decimals="-3" id="ixv-11469" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c81" decimals="-3" id="ixv-11470" unitRef="usd">4088000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c82" decimals="-3" id="ixv-11471" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c0" decimals="-3" id="ixv-11472" unitRef="usd">4088000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c79" decimals="-3" id="ixv-11473" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c80" decimals="-3" id="ixv-11474" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c81" decimals="-3" id="ixv-11475" unitRef="usd">745000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c82" decimals="-3" id="ixv-11476" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c0" decimals="-3" id="ixv-11477" unitRef="usd">745000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c79"
      decimals="-3"
      id="ixv-11478"
      unitRef="shares">3229000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross contextRef="c79" decimals="-3" id="ixv-11479" unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross contextRef="c80" decimals="-3" id="ixv-11480" unitRef="usd">84784000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross contextRef="c81" decimals="-3" id="ixv-11481" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross contextRef="c82" decimals="-3" id="ixv-11482" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross contextRef="c0" decimals="-3" id="ixv-11483" unitRef="usd">84787000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c79" decimals="-3" id="ixv-11484" unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c80" decimals="-3" id="ixv-11485" unitRef="usd">91989000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c81" decimals="-3" id="ixv-11486" unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c82" decimals="-3" id="ixv-11487" unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c0" decimals="-3" id="ixv-11488" unitRef="usd">91989000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:SharesIssued
      contextRef="c62"
      decimals="-3"
      id="ixv-11489"
      unitRef="shares">161138000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity contextRef="c62" decimals="-3" id="ixv-11490" unitRef="usd">161000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c63" decimals="-3" id="ixv-11491" unitRef="usd">3045585000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c64" decimals="-3" id="ixv-11492" unitRef="usd">-25978000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c65" decimals="-3" id="ixv-11493" unitRef="usd">-2401801000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="-3" id="ixv-11494" unitRef="usd">617967000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-11495" unitRef="usd">-151993000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c38" decimals="-3" id="ixv-11496" unitRef="usd">-349548000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation contextRef="c0" decimals="-3" id="ixv-11497" unitRef="usd">6749000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c38" decimals="-3" id="ixv-11498" unitRef="usd">7374000</us-gaap:Depreciation>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c0" decimals="-3" id="ixv-11499" unitRef="usd">6803000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c38" decimals="-3" id="ixv-11500" unitRef="usd">7472000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c0" decimals="-3" id="ixv-11501" unitRef="usd">1801000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c38" decimals="-3" id="ixv-11502" unitRef="usd">1877000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c0" decimals="-3" id="ixv-11503" unitRef="usd">18063000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c38" decimals="-3" id="ixv-11504" unitRef="usd">28283000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c0" decimals="-3" id="ixv-11505" unitRef="usd">4940000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c38" decimals="-3" id="ixv-11506" unitRef="usd">5016000</us-gaap:AmortizationOfFinancingCosts>
    <ions:RoyaltyPayments contextRef="c0" decimals="-3" id="ixv-11507" unitRef="usd">38478000</ions:RoyaltyPayments>
    <ions:RoyaltyPayments contextRef="c38" decimals="-3" id="ixv-11508" unitRef="usd">30422000</ions:RoyaltyPayments>
    <ions:InterestExpenseRelatedToSaleOfFutureRoyalties contextRef="c0" decimals="-3" id="ixv-11509" unitRef="usd">54964000</ions:InterestExpenseRelatedToSaleOfFutureRoyalties>
    <ions:InterestExpenseRelatedToSaleOfFutureRoyalties contextRef="c38" decimals="-3" id="ixv-11510" unitRef="usd">54330000</ions:InterestExpenseRelatedToSaleOfFutureRoyalties>
    <us-gaap:ShareBasedCompensation contextRef="c0" decimals="-3" id="ixv-11511" unitRef="usd">90554000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c38" decimals="-3" id="ixv-11512" unitRef="usd">94052000</us-gaap:ShareBasedCompensation>
    <us-gaap:RealizedInvestmentGainsLosses contextRef="c0" decimals="-3" id="ixv-11513" unitRef="usd">9437000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses contextRef="c38" decimals="-3" id="ixv-11514" unitRef="usd">-320000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c0" decimals="-3" id="ixv-11515" unitRef="usd">-3643000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c38" decimals="-3" id="ixv-11516" unitRef="usd">1009000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset contextRef="c0" decimals="-3" id="ixv-11517" unitRef="usd">-67580000</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset contextRef="c38" decimals="-3" id="ixv-11518" unitRef="usd">-79850000</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c0" decimals="-3" id="ixv-11519" unitRef="usd">14600000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c38" decimals="-3" id="ixv-11520" unitRef="usd">27000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c0" decimals="-3" id="ixv-11521" unitRef="usd">123489000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c38" decimals="-3" id="ixv-11522" unitRef="usd">8155000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c0" decimals="-3" id="ixv-11523" unitRef="usd">-29116000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c38" decimals="-3" id="ixv-11524" unitRef="usd">-19215000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable contextRef="c0" decimals="-3" id="ixv-11525" unitRef="usd">67000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable contextRef="c38" decimals="-3" id="ixv-11526" unitRef="usd">-2110000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInOtherEmployeeRelatedLiabilities contextRef="c0" decimals="-3" id="ixv-11527" unitRef="usd">-12595000</us-gaap:IncreaseDecreaseInOtherEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherEmployeeRelatedLiabilities contextRef="c38" decimals="-3" id="ixv-11528" unitRef="usd">-27169000</us-gaap:IncreaseDecreaseInOtherEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities contextRef="c0" decimals="-3" id="ixv-11529" unitRef="usd">87683000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities contextRef="c38" decimals="-3" id="ixv-11530" unitRef="usd">-28661000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c0" decimals="-3" id="ixv-11531" unitRef="usd">-50601000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c38" decimals="-3" id="ixv-11532" unitRef="usd">-142518000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="-3" id="ixv-11533" unitRef="usd">-130874000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c38" decimals="-3" id="ixv-11534" unitRef="usd">-384808000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c0" decimals="-3" id="ixv-11535" unitRef="usd">1126595000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c38" decimals="-3" id="ixv-11536" unitRef="usd">1519227000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="c0" decimals="-3" id="ixv-11537" unitRef="usd">1302751000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="c38" decimals="-3" id="ixv-11538" unitRef="usd">1339284000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c0" decimals="-3" id="ixv-11539" unitRef="usd">30152000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c38" decimals="-3" id="ixv-11540" unitRef="usd">19783000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c0" decimals="-3" id="ixv-11541" unitRef="usd">4275000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c38" decimals="-3" id="ixv-11542" unitRef="usd">2514000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c0" decimals="-3" id="ixv-11543" unitRef="usd">141729000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c38" decimals="-3" id="ixv-11544" unitRef="usd">-202240000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c0" decimals="-3" id="ixv-11545" unitRef="usd">84787000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c38" decimals="-3" id="ixv-11546" unitRef="usd">33207000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c0" decimals="-3" id="ixv-11547" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c38" decimals="-3" id="ixv-11548" unitRef="usd">489093000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:RepaymentsOfSecuredDebt contextRef="c0" decimals="-3" id="ixv-11549" unitRef="usd">123000</us-gaap:RepaymentsOfSecuredDebt>
    <us-gaap:RepaymentsOfSecuredDebt contextRef="c38" decimals="-3" id="ixv-11550" unitRef="usd">126000</us-gaap:RepaymentsOfSecuredDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c0" decimals="-3" id="ixv-11551" unitRef="usd">84664000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c38" decimals="-3" id="ixv-11552" unitRef="usd">522174000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c0" decimals="-3" id="ixv-11553" unitRef="usd">745000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c38" decimals="-3" id="ixv-11554" unitRef="usd">213000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c0" decimals="-3" id="ixv-11555" unitRef="usd">96264000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c38" decimals="-3" id="ixv-11556" unitRef="usd">-64661000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c3" decimals="-3" id="ixv-11557" unitRef="usd">242077000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c70" decimals="-3" id="ixv-11558" unitRef="usd">399266000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c2" decimals="-3" id="ixv-11559" unitRef="usd">338341000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c52" decimals="-3" id="ixv-11560" unitRef="usd">334605000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet contextRef="c0" decimals="-3" id="ixv-11561" unitRef="usd">5399000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c38" decimals="-3" id="ixv-11562" unitRef="usd">5714000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c0" decimals="-3" id="ixv-11563" unitRef="usd">-661000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c38" decimals="-3" id="ixv-11564" unitRef="usd">2072000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c0" decimals="-3" id="ixv-11565" unitRef="usd">86939000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c38" decimals="-3" id="ixv-11566" unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <ions:CapitalAndPatentExpendituresIncurredButNotYetPaid contextRef="c0" decimals="-3" id="ixv-11567" unitRef="usd">478000</ions:CapitalAndPatentExpendituresIncurredButNotYetPaid>
    <ions:CapitalAndPatentExpendituresIncurredButNotYetPaid contextRef="c38" decimals="-3" id="ixv-11568" unitRef="usd">2240000</ions:CapitalAndPatentExpendituresIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c0" id="ixv-3362">&lt;div style="text-align: justify;"&gt;
   &lt;span style="color: #000000; font-weight: bold;"&gt;1.&#160;&#160;Organization and Basis of Presentation&lt;/span&gt;
  &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span style="font-weight: bold;"&gt;Organization and Business Activity&lt;/span&gt;
  &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span&gt;We incorporated in California on January 10, 1989. In conjunction with our initial public offering, we reorganized as a Delaware corporation in April 1991. We are a fully integrated commercial-stage biotechnology company and a leader in the discovery and development of RNA-targeted therapeutics. &lt;/span&gt;&lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span style="color: #000000; font-weight: bold;"&gt;Basis of Presentation&lt;/span&gt;
  &lt;/div&gt;
  &lt;div&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span style="color: #000000;"&gt;We prepared the unaudited interim condensed consolidated financial statements for the three and nine months ended September 30, 2025 and 2024 on the same basis as the audited financial statements for the year ended December 31, 2024. We included all normal recurring adjustments in the financial statements, which we considered necessary for a fair presentation of our financial position at such dates and our operating results and cash flows for those periods. Our operating results for the interim periods may not be indicative of what our operating results will be for the entire year. For more complete financial information, these financial statements, and notes thereto, should be read in conjunction with the audited financial statements for the year ended December 31, 2024 included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission, or SEC. &lt;/span&gt; &lt;/div&gt;
  &lt;div&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span style="color: #000000;"&gt;In our condensed consolidated financial statements, we included the accounts of Ionis Pharmaceuticals, Inc. and the consolidated results of our wholly owned subsidiary, Akcea Therapeutics, Inc. and its wholly owned subsidiaries (&#x201c;we&#x201d;, &#x201c;us&#x201d; or &#x201c;our&#x201d;).&lt;/span&gt; &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span&gt;We operate as a &lt;/span&gt;&lt;span style="color: #000000;"&gt;single &lt;/span&gt;&lt;span&gt;segment, Ionis operations, because our chief operating decision maker, or CODM, reviews operating results on an aggregate basis and manages our operations as a &lt;/span&gt;&lt;span style="color: #000000;"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-0"&gt;single&lt;/span&gt; &lt;/span&gt;&lt;span&gt;operating segment. Refer to Note 15, &lt;/span&gt;&lt;span style="font-style: italic;"&gt;Segment Information&lt;/span&gt;&lt;span&gt;, for further details on our segment information.&lt;/span&gt; &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span style="color: #000000; font-weight: bold;"&gt;Use of Estimates&lt;/span&gt; &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span style="color: #000000;"&gt;We prepare our condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States, or &lt;/span&gt;&lt;span&gt;U.S., that require us to make estimates and assumptions that affect the amounts reported in our condensed consolidated financial statements and accompanying notes. Actual results could differ from our estimates.&lt;/span&gt;
  &lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c0" id="ixv-3375">&lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span style="color: #000000;"&gt;We prepared the unaudited interim condensed consolidated financial statements for the three and nine months ended September 30, 2025 and 2024 on the same basis as the audited financial statements for the year ended December 31, 2024. We included all normal recurring adjustments in the financial statements, which we considered necessary for a fair presentation of our financial position at such dates and our operating results and cash flows for those periods. Our operating results for the interim periods may not be indicative of what our operating results will be for the entire year. For more complete financial information, these financial statements, and notes thereto, should be read in conjunction with the audited financial statements for the year ended December 31, 2024 included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission, or SEC. &lt;/span&gt; &lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c0" id="ixv-3379">&lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span style="color: #000000;"&gt;In our condensed consolidated financial statements, we included the accounts of Ionis Pharmaceuticals, Inc. and the consolidated results of our wholly owned subsidiary, Akcea Therapeutics, Inc. and its wholly owned subsidiaries (&#x201c;we&#x201d;, &#x201c;us&#x201d; or &#x201c;our&#x201d;).&lt;/span&gt; &lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c0" id="ixv-3383">&lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span&gt;We operate as a &lt;/span&gt;&lt;span style="color: #000000;"&gt;single &lt;/span&gt;&lt;span&gt;segment, Ionis operations, because our chief operating decision maker, or CODM, reviews operating results on an aggregate basis and manages our operations as a &lt;/span&gt;&lt;span style="color: #000000;"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-0"&gt;single&lt;/span&gt; &lt;/span&gt;&lt;span&gt;operating segment. Refer to Note 15, &lt;/span&gt;&lt;span style="font-style: italic;"&gt;Segment Information&lt;/span&gt;&lt;span&gt;, for further details on our segment information.&lt;/span&gt; &lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c0" id="ixv-3394">&lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span style="color: #000000; font-weight: bold;"&gt;Use of Estimates&lt;/span&gt; &lt;/div&gt;&lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span style="color: #000000;"&gt;We prepare our condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States, or &lt;/span&gt;&lt;span&gt;U.S., that require us to make estimates and assumptions that affect the amounts reported in our condensed consolidated financial statements and accompanying notes. Actual results could differ from our estimates.&lt;/span&gt;
  &lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c0" id="ixv-3405">&lt;div&gt;
   &lt;span style="color: #000000; font-weight: bold;"&gt;2.&#160;&#160;Significant Accounting Policies&lt;/span&gt;
  &lt;/div&gt;
  &lt;div&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span style="color: #000000;"&gt;Below, we have included our accounting policies for revenue recognition related to product sales, net and cost of sales as a result of our launch of TRYNGOLZA and DAWNZERA in the U.S. Our other significant accounting policies have not changed substantially from those included in our Annual Report on Form 10-K for the year ended December 31, 2024.&lt;/span&gt;
  &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span style="color: #000000; font-weight: bold; font-style: italic;"&gt;Revenue Recognition&lt;/span&gt; &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span style="color: #000000; font-style: italic;"&gt;Product Sales, Net&lt;/span&gt;
  &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span style="color: #000000;"&gt;We recognize revenue from product sales when the customer obtains control of our product in the amount of the transaction price, which is the amount that reflects the consideration which we expect to receive. We estimate reserves for variable consideration related to applicable discounts, rebates, chargebacks and other allowances included in our agreements with customers, payors and other third parties. We include the amount of variable consideration in the transaction price to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If actual results vary significantly from our estimates, we adjust our estimates in the period that we become aware of such variances.&lt;/span&gt;
  &lt;/div&gt;&lt;div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"&gt; &lt;span style="color: #000000; font-weight: bold; font-style: italic;"&gt;Cost of Sales&lt;/span&gt; &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span&gt;Our cost of sales is comprised of costs related to our commercial revenue, including manufacturing costs, transportation and freight costs and indirect overhead costs associated with the manufacturing and distribution of our products. We also may include certain period costs related to manufacturing services and inventory adjustments in cost of sales.&lt;/span&gt;
  &lt;/div&gt;
  &lt;div&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span&gt;Cost of sales for a newly launched product, such as TRYNGOLZA or DAWNZERA, does not include the full cost of manufacturing until we manufacture and sell additional inventory after exhausting pre-launch inventory, which we previously recorded as research and development, or R&amp;amp;D, expense.&lt;/span&gt;
  &lt;/div&gt;
  &lt;div&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt;"&gt; &lt;span style="color: #000000; font-weight: bold;"&gt;Recent Accounting Standards&lt;/span&gt; &lt;/div&gt;
  &lt;div&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span style="color: #000000;"&gt;In November 2023, the Financial Accounting Standards Board, or FASB, issued Accounting Standard Update, or ASU, 2023-07, which provides updated guidance on segment reporting. The guidance requires public companies to disclose significant expenses that are regularly provided to the CODM, other segment items for each reportable segment and measures of segment profit or loss used by the CODM for allocating resources. In addition, the updated guidance requires public companies with a single reportable segment to provide all disclosures required under Accounting Standards Codification, or ASC, Topic 280, &lt;/span&gt;&lt;span style="color: #000000; font-style: italic;"&gt;Segment Reporting&lt;/span&gt;&lt;span style="color: #000000;"&gt;, and public companies to include in interim reports all disclosures related to a reportable segment&#x2019;s profit or loss and assets that are currently required in annual reports. We adopted the reporting requirements in our 2024 Annual Report on Form 10-K and began providing the interim reporting requirements in our Quarterly Report on Form 10-Q for the first quarter of 2025. Refer to Note 15, &lt;/span&gt;&lt;span style="color: #000000; font-style: italic;"&gt;Segment Information&lt;/span&gt;&lt;span style="color: #000000;"&gt;, for further details on our segment information.&lt;/span&gt;
  &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;&#160;&lt;/div&gt;
  &lt;div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"&gt;In July 2025, the FASB issued ASU 2025-05, which amended the guidance in ASC 326 to simplify the estimation of credit losses on accounts receivable and contract assets from revenue transactions. The amended guidance allows companies to elect a practical expedient to assume that conditions as of the balance sheet date will remain unchanged for the remaining life of the asset when estimating the expected credit losses of the asset. This update is effective for annual periods beginning after December 15, 2025 and interim periods within those annual periods. Early adoption of this guidance is permitted. Companies that elect the practical expedient are required to apply the amendments prospectively. We are currently assessing the impact and timing of adopting this update.&lt;/div&gt;&lt;div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"&gt;&#160;&lt;/div&gt;&lt;div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"&gt;&lt;span style="letter-spacing: normal; text-align: justify; text-indent: 48px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;In September 2025, the FASB issued ASU 2025-06, which amended and simplified the existing guidance for software costs. The amended guidance removes references to software development stages and allows companies to begin capitalizing software costs when management has authorized and committed to funding the software project and it is probable that the project will be completed with the software performing the intended function.&#160;This update is effective for annual periods beginning after December 15, 2027 and interim periods within those annual periods. Early adoption of this guidance is permitted at the beginning of an annual reporting period. The guidance may be applied on a prospective or retrospective basis. We expect to early adopt this update on January 1, 2026 on a prospective basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: justify;"&gt;&#160;&lt;/div&gt;&lt;div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"&gt;&lt;span style="letter-spacing: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;In September&#160;2025, the FASB issued ASU 2025-07, which clarifies that share-based non-cash consideration received from a customer in exchange for goods or services under a revenue contract is subject to the guidance on non-cash consideration under ASC 606.&#160;This update is effective for annual periods beginning after December 15, 2026 and interim periods within those annual periods. Early adoption of this guidance is permitted. The guidance may be applied on a prospective or modified retrospective basis. We are currently assessing the impact and timing of adopting this update.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: justify;"&gt;&#160;&lt;/div&gt;&lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span style="color: #000000;"&gt;We do not expect any recently issued accounting standards other than the standards mentioned above and those included in our Annual Report on Form 10-K for the year ended December 31, 2024 to have a material impact to our financial results.&lt;/span&gt;
  &lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="c0" id="ixv-3412">&lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span style="color: #000000; font-weight: bold; font-style: italic;"&gt;Revenue Recognition&lt;/span&gt; &lt;/div&gt;&lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span style="color: #000000; font-style: italic;"&gt;Product Sales, Net&lt;/span&gt;
  &lt;/div&gt;&lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span style="color: #000000;"&gt;We recognize revenue from product sales when the customer obtains control of our product in the amount of the transaction price, which is the amount that reflects the consideration which we expect to receive. We estimate reserves for variable consideration related to applicable discounts, rebates, chargebacks and other allowances included in our agreements with customers, payors and other third parties. We include the amount of variable consideration in the transaction price to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If actual results vary significantly from our estimates, we adjust our estimates in the period that we become aware of such variances.&lt;/span&gt;
  &lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:CostOfSalesPolicyTextBlock contextRef="c0" id="ixv-3433">&lt;div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"&gt; &lt;span style="color: #000000; font-weight: bold; font-style: italic;"&gt;Cost of Sales&lt;/span&gt; &lt;/div&gt;&lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span&gt;Our cost of sales is comprised of costs related to our commercial revenue, including manufacturing costs, transportation and freight costs and indirect overhead costs associated with the manufacturing and distribution of our products. We also may include certain period costs related to manufacturing services and inventory adjustments in cost of sales.&lt;/span&gt;
  &lt;/div&gt;&lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span&gt;Cost of sales for a newly launched product, such as TRYNGOLZA or DAWNZERA, does not include the full cost of manufacturing until we manufacture and sell additional inventory after exhausting pre-launch inventory, which we previously recorded as research and development, or R&amp;amp;D, expense.&lt;/span&gt;
  &lt;/div&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0" id="ixv-3445">&lt;div style="text-indent: 36pt;"&gt; &lt;span style="color: #000000; font-weight: bold;"&gt;Recent Accounting Standards&lt;/span&gt; &lt;/div&gt;&lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span style="color: #000000;"&gt;In November 2023, the Financial Accounting Standards Board, or FASB, issued Accounting Standard Update, or ASU, 2023-07, which provides updated guidance on segment reporting. The guidance requires public companies to disclose significant expenses that are regularly provided to the CODM, other segment items for each reportable segment and measures of segment profit or loss used by the CODM for allocating resources. In addition, the updated guidance requires public companies with a single reportable segment to provide all disclosures required under Accounting Standards Codification, or ASC, Topic 280, &lt;/span&gt;&lt;span style="color: #000000; font-style: italic;"&gt;Segment Reporting&lt;/span&gt;&lt;span style="color: #000000;"&gt;, and public companies to include in interim reports all disclosures related to a reportable segment&#x2019;s profit or loss and assets that are currently required in annual reports. We adopted the reporting requirements in our 2024 Annual Report on Form 10-K and began providing the interim reporting requirements in our Quarterly Report on Form 10-Q for the first quarter of 2025. Refer to Note 15, &lt;/span&gt;&lt;span style="color: #000000; font-style: italic;"&gt;Segment Information&lt;/span&gt;&lt;span style="color: #000000;"&gt;, for further details on our segment information.&lt;/span&gt;
  &lt;/div&gt;&lt;div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"&gt;In July 2025, the FASB issued ASU 2025-05, which amended the guidance in ASC 326 to simplify the estimation of credit losses on accounts receivable and contract assets from revenue transactions. The amended guidance allows companies to elect a practical expedient to assume that conditions as of the balance sheet date will remain unchanged for the remaining life of the asset when estimating the expected credit losses of the asset. This update is effective for annual periods beginning after December 15, 2025 and interim periods within those annual periods. Early adoption of this guidance is permitted. Companies that elect the practical expedient are required to apply the amendments prospectively. We are currently assessing the impact and timing of adopting this update.&lt;/div&gt;&lt;div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"&gt;&lt;span style="letter-spacing: normal; text-align: justify; text-indent: 48px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;In September 2025, the FASB issued ASU 2025-06, which amended and simplified the existing guidance for software costs. The amended guidance removes references to software development stages and allows companies to begin capitalizing software costs when management has authorized and committed to funding the software project and it is probable that the project will be completed with the software performing the intended function.&#160;This update is effective for annual periods beginning after December 15, 2027 and interim periods within those annual periods. Early adoption of this guidance is permitted at the beginning of an annual reporting period. The guidance may be applied on a prospective or retrospective basis. We expect to early adopt this update on January 1, 2026 on a prospective basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"&gt;&lt;span style="letter-spacing: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;In September&#160;2025, the FASB issued ASU 2025-07, which clarifies that share-based non-cash consideration received from a customer in exchange for goods or services under a revenue contract is subject to the guidance on non-cash consideration under ASC 606.&#160;This update is effective for annual periods beginning after December 15, 2026 and interim periods within those annual periods. Early adoption of this guidance is permitted. The guidance may be applied on a prospective or modified retrospective basis. We are currently assessing the impact and timing of adopting this update.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span style="color: #000000;"&gt;We do not expect any recently issued accounting standards other than the standards mentioned above and those included in our Annual Report on Form 10-K for the year ended December 31, 2024 to have a material impact to our financial results.&lt;/span&gt;
  &lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="c0" id="ixv-3474">&lt;div style="text-align: justify;"&gt;
   &lt;span style="color: #000000; font-weight: bold;"&gt;3. Supplemental Financial Data&lt;/span&gt;
  &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-align: justify; margin-left: 36pt;"&gt;
   &lt;span style="color: #000000; font-weight: bold;"&gt;Inventories&lt;/span&gt;
  &lt;/div&gt;
  &lt;div&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span style="color: #000000;"&gt;Our inventories consisted of the following (in thousands): &lt;/span&gt; &lt;/div&gt;

  &lt;div style="text-align: justify; color: #000000;"&gt;&#160;&lt;/div&gt;
  &lt;table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"&gt;&lt;tr style="height: 0px; font-size: 0px;"&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0px; font-size: 0px;"&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Supplemental Financial Data - B4"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;September 30, 2025&lt;/td&gt;&lt;td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Supplemental Financial Data - B4"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Supplemental Financial Data - D4"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;December 31, 2024&lt;/td&gt;&lt;td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Supplemental Financial Data - D4"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Raw materials&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 3. Supplemental Financial Data - B5"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;424&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 3. Supplemental Financial Data - B5"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 3. Supplemental Financial Data - D5"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;5,557&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 3. Supplemental Financial Data - D5"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Work in process&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 3. Supplemental Financial Data - B6"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;26,139&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 3. Supplemental Financial Data - B6"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 3. Supplemental Financial Data - D6"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;6,679&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 3. Supplemental Financial Data - D6"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Finished goods&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Supplemental Financial Data - B7"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;549&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 3. Supplemental Financial Data - B7"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Supplemental Financial Data - D7"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;276&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 3. Supplemental Financial Data - D7"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="padding-left: 20px;"&gt;Total&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Supplemental Financial Data - B8"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;27,112&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 3. Supplemental Financial Data - B8"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Supplemental Financial Data - D8"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;12,512&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 3. Supplemental Financial Data - D8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Reported as:&lt;/td&gt;&lt;td style="text-align: left; border-width: initial; border-style: none; border-color: initial; width: 1%;" title="Note 3. Supplemental Financial Data - B8"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-width: initial; border-style: none; border-color: initial; width: 9%;"&gt;&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;" title="Note 3. Supplemental Financial Data - B8"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-width: initial; border-style: none; border-color: initial; width: 1%;" title="Note 3. Supplemental Financial Data - D8"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-width: initial; border-style: none; border-color: initial; width: 9%;"&gt;&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;" title="Note 3. Supplemental Financial Data - D8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="padding-left: 10px;"&gt;Inventories&lt;/td&gt;&lt;td style="text-align: left; border-width: initial; border-style: none; border-color: initial; width: 1%;" title="Note 3. Supplemental Financial Data - B8"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-width: initial; border-style: none; border-color: initial; width: 9%;"&gt;10,470&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;" title="Note 3. Supplemental Financial Data - B8"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-width: initial; border-style: none; border-color: initial; width: 1%;" title="Note 3. Supplemental Financial Data - D8"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-width: initial; border-style: none; border-color: initial; width: 9%;"&gt;12,512&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;" title="Note 3. Supplemental Financial Data - D8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td style="padding-left: 10px;"&gt;Deposits and other assets&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Supplemental Financial Data - B8"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;16,642&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 3. Supplemental Financial Data - B8"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Supplemental Financial Data - D8"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt; - &lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 3. Supplemental Financial Data - D8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="padding-left: 20px;"&gt;Total&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Supplemental Financial Data - B8"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;27,112&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 3. Supplemental Financial Data - B8"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Supplemental Financial Data - D8"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;12,512&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 3. Supplemental Financial Data - D8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&#160;&lt;/div&gt;
  &lt;div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"&gt;We classify inventories as non-current assets when we expect  the inventories to remain on hand beyond one year. We include non-current inventories in deposits and other assets in our condensed consolidated balance sheets. The amount reported as deposits and other assets  as of September 30, 2025  consists of work in process inventory.&lt;/div&gt;&lt;div&gt;&#160;&lt;/div&gt;&lt;div style="text-indent: 36pt;"&gt;
   &lt;span style="font-weight: bold;"&gt;Accrued Liabilities&lt;/span&gt;
  &lt;/div&gt;
  &lt;div&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt;"&gt; &lt;span&gt;Our accrued liabilities consisted of the following (in thousands):&lt;/span&gt; &lt;/div&gt;


  &lt;div&gt;&#160;&lt;/div&gt;

  &lt;table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"&gt;&lt;tr style="height: 0px; font-size: 0px;"&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Accrued Liabilities - B4"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;September 30, 2025&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 3. Accrued Liabilities - B4"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Accrued Liabilities - D4"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;December 31, 2024&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 3. Accrued Liabilities - D4"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Clinical expenses&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 3. Accrued Liabilities - B5"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;54,842&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 3. Accrued Liabilities - B5"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 3. Accrued Liabilities - D5"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;77,436&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 3. Accrued Liabilities - D5"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;In-licensing expenses&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 3. Accrued Liabilities - B6"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;7,770&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 3. Accrued Liabilities - B6"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 3. Accrued Liabilities - D6"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;7,951&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 3. Accrued Liabilities - D6"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Commercial expenses&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 3. Accrued Liabilities - B7"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;15,017&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 3. Accrued Liabilities - B7"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 3. Accrued Liabilities - D7"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;3,589&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 3. Accrued Liabilities - D7"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Other miscellaneous expenses&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Accrued Liabilities - B8"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;21,681&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 3. Accrued Liabilities - B8"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Accrued Liabilities - D8"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;19,462&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 3. Accrued Liabilities - D8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td style="padding-left: 20px;"&gt;Total accrued liabilities&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Accrued Liabilities - B9"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;99,310&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 3. Accrued Liabilities - B9"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Accrued Liabilities - D9"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;108,438&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 3. Accrued Liabilities - D9"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <ions:ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock contextRef="c0" id="ixv-3481">&lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span style="color: #000000;"&gt;Our inventories consisted of the following (in thousands): &lt;/span&gt; &lt;/div&gt;

  &lt;div style="text-align: justify; color: #000000;"&gt;&#160;&lt;/div&gt;
  &lt;table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"&gt;&lt;tr style="height: 0px; font-size: 0px;"&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0px; font-size: 0px;"&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Supplemental Financial Data - B4"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;September 30, 2025&lt;/td&gt;&lt;td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Supplemental Financial Data - B4"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Supplemental Financial Data - D4"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;December 31, 2024&lt;/td&gt;&lt;td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Supplemental Financial Data - D4"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Raw materials&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 3. Supplemental Financial Data - B5"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;424&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 3. Supplemental Financial Data - B5"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 3. Supplemental Financial Data - D5"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;5,557&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 3. Supplemental Financial Data - D5"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Work in process&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 3. Supplemental Financial Data - B6"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;26,139&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 3. Supplemental Financial Data - B6"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 3. Supplemental Financial Data - D6"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;6,679&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 3. Supplemental Financial Data - D6"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Finished goods&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Supplemental Financial Data - B7"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;549&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 3. Supplemental Financial Data - B7"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Supplemental Financial Data - D7"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;276&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 3. Supplemental Financial Data - D7"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="padding-left: 20px;"&gt;Total&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Supplemental Financial Data - B8"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;27,112&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 3. Supplemental Financial Data - B8"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Supplemental Financial Data - D8"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;12,512&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 3. Supplemental Financial Data - D8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Reported as:&lt;/td&gt;&lt;td style="text-align: left; border-width: initial; border-style: none; border-color: initial; width: 1%;" title="Note 3. Supplemental Financial Data - B8"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-width: initial; border-style: none; border-color: initial; width: 9%;"&gt;&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;" title="Note 3. Supplemental Financial Data - B8"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-width: initial; border-style: none; border-color: initial; width: 1%;" title="Note 3. Supplemental Financial Data - D8"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-width: initial; border-style: none; border-color: initial; width: 9%;"&gt;&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;" title="Note 3. Supplemental Financial Data - D8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="padding-left: 10px;"&gt;Inventories&lt;/td&gt;&lt;td style="text-align: left; border-width: initial; border-style: none; border-color: initial; width: 1%;" title="Note 3. Supplemental Financial Data - B8"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-width: initial; border-style: none; border-color: initial; width: 9%;"&gt;10,470&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;" title="Note 3. Supplemental Financial Data - B8"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-width: initial; border-style: none; border-color: initial; width: 1%;" title="Note 3. Supplemental Financial Data - D8"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-width: initial; border-style: none; border-color: initial; width: 9%;"&gt;12,512&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;" title="Note 3. Supplemental Financial Data - D8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td style="padding-left: 10px;"&gt;Deposits and other assets&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Supplemental Financial Data - B8"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;16,642&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 3. Supplemental Financial Data - B8"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Supplemental Financial Data - D8"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt; - &lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 3. Supplemental Financial Data - D8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="padding-left: 20px;"&gt;Total&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Supplemental Financial Data - B8"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;27,112&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 3. Supplemental Financial Data - B8"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Supplemental Financial Data - D8"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;12,512&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 3. Supplemental Financial Data - D8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ions:ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock>
    <ions:InventoryRawMaterialsNet contextRef="c2" decimals="-3" id="ixv-11569" unitRef="usd">424000</ions:InventoryRawMaterialsNet>
    <ions:InventoryRawMaterialsNet contextRef="c3" decimals="-3" id="ixv-11570" unitRef="usd">5557000</ions:InventoryRawMaterialsNet>
    <ions:InventoryWorkInProcessNet contextRef="c2" decimals="-3" id="ixv-11571" unitRef="usd">26139000</ions:InventoryWorkInProcessNet>
    <ions:InventoryWorkInProcessNet contextRef="c3" decimals="-3" id="ixv-11572" unitRef="usd">6679000</ions:InventoryWorkInProcessNet>
    <ions:InventoryFinishedGoodsNet contextRef="c2" decimals="-3" id="ixv-11573" unitRef="usd">549000</ions:InventoryFinishedGoodsNet>
    <ions:InventoryFinishedGoodsNet contextRef="c3" decimals="-3" id="ixv-11574" unitRef="usd">276000</ions:InventoryFinishedGoodsNet>
    <ions:InventoryCurrentAndNoncurrent contextRef="c2" decimals="-3" id="ixv-11575" unitRef="usd">27112000</ions:InventoryCurrentAndNoncurrent>
    <ions:InventoryCurrentAndNoncurrent contextRef="c3" decimals="-3" id="ixv-11576" unitRef="usd">12512000</ions:InventoryCurrentAndNoncurrent>
    <us-gaap:InventoryNet contextRef="c2" decimals="-3" id="ixv-11577" unitRef="usd">10470000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c3" decimals="-3" id="ixv-11578" unitRef="usd">12512000</us-gaap:InventoryNet>
    <us-gaap:InventoryNoncurrent contextRef="c83" decimals="-3" id="ixv-11579" unitRef="usd">16642000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent contextRef="c84" decimals="-3" id="ixv-11580" unitRef="usd">0</us-gaap:InventoryNoncurrent>
    <ions:InventoryCurrentAndNoncurrent contextRef="c2" decimals="-3" id="ixv-11581" unitRef="usd">27112000</ions:InventoryCurrentAndNoncurrent>
    <ions:InventoryCurrentAndNoncurrent contextRef="c3" decimals="-3" id="ixv-11582" unitRef="usd">12512000</ions:InventoryCurrentAndNoncurrent>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c0" id="ixv-3591">&lt;div style="text-indent: 36pt;"&gt; &lt;span&gt;Our accrued liabilities consisted of the following (in thousands):&lt;/span&gt; &lt;/div&gt;


  &lt;div&gt;&#160;&lt;/div&gt;

  &lt;table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"&gt;&lt;tr style="height: 0px; font-size: 0px;"&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Accrued Liabilities - B4"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;September 30, 2025&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 3. Accrued Liabilities - B4"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Accrued Liabilities - D4"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;December 31, 2024&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 3. Accrued Liabilities - D4"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Clinical expenses&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 3. Accrued Liabilities - B5"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;54,842&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 3. Accrued Liabilities - B5"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 3. Accrued Liabilities - D5"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;77,436&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 3. Accrued Liabilities - D5"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;In-licensing expenses&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 3. Accrued Liabilities - B6"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;7,770&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 3. Accrued Liabilities - B6"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 3. Accrued Liabilities - D6"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;7,951&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 3. Accrued Liabilities - D6"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Commercial expenses&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 3. Accrued Liabilities - B7"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;15,017&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 3. Accrued Liabilities - B7"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 3. Accrued Liabilities - D7"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;3,589&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 3. Accrued Liabilities - D7"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Other miscellaneous expenses&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Accrued Liabilities - B8"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;21,681&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 3. Accrued Liabilities - B8"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Accrued Liabilities - D8"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;19,462&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 3. Accrued Liabilities - D8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td style="padding-left: 20px;"&gt;Total accrued liabilities&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Accrued Liabilities - B9"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;99,310&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 3. Accrued Liabilities - B9"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 3. Accrued Liabilities - D9"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;108,438&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 3. Accrued Liabilities - D9"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <ions:AccruedClinicalExpenses contextRef="c2" decimals="-3" id="ixv-11583" unitRef="usd">54842000</ions:AccruedClinicalExpenses>
    <ions:AccruedClinicalExpenses contextRef="c3" decimals="-3" id="ixv-11584" unitRef="usd">77436000</ions:AccruedClinicalExpenses>
    <ions:AccruedInLicensingFeesCurrent contextRef="c2" decimals="-3" id="ixv-11585" unitRef="usd">7770000</ions:AccruedInLicensingFeesCurrent>
    <ions:AccruedInLicensingFeesCurrent contextRef="c3" decimals="-3" id="ixv-11586" unitRef="usd">7951000</ions:AccruedInLicensingFeesCurrent>
    <ions:AccruedCommercialExpensesCurrent contextRef="c2" decimals="-3" id="ixv-11587" unitRef="usd">15017000</ions:AccruedCommercialExpensesCurrent>
    <ions:AccruedCommercialExpensesCurrent contextRef="c3" decimals="-3" id="ixv-11588" unitRef="usd">3589000</ions:AccruedCommercialExpensesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c2" decimals="-3" id="ixv-11589" unitRef="usd">21681000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c3" decimals="-3" id="ixv-11590" unitRef="usd">19462000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c2" decimals="-3" id="ixv-11591" unitRef="usd">99310000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c3" decimals="-3" id="ixv-11592" unitRef="usd">108438000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="c0" id="ixv-3666">&lt;div&gt;
   &lt;span style="font-weight: bold;"&gt;4. Revenues&lt;/span&gt;
  &lt;/div&gt;
  &lt;div&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span&gt;During the three and nine months ended September 30, 2025 and 2024, our revenues consisted of the following (in thousands):&lt;/span&gt; &lt;/div&gt;

  &lt;div&gt;&#160;&lt;/div&gt;
  &lt;table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"&gt;&lt;tr style="height: 0px; font-size: 0px;"&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td colspan="7" style="text-align: center; font-weight: bold;"&gt;Three Months Ended&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td colspan="7" style="text-align: center; font-weight: bold;"&gt;Nine Months Ended&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;September 30,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;September 30,&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - B4"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;2025&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - B4"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - D4"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;2024&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - D4"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - F4"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;2025&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - F4"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - H4"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;2024&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - H4"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Revenue:&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - B5"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - B5"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - D5"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - D5"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - F5"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - F5"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - H5"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - H5"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="padding-left: 10px;"&gt;Commercial revenue:&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - B6"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - B6"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - D6"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - D6"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - F6"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - F6"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - H6"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - H6"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="padding-left: 20px;"&gt;Product sales, net:&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - B7"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - B7"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - D7"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - D7"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - F7"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - F7"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - H7"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - H7"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td style="padding-left: 30px;"&gt;TRYNGOLZA sales, net&lt;/td&gt;&lt;td style="text-align: left; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none; width: 1%;" title="Note 4. Revenues - B8"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none; width: 9%;"&gt;31,792&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none;" title="Note 4. Revenues - B8"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none; width: 1%;" title="Note 4. Revenues - D8"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none; width: 9%;"&gt; - &lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none;" title="Note 4. Revenues - D8"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none; width: 1%;" title="Note 4. Revenues - F8"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none; width: 9%;"&gt;57,353&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none;" title="Note 4. Revenues - F8"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none; width: 1%;" title="Note 4. Revenues - H8"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none; width: 9%;"&gt; - &lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none;" title="Note 4. Revenues - H8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="padding-left: 30px;"&gt;Total product sales, net&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;" title="Note 4. Revenues - B9"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; border-width: initial; border-style: none; border-color: initial;"&gt;31,792&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;" title="Note 4. Revenues - B9"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;" title="Note 4. Revenues - D9"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; border-width: initial; border-style: none; border-color: initial;"&gt; - &lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;" title="Note 4. Revenues - D9"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;" title="Note 4. Revenues - F9"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; border-width: initial; border-style: none; border-color: initial;"&gt;57,353&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;" title="Note 4. Revenues - F9"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;" title="Note 4. Revenues - H9"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; border-width: initial; border-style: none; border-color: initial;"&gt; - &lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;" title="Note 4. Revenues - H9"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td style="padding-left: 20px;"&gt;Royalty revenue:&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - B10"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - B10"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - D10"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - D10"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - F10"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - F10"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - H10"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - H10"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="padding-left: 30px;"&gt;SPINRAZA royalties&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - B11"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;55,896&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - B11"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - D11"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;57,208&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - D11"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - F11"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;158,243&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - F11"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - H11"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;152,406&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - H11"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td style="padding-left: 30px;"&gt;WAINUA royalties&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - B12"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;13,320&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - B12"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - D12"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;5,371&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - D12"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - F12"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;33,107&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - F12"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - H12"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;10,278&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - H12"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="padding-left: 30px;"&gt;Other royalties&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 4. Revenues - B13"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1px solid black; border-top: none; width: 9%;"&gt;6,478&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - B13"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 4. Revenues - D13"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1px solid black; border-top: none; width: 9%;"&gt;4,228&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - D13"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 4. Revenues - F13"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1px solid black; border-top: none; width: 9%;"&gt;18,461&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - F13"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 4. Revenues - H13"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-right: none; width: 9%;"&gt;17,352&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - H13"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td style="padding-left: 50px;"&gt;Total royalty revenue&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - B14"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;75,694&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - B14"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - D14"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;66,807&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - D14"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - F14"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;209,811&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - F14"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - H14"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;180,036&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - H14"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="padding-left: 20px;"&gt;Other commercial revenue&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - B15"&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt; 8,112 &lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - B15"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - D15"&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt; 8,924 &lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - D15"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - F15"&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt; 27,359 &lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - F15"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - H15"&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt; 27,324 &lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - H15"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td style="padding-left: 70px;"&gt;Total commercial revenue&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - B19"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;115,598&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - B19"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - D19"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;75,731&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - D19"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - F19"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;294,523&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - F19"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - H19"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;207,360&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - H19"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="padding-left: 10px;"&gt;Research and development revenue:&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - B20"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - B20"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - D20"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - D20"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - F20"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - F20"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - H20"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - H20"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td style="padding-left: 30px;"&gt;Collaborative agreement revenue&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - B21"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;31,436&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - B21"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - D21"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;44,883&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - D21"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - F21"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;413,387&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - F21"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - H21"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;235,753&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - H21"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="padding-left: 30px;"&gt;WAINUA joint development revenue&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - B22"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;9,685&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - B22"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - D22"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;13,200&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - D22"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - F22"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;32,471&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - F22"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - H22"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;35,449&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - H22"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td style="padding-left: 70px;"&gt;Total research and development revenue&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - B23"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;41,121&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - B23"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - D23"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;58,083&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - D23"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - F23"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;445,858&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - F23"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - H23"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;271,202&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - H23"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="padding-left: 90px;"&gt;Total revenue  &lt;/td&gt;&lt;td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - B24"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;156,719&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - B24"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - D24"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;133,814&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - D24"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - F24"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;740,381&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - F24"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - H24"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;478,562&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - H24"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span style="font-weight: bold; text-decoration: underline;"&gt;Revenue Sources &lt;/span&gt;
  &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span&gt;The following are sources of revenue and when we typically recognize revenue.&lt;/span&gt;
  &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span style="font-style: italic;"&gt;Commercial Revenue &lt;/span&gt;
  &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span&gt;In December 2024, the U.S. Food and Drug Administration, or FDA, approved TRYNGOLZA (olezarsen) for the treatment of familial chylomicronemia syndrome, or FCS. Following the approval, we launched TRYNGOLZA and began earning revenue from TRYNGOLZA sales. &lt;/span&gt;
  &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;&#160;&lt;/div&gt;
  &lt;div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"&gt;In August 2025, the FDA approved DAWNZERA (donidalorsen) for prophylaxis to prevent attacks of hereditary angioedema, or HAE, in adult and pediatric patients 12 years of age and older. Our launch of DAWNZERA is currently underway.&lt;/div&gt;&lt;div style="text-align: justify;"&gt;&#160;&lt;/div&gt;&lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span&gt;We earn royalty payments primarily on net sales of SPINRAZA, WAINUA and QALSODY.&lt;/span&gt;
  &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span&gt;We earn commercial revenue from TEGSEDI and WAYLIVRA sales under our distribution agreements with Swedish Orphan Biovitrum AB, or Sobi. In addition, we receive royalties from PTC Therapeutics International Limited, or PTC, for TEGSEDI and WAYLIVRA sales. Refer to Part IV, Item 15, Note 4, &lt;/span&gt;&lt;span style="font-style: italic;"&gt;Collaborative Arrangements and Licensing Agreements&lt;/span&gt;&lt;span&gt;, of our audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2024 for details on our commercialization partnerships with Sobi and PTC.&lt;/span&gt;
  &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;&#160;&lt;/div&gt;
  &lt;div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"&gt;&lt;span style="letter-spacing: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;Under our distribution agreements with Sobi, we concluded that our performance obligation is to provide services to Sobi over the term of the agreement, which includes supplying finished goods inventory to Sobi. We are also responsible for maintaining the marketing authorization for TEGSEDI and WAYLIVRA in major markets and for leading the global commercial strategy for each medicine. We view this performance obligation as a series of distinct activities that are substantially the same. Therefore, we recognize as revenue the price Sobi pays us for the inventory when we deliver the finished goods inventory to Sobi. We also recognize distribution fee revenue based on Sobi&#x2019;s net sales of TEGSEDI and WAYLIVRA. Under our agreements with Sobi, Sobi does not generally have a right of return.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: justify;"&gt;&#160;&lt;/div&gt;&lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span style="font-style: italic;"&gt;Research and development revenue under collaboration agreements&lt;/span&gt;
  &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span&gt;We enter into collaboration agreements to license and sell our technology on an exclusive or non-exclusive basis. Our collaboration agreements typically contain multiple elements, or performance obligations, including technology licenses or options to obtain technology licenses, R&amp;amp;D services and manufacturing services.&lt;/span&gt;
  &lt;/div&gt;&lt;div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"&gt;
   For R&amp;amp;D services that we recognize over time, we measure our progress using an input method. The input methods we use are based on the effort we expend or costs we incur toward the satisfaction of our performance obligation. We estimate the amount of effort we expend, including the time we estimate it will take us to complete the activities, or costs we incur in a given period, relative to the estimated total effort or costs to satisfy the performance obligation. This results in a percentage that we multiply by the transaction price to determine the amount of revenue we recognize each period. This approach requires us to make numerous estimates that may involve judgement. If our estimates or judgements change over the course of the collaboration, they may affect the timing and amount of revenue that we recognize in the current and future periods.
  &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span style="font-style: italic; text-decoration: underline;"&gt;Upfront payments:&lt;/span&gt;&lt;span&gt; When we enter into a collaboration agreement and receive an upfront payment, we record the entire upfront payment as deferred revenue if our only performance obligation is for R&amp;amp;D services we will provide in the future. We amortize the upfront payment into revenue as we perform the R&amp;amp;D services. If part or all of the upfront payment is a license fee, we recognize as revenue the portion related to the license when we deliver the license to our partner because our partner has full use of the license and we do not have any additional performance obligations related to the license after delivery.&lt;/span&gt;
  &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span style="font-style: italic; text-decoration: underline;"&gt;Milestone payments:&lt;/span&gt;&lt;span&gt; We consider milestone payments to be variable consideration and include them in the transaction price when it is probable. We typically include milestone payments for R&amp;amp;D services in the transaction price when they are achieved. We include these milestone payments when they are achieved because there is considerable uncertainty in the research and development processes that trigger these payments. Similarly, we include regulatory milestone payments in the transaction price once the medicine is approved by the applicable regulatory agency. We will recognize sales-based milestone payments in the period in which we achieve the milestone under the sales-based royalty exception allowed under accounting rules.&lt;/span&gt;
  &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span&gt;We recognize milestone payments that relate to an ongoing performance obligation over our period of performance. For example, when we achieve a milestone payment from a partner for advancing a clinical study under a collaboration agreement, we add the milestone payment to the transaction price if the milestone relates to an ongoing R&amp;amp;D services performance obligation and recognize revenue related to the milestone payment over our estimated period of performance. If we have partially completed our performance obligation, then we record a cumulative-effect adjustment in the period we add the milestone payment to the transaction price.&lt;/span&gt;
  &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span&gt;Conversely, we recognize in full those milestone payments that we earn based on our partners&#x2019; activities when our partner achieves the milestone event and we do not have a remaining performance obligation.&lt;/span&gt;
  &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span style="font-style: italic; text-decoration: underline;"&gt;License fees:&lt;/span&gt;&lt;span&gt; We recognize as revenue the total amount we determine to be the relative stand-alone selling price of a license when we deliver the license to our partner because our partner has full use of the license and we do not have any additional performance obligations related to the license after delivery.&lt;/span&gt;
  &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span style="font-style: italic;"&gt;WAINUA (Eplontersen) Collaboration with AstraZeneca&lt;/span&gt;
  &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span&gt;In 2021, we entered into a joint development and commercialization agreement with AstraZeneca to develop and commercialize WAINUA for the treatment of transthyretin amyloidosis, or ATTR. Under the terms of the agreement, we received a $200 million upfront payment in 2021.&lt;/span&gt; &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span&gt;We evaluated our WAINUA collaboration under ASC Topic 808, &lt;/span&gt;&lt;span style="font-style: italic;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span&gt;, or ASC 808, and identified four material components: (i) the license we granted to AstraZeneca in 2021, (ii) the co-development activities that we and AstraZeneca are performing, (iii) the co-commercialization activities that we and AstraZeneca are performing and (iv) the co-medical affairs activities that we and AstraZeneca are performing.&lt;/span&gt; &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span&gt;We determined that we had a vendor-customer relationship within the scope of ASC Topic 606, &lt;/span&gt;&lt;span style="font-style: italic;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span&gt;, or ASC 606, for the license we granted to AstraZeneca and as a result we had one performance obligation. For our sole performance obligation, we determined the transaction price was the $200 million upfront payment we received. We recognized the upfront payment in full in 2021 because we did not have any remaining performance obligations after we delivered the license to AstraZeneca.&lt;/span&gt; &lt;/div&gt;&lt;div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"&gt;We also concluded that the co-development activities, the co-commercialization activities and the co-medical affairs activities are within the scope of ASC 808 because we and AstraZeneca are active participants exposed to the risks and benefits of the activities under the collaboration and therefore do not have a vendor-customer relationship. AstraZeneca is currently responsible for 55 percent of the costs associated with the ongoing global Phase 3 development program. Because we are leading the Phase 3 development program, we made an accounting policy election to recognize as non-customer revenue the cost-share funding from AstraZeneca, net of our share of AstraZeneca&#x2019;s development expenses, in the same period we incur the related development expenses. As AstraZeneca is responsible for the majority of the commercial and medical affairs costs in the U.S. and all costs associated with bringing WAINUA to market outside the U.S., we made an accounting policy election to recognize cost-share funding we receive from AstraZeneca related to commercial and medical affairs activities as reductions of our selling, general and administrative, or SG&amp;amp;A, expense and R&amp;amp;D expense, respectively. &lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="c0" id="ixv-3670">&lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span&gt;During the three and nine months ended September 30, 2025 and 2024, our revenues consisted of the following (in thousands):&lt;/span&gt; &lt;/div&gt;

  &lt;div&gt;&#160;&lt;/div&gt;
  &lt;table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"&gt;&lt;tr style="height: 0px; font-size: 0px;"&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td colspan="7" style="text-align: center; font-weight: bold;"&gt;Three Months Ended&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td colspan="7" style="text-align: center; font-weight: bold;"&gt;Nine Months Ended&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;September 30,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;September 30,&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - B4"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;2025&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - B4"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - D4"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;2024&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - D4"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - F4"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;2025&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - F4"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - H4"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;2024&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - H4"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Revenue:&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - B5"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - B5"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - D5"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - D5"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - F5"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - F5"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - H5"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - H5"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="padding-left: 10px;"&gt;Commercial revenue:&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - B6"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - B6"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - D6"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - D6"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - F6"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - F6"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - H6"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - H6"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="padding-left: 20px;"&gt;Product sales, net:&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - B7"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - B7"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - D7"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - D7"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - F7"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - F7"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - H7"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - H7"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td style="padding-left: 30px;"&gt;TRYNGOLZA sales, net&lt;/td&gt;&lt;td style="text-align: left; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none; width: 1%;" title="Note 4. Revenues - B8"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none; width: 9%;"&gt;31,792&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none;" title="Note 4. Revenues - B8"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none; width: 1%;" title="Note 4. Revenues - D8"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none; width: 9%;"&gt; - &lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none;" title="Note 4. Revenues - D8"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none; width: 1%;" title="Note 4. Revenues - F8"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none; width: 9%;"&gt;57,353&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none;" title="Note 4. Revenues - F8"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none; width: 1%;" title="Note 4. Revenues - H8"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none; width: 9%;"&gt; - &lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-top: none; border-right: none; border-bottom: 1px solid black; border-left: none;" title="Note 4. Revenues - H8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="padding-left: 30px;"&gt;Total product sales, net&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;" title="Note 4. Revenues - B9"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; border-width: initial; border-style: none; border-color: initial;"&gt;31,792&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;" title="Note 4. Revenues - B9"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;" title="Note 4. Revenues - D9"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; border-width: initial; border-style: none; border-color: initial;"&gt; - &lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;" title="Note 4. Revenues - D9"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;" title="Note 4. Revenues - F9"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; border-width: initial; border-style: none; border-color: initial;"&gt;57,353&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;" title="Note 4. Revenues - F9"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;" title="Note 4. Revenues - H9"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%; border-width: initial; border-style: none; border-color: initial;"&gt; - &lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-width: initial; border-style: none; border-color: initial;" title="Note 4. Revenues - H9"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td style="padding-left: 20px;"&gt;Royalty revenue:&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - B10"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - B10"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - D10"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - D10"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - F10"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - F10"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - H10"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - H10"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="padding-left: 30px;"&gt;SPINRAZA royalties&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - B11"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;55,896&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - B11"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - D11"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;57,208&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - D11"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - F11"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;158,243&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - F11"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - H11"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;152,406&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - H11"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td style="padding-left: 30px;"&gt;WAINUA royalties&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - B12"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;13,320&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - B12"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - D12"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;5,371&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - D12"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - F12"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;33,107&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - F12"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - H12"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;10,278&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - H12"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="padding-left: 30px;"&gt;Other royalties&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 4. Revenues - B13"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1px solid black; border-top: none; width: 9%;"&gt;6,478&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - B13"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 4. Revenues - D13"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1px solid black; border-top: none; width: 9%;"&gt;4,228&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - D13"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 4. Revenues - F13"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1px solid black; border-top: none; width: 9%;"&gt;18,461&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - F13"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 4. Revenues - H13"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-right: none; width: 9%;"&gt;17,352&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - H13"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td style="padding-left: 50px;"&gt;Total royalty revenue&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - B14"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;75,694&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - B14"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - D14"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;66,807&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - D14"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - F14"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;209,811&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - F14"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - H14"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;180,036&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - H14"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="padding-left: 20px;"&gt;Other commercial revenue&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - B15"&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt; 8,112 &lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - B15"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - D15"&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt; 8,924 &lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - D15"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - F15"&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt; 27,359 &lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - F15"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - H15"&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt; 27,324 &lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - H15"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td style="padding-left: 70px;"&gt;Total commercial revenue&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - B19"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;115,598&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - B19"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - D19"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;75,731&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - D19"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - F19"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;294,523&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - F19"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - H19"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;207,360&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - H19"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="padding-left: 10px;"&gt;Research and development revenue:&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - B20"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - B20"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - D20"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - D20"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - F20"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - F20"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - H20"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 4. Revenues - H20"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td style="padding-left: 30px;"&gt;Collaborative agreement revenue&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - B21"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;31,436&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - B21"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - D21"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;44,883&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - D21"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - F21"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;413,387&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - F21"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - H21"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;235,753&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 4. Revenues - H21"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="padding-left: 30px;"&gt;WAINUA joint development revenue&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - B22"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;9,685&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - B22"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - D22"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;13,200&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - D22"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - F22"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;32,471&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - F22"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - H22"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;35,449&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - H22"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td style="padding-left: 70px;"&gt;Total research and development revenue&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - B23"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;41,121&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - B23"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - D23"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;58,083&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - D23"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - F23"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;445,858&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - F23"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - H23"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;271,202&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - H23"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="padding-left: 90px;"&gt;Total revenue  &lt;/td&gt;&lt;td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - B24"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;156,719&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - B24"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - D24"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;133,814&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - D24"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - F24"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;740,381&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - F24"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 4. Revenues - H24"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;478,562&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 4. Revenues - H24"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c88" decimals="-3" id="ixv-11593" unitRef="usd">31792000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c89" decimals="-3" id="ixv-11594" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c90" decimals="-3" id="ixv-11595" unitRef="usd">57353000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c91" decimals="-3" id="ixv-11596" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c8" decimals="-3" id="ixv-11597" unitRef="usd">31792000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c9" decimals="-3" id="ixv-11598" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c10" decimals="-3" id="ixv-11599" unitRef="usd">57353000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c11" decimals="-3" id="ixv-11600" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c92" decimals="-3" id="ixv-11601" unitRef="usd">55896000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c93" decimals="-3" id="ixv-11602" unitRef="usd">57208000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c94" decimals="-3" id="ixv-11603" unitRef="usd">158243000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c95" decimals="-3" id="ixv-11604" unitRef="usd">152406000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c96" decimals="-3" id="ixv-11605" unitRef="usd">13320000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c97" decimals="-3" id="ixv-11606" unitRef="usd">5371000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c98" decimals="-3" id="ixv-11607" unitRef="usd">33107000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c99" decimals="-3" id="ixv-11608" unitRef="usd">10278000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c100"
      decimals="-3"
      id="ixv-11609"
      unitRef="usd">6478000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c101"
      decimals="-3"
      id="ixv-11610"
      unitRef="usd">4228000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c102"
      decimals="-3"
      id="ixv-11611"
      unitRef="usd">18461000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c103"
      decimals="-3"
      id="ixv-11612"
      unitRef="usd">17352000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c12" decimals="-3" id="ixv-11613" unitRef="usd">75694000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c13" decimals="-3" id="ixv-11614" unitRef="usd">66807000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c14" decimals="-3" id="ixv-11615" unitRef="usd">209811000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c15" decimals="-3" id="ixv-11616" unitRef="usd">180036000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c16" decimals="-3" id="ixv-11617" unitRef="usd">8112000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c17" decimals="-3" id="ixv-11618" unitRef="usd">8924000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c18" decimals="-3" id="ixv-11619" unitRef="usd">27359000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c19" decimals="-3" id="ixv-11620" unitRef="usd">27324000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c20" decimals="-3" id="ixv-11621" unitRef="usd">115598000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c21" decimals="-3" id="ixv-11622" unitRef="usd">75731000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c22" decimals="-3" id="ixv-11623" unitRef="usd">294523000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c23" decimals="-3" id="ixv-11624" unitRef="usd">207360000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c24" decimals="-3" id="ixv-11625" unitRef="usd">31436000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c25" decimals="-3" id="ixv-11626" unitRef="usd">44883000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c26" decimals="-3" id="ixv-11627" unitRef="usd">413387000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c27" decimals="-3" id="ixv-11628" unitRef="usd">235753000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c28" decimals="-3" id="ixv-11629" unitRef="usd">9685000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c29" decimals="-3" id="ixv-11630" unitRef="usd">13200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c30" decimals="-3" id="ixv-11631" unitRef="usd">32471000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c31" decimals="-3" id="ixv-11632" unitRef="usd">35449000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c32" decimals="-3" id="ixv-11633" unitRef="usd">41121000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c33" decimals="-3" id="ixv-11634" unitRef="usd">58083000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c34" decimals="-3" id="ixv-11635" unitRef="usd">445858000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c35" decimals="-3" id="ixv-11636" unitRef="usd">271202000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c36" decimals="-3" id="ixv-11637" unitRef="usd">156719000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c37" decimals="-3" id="ixv-11638" unitRef="usd">133814000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c0" decimals="-3" id="ixv-11639" unitRef="usd">740381000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c38" decimals="-3" id="ixv-11640" unitRef="usd">478562000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ions:UpfrontPaymentReceived contextRef="c85" decimals="-6" id="ixv-11641" unitRef="usd">200000000</ions:UpfrontPaymentReceived>
    <ions:NumberOfMaterialComponents
      contextRef="c86"
      decimals="INF"
      id="ixv-11642"
      unitRef="Component">4</ions:NumberOfMaterialComponents>
    <ions:RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations
      contextRef="c86"
      decimals="INF"
      id="ixv-11643"
      unitRef="PerformanceObligation">1</ions:RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations>
    <ions:RevenueFromContractWithCustomerTransactionPrice contextRef="c86" decimals="-6" id="ixv-11644" unitRef="usd">200000000</ions:RevenueFromContractWithCustomerTransactionPrice>
    <ions:PercentageOfCostsAssociatedWithOngoingGlobalPhase3DevelopmentProgramPaidByCollaborationPartner contextRef="c87" decimals="2" id="ixv-11645" unitRef="pure">0.55</ions:PercentageOfCostsAssociatedWithOngoingGlobalPhase3DevelopmentProgramPaidByCollaborationPartner>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="c0" id="ixv-4099">&lt;div&gt;
   &lt;span style="color: #000000; font-weight: bold;"&gt;5.  Collaborative Arrangements and Licensing Agreements&lt;/span&gt;
  &lt;/div&gt;
  &lt;div&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; font-family: Calibri; font-size: 11pt; color: rgb(0, 0, 0); text-align: justify;"&gt;
   &lt;span style="font-family: Times New Roman; font-size: 10.0pt;"&gt;Below, we have included our AstraZeneca and Ono collaborations, which were the only collaborations that had either substantive changes or were new from those included in Part IV, Item 15, Note 4, &lt;/span&gt;&lt;span style="font-family: Times New Roman; font-size: 10.0pt; font-style: italic;"&gt;Collaborative Arrangements and Licensing Agreements&lt;/span&gt;&lt;span style="font-family: Times New Roman; font-size: 10.0pt;"&gt;, of our audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2024. &lt;/span&gt;
  &lt;/div&gt;
  &lt;div&gt;&#160;&lt;/div&gt;
  &lt;div&gt;&#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160;&lt;b&gt;AstraZeneca&lt;/b&gt;&lt;/div&gt;&lt;div&gt;&#160;&lt;/div&gt;&lt;div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"&gt;We have two collaborations with AstraZeneca: one focused on the joint development and commercialization of WAINUA and one focused on the treatment of cardiovascular, renal and metabolic diseases. From inception through September 30, 2025, we have received more than $960 million from these collaborations.&lt;/div&gt;&lt;div&gt;&#160;&lt;/div&gt;&lt;div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"&gt;In the second quarter of 2025, we earned a $30 million milestone payment under our cardiovascular, renal and metabolic diseases collaboration when AstraZeneca initiated the Phase 2b study of opemalirsen (formerly ION532), an investigational medicine designed to reduce the production of apolipoprotein L1, or APOL1, for the treatment of APOL1-mediated kidney disease. We recognized this milestone payment as R&amp;amp;D revenue in full in the second quarter of 2025 because we did not have any remaining performance obligations related to the milestone payment. We will achieve the next payment of $20 million if AstraZeneca advances a medicine under this collaboration.&lt;/div&gt;&lt;div&gt;&#160;&lt;/div&gt;&lt;div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"&gt;During the three and nine months ended September 30, 2025 and 2024, we earned the following revenue from our relationship with AstraZeneca (in thousands, except percentage amounts):&lt;/div&gt;&lt;div&gt;&#160;&lt;/div&gt;&lt;table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"&gt;&lt;tr style="height: 0px; font-size: 0px;"&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td colspan="7" style="text-align: center; font-weight: bold;"&gt;Three Months Ended&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td colspan="7" style="text-align: center; font-weight: bold;"&gt;Nine Months Ended&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;September 30,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;September 30,&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 5. Collaborations - B6"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;2025&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 5. Collaborations - B6"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 5. Collaborations - D6"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;2024&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 5. Collaborations - D6"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 5. Collaborations - F6"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;2025&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 5. Collaborations - F6"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 5. Collaborations - H6"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;2024&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 5. Collaborations - H6"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Revenue from our relationship with AstraZeneca&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 5. Collaborations - B7"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;27,128&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 5. Collaborations - B7"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 5. Collaborations - D7"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;19,461&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 5. Collaborations - D7"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 5. Collaborations - F7"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;101,705&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 5. Collaborations - F7"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 5. Collaborations - H7"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;47,106&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 5. Collaborations - H7"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Percentage of total revenue&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 5. Collaborations - B8"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;17&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 5. Collaborations - B8"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 5. Collaborations - D8"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;15&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 5. Collaborations - D8"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 5. Collaborations - F8"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;14&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 5. Collaborations - F8"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 5. Collaborations - H8"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;10&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 5. Collaborations - H8"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&#160;&lt;/div&gt;&lt;div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"&gt;&#160;We did not have any deferred revenue from our relationship with AstraZeneca at September 30, 2025 and December 31, 2024.&lt;/div&gt;&lt;div&gt;&#160;&lt;/div&gt;&lt;div style="text-indent: 36pt;"&gt;
   &lt;span style="color: #000000; font-weight: bold; font-style: italic;"&gt;Ono&lt;/span&gt;
  &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span style="color: #000000;"&gt;In March 2025, we entered into an agreement with Ono Pharmaceutical Co., Ltd., or Ono, to develop and commercialize sapablursen, an investigational RNA-targeted medicine for the potential treatment of polycythemia vera, or PV, a rare and potentially life-threatening hematologic disease. We are responsible for completing the ongoing Phase 2 IMPRSSION study, while Ono will be solely responsible for subsequent development, regulatory filings and commercialization of sapablursen.&lt;/span&gt;
  &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span style="color: #000000;"&gt;Over the term of this collaboration, we are eligible to receive up to $940 million, which is comprised of a $280 million upfront payment, a $20 million development milestone payment, up to $20 million in regulatory milestone payments and up to $620 million in sales milestone payments. In addition, we are eligible to receive royalties in the mid-teen percentage range on net sales. From inception through September 30, 2025, we received more than $280 million from this collaboration, which includes the upfront payment and reimbursements for additional R&amp;amp;D services. We will achieve the next payment of $20 million if Ono initiates a pivotal clinical trial under this collaboration.&lt;/span&gt;&#160;&lt;/div&gt;


  &lt;div style="text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/div&gt;&lt;div style="text-indent: 36pt; text-align: justify;"&gt;At inception, we identified two performance obligations under this agreement, comprised of our license of sapablursen to Ono and R&amp;amp;D services for sapablursen. We determined the transaction price to be the $280 million upfront payment we received &lt;span style="letter-spacing: normal; text-indent: 48px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;when this transaction received clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, or HSR Act,&#160;&lt;/span&gt;in the second quarter of 2025. We allocated the transaction price based on the estimated stand-alone selling price of each performance obligation as follows:&lt;/div&gt;&lt;div style="text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/div&gt;&lt;div style="text-indent: 36pt; text-align: justify;"&gt;&#x25cf;&#160;&#160;&#160;&#160;$278 million for the license of sapablursen; and&lt;/div&gt;&lt;div style="text-indent: 36pt; text-align: justify;"&gt;&#x25cf;&#160; &#160; $2 million for the R&amp;amp;D services for sapablursen.&lt;/div&gt;&lt;div style="text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/div&gt;&lt;div style="text-indent: 36pt; text-align: justify;"&gt;We recognized $278 million of R&amp;amp;D revenue for the license of sapablursen in the second quarter of 2025 because we completed the performance obligation when we delivered the license to Ono. We recognized revenue for our R&amp;amp;D services performance obligation as we performed services based on our effort to satisfy our performance obligation relative to our total effort expected to satisfy our performance obligation. In the second quarter of 2025, we completed our R&amp;amp;D services performance obligation and recognized $2 million of R&amp;amp;D revenue.&lt;/div&gt;&lt;div style="text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/div&gt;&lt;div style="text-indent: 36pt; text-align: justify;"&gt;During&#160;&lt;span style="letter-spacing: normal; text-indent: 48px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;the three and nine months ended September 30, 2025&#160;and 2024, we earned the following revenue from our relationship with Ono&#160;(in thousands, except percentage amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/div&gt;&lt;table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"&gt;&lt;tr style="height: 0px; font-size: 0px;"&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 5. Collaborations - Ono - B2"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; width: 9%;"&gt;Three Months Ended&lt;/td&gt;&lt;td style="width: 1%;" title="Note 5. Collaborations - Ono - B2"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 5. Collaborations - Ono - D2"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; width: 9%;"&gt;Nine Months Ended&lt;/td&gt;&lt;td style="width: 1%;" title="Note 5. Collaborations - Ono - D2"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="border-left: none; border-right: none; border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 5. Collaborations - Ono - B3"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-top: none; border-left: none; border-right: none; border-bottom: 1px solid black; width: 9%;"&gt;September 30, 2025&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 5. Collaborations - Ono - B3"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid black; border-left: none; border-right: none; border-top: none; width: 1%;" title="Note 5. Collaborations - Ono - D3"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-left: none; border-right: none; border-bottom: 1px solid black; border-top: none; width: 9%;"&gt;September 30, 2025&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 5. Collaborations - Ono - D3"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Revenue from our relationship with Ono&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 5. Collaborations - Ono - B4"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;2,979&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 5. Collaborations - Ono - B4"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 5. Collaborations - Ono - D4"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;282,979&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 5. Collaborations - Ono - D4"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Percentage of total revenue&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 5. Collaborations - Ono - B5"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;2&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 5. Collaborations - Ono - B5"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 5. Collaborations - Ono - D5"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;38&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 5. Collaborations - Ono - D5"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/div&gt;&lt;div style="text-indent: 36pt; text-align: justify;"&gt;&lt;span style="letter-spacing: normal; text-indent: 48px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;Our condensed consolidated balance sheet at September 30, 2025 included deferred revenue of $2.9 million from our relationship with Ono. We did not have any deferred revenue from our relationship with Ono at&#160;December 31, 2024.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <ions:NumberOfCollaborationAgreements
      contextRef="c104"
      decimals="0"
      id="ixv-11646"
      unitRef="Agreement">2</ions:NumberOfCollaborationAgreements>
    <ions:NumberOfCollaborationAgreements
      contextRef="c105"
      decimals="0"
      id="ixv-11647"
      unitRef="Agreement">1</ions:NumberOfCollaborationAgreements>
    <ions:NumberOfCollaborationAgreements
      contextRef="c106"
      decimals="0"
      id="ixv-11648"
      unitRef="Agreement">1</ions:NumberOfCollaborationAgreements>
    <ions:CumulativePaymentsReceived
      contextRef="c104"
      decimals="-6"
      id="ixv-11649"
      unitRef="usd">960000000</ions:CumulativePaymentsReceived>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c107"
      decimals="-6"
      id="ixv-11650"
      unitRef="usd">30000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ions:NextPaymentToBeAchieved
      contextRef="c106"
      decimals="-6"
      id="ixv-11651"
      unitRef="usd">20000000</ions:NextPaymentToBeAchieved>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock contextRef="c117" id="ixv-4115">&lt;div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"&gt;During the three and nine months ended September 30, 2025 and 2024, we earned the following revenue from our relationship with AstraZeneca (in thousands, except percentage amounts):&lt;/div&gt;&lt;div&gt;&#160;&lt;/div&gt;&lt;table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"&gt;&lt;tr style="height: 0px; font-size: 0px;"&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td colspan="7" style="text-align: center; font-weight: bold;"&gt;Three Months Ended&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td colspan="7" style="text-align: center; font-weight: bold;"&gt;Nine Months Ended&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;September 30,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;September 30,&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 5. Collaborations - B6"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;2025&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 5. Collaborations - B6"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 5. Collaborations - D6"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;2024&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 5. Collaborations - D6"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 5. Collaborations - F6"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;2025&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 5. Collaborations - F6"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 5. Collaborations - H6"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;2024&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 5. Collaborations - H6"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Revenue from our relationship with AstraZeneca&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 5. Collaborations - B7"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;27,128&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 5. Collaborations - B7"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 5. Collaborations - D7"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;19,461&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 5. Collaborations - D7"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 5. Collaborations - F7"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;101,705&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 5. Collaborations - F7"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 5. Collaborations - H7"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;47,106&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 5. Collaborations - H7"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Percentage of total revenue&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 5. Collaborations - B8"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;17&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 5. Collaborations - B8"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 5. Collaborations - D8"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;15&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 5. Collaborations - D8"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 5. Collaborations - F8"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;14&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 5. Collaborations - F8"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 5. Collaborations - H8"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;10&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 5. Collaborations - H8"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c118"
      decimals="-3"
      id="ixv-11652"
      unitRef="usd">27128000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c119"
      decimals="-3"
      id="ixv-11653"
      unitRef="usd">19461000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c117"
      decimals="-3"
      id="ixv-11654"
      unitRef="usd">101705000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c120"
      decimals="-3"
      id="ixv-11655"
      unitRef="usd">47106000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c121"
      decimals="2"
      id="ixv-11656"
      unitRef="pure">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c122"
      decimals="2"
      id="ixv-11657"
      unitRef="pure">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c123"
      decimals="2"
      id="ixv-11658"
      unitRef="pure">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c124"
      decimals="2"
      id="ixv-11659"
      unitRef="pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ContractWithCustomerLiability
      contextRef="c104"
      decimals="-6"
      id="ixv-11660"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="c108"
      decimals="-6"
      id="ixv-11661"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <ions:MaximumAmountOfPaymentsReceivableOverTermOfCollaboration
      contextRef="c109"
      decimals="-6"
      id="ixv-11662"
      unitRef="usd">940000000</ions:MaximumAmountOfPaymentsReceivableOverTermOfCollaboration>
    <ions:MaximumAmountOfUpfrontPaymentsOverTermOfCollaboration
      contextRef="c109"
      decimals="-6"
      id="ixv-11663"
      unitRef="usd">280000000</ions:MaximumAmountOfUpfrontPaymentsOverTermOfCollaboration>
    <ions:MaximumAmountOfDevelopmentMilestonePaymentsOverTermOfCollaboration
      contextRef="c109"
      decimals="-6"
      id="ixv-11664"
      unitRef="usd">20000000</ions:MaximumAmountOfDevelopmentMilestonePaymentsOverTermOfCollaboration>
    <ions:MaximumAmountOfRegulatoryMilestonePaymentsOverTermOfCollaboration
      contextRef="c109"
      decimals="-6"
      id="ixv-11665"
      unitRef="usd">20000000</ions:MaximumAmountOfRegulatoryMilestonePaymentsOverTermOfCollaboration>
    <ions:MaximumAmountOfSalesMilestonePaymentsOverTermOfCollaboration
      contextRef="c109"
      decimals="-6"
      id="ixv-11666"
      unitRef="usd">620000000</ions:MaximumAmountOfSalesMilestonePaymentsOverTermOfCollaboration>
    <ions:CumulativePaymentsReceived
      contextRef="c109"
      decimals="-6"
      id="ixv-11667"
      unitRef="usd">280000000</ions:CumulativePaymentsReceived>
    <ions:NextPaymentToBeAchieved
      contextRef="c109"
      decimals="-6"
      id="ixv-11668"
      unitRef="usd">20000000</ions:NextPaymentToBeAchieved>
    <ions:NumberOfPerformanceObligationsIdentified
      contextRef="c110"
      decimals="0"
      id="ixv-11669"
      unitRef="PerformanceObligation">2</ions:NumberOfPerformanceObligationsIdentified>
    <ions:RevenueFromContractWithCustomerTransactionPrice
      contextRef="c111"
      decimals="-6"
      id="ixv-11670"
      unitRef="usd">280000000</ions:RevenueFromContractWithCustomerTransactionPrice>
    <ions:RevenueFromContractWithCustomerTransactionPrice
      contextRef="c112"
      decimals="-6"
      id="ixv-11671"
      unitRef="usd">278000000</ions:RevenueFromContractWithCustomerTransactionPrice>
    <ions:RevenueFromContractWithCustomerTransactionPrice
      contextRef="c113"
      decimals="-6"
      id="ixv-11672"
      unitRef="usd">2000000</ions:RevenueFromContractWithCustomerTransactionPrice>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c114"
      decimals="-6"
      id="ixv-11673"
      unitRef="usd">278000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c115"
      decimals="-6"
      id="ixv-11674"
      unitRef="usd">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock contextRef="c125" id="ixv-4217">&lt;div style="text-indent: 36pt; text-align: justify;"&gt;During&#160;&lt;span style="letter-spacing: normal; text-indent: 48px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;the three and nine months ended September 30, 2025&#160;and 2024, we earned the following revenue from our relationship with Ono&#160;(in thousands, except percentage amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/div&gt;&lt;table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"&gt;&lt;tr style="height: 0px; font-size: 0px;"&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 5. Collaborations - Ono - B2"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; width: 9%;"&gt;Three Months Ended&lt;/td&gt;&lt;td style="width: 1%;" title="Note 5. Collaborations - Ono - B2"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 5. Collaborations - Ono - D2"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; width: 9%;"&gt;Nine Months Ended&lt;/td&gt;&lt;td style="width: 1%;" title="Note 5. Collaborations - Ono - D2"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="border-left: none; border-right: none; border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 5. Collaborations - Ono - B3"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-top: none; border-left: none; border-right: none; border-bottom: 1px solid black; width: 9%;"&gt;September 30, 2025&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 5. Collaborations - Ono - B3"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid black; border-left: none; border-right: none; border-top: none; width: 1%;" title="Note 5. Collaborations - Ono - D3"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-left: none; border-right: none; border-bottom: 1px solid black; border-top: none; width: 9%;"&gt;September 30, 2025&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 5. Collaborations - Ono - D3"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Revenue from our relationship with Ono&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 5. Collaborations - Ono - B4"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;2,979&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 5. Collaborations - Ono - B4"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 5. Collaborations - Ono - D4"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;282,979&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 5. Collaborations - Ono - D4"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Percentage of total revenue&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 5. Collaborations - Ono - B5"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;2&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 5. Collaborations - Ono - B5"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 5. Collaborations - Ono - D5"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;38&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 5. Collaborations - Ono - D5"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c126"
      decimals="-3"
      id="ixv-11675"
      unitRef="usd">2979000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c125"
      decimals="-3"
      id="ixv-11676"
      unitRef="usd">282979000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c127"
      decimals="2"
      id="ixv-11677"
      unitRef="pure">0.02</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c128"
      decimals="2"
      id="ixv-11678"
      unitRef="pure">0.38</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ContractWithCustomerLiability
      contextRef="c109"
      decimals="-5"
      id="ixv-11679"
      unitRef="usd">2900000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="c116"
      decimals="-6"
      id="ixv-11680"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:EarningsPerShareTextBlock contextRef="c0" id="ixv-4272">&lt;div&gt;
   &lt;span style="color: #000000; font-weight: bold;"&gt;6. Basic and Diluted Net Loss Per Share&lt;/span&gt;
  &lt;/div&gt;
  &lt;div style="font-size: 8pt;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span style="color: #000000; font-weight: bold;"&gt;Basic net loss&#160;per share&lt;/span&gt; &lt;/div&gt;
  &lt;div style="text-align: justify; font-size: 8pt;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span style="color: #000000;"&gt;We calculated our basic net loss per share for the three and nine months ended September 30, 2025 and 2024 by dividing our net loss&#160;by our weighted-average number of common shares outstanding during the period.&lt;/span&gt;
  &lt;/div&gt;&lt;div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"&gt;
   &lt;span style="color: #000000; font-weight: bold;"&gt;Diluted net loss&#160;per share&lt;/span&gt;
  &lt;/div&gt;


  &lt;div style="text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/div&gt;&lt;div style="text-indent: 36pt; text-align: justify;"&gt;&lt;span style="color: #000000;"&gt;For the three and&#160;nine months ended&#160;September 30, 2025 and 2024, we incurred a net loss; therefore, we did not include dilutive common equivalent shares in the computation of diluted net loss per share because the effect would have been anti-dilutive. Common stock from the following would have had an anti-dilutive effect on net loss per share:&lt;/span&gt;
  &lt;/div&gt;&lt;div&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: -18pt; padding-left: 54pt;"&gt;

    &lt;div&gt; &lt;span style="color: #000000;"&gt;&#x25cf;&#160;&#160;&#160;&#160;1.75 percent convertible senior notes, or 1.75% Notes;&lt;/span&gt; &lt;/div&gt;
  &lt;/div&gt;
  &lt;div style="text-indent: -18pt; padding-left: 54pt;"&gt;

    &lt;div&gt; &lt;span style="color: #000000;"&gt;&#x25cf;&#160;&#160;&#160;&#160;0 percent convertible senior notes, or 0% Notes;&lt;/span&gt; &lt;/div&gt;
  &lt;/div&gt;
  &lt;div style="text-indent: -18pt; padding-left: 54pt;"&gt;

    &lt;div&gt; &lt;span style="color: #000000;"&gt;&#x25cf;&#160;&#160;&#160;&#160;Note hedges related to the 0% Notes;&lt;/span&gt; &lt;/div&gt;
  &lt;/div&gt;
  &lt;div style="text-indent: -18pt; padding-left: 54pt;"&gt;

    &lt;div&gt;
     &lt;span style="color: #000000;"&gt;&#x25cf;&#160;&#160;&#160;&#160;Dilutive stock options; &lt;/span&gt;
    &lt;/div&gt;
  &lt;/div&gt;
  &lt;div style="text-indent: -18pt; padding-left: 54pt;"&gt;

    &lt;div&gt;
     &lt;span style="color: #000000;"&gt;&#x25cf;&#160;&#160;&#160;&#160;Unvested restricted stock units, or RSUs; &lt;/span&gt;
    &lt;/div&gt;
  &lt;/div&gt;
  &lt;div style="text-indent: -18pt; padding-left: 54pt;"&gt;

    &lt;div&gt;
     &lt;span style="color: #000000;"&gt;&#x25cf;&#160;&#160;&#160;&#160;Unvested performance restricted stock units, or PRSUs; and&lt;/span&gt;
    &lt;/div&gt;
  &lt;/div&gt;
  &lt;div style="text-indent: -18pt; padding-left: 54pt;"&gt;

    &lt;div&gt;
     &lt;span style="color: #000000;"&gt;&#x25cf;&#160;&#160;&#160;&#160;Employee Stock Purchase Plan, or ESPP.&lt;/span&gt;
    &lt;/div&gt;
  &lt;/div&gt;
  &lt;div&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span&gt;For the three and nine months ended September 30, 2024, common stock underlying the 0.125 percent&lt;/span&gt;&lt;span style="color: #000000;"&gt; convertible senior notes, or 0.125% Notes&lt;/span&gt;&lt;span&gt;, and n&lt;/span&gt;&lt;span style="color: #000000;"&gt;ote hedges related to the 0.125% Notes &lt;/span&gt;&lt;span&gt;would also have had an anti-dilutive effect on net loss per share.&lt;/span&gt; &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;&#160;
  &lt;/div&gt;

  &lt;div style="text-indent: 36pt; text-align: justify;"&gt; As of&#160;September 30, 2025&lt;span style="letter-spacing: normal; text-indent: 48px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;, we had warrants related to our 0% Notes outstanding.&lt;/span&gt; As of September 30, 2024,&#160;we had warrants related to our 0% and 0.125% Notes outstanding. We will include the shares issuable under these warrants in our calculation of diluted earnings per share when the average market price per share of our common stock for the reporting period exceeds the strike price of the warrants. &lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c0" id="ixv-4276">&lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span style="color: #000000; font-weight: bold;"&gt;Basic net loss&#160;per share&lt;/span&gt; &lt;/div&gt;&lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span style="color: #000000;"&gt;We calculated our basic net loss per share for the three and nine months ended September 30, 2025 and 2024 by dividing our net loss&#160;by our weighted-average number of common shares outstanding during the period.&lt;/span&gt;
  &lt;/div&gt;&lt;div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"&gt;
   &lt;span style="color: #000000; font-weight: bold;"&gt;Diluted net loss&#160;per share&lt;/span&gt;
  &lt;/div&gt;&lt;div style="text-indent: 36pt; text-align: justify;"&gt;&lt;span style="color: #000000;"&gt;For the three and&#160;nine months ended&#160;September 30, 2025 and 2024, we incurred a net loss; therefore, we did not include dilutive common equivalent shares in the computation of diluted net loss per share because the effect would have been anti-dilutive. Common stock from the following would have had an anti-dilutive effect on net loss per share:&lt;/span&gt;
  &lt;/div&gt;&lt;div&gt; &lt;span style="color: #000000;"&gt;&#x25cf;&#160;&#160;&#160;&#160;1.75 percent convertible senior notes, or 1.75% Notes;&lt;/span&gt; &lt;/div&gt;&lt;div&gt; &lt;span style="color: #000000;"&gt;&#x25cf;&#160;&#160;&#160;&#160;0 percent convertible senior notes, or 0% Notes;&lt;/span&gt; &lt;/div&gt;&lt;div&gt; &lt;span style="color: #000000;"&gt;&#x25cf;&#160;&#160;&#160;&#160;Note hedges related to the 0% Notes;&lt;/span&gt; &lt;/div&gt;&lt;div&gt;
     &lt;span style="color: #000000;"&gt;&#x25cf;&#160;&#160;&#160;&#160;Dilutive stock options; &lt;/span&gt;
    &lt;/div&gt;&lt;div&gt;
     &lt;span style="color: #000000;"&gt;&#x25cf;&#160;&#160;&#160;&#160;Unvested restricted stock units, or RSUs; &lt;/span&gt;
    &lt;/div&gt;&lt;div&gt;
     &lt;span style="color: #000000;"&gt;&#x25cf;&#160;&#160;&#160;&#160;Unvested performance restricted stock units, or PRSUs; and&lt;/span&gt;
    &lt;/div&gt;&lt;div&gt;
     &lt;span style="color: #000000;"&gt;&#x25cf;&#160;&#160;&#160;&#160;Employee Stock Purchase Plan, or ESPP.&lt;/span&gt;
    &lt;/div&gt;&lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span&gt;For the three and nine months ended September 30, 2024, common stock underlying the 0.125 percent&lt;/span&gt;&lt;span style="color: #000000;"&gt; convertible senior notes, or 0.125% Notes&lt;/span&gt;&lt;span&gt;, and n&lt;/span&gt;&lt;span style="color: #000000;"&gt;ote hedges related to the 0.125% Notes &lt;/span&gt;&lt;span&gt;would also have had an anti-dilutive effect on net loss per share.&lt;/span&gt; &lt;/div&gt;&lt;div style="text-indent: 36pt; text-align: justify;"&gt; As of&#160;September 30, 2025&lt;span style="letter-spacing: normal; text-indent: 48px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;, we had warrants related to our 0% Notes outstanding.&lt;/span&gt; As of September 30, 2024,&#160;we had warrants related to our 0% and 0.125% Notes outstanding. We will include the shares issuable under these warrants in our calculation of diluted earnings per share when the average market price per share of our common stock for the reporting period exceeds the strike price of the warrants. &lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c6"
      decimals="INF"
      id="ixv-11681"
      unitRef="pure">0.0175</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c129"
      decimals="INF"
      id="ixv-11682"
      unitRef="pure">0.0175</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c6"
      decimals="INF"
      id="ixv-11683"
      unitRef="pure">0.0175</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c129"
      decimals="INF"
      id="ixv-11684"
      unitRef="pure">0.0175</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c4"
      decimals="INF"
      id="ixv-11685"
      unitRef="pure">0</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c130"
      decimals="INF"
      id="ixv-11686"
      unitRef="pure">0</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c4"
      decimals="INF"
      id="ixv-11687"
      unitRef="pure">0</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c130"
      decimals="INF"
      id="ixv-11688"
      unitRef="pure">0</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c4"
      decimals="INF"
      id="ixv-11689"
      unitRef="pure">0</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c130"
      decimals="INF"
      id="ixv-11690"
      unitRef="pure">0</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c131"
      decimals="INF"
      id="ixv-11691"
      unitRef="pure">0.00125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c131"
      decimals="INF"
      id="ixv-11692"
      unitRef="pure">0.00125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c131"
      decimals="INF"
      id="ixv-11693"
      unitRef="pure">0.00125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c131"
      decimals="INF"
      id="ixv-11694"
      unitRef="pure">0.00125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c131"
      decimals="INF"
      id="ixv-11695"
      unitRef="pure">0.00125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c131"
      decimals="INF"
      id="ixv-11696"
      unitRef="pure">0.00125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c4"
      decimals="INF"
      id="ixv-11697"
      unitRef="pure">0</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c130"
      decimals="INF"
      id="ixv-11698"
      unitRef="pure">0</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c131"
      decimals="INF"
      id="ixv-11699"
      unitRef="pure">0.00125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:InvestmentTextBlock contextRef="c0" id="ixv-4343">&lt;div&gt;
   &lt;span style="color: #000000; font-weight: bold;"&gt;7.&#160;&#160;Investments&lt;/span&gt;
  &lt;/div&gt;
  &lt;div&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span style="color: #000000;"&gt;The following table summarizes the contract maturity of the available-for-sale securities we held as of September 30, 2025:&lt;/span&gt; &lt;/div&gt;
  &lt;div&gt;&#160;&lt;/div&gt;
  &lt;div&gt;&#160;&lt;/div&gt;&lt;table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;One year or less &lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - B4"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;67&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - B4"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;After one year but within two years &lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - B5"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;29&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - B5"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;After two years but within &lt;span style="-sec-ix-hidden: hidden-fact-1"&gt;three and a half years&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B6"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;4&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B6"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Total &lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B7"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;"&gt;100&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B7"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
  &lt;div&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span style="color: #000000;"&gt;As illustrated above, at September 30, 2025, 96 percent of our available-for-sale securities had a maturity of less than two years.&lt;/span&gt; &lt;/div&gt;
  &lt;div&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span style="color: #000000;"&gt;All of our available-for-sale debt securities are available to us for use in our current operations. As a result, we categorize all of these securities as current assets even though the stated maturity of some individual securities may be one year or more beyond the balance sheet date.&lt;/span&gt;
  &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span style="color: #000000;"&gt;We invest in debt securities&lt;/span&gt;&lt;span&gt; with strong credit ratings and an investment grade rating at or above A-1, P-1 or F-1 by Standard &amp;amp; Poor&#x2019;s, Moody&#x2019;s or Fitch, respectively. &lt;/span&gt;
  &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span style="color: #000000;"&gt;At September 30, 2025, we had an equity ownership interest of less than 20 percent in seven private companies and three public companies with which we conduct business. &lt;/span&gt; &lt;/div&gt;&lt;div&gt; &lt;span style="color: #000000;"&gt;The following is a summary of our investments (in thousands):&lt;/span&gt; &lt;/div&gt;

  &lt;div&gt;&#160;&lt;/div&gt;&lt;table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"&gt;&lt;tr style="height: 0px; font-size: 0px;"&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - B9"&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; width: 9%;"&gt;Amortized&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - B9"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td colspan="7" style="font-weight: bold; text-align: center; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;Gross Unrealized&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - H9"&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; width: 9%;"&gt;Estimated&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - H9"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="font-weight: bold; text-align: left;"&gt;September 30, 2025&lt;/td&gt;&lt;td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - B10"&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;Cost&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B10"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - D10"&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;Gains&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D10"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - F10"&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;Losses&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F10"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - H10"&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;Fair Value&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H10"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="text-decoration: underline;"&gt;Available-for-sale debt securities:&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - B11"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - B11"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - D11"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - D11"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - F11"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - F11"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - H11"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - H11"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td style="vertical-align: bottom;"&gt;Corporate debt securities (1)&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B12"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; vertical-align: bottom;"&gt;639,937&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B12"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D12"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; vertical-align: bottom;"&gt;815&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D12"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F12"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; vertical-align: bottom;"&gt;(69&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F12"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H12"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; vertical-align: bottom;"&gt;640,683&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H12"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align: bottom;"&gt;Debt securities issued by U.S. government agencies&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B13"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; vertical-align: bottom;"&gt;73,905&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B13"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D13"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; vertical-align: bottom;"&gt;66&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D13"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F13"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; vertical-align: bottom;"&gt;(16&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F13"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H13"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; vertical-align: bottom;"&gt;73,955&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H13"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td style="vertical-align: bottom;"&gt;Debt securities issued by the U.S. Treasury (1)&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B14"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; vertical-align: bottom;"&gt;562,662&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B14"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D14"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; vertical-align: bottom;"&gt;384&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D14"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F14"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; vertical-align: bottom;"&gt;(61&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F14"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H14"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; vertical-align: bottom;"&gt;562,985&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H14"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align: bottom;"&gt;Debt securities issued by states of the U.S. and political subdivisions of&#160;the states&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - B15"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"&gt;5,151&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B15"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - D15"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"&gt;11&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D15"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - F15"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"&gt; - &lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F15"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - H15"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"&gt;5,162&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H15"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td style="vertical-align: bottom; padding-left: 20px;"&gt;Total debt securities with a maturity of one year&#160;or less&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - B16"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"&gt;1,281,655&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B16"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - D16"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"&gt;1,276&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D16"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - F16"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"&gt;(146&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F16"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - H16"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"&gt;1,282,785&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H16"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align: bottom;"&gt;Corporate debt securities&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B17"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; vertical-align: bottom;"&gt;415,818&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B17"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D17"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; vertical-align: bottom;"&gt;1,688&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D17"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F17"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; vertical-align: bottom;"&gt;(121&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F17"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H17"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; vertical-align: bottom;"&gt;417,385&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H17"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td style="vertical-align: bottom;"&gt;Debt securities issued by U.S. government agencies&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B18"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; vertical-align: bottom;"&gt;76,548&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B18"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D18"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; vertical-align: bottom;"&gt;147&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D18"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F18"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; vertical-align: bottom;"&gt;(60&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F18"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H18"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; vertical-align: bottom;"&gt;76,635&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H18"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align: bottom;"&gt;Debt securities issued by the U.S. Treasury  &lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B19"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; vertical-align: bottom;"&gt;204,656&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B19"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D19"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; vertical-align: bottom;"&gt;493&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D19"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F19"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; vertical-align: bottom;"&gt;(49&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F19"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H19"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; vertical-align: bottom;"&gt;205,100&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H19"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td style="vertical-align: bottom;"&gt;Debt securities issued by states of the U.S. and political subdivisions of&#160;the states&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B20"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; vertical-align: bottom;"&gt;1,117&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B20"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D20"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; vertical-align: bottom;"&gt;5&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D20"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F20"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; vertical-align: bottom;"&gt; - &lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F20"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H20"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; vertical-align: bottom;"&gt;1,122&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H20"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align: bottom;"&gt;Other municipal debt securities&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - B21"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"&gt;698&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B21"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - D21"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"&gt; - &lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D21"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - F21"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"&gt; - &lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F21"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - H21"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"&gt;698&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H21"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td style="vertical-align: bottom; padding-left: 20px;"&gt;Total debt securities with a maturity of more than one year&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - B22"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"&gt;698,837&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B22"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - D22"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"&gt;2,333&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D22"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - F22"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"&gt;(230&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F22"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - H22"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"&gt;700,940&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H22"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align: bottom; padding-left: 40px;"&gt;Total available-for-sale debt securities&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - B23"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"&gt;1,980,492&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B23"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - D23"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"&gt;3,609&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D23"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - F23"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"&gt;(376&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F23"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - H23"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"&gt;1,983,725&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H23"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-decoration: underline; vertical-align: bottom;"&gt;Equity securities:&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - B25"&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - B25"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - D25"&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - D25"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - F25"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - F25"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - H25"&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - H25"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align: bottom;"&gt;Publicly traded equity securities included in other current assets (2)&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B26"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; vertical-align: bottom;"&gt;11,897&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B26"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D26"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; vertical-align: bottom;"&gt;40&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D26"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F26"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; vertical-align: bottom;"&gt;(8,681&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F26"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H26"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; vertical-align: bottom;"&gt;3,256&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H26"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td style="vertical-align: bottom;"&gt;Privately held equity securities included in deposits and&#160;other assets (3)&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; vertical-align: bottom;" title="Note 7. Investments - B27"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;"&gt;4,905&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B27"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;" title="Note 7. Investments - D27"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;"&gt;54,395&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D27"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;" title="Note 7. Investments - F27"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;"&gt;(7,090&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F27"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;" title="Note 7. Investments - H27"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;"&gt;52,210&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H27"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align: bottom; padding-left: 20px;"&gt;Total equity securities  &lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;" title="Note 7. Investments - B28"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;"&gt;16,802&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B28"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;" title="Note 7. Investments - D28"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;"&gt;54,435&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D28"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;" title="Note 7. Investments - F28"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;"&gt;(15,771&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F28"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;" title="Note 7. Investments - H28"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-right: none; vertical-align: bottom;"&gt;55,466&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H28"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td style="vertical-align: bottom; padding-left: 40px;"&gt;Total available-for-sale debt and equity securities&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - B29"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"&gt;1,997,294&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B29"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - D29"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"&gt;58,044&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D29"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - F29"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"&gt;(16,147&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F29"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - H29"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"&gt;2,039,191&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H29"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"&gt;&lt;tr style="height: 0px; font-size: 0px;"&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; width: 1%;" title="Note 7. Investments - B30"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; width: 9%;"&gt;Amortized&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - B30"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;Gross Unrealized&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; width: 1%;" title="Note 7. Investments - H30"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; width: 9%;"&gt;Estimated&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - H30"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="font-weight: bold;"&gt;December 31, 2024&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - B31"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;Cost&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B31"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - D31"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;Gains&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D31"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - F31"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;Losses&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F31"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - H31"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;Fair Value&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H31"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="text-decoration: underline;"&gt;Available-for-sale debt securities:&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - B32"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - B32"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - D32"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - D32"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - F32"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - F32"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - H32"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - H32"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Corporate debt securities (1)&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - B33"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;593,810&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - B33"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - D33"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;487&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - D33"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - F33"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;(240&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - F33"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - H33"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;594,057&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - H33"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Debt securities issued by U.S. government agencies&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - B34"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;143,647&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - B34"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - D34"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;287&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - D34"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - F34"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;(39&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - F34"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - H34"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;143,895&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - H34"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Debt securities issued by the U.S. Treasury (1)&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - B35"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;657,285&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - B35"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - D35"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;825&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - D35"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - F35"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;(120&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - F35"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - H35"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;657,990&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - H35"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Debt securities issued by states of the U.S. and political subdivisions of&#160;the states&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B36"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;7,516&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B36"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D36"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;8&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D36"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F36"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt; - &lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F36"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H36"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;7,524&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H36"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td style="padding-left: 20px;"&gt;Total debt securities with a maturity of one year&#160;or less&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B37"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;1,402,258&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B37"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D37"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;1,607&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D37"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F37"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;(399&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F37"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H37"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;1,403,466&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H37"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Corporate debt securities&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - B38"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;439,561&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - B38"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - D38"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;723&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - D38"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - F38"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;(2,275&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - F38"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - H38"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;438,009&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - H38"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Debt securities issued by U.S. government agencies&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - B39"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;65,255&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - B39"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - D39"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;137&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - D39"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - F39"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;(289&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - F39"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - H39"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;65,103&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - H39"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Debt securities issued by the U.S. Treasury  &lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - B40"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;149,086&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - B40"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - D40"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;124&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - D40"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - F40"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;(476&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - F40"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - H40"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;148,734&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - H40"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Other municipal debt securities&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B41"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;698&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B41"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D41"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt; - &lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D41"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F41"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;(2&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F41"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H41"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;696&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H41"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="padding-left: 20px;"&gt;Total debt securities with a maturity of more than one year&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none;" title="Note 7. Investments - B42"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;"&gt;654,600&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B42"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - D42"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;"&gt;984&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D42"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - F42"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;"&gt;(3,042&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F42"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - H42"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;"&gt;652,542&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H42"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td style="padding-left: 40px;"&gt;Total available-for-sale debt securities&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - B43"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;"&gt;2,056,858&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B43"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - D43"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;"&gt;2,591&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D43"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - F43"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;"&gt;(3,441&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F43"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - H43"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-right: none;"&gt;2,056,008&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H43"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="text-decoration: underline;"&gt;Equity securities:&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - B44"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - B44"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - D44"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - D44"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - F44"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - F44"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - H44"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - H44"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Publicly traded equity securities included in other current assets (2)&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - B45"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;11,897&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - B45"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - D45"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;26&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - D45"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - F45"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;(6,660&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - F45"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - H45"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;5,263&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - H45"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Privately held equity securities included in deposits and&#160;other assets (3)&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none;" title="Note 7. Investments - B46"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;"&gt;23,115&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B46"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - D46"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;"&gt;25,001&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D46"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - F46"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;"&gt;(7,093&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F46"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - H46"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;"&gt;41,023&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H46"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td style="padding-left: 20px;"&gt;Total equity securities  &lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - B47"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;"&gt;35,012&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B47"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - D47"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;"&gt;25,027&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D47"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - F47"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;"&gt;(13,753&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F47"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - H47"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-right: none;"&gt;46,286&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H47"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="padding-left: 40px;"&gt;Total available-for-sale debt and equity securities&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B48"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;"&gt;2,091,870&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B48"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D48"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;"&gt;27,618&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D48"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F48"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;"&gt;(17,194&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F48"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H48"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;"&gt;2,102,294&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H48"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-align: justify;"&gt;&#160;&lt;/div&gt;&lt;div style="text-indent: -18pt; text-align: justify; padding-left: 18pt;"&gt;

    &lt;div&gt; &lt;span style="color: #000000;"&gt;(1)&#160;&#160;&#160;Includes investments classified as cash equivalents in our condensed consolidated balance sheets.&lt;/span&gt; &lt;/div&gt;
  &lt;/div&gt;
  &lt;div style="margin-left: 18pt;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: -18pt; text-align: justify; padding-left: 18pt;"&gt;

    &lt;div&gt; &lt;span style="color: #000000;"&gt;(2)&#160;&#160;Our publicly traded equity securities are included in other current assets. We recognize publicly traded equity securities at fair value. In the nine months ended September 30, 2025, we recorded a $2.0 million net unrealized loss in our condensed consolidated statements of operations related to changes in the fair value of our investments in publicly traded companies.&lt;/span&gt; &lt;/div&gt;
  &lt;/div&gt;
  &lt;div style="margin-left: 18pt;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: -18pt; text-align: justify; padding-left: 18pt;"&gt;

    &lt;div&gt; &lt;span style="color: #000000;"&gt;(3)&#160; Our privately held equity securities are included in deposits and other assets. We recognize our privately held equity securities at&lt;/span&gt;&lt;span&gt; cost minus impairments, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer, which are Level 3 inputs&lt;/span&gt;&lt;span style="color: #000000;"&gt;. In the nine months ended September 30, 2025, the amortized cost of our privately held equity securities increased $11.2 million. In the third quarter of 2025, we recorded a $29.4 million unrealized gain related to our investment in a privately held company due to an observable price change in an orderly transaction for a similar investment of the investee. This increase was partially offset by a loss of $18.2 million related to an impairment of our investment in another privately held company that we recorded in the second quarter of 2025.&lt;/span&gt;&lt;/div&gt;
  &lt;/div&gt;
  &lt;div style="text-align: justify; margin-left: 18pt;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span style="color: #000000;"&gt;The following is a summary of our investments we consider to be temporarily impaired at September 30, 2025 (in thousands, except for number of investments): &lt;/span&gt; &lt;/div&gt;

  &lt;div&gt;&#160;&lt;/div&gt;
  &lt;table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"&gt;&lt;tr style="height: 0px; font-size: 0px;"&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - B52"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - B52"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;Less than 12 Months of Temporary Impairment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;More than 12 Months of Temporary Impairment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;Total Temporary Impairment&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - B53"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;Number&#160;of Investments&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B53"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - D53"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;Estimated Fair&#160;Value&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D53"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - F53"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;Unrealized Losses&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F53"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - H53"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;Estimated Fair&#160;Value&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H53"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - J53"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;Unrealized Losses&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - J53"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - L53"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;Estimated Fair&#160;Value&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - L53"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - N53"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;Unrealized Losses&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - N53"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Corporate debt securities  &lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - B54"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;105&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - B54"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - D54"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;179,031&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - D54"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - F54"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;(127&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - F54"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - H54"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;55,955&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - H54"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - J54"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;(63&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - J54"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - L54"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;234,986&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - L54"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - N54"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;(190&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - N54"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Debt securities issued by&#160;U.S. government agencies&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - B55"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;43&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - B55"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - D55"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;71,369&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - D55"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - F55"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;(60&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - F55"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - H55"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;17,286&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - H55"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - J55"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;(16&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - J55"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - L55"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;88,655&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - L55"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - N55"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;(76&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - N55"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Debt securities issued by the U.S. Treasury  &lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - B56"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;25&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - B56"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - D56"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;141,191&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - D56"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - F56"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;(74&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - F56"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - H56"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;46,285&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - H56"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - J56"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;(36&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - J56"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - L56"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;187,476&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - L56"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - N56"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;(110&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - N56"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Other municipal debt securities&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B58"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;1&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B58"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D58"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;698&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D58"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F58"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt; - &lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F58"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H58"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt; - &lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H58"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - J58"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt; - &lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - J58"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - L58"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;698&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - L58"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - N58"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt; - &lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - N58"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Total temporarily impaired&#160;debt securities&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B59"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;"&gt;174&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B59"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D59"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;"&gt;392,289&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D59"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F59"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;"&gt;(261&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F59"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H59"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;"&gt;119,526&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H59"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - J59"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;"&gt;(115&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - J59"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - L59"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;"&gt;511,815&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - L59"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - N59"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;"&gt;(376&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - N59"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span&gt;We believe that the decline in value of these securities is temporary and is primarily related to the change in market interest rates since purchase rather than underlying credit deterioration for any of the issuers. We believe it is more likely than not that we will be able to hold our debt securities with declines in value to maturity. Therefore, we intend to hold these securities to maturity and anticipate full recovery of our debt securities&#x2019; amortized cost basis at maturity.&lt;/span&gt;
  &lt;/div&gt;</us-gaap:InvestmentTextBlock>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock contextRef="c0" id="ixv-4347">&lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span style="color: #000000;"&gt;The following table summarizes the contract maturity of the available-for-sale securities we held as of September 30, 2025:&lt;/span&gt; &lt;/div&gt;
  &lt;div&gt;&#160;&lt;/div&gt;
  &lt;div&gt;&#160;&lt;/div&gt;&lt;table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;One year or less &lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - B4"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;67&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - B4"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;After one year but within two years &lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - B5"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;29&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - B5"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;After two years but within &lt;span style="-sec-ix-hidden: hidden-fact-1"&gt;three and a half years&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B6"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;4&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B6"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Total &lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B7"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;"&gt;100&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B7"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <ions:MaximumContractMaturityPeriodRange1 contextRef="c0" id="ixv-11700">P1Y</ions:MaximumContractMaturityPeriodRange1>
    <ions:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage contextRef="c2" decimals="2" id="ixv-11701" unitRef="pure">0.67</ions:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage>
    <ions:MaximumContractMaturityPeriodRange1 contextRef="c0" id="ixv-11702">P1Y</ions:MaximumContractMaturityPeriodRange1>
    <ions:MaximumContractMaturityPeriodRange2 contextRef="c0" id="ixv-11703">P2Y</ions:MaximumContractMaturityPeriodRange2>
    <ions:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage contextRef="c2" decimals="2" id="ixv-11704" unitRef="pure">0.29</ions:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage>
    <ions:MaximumContractMaturityPeriodRange2 contextRef="c0" id="ixv-11705">P2Y</ions:MaximumContractMaturityPeriodRange2>
    <ions:AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage contextRef="c2" decimals="2" id="ixv-11706" unitRef="pure">0.04</ions:AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage>
    <ions:AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage
      contextRef="c2"
      decimals="INF"
      id="ixv-11707"
      unitRef="pure">1</ions:AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage>
    <ions:AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage contextRef="c2" decimals="2" id="ixv-11708" unitRef="pure">0.96</ions:AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage>
    <ions:MaximumContractMaturityPeriodRange2 contextRef="c0" id="ixv-11709">P2Y</ions:MaximumContractMaturityPeriodRange2>
    <ions:NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment
      contextRef="c2"
      decimals="INF"
      id="ixv-11710"
      unitRef="Company">7</ions:NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment>
    <ions:NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment
      contextRef="c2"
      decimals="INF"
      id="ixv-11711"
      unitRef="Company">3</ions:NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment>
    <us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock contextRef="c0" id="ixv-4396">&lt;div&gt; &lt;span style="color: #000000;"&gt;The following is a summary of our investments (in thousands):&lt;/span&gt; &lt;/div&gt;

  &lt;div&gt;&#160;&lt;/div&gt;&lt;table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"&gt;&lt;tr style="height: 0px; font-size: 0px;"&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - B9"&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; width: 9%;"&gt;Amortized&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - B9"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td colspan="7" style="font-weight: bold; text-align: center; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;Gross Unrealized&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - H9"&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; width: 9%;"&gt;Estimated&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - H9"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="font-weight: bold; text-align: left;"&gt;September 30, 2025&lt;/td&gt;&lt;td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - B10"&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;Cost&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B10"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - D10"&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;Gains&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D10"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - F10"&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;Losses&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F10"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - H10"&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;Fair Value&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H10"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="text-decoration: underline;"&gt;Available-for-sale debt securities:&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - B11"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - B11"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - D11"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - D11"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - F11"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - F11"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - H11"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - H11"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td style="vertical-align: bottom;"&gt;Corporate debt securities (1)&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B12"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; vertical-align: bottom;"&gt;639,937&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B12"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D12"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; vertical-align: bottom;"&gt;815&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D12"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F12"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; vertical-align: bottom;"&gt;(69&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F12"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H12"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; vertical-align: bottom;"&gt;640,683&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H12"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align: bottom;"&gt;Debt securities issued by U.S. government agencies&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B13"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; vertical-align: bottom;"&gt;73,905&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B13"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D13"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; vertical-align: bottom;"&gt;66&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D13"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F13"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; vertical-align: bottom;"&gt;(16&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F13"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H13"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; vertical-align: bottom;"&gt;73,955&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H13"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td style="vertical-align: bottom;"&gt;Debt securities issued by the U.S. Treasury (1)&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B14"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; vertical-align: bottom;"&gt;562,662&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B14"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D14"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; vertical-align: bottom;"&gt;384&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D14"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F14"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; vertical-align: bottom;"&gt;(61&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F14"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H14"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; vertical-align: bottom;"&gt;562,985&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H14"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align: bottom;"&gt;Debt securities issued by states of the U.S. and political subdivisions of&#160;the states&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - B15"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"&gt;5,151&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B15"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - D15"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"&gt;11&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D15"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - F15"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"&gt; - &lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F15"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - H15"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"&gt;5,162&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H15"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td style="vertical-align: bottom; padding-left: 20px;"&gt;Total debt securities with a maturity of one year&#160;or less&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - B16"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"&gt;1,281,655&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B16"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - D16"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"&gt;1,276&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D16"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - F16"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"&gt;(146&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F16"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - H16"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"&gt;1,282,785&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H16"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align: bottom;"&gt;Corporate debt securities&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B17"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; vertical-align: bottom;"&gt;415,818&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B17"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D17"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; vertical-align: bottom;"&gt;1,688&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D17"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F17"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; vertical-align: bottom;"&gt;(121&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F17"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H17"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; vertical-align: bottom;"&gt;417,385&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H17"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td style="vertical-align: bottom;"&gt;Debt securities issued by U.S. government agencies&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B18"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; vertical-align: bottom;"&gt;76,548&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B18"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D18"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; vertical-align: bottom;"&gt;147&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D18"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F18"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; vertical-align: bottom;"&gt;(60&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F18"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H18"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; vertical-align: bottom;"&gt;76,635&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H18"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align: bottom;"&gt;Debt securities issued by the U.S. Treasury  &lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B19"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; vertical-align: bottom;"&gt;204,656&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B19"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D19"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; vertical-align: bottom;"&gt;493&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D19"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F19"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; vertical-align: bottom;"&gt;(49&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F19"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H19"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; vertical-align: bottom;"&gt;205,100&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H19"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td style="vertical-align: bottom;"&gt;Debt securities issued by states of the U.S. and political subdivisions of&#160;the states&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B20"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; vertical-align: bottom;"&gt;1,117&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B20"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D20"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; vertical-align: bottom;"&gt;5&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D20"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F20"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; vertical-align: bottom;"&gt; - &lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F20"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H20"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; vertical-align: bottom;"&gt;1,122&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H20"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align: bottom;"&gt;Other municipal debt securities&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - B21"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"&gt;698&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B21"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - D21"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"&gt; - &lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D21"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - F21"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"&gt; - &lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F21"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - H21"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"&gt;698&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H21"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td style="vertical-align: bottom; padding-left: 20px;"&gt;Total debt securities with a maturity of more than one year&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - B22"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"&gt;698,837&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B22"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - D22"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"&gt;2,333&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D22"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - F22"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"&gt;(230&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F22"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - H22"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"&gt;700,940&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H22"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align: bottom; padding-left: 40px;"&gt;Total available-for-sale debt securities&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - B23"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"&gt;1,980,492&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B23"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - D23"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"&gt;3,609&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D23"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - F23"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"&gt;(376&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F23"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - H23"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"&gt;1,983,725&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H23"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-decoration: underline; vertical-align: bottom;"&gt;Equity securities:&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - B25"&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - B25"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - D25"&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - D25"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - F25"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - F25"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - H25"&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - H25"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align: bottom;"&gt;Publicly traded equity securities included in other current assets (2)&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B26"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; vertical-align: bottom;"&gt;11,897&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - B26"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D26"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; vertical-align: bottom;"&gt;40&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - D26"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F26"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; vertical-align: bottom;"&gt;(8,681&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - F26"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H26"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; vertical-align: bottom;"&gt;3,256&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom;" title="Note 7. Investments - H26"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td style="vertical-align: bottom;"&gt;Privately held equity securities included in deposits and&#160;other assets (3)&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; vertical-align: bottom;" title="Note 7. Investments - B27"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;"&gt;4,905&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B27"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;" title="Note 7. Investments - D27"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;"&gt;54,395&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D27"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;" title="Note 7. Investments - F27"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;"&gt;(7,090&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F27"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;" title="Note 7. Investments - H27"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;"&gt;52,210&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H27"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align: bottom; padding-left: 20px;"&gt;Total equity securities  &lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;" title="Note 7. Investments - B28"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;"&gt;16,802&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B28"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;" title="Note 7. Investments - D28"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;"&gt;54,435&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D28"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;" title="Note 7. Investments - F28"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;"&gt;(15,771&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F28"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; vertical-align: bottom;" title="Note 7. Investments - H28"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-right: none; vertical-align: bottom;"&gt;55,466&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H28"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td style="vertical-align: bottom; padding-left: 40px;"&gt;Total available-for-sale debt and equity securities&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - B29"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"&gt;1,997,294&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B29"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - D29"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"&gt;58,044&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D29"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - F29"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"&gt;(16,147&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F29"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;" title="Note 7. Investments - H29"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; vertical-align: bottom;"&gt;2,039,191&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: bottom; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H29"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"&gt;&lt;tr style="height: 0px; font-size: 0px;"&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; width: 1%;" title="Note 7. Investments - B30"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; width: 9%;"&gt;Amortized&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - B30"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;Gross Unrealized&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; width: 1%;" title="Note 7. Investments - H30"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; width: 9%;"&gt;Estimated&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - H30"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="font-weight: bold;"&gt;December 31, 2024&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - B31"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;Cost&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B31"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - D31"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;Gains&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D31"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - F31"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;Losses&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F31"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - H31"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;Fair Value&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H31"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="text-decoration: underline;"&gt;Available-for-sale debt securities:&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - B32"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - B32"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - D32"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - D32"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - F32"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - F32"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - H32"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - H32"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Corporate debt securities (1)&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - B33"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;593,810&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - B33"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - D33"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;487&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - D33"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - F33"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;(240&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - F33"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - H33"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;594,057&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - H33"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Debt securities issued by U.S. government agencies&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - B34"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;143,647&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - B34"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - D34"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;287&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - D34"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - F34"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;(39&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - F34"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - H34"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;143,895&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - H34"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Debt securities issued by the U.S. Treasury (1)&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - B35"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;657,285&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - B35"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - D35"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;825&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - D35"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - F35"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;(120&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - F35"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - H35"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;657,990&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - H35"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Debt securities issued by states of the U.S. and political subdivisions of&#160;the states&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B36"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;7,516&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B36"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D36"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;8&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D36"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F36"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt; - &lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F36"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H36"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;7,524&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H36"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td style="padding-left: 20px;"&gt;Total debt securities with a maturity of one year&#160;or less&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B37"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;1,402,258&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B37"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D37"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;1,607&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D37"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F37"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;(399&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F37"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H37"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;1,403,466&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H37"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Corporate debt securities&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - B38"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;439,561&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - B38"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - D38"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;723&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - D38"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - F38"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;(2,275&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - F38"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - H38"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;438,009&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - H38"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Debt securities issued by U.S. government agencies&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - B39"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;65,255&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - B39"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - D39"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;137&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - D39"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - F39"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;(289&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - F39"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - H39"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;65,103&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - H39"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Debt securities issued by the U.S. Treasury  &lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - B40"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;149,086&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - B40"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - D40"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;124&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - D40"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - F40"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;(476&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - F40"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - H40"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;148,734&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - H40"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Other municipal debt securities&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B41"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;698&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B41"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D41"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt; - &lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D41"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F41"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;(2&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F41"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H41"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;696&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H41"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="padding-left: 20px;"&gt;Total debt securities with a maturity of more than one year&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none;" title="Note 7. Investments - B42"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;"&gt;654,600&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B42"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - D42"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;"&gt;984&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D42"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - F42"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;"&gt;(3,042&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F42"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - H42"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;"&gt;652,542&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H42"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td style="padding-left: 40px;"&gt;Total available-for-sale debt securities&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - B43"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;"&gt;2,056,858&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B43"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - D43"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;"&gt;2,591&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D43"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - F43"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;"&gt;(3,441&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F43"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - H43"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-right: none;"&gt;2,056,008&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H43"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="text-decoration: underline;"&gt;Equity securities:&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - B44"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - B44"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - D44"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - D44"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - F44"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - F44"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - H44"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - H44"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Publicly traded equity securities included in other current assets (2)&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - B45"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;11,897&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - B45"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - D45"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;26&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - D45"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - F45"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;(6,660&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - F45"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - H45"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;5,263&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - H45"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Privately held equity securities included in deposits and&#160;other assets (3)&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none;" title="Note 7. Investments - B46"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;"&gt;23,115&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B46"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - D46"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;"&gt;25,001&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D46"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - F46"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;"&gt;(7,093&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F46"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - H46"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;"&gt;41,023&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H46"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td style="padding-left: 20px;"&gt;Total equity securities  &lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - B47"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;"&gt;35,012&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B47"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - D47"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;"&gt;25,027&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D47"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - F47"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;"&gt;(13,753&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F47"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 7. Investments - H47"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-right: none;"&gt;46,286&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H47"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="padding-left: 40px;"&gt;Total available-for-sale debt and equity securities&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B48"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;"&gt;2,091,870&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B48"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D48"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;"&gt;27,618&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D48"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F48"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;"&gt;(17,194&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F48"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H48"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;"&gt;2,102,294&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H48"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-align: justify;"&gt;&#160;&lt;/div&gt;&lt;div style="text-indent: -18pt; text-align: justify; padding-left: 18pt;"&gt;

    &lt;div&gt; &lt;span style="color: #000000;"&gt;(1)&#160;&#160;&#160;Includes investments classified as cash equivalents in our condensed consolidated balance sheets.&lt;/span&gt; &lt;/div&gt;
  &lt;/div&gt;
  &lt;div style="margin-left: 18pt;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: -18pt; text-align: justify; padding-left: 18pt;"&gt;

    &lt;div&gt; &lt;span style="color: #000000;"&gt;(2)&#160;&#160;Our publicly traded equity securities are included in other current assets. We recognize publicly traded equity securities at fair value. In the nine months ended September 30, 2025, we recorded a $2.0 million net unrealized loss in our condensed consolidated statements of operations related to changes in the fair value of our investments in publicly traded companies.&lt;/span&gt; &lt;/div&gt;
  &lt;/div&gt;
  &lt;div style="margin-left: 18pt;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: -18pt; text-align: justify; padding-left: 18pt;"&gt;

    &lt;div&gt; &lt;span style="color: #000000;"&gt;(3)&#160; Our privately held equity securities are included in deposits and other assets. We recognize our privately held equity securities at&lt;/span&gt;&lt;span&gt; cost minus impairments, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer, which are Level 3 inputs&lt;/span&gt;&lt;span style="color: #000000;"&gt;. In the nine months ended September 30, 2025, the amortized cost of our privately held equity securities increased $11.2 million. In the third quarter of 2025, we recorded a $29.4 million unrealized gain related to our investment in a privately held company due to an observable price change in an orderly transaction for a similar investment of the investee. This increase was partially offset by a loss of $18.2 million related to an impairment of our investment in another privately held company that we recorded in the second quarter of 2025.&lt;/span&gt;&lt;/div&gt;
  &lt;/div&gt;</us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="c136"
      decimals="-3"
      id="ix_0_fact"
      unitRef="usd">639937000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="c136"
      decimals="-3"
      id="ixv-11713"
      unitRef="usd">815000</ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="c136"
      decimals="-3"
      id="ixv-11714"
      unitRef="usd">69000</ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="c136"
      decimals="-3"
      id="ixv-11715"
      unitRef="usd">640683000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="c137"
      decimals="-3"
      id="ixv-11716"
      unitRef="usd">73905000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="c137"
      decimals="-3"
      id="ixv-11717"
      unitRef="usd">66000</ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="c137"
      decimals="-3"
      id="ixv-11718"
      unitRef="usd">16000</ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="c137"
      decimals="-3"
      id="ixv-11719"
      unitRef="usd">73955000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="c138"
      decimals="-3"
      id="ix_1_fact"
      unitRef="usd">562662000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="c138"
      decimals="-3"
      id="ixv-11721"
      unitRef="usd">384000</ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="c138"
      decimals="-3"
      id="ixv-11722"
      unitRef="usd">61000</ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="c138"
      decimals="-3"
      id="ixv-11723"
      unitRef="usd">562985000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="c139"
      decimals="-3"
      id="ixv-11724"
      unitRef="usd">5151000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="c139"
      decimals="-3"
      id="ixv-11725"
      unitRef="usd">11000</ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="c139"
      decimals="-3"
      id="ixv-11726"
      unitRef="usd">0</ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="c139"
      decimals="-3"
      id="ixv-11727"
      unitRef="usd">5162000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent contextRef="c2" decimals="-3" id="ixv-11728" unitRef="usd">1281655000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent contextRef="c2" decimals="-3" id="ixv-11729" unitRef="usd">1276000</ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent contextRef="c2" decimals="-3" id="ixv-11730" unitRef="usd">146000</ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c2" decimals="-3" id="ixv-11731" unitRef="usd">1282785000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
      contextRef="c136"
      decimals="-3"
      id="ixv-11732"
      unitRef="usd">415818000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent
      contextRef="c136"
      decimals="-3"
      id="ixv-11733"
      unitRef="usd">1688000</ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent>
    <ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent
      contextRef="c136"
      decimals="-3"
      id="ixv-11734"
      unitRef="usd">121000</ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="c136"
      decimals="-3"
      id="ixv-11735"
      unitRef="usd">417385000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
      contextRef="c137"
      decimals="-3"
      id="ixv-11736"
      unitRef="usd">76548000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent
      contextRef="c137"
      decimals="-3"
      id="ixv-11737"
      unitRef="usd">147000</ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent>
    <ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent
      contextRef="c137"
      decimals="-3"
      id="ixv-11738"
      unitRef="usd">60000</ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="c137"
      decimals="-3"
      id="ixv-11739"
      unitRef="usd">76635000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
      contextRef="c138"
      decimals="-3"
      id="ixv-11740"
      unitRef="usd">204656000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent
      contextRef="c138"
      decimals="-3"
      id="ixv-11741"
      unitRef="usd">493000</ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent>
    <ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent
      contextRef="c138"
      decimals="-3"
      id="ixv-11742"
      unitRef="usd">49000</ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="c138"
      decimals="-3"
      id="ixv-11743"
      unitRef="usd">205100000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
      contextRef="c139"
      decimals="-3"
      id="ixv-11744"
      unitRef="usd">1117000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent
      contextRef="c139"
      decimals="-3"
      id="ixv-11745"
      unitRef="usd">5000</ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent>
    <ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent
      contextRef="c139"
      decimals="-3"
      id="ixv-11746"
      unitRef="usd">0</ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="c139"
      decimals="-3"
      id="ixv-11747"
      unitRef="usd">1122000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
      contextRef="c140"
      decimals="-3"
      id="ixv-11748"
      unitRef="usd">698000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent
      contextRef="c140"
      decimals="-3"
      id="ixv-11749"
      unitRef="usd">0</ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent>
    <ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent
      contextRef="c140"
      decimals="-3"
      id="ixv-11750"
      unitRef="usd">0</ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="c140"
      decimals="-3"
      id="ixv-11751"
      unitRef="usd">698000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent contextRef="c2" decimals="-3" id="ixv-11752" unitRef="usd">698837000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent contextRef="c2" decimals="-3" id="ixv-11753" unitRef="usd">2333000</ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent>
    <ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent contextRef="c2" decimals="-3" id="ixv-11754" unitRef="usd">230000</ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent contextRef="c2" decimals="-3" id="ixv-11755" unitRef="usd">700940000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c2" decimals="-3" id="ixv-11756" unitRef="usd">1980492000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c2" decimals="-3" id="ixv-11757" unitRef="usd">3609000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c2" decimals="-3" id="ixv-11758" unitRef="usd">376000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c2" decimals="-3" id="ixv-11759" unitRef="usd">1983725000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="c141"
      decimals="-3"
      id="ix_4_fact"
      unitRef="usd">11897000</us-gaap:EquitySecuritiesFvNiCost>
    <ions:EquitySecuritiesFvNiAccumulatedGrossUnrealizedGain
      contextRef="c141"
      decimals="-3"
      id="ixv-11761"
      unitRef="usd">40000</ions:EquitySecuritiesFvNiAccumulatedGrossUnrealizedGain>
    <ions:EquitySecuritiesFvNiAccumulatedGrossUnrealizedLoss
      contextRef="c141"
      decimals="-3"
      id="ixv-11762"
      unitRef="usd">8681000</ions:EquitySecuritiesFvNiAccumulatedGrossUnrealizedLoss>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="c141"
      decimals="-3"
      id="ixv-11763"
      unitRef="usd">3256000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="c142"
      decimals="-3"
      id="ix_6_fact"
      unitRef="usd">4905000</us-gaap:EquitySecuritiesFvNiCost>
    <ions:EquitySecuritiesFvNiAccumulatedGrossUnrealizedGain
      contextRef="c142"
      decimals="-3"
      id="ixv-11765"
      unitRef="usd">54395000</ions:EquitySecuritiesFvNiAccumulatedGrossUnrealizedGain>
    <ions:EquitySecuritiesFvNiAccumulatedGrossUnrealizedLoss
      contextRef="c142"
      decimals="-3"
      id="ixv-11766"
      unitRef="usd">7090000</ions:EquitySecuritiesFvNiAccumulatedGrossUnrealizedLoss>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="c142"
      decimals="-3"
      id="ixv-11767"
      unitRef="usd">52210000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiCost contextRef="c2" decimals="-3" id="ixv-11768" unitRef="usd">16802000</us-gaap:EquitySecuritiesFvNiCost>
    <ions:EquitySecuritiesFvNiAccumulatedGrossUnrealizedGain contextRef="c2" decimals="-3" id="ixv-11769" unitRef="usd">54435000</ions:EquitySecuritiesFvNiAccumulatedGrossUnrealizedGain>
    <ions:EquitySecuritiesFvNiAccumulatedGrossUnrealizedLoss contextRef="c2" decimals="-3" id="ixv-11770" unitRef="usd">15771000</ions:EquitySecuritiesFvNiAccumulatedGrossUnrealizedLoss>
    <us-gaap:EquitySecuritiesFvNi contextRef="c2" decimals="-3" id="ixv-11771" unitRef="usd">55466000</us-gaap:EquitySecuritiesFvNi>
    <ions:DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost contextRef="c2" decimals="-3" id="ixv-11772" unitRef="usd">1997294000</ions:DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost>
    <ions:DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain contextRef="c2" decimals="-3" id="ixv-11773" unitRef="usd">58044000</ions:DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain>
    <ions:DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss contextRef="c2" decimals="-3" id="ixv-11774" unitRef="usd">16147000</ions:DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss>
    <ions:DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi contextRef="c2" decimals="-3" id="ixv-11775" unitRef="usd">2039191000</ions:DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="c143"
      decimals="-3"
      id="ix_2_fact"
      unitRef="usd">593810000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="c143"
      decimals="-3"
      id="ixv-11777"
      unitRef="usd">487000</ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="c143"
      decimals="-3"
      id="ixv-11778"
      unitRef="usd">240000</ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="c143"
      decimals="-3"
      id="ixv-11779"
      unitRef="usd">594057000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="c144"
      decimals="-3"
      id="ixv-11780"
      unitRef="usd">143647000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="c144"
      decimals="-3"
      id="ixv-11781"
      unitRef="usd">287000</ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="c144"
      decimals="-3"
      id="ixv-11782"
      unitRef="usd">39000</ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="c144"
      decimals="-3"
      id="ixv-11783"
      unitRef="usd">143895000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="c145"
      decimals="-3"
      id="ix_3_fact"
      unitRef="usd">657285000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="c145"
      decimals="-3"
      id="ixv-11785"
      unitRef="usd">825000</ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="c145"
      decimals="-3"
      id="ixv-11786"
      unitRef="usd">120000</ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="c145"
      decimals="-3"
      id="ixv-11787"
      unitRef="usd">657990000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="c146"
      decimals="-3"
      id="ixv-11788"
      unitRef="usd">7516000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="c146"
      decimals="-3"
      id="ixv-11789"
      unitRef="usd">8000</ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="c146"
      decimals="-3"
      id="ixv-11790"
      unitRef="usd">0</ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="c146"
      decimals="-3"
      id="ixv-11791"
      unitRef="usd">7524000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent contextRef="c3" decimals="-3" id="ixv-11792" unitRef="usd">1402258000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent contextRef="c3" decimals="-3" id="ixv-11793" unitRef="usd">1607000</ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent contextRef="c3" decimals="-3" id="ixv-11794" unitRef="usd">399000</ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c3" decimals="-3" id="ixv-11795" unitRef="usd">1403466000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
      contextRef="c143"
      decimals="-3"
      id="ixv-11796"
      unitRef="usd">439561000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent
      contextRef="c143"
      decimals="-3"
      id="ixv-11797"
      unitRef="usd">723000</ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent>
    <ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent
      contextRef="c143"
      decimals="-3"
      id="ixv-11798"
      unitRef="usd">2275000</ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="c143"
      decimals="-3"
      id="ixv-11799"
      unitRef="usd">438009000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
      contextRef="c144"
      decimals="-3"
      id="ixv-11800"
      unitRef="usd">65255000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent
      contextRef="c144"
      decimals="-3"
      id="ixv-11801"
      unitRef="usd">137000</ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent>
    <ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent
      contextRef="c144"
      decimals="-3"
      id="ixv-11802"
      unitRef="usd">289000</ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="c144"
      decimals="-3"
      id="ixv-11803"
      unitRef="usd">65103000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
      contextRef="c145"
      decimals="-3"
      id="ixv-11804"
      unitRef="usd">149086000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent
      contextRef="c145"
      decimals="-3"
      id="ixv-11805"
      unitRef="usd">124000</ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent>
    <ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent
      contextRef="c145"
      decimals="-3"
      id="ixv-11806"
      unitRef="usd">476000</ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="c145"
      decimals="-3"
      id="ixv-11807"
      unitRef="usd">148734000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
      contextRef="c147"
      decimals="-3"
      id="ixv-11808"
      unitRef="usd">698000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent
      contextRef="c147"
      decimals="-3"
      id="ixv-11809"
      unitRef="usd">0</ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent>
    <ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent
      contextRef="c147"
      decimals="-3"
      id="ixv-11810"
      unitRef="usd">2000</ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="c147"
      decimals="-3"
      id="ixv-11811"
      unitRef="usd">696000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent contextRef="c3" decimals="-3" id="ixv-11812" unitRef="usd">654600000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent contextRef="c3" decimals="-3" id="ixv-11813" unitRef="usd">984000</ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent>
    <ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent contextRef="c3" decimals="-3" id="ixv-11814" unitRef="usd">3042000</ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent contextRef="c3" decimals="-3" id="ixv-11815" unitRef="usd">652542000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c3" decimals="-3" id="ixv-11816" unitRef="usd">2056858000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c3" decimals="-3" id="ixv-11817" unitRef="usd">2591000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c3" decimals="-3" id="ixv-11818" unitRef="usd">3441000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c3" decimals="-3" id="ixv-11819" unitRef="usd">2056008000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="c148"
      decimals="-3"
      id="ix_5_fact"
      unitRef="usd">11897000</us-gaap:EquitySecuritiesFvNiCost>
    <ions:EquitySecuritiesFvNiAccumulatedGrossUnrealizedGain
      contextRef="c148"
      decimals="-3"
      id="ixv-11821"
      unitRef="usd">26000</ions:EquitySecuritiesFvNiAccumulatedGrossUnrealizedGain>
    <ions:EquitySecuritiesFvNiAccumulatedGrossUnrealizedLoss
      contextRef="c148"
      decimals="-3"
      id="ixv-11822"
      unitRef="usd">6660000</ions:EquitySecuritiesFvNiAccumulatedGrossUnrealizedLoss>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="c148"
      decimals="-3"
      id="ixv-11823"
      unitRef="usd">5263000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="c149"
      decimals="-3"
      id="ix_7_fact"
      unitRef="usd">23115000</us-gaap:EquitySecuritiesFvNiCost>
    <ions:EquitySecuritiesFvNiAccumulatedGrossUnrealizedGain
      contextRef="c149"
      decimals="-3"
      id="ixv-11825"
      unitRef="usd">25001000</ions:EquitySecuritiesFvNiAccumulatedGrossUnrealizedGain>
    <ions:EquitySecuritiesFvNiAccumulatedGrossUnrealizedLoss
      contextRef="c149"
      decimals="-3"
      id="ixv-11826"
      unitRef="usd">7093000</ions:EquitySecuritiesFvNiAccumulatedGrossUnrealizedLoss>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="c149"
      decimals="-3"
      id="ixv-11827"
      unitRef="usd">41023000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiCost contextRef="c3" decimals="-3" id="ixv-11828" unitRef="usd">35012000</us-gaap:EquitySecuritiesFvNiCost>
    <ions:EquitySecuritiesFvNiAccumulatedGrossUnrealizedGain contextRef="c3" decimals="-3" id="ixv-11829" unitRef="usd">25027000</ions:EquitySecuritiesFvNiAccumulatedGrossUnrealizedGain>
    <ions:EquitySecuritiesFvNiAccumulatedGrossUnrealizedLoss contextRef="c3" decimals="-3" id="ixv-11830" unitRef="usd">13753000</ions:EquitySecuritiesFvNiAccumulatedGrossUnrealizedLoss>
    <us-gaap:EquitySecuritiesFvNi contextRef="c3" decimals="-3" id="ixv-11831" unitRef="usd">46286000</us-gaap:EquitySecuritiesFvNi>
    <ions:DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost contextRef="c3" decimals="-3" id="ixv-11832" unitRef="usd">2091870000</ions:DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost>
    <ions:DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain contextRef="c3" decimals="-3" id="ixv-11833" unitRef="usd">27618000</ions:DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain>
    <ions:DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss contextRef="c3" decimals="-3" id="ixv-11834" unitRef="usd">17194000</ions:DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss>
    <ions:DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi contextRef="c3" decimals="-3" id="ixv-11835" unitRef="usd">2102294000</ions:DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss
      contextRef="c132"
      decimals="-5"
      id="ixv-11838"
      unitRef="usd">2000000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="c133"
      decimals="-5"
      id="ixv-11840"
      unitRef="usd">11200000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGain
      contextRef="c134"
      decimals="-5"
      id="ixv-11841"
      unitRef="usd">29400000</us-gaap:EquitySecuritiesFvNiUnrealizedGain>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss
      contextRef="c135"
      decimals="-5"
      id="ixv-11842"
      unitRef="usd">18200000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock contextRef="c0" id="ixv-5115">&lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span style="color: #000000;"&gt;The following is a summary of our investments we consider to be temporarily impaired at September 30, 2025 (in thousands, except for number of investments): &lt;/span&gt; &lt;/div&gt;

  &lt;div&gt;&#160;&lt;/div&gt;
  &lt;table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"&gt;&lt;tr style="height: 0px; font-size: 0px;"&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - B52"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - B52"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;Less than 12 Months of Temporary Impairment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;More than 12 Months of Temporary Impairment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;Total Temporary Impairment&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 7. Investments - B53"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;Number&#160;of Investments&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B53"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - D53"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;Estimated Fair&#160;Value&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D53"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - F53"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;Unrealized Losses&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F53"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - H53"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;Estimated Fair&#160;Value&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H53"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - J53"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;Unrealized Losses&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - J53"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - L53"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;Estimated Fair&#160;Value&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - L53"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 7. Investments - N53"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;Unrealized Losses&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - N53"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Corporate debt securities  &lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - B54"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;105&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - B54"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - D54"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;179,031&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - D54"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - F54"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;(127&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - F54"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - H54"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;55,955&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - H54"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - J54"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;(63&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - J54"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - L54"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;234,986&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - L54"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - N54"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;(190&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - N54"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Debt securities issued by&#160;U.S. government agencies&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - B55"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;43&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - B55"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - D55"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;71,369&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - D55"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - F55"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;(60&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - F55"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - H55"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;17,286&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - H55"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - J55"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;(16&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - J55"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - L55"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;88,655&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - L55"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - N55"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;(76&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - N55"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Debt securities issued by the U.S. Treasury  &lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - B56"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;25&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - B56"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - D56"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;141,191&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - D56"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - F56"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;(74&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - F56"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - H56"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;46,285&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - H56"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - J56"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;(36&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - J56"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - L56"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;187,476&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - L56"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - N56"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;(110&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 7. Investments - N56"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Other municipal debt securities&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B58"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;1&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B58"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D58"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;698&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D58"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F58"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt; - &lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F58"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H58"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt; - &lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H58"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - J58"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt; - &lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - J58"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - L58"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;698&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - L58"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - N58"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt; - &lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - N58"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Total temporarily impaired&#160;debt securities&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B59"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;"&gt;174&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - B59"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D59"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;"&gt;392,289&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - D59"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F59"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;"&gt;(261&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - F59"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H59"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;"&gt;119,526&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - H59"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - J59"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;"&gt;(115&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - J59"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - L59"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;"&gt;511,815&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - L59"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - N59"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;"&gt;(376&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 7. Investments - N59"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="c136"
      decimals="INF"
      id="ixv-11843"
      unitRef="Investment">105</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="c136"
      decimals="-3"
      id="ixv-11844"
      unitRef="usd">179031000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="c136"
      decimals="-3"
      id="ixv-11845"
      unitRef="usd">127000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="c136"
      decimals="-3"
      id="ixv-11846"
      unitRef="usd">55955000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="c136"
      decimals="-3"
      id="ixv-11847"
      unitRef="usd">63000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="c136"
      decimals="-3"
      id="ixv-11848"
      unitRef="usd">234986000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="c136"
      decimals="-3"
      id="ixv-11849"
      unitRef="usd">190000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="c137"
      decimals="INF"
      id="ixv-11850"
      unitRef="Investment">43</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="c137"
      decimals="-3"
      id="ixv-11851"
      unitRef="usd">71369000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="c137"
      decimals="-3"
      id="ixv-11852"
      unitRef="usd">60000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="c137"
      decimals="-3"
      id="ixv-11853"
      unitRef="usd">17286000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="c137"
      decimals="-3"
      id="ixv-11854"
      unitRef="usd">16000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="c137"
      decimals="-3"
      id="ixv-11855"
      unitRef="usd">88655000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="c137"
      decimals="-3"
      id="ixv-11856"
      unitRef="usd">76000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="c138"
      decimals="INF"
      id="ixv-11857"
      unitRef="Investment">25</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="c138"
      decimals="-3"
      id="ixv-11858"
      unitRef="usd">141191000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="c138"
      decimals="-3"
      id="ixv-11859"
      unitRef="usd">74000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="c138"
      decimals="-3"
      id="ixv-11860"
      unitRef="usd">46285000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="c138"
      decimals="-3"
      id="ixv-11861"
      unitRef="usd">36000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="c138"
      decimals="-3"
      id="ixv-11862"
      unitRef="usd">187476000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="c138"
      decimals="-3"
      id="ixv-11863"
      unitRef="usd">110000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="c140"
      decimals="INF"
      id="ixv-11864"
      unitRef="Investment">1</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="c140"
      decimals="-3"
      id="ixv-11865"
      unitRef="usd">698000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="c140"
      decimals="-3"
      id="ixv-11866"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="c140"
      decimals="-3"
      id="ixv-11867"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="c140"
      decimals="-3"
      id="ixv-11868"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="c140"
      decimals="-3"
      id="ixv-11869"
      unitRef="usd">698000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="c140"
      decimals="-3"
      id="ixv-11870"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="c2"
      decimals="INF"
      id="ixv-11871"
      unitRef="Investment">174</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c2" decimals="-3" id="ixv-11872" unitRef="usd">392289000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c2" decimals="-3" id="ixv-11873" unitRef="usd">261000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c2" decimals="-3" id="ixv-11874" unitRef="usd">119526000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c2" decimals="-3" id="ixv-11875" unitRef="usd">115000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c2" decimals="-3" id="ixv-11876" unitRef="usd">511815000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c2" decimals="-3" id="ixv-11877" unitRef="usd">376000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c0" id="ixv-5346">&lt;div&gt;
   &lt;span style="color: #000000; font-weight: bold;"&gt;8.&#160;&#160;Fair Value Measurements&lt;/span&gt;
  &lt;/div&gt;
  &lt;div&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span style="color: #000000;"&gt;The following tables present the major security types we held at September 30, 2025 and December 31, 2024 that we regularly measure and carry at fair value. The following tables segregate each security type by the level within the fair value hierarchy of the valuation techniques we utilized to determine the respective security&#x2019;s fair value (in thousands):&lt;/span&gt; &lt;/div&gt;


  &lt;div&gt;&#160;&lt;/div&gt;
  &lt;table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"&gt;&lt;tr style="height: 0px; font-size: 0px;"&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 8. Fair Value Measurements - B3"&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; width: 9%;"&gt;At&lt;/td&gt;&lt;td style="width: 1%;" title="Note 8. Fair Value Measurements - B3"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 8. Fair Value Measurements - D3"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom; width: 9%;"&gt;Quoted&#160;Prices&#160;in Active&#160;Markets&lt;/td&gt;&lt;td style="width: 1%;" title="Note 8. Fair Value Measurements - D3"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 8. Fair Value Measurements - F3"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; width: 9%;"&gt;Significant&#160;Other Observable Inputs&lt;/td&gt;&lt;td style="width: 1%;" title="Note 8. Fair Value Measurements - F3"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 8. Fair Value Measurements - B4"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; width: 9%;"&gt;September 30, 2025&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - B4"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 8. Fair Value Measurements - D4"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; width: 9%;"&gt;(Level 1)&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - D4"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 8. Fair Value Measurements - F4"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; width: 9%;"&gt;(Level 2)&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - F4"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Cash equivalents (1)  &lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B5"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;167,298&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B5"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D5"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;167,298&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D5"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F5"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt; - &lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F5"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Corporate debt securities (2)  &lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B6"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;1,058,068&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B6"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D6"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt; - &lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D6"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F6"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;1,058,068&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F6"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Debt securities issued by U.S. government agencies (3)  &lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B7"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;150,590&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B7"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D7"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt; - &lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D7"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F7"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;150,590&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F7"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Debt securities issued by the U.S. Treasury (4)&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B8"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;768,085&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B8"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D8"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;768,085&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D8"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F8"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt; - &lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Debt securities issued by states of the U.S. and political subdivisions of the states (5)&lt;/td&gt;&lt;td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - B9"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; vertical-align: bottom; width: 9%;"&gt;6,284&lt;/td&gt;&lt;td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - B9"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - D9"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; vertical-align: bottom; width: 9%;"&gt; - &lt;/td&gt;&lt;td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - D9"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - F9"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; vertical-align: bottom; width: 9%;"&gt;6,284&lt;/td&gt;&lt;td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - F9"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Other municipal debt securities (5)&lt;/td&gt;&lt;td style="text-align: left; border-width: initial; border-style: none; border-color: initial; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - B10"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-width: initial; border-style: none; border-color: initial; vertical-align: bottom; width: 9%;"&gt;698&lt;/td&gt;&lt;td style="text-align: left; vertical-align: bottom; border-width: initial; border-style: none; border-color: initial; width: 1%;" title="Note 8. Fair Value Measurements - B10"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-width: initial; border-style: none; border-color: initial; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - D10"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-width: initial; border-style: none; border-color: initial; vertical-align: bottom; width: 9%;"&gt; - &lt;/td&gt;&lt;td style="text-align: left; vertical-align: bottom; border-width: initial; border-style: none; border-color: initial; width: 1%;" title="Note 8. Fair Value Measurements - D10"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-width: initial; border-style: none; border-color: initial; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - F10"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-width: initial; border-style: none; border-color: initial; vertical-align: bottom; width: 9%;"&gt;698&lt;/td&gt;&lt;td style="text-align: left; vertical-align: bottom; border-width: initial; border-style: none; border-color: initial; width: 1%;" title="Note 8. Fair Value Measurements - F10"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Publicly traded equity securities included in other current assets (6)&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1px solid black; border-top: none; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - B10"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1px solid black; border-top: none; vertical-align: bottom; width: 9%;"&gt;3,256&lt;/td&gt;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - B10"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1px solid black; border-top: none; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - D10"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1px solid black; border-top: none; vertical-align: bottom; width: 9%;"&gt;3,256&lt;/td&gt;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - D10"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1px solid black; border-top: none; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - F10"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-right: none; vertical-align: bottom; width: 9%;"&gt; - &lt;/td&gt;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - F10"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="padding-left: 20px;"&gt;Total  &lt;/td&gt;&lt;td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 8. Fair Value Measurements - B11"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;2,154,279&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - B11"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 8. Fair Value Measurements - D11"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;938,639&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - D11"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 8. Fair Value Measurements - F11"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;1,215,640&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - F11"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&#160;&lt;/div&gt;
  &lt;table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"&gt;&lt;tr style="height: 0px; font-size: 0px;"&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 8. Fair Value Measurements - B13"&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; width: 9%;"&gt;At&lt;/td&gt;&lt;td style="width: 1%;" title="Note 8. Fair Value Measurements - B13"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 8. Fair Value Measurements - D13"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom; width: 9%;"&gt;Quoted&#160;Prices&#160;in Active&#160;Markets&lt;/td&gt;&lt;td style="width: 1%;" title="Note 8. Fair Value Measurements - D13"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 8. Fair Value Measurements - F13"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; width: 9%;"&gt;Significant&#160;Other Observable Inputs&lt;/td&gt;&lt;td style="width: 1%;" title="Note 8. Fair Value Measurements - F13"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 8. Fair Value Measurements - B14"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; width: 9%;"&gt;December 31, 2024&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - B14"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 8. Fair Value Measurements - D14"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; width: 9%;"&gt;(Level 1)&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - D14"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 8. Fair Value Measurements - F14"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; width: 9%;"&gt;(Level 2)&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - F14"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Cash equivalents (1) &lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B15"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;180,445&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B15"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D15"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;180,445&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D15"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F15"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F15"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Corporate debt securities (5)&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B16"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;1,032,066&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B16"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D16"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D16"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F16"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;1,032,066&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F16"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Debt securities issued by U.S. government agencies (5)&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B17"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;208,998&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B17"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D17"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D17"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F17"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;208,998&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F17"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Debt securities issued by the U.S. Treasury (5)&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B18"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;806,724&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B18"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D18"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;806,724&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D18"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F18"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F18"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Debt securities issued by states of the U.S. and political subdivisions of the states (5)&lt;/td&gt;&lt;td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - B19"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; vertical-align: bottom; width: 9%;"&gt;7,524&lt;/td&gt;&lt;td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - B19"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - D19"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; vertical-align: bottom; width: 9%;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - D19"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - F19"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; vertical-align: bottom; width: 9%;"&gt;7,524&lt;/td&gt;&lt;td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - F19"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Other municipal debt securities (5)&lt;/td&gt;&lt;td style="text-align: left; vertical-align: bottom; border-width: initial; border-style: none; border-color: initial; width: 1%;" title="Note 8. Fair Value Measurements - B20"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; vertical-align: bottom; border-width: initial; border-style: none; border-color: initial; width: 9%;"&gt;696&lt;/td&gt;&lt;td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - B20"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; vertical-align: bottom; border-width: initial; border-style: none; border-color: initial; width: 1%;" title="Note 8. Fair Value Measurements - D20"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; vertical-align: bottom; border-width: initial; border-style: none; border-color: initial; width: 9%;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - D20"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; vertical-align: bottom; border-width: initial; border-style: none; border-color: initial; width: 1%;" title="Note 8. Fair Value Measurements - F20"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; vertical-align: bottom; border-width: initial; border-style: none; border-color: initial; width: 9%;"&gt;696&lt;/td&gt;&lt;td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - F20"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Publicly traded equity securities included in other current assets (6)&lt;/td&gt;&lt;td style="text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 8. Fair Value Measurements - B20"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; width: 9%;"&gt;5,263&lt;/td&gt;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - B20"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 8. Fair Value Measurements - D20"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; width: 9%;"&gt;5,263&lt;/td&gt;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - D20"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 8. Fair Value Measurements - F20"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-right: none; width: 9%;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - F20"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="padding-left: 20px;"&gt;Total &lt;/td&gt;&lt;td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 8. Fair Value Measurements - B21"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;2,241,716&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - B21"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 8. Fair Value Measurements - D21"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;992,432&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - D21"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 8. Fair Value Measurements - F21"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;1,249,284&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - F21"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-align: justify; margin-left: 18pt;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt; &lt;span style="color: #000000;"&gt;The following footnotes reference lines in our condensed consolidated balance sheets:&lt;/span&gt;&lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;&#160;&lt;/div&gt;&lt;div style="text-align: justify;"&gt;(1)&#160; &#160; Included in cash and cash equivalents.&lt;/div&gt;&lt;div style="text-align: justify;"&gt;&#160;&lt;/div&gt;&lt;div style="text-align: justify;"&gt;(2)&#160;&#160;&#160;&#160;$39.9 million was included in cash and cash equivalents, with the difference included in short-term investments.&lt;/div&gt;&lt;div style="text-align: justify;"&gt;&#160;&lt;/div&gt;&lt;div style="text-align: justify;"&gt;(3)&#160; &#160; $6.0 million was included in cash and cash equivalents, with the difference i&lt;span style="letter-spacing: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;ncluded in short-term investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: justify;"&gt;&#160;&lt;/div&gt;&lt;div style="text-align: justify;"&gt;(4)&#160; &#160; &lt;span style="letter-spacing: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;$36.0 million was included in cash and cash equivalents, with the difference included in short-term investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: justify;"&gt;&#160;&lt;/div&gt;&lt;div style="text-align: justify;"&gt;(5)&#160; &#160; Included in short-term investments.&lt;/div&gt;&lt;div style="text-align: justify;"&gt;&#160;&lt;/div&gt;&lt;div style="text-align: justify;"&gt;(6)&#160; &#160; Included in other current assets.&lt;/div&gt;
  &lt;div style="text-indent: -18pt; text-align: justify; padding-left: 18pt;"&gt;


  &#160;&lt;/div&gt;








  &lt;div style="text-indent: 36pt;"&gt;&lt;span style="color: #000000; font-style: italic;"&gt;Convertible Notes&lt;/span&gt;
  &lt;/div&gt;&lt;div&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span style="color: #000000;"&gt;Our 1.75% Notes and 0% Notes had a fair value of $794.5 million and $777.0 million at September 30, 2025, respectively. Our 1.75% Notes and 0% Notes had a fair value of $569.3 million and $612.8 million at December 31, 2024, respectively. We determine the fair value of our notes based on quoted market prices for these notes, which are Level 2 measurements because the notes do not trade regularly.&lt;/span&gt; &lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="c0" id="ixv-5350">&lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span style="color: #000000;"&gt;The following tables present the major security types we held at September 30, 2025 and December 31, 2024 that we regularly measure and carry at fair value. The following tables segregate each security type by the level within the fair value hierarchy of the valuation techniques we utilized to determine the respective security&#x2019;s fair value (in thousands):&lt;/span&gt; &lt;/div&gt;


  &lt;div&gt;&#160;&lt;/div&gt;
  &lt;table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"&gt;&lt;tr style="height: 0px; font-size: 0px;"&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 8. Fair Value Measurements - B3"&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; width: 9%;"&gt;At&lt;/td&gt;&lt;td style="width: 1%;" title="Note 8. Fair Value Measurements - B3"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 8. Fair Value Measurements - D3"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom; width: 9%;"&gt;Quoted&#160;Prices&#160;in Active&#160;Markets&lt;/td&gt;&lt;td style="width: 1%;" title="Note 8. Fair Value Measurements - D3"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 8. Fair Value Measurements - F3"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; width: 9%;"&gt;Significant&#160;Other Observable Inputs&lt;/td&gt;&lt;td style="width: 1%;" title="Note 8. Fair Value Measurements - F3"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 8. Fair Value Measurements - B4"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; width: 9%;"&gt;September 30, 2025&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - B4"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 8. Fair Value Measurements - D4"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; width: 9%;"&gt;(Level 1)&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - D4"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 8. Fair Value Measurements - F4"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; width: 9%;"&gt;(Level 2)&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - F4"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Cash equivalents (1)  &lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B5"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;167,298&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B5"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D5"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;167,298&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D5"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F5"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt; - &lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F5"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Corporate debt securities (2)  &lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B6"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;1,058,068&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B6"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D6"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt; - &lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D6"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F6"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;1,058,068&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F6"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Debt securities issued by U.S. government agencies (3)  &lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B7"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;150,590&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B7"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D7"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt; - &lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D7"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F7"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;150,590&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F7"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Debt securities issued by the U.S. Treasury (4)&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B8"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;768,085&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B8"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D8"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;768,085&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D8"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F8"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt; - &lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Debt securities issued by states of the U.S. and political subdivisions of the states (5)&lt;/td&gt;&lt;td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - B9"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; vertical-align: bottom; width: 9%;"&gt;6,284&lt;/td&gt;&lt;td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - B9"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - D9"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; vertical-align: bottom; width: 9%;"&gt; - &lt;/td&gt;&lt;td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - D9"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - F9"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; vertical-align: bottom; width: 9%;"&gt;6,284&lt;/td&gt;&lt;td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - F9"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Other municipal debt securities (5)&lt;/td&gt;&lt;td style="text-align: left; border-width: initial; border-style: none; border-color: initial; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - B10"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-width: initial; border-style: none; border-color: initial; vertical-align: bottom; width: 9%;"&gt;698&lt;/td&gt;&lt;td style="text-align: left; vertical-align: bottom; border-width: initial; border-style: none; border-color: initial; width: 1%;" title="Note 8. Fair Value Measurements - B10"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-width: initial; border-style: none; border-color: initial; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - D10"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-width: initial; border-style: none; border-color: initial; vertical-align: bottom; width: 9%;"&gt; - &lt;/td&gt;&lt;td style="text-align: left; vertical-align: bottom; border-width: initial; border-style: none; border-color: initial; width: 1%;" title="Note 8. Fair Value Measurements - D10"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-width: initial; border-style: none; border-color: initial; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - F10"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-width: initial; border-style: none; border-color: initial; vertical-align: bottom; width: 9%;"&gt;698&lt;/td&gt;&lt;td style="text-align: left; vertical-align: bottom; border-width: initial; border-style: none; border-color: initial; width: 1%;" title="Note 8. Fair Value Measurements - F10"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Publicly traded equity securities included in other current assets (6)&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1px solid black; border-top: none; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - B10"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1px solid black; border-top: none; vertical-align: bottom; width: 9%;"&gt;3,256&lt;/td&gt;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - B10"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1px solid black; border-top: none; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - D10"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1px solid black; border-top: none; vertical-align: bottom; width: 9%;"&gt;3,256&lt;/td&gt;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - D10"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1px solid black; border-top: none; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - F10"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1px solid black; border-top: none; border-right: none; vertical-align: bottom; width: 9%;"&gt; - &lt;/td&gt;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - F10"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="padding-left: 20px;"&gt;Total  &lt;/td&gt;&lt;td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 8. Fair Value Measurements - B11"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;2,154,279&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - B11"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 8. Fair Value Measurements - D11"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;938,639&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - D11"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 8. Fair Value Measurements - F11"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;1,215,640&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - F11"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&#160;&lt;/div&gt;
  &lt;table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"&gt;&lt;tr style="height: 0px; font-size: 0px;"&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 8. Fair Value Measurements - B13"&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; width: 9%;"&gt;At&lt;/td&gt;&lt;td style="width: 1%;" title="Note 8. Fair Value Measurements - B13"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 8. Fair Value Measurements - D13"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom; width: 9%;"&gt;Quoted&#160;Prices&#160;in Active&#160;Markets&lt;/td&gt;&lt;td style="width: 1%;" title="Note 8. Fair Value Measurements - D13"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 8. Fair Value Measurements - F13"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; width: 9%;"&gt;Significant&#160;Other Observable Inputs&lt;/td&gt;&lt;td style="width: 1%;" title="Note 8. Fair Value Measurements - F13"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 8. Fair Value Measurements - B14"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; width: 9%;"&gt;December 31, 2024&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - B14"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 8. Fair Value Measurements - D14"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; width: 9%;"&gt;(Level 1)&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - D14"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 8. Fair Value Measurements - F14"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; width: 9%;"&gt;(Level 2)&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - F14"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Cash equivalents (1) &lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B15"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;180,445&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B15"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D15"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;180,445&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D15"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F15"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F15"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Corporate debt securities (5)&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B16"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;1,032,066&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B16"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D16"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D16"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F16"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;1,032,066&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F16"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Debt securities issued by U.S. government agencies (5)&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B17"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;208,998&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B17"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D17"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D17"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F17"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;208,998&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F17"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Debt securities issued by the U.S. Treasury (5)&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B18"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;806,724&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - B18"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D18"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;806,724&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - D18"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F18"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 8. Fair Value Measurements - F18"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Debt securities issued by states of the U.S. and political subdivisions of the states (5)&lt;/td&gt;&lt;td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - B19"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; vertical-align: bottom; width: 9%;"&gt;7,524&lt;/td&gt;&lt;td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - B19"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - D19"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; vertical-align: bottom; width: 9%;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - D19"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - F19"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; vertical-align: bottom; width: 9%;"&gt;7,524&lt;/td&gt;&lt;td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - F19"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Other municipal debt securities (5)&lt;/td&gt;&lt;td style="text-align: left; vertical-align: bottom; border-width: initial; border-style: none; border-color: initial; width: 1%;" title="Note 8. Fair Value Measurements - B20"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; vertical-align: bottom; border-width: initial; border-style: none; border-color: initial; width: 9%;"&gt;696&lt;/td&gt;&lt;td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - B20"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; vertical-align: bottom; border-width: initial; border-style: none; border-color: initial; width: 1%;" title="Note 8. Fair Value Measurements - D20"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; vertical-align: bottom; border-width: initial; border-style: none; border-color: initial; width: 9%;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - D20"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; vertical-align: bottom; border-width: initial; border-style: none; border-color: initial; width: 1%;" title="Note 8. Fair Value Measurements - F20"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; vertical-align: bottom; border-width: initial; border-style: none; border-color: initial; width: 9%;"&gt;696&lt;/td&gt;&lt;td style="text-align: left; vertical-align: bottom; width: 1%;" title="Note 8. Fair Value Measurements - F20"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Publicly traded equity securities included in other current assets (6)&lt;/td&gt;&lt;td style="text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 8. Fair Value Measurements - B20"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; width: 9%;"&gt;5,263&lt;/td&gt;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - B20"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 8. Fair Value Measurements - D20"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; width: 9%;"&gt;5,263&lt;/td&gt;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - D20"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; width: 1%;" title="Note 8. Fair Value Measurements - F20"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-right: none; width: 9%;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - F20"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="padding-left: 20px;"&gt;Total &lt;/td&gt;&lt;td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 8. Fair Value Measurements - B21"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;2,241,716&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - B21"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 8. Fair Value Measurements - D21"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;992,432&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - D21"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 8. Fair Value Measurements - F21"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;1,249,284&lt;/td&gt;&lt;td style="text-align: left; width: 1%; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 8. Fair Value Measurements - F21"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-align: justify; margin-left: 18pt;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt; &lt;span style="color: #000000;"&gt;The following footnotes reference lines in our condensed consolidated balance sheets:&lt;/span&gt;&lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;&#160;&lt;/div&gt;&lt;div style="text-align: justify;"&gt;(1)&#160; &#160; Included in cash and cash equivalents.&lt;/div&gt;&lt;div style="text-align: justify;"&gt;&#160;&lt;/div&gt;&lt;div style="text-align: justify;"&gt;(2)&#160;&#160;&#160;&#160;$39.9 million was included in cash and cash equivalents, with the difference included in short-term investments.&lt;/div&gt;&lt;div style="text-align: justify;"&gt;&#160;&lt;/div&gt;&lt;div style="text-align: justify;"&gt;(3)&#160; &#160; $6.0 million was included in cash and cash equivalents, with the difference i&lt;span style="letter-spacing: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;ncluded in short-term investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: justify;"&gt;&#160;&lt;/div&gt;&lt;div style="text-align: justify;"&gt;(4)&#160; &#160; &lt;span style="letter-spacing: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;$36.0 million was included in cash and cash equivalents, with the difference included in short-term investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: justify;"&gt;&#160;&lt;/div&gt;&lt;div style="text-align: justify;"&gt;(5)&#160; &#160; Included in short-term investments.&lt;/div&gt;&lt;div style="text-align: justify;"&gt;&#160;&lt;/div&gt;&lt;div style="text-align: justify;"&gt;(6)&#160; &#160; Included in other current assets.&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="c157"
      decimals="-3"
      id="ix_8_fact"
      unitRef="usd">167298000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="c158"
      decimals="-3"
      id="ix_9_fact"
      unitRef="usd">167298000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="c159"
      decimals="-3"
      id="ix_10_fact"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c160"
      decimals="-3"
      id="ix_14_fact"
      unitRef="usd">1058068000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c161"
      decimals="-3"
      id="ix_15_fact"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c162"
      decimals="-3"
      id="ix_16_fact"
      unitRef="usd">1058068000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c163"
      decimals="-3"
      id="ix_17_fact"
      unitRef="usd">150590000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c164"
      decimals="-3"
      id="ix_18_fact"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c165"
      decimals="-3"
      id="ix_19_fact"
      unitRef="usd">150590000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c166"
      decimals="-3"
      id="ix_41_fact"
      unitRef="usd">768085000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c167"
      decimals="-3"
      id="ix_42_fact"
      unitRef="usd">768085000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c168"
      decimals="-3"
      id="ix_43_fact"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c169"
      decimals="-3"
      id="ix_20_fact"
      unitRef="usd">6284000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c170"
      decimals="-3"
      id="ix_21_fact"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c171"
      decimals="-3"
      id="ix_22_fact"
      unitRef="usd">6284000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c172"
      decimals="-3"
      id="ix_23_fact"
      unitRef="usd">698000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c173"
      decimals="-3"
      id="ix_24_fact"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c174"
      decimals="-3"
      id="ix_25_fact"
      unitRef="usd">698000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="c175"
      decimals="-3"
      id="ix_44_fact"
      unitRef="usd">3256000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="c176"
      decimals="-3"
      id="ix_45_fact"
      unitRef="usd">3256000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="c177"
      decimals="-3"
      id="ix_46_fact"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c157"
      decimals="-3"
      id="ixv-11899"
      unitRef="usd">2154279000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c158"
      decimals="-3"
      id="ixv-11900"
      unitRef="usd">938639000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c159"
      decimals="-3"
      id="ixv-11901"
      unitRef="usd">1215640000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="c178"
      decimals="-3"
      id="ix_11_fact"
      unitRef="usd">180445000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="c179"
      decimals="-3"
      id="ix_12_fact"
      unitRef="usd">180445000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="c180"
      decimals="-3"
      id="ix_13_fact"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c181"
      decimals="-3"
      id="ix_26_fact"
      unitRef="usd">1032066000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c182"
      decimals="-3"
      id="ix_27_fact"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c183"
      decimals="-3"
      id="ix_28_fact"
      unitRef="usd">1032066000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c184"
      decimals="-3"
      id="ix_29_fact"
      unitRef="usd">208998000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c185"
      decimals="-3"
      id="ix_30_fact"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c186"
      decimals="-3"
      id="ix_31_fact"
      unitRef="usd">208998000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c187"
      decimals="-3"
      id="ix_32_fact"
      unitRef="usd">806724000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c188"
      decimals="-3"
      id="ix_33_fact"
      unitRef="usd">806724000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c189"
      decimals="-3"
      id="ix_34_fact"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c190"
      decimals="-3"
      id="ix_35_fact"
      unitRef="usd">7524000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c191"
      decimals="-3"
      id="ix_36_fact"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c192"
      decimals="-3"
      id="ix_37_fact"
      unitRef="usd">7524000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c193"
      decimals="-3"
      id="ix_38_fact"
      unitRef="usd">696000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c194"
      decimals="-3"
      id="ix_39_fact"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c195"
      decimals="-3"
      id="ix_40_fact"
      unitRef="usd">696000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="c196"
      decimals="-3"
      id="ix_47_fact"
      unitRef="usd">5263000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="c197"
      decimals="-3"
      id="ix_48_fact"
      unitRef="usd">5263000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="c198"
      decimals="-3"
      id="ix_49_fact"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c178"
      decimals="-3"
      id="ixv-11923"
      unitRef="usd">2241716000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c179"
      decimals="-3"
      id="ixv-11924"
      unitRef="usd">992432000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c180"
      decimals="-3"
      id="ixv-11925"
      unitRef="usd">1249284000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c150"
      decimals="-5"
      id="ixv-11928"
      unitRef="usd">39900000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c151"
      decimals="-5"
      id="ixv-11929"
      unitRef="usd">6000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c152"
      decimals="-5"
      id="ixv-11930"
      unitRef="usd">36000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c6"
      decimals="INF"
      id="ixv-11933"
      unitRef="pure">0.0175</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c4"
      decimals="INF"
      id="ixv-11934"
      unitRef="pure">0</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="c153"
      decimals="-5"
      id="ixv-11935"
      unitRef="usd">794500000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="c154"
      decimals="-5"
      id="ixv-11936"
      unitRef="usd">777000000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c7"
      decimals="INF"
      id="ixv-11937"
      unitRef="pure">0.0175</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c5"
      decimals="INF"
      id="ixv-11938"
      unitRef="pure">0</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="c155"
      decimals="-5"
      id="ixv-11939"
      unitRef="usd">569300000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="c156"
      decimals="-5"
      id="ixv-11940"
      unitRef="usd">612800000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c0" id="ixv-5676">&lt;div&gt;
   &lt;span style="color: #000000; font-weight: bold;"&gt;9. Stock-based Compensation Expense&lt;/span&gt;
  &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span style="color: #000000;"&gt;The following table summarizes stock-based compensation expense for the three and nine months ended September 30, 2025 and 2024 (in thousands):&lt;/span&gt; &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/div&gt;
  &lt;table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"&gt;&lt;tr style="height: 0px; font-size: 0px;"&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td colspan="7" style="text-align: center; font-weight: bold;"&gt;Three Months Ended&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td colspan="7" style="text-align: center; font-weight: bold;"&gt;Nine Months Ended&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;September 30,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;September 30,&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 9. Stock-based Compensation Expense - B5"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;2025&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none;" title="Note 9. Stock-based Compensation Expense - B5"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 9. Stock-based Compensation Expense - D5"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;2024&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none;" title="Note 9. Stock-based Compensation Expense - D5"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 9. Stock-based Compensation Expense - F5"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;2025&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none;" title="Note 9. Stock-based Compensation Expense - F5"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 9. Stock-based Compensation Expense - H5"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;2024&lt;/td&gt;&lt;td style="width: 1%;" title="Note 9. Stock-based Compensation Expense - H5"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Cost of sales&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B6"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;145&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B6"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D6"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;159&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D6"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - F6"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;855&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - F6"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - H6"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;609&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-width: initial; border-style: none; border-color: initial;" title="Note 9. Stock-based Compensation Expense - H6"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Research, development and patent expense&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B7"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;20,757&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B7"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D7"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;22,120&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D7"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - F7"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;60,597&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - F7"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - H7"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;67,111&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - H7"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Selling, general and administrative expense&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - B8"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;10,244&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 9. Stock-based Compensation Expense - B8"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - D8"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;9,705&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 9. Stock-based Compensation Expense - D8"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - F8"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;29,102&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 9. Stock-based Compensation Expense - F8"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - H8"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;26,332&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 9. Stock-based Compensation Expense - H8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="padding-left: 20px;"&gt;Stock-based compensation expense, net of amounts capitalized&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - B9"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;31,146&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 9. Stock-based Compensation Expense - B9"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - D9"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;31,984&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 9. Stock-based Compensation Expense - D9"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - F9"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;90,554&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 9. Stock-based Compensation Expense - F9"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - H9"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;94,052&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 9. Stock-based Compensation Expense - H9"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Capitalized stock-based compensation expense&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - B10"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;435&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - B10"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - D10"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;506&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 9. Stock-based Compensation Expense - D10"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - F10"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;1,435&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 9. Stock-based Compensation Expense - F10"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - H10"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;506&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 9. Stock-based Compensation Expense - H10"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="padding-left: 20px;"&gt;Total stock-based compensation expense&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - B11"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;"&gt;31,581&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - B11"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - D11"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;"&gt;32,490&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - D11"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - F11"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;"&gt;91,989&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - F11"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - H11"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;"&gt;94,558&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - H11"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/div&gt;

  &lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span style="color: #000000;"&gt;As of September 30, 2025, total unrecognized estimated stock-based compensation expense related to non-vested stock options, RSUs and PRSUs was $37.2 million, $88.1 million and $13.0 million, respectively. Our actual expenses will likely differ from these estimates because we will adjust our unrecognized stock-based compensation expense for future forfeitures, including any PRSUs that do not vest. We expect to recognize the cost of stock-based compensation expense related to our non-vested stock options, RSUs and PRSUs over a weighted average amortization period of 1.2 years, 1.5 years and 1.4 years, respectively.&lt;/span&gt; &lt;/div&gt;
  &lt;div&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span style="color: #000000;"&gt;Refer to Part IV, Item 15, Note 1, &lt;/span&gt;&lt;span style="color: #000000; font-style: italic;"&gt;Organization and Significant Accounting Policies&lt;/span&gt;&lt;span style="color: #000000;"&gt;, of our audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2024 for further details on how we determine the fair value of stock options granted, RSUs, PRSUs and stock purchase rights under the ESPP.&lt;/span&gt;
  &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span style="color: #000000;"&gt;For the nine months ended  September 30, 2025 and 2024, we used the following weighted-average assumptions in our Black-Scholes calculations:&lt;/span&gt;
  &lt;/div&gt;
  &lt;div&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"&gt; &lt;span style="color: #000000; font-style: italic;"&gt;Employee Stock Options:&lt;/span&gt;&lt;/div&gt;


  &lt;div style="text-indent: 36pt;"&gt;&#160;&lt;/div&gt;&lt;table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"&gt;&lt;tr style="height: 0px; font-size: 0px;"&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td colspan="7" style="text-align: center; font-weight: bold;"&gt;Nine Months Ended&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;September 30,&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 9. Stock-based Compensation Expense - B17"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;2025&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - B17"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 9. Stock-based Compensation Expense - D17"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;2024&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - D17"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Risk-free interest rate &lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B18"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;4.4&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B18"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D18"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;4.1&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D18"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dividend yield &lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B19"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;0.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B19"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D19"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;0.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D19"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Volatility &lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B20"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;42.1&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B20"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D20"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;43.8&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D20"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Expected life&lt;/td&gt;&lt;td style="width: 1%;" title="Note 9. Stock-based Compensation Expense - B21"&gt;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;6.3 years&lt;/td&gt;&lt;td style="width: 1%;" title="Note 9. Stock-based Compensation Expense - B21"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 9. Stock-based Compensation Expense - D21"&gt;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;6.3 years&lt;/td&gt;&lt;td style="width: 1%;" title="Note 9. Stock-based Compensation Expense - D21"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&#160;&lt;/div&gt;&lt;div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"&gt;&lt;i&gt;Board of Director Stock Options:&lt;/i&gt;&lt;/div&gt;&lt;div&gt;&#160;&lt;/div&gt;&lt;table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"&gt;&lt;tr style="height: 0px; font-size: 0px;"&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td colspan="7" style="text-align: center; font-weight: bold;"&gt;Nine Months Ended&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;September 30,&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 9. Stock-based Compensation Expense - B35"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;2025&lt;/td&gt;&lt;td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 9. Stock-based Compensation Expense - B35"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 9. Stock-based Compensation Expense - D35"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;2024&lt;/td&gt;&lt;td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 9. Stock-based Compensation Expense - D35"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Risk-free interest rate &lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B36"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;4.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B36"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D36"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;4.5&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D36"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dividend yield &lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B37"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;0.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B37"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D37"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;0.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D37"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Volatility &lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B38"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;43.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B38"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D38"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;49.8&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D38"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Expected life&lt;/td&gt;&lt;td style="width: 1%;" title="Note 9. Stock-based Compensation Expense - B39"&gt;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;7.4 years&lt;/td&gt;&lt;td style="width: 1%;" title="Note 9. Stock-based Compensation Expense - B39"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 9. Stock-based Compensation Expense - D39"&gt;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;7.5 years&lt;/td&gt;&lt;td style="width: 1%;" title="Note 9. Stock-based Compensation Expense - D39"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&#160;&lt;/div&gt;&lt;div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"&gt; &lt;span style="color: #000000; font-style: italic;"&gt;ESPP:&lt;/span&gt;&lt;/div&gt;



  &lt;div style="text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/div&gt;&lt;table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"&gt;&lt;tr style="height: 0px; font-size: 0px;"&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td colspan="7" style="text-align: center; font-weight: bold;"&gt;Nine Months Ended&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;September 30,&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 9. Stock-based Compensation Expense - B26"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;2025&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - B26"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 9. Stock-based Compensation Expense - D26"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;2024&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - D26"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Risk-free interest rate &lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B27"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;4.2&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B27"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D27"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;5.2&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D27"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dividend yield &lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B28"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;0.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B28"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D28"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;0.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D28"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Volatility &lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B29"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;48.2&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B29"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D29"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;37.8&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D29"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Expected life&lt;/td&gt;&lt;td style="width: 1%;" title="Note 9. Stock-based Compensation Expense - B30"&gt;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;6 months&lt;/td&gt;&lt;td style="width: 1%;" title="Note 9. Stock-based Compensation Expense - B30"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 9. Stock-based Compensation Expense - D30"&gt;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;6 months&lt;/td&gt;&lt;td style="width: 1%;" title="Note 9. Stock-based Compensation Expense - D30"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"&gt;&lt;i&gt;Stock Options:&lt;/i&gt;&lt;/div&gt;
  &lt;div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"&gt;&#160;&lt;/div&gt;&lt;div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"&gt;&lt;span style="letter-spacing: normal; text-align: justify; text-indent: 48px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;The weighted-average grant date fair value of stock options granted to employees for the&#160;&lt;/span&gt;&lt;span style="cursor: pointer; letter-spacing: normal; text-align: justify; text-indent: 48px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"&gt;nine months ended&#160;September 30, 2025&lt;/span&gt;&lt;span style="letter-spacing: normal; text-align: justify; text-indent: 48px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;&#160;and&#160;&lt;/span&gt;&lt;span style="cursor: pointer; letter-spacing: normal; text-align: justify; text-indent: 48px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"&gt;2024&lt;/span&gt;&lt;span style="letter-spacing: normal; text-align: justify; text-indent: 48px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;&#160;was $17.21 and $24.73 per share, respectively.&#160;&lt;span style="text-decoration-thickness: initial; float: none; display: inline !important;"&gt;The weighted-average grant date fair value of stock options granted to non-employee directors for the&#160;&lt;/span&gt;&lt;span style="cursor: pointer; text-decoration-thickness: initial;"&gt;nine months ended&#160;September 30, 2025&lt;/span&gt;&lt;span style="text-decoration-thickness: initial; float: none; display: inline !important;"&gt;&#160;and&#160;&lt;/span&gt;&lt;span style="cursor: pointer; text-decoration-thickness: initial;"&gt;2024&lt;/span&gt;&lt;span style="text-decoration-thickness: initial; float: none; display: inline !important;"&gt;&#160;was $20.86 and $27.47 per share, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"&gt;&#160;&lt;/div&gt;&lt;div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"&gt;&lt;span style="color: #000000; font-style: italic;"&gt;RSUs:&lt;/span&gt;
  &lt;/div&gt;&lt;div style="text-align: justify;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span style="color: #000000;"&gt;The weighted-average grant date fair value of RSUs granted to employees for the nine months ended September 30, 2025 and 2024 was $33.78 and $52.08 per share, respectively. &lt;/span&gt; &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt;"&gt;
   &lt;span style="color: #000000; font-style: italic;"&gt;PRSUs:&lt;/span&gt;
  &lt;/div&gt;
  &lt;div&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span&gt;Under the terms of the PRSUs we granted in 2025 and 2024, the PRSUs may vest at the end of the three-year performance period based on our relative total shareholder return, or TSR, as compared to a peer group of companies and as measured at the end of the performance period. Under the terms of the grants, no number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of each performance period may be anywhere from zero to 200 percent of the target number depending on our relative TSR.&lt;/span&gt; &lt;/div&gt;
  &lt;div&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span&gt;The weighted-average grant date fair value of PRSUs we granted to our executive officers for the nine months ended September 30, 2025 and 2024 was $48.81 and $78.41 per share, respectively.&lt;/span&gt; &lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c0" id="ixv-5680">&lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span style="color: #000000;"&gt;The following table summarizes stock-based compensation expense for the three and nine months ended September 30, 2025 and 2024 (in thousands):&lt;/span&gt; &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/div&gt;
  &lt;table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"&gt;&lt;tr style="height: 0px; font-size: 0px;"&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td colspan="7" style="text-align: center; font-weight: bold;"&gt;Three Months Ended&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td colspan="7" style="text-align: center; font-weight: bold;"&gt;Nine Months Ended&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;September 30,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;September 30,&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 9. Stock-based Compensation Expense - B5"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;2025&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none;" title="Note 9. Stock-based Compensation Expense - B5"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 9. Stock-based Compensation Expense - D5"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;2024&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none;" title="Note 9. Stock-based Compensation Expense - D5"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 9. Stock-based Compensation Expense - F5"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;2025&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none;" title="Note 9. Stock-based Compensation Expense - F5"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 9. Stock-based Compensation Expense - H5"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;2024&lt;/td&gt;&lt;td style="width: 1%;" title="Note 9. Stock-based Compensation Expense - H5"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Cost of sales&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B6"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;145&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B6"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D6"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;159&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D6"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - F6"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;855&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - F6"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - H6"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;609&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-width: initial; border-style: none; border-color: initial;" title="Note 9. Stock-based Compensation Expense - H6"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Research, development and patent expense&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B7"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;20,757&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B7"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D7"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;22,120&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D7"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - F7"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;60,597&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - F7"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - H7"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;67,111&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - H7"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Selling, general and administrative expense&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - B8"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;10,244&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 9. Stock-based Compensation Expense - B8"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - D8"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;9,705&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 9. Stock-based Compensation Expense - D8"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - F8"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;29,102&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 9. Stock-based Compensation Expense - F8"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - H8"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;26,332&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 9. Stock-based Compensation Expense - H8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="padding-left: 20px;"&gt;Stock-based compensation expense, net of amounts capitalized&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - B9"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;31,146&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 9. Stock-based Compensation Expense - B9"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - D9"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;31,984&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 9. Stock-based Compensation Expense - D9"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - F9"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;90,554&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 9. Stock-based Compensation Expense - F9"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - H9"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;94,052&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 9. Stock-based Compensation Expense - H9"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Capitalized stock-based compensation expense&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - B10"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;435&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - B10"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - D10"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;506&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 9. Stock-based Compensation Expense - D10"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - F10"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;1,435&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 9. Stock-based Compensation Expense - F10"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - H10"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;506&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 9. Stock-based Compensation Expense - H10"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="padding-left: 20px;"&gt;Total stock-based compensation expense&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - B11"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;"&gt;31,581&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - B11"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - D11"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;"&gt;32,490&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - D11"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - F11"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;"&gt;91,989&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - F11"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - H11"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;"&gt;94,558&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - H11"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c221"
      decimals="-3"
      id="ixv-11941"
      unitRef="usd">145000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c222"
      decimals="-3"
      id="ixv-11942"
      unitRef="usd">159000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c223"
      decimals="-3"
      id="ixv-11943"
      unitRef="usd">855000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c224"
      decimals="-3"
      id="ixv-11944"
      unitRef="usd">609000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c225"
      decimals="-3"
      id="ixv-11945"
      unitRef="usd">20757000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c226"
      decimals="-3"
      id="ixv-11946"
      unitRef="usd">22120000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c227"
      decimals="-3"
      id="ixv-11947"
      unitRef="usd">60597000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c228"
      decimals="-3"
      id="ixv-11948"
      unitRef="usd">67111000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c229"
      decimals="-3"
      id="ixv-11949"
      unitRef="usd">10244000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c230"
      decimals="-3"
      id="ixv-11950"
      unitRef="usd">9705000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c231"
      decimals="-3"
      id="ixv-11951"
      unitRef="usd">29102000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c232"
      decimals="-3"
      id="ixv-11952"
      unitRef="usd">26332000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c36" decimals="-3" id="ixv-11953" unitRef="usd">31146000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c37" decimals="-3" id="ixv-11954" unitRef="usd">31984000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c0" decimals="-3" id="ixv-11955" unitRef="usd">90554000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c38" decimals="-3" id="ixv-11956" unitRef="usd">94052000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="c36" decimals="-3" id="ixv-11957" unitRef="usd">435000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="c37" decimals="-3" id="ixv-11958" unitRef="usd">506000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="c0" decimals="-3" id="ixv-11959" unitRef="usd">1435000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="c38" decimals="-3" id="ixv-11960" unitRef="usd">506000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1 contextRef="c36" decimals="-3" id="ixv-11961" unitRef="usd">31581000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1 contextRef="c37" decimals="-3" id="ixv-11962" unitRef="usd">32490000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1 contextRef="c0" decimals="-3" id="ixv-11963" unitRef="usd">91989000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1 contextRef="c38" decimals="-3" id="ixv-11964" unitRef="usd">94558000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="c199"
      decimals="-5"
      id="ixv-11965"
      unitRef="usd">37200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="c200"
      decimals="-5"
      id="ixv-11966"
      unitRef="usd">88100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="c201"
      decimals="-5"
      id="ixv-11967"
      unitRef="usd">13000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c202" id="ixv-11968">P1Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c203" id="ixv-11969">P1Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c204" id="ixv-11970">P1Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c0" id="ixv-5843">&lt;div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"&gt; &lt;span style="color: #000000; font-style: italic;"&gt;Employee Stock Options:&lt;/span&gt;&lt;/div&gt;


  &lt;div style="text-indent: 36pt;"&gt;&#160;&lt;/div&gt;&lt;table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"&gt;&lt;tr style="height: 0px; font-size: 0px;"&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td colspan="7" style="text-align: center; font-weight: bold;"&gt;Nine Months Ended&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;September 30,&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 9. Stock-based Compensation Expense - B17"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;2025&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - B17"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 9. Stock-based Compensation Expense - D17"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;2024&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - D17"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Risk-free interest rate &lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B18"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;4.4&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B18"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D18"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;4.1&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D18"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dividend yield &lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B19"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;0.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B19"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D19"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;0.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D19"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Volatility &lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B20"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;42.1&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B20"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D20"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;43.8&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D20"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Expected life&lt;/td&gt;&lt;td style="width: 1%;" title="Note 9. Stock-based Compensation Expense - B21"&gt;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;6.3 years&lt;/td&gt;&lt;td style="width: 1%;" title="Note 9. Stock-based Compensation Expense - B21"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 9. Stock-based Compensation Expense - D21"&gt;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;6.3 years&lt;/td&gt;&lt;td style="width: 1%;" title="Note 9. Stock-based Compensation Expense - D21"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&#160;&lt;/div&gt;&lt;div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"&gt;&lt;i&gt;Board of Director Stock Options:&lt;/i&gt;&lt;/div&gt;&lt;div&gt;&#160;&lt;/div&gt;&lt;table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"&gt;&lt;tr style="height: 0px; font-size: 0px;"&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td colspan="7" style="text-align: center; font-weight: bold;"&gt;Nine Months Ended&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;September 30,&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 9. Stock-based Compensation Expense - B35"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;2025&lt;/td&gt;&lt;td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 9. Stock-based Compensation Expense - B35"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 9. Stock-based Compensation Expense - D35"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;2024&lt;/td&gt;&lt;td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 9. Stock-based Compensation Expense - D35"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Risk-free interest rate &lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B36"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;4.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B36"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D36"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;4.5&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D36"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dividend yield &lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B37"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;0.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B37"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D37"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;0.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D37"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Volatility &lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B38"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;43.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B38"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D38"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;49.8&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D38"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Expected life&lt;/td&gt;&lt;td style="width: 1%;" title="Note 9. Stock-based Compensation Expense - B39"&gt;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;7.4 years&lt;/td&gt;&lt;td style="width: 1%;" title="Note 9. Stock-based Compensation Expense - B39"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 9. Stock-based Compensation Expense - D39"&gt;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;7.5 years&lt;/td&gt;&lt;td style="width: 1%;" title="Note 9. Stock-based Compensation Expense - D39"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c205"
      decimals="3"
      id="ixv-11971"
      unitRef="pure">0.044</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c206"
      decimals="3"
      id="ixv-11972"
      unitRef="pure">0.041</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c205"
      decimals="3"
      id="ixv-11973"
      unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c206"
      decimals="3"
      id="ixv-11974"
      unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="c205"
      decimals="3"
      id="ixv-11975"
      unitRef="pure">0.421</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="c206"
      decimals="3"
      id="ixv-11976"
      unitRef="pure">0.438</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c205" id="ixv-11977">P6Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c206" id="ixv-11978">P6Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c233"
      decimals="3"
      id="ixv-11979"
      unitRef="pure">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c234"
      decimals="3"
      id="ixv-11980"
      unitRef="pure">0.045</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c233"
      decimals="3"
      id="ixv-11981"
      unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c234"
      decimals="3"
      id="ixv-11982"
      unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="c233"
      decimals="3"
      id="ixv-11983"
      unitRef="pure">0.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="c234"
      decimals="3"
      id="ixv-11984"
      unitRef="pure">0.498</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c233" id="ixv-11985">P7Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c234" id="ixv-11986">P7Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock contextRef="c0" id="ixv-5974">&lt;div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"&gt; &lt;span style="color: #000000; font-style: italic;"&gt;ESPP:&lt;/span&gt;&lt;/div&gt;



  &lt;div style="text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/div&gt;&lt;table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"&gt;&lt;tr style="height: 0px; font-size: 0px;"&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td colspan="7" style="text-align: center; font-weight: bold;"&gt;Nine Months Ended&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;September 30,&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 9. Stock-based Compensation Expense - B26"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;2025&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - B26"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 9. Stock-based Compensation Expense - D26"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;2024&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 9. Stock-based Compensation Expense - D26"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Risk-free interest rate &lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B27"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;4.2&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B27"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D27"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;5.2&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D27"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dividend yield &lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B28"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;0.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B28"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D28"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;0.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D28"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Volatility &lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B29"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;48.2&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - B29"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D29"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;37.8&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 9. Stock-based Compensation Expense - D29"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Expected life&lt;/td&gt;&lt;td style="width: 1%;" title="Note 9. Stock-based Compensation Expense - B30"&gt;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;6 months&lt;/td&gt;&lt;td style="width: 1%;" title="Note 9. Stock-based Compensation Expense - B30"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 9. Stock-based Compensation Expense - D30"&gt;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;6 months&lt;/td&gt;&lt;td style="width: 1%;" title="Note 9. Stock-based Compensation Expense - D30"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c235"
      decimals="3"
      id="ixv-11987"
      unitRef="pure">0.042</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c236"
      decimals="3"
      id="ixv-11988"
      unitRef="pure">0.052</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c235"
      decimals="3"
      id="ixv-11989"
      unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c236"
      decimals="3"
      id="ixv-11990"
      unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="c235"
      decimals="3"
      id="ixv-11991"
      unitRef="pure">0.482</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="c236"
      decimals="3"
      id="ixv-11992"
      unitRef="pure">0.378</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c235" id="ixv-11993">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c236" id="ixv-11994">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c205"
      decimals="2"
      id="ixv-11995"
      unitRef="usdPershares">17.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c206"
      decimals="2"
      id="ixv-11996"
      unitRef="usdPershares">24.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c207"
      decimals="2"
      id="ixv-11997"
      unitRef="usdPershares">20.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c208"
      decimals="2"
      id="ixv-11998"
      unitRef="usdPershares">27.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c209"
      decimals="2"
      id="ixv-11999"
      unitRef="usdPershares">33.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c210"
      decimals="2"
      id="ixv-12000"
      unitRef="usdPershares">52.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c212" id="ixv-12001">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c211" id="ixv-12002">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <ions:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfUnitsGuaranteedToVest
      contextRef="c213"
      decimals="INF"
      id="ixv-12003"
      unitRef="shares">0</ions:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfUnitsGuaranteedToVest>
    <ions:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfUnitsGuaranteedToVest
      contextRef="c214"
      decimals="INF"
      id="ixv-12004"
      unitRef="shares">0</ions:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfUnitsGuaranteedToVest>
    <ions:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfUnitsGuaranteedToVest
      contextRef="c215"
      decimals="INF"
      id="ixv-12005"
      unitRef="pure">0</ions:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfUnitsGuaranteedToVest>
    <ions:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfUnitsGuaranteedToVest
      contextRef="c216"
      decimals="INF"
      id="ixv-12006"
      unitRef="pure">0</ions:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfUnitsGuaranteedToVest>
    <ions:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfUnitsGuaranteedToVest
      contextRef="c217"
      decimals="INF"
      id="ixv-12007"
      unitRef="pure">2</ions:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfUnitsGuaranteedToVest>
    <ions:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfUnitsGuaranteedToVest
      contextRef="c218"
      decimals="INF"
      id="ixv-12008"
      unitRef="pure">2</ions:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfUnitsGuaranteedToVest>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c219"
      decimals="2"
      id="ixv-12009"
      unitRef="usdPershares">48.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c220"
      decimals="2"
      id="ixv-12010"
      unitRef="usdPershares">78.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c0" id="ixv-6079">&lt;div style="text-indent: -36pt; padding-left: 36pt;"&gt;
   &lt;span style="color: #000000; font-weight: bold;"&gt;10.&#160;&#160;Income Taxes&lt;/span&gt;
  &lt;/div&gt;
  &lt;div&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span style="color: #000000;"&gt;We recorded nominal income tax expense for the three and nine months ended September 30, 2025 compared to income tax benefit of $3.6 million and $3.5 million for the same periods in 2024.&lt;/span&gt;&lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;&#160;&lt;/div&gt;
  &lt;div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"&gt;The benefit for the three and nine months ended September 30, 2024 was primarily related to the 2023 tax return position for the royalty purchase agreement with Royalty Pharma that we finalized during the third quarter of 2024.&lt;/div&gt;&lt;div style="text-align: justify;"&gt;&#160;&lt;/div&gt;&lt;div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"&gt;In July 2025, the One Big Beautiful Bill Act, or OBBBA, was signed into law, introducing significant changes to U.S. federal tax law. The new law restores current expensing of domestic R&amp;amp;D costs and allows us to accelerate the deduction for a significant amount of such costs we capitalized since 2022.
 The tax law changes from the OBBBA did not have a material effect on our tax expense for the three and nine months ended September 30, 2025.&lt;/div&gt;&lt;div style="text-align: justify;"&gt;&#160;&lt;/div&gt;&lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span style="color: #000000;"&gt;We continue to maintain a full valuation allowance on all of our net deferred tax assets.&lt;/span&gt;
  &lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c37" decimals="-5" id="ixv-12011" unitRef="usd">-3600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c38" decimals="-5" id="ixv-12012" unitRef="usd">-3500000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:OtherLiabilitiesDisclosureTextBlock contextRef="c0" id="ixv-6095">&lt;div&gt;
   &lt;span style="font-weight: bold;"&gt;11. Liability Related to Sale of Future Royalties&lt;/span&gt;
  &lt;/div&gt;
  &lt;div&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span style="color: #000000;"&gt;In 2023, we entered into a royalty purchase agreement with Royalty Pharma Investments, or Royalty Pharma, to monetize a portion of our future SPINRAZA and pelacarsen royalties we are entitled to under our arrangements with Biogen and Novartis, respectively. As a result, we received an upfront payment of $500 million and we are eligible to receive up to $625 million in additional milestone payments. Under the terms of the agreement, Royalty Pharma will receive 25 percent of our SPINRAZA royalty payments from 2023 through 2027, increasing to 45 percent of royalty payments in 2028, on up to $1.5 billion in annual sales. In addition, Royalty Pharma will receive 25 percent of any future royalty payments on pelacarsen, our medicine in development to treat patients with elevated lipoprotein(a)-driven cardiovascular disease. Royalty Pharma&#x2019;s royalty interest in SPINRAZA will revert to us after total SPINRAZA royalty payments to Royalty Pharma reach either $475 million or $550 million, depending on the timing and occurrence of FDA approval of pelacarsen.&lt;/span&gt; &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span style="color: #000000;"&gt;We recorded the upfront payment of $500 million as a liability related to the sale of future royalties, net of transaction costs of $10.4 million, which we are amortizing over the estimated life of the arrangement using the effective interest rate method. We recognize royalty revenue in the period in which the counterparty sells the related product and recognizes the related revenue. We record royalty payments made to Royalty Pharma as a reduction of the liability.&lt;/span&gt; &lt;/div&gt;
  &lt;div&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span style="color: #000000;"&gt;We determine the effective interest rate used to record interest expense under this agreement based on an estimate of future royalty payments to Royalty Pharma. As of September 30, 2025 and 2024, the estimated effective interest rate under the agreement was 12.4 percent and 13.5 percent, respectively.&lt;/span&gt; &lt;/div&gt;&lt;div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"&gt; &lt;span style="color: #000000;"&gt;The following table sets forth information on our liability related to sale of future royalties (in thousands):&lt;/span&gt; &lt;/div&gt;

  &lt;div style="text-align: justify;"&gt;&#160;&lt;/div&gt;&lt;table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Liability related to sale of future royalties, net as of December 31, 2024&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 11. Liability Related to Sale of Future Royalties - B4"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;542,212&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 11. Liability Related to Sale of Future Royalties - B4"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Royalty payments to Royalty Pharma&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 11. Liability Related to Sale of Future Royalties - B5"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;(38,478&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 11. Liability Related to Sale of Future Royalties - B5"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Interest expense related to sale of future royalties&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 11. Liability Related to Sale of Future Royalties - B6"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;54,964&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 11. Liability Related to Sale of Future Royalties - B6"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Amortization of issuance costs related to sale of future royalties&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none;" title="Note 11. Liability Related to Sale of Future Royalties - B7"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;"&gt;458&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 11. Liability Related to Sale of Future Royalties - B7"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Liability related to sale of future royalties, net as of September 30, 2025&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 11. Liability Related to Sale of Future Royalties - B8"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;559,156&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 11. Liability Related to Sale of Future Royalties - B8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Less: Current portion (1)&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 11. Liability Related to Sale of Future Royalties - B9"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-right: none;"&gt;(13,974&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 11. Liability Related to Sale of Future Royalties - B9"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Liability related to sale of future royalties, net as of September 30, 2025 &#x2013; Non-current&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 11. Liability Related to Sale of Future Royalties - B10"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;"&gt;545,182&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 11. Liability Related to Sale of Future Royalties - B10"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
  &lt;div&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: -18pt; text-align: justify; padding-left: 18pt;"&gt;

    &lt;div&gt;
     &lt;span style="color: #000000;"&gt;(1)&#160; &#160;Included in other current liabilities in our condensed consolidated balance sheet.&lt;/span&gt;
    &lt;/div&gt;
  &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span style="color: #000000;"&gt;There are numerous factors, most of which are not within our control, that could materially impact the amount and timing of royalty payments from Biogen and Novartis, and result in changes to our estimate of future royalty payments to Royalty Pharma. Such factors include, but are not limited to, the commercial sales of SPINRAZA, the regulatory approval and commercial sales of pelacarsen, competing products or other significant events. &lt;/span&gt;
  &lt;/div&gt;</us-gaap:OtherLiabilitiesDisclosureTextBlock>
    <ions:UpfrontRoyaltyPaymentReceived
      contextRef="c237"
      decimals="-6"
      id="ixv-12013"
      unitRef="usd">500000000</ions:UpfrontRoyaltyPaymentReceived>
    <ions:MaximumAmountOfPaymentsReceivableForAdditionalMilestones
      contextRef="c238"
      decimals="-6"
      id="ixv-12014"
      unitRef="usd">625000000</ions:MaximumAmountOfPaymentsReceivableForAdditionalMilestones>
    <ions:PercentageOfRoyaltyPaymentsPaidOnAnnualSalesOfMedicine
      contextRef="c239"
      decimals="INF"
      id="ixv-12015"
      unitRef="pure">0.25</ions:PercentageOfRoyaltyPaymentsPaidOnAnnualSalesOfMedicine>
    <ions:PercentageOfRoyaltyPaymentsPaidOnAnnualSalesOfMedicine
      contextRef="c240"
      decimals="INF"
      id="ixv-12016"
      unitRef="pure">0.45</ions:PercentageOfRoyaltyPaymentsPaidOnAnnualSalesOfMedicine>
    <ions:MaximumAmountOfAnnualSalesOnWhichRoyaltyPaymentsArePaid
      contextRef="c241"
      decimals="-8"
      id="ixv-12017"
      unitRef="usd">1500000000</ions:MaximumAmountOfAnnualSalesOnWhichRoyaltyPaymentsArePaid>
    <ions:PercentageOfRoyaltyPaymentsPaidOnAnnualSalesOfMedicine
      contextRef="c242"
      decimals="INF"
      id="ixv-12018"
      unitRef="pure">0.25</ions:PercentageOfRoyaltyPaymentsPaidOnAnnualSalesOfMedicine>
    <ions:MaximumRoyaltyPaymentsMadeBeforeRoyaltyInterestRevertsBack
      contextRef="c239"
      decimals="-6"
      id="ixv-12019"
      unitRef="usd">475000000</ions:MaximumRoyaltyPaymentsMadeBeforeRoyaltyInterestRevertsBack>
    <ions:MaximumRoyaltyPaymentsMadeBeforeRoyaltyInterestRevertsBack
      contextRef="c240"
      decimals="-6"
      id="ixv-12020"
      unitRef="usd">550000000</ions:MaximumRoyaltyPaymentsMadeBeforeRoyaltyInterestRevertsBack>
    <ions:UpfrontRoyaltyPaymentReceived
      contextRef="c237"
      decimals="-6"
      id="ixv-12021"
      unitRef="usd">500000000</ions:UpfrontRoyaltyPaymentReceived>
    <ions:PaymentsForTransactionCostsRelatedToSaleOfFutureRoyalties
      contextRef="c237"
      decimals="-5"
      id="ixv-12022"
      unitRef="usd">10400000</ions:PaymentsForTransactionCostsRelatedToSaleOfFutureRoyalties>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c238"
      decimals="3"
      id="ixv-12023"
      unitRef="pure">0.124</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c243"
      decimals="3"
      id="ixv-12024"
      unitRef="pure">0.135</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:OtherNoncurrentLiabilitiesTableTextBlock contextRef="c0" id="ixv-6117">&lt;div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"&gt; &lt;span style="color: #000000;"&gt;The following table sets forth information on our liability related to sale of future royalties (in thousands):&lt;/span&gt; &lt;/div&gt;

  &lt;div style="text-align: justify;"&gt;&#160;&lt;/div&gt;&lt;table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Liability related to sale of future royalties, net as of December 31, 2024&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 11. Liability Related to Sale of Future Royalties - B4"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;542,212&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 11. Liability Related to Sale of Future Royalties - B4"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Royalty payments to Royalty Pharma&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 11. Liability Related to Sale of Future Royalties - B5"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;(38,478&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 11. Liability Related to Sale of Future Royalties - B5"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Interest expense related to sale of future royalties&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 11. Liability Related to Sale of Future Royalties - B6"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;54,964&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 11. Liability Related to Sale of Future Royalties - B6"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Amortization of issuance costs related to sale of future royalties&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none;" title="Note 11. Liability Related to Sale of Future Royalties - B7"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none;"&gt;458&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 11. Liability Related to Sale of Future Royalties - B7"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Liability related to sale of future royalties, net as of September 30, 2025&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 11. Liability Related to Sale of Future Royalties - B8"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;559,156&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 11. Liability Related to Sale of Future Royalties - B8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Less: Current portion (1)&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none;" title="Note 11. Liability Related to Sale of Future Royalties - B9"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-right: none;"&gt;(13,974&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 11. Liability Related to Sale of Future Royalties - B9"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Liability related to sale of future royalties, net as of September 30, 2025 &#x2013; Non-current&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 11. Liability Related to Sale of Future Royalties - B10"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;"&gt;545,182&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 11. Liability Related to Sale of Future Royalties - B10"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:OtherNoncurrentLiabilitiesTableTextBlock>
    <ions:LiabilityRelatedToSaleOfFutureRoyaltiesNet
      contextRef="c244"
      decimals="-3"
      id="ixv-12025"
      unitRef="usd">542212000</ions:LiabilityRelatedToSaleOfFutureRoyaltiesNet>
    <ions:RoyaltyPayments
      contextRef="c245"
      decimals="-3"
      id="ixv-12026"
      unitRef="usd">38478000</ions:RoyaltyPayments>
    <ions:InterestExpenseRelatedToSaleOfFutureRoyalties
      contextRef="c245"
      decimals="-3"
      id="ixv-12027"
      unitRef="usd">54964000</ions:InterestExpenseRelatedToSaleOfFutureRoyalties>
    <ions:AmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties
      contextRef="c245"
      decimals="-3"
      id="ixv-12028"
      unitRef="usd">458000</ions:AmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties>
    <ions:LiabilityRelatedToSaleOfFutureRoyaltiesNet
      contextRef="c238"
      decimals="-3"
      id="ixv-12029"
      unitRef="usd">559156000</ions:LiabilityRelatedToSaleOfFutureRoyaltiesNet>
    <ions:LiabilityRelatedToSaleOfFutureRoyaltiesNetCurrent
      contextRef="c246"
      decimals="-3"
      id="ixv-12030"
      unitRef="usd">13974000</ions:LiabilityRelatedToSaleOfFutureRoyaltiesNetCurrent>
    <ions:LiabilityRelatedToSaleOfFutureRoyaltiesNetNoncurrent
      contextRef="c238"
      decimals="-3"
      id="ixv-12031"
      unitRef="usd">545182000</ions:LiabilityRelatedToSaleOfFutureRoyaltiesNetNoncurrent>
    <us-gaap:DebtDisclosureTextBlock contextRef="c0" id="ixv-6167">&lt;div&gt;
   &lt;span style="font-weight: bold;"&gt;12. Convertible Debt&lt;/span&gt;
  &lt;/div&gt;
  &lt;div style="font-size: 9pt;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span style="color: #000000; font-style: italic;"&gt;1.75 Percent Convertible Senior Notes&lt;/span&gt; &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span style="font-family: Times;"&gt;In 2023, we completed a $575.0 million offering of our 1.75% Notes. &lt;/span&gt; &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span&gt;At September 30, 2025, we had the following 1.75% Notes outstanding (in millions except interest rate and price per share data):&lt;/span&gt; &lt;/div&gt;
  &lt;div style="text-align: justify; color: #000000;"&gt;&#160;
  &lt;/div&gt;

  &lt;div&gt;&#160;&lt;/div&gt;
  &lt;table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"&gt;&lt;tr style="height: 0px; font-size: 0px;"&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 12. Convertible Debt - B4"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;1.75% Notes&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 12. Convertible Debt - B4"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Outstanding principal balance&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B5"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;575.0&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B5"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Unamortized debt issuance costs&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B6"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;7.9&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B6"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Maturity date&lt;/td&gt;&lt;td style="width: 1%;" title="Note 12. Convertible Debt - B7"&gt;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-2"&gt;June 2028&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 12. Convertible Debt - B7"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Interest rate&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B8"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;1.75&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B8"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Effective interest rate&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B9"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;2.30&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B9"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Conversion price per share&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B10"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;53.73&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B10"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Total shares of common stock subject to conversion&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B11"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;10.7&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B11"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&#160;&lt;/div&gt;&lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span style="color: #000000; font-style: italic;"&gt;0 Percent Convertible Senior Notes and Call Spread&lt;/span&gt;&lt;span style="color: #000000; font-weight: bold; font-style: italic;"&gt;&#160;&lt;/span&gt; &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span&gt;In 2021, we completed a $632.5 million offering of our 0% Notes. &lt;/span&gt;&lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span&gt;At September 30, 2025, we had the following &lt;/span&gt;&lt;span style="font-family: Times;"&gt;0%&lt;/span&gt;&lt;span&gt; Notes outstanding (in millions except interest rate and price per share data):&lt;/span&gt; &lt;/div&gt;
  &lt;div style="text-align: justify; color: #000000;"&gt;&#160;&lt;/div&gt;
  &lt;div style="text-align: justify; color: #000000;"&gt;&#160;&lt;/div&gt;
  &lt;table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"&gt;&lt;tr style="height: 0px; font-size: 0px;"&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 12. Convertible Debt - B15"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;0% Notes&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 12. Convertible Debt - B15"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Outstanding principal balance&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B16"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;632.5&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B16"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Unamortized debt issuance costs&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B17"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;1.6&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B17"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Maturity date&lt;/td&gt;&lt;td style="width: 1%;" title="Note 12. Convertible Debt - B18"&gt;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-3"&gt;April 2026&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 12. Convertible Debt - B18"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Interest rate&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B19"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;0&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B19"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Effective interest rate&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B20"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;0.50&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B20"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Conversion price per share&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B21"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;57.84&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B21"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Effective conversion price per share with call spread&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B22"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;76.39&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B22"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Total shares of common stock subject to conversion&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B23"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;10.9&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B23"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"&gt; In conjunction with the 2021 offering, we entered into a call spread transaction, which was comprised of purchasing note hedges and selling warrants, to minimize the impact of potential economic dilution upon conversion of our &lt;span style="font-family: Times;"&gt;0%&lt;/span&gt; Notes by increasing the effective conversion price on our &lt;span style="font-family: Times;"&gt;0%&lt;/span&gt;&#160;Notes. We increased our effective conversion price to $76.39 with the same number of underlying shares as our &lt;span style="font-family: Times;"&gt;0% &lt;/span&gt;Notes. The call spread cost us $46.9 million, of which $136.7 million was for the note hedge purchase, offset by $89.8 million we received for selling the warrants. Similar to our &lt;span style="font-family: Times;"&gt;0%&lt;/span&gt; Notes, our note hedges are subject to adjustment. Additionally, our note hedges are exercisable upon conversion of the &lt;span style="font-family: Times;"&gt;0%&lt;/span&gt;&#160;Notes. The note hedges will expire upon maturity of the &lt;span style="font-family: Times;"&gt;0%&lt;/span&gt; Notes, or April 2026. The warrants will expire in July 2026. The note hedges and warrants are separate transactions and are not part of the terms of our &lt;span style="font-family: Times;"&gt;0%&lt;/span&gt; Notes. The holders of the &lt;span style="font-family: Times;"&gt;0%&lt;/span&gt; Notes do not have any rights with respect to the note hedges and warrants. &lt;/div&gt;
  &lt;div style="text-align: justify; color: #000000;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span&gt;We recorded the amount we paid for the note hedges and the amount we received for the warrants in additional paid-in capital in our condensed consolidated balance sheets. Refer to Part IV, Item 15, Note 1, &lt;/span&gt;&lt;span style="font-style: italic;"&gt;Organization and Significant Accounting Policies&lt;/span&gt;&lt;span&gt;, of our audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2024 for our Call Spread accounting policy. We reassess our ability to continue to classify the note hedges and warrants in shareholders&#x2019; equity at each reporting period.&lt;/span&gt;
  &lt;/div&gt;
  &lt;div&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span style="font-style: italic;"&gt;Other Terms of Convertible Senior Notes&lt;/span&gt;
  &lt;/div&gt;
  &lt;div&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span style="color: #000000;"&gt;The 1.75% and 0% Notes are convertible under certain conditions, at the option of the note holders. We can settle conversions of the notes, at our election, in cash, shares of our common stock or a combination of both. We may not redeem the notes prior to maturity, and we do not have to provide a sinking fund for them. Holders of the notes may require us to purchase some or all of their notes upon the occurrence of certain fundamental changes, as set forth in the indentures governing the notes, at a purchase price equal to 100 percent of the principal amount of the notes to be purchased, plus any accrued and unpaid interest.&lt;/span&gt; &lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c6"
      decimals="INF"
      id="ixv-12032"
      unitRef="pure">0.0175</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="c247"
      decimals="-5"
      id="ixv-12033"
      unitRef="usd">575000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c6"
      decimals="INF"
      id="ixv-12034"
      unitRef="pure">0.0175</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ConvertibleDebtTableTextBlock contextRef="c250" id="ixv-6177">&lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span&gt;At September 30, 2025, we had the following 1.75% Notes outstanding (in millions except interest rate and price per share data):&lt;/span&gt; &lt;/div&gt;
  &lt;div style="text-align: justify; color: #000000;"&gt;&#160;
  &lt;/div&gt;

  &lt;div&gt;&#160;&lt;/div&gt;
  &lt;table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"&gt;&lt;tr style="height: 0px; font-size: 0px;"&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 12. Convertible Debt - B4"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;1.75% Notes&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 12. Convertible Debt - B4"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Outstanding principal balance&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B5"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;575.0&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B5"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Unamortized debt issuance costs&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B6"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;7.9&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B6"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Maturity date&lt;/td&gt;&lt;td style="width: 1%;" title="Note 12. Convertible Debt - B7"&gt;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-2"&gt;June 2028&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 12. Convertible Debt - B7"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Interest rate&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B8"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;1.75&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B8"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Effective interest rate&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B9"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;2.30&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B9"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Conversion price per share&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B10"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;53.73&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B10"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Total shares of common stock subject to conversion&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B11"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;10.7&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B11"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ConvertibleDebtTableTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c6"
      decimals="INF"
      id="ixv-12035"
      unitRef="pure">0.0175</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c6" decimals="-5" id="ixv-12036" unitRef="usd">575000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DeferredFinanceCostsNet contextRef="c6" decimals="-5" id="ixv-12037" unitRef="usd">7900000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c6" decimals="4" id="ixv-12038" unitRef="pure">0.0175</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c6" decimals="4" id="ixv-12039" unitRef="pure">0.023</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c6"
      decimals="2"
      id="ixv-12040"
      unitRef="usdPershares">53.73</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <ions:DebtInstrumentConvertibleSharesSubjectToConversion
      contextRef="c6"
      decimals="-5"
      id="ixv-12041"
      unitRef="shares">10700000</ions:DebtInstrumentConvertibleSharesSubjectToConversion>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c4"
      decimals="INF"
      id="ixv-12042"
      unitRef="pure">0</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="c248"
      decimals="-5"
      id="ixv-12043"
      unitRef="usd">632500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c4"
      decimals="INF"
      id="ixv-12044"
      unitRef="pure">0</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ConvertibleDebtTableTextBlock contextRef="c251" id="ixv-6237">&lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span&gt;At September 30, 2025, we had the following &lt;/span&gt;&lt;span style="font-family: Times;"&gt;0%&lt;/span&gt;&lt;span&gt; Notes outstanding (in millions except interest rate and price per share data):&lt;/span&gt; &lt;/div&gt;
  &lt;div style="text-align: justify; color: #000000;"&gt;&#160;&lt;/div&gt;
  &lt;div style="text-align: justify; color: #000000;"&gt;&#160;&lt;/div&gt;
  &lt;table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"&gt;&lt;tr style="height: 0px; font-size: 0px;"&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 12. Convertible Debt - B15"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;0% Notes&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 12. Convertible Debt - B15"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Outstanding principal balance&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B16"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;632.5&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B16"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Unamortized debt issuance costs&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B17"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;1.6&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B17"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Maturity date&lt;/td&gt;&lt;td style="width: 1%;" title="Note 12. Convertible Debt - B18"&gt;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-3"&gt;April 2026&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 12. Convertible Debt - B18"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Interest rate&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B19"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;0&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B19"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Effective interest rate&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B20"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;0.50&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B20"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Conversion price per share&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B21"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;57.84&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B21"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Effective conversion price per share with call spread&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B22"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;76.39&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B22"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Total shares of common stock subject to conversion&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B23"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%;"&gt;10.9&lt;/td&gt;&lt;td style="text-align: left; width: 1%;" title="Note 12. Convertible Debt - B23"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ConvertibleDebtTableTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c4"
      decimals="INF"
      id="ixv-12045"
      unitRef="pure">0</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c4" decimals="-5" id="ixv-12046" unitRef="usd">632500000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DeferredFinanceCostsNet contextRef="c4" decimals="-5" id="ixv-12047" unitRef="usd">1600000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c4" decimals="2" id="ixv-12048" unitRef="pure">0</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c4" decimals="4" id="ixv-12049" unitRef="pure">0.005</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c4"
      decimals="2"
      id="ixv-12050"
      unitRef="usdPershares">57.84</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <ions:DebtInstrumentConvertibleConversionPriceIncludingCallSpread
      contextRef="c4"
      decimals="2"
      id="ixv-12051"
      unitRef="usdPershares">76.39</ions:DebtInstrumentConvertibleConversionPriceIncludingCallSpread>
    <ions:DebtInstrumentConvertibleSharesSubjectToConversion
      contextRef="c4"
      decimals="-5"
      id="ixv-12052"
      unitRef="shares">10900000</ions:DebtInstrumentConvertibleSharesSubjectToConversion>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c4"
      decimals="INF"
      id="ixv-12053"
      unitRef="pure">0</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c4"
      decimals="INF"
      id="ixv-12054"
      unitRef="pure">0</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <ions:DebtInstrumentConvertibleConversionPriceIncludingCallSpread
      contextRef="c4"
      decimals="2"
      id="ixv-12055"
      unitRef="usdPershares">76.39</ions:DebtInstrumentConvertibleConversionPriceIncludingCallSpread>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c4"
      decimals="INF"
      id="ixv-12056"
      unitRef="pure">0</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <ions:CallSpread
      contextRef="c249"
      decimals="-5"
      id="ixv-12057"
      unitRef="usd">46900000</ions:CallSpread>
    <us-gaap:PaymentsForHedgeFinancingActivities
      contextRef="c249"
      decimals="-5"
      id="ixv-12058"
      unitRef="usd">136700000</us-gaap:PaymentsForHedgeFinancingActivities>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="c249"
      decimals="-5"
      id="ixv-12059"
      unitRef="usd">89800000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c4"
      decimals="INF"
      id="ixv-12060"
      unitRef="pure">0</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c4"
      decimals="INF"
      id="ixv-12061"
      unitRef="pure">0</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c4"
      decimals="INF"
      id="ixv-12062"
      unitRef="pure">0</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c4"
      decimals="INF"
      id="ixv-12063"
      unitRef="pure">0</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c4"
      decimals="INF"
      id="ixv-12064"
      unitRef="pure">0</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c6"
      decimals="INF"
      id="ixv-12065"
      unitRef="pure">0.0175</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c4"
      decimals="INF"
      id="ixv-12066"
      unitRef="pure">0</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <ions:DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange
      contextRef="c250"
      decimals="INF"
      id="ixv-12067"
      unitRef="pure">1</ions:DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange>
    <ions:DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange
      contextRef="c251"
      decimals="INF"
      id="ixv-12068"
      unitRef="pure">1</ions:DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c0" id="ixv-6328">&lt;div&gt;&lt;span style="font-weight: 700; letter-spacing: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;13. Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&#160;&lt;/div&gt;&lt;div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"&gt;In 2022, we concurrently entered into two purchase and sale agreements with a real estate investor. In the same period, we closed the first transaction in which we sold the facilities at our headquarters in Carlsbad, California, which includes our primary R&amp;amp;D facility, for a purchase price of $263.4 million. In connection with this transaction, we leased back our headquarters facilities for an initial lease term of 15 years with options to extend the lease for two additional terms of five years each.
&lt;/div&gt;&lt;div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"&gt;&#160;&lt;/div&gt;&lt;div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"&gt;In 2023, we closed the second transaction and transferred legal ownership of two lots of undeveloped land adjacent to our headquarters to the real estate investor for a purchase price of $33.0 million. In connection with this transaction, we entered into a build-to-suit lease agreement with the same real estate investor to lease a new R&amp;amp;D facility. The lessor developed and constructed a new building composed of R&amp;amp;D and office space. We are designing and constructing tenant improvements to customize the facility&#x2019;s interior space.
&lt;/div&gt;&lt;div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"&gt;&#160;&lt;/div&gt;&lt;div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"&gt;The lease commenced in September 2025 when the lessor completed constructing the structure of the new facility. The initial lease term for this facility is 15 years with options to extend the lease for 2 additional terms of five years each. We determined at lease inception that it was not reasonably certain that we would exercise any of the options to extend the lease. We estimated our lease payments over the initial term to total approximately $230 million. In addition, we expect to receive reimbursements totaling $41.2 million from the lessor for tenant improvements that we own.
&lt;/div&gt;&lt;div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"&gt;&#160;&lt;/div&gt;&lt;div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"&gt;Since the building was under construction and unavailable to lease, we were unable to complete the sale-leaseback evaluation under ASC Topic 842, Leases, in 2023. As a result, the land remained in our consolidated balance sheets and we accounted for the proceeds as a financial liability. In September 2025, we reassessed the transaction under the sale-leaseback accounting guidance when the facility became available for lease commencement. We determined the transaction qualified as a sale-leaseback transaction upon lease commencement. As a result, we de-recognized the land and recorded a net gain of $4.2 million that we reported within operating loss in our condensed consolidated statements of operations. In addition, we recorded a financial liability of $19.6 million, which reflects the difference in the fair value of the land as of the lease commencement date compared to the purchase price of the land in 2023. W&lt;span style="letter-spacing: normal; text-align: justify; text-indent: 48px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;e reported the current portion of the financial liability in other current liabilities and the non-current portion of the financial liability in long-term obligations in our condensed consolidated balance sheets. We recognize interest expense related to the financial liability based on our incremental borrowing rate at the commencement of the lease. We allocate payments to the lessor between the financial liability and lease expense.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <ions:NumberOfPurchaseAndSaleAgreementsEnteredIntoWithRealEstateInvestor
      contextRef="c252"
      decimals="INF"
      id="ixv-12069"
      unitRef="Agreement">2</ions:NumberOfPurchaseAndSaleAgreementsEnteredIntoWithRealEstateInvestor>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="c253"
      decimals="-5"
      id="ixv-12070"
      unitRef="usd">263400000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c254" id="ixv-12071">P15Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <ions:LesseeOperatingLeaseNumberOfOptionsToExtendLease
      contextRef="c254"
      decimals="INF"
      id="ixv-12072"
      unitRef="Option">2</ions:LesseeOperatingLeaseNumberOfOptionsToExtendLease>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c254" id="ixv-12073">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <ions:NumberOfLotsOfUndevelopedLandTransferredToRealEstateInvestor
      contextRef="c255"
      decimals="INF"
      id="ixv-12074"
      unitRef="Lot">2</ions:NumberOfLotsOfUndevelopedLandTransferredToRealEstateInvestor>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="c255"
      decimals="-5"
      id="ixv-12075"
      unitRef="usd">33000000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c254" id="ixv-12076">P15Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <ions:LesseeOperatingLeaseNumberOfOptionsToExtendLease
      contextRef="c254"
      decimals="INF"
      id="ixv-12077"
      unitRef="Option">2</ions:LesseeOperatingLeaseNumberOfOptionsToExtendLease>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c254" id="ixv-12078">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="c254"
      decimals="-6"
      id="ixv-12079"
      unitRef="usd">230000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:IncentiveFromLessor
      contextRef="c254"
      decimals="-5"
      id="ixv-12080"
      unitRef="usd">41200000</us-gaap:IncentiveFromLessor>
    <us-gaap:SaleAndLeasebackTransactionGainLossNet contextRef="c0" decimals="-5" id="ixv-12081" unitRef="usd">4200000</us-gaap:SaleAndLeasebackTransactionGainLossNet>
    <us-gaap:OtherLiabilities contextRef="c2" decimals="-5" id="ixv-12082" unitRef="usd">19600000</us-gaap:OtherLiabilities>
    <us-gaap:LegalMattersAndContingenciesTextBlock contextRef="c0" id="ixv-6341">&lt;div&gt;
   &lt;span style="font-weight: bold;"&gt;14. Legal Proceedings&lt;/span&gt;
  &lt;/div&gt;
  &lt;div&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span style="color: #000000;"&gt;From time to time, we are involved in legal proceedings arising in the ordinary course of our business. Periodically, we evaluate the status of each legal matter and assess our potential financial exposure. If we consider the potential loss from any legal proceeding to be probable and we can reasonably estimate the amount, we accrue a liability for the estimated loss. The outcome of any proceeding is not determinable in advance. Therefore, we are required to use significant judgment to determine the probability of a loss and whether the amount of the loss is reasonably estimable. Our assessment of a potential liability and the amount of accruals we recorded are based only on the information available to us at the time. As additional information becomes available, we reassess the potential liability related to the legal proceeding and may revise our estimates.&lt;/span&gt;
  &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;&#160;
  &lt;/div&gt;

  &lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   On September 10, 2025, Arrowhead Pharmaceuticals, Inc., or Arrowhead, filed a lawsuit in the District of Delaware seeking a declaratory judgment that our patent US9,593,333 is invalid or not infringed by use of Arrowhead&#x2019;s ApoCIII inhibitor plozasiran.  On September 11, 2025, we filed suit in the Central District of California asserting infringement of that same patent by Arrowhead&#x2019;s announced intention to commercialize plozasiran in November 2025. On October 8, 2025, we filed a motion to dismiss, or in the alternative, transfer Arrowhead&#x2019;s Delaware suit in favor of the case we brought in the Central District of California.  At present, both lawsuits remain pending.   &lt;/div&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c0" id="ixv-6351">&lt;div&gt;
   &lt;span style="font-weight: bold;"&gt;15. Segment Information&lt;/span&gt;
  &lt;/div&gt;
  &lt;div&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span&gt;We operate as a &lt;span style="-sec-ix-hidden: hidden-fact-4"&gt;single&lt;/span&gt; operating segment, Ionis operations, focused on the research, development and commercialization of our RNA-targeted medicines to bring better futures to people with serious diseases. The CODM, our Chief Executive Officer, manages our company, reviews operating results, assesses performance and allocates resources on an aggregate basis using consolidated net income or loss as the key measure of segment profit or loss. As such, results of our operations are reported on a consolidated basis for purposes of management and segment reporting.&lt;/span&gt; &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: 36pt; text-align: justify;"&gt;
   &lt;span&gt;Ionis operations derives its revenues from commercial and R&amp;amp;D revenue sources. Refer to Note 4, &lt;/span&gt;&lt;span style="font-style: italic;"&gt;Revenues&lt;/span&gt;&lt;span&gt;, for further details on our sources of revenue.&lt;/span&gt;
  &lt;/div&gt;&lt;div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"&gt; The following table sets forth information on segment profit or loss, including significant segment expenses (in thousands): &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;&#160;&lt;/div&gt;

  &lt;table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"&gt;&lt;tr style="height: 0px; font-size: 0px;"&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td colspan="7" style="text-align: center; font-weight: bold;"&gt;Three Months Ended&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td colspan="7" style="text-align: center; font-weight: bold;"&gt;Nine Months Ended&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;September 30,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;September 30,&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 14. Segment Information - B5"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;2025&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - B5"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 14. Segment Information - D5"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;2024&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - D5"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 14. Segment Information - F5"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;2025&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - F5"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 14. Segment Information - H5"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;2024&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - H5"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Revenue&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B6"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;156,719&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B6"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D6"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;133,814&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D6"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F6"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;740,381&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F6"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H6"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;478,562&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H6"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 14. Segment Information - B7"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 14. Segment Information - B7"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 14. Segment Information - D7"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 14. Segment Information - D7"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 14. Segment Information - F7"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 14. Segment Information - F7"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 14. Segment Information - H7"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 14. Segment Information - H7"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Less:&lt;/td&gt;&lt;td style="width: 1%;" title="Note 14. Segment Information - B8"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 14. Segment Information - B8"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 14. Segment Information - D8"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 14. Segment Information - D8"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 14. Segment Information - F8"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 14. Segment Information - F8"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 14. Segment Information - H8"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 14. Segment Information - H8"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="padding-left: 10px;"&gt;Cost of sales&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B9"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;2,193&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B9"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D9"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;912&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D9"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F9"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;7,097&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F9"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H9"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;6,815&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H9"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td style="padding-left: 10px;"&gt;Drug discovery&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B10"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;28,412&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B10"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D10"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;25,790&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D10"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F10"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;85,656&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F10"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H10"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;80,652&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H10"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="padding-left: 10px;"&gt;Drug development&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B11"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;120,828&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B11"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D11"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;132,201&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D11"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F11"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;351,463&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F11"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H11"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;392,151&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H11"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td style="padding-left: 10px;"&gt;Medical affairs&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B12"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;8,874&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B12"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D12"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;5,511&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D12"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F12"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;22,342&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F12"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H12"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;17,279&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H12"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="padding-left: 10px;"&gt;Manufacturing and development chemistry&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B13"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;15,790&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B13"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D13"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;14,087&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D13"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F13"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;51,616&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F13"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H13"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;39,723&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H13"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td style="padding-left: 10px;"&gt;R&amp;amp;D support&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B14"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;23,092&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B14"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D14"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;20,052&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D14"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F14"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;64,252&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F14"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H14"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;59,065&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H14"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="padding-left: 10px;"&gt;Selling, general and administrative&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B15"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;86,565&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B15"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D15"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;51,933&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D15"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F15"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;234,626&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F15"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H15"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;153,083&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H15"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td style="padding-left: 10px;"&gt;Other segment items (1)&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - B16"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;(429&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - B16"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - D16"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;23,808&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - D16"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - F16"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;75,322&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - F16"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - H16"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;79,342&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - H16"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Consolidated net loss&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - B17"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;"&gt;(128,606&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - B17"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - D17"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;"&gt;(140,480&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - D17"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - F17"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;"&gt;(151,993&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - F17"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - H17"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;"&gt;(349,548&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - H17"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-align: justify; margin-left: 18pt;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: -18pt; text-align: justify; padding-left: 18pt;"&gt;

    &lt;div style="text-align: justify;"&gt; &lt;span style="color: #000000;"&gt;(1)&#160; Other segment items include stock-based compensation expense, investment income, interest expense, gain or loss on investments, other income or expense and income tax expense or benefit.&lt;/span&gt; &lt;/div&gt;
  &lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="c0" id="ixv-6372">&lt;div style="text-indent: 36pt; line-height: 1.15; text-align: justify;"&gt; The following table sets forth information on segment profit or loss, including significant segment expenses (in thousands): &lt;/div&gt;
  &lt;div style="text-align: justify;"&gt;&#160;&lt;/div&gt;

  &lt;table cellpadding="0" class="worksheetTable" style="border-collapse: collapse; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; vertical-align: bottom; border-spacing: 0px;"&gt;&lt;tr style="height: 0px; font-size: 0px;"&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td colspan="7" style="text-align: center; font-weight: bold;"&gt;Three Months Ended&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td colspan="7" style="text-align: center; font-weight: bold;"&gt;Nine Months Ended&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;September 30,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td colspan="7" style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;September 30,&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 14. Segment Information - B5"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;2025&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - B5"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 14. Segment Information - D5"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;2024&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - D5"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 14. Segment Information - F5"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;2025&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - F5"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 1%;" title="Note 14. Segment Information - H5"&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; width: 9%;"&gt;2024&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - H5"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Revenue&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B6"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;156,719&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B6"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D6"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;133,814&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D6"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F6"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;740,381&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F6"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H6"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;478,562&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H6"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 14. Segment Information - B7"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 14. Segment Information - B7"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 14. Segment Information - D7"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 14. Segment Information - D7"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 14. Segment Information - F7"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 14. Segment Information - F7"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 14. Segment Information - H7"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 14. Segment Information - H7"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Less:&lt;/td&gt;&lt;td style="width: 1%;" title="Note 14. Segment Information - B8"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 14. Segment Information - B8"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 14. Segment Information - D8"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 14. Segment Information - D8"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 14. Segment Information - F8"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 14. Segment Information - F8"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 14. Segment Information - H8"&gt;&lt;/td&gt;&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;" title="Note 14. Segment Information - H8"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="padding-left: 10px;"&gt;Cost of sales&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B9"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;2,193&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B9"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D9"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;912&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D9"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F9"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;7,097&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F9"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H9"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;6,815&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H9"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td style="padding-left: 10px;"&gt;Drug discovery&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B10"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;28,412&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B10"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D10"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;25,790&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D10"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F10"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;85,656&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F10"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H10"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;80,652&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H10"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="padding-left: 10px;"&gt;Drug development&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B11"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;120,828&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B11"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D11"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;132,201&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D11"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F11"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;351,463&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F11"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H11"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;392,151&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H11"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td style="padding-left: 10px;"&gt;Medical affairs&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B12"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;8,874&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B12"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D12"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;5,511&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D12"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F12"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;22,342&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F12"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H12"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;17,279&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H12"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="padding-left: 10px;"&gt;Manufacturing and development chemistry&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B13"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;15,790&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B13"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D13"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;14,087&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D13"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F13"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;51,616&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F13"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H13"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;39,723&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H13"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td style="padding-left: 10px;"&gt;R&amp;amp;D support&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B14"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;23,092&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B14"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D14"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;20,052&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D14"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F14"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;64,252&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F14"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H14"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;59,065&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H14"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="padding-left: 10px;"&gt;Selling, general and administrative&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B15"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;86,565&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - B15"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D15"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;51,933&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - D15"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F15"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;234,626&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - F15"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H15"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;153,083&lt;/td&gt;&lt;td style="width: 1%; text-align: left;" title="Note 14. Segment Information - H15"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td style="padding-left: 10px;"&gt;Other segment items (1)&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - B16"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;(429&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - B16"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - D16"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;23,808&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - D16"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - F16"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;75,322&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - F16"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - H16"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;79,342&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - H16"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Consolidated net loss&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - B17"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;"&gt;(128,606&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - B17"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - D17"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;"&gt;(140,480&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - D17"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - F17"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;"&gt;(151,993&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - F17"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - H17"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;"&gt;(349,548&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 3px double black; border-top: none; border-left: none; border-right: none;" title="Note 14. Segment Information - H17"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-align: justify; margin-left: 18pt;"&gt;&#160;
  &lt;/div&gt;
  &lt;div style="text-indent: -18pt; text-align: justify; padding-left: 18pt;"&gt;

    &lt;div style="text-align: justify;"&gt; &lt;span style="color: #000000;"&gt;(1)&#160; Other segment items include stock-based compensation expense, investment income, interest expense, gain or loss on investments, other income or expense and income tax expense or benefit.&lt;/span&gt; &lt;/div&gt;
  &lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c256"
      decimals="-3"
      id="ixv-12083"
      unitRef="usd">156719000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c257"
      decimals="-3"
      id="ixv-12084"
      unitRef="usd">133814000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c258"
      decimals="-3"
      id="ixv-12085"
      unitRef="usd">740381000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c259"
      decimals="-3"
      id="ixv-12086"
      unitRef="usd">478562000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="c256"
      decimals="-3"
      id="ixv-12087"
      unitRef="usd">2193000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="c257"
      decimals="-3"
      id="ixv-12088"
      unitRef="usd">912000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="c258"
      decimals="-3"
      id="ixv-12089"
      unitRef="usd">7097000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="c259"
      decimals="-3"
      id="ixv-12090"
      unitRef="usd">6815000</us-gaap:CostOfGoodsAndServicesSold>
    <ions:DrugDiscoveryExpenses
      contextRef="c256"
      decimals="-3"
      id="ixv-12091"
      unitRef="usd">28412000</ions:DrugDiscoveryExpenses>
    <ions:DrugDiscoveryExpenses
      contextRef="c257"
      decimals="-3"
      id="ixv-12092"
      unitRef="usd">25790000</ions:DrugDiscoveryExpenses>
    <ions:DrugDiscoveryExpenses
      contextRef="c258"
      decimals="-3"
      id="ixv-12093"
      unitRef="usd">85656000</ions:DrugDiscoveryExpenses>
    <ions:DrugDiscoveryExpenses
      contextRef="c259"
      decimals="-3"
      id="ixv-12094"
      unitRef="usd">80652000</ions:DrugDiscoveryExpenses>
    <ions:DrugDevelopmentExpenses
      contextRef="c256"
      decimals="-3"
      id="ixv-12095"
      unitRef="usd">120828000</ions:DrugDevelopmentExpenses>
    <ions:DrugDevelopmentExpenses
      contextRef="c257"
      decimals="-3"
      id="ixv-12096"
      unitRef="usd">132201000</ions:DrugDevelopmentExpenses>
    <ions:DrugDevelopmentExpenses
      contextRef="c258"
      decimals="-3"
      id="ixv-12097"
      unitRef="usd">351463000</ions:DrugDevelopmentExpenses>
    <ions:DrugDevelopmentExpenses
      contextRef="c259"
      decimals="-3"
      id="ixv-12098"
      unitRef="usd">392151000</ions:DrugDevelopmentExpenses>
    <ions:MedicalAffairsExpenses
      contextRef="c256"
      decimals="-3"
      id="ixv-12099"
      unitRef="usd">8874000</ions:MedicalAffairsExpenses>
    <ions:MedicalAffairsExpenses
      contextRef="c257"
      decimals="-3"
      id="ixv-12100"
      unitRef="usd">5511000</ions:MedicalAffairsExpenses>
    <ions:MedicalAffairsExpenses
      contextRef="c258"
      decimals="-3"
      id="ixv-12101"
      unitRef="usd">22342000</ions:MedicalAffairsExpenses>
    <ions:MedicalAffairsExpenses
      contextRef="c259"
      decimals="-3"
      id="ixv-12102"
      unitRef="usd">17279000</ions:MedicalAffairsExpenses>
    <ions:ManufacturingAndDevelopmentChemistryExpenses
      contextRef="c256"
      decimals="-3"
      id="ixv-12103"
      unitRef="usd">15790000</ions:ManufacturingAndDevelopmentChemistryExpenses>
    <ions:ManufacturingAndDevelopmentChemistryExpenses
      contextRef="c257"
      decimals="-3"
      id="ixv-12104"
      unitRef="usd">14087000</ions:ManufacturingAndDevelopmentChemistryExpenses>
    <ions:ManufacturingAndDevelopmentChemistryExpenses
      contextRef="c258"
      decimals="-3"
      id="ixv-12105"
      unitRef="usd">51616000</ions:ManufacturingAndDevelopmentChemistryExpenses>
    <ions:ManufacturingAndDevelopmentChemistryExpenses
      contextRef="c259"
      decimals="-3"
      id="ixv-12106"
      unitRef="usd">39723000</ions:ManufacturingAndDevelopmentChemistryExpenses>
    <ions:ResearchAndDevelopmentSupportExpenses
      contextRef="c256"
      decimals="-3"
      id="ixv-12107"
      unitRef="usd">23092000</ions:ResearchAndDevelopmentSupportExpenses>
    <ions:ResearchAndDevelopmentSupportExpenses
      contextRef="c257"
      decimals="-3"
      id="ixv-12108"
      unitRef="usd">20052000</ions:ResearchAndDevelopmentSupportExpenses>
    <ions:ResearchAndDevelopmentSupportExpenses
      contextRef="c258"
      decimals="-3"
      id="ixv-12109"
      unitRef="usd">64252000</ions:ResearchAndDevelopmentSupportExpenses>
    <ions:ResearchAndDevelopmentSupportExpenses
      contextRef="c259"
      decimals="-3"
      id="ixv-12110"
      unitRef="usd">59065000</ions:ResearchAndDevelopmentSupportExpenses>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="c256"
      decimals="-3"
      id="ixv-12111"
      unitRef="usd">86565000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="c257"
      decimals="-3"
      id="ixv-12112"
      unitRef="usd">51933000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="c258"
      decimals="-3"
      id="ixv-12113"
      unitRef="usd">234626000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="c259"
      decimals="-3"
      id="ixv-12114"
      unitRef="usd">153083000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="c256"
      decimals="-3"
      id="ixv-12115"
      unitRef="usd">-429000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="c257"
      decimals="-3"
      id="ixv-12116"
      unitRef="usd">23808000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="c258"
      decimals="-3"
      id="ixv-12117"
      unitRef="usd">75322000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="c259"
      decimals="-3"
      id="ixv-12118"
      unitRef="usd">79342000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:NetIncomeLoss
      contextRef="c256"
      decimals="-3"
      id="ixv-12119"
      unitRef="usd">-128606000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c257"
      decimals="-3"
      id="ixv-12120"
      unitRef="usd">-140480000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c258"
      decimals="-3"
      id="ixv-12121"
      unitRef="usd">-151993000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c259"
      decimals="-3"
      id="ixv-12122"
      unitRef="usd">-349548000</us-gaap:NetIncomeLoss>
    <us-gaap:SegmentReportingOtherItemCompositionDescription contextRef="c0" id="ixv-12123">Other segment items include stock-based compensation expense, investment income, interest expense, gain or loss on investments, other income or expense and income tax expense or benefit.</us-gaap:SegmentReportingOtherItemCompositionDescription>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="c36" id="ixv-10827">&lt;div style="text-indent: 36pt; text-align: justify;"&gt; &lt;span style="color: #000000;"&gt;During the quarter ended September 30, 2025, our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act), or Section 16 officers and directors, adopted or terminated contracts, instructions or written plans for the purchase or sale of our securities as noted in the table below.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;*&#160; &#160; &#160;&#160;&#160;Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.&lt;/div&gt;&lt;div&gt;**&#160; &#160; "Non-Rule 10b5-1 trading arrangement" as defined in item 408(c) of Regulation S-K under the Exchange Act.&lt;/div&gt;&lt;table cellpadding="0" class="worksheetTable" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-spacing: 0px;"&gt;&lt;tr style="height: 0px; font-size: 0px;"&gt;&lt;td style="width: 8%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 7%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 7%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 8%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 7%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 8%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 8%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 40%;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="font-weight: bold; text-align: center;"&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center;"&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center;"&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center;"&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center;"&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center;"&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center;"&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center;"&gt;&lt;/td&gt;&lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;Trading Arrangement&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center;"&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center;"&gt;Total Shares&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center;"&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="font-weight: bold; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none; text-align: left;"&gt;Name&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;Title&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;Action&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;Date&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;Rule 10b5-1*&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;Non-Rule 10b5-1**&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;to be Sold&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; vertical-align: bottom; border-bottom: 1px solid black; border-top: none; border-left: none; border-right: none;"&gt;Expiration Date&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align: bottom;"&gt;Spencer Berthelsen&lt;/td&gt;&lt;td style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center;"&gt;Board Member&lt;/td&gt;&lt;td style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom;"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-5"&gt;Adoption&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom;"&gt;September 12, 2025&lt;/td&gt;&lt;td style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom;"&gt;X&lt;/td&gt;&lt;td style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom;"&gt;16,000&lt;/td&gt;&lt;td style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom;"&gt;The earlier to occur of (i) July 1, 2026, and (ii) Upon the execution of all instructions provided in the plan&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c36" id="ixv-12124">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:TrdArrIndName contextRef="c36" id="ixv-12125">Spencer Berthelsen</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c36" id="ixv-12126">Board Member</ecd:TrdArrIndTitle>
    <ecd:TrdArrAdoptionDate contextRef="c36" id="ixv-12127">September 12, 2025</ecd:TrdArrAdoptionDate>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c36" id="ixv-12128">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c2"
      decimals="INF"
      id="ixv-12129"
      unitRef="shares">16000</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrExpirationDate contextRef="c36" id="ixv-12130">July 1, 2026</ecd:TrdArrExpirationDate>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c0"
      decimals="INF"
      id="hidden-fact-0"
      unitRef="Segment">1</us-gaap:NumberOfOperatingSegments>
    <ions:MaximumContractMaturityPeriodRange3 contextRef="c0" id="hidden-fact-1">P3Y6M</ions:MaximumContractMaturityPeriodRange3>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c250" id="hidden-fact-2">2028-06-30</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c251" id="hidden-fact-3">2026-04-30</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:NumberOfReportableSegments
      contextRef="c0"
      decimals="INF"
      id="hidden-fact-4"
      unitRef="pure">1</us-gaap:NumberOfReportableSegments>
    <ecd:TrdArrDuration contextRef="c36" id="hidden-fact-5">P293D</ecd:TrdArrDuration>
    <dei:EntityCentralIndexKey contextRef="c0" id="ixv-12139">0000874015</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c0" id="ixv-12140">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="c0" id="ixv-12141">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate contextRef="c0" id="ixv-12142">--12-31</dei:CurrentFiscalYearEndDate>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#ix_0_fact"
          xlink:label="ix_0_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_3_fact"
          xlink:label="ix_3_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_1_fact"
          xlink:label="ix_1_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_2_fact"
          xlink:label="ix_2_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_0_footnote" xlink:label="ix_0_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Includes investments classified as cash equivalents in our condensed consolidated balance sheets.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_0_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_3_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_1_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_2_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_4_fact"
          xlink:label="ix_4_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_5_fact"
          xlink:label="ix_5_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_1_footnote" xlink:label="ix_1_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Our publicly traded equity securities are included in other current assets. We recognize publicly traded equity securities at fair value. In the nine months ended September 30, 2025, we recorded a $2.0 million net unrealized loss in our condensed consolidated statements of operations related to changes in the fair value of our investments in publicly traded companies.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_4_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_5_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_7_fact"
          xlink:label="ix_7_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_6_fact"
          xlink:label="ix_6_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_2_footnote" xlink:label="ix_2_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Our privately held equity securities are included in deposits and other assets. We recognize our privately held equity securities at<xhtml:span> cost minus impairments, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer, which are Level 3 inputs</xhtml:span><xhtml:span style="color: #000000;">. In the nine months ended September 30, 2025, the amortized cost of our privately held equity securities increased $11.2 million. In the third quarter of 2025, we recorded a $29.4 million unrealized gain related to our investment in a privately held company due to an observable price change in an orderly transaction for a similar investment of the investee. This increase was partially offset by a loss of $18.2 million related to an impairment of our investment in another privately held company that we recorded in the second quarter of 2025.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_7_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_6_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_13_fact"
          xlink:label="ix_13_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_12_fact"
          xlink:label="ix_12_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_11_fact"
          xlink:label="ix_11_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_10_fact"
          xlink:label="ix_10_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_9_fact"
          xlink:label="ix_9_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_8_fact"
          xlink:label="ix_8_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_3_footnote" xlink:label="ix_3_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Included in cash and cash equivalents.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_13_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_12_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_11_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_10_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_9_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_8_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_16_fact"
          xlink:label="ix_16_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_14_fact"
          xlink:label="ix_14_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_15_fact"
          xlink:label="ix_15_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_4_footnote" xlink:label="ix_4_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">$39.9 million was included in cash and cash equivalents, with the difference included in short-term investments.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_16_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_14_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_15_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_36_fact"
          xlink:label="ix_36_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_27_fact"
          xlink:label="ix_27_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_32_fact"
          xlink:label="ix_32_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_21_fact"
          xlink:label="ix_21_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_29_fact"
          xlink:label="ix_29_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_18_fact"
          xlink:label="ix_18_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_24_fact"
          xlink:label="ix_24_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_23_fact"
          xlink:label="ix_23_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_22_fact"
          xlink:label="ix_22_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_39_fact"
          xlink:label="ix_39_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_35_fact"
          xlink:label="ix_35_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_28_fact"
          xlink:label="ix_28_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_25_fact"
          xlink:label="ix_25_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_38_fact"
          xlink:label="ix_38_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_31_fact"
          xlink:label="ix_31_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_26_fact"
          xlink:label="ix_26_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_34_fact"
          xlink:label="ix_34_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_20_fact"
          xlink:label="ix_20_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_30_fact"
          xlink:label="ix_30_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_37_fact"
          xlink:label="ix_37_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_17_fact"
          xlink:label="ix_17_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_19_fact"
          xlink:label="ix_19_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_33_fact"
          xlink:label="ix_33_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_40_fact"
          xlink:label="ix_40_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_5_footnote" xlink:label="ix_5_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Included in short-term investments.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_36_fact"
          xlink:to="ix_5_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_27_fact"
          xlink:to="ix_5_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_32_fact"
          xlink:to="ix_5_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_21_fact"
          xlink:to="ix_5_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_29_fact"
          xlink:to="ix_5_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_18_fact"
          xlink:to="ix_5_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_24_fact"
          xlink:to="ix_5_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_23_fact"
          xlink:to="ix_5_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_22_fact"
          xlink:to="ix_5_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_39_fact"
          xlink:to="ix_5_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_35_fact"
          xlink:to="ix_5_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_28_fact"
          xlink:to="ix_5_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_25_fact"
          xlink:to="ix_5_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_38_fact"
          xlink:to="ix_5_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_31_fact"
          xlink:to="ix_5_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_26_fact"
          xlink:to="ix_5_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_34_fact"
          xlink:to="ix_5_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_20_fact"
          xlink:to="ix_5_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_30_fact"
          xlink:to="ix_5_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_37_fact"
          xlink:to="ix_5_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_17_fact"
          xlink:to="ix_5_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_19_fact"
          xlink:to="ix_5_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_33_fact"
          xlink:to="ix_5_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_40_fact"
          xlink:to="ix_5_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_41_fact"
          xlink:label="ix_41_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_43_fact"
          xlink:label="ix_43_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_42_fact"
          xlink:label="ix_42_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_6_footnote" xlink:label="ix_6_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="letter-spacing: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">$36.0 million was included in cash and cash equivalents, with the difference included in short-term investments.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_41_fact"
          xlink:to="ix_6_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_43_fact"
          xlink:to="ix_6_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_42_fact"
          xlink:to="ix_6_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_48_fact"
          xlink:label="ix_48_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_47_fact"
          xlink:label="ix_47_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_49_fact"
          xlink:label="ix_49_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_46_fact"
          xlink:label="ix_46_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_44_fact"
          xlink:label="ix_44_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_45_fact"
          xlink:label="ix_45_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_7_footnote" xlink:label="ix_7_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Included in other current assets.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_48_fact"
          xlink:to="ix_7_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_47_fact"
          xlink:to="ix_7_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_49_fact"
          xlink:to="ix_7_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_46_fact"
          xlink:to="ix_7_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_44_fact"
          xlink:to="ix_7_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_45_fact"
          xlink:to="ix_7_footnote"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
